PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BEG, AA; SHA, WC; BRONSON, RT; GHOSH, S; BALTIMORE, D				BEG, AA; SHA, WC; BRONSON, RT; GHOSH, S; BALTIMORE, D			EMBRYONIC LETHALITY AND LIVER DEGENERATION IN MICE LACKING THE RELA COMPONENT OF NF-KAPPA-B	NATURE			English	Article								NF-kappa B, which consists of two polypeptides, p50 (M, 50K) and p65/RelA (M(r) 65K), is thought to be a key regulator of genes involved in responses to infection, inflammation and stress(1). Indeed, although developmentally normal, mice deficient in p50 display functional defects in immune responses(2). Here we describe the generation of mice deficient in the RelA subunit of NF-kappa B. Disruption of the relA locus leads to embryonic lethality at 15-16 days of gestation, concomitant with a massive degeneration of the liver by programmed cell death or apoptosis. Embryonic fibroblasts from RelA-deficient mice are defective in the tumour necrosis factor (TNF)-mediated induction of messenger RNAs for I kappa B alpha and granulocyte/macrophage colony stimulating factor (GM-CSF), although basal levels of these transcripts are unaltered. These results indicate that RelA controls inducible, but not basal, transcription in NF-kappa B-regulated pathways.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED & VET MED,DEPT PATHOL,BOSTON,MA 02111; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Massachusetts Institute of Technology (MIT); Tufts University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University								ABBADIE C, 1993, CELL, V75, P889; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CRESSMANDE, 1994, J BIOL CHEM, V269, P30429; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRILLI M, 1991, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STEIN B, 1993, EMBO J, V10, P3879; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEIH F, 1994, CELL, V80, P331; WYLLIE AH, 1994, J PATHOL, V142, P67	23	1584	1644	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					167	170		10.1038/376167a0	http://dx.doi.org/10.1038/376167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603567				2022-12-01	WOS:A1995RJ02800059
J	BOORE, JL; COLLINS, TM; STANTON, D; DAEHLER, LL; BROWN, WM				BOORE, JL; COLLINS, TM; STANTON, D; DAEHLER, LL; BROWN, WM			DEDUCING THE PATTERN OF ARTHROPOD PHYLOGENY FROM MITOCHONDRIAL-DNA REARRANGEMENTS	NATURE			English	Article							RIBOSOMAL-RNA; GENE; EVOLUTION; SEQUENCE; ORIGIN; GENOME	THE origins of arthropods and the phylogenetic relationships among their three major living groups (atdocerates, crustaceans and chelicerates) are vigorously contended. To help resolve this, we determined mitochondrial gene arrangements for a chelicerate, a myriapod, two crustaceans, an onychophoran, a mollusc and an annelid, and compared them with published gene orders of other species. The result strongly supports the monophyly of Arthropoda and of Mandibulata (atelocerates plus crustaceans) and refutes the Uniramia (atelocerates plus onychophorans). Gene arrangement comparisons are emerging as a powerful new tool for resolving ancient phylogenetic relationships.	UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Brown, William/GXN-2777-2022					Adoutte Andre, 1993, Experientia Supplementum (Basel), V63, P1; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; BOORE JL, 1994, GENETICS, V138, P423; BOORE JL, 1994, NAUTILUS, V108, P61; Boudreaux H.B., 1979, ARTHROPOD PHYLOGENY; Brusca R.C., 1990, INVERTEBRATES; CISNE JL, 1974, SCIENCE, V186, P13, DOI 10.1126/science.186.4158.13; CROZIER RH, 1993, GENETICS, V133, P97; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; HAUCKE HR, 1988, CURR GENET, V14, P471, DOI 10.1007/BF00521271; HENDRIKS L, 1988, EUR J BIOCHEM, V177, P15, DOI 10.1111/j.1432-1033.1988.tb14339.x; HESSLER R R, 1975, Fossils and Strata, V4, P437; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Liu H, 1992, MOL PHYLOGENET EVOL, V1, P41, DOI 10.1016/1055-7903(92)90034-E; Maddison W.P., 1992, ANAL PHYLOGENY CHARA; Manton S. M., 1979, ORIGIN MAJOR INVERTE, P269; MITCHELL SE, 1993, GENOME, V36, P1058, DOI 10.1139/g93-141; PASHLEY DP, 1992, MOL BIOL EVOL, V9, P1061; PATTERSON C, 1993, ANNU REV ECOL SYST, V24, P153; PREUSS K, 1992, J MED ENTOMOL, V29, P644; SANKOFF D, 1992, P NATL ACAD SCI USA, V89, P6575, DOI 10.1073/pnas.89.14.6575; SMITH MJ, 1993, J MOL EVOL, V36, P545, DOI 10.1007/BF00556359; TIEGS OWQ, 1947, J MICROSC SCI, V82, P165; VALENTINE JW, 1989, P NATL ACAD SCI USA, V86, P2272, DOI 10.1073/pnas.86.7.2272; VALVERDE JR, 1994, J MOL EVOL, V39, P400, DOI 10.1007/BF00160272; VAWTER L, 1993, GENETICS, V134, P597; WHEELER WC, 1993, CLADISTICS, V9, P11; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5	30	336	350	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					163	165		10.1038/376163a0	http://dx.doi.org/10.1038/376163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603565	Green Submitted			2022-12-01	WOS:A1995RJ02800057
J	CALLAHAN, CA; MURALIDHAR, MG; LUNDGREN, SE; SCULLY, AL; THOMAS, JB				CALLAHAN, CA; MURALIDHAR, MG; LUNDGREN, SE; SCULLY, AL; THOMAS, JB			CONTROL OF NEURONAL PATHWAY SELECTION BY A DROSOPHILA RECEPTOR PROTEIN-TYROSINE KINASE FAMILY MEMBER	NATURE			English	Article							CELL-ADHESION MOLECULE; GENE; DOMAIN; ELEGANS; EMBRYOS; MUSCLES; ENCODES; HOMOLOG; SUBSET; RYK	DURING development, neurons are capable of selecting specific pathways that lead them to their appropriate target areas. A variety of molecular mechanisms are thought to be involved in pathway recognition, including cell adhesion(1), repulsion(2,3) and chemotropism(4). However, apart from a few genes whose involvement has been shown genetically(5-8), the mechanisms underlying neuronal pathway selection are largely unknown. Here we report the isolation of the Drosophila derailed (drl) gene, which encodes a novel member of the receptor protein-tyrosine kinase family. Using a newly developed axon-targeted reporter gene(9) we find that drl is expressed by a small subset of embryonic interneurons whose growth cones choose common pathways during development. In drl mutant embryos these neurons fail to make the correct pathway choices. Our results provide evidence for receptor protein-tyrosine kinase involvement in key aspects of neuronal pathway recognition.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego								AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DOE CQ, 1993, DEV DROSOPHILA MELAN, P1131; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GAY P, 1993, MOL GEN GENET, V239, P361, DOI 10.1007/BF00276934; GILBERT D, 1984, GENETICS, V106, P679; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; SMITH HK, 1991, ROUX ARCH DEV BIOL, V200, P306, DOI 10.1007/BF00665525; STACKER SA, 1993, ONCOGENE, V8, P1347; THOMAS JB, 1982, NATURE, V298, P650, DOI 10.1038/298650a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR D, 1993, CELL, V73, P1155; WRIGHT TRF, 1981, CHROMOSOMA, V83, P45, DOI 10.1007/BF00286015	30	153	158	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					171	174		10.1038/376171a0	http://dx.doi.org/10.1038/376171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603568				2022-12-01	WOS:A1995RJ02800060
J	CHEN, YH; INOBE, J; MARKS, R; GONNELLA, P; KUCHROO, VK; WEINER, HL				CHEN, YH; INOBE, J; MARKS, R; GONNELLA, P; KUCHROO, VK; WEINER, HL			PERIPHERAL DELETION OF ANTIGEN-REACTIVE T-CELLS IN ORAL TOLERANCE	NATURE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COLLAGEN-INDUCED ARTHRITIS; MYELIN BASIC-PROTEIN; II COLLAGEN; SUPPRESSION; INDUCTION; MICE	ORAL administration of antigen is used to induce antigen-specific peripheral immune tolerance(1,2). As well as preventing systemic immune responses to ingested proteins(3), oral tolerance to autoantigens has also been used to suppress autoimmune diseases in animals(4-10) and humans(11,12). Both active suppression and clonal anergy are suggested to be mechanisms of oral tolerance, depending on the dose of antigen fed(13,14). Here we report that oral antigen can delete antigen-reactive T cells in Peyer's patches, in mice transgenic for the ovalbumin-specific T-cell receptor genes, The deletion was mediated by apoptosis, and was dependent on dosage and frequency of feeding. At lower doses deletion was not observed; instead there was induction of antigen-specific cells that produced transforming growth factor (TGF)beta and interleukin (IL)-4 and IL-10 cytokines. At higher doses, both Th1 and Th2 cells were deleted following their initial activation, whereas cells which secrete TGF-beta were resistant to deletion. These findings demonstrate that orally administered antigen can induce tolerance not only by active suppression and clonal anergy	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Chen, Youhai/AAJ-4031-2021					BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN R, 1989, J EXP MED, V144, P3411; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HUANG L, 1994, INT IMMUNOL, V6, P533, DOI 10.1093/intimm/6.4.533; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NOGUCHI PD, 1994, CURRENT PROTOCOLS IM; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; ROCHA B, 1992, SCIENCE, V251, P1225; SANTOS LMB, 1994, CELL IMMUNOL, V157, P439, DOI 10.1006/cimm.1994.1240; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wells HG, 1911, J INFECT DIS, V8, P147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; XUAMANO JC, 1992, INT IMMUNOL, V4, P433, DOI 10.1093/intimm/4.4.433; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	25	697	721	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					177	180		10.1038/376177a0	http://dx.doi.org/10.1038/376177a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603570				2022-12-01	WOS:A1995RJ02800062
J	DURING, MJ; RYDER, KM; SPENCER, DD				DURING, MJ; RYDER, KM; SPENCER, DD			HIPPOCAMPAL GABA TRANSPORTER FUNCTION IN TEMPORAL-LOBE EPILEPSY	NATURE			English	Article							GAMMA-AMINOBUTYRIC ACID; EXCITATORY AMINO-ACIDS; PRIMARY CULTURE; RELEASE; NEURONS; RECEPTORS; BRAIN; GLUTAMATE; INVITRO; SEIZURE	ELECTROPHYSIOLOGICAL studies of human temporal-lobe epilepsy suggest that a loss of hippocampal GABA-mediated inhibition may underlie the neuronal hyperexcitability(1-3). However, GABA (gamma-aminobutyric acid)-containing cells are preserved(4) and GABA receptors are maintained in the surviving hippocampal neurons(5). Diminished GABA release may therefore mediate the loss of inhibition. Here we show that, in the human brain, potassium-stimulated release of GABA was increased, and glutamate-induced, calcium-independent release of GABA was markedly decreased, in epileptogenic hippocampi, in contrast with contralateral, non-epileptogenic hippocampi. The glutamate-induced GABA release in vivo was transporter-mediated in rats. Furthermore, in amygdala-kindled rats, a model for human epilepsy, a decease in glutamate-induced GABA release was associated with a 48% decrease in tbe number of GABA transporters. These data suggest that temporal-lobe epilepsy is characterized in part by a loss of glutamate-stimulated GABA release that is secondary to a reduction in the number of GABA transporters.	YALE UNIV,SCH MED,DEPT SURG,ENDOCRINOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University; Yale University	DURING, MJ (corresponding author), YALE UNIV,SCH MED,DEPT SURG,NEUROSURG SECT,MOLEC PHARMACOL & NEUROGENET LAB,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		During, Matthew/AAC-1388-2020					ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; BABB TL, 1989, J NEUROSCI, V9, P2562; BRAESTRUP C, 1990, J NEUROCHEM, V54, P639, DOI 10.1111/j.1471-4159.1990.tb01919.x; DELANEROLLE NC, 1991, DENTATE GYRUS ITS RO, P235; DREJER J, 1987, J NEUROSCI, V7, P2910; During M., 1992, Epilepsia, V33, P83; DURING MJ, 1993, LANCET, V341, P1607; DURING MJ, 1992, BRAIN RES, V584, P36, DOI 10.1016/0006-8993(92)90875-A; GALLO V, 1991, GLIA, V4, P245, DOI 10.1002/glia.440040302; GEDDES JW, 1990, EXP NEUROL, V108, P214, DOI 10.1016/0014-4886(90)90125-C; GONSALVES SF, 1989, EPILEPSY RES, V4, P34, DOI 10.1016/0920-1211(89)90056-9; HARRIS KM, 1989, BRAIN RES, V482, P23, DOI 10.1016/0006-8993(89)90538-6; HORTON RW, 1979, EUR J PHARMACOL, V59, P75, DOI 10.1016/0014-2999(79)90026-8; ISOKAWA M, 1991, EPILEPSY RES, V9, P242, DOI 10.1016/0920-1211(91)90058-N; JOHNSON EW, 1992, NEUROLOGY, V42, P811, DOI 10.1212/WNL.42.4.811; KNOWLES WD, 1992, EPILEPSIA, V33, P601, DOI 10.1111/j.1528-1157.1992.tb02335.x; MANGANO RM, 1983, BRAIN RES BULL, V10, P47, DOI 10.1016/0361-9230(83)90073-4; MCDONALD JW, 1991, ANN NEUROL, V29, P325; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MORRISON PF, 1991, MONITORING MOLECULES IN NEUROSCIENCE, P47; PIN JP, 1989, J NEUROSCI, V9, P648; RADIAN R, 1990, J NEUROSCI, V10, P1319; SIMPSON MD, 1988, NEUROSCI LETT, V107, P211; SZERB JC, 1982, J NEUROCHEM, V39, P850, DOI 10.1111/j.1471-4159.1982.tb07970.x; WILLIAMSON A, 1994, CLIN NEUROSCI, V2, P47; WILLIAMSON A, IN PRESS J NEUROPHYS	26	298	304	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					174	177		10.1038/376174a0	http://dx.doi.org/10.1038/376174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603569				2022-12-01	WOS:A1995RJ02800061
J	FRIEDRICH, M; TAUTZ, D				FRIEDRICH, M; TAUTZ, D			RIBOSOMAL DNA PHYLOGENY OF THE MAJOR EXTANT ARTHROPOD CLASSES AND THE EVOLUTION OF MYRIAPODS	NATURE			English	Article								THE evolutionary relationships among arthropods are of particular interest because the best-studied model system for ontogenetic pattern formation, the insect Drosophila, is a member of this phylum. Evolutionary inferences about the developmental mechanisms that have led to the various designs of the arthropod body plan depend on a knowledge of the phylogenetic framework of arthropod evolution, Based on morphological evidence(1-3), but also on palaeontological considerations(4), the sister group of the insects is believed to be found among the myriapods. Using nuclear ribosomal gene sequences for constructing a molecular phylogeny, we provide strong evidence that the crustaceans and not the myriapods should be considered to be the sister group of the insects. Moreover, the degree of sequence divergence suggests that the diversification of the myriapods occurred during the Cambrian. Our findings have general implications for the course of land colonization by the different arthropod groups, as well as for the interpretation of primitive and derived features of arthropod morphology.			FRIEDRICH, M (corresponding author), UNIV MUNICH,INST ZOOL,LUISENSTR 14,D-80333 MUNICH,GERMANY.		Tautz, Diethard/D-4304-2011; Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				Anderson D. T., 1973, EMBRYOLOGY PHYLOGENY; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; AVEROF M, 1995, PHILOS T R SOC B, V347, P293, DOI 10.1098/rstb.1995.0028; Boudreaux H.B., 1979, P551; Brusca C.R., 1990, INVERTEBRATES; Dohle W, 1980, ABHANDLUNGEN NATURWI, V23, P45; FELSENSTEIN J, 1985, EVOLUTION, V39, P791; FELSENSTEIN J, 1989, PHYLOGENETIC INFEREN; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1994, NATURE, V369, P363, DOI 10.1038/369363a0; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; JERAM AJ, 1990, SCIENCE, V250, P685; Kristensen N.P., 1991, P125; Kukalova-Peck J., 1991, P141; Lauterbach K.-E., 1980, Abhandlungen des Naturwissenschaftlichen Vereins in Hamburg, V23, P105; MANTON SM, 1964, PHILOS T ROY SOC B, V247, P1, DOI 10.1098/rstb.1964.0001; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; Paulus H.F., 1979, P299; ROBISON R, 1987, FOSSIL INVERTEBRATES, P206; ROBISON RA, 1990, NATURE, V343, P163, DOI 10.1038/343163a0; STYS P, 1994, EUR J ENTOMOL, V91, P257; Swofford D, 1993, PHYLOGENETIC ANAL US; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; Weir BS, 1990, GENETIC DATA ANAL; WEYGOLDT P, 1986, Z ZOOL SYST EVOL, V24, P19; Weygoldt P., 1985, P20; WHITINGTON PM, 1993, DEVELOPMENT, V118, P449; WHITINGTON PM, 1991, ROUX ARCH DEV BIOL, V199, P349, DOI 10.1007/BF01705928; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741	30	297	320	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					165	167		10.1038/376165a0	http://dx.doi.org/10.1038/376165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603566				2022-12-01	WOS:A1995RJ02800058
J	JONES, C; PENNY, L; MATTINA, T; YU, S; BAKER, E; VOULLAIRE, L; LANGDON, WY; SUTHERLAND, GR; RICHARDS, RI; TUNNACLIFFE, A				JONES, C; PENNY, L; MATTINA, T; YU, S; BAKER, E; VOULLAIRE, L; LANGDON, WY; SUTHERLAND, GR; RICHARDS, RI; TUNNACLIFFE, A			ASSOCIATION OF A CHROMOSOME DELETION SYNDROME WITH A FRAGILE SITE WITHIN THE PROTOONCOGENE CBL2	NATURE			English	Article							LINKED MENTAL-RETARDATION; SOMATIC-CELL HYBRIDS; X-SYNDROME; MICROSATELLITE INSTABILITY; CGG REPEAT; DNA; REGION; CANCER; FMR-1; 11Q23	The fragile site FRA11B has been localized to the p(CCG)(n) repeat of the CBL2 proto-oncogene. A proportion of Jacobsen (11q(-)) syndrome patients inherited a chromosome carrying a CBL2 p(CCG)(n) expansion, which was truncated close to FRA11B. These results have broad implications for the role of p(CCG)(n) repeat expansion in the aetiology of genetic disease involving chromosome rearrangements.	UNIV CALIF SAN DIEGO,DEPT MED,DIV MED GENET,LA JOLLA,CA 92093; UNIV CATANIA 1,PEDIAT CLIN,CATANIA,ITALY; ADELAIDE WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; ROYAL CHILDRENS HOSP,MURDOCH INST,MELBOURNE,VIC 3052,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA; QUADRANT RES FDN,CAMBRIDGE CB2 2SY,ENGLAND	University of California System; University of California San Diego; University of Catania; Womens & Childrens Hospital Australia; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Western Australia	JONES, C (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Mattina, Teresa/AGB-4604-2022	Tunnacliffe, Alan/0000-0001-8570-125X; Richards, Robert Ian/0000-0002-5978-6453; Mattina, Teresa/0000-0001-6143-6682				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BLAKE TJ, 1991, ONCOGENE, V6, P653; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown W T, 1992, Mol Genet Med, V2, P39; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLYNN GA, 1993, J MED GENET, V30, P97, DOI 10.1136/jmg.30.2.97; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIRAUD F, 1976, HUM GENET, V34, P125, DOI 10.1007/BF00278880; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARVEY J, 1977, J MED GENET, V14, P46, DOI 10.1136/jmg.14.1.46; HUMMERICH H, 1994, HUM MOL GENET, V3, P73, DOI 10.1093/hmg/3.1.73; JACOBSEN P, 1973, HUM HERED, V23, P568, DOI 10.1159/000152624; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Knudson AG, 1973, ADV CANCER RES, V17, P317; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MULLEY JC, 1995, J MED GENET, V32, P162, DOI 10.1136/jmg.32.3.162; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PENNY LA, 1995, AM J HUM GENET, V56, P676; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHINZEL A, 1977, J MED GENET, V14, P438, DOI 10.1136/jmg.14.6.438; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1983, AM J HUM GENET, V35, P432; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOULLAIRE LE, 1987, HUM GENET, V76, P202, DOI 10.1007/BF00284923; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	46	130	131	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					145	149		10.1038/376145a0	http://dx.doi.org/10.1038/376145a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603564				2022-12-01	WOS:A1995RJ02800052
J	LIU, D; BIENKOWSKA, J; PETOSA, C; COLLIER, RJ; FU, H; LIDDINGTON, R				LIU, D; BIENKOWSKA, J; PETOSA, C; COLLIER, RJ; FU, H; LIDDINGTON, R			CRYSTAL-STRUCTURE OF THE ZETA-ISOFORM OF THE 14-3-3 PROTEIN	NATURE			English	Article								THE 14-3-3 family of proteins have recently been identified as regulatory elements in intracellular signalling pathways(1): 14-3-3 proteins bind to oncogene and proto-oncogene products, including c-Raf-1 (refs 2-5), c-Bcr (ref. 6) and polyomavirus middle-T antigen(7); overexpression of 14-3-3 activates Raf kinase in yeast(2,3) and induces meiotic maturation in Xenopus oocytes(5). Here we report the crystal structure of the major isoform of mammalian 14-3-3 proteins at 2.9 Angstrom resolution. Each subunit of the dimeric protein consists of a bundle of nine antiparallel helices that form a palisade around an amphipathic groove. The groove is large enough to accommodate a tenth helix, and we propose that binding to an amphipathic helix represents a general mechanism for the interaction of 14-3-3 with diverse cellular proteins. The residues in the dimer interface and the putative ligand-binding surface are invariant among vertebrates, yeast and plants, suggesting a conservation of structure and function throughout the 14-3-3 family.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Emory University	LIU, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.			Collier, R John/0000-0002-2427-4239; Petosa, Carlo/0000-0002-9975-1167				ADAM R, 1994, J BIOCHEM-TOKYO, V116, P416; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	21	430	449	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					191	194		10.1038/376191a0	http://dx.doi.org/10.1038/376191a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603574				2022-12-01	WOS:A1995RJ02800066
J	MACALLAN, DC; NOBLE, C; BALDWIN, C; JEBB, SA; PRENTICE, AM; COWARD, WA; SAWYER, MB; MCMANUS, TJ; GRIFFIN, GE				MACALLAN, DC; NOBLE, C; BALDWIN, C; JEBB, SA; PRENTICE, AM; COWARD, WA; SAWYER, MB; MCMANUS, TJ; GRIFFIN, GE			ENERGY-EXPENDITURE AND WASTING IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-COMPOSITION; WEIGHT CHANGE; MEN	Background. Increased expenditure of energy at rest has been considered a contributing factor to the negative energy balance and weight loss that occur in patients with human immunodeficiency virus (HIV) infection. However, the true determinant of energy balance is not resting but total energy expenditure. We sought to determine the contribution of total energy expenditure to weight changes in patients with HIV-associated wasting. Methods. We performed 51 assessments of energy metabolism in 27 men with HIV infection at different stages of disease, including periods of both rapid and slow weight loss. Resting energy expenditure was measured by indirect calorimetry, total energy expenditure by the doubly-labeled-water technique, and energy intake by recording the weight of food consumed. The results were compared with the rate of weight loss or gain. Results. The mean (+/-SD) total energy expended by the HIV-infected men was 2750+/-670 kcal per day, no more than that expended by normal men. There was a significant positive relation between total energy expenditure and the rate of weight change (r=0.61, P<0.001); thus, during rapid weight loss, total energy expenditure was reduced to 2180+/-580 kcal per day (P = 0.009), primarily because of reduced physical activity. During rapid weight loss, the negative energy balance (-8501+/-580 kcal per day) was primarily the result of the reduction in energy intake, to 1330+/-610 kcal per day; intake correlated strongly with the rate of weight change (r=0.84, P<0.001). Conclusions. In patients with HIV infection, total energy expenditure is reduced during episodes of weight loss. Reduced energy intake, not elevated energy expenditure, is the prime determinant of weight loss in HIV-associated wasting.	KINGS HEALTHCARE,DEPT GENITOURINARY MED,LONDON,ENGLAND; DUNN CLIN NUTR CTR,CAMBRIDGE,ENGLAND		MACALLAN, DC (corresponding author), ST GEORGE HOSP,SCH MED,DIV INFECT DIS,LONDON SW17 0RE,ENGLAND.		Prentice, Andrew/AAG-1961-2019	Macallan, Derek/0000-0002-3014-7148; Jebb, Susan/0000-0001-9190-2920				BLACK AE, IN PRESS EUR J CLIN; COLE TJ, 1992, AM J PHYSIOL, V263, pE965, DOI 10.1152/ajpendo.1992.263.5.E965; Coward W, 1991, NEW TECHNIQUES NUTR, P139; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; FOSKETT M, 1991, J HUM NUTR DIET, V4, P149, DOI 10.1111/j.1365-277X.1991.tb00092.x; GORAN MI, 1993, METABOLISM, V42, P487, DOI 10.1016/0026-0495(93)90108-Z; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GRUNFELD C, 1992, AM J CLIN NUTR, V55, P455, DOI 10.1093/ajcn/55.2.455; HOMMES MJT, 1991, METABOLISM, V40, P651, DOI 10.1016/0026-0495(91)90059-6; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; MACALLAN DC, 1995, AM J CLIN NUTR, V61, P818, DOI 10.1093/ajcn/61.4.818; MACALLAN DC, 1993, AM J CLIN NUTR, V58, P417, DOI 10.1093/ajcn/58.3.417; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Prentice A.M., 1991, NEW TECHNIQUES NUTR, P177; RAVUSSIN E, 1989, AM J CLIN NUTR, V49, P968, DOI 10.1093/ajcn/49.5.968; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; STEIN TP, 1990, METABOLISM, V39, P876, DOI 10.1016/0026-0495(90)90136-Z; SUTTMANN U, 1994, CLIN SCI, V86, P461; 1987, MMWR CDC SURVEILL S3, V36, pS3; 1990, DOUBLY LABELLED WATE	22	294	297	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					83	88		10.1056/NEJM199507133330202	http://dx.doi.org/10.1056/NEJM199507133330202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777033	Bronze			2022-12-01	WOS:A1995RH22500002
J	MITCHELL, AA; VANBENNEKOM, CM; LOUIK, C				MITCHELL, AA; VANBENNEKOM, CM; LOUIK, C			A PREGNANCY-PREVENTION PROGRAM IN WOMEN OF CHILDBEARING AGE RECEIVING ISOTRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THALIDOMIDE	Background. Isotretinoin is effective in treating severe acne, but it is also teratogenic. To minimize pregnancies among exposed women, the manufacturer, together with the U.S. Food and Drug Administration, implemented a multicomponent Pregnancy Prevention Program in 1988. We report the results of an ongoing survey designed to assess compliance with this program. Methods. Treated women enrolled in the survey through their physician, by filling out a form in the medication package, or by calling a toll-free telephone number. They were randomly assigned to be followed by telephone or by mail. Telephone interviews were conducted at the start of therapy, in the middle of it, and 6 months after it ended; mailed questionnaires were completed 6 months after therapy ended (median duration of therapy, 20 weeks). Results. Between 1989 and 1993, 177,216 eligible women enrolled in the survey. Interviews with 24,503 women within one month of enrollment revealed that 99 percent had been told to avoid pregnancy. At that time, approximately 54 percent were not sexually active (of whom 37 percent used contraception) and 42 percent were sexually active (of whom 99 percent used contraception); 4 percent were infertile. Among 124,216 women with completed telephone or mail follow-up results, there were 402 pregnancies during therapy (3.4 per 1000 courses of isotretinoin); 72 percent of the pregnant women had elective abortions, 16 percent spontaneous abortions, 3 percent ectopic pregnancies, and 8 percent live births. Conclusions. The pregnancy rate among women receiving isotretinoin therapy was substantially lower than that in the general population and was compatible with the characteristics and behavior of the enrolled women.			MITCHELL, AA (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Louik, Carol/0000-0001-5429-5084; Mitchell, Allen/0000-0003-0950-6799				DAI WS, 1992, J AM ACAD DERMATOL, V26, P599, DOI 10.1016/0190-9622(92)70088-W; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; GORMAN C, 1994, TIME            0613, P67; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P287; LAMMER EJ, 1985, NEW ENGL J MED, V343, P837; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; MOSHER WD, 1990, DHHS PHS901250 PUBL; SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408; STERN RS, 1989, NEW ENGL J MED, V320, P1007, DOI 10.1056/NEJM198904133201510; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; UNDERWOOD AA, 1994, NEWSWEEK        0919, P58; VENTURA SJ, 1992, MON VITAL STAT REP S, V41; WEINBLATT ME, 1995, NEW ENGL J MED, V332, P330, DOI 10.1056/NEJM199502023320512	14	132	141	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					101	106		10.1056/NEJM199507133330206	http://dx.doi.org/10.1056/NEJM199507133330206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777014	Bronze			2022-12-01	WOS:A1995RH22500006
J	PARTANEN, J; NISKANEN, L; LEHTINEN, J; MERVAALA, E; SIITONEN, O; UUSITUPA, M				PARTANEN, J; NISKANEN, L; LEHTINEN, J; MERVAALA, E; SIITONEN, O; UUSITUPA, M			NATURAL-HISTORY OF PERIPHERAL NEUROPATHY IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEWLY DIAGNOSED NIDDM; 5-YEAR FOLLOW-UP; NONDIABETIC SUBJECTS; PREVALENCE	Background. There is little information on the incidence and natural history of neuropathy in patients with non-insulin-dependent diabetes mellitus (NIDDM). Methods. We studied patients with newly diagnosed NIDDM and control subjects both at base line and 5 and 10 years later. Polyneuropathy was diagnosed on the basis of clinical criteria (pain and paresthesias) and electrodiagnostic studies (nerve conduction velocity and response-amplitude values). We investigated the relation between metabolic variables (results of oral glucose-tolerance tests, serum lipid and insulin concentrations, and glycosylated hemoglobin values) and the development of polyneuropathy. Results. In 10 years, 36 patients with NIDDM and 8 control subjects died; 86 patients and 121 control subjects completed the study. When the study ended, 18 percent of the patients were being treated only with diet, 59 percent with oral hypoglycemic drugs alone, 12 percent with insulin alone, and 11 percent with both insulin and oral hypoglycemic agents. At base line the prevalence of definite or probable polyneuropathy among the patients with NIDDM was 8.3 percent, as compared with 2.1 percent among the control subjects. These values 10 years later were 41.9 percent and 5.8 percent, respectively. The number of patients with NIDDM who had nerve-conduction abnormalities in the legs and feet increased from 8.3 percent at base line to 16.7 percent after 5 years and to 41.9 percent after 10 years. The decrease in sensory and motor amplitudes, indicating axonal destruction, was more pronounced than the slowing of the nerve conduction velocities, which indicates demyelination. Among the patients with NIDDM, those with polyneuropathy had poorer glycemic control than those without. Low serum insulin concentrations before and after the oral administration of glucose were associated with the development of polyneuropathy, regardless of the degree of glycemia. Conclusions. The prevalence of polyneuropathy among patients with NIDDM increases with time, and the increase may be greater in patients with hypoinsulinemia.	KUOPIO UNIV HOSP, DEPT CLIN NUTR, SF-70211 KUOPIO, FINLAND; KUOPIO UNIV HOSP, DEPT INTERNAL MED, SF-70211 KUOPIO, FINLAND; KUOPIO UNIV, KUOPIO, FINLAND	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	PARTANEN, J (corresponding author), KUOPIO UNIV HOSP, DEPT CLIN NEUROPHYSIOL, POB 1777, SF-70211 KUOPIO, FINLAND.		Uusitupa, Matti Ilmari Julius/AAX-4929-2020					CAMERON NE, 1994, DIABETES METAB REV, V10, P189, DOI 10.1002/dmr.5610100302; DYCK PJ, 1986, ANN NEUROL, V19, P440, DOI 10.1002/ana.410190504; HARATI Y, 1992, NEUROL CLIN, V10, P783, DOI 10.1016/S0733-8619(18)30208-1; LANG AH, 1977, J NEUROL SCI, V33, P229, DOI 10.1016/0022-510X(77)90196-4; LEHTINEN J, 1987, THEIS U KUOPIO KUOPI; LEHTINEN JM, 1989, DIABETES, V38, P1307, DOI 10.2337/diabetes.38.10.1307; LEHTINEN JM, 1993, DIABETOLOGIA, V36, P68, DOI 10.1007/BF00399096; LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867; Mincu I, 1980, Med Interne, V18, P155; NISKANEN L, 1994, J INTERN MED, V236, P263, DOI 10.1111/j.1365-2796.1994.tb00794.x; NISKANEN LK, 1990, DIABETES CARE, V13, P41, DOI 10.2337/diacare.13.1.41; PENTTILA IM, 1981, SCAND J CLIN LAB INV, V41, P353, DOI 10.3109/00365518109092057; Pirart J., 1978, DIABETES CARE, V1, P168, DOI DOI 10.2337/DIACARE.1.3.168; RATZMANN K P, 1991, Journal of Diabetic Complications, V5, P1, DOI 10.1016/0891-6632(91)90002-7; SCARPINI E, 1993, J NEUROL SCI, V120, P159, DOI 10.1016/0022-510X(93)90268-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; UUSITUPA M, 1985, DIABETOLOGIA, V28, P22, DOI 10.1007/BF00276995; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WAHREN J, 1994, DIABETOLOGIA, V37, pS99, DOI 10.1007/BF00400832; 1980, WHO TECH REP SER, V646, P7	20	429	456	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					89	94		10.1056/NEJM199507133330203	http://dx.doi.org/10.1056/NEJM199507133330203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777034	Bronze			2022-12-01	WOS:A1995RH22500003
J	RATHMELL, JC; COOKE, MP; HO, WY; GREIN, J; TOWNSEND, SE; DAVIS, MM; GOODNOW, CC				RATHMELL, JC; COOKE, MP; HO, WY; GREIN, J; TOWNSEND, SE; DAVIS, MM; GOODNOW, CC			CD95 (FAS) DEPENDENT ELIMINATION OF SELF-REACTIVE B-CELLS UPON INTERACTION WITH CD4(+) T-CELLS	NATURE			English	Article							LYMPHOCYTES-B; LPR/LPR MICE; SYSTEMIC AUTOIMMUNITY; LPR; APOPTOSIS; ANTIGEN; DEFECT; MOUSE; INDUCTION; TOLERANCE	THE recessive mouse mutations lpr and gld create deficiencies in an interacting pair of cell surface molecules, CD95 (Fas/APO-1) and Fas-ligand (FasL), respectively(1-3), resulting in autoantibody production resembling human systemic lupus erythematosus(4). The mechanisms of self-tolerance affected by deficiency in either molecule are not established, but CD95 deficiency both in B cells and in CD4(+) T cells recognizing major histocompatibility complex (MHC) class II molecules is required for autoimmunity in lpr mice(5-8). Here we track the outcome of in vivo interactions between B cells and CD4(+) T cells that recognize a transgene-encoded autoantigen, hen egg lysozyme (HEL), using cells from mice transgenic for immunoglobulin and T-cell receptor (TCR) genes. B cells that had not previously encountered HEL autoantigen (naive cells) were triggered into proliferation and antibody-production upon interaction with antigen and HEL-specific CD4(+) T cells. By contrast, B cells that had been chronically exposed to HEL during their development and carried desensitized surface immunoglobulin (sIg) antigen receptors(9) (anergic cells) did not produce antibody but instead were eliminated in the presence of HEL-specific CD4(+) T cells. CD95-deficient anergic B cells, however, were not eliminated by CD4(+) T cells and were triggered to proliferate. These findings identify a novel regulatory step for eliminating autoreactive B cells that seems unique in its dependence on CD95.	STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University; Stanford University	RATHMELL, JC (corresponding author), STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Davis, Mark/0000-0001-6868-657X				BOSSU P, 1993, J IMMUNOL, V151, P7233; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V4, P1181; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KANOST D, 1994, EUR J IMMUNOL, V24, P1186, DOI 10.1002/eji.1830240527; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEMAZEE D, 1991, J IMMUNOL, V147, P2536; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; SOBEL ES, 1993, J IMMUNOL, V150, P4160; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTON KM, 1988, J IMMUNOL, V141, P1941; ZHOU T, 1991, J IMMUNOL, V147, P466; ZHOU T, 1992, J EXP MED, V176, P1063, DOI 10.1084/jem.176.4.1063	29	411	415	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					181	184		10.1038/376181a0	http://dx.doi.org/10.1038/376181a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603571				2022-12-01	WOS:A1995RJ02800063
J	YOKOYAMA, N; HAYASHI, N; SEKI, T; PANTE, N; OHBA, T; NISHII, K; KUMA, K; HAYASHIDA, T; MIYATA, T; AEBI, U; FUKUI, M; NISHIMOTO, T				YOKOYAMA, N; HAYASHI, N; SEKI, T; PANTE, N; OHBA, T; NISHII, K; KUMA, K; HAYASHIDA, T; MIYATA, T; AEBI, U; FUKUI, M; NISHIMOTO, T			A GIANT NUCLEOPORE PROTEIN THAT BINDS RAN/TC4	NATURE			English	Article							NUCLEAR-PORE COMPLEX; CELL-CYCLE; CHROMOSOME CONDENSATION; MESSENGER-RNA; RCC1; IMPORT; GENES; DNA	RAN/TC4 is a small nuclear G protein(1) that forms a complex with the chromatin-bound guanine nucleotide release factor RCC1 (ref. 2). Loss of RCC1 causes defects in cell-cycle progression(3,4), RNA export(5-7) and nuclear protein import(8). Some of these can be suppressed by overexpression of Ran/TC4 (ref. 1), suggesting that Ran/TC4 functions downstream of RCC1. We have searched for proteins that bind Ran/TC4 by using a two-hybrid screen, and here we report the identification of RanBP2, a novel protein of 3,224 residues. This giant protein comprises an amino-terminal 700-residue leucine-rich region, four RanBP1-homologous (refs 9, 10) domains, eight zinc-finger motifs similar to those of NUP153 (refs 11, 12), and a carboxy terminus with high homology to cyclophilin(13). The molecule contains the XFXFG pentapeptide motif characteristic of nuclear pore complex (NPC) proteins(14), and immunolocalization suggests that RanBP2 is a constituent of the NPC. The fact that NLS-mediated nuclear import can be inhibited by an antibody directed against RanBP2 supports a functional role in protein import through the NPC.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT NEUROSURG,HIGASHI KU,FUKUOKA 81282,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT ANAT,HIGASHI KU,FUKUOKA 81282,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN; UNIV BASEL,BIOZENTRUM,ME MULLER INST MICROSCOPY,CH-4056 BASEL,SWITZERLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Kyushu University; Kyushu University; Kyoto University; University of Basel; Johns Hopkins University	YOKOYAMA, N (corresponding author), KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,MAIDASHI 3-1-1,FUKUOKA 81282,JAPAN.		Oba, Tomoyuki/ABT-2152-2022; Pante, Nelly/GVR-8478-2022	Oba, Tomoyuki/0000-0002-6715-7892; Hayashi, Naoyuki/0000-0001-9626-3689				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GERACE L, 1984, J CELL SCI S, V1, P137; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, IN PRESS MOL GEN GEN; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MCMORROW I, 1994, BBA-GENE STRUCT EXPR, V1217, P219, DOI 10.1016/0167-4781(94)90040-X; MELCHIOR F, 1993, J CELL BIOL 2, V123, P1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; PANTE N, 1994, J STRUCT BIOL, V113, P179, DOI 10.1006/jsbi.1994.1052; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1994, J BIOL CHEM, V269, P17600; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687	32	425	431	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 13	1995	376	6536					184	188		10.1038/376184a0	http://dx.doi.org/10.1038/376184a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ028	7603572				2022-12-01	WOS:A1995RJ02800064
J	GOLDIE, AS; FEARON, KCH; ROSS, JA; BARCLAY, GR; JACKSON, RE; GRANT, IS; RAMSAY, G; BLYTH, AS; HOWIE, JC				GOLDIE, AS; FEARON, KCH; ROSS, JA; BARCLAY, GR; JACKSON, RE; GRANT, IS; RAMSAY, G; BLYTH, AS; HOWIE, JC			NATURAL CYTOKINE ANTAGONISTS AND ENDOGENOUS ANTIENDOTOXIN CORE ANTIBODIES IN SEPSIS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-NECROSIS-FACTOR; CONTROLLED CLINICAL-TRIAL; NEGATIVE SEPTIC SHOCK; ORGAN FAILURE; FACTOR TNF; ENDOTOXIN; RECEPTORS; SERUM; INTERLEUKIN-6; SURVIVAL	Objective.-To assess the value of measuring circulating concentrations of mediators (endotoxin, tumor necrosis factor-alpha [TNF-alpha], interleukin-1 beta [IL-1 beta], and interleukin-6 [IL-6]) and their endogenous antagonists (antiendotoxin core antibody [EndoCAb], interleukin-1 receptor antagonist [lL-1ra], and soluble TNF receptors [sTNF-R]) in predicting mortality and organ failure in sepsis syndrome. Design.-Cohort study with a follow-up period of 30 days. Setting.-Intensive therapy units of five tertiary referral centers in Scotland. Subjects.-A total of 146 intensive therapy unit patients with sepsis syndrome underwent repeated sampling during a 10-day period following admission to an intensive therapy unit. Main Outcome Measures.-Circulating concentrations of mediators and antagonists were compared in survivors and nonsurvivors. Results.-Median Acute Physiology and Chronic Health Evaluation II score was 23 (range, 8 to 40). Mortality at 30 days was 49%. On entry to the study, circulating endotoxin was detected in 66% of patients, TNF-alpha in 14%, and IL-1 beta in 29%. Levels did not predict mortality or organ failure. Patients with IL-6 concentrations in excess of 3000 pg/mL had an increased mortality rate (64% vs 40%, P=.02). The incidence of IgG EndoCAb depletion on entry to the study was 26% in nonsurvivors and 10% in survivors (P=.02). Initial concentrations of both type I and type II sTNF-R were significantly higher in nonsurvivors (P<.01). Initial circulating IL-1ra concentrations were not of value in predicting mortality, Cytokine antagonists were present in concentrations 30- to 100 000-fold greater than their corresponding cytokine. Conclusion.-The observed high circulating levels of the cytokine antagonists IL-1ra and sTNF-R and the relatively small proportion of patients developing EndoCAb depletion may contribute to the limitations of therapies that aim to augment natural defenses against endotoxin or the proinflammatory cytokines.	UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; SCOTTISH NATL BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, INTENS THERAPY UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP, DEPT ANAESTHET, GLASGOW, LANARK, SCOTLAND; VICTORIA INFIRM, DEPT ANAESTHET, GLASGOW G42 9TY, LANARK, SCOTLAND; ACAD ZEIKENHUIS, MAASTRICHT, NETHERLANDS	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Maastricht University; Maastricht University Medical Centre (MUMC)								BARCLAY GR, 1989, CIRC SHOCK, V29, P93; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CERRA FB, 1987, SURGERY, V101, P1; COYLE SM, 1993, CLIN NUTR S2, V12, P29; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DEGROOTE MA, 1989, JAMA-J AM MED ASSOC, V262, P249, DOI 10.1001/jama.262.2.249; DHAINAUT JF, 1993, AUG INT C END AMST; DING AH, 1989, J BIOL CHEM, V264, P3924; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FROON AHM, IN PRESS CRIT CARE M; GILBERT ROBERT P., 1960, PHYSIOL REVS, V40, P245; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HACK CE, 1989, BLOOD, V74, P1704; HURLEY JC, 1992, CLIN INFECT DIS, V15, P840, DOI 10.1093/clind/15.5.840; ISPAHANI P, 1987, Q J MED, V63, P427; KISHIMOTO T, 1993, 8TH P INT C IMM BUD, P887; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MOHLER KM, 1993, J IMMUNOL, V151, P1548; NYS M, 1993, ANN SURG, V217, P300, DOI 10.1097/00000658-199303000-00013; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; POLLACK M, 1983, J CLIN INVEST, V72, P1874, DOI 10.1172/JCI111150; SCHEDEL I, 1991, CRIT CARE MED, V19, P1104, DOI 10.1097/00003246-199109000-00003; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; WAAGE A, 1987, LANCET, V1, P355; WHICHER JT, 1978, ANN CLIN BIOCHEM, V15, P77, DOI 10.1177/000456327801500117; WORTEL CH, 1992, J INFECT DIS, V166, P1367, DOI 10.1093/infdis/166.6.1367; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	37	224	229	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					172	177		10.1001/jama.274.2.172	http://dx.doi.org/10.1001/jama.274.2.172			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596007				2022-12-01	WOS:A1995RH22200032
J	HUNINK, MGM; WONG, JB; DONALDSON, MC; MEYEROVITZ, MF; DEVRIES, J; HARRINGTON, DP				HUNINK, MGM; WONG, JB; DONALDSON, MC; MEYEROVITZ, MF; DEVRIES, J; HARRINGTON, DP			REVASCULARIZATION FOR FEMOROPOPLITEAL DISEASE - A DECISION AND COST-EFFECTIVENESS ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-LUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR-DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; LOWER-EXTREMITY ISCHEMIA; LOWER-LIMB ISCHEMIA; SAPHENOUS-VEIN; POLYTETRAFLUOROETHYLENE GRAFTS; BALLOON ANGIOPLASTY; INTERMITTENT CLAUDICATION; ARTERIAL RECONSTRUCTIONS	Objective.-To evaluate the relative benefits and cost-effectiveness of revascularization for femoropopliteal disease using percutaneous transluminal angioplasty or bypass surgery. Design.-Decision analysis using a multistate transition simulation model (Markov process) and cost-effectiveness analysis from the perspective of the health care system. Setting.-Based on mortality, morbidity, patency, and cost data from a literature review. Patients.-Hypothetical cohort of patients with chronic femoropopliteal disease who desire revascularization. Subgroup analysis for patients defined by age, sex, indication, lesion type, and graft type. Interventions.-Percutaneous transluminal angioplasty, bypass surgery, and a strategies combining the two treatments. Main Outcome Measures.-Five-year patency results, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios. Results.-For 65-year-old men with disabling claudication and a femoropoptiteal stenosis or occlusion and for 65-year-old men with chronic critical ischemia and a femoropopliteal stenosis, initial angioplasty increased quality-adjusted life expectancy by 2 to 13 months and resulted in decreased lifetime expenditures compared with bypass surgery. For patients with chronic critical ischemia and a femoropopliteal occlusion, initial bypass surgery increased quality-adjusted life expectancy by 1 to 4 months and resulted in decreased lifetime expenditures compared with angioplasty. Sensitivity analysis demonstrated that angioplasty would always be the preferred initial treatment if the angioplasty 5-year patency rate exceeds 30%. Conclusion.-Angioplasty is the preferred initial treatment in patients with disabling claudication and a femoropopliteal stenosis or occlusion and in those with chronic critical ischemia and a stenosis. Bypass surgery is the preferred initial treatment in patients with chronic critical ischemia and a femoropopliteal occlusion.	UNIV GRONINGEN HOSP, OFF MED TECHNOL ASSESSMENT, GRONINGEN, NETHERLANDS; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV VASC SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RADIOL, BOSTON, MA 02115 USA; SUNY STONY BROOK, DEPT RADIOL, STONY BROOK, NY 11794 USA	University of Groningen; Harvard University; Harvard T.H. Chan School of Public Health; Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	HUNINK, MGM (corresponding author), UNIV GRONINGEN, FAC MED, DEPT HLTH SCI, ANT DEUSINGLAAN 1, 9713 AV GRONINGEN, NETHERLANDS.			Wong, John/0000-0003-4203-9010	AHRQ HHS [HS-06665, HS-06503] Funding Source: Medline; NLM NIH HHS [LM04493] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BECKER GJ, 1989, RADIOLOGY, V170, P921, DOI 10.1148/radiology.170.3.2521745; BELLI AM, 1990, CLIN RADIOL, V41, P380, DOI 10.1016/S0009-9260(05)80595-1; BERGAMINI TM, 1991, J VASC SURG, V13, P137, DOI 10.1016/0741-5214(91)90021-L; CALLOW AD, 1988, INT SURG, V73, P237; CAPEK P, 1991, CIRCULATION, V83, P70; CHESHIRE NJW, 1992, J VASC SURG, V15, P167, DOI 10.1016/0741-5214(92)70025-G; COFFMAN JD, 1991, NEW ENGL J MED, V325, P577, DOI 10.1056/NEJM199108223250810; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; Donaldson M C, 1991, Adv Surg, V24, P69; DONALDSON MC, 1991, ANN SURG, V213, P457, DOI 10.1097/00000658-199105000-00011; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; DRUMMOND MF, 1987, METHODS EX EVALUATIO; Fowkes F G, 1988, Eur J Vasc Surg, V2, P283, DOI 10.1016/S0950-821X(88)80002-1; GILLUM RF, 1990, AM HEART J, V120, P1414, DOI 10.1016/0002-8703(90)90257-X; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; Gupta S K, 1988, Eur J Vasc Surg, V2, P151, DOI 10.1016/S0950-821X(88)80067-7; GUPTA SK, 1990, J VASC SURG, V11, P348, DOI 10.1067/mva.1990.16967; GUPTA SK, 1991, J VASC SURG, V13, P162; HASSON JE, 1990, SURGERY, V108, P748; HENRIKSEN LO, 1988, ACTA CHIR SCAND, V154, P573; HOBSON RW, 1985, J VASC SURG, V2, P174, DOI 10.1067/mva.1985.avs0020174; Holm J, 1991, Eur J Vasc Surg, V5, P517, DOI 10.1016/S0950-821X(05)80338-X; HOWELL MA, 1989, J VASC SURG, V9, P691, DOI 10.1067/mva.1989.vs0090691; HUNINK MGM, 1994, J VASC SURG, V19, P632, DOI 10.1016/S0741-5214(94)70036-2; HUNINK MGM, 1994, MED DECIS MAKING, V14, P71, DOI 10.1177/0272989X9401400109; HUNINK MGM, 1994, MED DECIS MAKING, V14, P59, DOI 10.1177/0272989X9401400108; HUNINK MGM, 1993, J VASC SURG, V17, P183; JEANS WD, 1990, RADIOLOGY, V177, P559, DOI 10.1148/radiology.177.2.2145608; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; JOHNSTON KW, 1992, RADIOLOGY, V183, P767, DOI 10.1148/radiology.183.3.1294068; JONES BA, 1985, CAN J SURG, V28, P150; JORGENSEN B, 1988, ACTA CHIR SCAND, V154, P647; KENT KC, 1988, ARCH SURG-CHICAGO, V123, P1196; KINNISON ML, 1985, AM J ROENTGENOL, V145, P1241, DOI 10.2214/ajr.145.6.1241; KRAM HB, 1991, J VASC SURG, V14, P386, DOI 10.1016/0741-5214(91)90092-9; LEATHER RP, 1988, ANN SURG, V208, P435, DOI 10.1097/00000658-198810000-00005; MACKEY WC, 1986, SURGERY, V99, P26; MARTIN EC, 1991, CIRCULATION, V83, P1; McDaniel M D, 1989, Ann Vasc Surg, V3, P273, DOI 10.1016/S0890-5096(07)60040-5; MILFORD MA, 1988, J VASC SURG, V8, P292, DOI 10.1067/mva.1988.avs0080292; MILLER N, 1991, J VASC SURG, V13, P705, DOI 10.1016/0741-5214(91)90357-Z; MORSE MH, 1991, BRIT J RADIOL, V64, P5, DOI 10.1259/0007-1285-64-757-5; PENTECOST MJ, 1994, CIRCULATION, V89, P511, DOI 10.1161/01.CIR.89.1.511; PLECHA FR, 1985, J VASC SURG, V2, P769, DOI 10.1067/mva.1985.avs0020769; QUINONESBALDRICH WJ, 1988, J VASC SURG, V8, P219, DOI 10.1067/mva.1988.avs0080219; RAVIOLA CA, 1988, ARCH SURG-CHICAGO, V123, P495; RUTHERFORD RB, 1991, RADIOLOGY, V181, P277, DOI 10.1148/radiology.181.1.1887047; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P170; TAYLOR LM, 1990, J VASC SURG, V11, P193, DOI 10.1067/mva.1990.17235; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VEITH FJ, 1986, J VASC SURG, V3, P104; WALDEN R, 1986, J VASC SURG, V3, P583, DOI 10.1067/mva.1986.avs0030583; WEIBULL H, 1987, J VASC SURG, V5, P681, DOI 10.1067/mva.1987.avs0050681; Weinstein MC, 1980, CLIN DECISION ANAL; WEISS GN, 1990, J AM GERIATR SOC, V38, P877, DOI 10.1111/j.1532-5415.1990.tb05703.x; WHITTEMORE AD, 1989, J VASC SURG, V10, P299, DOI 10.1067/mva.1989.14116; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; Wolf G L, 1993, J Vasc Interv Radiol, V4, P639, DOI 10.1016/S1051-0443(93)71939-9; WOLF GL, 1984, SEMIN INTERVENT RAD, V1, P237; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; 1991, VITAL STATISTICS U A, V2; 1992, VITAL HLTH STAT 13, V113	65	190	200	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					165	171		10.1001/jama.274.2.165	http://dx.doi.org/10.1001/jama.274.2.165			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596006				2022-12-01	WOS:A1995RH22200031
J	STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA				STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA			COMBINED ESTROGEN AND PROGESTIN HORMONE REPLACEMENT THERAPY IN RELATION TO RISK OF BREAST-CANCER IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; SURVEILLANCE; PREVENTION; MODELS	Objective.-To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT). Design.-A population-based case-control study. Setting.-The general female population of King County in western Washington State. Participants.-Middle-aged (50 to 64 years) women, including 537 patients with incident primary breast cancer diagnosed between January 1, 1988, and June 30, 1990, who were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry and 492 randomly selected control women without a history of breast cancer. Main Outcome Measure,-Breast cancer risk in relation to use of menopausal hormones. Results.-Menopausal hormones of some type had been used by 57.6% of breast cancer cases and 61.0% of comparison women. The women who had ever taken combined estrogen-progestin HRT, representing 21.5% of cases and 21.3% of controls, were not at increased risk of breast cancer (relative odds [RO]=0.9; 95% confidence interval [CI], 0.7 to 1.3). Compared with nonusers of menopausal hormones, those who used estrogen-progestin HRT for 8 or more years had, if anything, a reduced risk of breast cancer (RO=0.4; 95% CI, 0.2 to 1.0). Conclusions.-On the whole, the use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women. Nonetheless, since the use of combined estrogen-progestin HRT has only recently become prevalent, future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin HRT has been initiated, particularly among long-term users.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	STANFORD, JL (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1124 COLUMBIA ST,MP-474,SEATTLE,WA 98104, USA.			Habel, Laurel/0000-0002-7230-587X	NCI NIH HHS [R35-CA39779, N01-CN-05230, K07-CA01364] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K07CA001364, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1990, NEW ENGL J MED, V322, P204; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; Breslow NE, 1980, ANAL CASE CONTROL ST; Breslow NE Day NE, 1987, DESIGN ANAL COHORT S; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER WB, 1990, NEW ENGL J MED, V322, P202; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1986, MATURITAS, V8, P169, DOI 10.1016/0378-5122(86)90023-X; GENALO MA, 1988, P SECTION SURVEY RES; GINSBURG KA, 1988, FERTIL STERIL, V49, pS16; GOING JJ, 1988, AM J PATHOL, V130, P193; HARLOW BL, 1988, AM J EPIDEMIOL, V127, P857, DOI 10.1093/oxfordjournals.aje.a114869; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JORDAN VC, 1993, CANCER, V71, P1501, DOI 10.1002/cncr.2820710415; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.1093/biomet/65.1.153; RISCH HA, 1994, AM J EPIDEMIOL, V139, P670, DOI 10.1093/oxfordjournals.aje.a117057; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SEBOLD J, 1988, TELEPHONE SURVEY MET; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	35	310	314	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					137	142		10.1001/jama.274.2.137	http://dx.doi.org/10.1001/jama.274.2.137			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596001				2022-12-01	WOS:A1995RH22200026
J	WANNAMETHEE, SG; SHAPER, AG; WHINCUP, PH; WALKER, M				WANNAMETHEE, SG; SHAPER, AG; WHINCUP, PH; WALKER, M			SMOKING CESSATION AND THE RISK OF STROKE IN MIDDLE-AGED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISCHEMIC-HEART-DISEASE; CIGARETTE-SMOKING; BRITISH MEN; WOMEN; INFARCTION; SMOKERS	Objective.-To examine the effects of giving up smoking, years since quitting smoking and the quantity of cigarettes smoked, and primary pipe or cigar smoking on the risk of stroke. Design, Subjects, and Setting.-A prospective study of cardiovascular disease and its risk factors in 7735 men aged 40 through 59 years drawn at random from the age-sex registers of one general practice in each of 24 British towns from 1978 through 1980 (the British Regional Heart Study). Main Outcome Measure.-Incidence of fatal and nonfatal major stroke events (strokes) during an average follow-up period of 12.75 years. Results.-During the 12.75 years of follow-up, there were 167 major stroke events (43 fatal and 124 nonfatal) in the 7264 men with no recall of previous ischemic heart disease or stroke. After full adjustment for other risk factors, current smokers had a nearly fourfold relative risk (RR) of stroke compared with never smokers (RR, 3.7; 95% confidence interval [CI], 2.0 to 6.9). Ex-cigarette smokers showed lower risk than current smokers but showed excess risk compared with never smokers (RR, 1.7, 95% CI, 0.9 to 3.3; P=.11); those who switched to pipe or cigar smoking showed a significantly increased risk (RR, 3.3; 95% CI, 1.6 to 7.1) similar to that of current light smokers. Primary pipe or cigar smokers also showed increased risk (RR, 2.2; 95% CI, 0.6 to 8.0), but the number of subjects involved was small. The benefit of giving up smoking completely was seen within 5 years of quitting, with no further consistent decline in risk thereafter, but this was dependent on the amount of tobacco smoked. Light smokers (<20 cigarettes/d) reverted to the risk level of those who had never smoked. Heavy smokers retained a more than twofold risk compared with never smokers (RR, 2.2; 95% CI, 1.1 to 4.3). The age-adjusted RR of stroke in those who quit smoking during the first 5 years of follow-up (recent quitters) was reduced compared with continuing smokers (RR, 1.8; 95% CI, 0.7 to 4.6 vs RR, 4.3; 95% CI, 2.1 to 8.8). The benefit of quitting smoking was observed in both normotensive and hypertensive men, but the absolute benefit was greater in hypertensive subjects. Conclusion.-Smoking cessation is associated with a considerable and rapid benefit in decreasing the risk of stroke, particularly in light smokers (<20 cigarettes/d); a complete loss of risk is not seen in heavy smokers. Switching to pipe or cigar smoking confers little benefit, emphasizing the need for complete cessation of smoking. The absolute benefit of quitting smoking on risk of stroke is most marked in hypertensive subjects.			WANNAMETHEE, SG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BRUCE NG, 1988, J HYPERTENS, V6, P375; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COOK DG, 1986, LANCET, V2, P1376; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; COOK DG, 1990, J SMOKING RELATED DI, V1, P45; COX DR, 1972, J R STAT SOC B, V34, P187; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; MEADE TW, 1987, LANCET, V2, P986; POCOCK SJ, 1988, HUM TOXICOL, V7, P95, DOI 10.1177/096032718800700201; POCOCK SJ, 1987, LANCET, V2, P197; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGERS RL, 1983, JAMA-J AM MED ASSOC, V250, P2796, DOI 10.1001/jama.250.20.2796; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; Tang J, 1992, J SMOKING RELATED DI, V3, P203; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1994, THROMB HAEMOSTASIS, V72, P58; Wannamethee G, 1994, J Cardiovasc Risk, V1, P223; WANNAMETHEE G, 1994, J INTERN MED, V235, P164; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YARNELL JWG, 1987, J CLIN PATHOL, V40, P909, DOI 10.1136/jcp.40.8.909; 1991, SAS R217 SAS I TECHN; [No title captured]; 1990, CDC908416 US DEP HLT	32	192	202	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					155	160						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596004				2022-12-01	WOS:A1995RH22200029
J	BOYD, JW; HIMMELSTEIN, DU; WOOLHANDLER, S				BOYD, JW; HIMMELSTEIN, DU; WOOLHANDLER, S			THE TOBACCO HEALTH-INSURANCE CONNECTION	LANCET			English	Editorial Material									HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT MED,CAMBRIDGE,MA; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,CAMBRIDGE,MA 02138	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University	BOYD, JW (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT PSYCHIAT,CAMBRIDGE,MA 02138, USA.							ANDERS G, 1994, WALL STREET J   1221, P1; DAVIS RM, 1991, JAMA-J AM MED ASSOC, V266, P3186, DOI 10.1001/jama.266.22.3186; Friedman M, 1962, CAPITALISM FREEDOM, DOI DOI 10.2307/825316; MACKAY J, 1992, NATL CANCER I MONOGR, V12, P25; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; SALMON J, 1994, CORPORATE TRANSFORMA; Taylor Peter, 1984, SMOKE RING TOBACCO M; Tudor Hart J, 1994, FEASIBLE SOCIALISM N; 1995, COMPACT DISCLOSURE D	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					64	64		10.1016/S0140-6736(95)92104-4	http://dx.doi.org/10.1016/S0140-6736(95)92104-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603209				2022-12-01	WOS:A1995RH22000002
J	FORSTER, A; YOUNG, J				FORSTER, A; YOUNG, J			INCIDENCE AND CONSEQUENCES OF FALLS DUE TO STROKE - A SYSTEMATIC INQUIRY	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PEOPLE; NUMBER; HOME; RISK	Objective-To undertake a systematic inquiry into the incidence and consequences of falls in a cohort of elderly patients with stroke after discharge from hospital. Design-Administration of a questionnaire to patients and main carers at discharge from hospital and eight weeks and six months later. Setting-Bradford Metropolitan District. Subjects-108 patients recruited to the Bradford community stroke trial. Patients were recruited to the trial if they were 60 years or over and resident at home with some residual disability. Main outcome measures-Number of falls, motor club assessment, Barthel index, Frenchay activities index, and Nottingham health profile. Stress in carers was indicated by the general health questionnaire. Results-Of 108 patients, 79 (73%) fell in the six months after discharge from hospital with a total of 270 falls reported. Patients who fell in hospital were significantly more likely to fall at least twice at home after discharge (chi(2)=8.16; P=0.004). ''Fallers'' (two or more falls) were less socially active at six months and more had depressed mood. Carers of these patients were significantly more stressed at six months (53% v 18%; chi(2)=8.5; P=0.003). Conclusion-Stroke is associated with a risk of falling at home and affects the lives of patients with stroke and their carers. Falling and fear of falling is an important issue which needs to be dealt with by the multidisciplinary team.			FORSTER, A (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			Forster, Anne/0000-0001-7466-4414; young, john/0000-0003-4085-9306				Ashburn A, 1982, Physiotherapy, V68, P109; Askham J, 1990, HOME LEISURE ACCIDEN; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; EBRAHIM S, 1986, J EPIDEMIOL COMMUN H, V40, P166, DOI 10.1136/jech.40.2.166; EVANS JG, 1990, AGE AGEING, V19, P268, DOI 10.1093/ageing/19.4.268; FULLERTON KJ, 1986, LANCET, V1, P430; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Hunt SM, 1986, MEASURING HLTH STATU; Isaacs B, 1985, Clin Geriatr Med, V1, P513; MAHONEY F I, 1965, Md State Med J, V14, P61; Obonyo T, 1983, Int Rehabil Med, V5, P157; OVERSTALL PW, 1992, REV CLIN GERONTOLOGY, V2, P31; SIMPSON JM, 1993, AGE AGEING, V22, P294, DOI 10.1093/ageing/22.4.294; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TUTUARIMA JA, 1993, J ADV NURS, V18, P1101, DOI 10.1046/j.1365-2648.1993.18071101.x; VLAVHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WILD D, 1981, J EPIDEMIOL COMMUN H, V35, P200, DOI 10.1136/jech.35.3.200; WOODHOUSE P, 1983, J CLIN EXPT GERONTOL, V54, P309; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	26	410	425	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					83	86		10.1136/bmj.311.6997.83	http://dx.doi.org/10.1136/bmj.311.6997.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613406	Green Published			2022-12-01	WOS:A1995RJ03000018
J	HANIF, M; MOBARAK, MR; RONAN, A; RAHMAN, D; DONOVAN, JJ; BENNISH, ML				HANIF, M; MOBARAK, MR; RONAN, A; RAHMAN, D; DONOVAN, JJ; BENNISH, ML			FATAL RENAL-FAILURE CAUSED BY DIETHYLENE GLYCOL IN PARACETAMOL ELIXIR - THE BANGLADESH EPIDEMIC	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN	Objective-To determine the cause of a large increase in the number of children with unexplained renal failure. Design-Case-control study. Setting-Children's hospital in Dhaka, Bangladesh. Subjects-Cases were all 339 children with initially unexplained renal failure; controls were 90 children with cause of renal failure identified; all were admitted to hospital during 35 months after January 1990. Main outcome measures-Differences between the case and control patients in clinical and histological features and outcome; toxicological examination of 69 bottles of paracetamol from patients and pharmacies. Results-Compared with children with an identified cause for their renal failure, children with initially unexplained renal failure were significantly (P < 0 . 05) more likely to have hepatomegaly (58% v 33%), oedema (37% v 20%), and hypertension (58% v 23%); to have a higher serum creatinine concentration (mean 519 mu mol/l v 347 mu mol/l) and lower serum bicarbonate concentration (10 . 1 mmol/l v 12 . 4 mmol/l); to have been given a drug for fever (91% v 31%); to have ingested a brand of paracetamol shown to contain diethylene glycol (20% v 0%); and to have died in hospital (70% v 33%). Diethylene glycol was identified in 19 bottles of paracetamol, from 7 of 28 brands tested. In the 12 months after a government ban on the sale of paracetamol elixir, new cases of renal failure decreased by 54%, and cases of unexplained renal failure decreased by 84%. Conclusion-Paracetamol elixirs with diethylene glycol as a diluent were responsible for a large outbreak of fatal renal failure in Bangladesh.	TUFTS UNIV NEW ENGLAND MED CTR,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111; DHAKA SHISHU HOSP,DEPT NEPHROL,DHAKA,BANGLADESH; INT CTR DIARRHOEAL DIS RES,DHAKA,BANGLADESH; MASSACHUSETTS DEPT PUBL HLTH,STATE LAB INST,BOSTON,MA 02116	Tufts Medical Center; International Centre for Diarrhoeal Disease Research (ICDDR); Massachusetts Department of Public Health								ANDREWS LS, 1991, CASARETT DOULLS TOXI, P704; BOWIE MD, 1972, S AFR MED J, V46, P931; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Castelo A, 1991, J Clin Epidemiol, V44 Suppl 2, p21S; CHETLEY A, 1992, POLICY PRACTICE FUTU, P53; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GRANT JP, 1994, STATE WORLDS CHILDRE, P64; MASLAND T, 1990, NEWSWEEK        1105, P22; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; REICH MR, 1994, HEALTH POLICY PLANN, V9, P130, DOI 10.1093/heapol/9.2.130; ROY SK, 1993, WHO SEA98 DRUGS DRUG; SILVERMAN M, 1992, BAD MED PRESCRIPTION, P209; TIRANTI DJ, 1986, ESSENTIAL DRUGS BANG, P11; van Leusen R, 1987, Ned Tijdschr Geneeskd, V131, P768; VANDERLINDENCRE.PM, 1985, NED TIJDSCHR GENEESK, V129, P1890; WINDHOLZ M, 1983, MERCK INDEX, P453; 1977, PEDIATR S, V59, P803; 1985, LANCET, V2, P254; 1981, TREATMENT MANAGEMENT; 1992, WHO TECHNICAL REPORT, V825, P22	21	103	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					88	91		10.1136/bmj.311.6997.88	http://dx.doi.org/10.1136/bmj.311.6997.88			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613408	Green Published			2022-12-01	WOS:A1995RJ03000020
J	LICINIO, J; GOLD, PW; WONG, ML				LICINIO, J; GOLD, PW; WONG, ML			A MOLECULAR MECHANISM FOR STRESS-INDUCED ALTERATIONS IN SUSCEPTIBILITY TO DISEASE	LANCET			English	Note							CORTICOTROPIN-RELEASING-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD IMMUNOCYTES; INTERLEUKIN-1; REPLICATION; EXPRESSION; SEQUENCE; HORMONE; CLONING; GENE	Corticotropin-releasing hormone (CRH) is a 41-aminoacid peptide which mediates behavioural and physiological responses to stress. A major target of CRH is the proopiomelanocortin (POMC) gene. Three transcription factors have been identified that affect transcription of the POMC gene by binding to two different sites within the CRH-responsive element of that promoter. We searched Genbank and found that nucleotide sequences in the POMC promoter which bind POMC-transcription factors are also contained in the genome of HIV-1 and cytomegalovirus, in c-fes and human MAT-1 breast cancer oncogenes, and in proinflammatory molecules, such as the interleukin-1 beta converting enzyme. We hypothesise a mechanism of hormone action by which a peptide hormone, such as CRH, might affect disease susceptibility by eliciting the production of transcription factors which may bind to unexpected intracellular targets, such as viruses, oncogenes, or the genes encoding for inflammatory mediators, infection, inflammation, and neoplastic transformation would thus be facilitated. This hypothesis can be tested, if confirmed. CRH antagonists may prove useful in the treatment of disorders whose pathophysiology involves molecules that respond to CRH-regulated POMC transcription factors.			LICINIO, J (corresponding author), NIMH, CLIN NEUROENDOCRINOL BRANCH, BETHESDA, MD 20892 USA.		Licinio, Julio/L-4244-2013; Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020	Licinio, Julio/0000-0001-6905-5884; Wong, Ma-Li/0000-0003-1512-3073; 				ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ALCALAY M, 1990, ONCOGENE, V5, P267; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DEBELLIS MD, 1993, AM J PSYCHIAT, V150, P656; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; GAGNER JP, 1985, MOL CELL ENDOCRINOL, V40, P25, DOI 10.1016/0303-7207(85)90154-6; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; JUCKER M, 1992, ONCOGENE, V7, P943; KARALIS K, 1991, SCIENCE, V254, P421, DOI 10.1126/science.1925600; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LU Y, 1993, BIOCHEM BIOPH RES CO, V193, P779, DOI 10.1006/bbrc.1993.1693; POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777; RIEGEL AT, 1990, NUCLEIC ACIDS RES, V18, P4513, DOI 10.1093/nar/18.15.4513; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; SINGH VK, 1993, IMMUNOL LETT, V35, P239, DOI 10.1016/0165-2478(93)90189-9; SPIEGEL D, 1989, LANCET, V2, P888; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STRAYER DS, 1991, VIROLOGY, V185, P585, DOI 10.1016/0042-6822(91)90529-K; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WONG ML, 1994, ENDOCRINOLOGY, V135, P2275, DOI 10.1210/en.135.5.2275	30	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	1995	346	8967					104	106		10.1016/S0140-6736(95)92119-2	http://dx.doi.org/10.1016/S0140-6736(95)92119-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7626147				2022-12-01	WOS:A1995RH22000017
J	MACLEOD, RJ; BENNETT, HPJ; HAMILTON, JR				MACLEOD, RJ; BENNETT, HPJ; HAMILTON, JR			INHIBITION OF INTESTINAL SECRETION BY RICE	LANCET			English	Note							LIQUID-CHROMATOGRAPHY	Rates of stool output are reduced when cooked rice is incorporated into oral rehydration solutions. We found that a fraction extracted from rice inhibited the response of intestinal epithelial crypt cells to adenosine 3'5'-cyclic monophosphate, a major intracellular mediator of secretion. This response to rice was seen as an inhibition of cell shrinkage and of chloride efflux in fresh suspended guineapig crypt cells. The active fraction was of low molecular weight (<1.5 kDa), hydrophobic, and not a peptide or glycoprotein. It may be chloride-channel blocker.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital								BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BROWNE CA, 1982, ANAL BIOCHEM, V124, P201, DOI 10.1016/0003-2697(82)90238-X; FIELD M, 1993, ANNU REV PHYSIOL, V55, P631, DOI 10.1146/annurev.ph.55.030193.003215; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; MACLEOD RJ, 1994, AM J PHYSIOL, V267, pG387, DOI 10.1152/ajpgi.1994.267.3.G387; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358	6	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					90	92		10.1016/S0140-6736(95)92115-X	http://dx.doi.org/10.1016/S0140-6736(95)92115-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603220				2022-12-01	WOS:A1995RH22000013
J	MALES, MA				MALES, MA			ADULT INVOLVEMENT IN TEENAGE CHILDBEARING AND STD	LANCET			English	Editorial Material							PREGNANCY				MALES, MA (corresponding author), UNIV CALIF IRVINE,SCH SOCIAL ECOL,IRVINE,CA 92717, USA.							BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; BOYER D, 1992, FAMILY PLANNING PERS, V24, P19; DEAN M, 1994, LANCET, V343, P1149, DOI 10.1016/S0140-6736(94)90243-7; GERSHENSON H, 1989, J INTERPERS VIOLENCE, V4, P204; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; MALES M, 1994, APR ANN M POP ASS AM; 1994, SEX AM TEENAGERS; 1994, IV AIDS SURVEILLANCE; 1994, LANCET, V344, P899; 1994, CALIFORNIA RESIDENT; 1994, BRITHS TEEN MOMS AGE	11	19	19	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					64	65		10.1016/S0140-6736(95)92105-2	http://dx.doi.org/10.1016/S0140-6736(95)92105-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603210				2022-12-01	WOS:A1995RH22000003
J	MASTERS, GA; GOLOMB, HM				MASTERS, GA; GOLOMB, HM			MANAGEMENT OF PULMONARY METASTASES	LANCET			English	Editorial Material							SARCOMA; LUNG				MASTERS, GA (corresponding author), UNIV CHICAGO,MED CTR,CHEST ONCOL PROGRAM,CHICAGO,IL 60637, USA.							CASSON AG, 1992, CANCER, V69, P662, DOI 10.1002/1097-0142(19920201)69:3<662::AID-CNCR2820690311>3.0.CO;2-I; CROW J, 1981, CANCER, V47, P2595, DOI 10.1002/1097-0142(19810601)47:11<2595::AID-CNCR2820471114>3.0.CO;2-Q; GIRARD P, 1994, AM J RESP CRIT CARE, V149, P469, DOI 10.1164/ajrccm.149.2.8306048; GIRARD P, 1994, CANCER, V74, P2791, DOI 10.1002/1097-0142(19941115)74:10<2791::AID-CNCR2820741008>3.0.CO;2-Q; HARPOLE DH, 1992, J THORAC CARDIOV SUR, V103, P743; HELLMAN S, 1995, J CLIN ONCOL, V113, P8; MATTHAY RA, 1993, AM REV RESPIR DIS, V148, P1691, DOI 10.1164/ajrccm/148.6_Pt_1.1691; MENTZER SJ, 1993, J SURG ONCOL, V53, P54, DOI 10.1002/jso.2930530114; MOUNTAIN CF, 1984, ANN THORAC SURG, V38, P323, DOI 10.1016/S0003-4975(10)62280-1; TODD TR, 1993, CHEST, V103, pS401, DOI 10.1378/chest.103.4_Supplement.401S	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					68	68		10.1016/S0140-6736(95)92109-5	http://dx.doi.org/10.1016/S0140-6736(95)92109-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603214				2022-12-01	WOS:A1995RH22000007
J	MEYER, HE; TVERDAL, A; FALCH, JA				MEYER, HE; TVERDAL, A; FALCH, JA			CHANGES IN BODY-WEIGHT AND INCIDENCE OF HIP FRACTURE AMONG MIDDLE-AGED NORWEGIANS	BRITISH MEDICAL JOURNAL			English	Article									AKER HOSP,DEPT INTERNAL MED,N-0514 OSLO,NORWAY	University of Oslo	MEYER, HE (corresponding author), NATL HLTH SCREENING SERV,POB 8155,N-0033 OSLO,NORWAY.		Meyer, Haakon E./AAH-9333-2019	Tverdal, Aage/0000-0002-2909-5678				CUMMING RG, 1994, AM J EPIDEMIOL, V139, P493, DOI 10.1093/oxfordjournals.aje.a117032; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; REID IR, 1994, J CLIN ENDOCR METAB, V79, P950, DOI 10.1210/jc.79.4.950; 1988, CARDIOVASCULAR DISEA	5	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					91	92		10.1136/bmj.311.6997.91	http://dx.doi.org/10.1136/bmj.311.6997.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613409	Green Published			2022-12-01	WOS:A1995RJ03000021
J	OKADA, F; KINOSHITA, S				OKADA, F; KINOSHITA, S			SHINSHINSHO - CLINICAL ENTITY OR PSEUDOSCIENCE	LANCET			English	Editorial Material											OKADA, F (corresponding author), HOKKAIDO UNIV,CTR HLTH ADM,SAPPORO,HOKKAIDO 060,JAPAN.							Alexander F, 1950, PSYCHOSOMATIC MED IT; IKEMI Y, 1975, SEISHIN IGAKU JITEN, P331; IKEMI Y, 1962, THEORY PRACTICE PSYC; Okada F, 1994, Clin Auton Res, V4, P189, DOI 10.1007/BF01826185; SIMOSAKA K, 1979, SERIES MODERN PSYC A, V7, P3	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					66	67		10.1016/S0140-6736(95)92107-9	http://dx.doi.org/10.1016/S0140-6736(95)92107-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603212				2022-12-01	WOS:A1995RH22000005
J	PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC				PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC			HORMONE REPLACEMENT THERAPY AND SERUM ANGIOTENSIN CONVERTING-ENZYME ACTIVITY IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							DELETION POLYMORPHISM; HYPERTENSION; PLASMA; GENE	The mechanisms by which hormone replacement therapy (HRT) reduces the risk of coronary heart disease (CHD) are incompletely understood, but may include direct arterial effects. We examined the effect of oestrogen/progestagen HRT on serum angiotensin-converting-enzyme (ACE) activity in postmenopausal women. After 6 months, ACE activity was reduced by 20% (p<0.001) on average in 28 treated women but remained unchanged in 16 controls. Serum ACE activity is modifiable by gonadal steroids and changes in serum ACE may represent a novel mechanism by which HRT reduces CHD risk in women.	GUYS HOSP,DEPT NUCL MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	PROUDLER, AJ (corresponding author), NATL HEART & LUNG INST,WYNN DEPT METAB MED,LONDON NW8 9SQ,ENGLAND.			Crook, David/0000-0002-9587-3730				ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; BUTTERY JE, 1993, CLIN CHEM, V39, P312; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; DUX S, 1984, ISRAEL J MED SCI, V20, P1138; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SASSANO P, 1987, AM J MED, V83, P227, DOI 10.1016/0002-9343(87)90690-5; STAMPFER MJ, 1991, PREV MED, V28, P47; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007	9	166	168	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					89	90		10.1016/S0140-6736(95)92114-1	http://dx.doi.org/10.1016/S0140-6736(95)92114-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603219				2022-12-01	WOS:A1995RH22000012
J	SHORT, RV				SHORT, RV			PERCUSSION AS A WAY OF LIFE	LANCET			English	Editorial Material											SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,CLAYTON,VIC,AUSTRALIA.							FEISTNER ATC, 1994, FOLIA PRIMATOL, P62	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					67	68		10.1016/S0140-6736(95)92108-7	http://dx.doi.org/10.1016/S0140-6736(95)92108-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603213	Bronze			2022-12-01	WOS:A1995RH22000006
J	THRASHER, AJ; CASIMIR, CM; KINNON, C; MORGAN, G; SEGAL, AW; LEVINSKY, RJ				THRASHER, AJ; CASIMIR, CM; KINNON, C; MORGAN, G; SEGAL, AW; LEVINSKY, RJ			GENE-TRANSFER TO PRIMARY CHRONIC GRANULOMATOUS-DISEASE MONOCYTES	LANCET			English	Note								For somatic gene therapy to become a realistic therapeutic strategy for chronic granulomatous disease (CGD),we have to be able to assign the molecular lesion to a specific component of the NADPH oxidase and to confirm that transfer of a functional copy of the corresponding defective gene will result in correction of the cellular defect. We used an adenovirus Vector expressing p47phox to transduce monocytes from patients with CGD. We showed by nitroblue-tetrazolium staining that NADPH-oxidase activity was restored to these cells. This technique offers a rapid means for molecular diagnosis. in the short term, this approach may have therapeutic potential.	UCL, SCH MED, LONDON W1N 8AA, ENGLAND	University of London; University College London; UCL Medical School	THRASHER, AJ (corresponding author), INST CHILD HLTH, MOLEC IMMUNOL UNIT, 30 GUILFORD ST, LONDON WC1N 1EH, ENGLAND.		Kinnon, Christine/A-1585-2010	Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUESCHER ES, 1982, NEW ENGL J MED, V307, P800, DOI 10.1056/NEJM198209233071306; CASIMIR C, 1992, EUR J CLIN INVEST, V22, P403, DOI 10.1111/j.1365-2362.1992.tb01481.x; LEI F, 1994, BLOOD, V84, P53; OCHS HD, 1973, J PEDIATR-US, V83, P77, DOI 10.1016/S0022-3476(73)80316-6; PORTER CD, 1993, BLOOD, V82, P2196; THRASHER A, 1992, BLOOD, V80, P1125; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7	7	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 8	1995	346	8967					92	93		10.1016/S0140-6736(95)92116-8	http://dx.doi.org/10.1016/S0140-6736(95)92116-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7541496				2022-12-01	WOS:A1995RH22000014
J	WARRELL, MJ				WARRELL, MJ			HUMAN DEATHS FROM CRYPTIC BAT RABIES IN THE USA	LANCET			English	Editorial Material							VIRUS				WARRELL, MJ (corresponding author), CTR TROP MED, OXFORD, ENGLAND.							BOURHY H, 1993, VIROLOGY, V194, P70, DOI 10.1006/viro.1993.1236; BRASS DA, 1994, RABIES BATS NATURAL; Campbell J B, 1994, Curr Top Microbiol Immunol, V187, P245; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P455; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P93; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P132; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P765; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; COE CL, 1995, MMWR-MORBID MORTAL W, V44, P269; Constantine DG, 1970, BIOLOGY BATS, VII, P319; Debbie J. G., 1993, Morbidity and Mortality Weekly Report, V42, P799; DEBBIE JG, 1993, MMWR-MORBID MORTAL W, V42, P805; HARDMAN MS, 1995, MMWR-MORBID MORTAL W, V44, P93; HARDMAN MS, 1995, MMWR-MORBID MORTAL W, V44, P86; HOUFF SA, 1979, NEW ENGL J MED, V300, P603, DOI 10.1056/NEJM197903153001105; LUMIO J, 1986, LANCET, V1, P378; SELIMOV MA, 1989, ACTA VIROL, V33, P542; Smith J.S., 1988, P267; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; WINKLER WG, 1975, NATURAL HIST RABIES, V2, P115	20	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	1995	346	8967					65	66		10.1016/S0140-6736(95)92106-0	http://dx.doi.org/10.1016/S0140-6736(95)92106-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603211	Bronze			2022-12-01	WOS:A1995RH22000004
J	BERTHOZ, A; ISRAEL, I; GEORGESFRANCOIS, P; GRASSO, R; TSUZUKU, T				BERTHOZ, A; ISRAEL, I; GEORGESFRANCOIS, P; GRASSO, R; TSUZUKU, T			SPATIAL MEMORY OF BODY LINEAR DISPLACEMENT - WHAT IS BEING STORED	SCIENCE			English	Article							GUIDED SACCADES; HUMANS; NAVIGATION; ROTATION; OTOLITHS	The ability to evaluate traveled distance is common to most animal species. Head trajectory in space is measured on the basis of the converging signals of the visual, vestibular, and somatosensory systems, together with efferent copies of motor commands. Recent evidence from human studies has shown that head trajectory in space can be stored in spatial memory. A fundamental question, however, remains unanswered: How is movement stored? In this study, humans who were asked to reproduce passive linear whole-body displacement distances while blindfolded were also able to reproduce velocity profiles. This finding suggests that a spatiotemporal dynamic pattern of motion is stored and can be retrieved with the use of vestibular and somesthetic cues.	COLL FRANCE, PHYSIOL PERCEPT & ACT LAB, CNRS, F-75006 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Universite Paris Cite								BERITOFF JS, 1965, NEURAL MECHANISMS HI, P107; BERTHOZ A, 1987, NEUROSCI LETT, V82, P285, DOI 10.1016/0304-3940(87)90270-9; Berthoz A, 1988, Adv Otorhinolaryngol, V41, P76; BLOOMBERG J, 1991, EXP BRAIN RES, V84, P47; BLOOMBERG J, 1988, ADV OTORHINOLARYNGOL, V40, P71; ETIENNE AS, 1986, ANIM BEHAV, V34, P696, DOI 10.1016/S0003-3472(86)80054-9; ETIENNE AS, 1988, BEHAVIOUR, V106, P81, DOI 10.1163/156853988X00106; GLASAUER S, 1994, EXP BRAIN RES, V98, P323; GUEDRY FE, 1963, LABYRINTHINE FUNCTIO; GUILFORD T, 1993, NATURE, V363, P112, DOI 10.1038/363112a0; ISRAEL I, 1993, J NEUROPHYSIOL, V70, P1270, DOI 10.1152/jn.1993.70.3.1270; ISRAEL I, 1989, J NEUROPHYSIOL, V62, P247, DOI 10.1152/jn.1989.62.1.247; ISRAEL I, 1992, ANN NY ACAD SCI, V656, P472, DOI 10.1111/j.1749-6632.1992.tb25229.x; ISRAEL I, 1995, ACTA OTO-LARYNGOL, V115, P3, DOI 10.3109/00016489509133338; ISRAEL I, 1991, NATO ADV SCI I D-BEH, V62, P599; ISRAEL I, 1993, EXP BRAIN RES, V96, P335; ISRAEL I, IN PRESS BRAIN; ISRAEL I, 1992, TUTORIALS MOTOR BEHA, V2, P195; LICHTENBERG BK, 1982, EXP BRAIN RES, V48, P127; MATTHEWS GVT, 1951, J EXP BIOL, V28, P508; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1391; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; METCALFE T, 1992, ANN NY ACAD SCI, V656, P695; MILLER S, 1983, PHYSIOL PSYCHOL, V11, P1; Mittelstaedt H., 1982, P290; MITTELSTAEDT ML, 1991, ZOOL JAHRB ALLG ZOOL, V95, P427; MITTELSTAEDT ML, 1980, NATURWISSENSCHAFTEN, V67, P566, DOI 10.1007/BF00450672; OMARA SM, 1994, J NEUROSCI, V14, P6511; PIERROTDESEILLIGNY C, 1993, EXP BRAIN RES, V95, P166; Potegal M, 1982, SPATIAL ABILITIES DE, P361; Poulton E. C., 1981, HDB PHYSL NERVOUS SY, V2, P1337; SHARP PE, 1995, J NEUROSCI, V15, P173; Shelhamer M, 1994, J Vestib Res, V4, P1; STEVENS SS, 1960, AM SCI, V48, P226; WIENER SI, 1989, J NEUROSCI, V9, P2737; Wiener SI, 1993, MULTISENSORY CONTROL, P427, DOI [10.1093/acprof:oso/9780198547853.003.0208, DOI 10.1093/ACPROF:OSO/9780198547853.003.0208]; Young L.R, 1984, HDB PHYSL NERVOUS SY, P978; YOUNG LR, 1968, AEROSPACE MED, V39, P606	39	178	180	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	1995	269	5220					95	98		10.1126/science.7604286	http://dx.doi.org/10.1126/science.7604286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604286				2022-12-01	WOS:A1995RG98000043
J	HEDGES, LV; NOWELL, A				HEDGES, LV; NOWELL, A			SEX-DIFFERENCES IN MENTAL TEST-SCORES, VARIABILITY, AND NUMBERS OF HIGH-SCORING INDIVIDUALS	SCIENCE			English	Article							COGNITIVE GENDER DIFFERENCES; META-ANALYSIS; INTELLECTUAL ABILITIES; METAANALYSIS; MATHEMATICS	Sex differences in central tendency, variability, and numbers of high scores on mental tests have been extensively studied. Research has not always seemed to yield consistent results, partly because most studies have not used representative samples of national populations. An analysis of mental test scores from six studies that used national probability samples provided evidence that although average sex differences have been generally small and stable over time, the test scores of males consistently have larger variance. Except in tests of reading comprehension, perceptual speed, and associative memory, males typically outnumber females substantially among high-scoring individuals.			HEDGES, LV (corresponding author), UNIV CHICAGO,DEPT EDUC,5835 S KIMBARK AVE,CHICAGO,IL 60637, USA.			Hedges, Larry/0000-0002-7531-0631				BECKER BJ, 1988, BEHAV BRAIN SCI, V11, P183; BECKER BJ, 1984, J EDUC PSYCHOL, V76, P583, DOI 10.1037/0022-0663.76.4.583; BENBOW CP, 1988, BEHAV BRAIN SCI, V11, P169, DOI 10.1017/S0140525X00049244; BOCK RD, 1986, ADVANTAGE DISADVANTA; Cochran WG., 1963, SAMPLING TECHNIQUES, V2, DOI 10.1002/bimj.19650070312; COHEN J, 1977, STATISTICAL POWER AN; ELLIS H, 1984, MAN WOMAN STUDY HUMA; FEINGOLD A, 1988, AM PSYCHOL, V43, P95, DOI 10.1037/0003-066X.43.2.95; FEINGOLD A, 1992, REV EDUC RES, V62, P61, DOI 10.3102/00346543062001061; Flanagan J. C., 1962, DESIGN STUDY AM YOUT; FRIEDMAN L, 1989, REV EDUC RES, V59, P185; Hansen M.H., 1953, SAMPLE SURVEY METHOD; HEDGES LV, 1993, REV EDUC RES, V63, P94, DOI 10.3102/00346543063001094; HOLLINGWORTH LS, 1914, AM J SOCIOL, V22, P19; HYDE JS, 1990, PSYCHOL BULL, V107, P139, DOI 10.1037/0033-2909.107.2.139; HYDE JS, 1988, PSYCHOL BULL, V104, P53, DOI 10.1037/0033-2909.104.1.53; HYDE JS, 1981, AM PSYCHOL, V36, P892, DOI 10.1037/0003-066X.36.8.892; Jensen A, 1971, INTELLIGENCE GENETIC, P107; Kish L., 1995, SURVEY SAMPLING; LAZEAR EP, 1990, J LABOR ECON, V8, pS106, DOI 10.1086/298246; LEWIS C, 1995, ETS RR9513 ED TEST S; Maccoby E.E., 1974, PSYCHOL SEX DIFFEREN; Maccoby E.E., 1966, DEV SEX DIFFERENCES; MICCERI T, 1989, PSYCHOL BULL, V105, P156, DOI 10.1037/0033-2909.105.1.156; MULLIS IVS, 1991, TRENDS ACADEMIC PROG; PAGLIN M, 1990, J LABOR ECON, V8, P123, DOI 10.1086/298239; PEARSON K, 1897, CHANCES DEATH, V1, pCH8; ROCK DA, 1985, PSYCHOMETRIC ANAL NL; ROSEN S, 1981, AM ECON REV, V71, P845; SHAYCROFT MF, 1963, STUDIES COMPLETE AGE; SHIELDS SA, 1975, AM PSYCHOL, V30, P739, DOI 10.1037/h0076948; Stanley J. C., 1992, TALENT DEV, P42; Terman L. M., 1925, GENETIC STUDIES GENI, VI; TERMAN LM, 1954, MANUAL CHILD PSYCHOL, P1064; Thorndike E. L., 1910, ED PSYCHOL; WISE LL, 1979, ORIGINS CAREER CONSE	36	614	623	4	101	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					41	45		10.1126/science.7604277	http://dx.doi.org/10.1126/science.7604277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RG980	7604277				2022-12-01	WOS:A1995RG98000025
J	KOOYMAN, DL; BYRNE, GW; MCCLELLAN, S; NIELSEN, D; TONE, M; WALDMANN, H; COFFMAN, TM; MCCURRY, KR; PLATT, JL; LOGAN, JS				KOOYMAN, DL; BYRNE, GW; MCCLELLAN, S; NIELSEN, D; TONE, M; WALDMANN, H; COFFMAN, TM; MCCURRY, KR; PLATT, JL; LOGAN, JS			IN-VIVO TRANSFER OF GPI-LINKED COMPLEMENT RESTRICTION FACTORS FROM ERYTHROCYTES TO THE ENDOTHELIUM	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; VARIANT SURFACE GLYCOPROTEIN; RAPID LATERAL DIFFUSION; TRANSGENIC MICE; MEMBRANE-PROTEIN; HUMAN-HEMOGLOBIN; LYMPHOID-CELLS; GLOBIN GENE; HIGH-LEVEL; EXPRESSION	Many proteins are associated with the outer layer of the cell membrane through a posttranslationally added glycosyl phosphatidylinositol (GPI) anchor. The functional significance of this type of protein linkage is unclear, although it results in increased lateral mobility, sorting to the apical surface of the cell, reinsertion into cell membranes, and possibly cell signaling. Here evidence is presented that GPI-linked proteins can undergo intermembrane transfer in vivo. GPI-linked proteins expressed on the surface of transgenic mouse red blood cells were transferred in a functional form to endothelial cells in vivo. This feature of GPI linkage may be potentially useful for the delivery of therapeutic proteins to vascular endothelium.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; DUKE UNIV,MED CTR,DURHAM,NC 27705; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	University of Oxford; Duke University; Duke University; Duke University; Duke University	KOOYMAN, DL (corresponding author), NEXTRAN,303B COLL RD E,PRINCETON,NJ 08540, USA.		waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720; Platt, Jeffrey/0000-0002-4915-0419	NHLBI NIH HHS [HL 52297, HL 50985, HL 46810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046810, P01HL050985, R37HL052297, R01HL052297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; FALK RJ, 1983, J CLIN INVEST, V72, P560, DOI 10.1172/JCI111004; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; Hogan B., 1986, MANIPULATING MOUSE E; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; LEONG LYW, 1992, EUR J IMMUNOL, V22, P2825, DOI 10.1002/eji.1830221111; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MERI S, 1990, IMMUNOLOGY, V71, P1; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; PEARCE EJ, 1990, J IMMUNOL, V144, P2751; PLATT JL, 1983, J EXP MED, V158, P1227, DOI 10.1084/jem.158.4.1227; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VAKEVA A, 1994, IMMUNOLOGY, V82, P28; WAGNER RC, 1975, MICROVASC RES, V10, P286, DOI 10.1016/0026-2862(75)90033-3; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	28	221	228	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					89	92		10.1126/science.7541557	http://dx.doi.org/10.1126/science.7541557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541557				2022-12-01	WOS:A1995RG98000041
J	MIGONE, TS; LIN, JX; CERESETO, A; MULLOY, JC; O'SHEA, JJ; FRANCHINI, G; LEONARD, WJ				MIGONE, TS; LIN, JX; CERESETO, A; MULLOY, JC; O'SHEA, JJ; FRANCHINI, G; LEONARD, WJ			CONSTITUTIVELY ACTIVATED JAK-STAT PATHWAY IN T-CELLS TRANSFORMED WITH HTLV-I	SCIENCE			English	Article							VIRUS TYPE-I; RECEPTOR GAMMA-CHAIN; LEUKEMIA-LYMPHOMA; FUNCTIONAL COMPONENT; INFECTED-CELLS; IL-2 RECEPTOR; PROTEINS; LEUKOCYTES; EXPRESSION; GROWTH	Human T cell lymphotropic virus I (HTLV-I) is the etiological agent for adult T cell leukemia and tropical spastic paraparesis (also termed HTLV-I-associated myelopathy). HTLV-I-infected peripheral blood T cells exhibit an initial phase of interleukin-2 (IL-2)-dependent growth; over time, by an un known mechanism, the cells become IL-2-independent. Whereas the Jak kinases Jak1 and Jak3 and the signal transducer and activator of transcription proteins Stat3 and Stat5 are activated in normal T cells in response to IL-2, this signaling pathway was constitutively activated in HTLV-I-transformed cells. In HTLV-I-infected cord blood lymphocytes, the transition from IL-2-dependent to IL-2-independent growth correlated with the acquisition of a constitutively activated Jak-STAT pathway, which suggests that this pathway participates in HTLV-I-mediated T cell transformation.	NHLBI, MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			Leonard, Warren/AAA-1397-2022	Cereseto, Anna/0000-0003-4453-2597				ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; DANIAL PB, IN PRESS SCIENCE; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FRIEDMANN M, UNPUB; GALLO RC, 1986, SCI AM, V255, P88, DOI 10.1038/scientificamerican1286-88; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAEDA M, 1987, BLOOD, V70, P1407; MIGONE TS, UNPUB; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MULLOY JC, UNPUB; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; ROHWER F, 1994, INT J ONCOL, V5, P1163; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YODOI J, 1992, IMMUNOL TODAY, V13, P4; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YSSEL H, 1989, J IMMUNOL, V142, P2279	43	501	518	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					79	81		10.1126/science.7604283	http://dx.doi.org/10.1126/science.7604283			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604283				2022-12-01	WOS:A1995RG98000037
J	PEISACH, E; CASEBIER, D; GALLION, SL; FURTH, P; PETSKO, GA; HOGAN, JC; RINGE, D				PEISACH, E; CASEBIER, D; GALLION, SL; FURTH, P; PETSKO, GA; HOGAN, JC; RINGE, D			INTERACTION OF A PEPTIDOMIMETIC AMINIMIDE INHIBITOR WITH ELASTASE	SCIENCE			English	Article							LIBRARY; LIGANDS; BINDING	The crystal structure of an aminimide analog of a dipeptide inhibitor of porcine pancreatic elastase bound to its target serine protease has been solved. The peptidomimetic molecule binds in the same fashion as the class of dipeptides from which it was derived, making similar interactions with the subsites on the elastase surface. Because aminimides are readily synthesized from a wide variety of starting materials, they form the basis for a combinatorial chemistry approach to rational drug design.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,PROGRAM BIOPHYS,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University; Brandeis University			Petsko, Gregory/AAO-7962-2020	Peisach, Ezra/0000-0002-7905-6327	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007596] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GMO7596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUR A, 1994, INT J PEPT PROT RES, V43, P297; AUBURY A, 1994, INT J PEPT PROT RES, V43, P305; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DELASIERRA IL, 1990, J MOL RECOG, V0003; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GEYSEN HM, 1986, CIBA F S, V119; HUGHES DL, 1982, J MOL BIOL, V162, P645, DOI 10.1016/0022-2836(82)90393-X; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVIE A, COMMUNICATION; MATTOS C, 1994, NAT STRUCT BIOL, V1, P55, DOI 10.1038/nsb0194-55; MATTOS C, 1995, BIOCHEMISTRY-US, V34, P3193, DOI 10.1021/bi00010a008; MATTOS C, 1993, QSAR DRUG DESIGN THE, P226; RENAUD A, 1983, J BIOL CHEM, V258, P8312; RINGE D, 1995, NEW PERSPECTIVES IN DRUG DESIGN, P89; RINGE D, UNPUB; SAWYER L, 1978, J MOL BIOL, V118, P137, DOI 10.1016/0022-2836(78)90412-6; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0	23	42	46	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					66	69		10.1126/science.7604279	http://dx.doi.org/10.1126/science.7604279			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604279				2022-12-01	WOS:A1995RG98000033
J	SASAKI, J; BROWN, LS; CHON, YS; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK				SASAKI, J; BROWN, LS; CHON, YS; KANDORI, H; MAEDA, A; NEEDLEMAN, R; LANYI, JK			CONVERSION OF BACTERIORHODOPSIN INTO A CHLORIDE-ION PUMP	SCIENCE			English	Article							X-RAY-DIFFRACTION; NATRONOBACTERIUM-PHARAONIS; BACTERIAL RHODOPSINS; PROTON TRANSLOCATION; STRUCTURAL-CHANGES; HALORHODOPSIN; PHOTOCYCLE; IDENTIFICATION; INTERMEDIATE; TRANSPORT	In the light-driven proton pump bacteriorhodopsin, proton transfer from the retinal Schiff base to aspartate-85 is the crucial reaction of the transport cycle. In halorhodopsin, a light-driven chloride ion pump, the equivalent of residue 85 is threonine. When aspartate-85 was replaced with threonine, the mutated bacteriorhodopsin became a chloride ion pump when expressed in Halobacterium salinarium and, like halorhodopsin, actively transported chloride ions in the direction opposite from the proton pump. Chloride was bound to it, as revealed by large shifts of the absorption maximum of the chromophore, and its photointermediates included a red-shifted state in the millisecond time domain, with its amplitude and decay rate dependent on chloride concentration. Bacteriorhodopsin and halorhodopsin thus share a common transport mechanism, and the interaction of residue 85 with the retinal Schiff base determines the ionic specificity.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; WAYNE STATE UNIV,DEPT BIOCHEM,DETROIT,MI 48201	University of California System; University of California Irvine; Kyoto University; Wayne State University			Brown, Leonid/X-7445-2019; Brown, Leonid/A-1050-2008; Lanyi, Janos/C-3808-2011	Brown, Leonid/0000-0002-5614-8317; Brown, Leonid/0000-0002-5614-8317; 	NIGMS NIH HHS [GM29498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029498, R37GM029498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BROWN LO, UNPUB; DUSCHL A, 1990, J BIOL CHEM, V265, P1261; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; Lanyi J K, 1979, Methods Enzymol, V56, P398; LANYI JK, 1982, J BIOL CHEM, V257, P2674; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LANYI JK, 1990, PHYSIOL REV, V70, P319, DOI 10.1152/physrev.1990.70.2.319; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LANYI JK, 1986, BIOCHEMISTRY-US, V25, P1465, DOI 10.1021/bi00354a042; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MATSUNOYAGI A, 1977, BIOCHEM BIOPH RES CO, V78, P237, DOI 10.1016/0006-291X(77)91245-1; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1989, TRENDS BIOCHEM SCI, V14, P57, DOI 10.1016/0968-0004(89)90044-3; OGURUSU T, 1984, J BIOCHEM-TOKYO, V95, P1073, DOI 10.1093/oxfordjournals.jbchem.a134695; OTOMO J, 1992, BIOCHIM BIOPHYS ACTA, V1112, P7, DOI 10.1016/0005-2736(92)90246-I; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; SASAKI J, UNPUB; SCHARF B, 1994, BIOCHEMISTRY-US, V33, P6387, DOI 10.1021/bi00187a002; SCHOBERT B, 1986, J BIOL CHEM, V261, P2690; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SOPPA J, 1993, J BACTERIOL, V175, P2720, DOI 10.1128/JB.175.9.2720-2726.1993; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SUNDBERG SA, 1990, J BACTERIOL, V172, P2328, DOI 10.1128/jb.172.5.2328-2335.1990; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; TITTOR J, 1987, BIOPHYS J, V52, P999, DOI 10.1016/S0006-3495(87)83292-7; VARO G, 1995, BIOPHYS J, V68, P2062, DOI 10.1016/S0006-3495(95)80385-1; VARO G, UNPUB; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P5165, DOI 10.1021/bi00438a038; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010	37	210	215	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					73	75		10.1126/science.7604281	http://dx.doi.org/10.1126/science.7604281			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604281				2022-12-01	WOS:A1995RG98000035
J	SRETAVAN, DW; PURE, E; SIEGEL, MW; REICHARDT, LF				SRETAVAN, DW; PURE, E; SIEGEL, MW; REICHARDT, LF			DISRUPTION OF RETINAL AXON INGROWTH BY ABLATION OF EMBRYONIC MOUSE OPTIC CHIASM NEURONS	SCIENCE			English	Article							SUBPLATE NEURONS; CONNECTIONS; OUTGROWTH; CELLS	Mouse retinal ganglion cell axons growing from the eye encounter embryonic neurons at the future site of the optic chiasm. After in vivo ablation of these chiasm neurons with a monoclonal antibody and complement, retinal axons did not cross the midline and stalled at approximately the entry site into the chiasm region. Thus, in the mouse, the presence of early-generated neurons that reside at the site of the future chiasm is required for formation of the optic chiasm by retinal ganglion cell axons.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; GENENTECH INC,DEPT METAB & PHARMACOKINET,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	The Wistar Institute; Roche Holding; Genentech; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SRETAVAN, DW (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL K107,NEUROSCI PROGRAM,10 KIRKHAM ST,SAN FRANCISCO,CA 94143, USA.				NEI NIH HHS [EY10688] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010688] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; COLELLO RJ, 1990, DEVELOPMENT, V108, P515; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; EASTER SS, 1993, J NEUROSCI, V13, P285; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; HENRY C, 1980, SELECTED METHODS CEL, P211; KLOSE M, 1989, SCIENCE, V245, P982, DOI 10.1126/science.2772651; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SRETAVAN DW, 1994, NEURON, V12, P957, DOI 10.1016/0896-6273(94)90307-7; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; SRETAVAN DW, UNPUB; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WILLIAMS RW, 1994, NATURE, V367, P637, DOI 10.1038/367637a0; WISENMANN A, 1993, DEVELOPMENT, V117, P725	19	70	70	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					98	101		10.1126/science.7541558	http://dx.doi.org/10.1126/science.7541558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541558				2022-12-01	WOS:A1995RG98000044
J	STACHELHAUS, T; SCHNEIDER, A; MARAHIEL, MA				STACHELHAUS, T; SCHNEIDER, A; MARAHIEL, MA			RATIONAL DESIGN OF PEPTIDE ANTIBIOTICS BY TARGETED REPLACEMENT OF BACTERIAL AND FUNGAL DOMAINS	SCIENCE			English	Article							OPEN READING FRAME; BACILLUS-SUBTILIS; GENE; BIOSYNTHESIS; SURFACTIN; SEQUENCE; ENZYMES; BREVIS; GRSB	Peptide synthetases involved in the nonribosomal synthesis of peptide secondary metabolites possess a highly conserved domain structure. The arrangement of these domains within the multifunctional enzymes determines the number and order of the amino acid constituents of the peptide product. A general approach has been developed for targeted substitution of amino acid-activating domains within the srfA operon, which encodes the protein templates for the synthesis of the lipopeptide antibiotic surfactin in Bacillus subtilis. Exchange of domain-coding regions of bacterial and fungal origin led to the construction of hybrid genes that encoded peptide synthetases with altered amino acid specificities and the production of peptides with modified amino acid sequences.	UNIV MARBURG,FACHBEREICH CHEM,D-35032 MARBURG,GERMANY	Philipps University Marburg								ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; COOPER DG, 1986, MICROBIOL SCI, V3, P145; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; CUTTING SM, 1990, MOL BIOL METHODS BAC; DSOUZA C, 1994, P NATL ACAD SCI USA, V91, P9397, DOI 10.1073/pnas.91.20.9397; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HAMOEN LW, 1994, MOL MICROBIOL, V15, P55; ITAYA M, 1990, MOL GEN GENET, V223, P268, DOI 10.1007/BF00265063; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KRAUSE M, 1985, J BACTERIOL, V162, P1120, DOI 10.1128/JB.162.3.1120-1125.1985; LAEMMLI UK, 1970, NATURE, V227, P491; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STACHELHAUS T, UNPUB; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURGAY K, 1994, PEPTIDE RES, V7, P238; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Zuber Peter, 1993, P897	29	243	264	1	41	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					69	72		10.1126/science.7604280	http://dx.doi.org/10.1126/science.7604280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604280				2022-12-01	WOS:A1995RG98000034
J	STARGELL, LA; STRUHL, K				STARGELL, LA; STRUHL, K			THE TBP-TFIIA INTERACTION IN THE RESPONSE TO ACIDIC ACTIVATORS IN-VIVO	SCIENCE			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; GENERAL TRANSCRIPTION FACTOR; YEAST; INITIATION; PROMOTERS; CLONING; MUTANTS; DOMAIN; VP16	A yeast TBP mutant (N2-1) is described here that is defective specifically in responding to acidic activators in vivo. N2-1 does not support activation by Gal4, Ace1, and Gcn4, but appears unaffected for constitutive transcription, repression by the Cyc8-Tup1 and Not complexes, and transcription by polymerase I (Pol) and Pol III. In vitro, N2-1 fails to interact with TFIIA, but it associates normally with a TATA element, an acidic activation domain, and TFIIB. Fusion of the small subunit of TFIIA to N2-1 restores activation function in vivo. Thus, an efficient interaction between TBP and TFIIA is required for transcriptional activation in vivo.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Stargell, Laurie/GWC-7423-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM K, 1994, J BIOL CHEM, V269, P4891; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STARGELL LA, 1994, MOL CELL BIOL, V14, P723, DOI 10.1128/MCB.14.1.723; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; YOKOMORI K, 1994, GENE DEV, V8, P2336; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	103	103	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					75	78		10.1126/science.7604282	http://dx.doi.org/10.1126/science.7604282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604282				2022-12-01	WOS:A1995RG98000036
J	TRUDEAU, MC; WARMKE, JW; GANETZKY, B; ROBERTSON, GA				TRUDEAU, MC; WARMKE, JW; GANETZKY, B; ROBERTSON, GA			HERG, A HUMAN INWARD RECTIFIER IN THE VOLTAGE-GATED POTASSIUM CHANNEL FAMILY	SCIENCE			English	Article							MAMMALIAN K+ CHANNEL; FUNCTIONAL EXPRESSION; DROSOPHILA; SHAKER; INACTIVATION; RECTIFICATION; BLOCKING; CLONING; REGION; LOCUS	In contrast to other members of the Eag family of voltage-gated, outwardly rectifying potassium channels, the human eag-related gene (HERG) has now been shown to encode an inwardly rectifying potassium channel. The properties of HERG channels are consistent with the gating properties of Eag-related and other outwardly rectifying, S4-containing potassium channels, but with the addition of an inactivation mechanism that attenuates potassium efflux during depolarization. Because mutations in HERG cause a form of long-QT syndrome, these properties of HERG channel function may be critical to the maintenance of normal cardiac rhythmicity.	UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Robertson, Gail/0000-0003-4694-5790				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUCHANAN LV, 1993, J CARDIOVASC PHARM, V22, P540; CRANEFIELD PF, 1988, CARDIAC ARRHYTHMIAS, P553; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P612; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KAPLAN WD, 1969, GENETICS, V61, P399; KAPLAN WD, 1995, TRENDS GENETICS GUID; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; ROBERTSON GA, 1993, BIOPHYS J, V64, pA340; Robertson Gail A., 1995, Biophysical Journal, V68, pA363; RUDY B, 1992, METHOD ENZYMOL, V207, P225; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Trudeau Matthew C., 1995, Biophysical Journal, V68, pA32; TSENG GN, 1995, CARDIAC ELECTROPHYSI, P260; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zei Paul C., 1995, Biophysical Journal, V68, pA32	41	1050	1082	0	50	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					92	95		10.1126/science.7604285	http://dx.doi.org/10.1126/science.7604285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604285				2022-12-01	WOS:A1995RG98000042
J	VISWANATHAN, R; MADSEN, LL; ZASADZINSKI, JA; SCHWARTZ, DK				VISWANATHAN, R; MADSEN, LL; ZASADZINSKI, JA; SCHWARTZ, DK			LIQUID TO HEXATIC TO CRYSTALLINE ORDER IN LANGMUIR-BLODGETT-FILMS	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPY; BOND-ORIENTATIONAL ORDER; NORMAL-ALKANES; ELECTRON-DIFFRACTION; ROTATOR PHASES; VORTEX GLASS; MONOLAYERS; RESOLUTION; LATTICE; SUPERSTRUCTURES	Atomic force microscope images of zinc arachidate (ZnA(2)) Langmuir-Blodgett films show that three- and five-layer films are ''hexatic,'' with long-range bond-orientational order and short-range positional correlations of three to five lattice repeats. The monolayer in contact with the substrate is disordered. Films of seven or more layers of ZnA(2) are crystalline. A population of dislocations, most likely originating at the substrate, disrupts the positional but not the orientational order of the lattice, leading to hexatic layers intermediate between crystal and liquid. The influence of the substrate propagates farther into ZnA(2) films than into cadmium arachidate films because the molecular cohesion is much weaker in ZnA(2) than in cadmium arachidate, as evidenced by a less dense molecular packing.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; TULANE UNIV,DEPT CHEM,NEW ORLEANS,LA 70118	University of California System; University of California Santa Barbara; Tulane University			Schwartz, Daniel K/H-5153-2012	Schwartz, Daniel K/0000-0001-5397-7200	NHLBI NIH HHS [HL51177] Funding Source: Medline; NIGMS NIH HHS [GM47334] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BIRGENEAU RJ, 1978, J PHYS LETT-PARIS, V39, pL399; BISHOP DJ, 1992, SCIENCE, V255, P165, DOI 10.1126/science.255.5041.165; BONNEROT A, 1985, CHEM PHYS, V97, P365, DOI 10.1016/0301-0104(85)87045-2; BOURDIEU L, 1991, PHYS REV LETT, V67, P2029, DOI 10.1103/PhysRevLett.67.2029; BROCK JD, 1986, PHYS REV LETT, V57, P98, DOI 10.1103/PhysRevLett.57.98; CHENG M, 1987, PHYS REV LETT, V59, P1112, DOI 10.1103/PhysRevLett.59.1112; CHUDNOVSKY EM, 1989, PHYS REV B, V40, P11355, DOI 10.1103/PhysRevB.40.11355; DAI HJ, 1992, PHYS REV LETT, V69, P1576, DOI 10.1103/PhysRevLett.69.1576; DAI HJ, 1991, PHYS REV LETT, V66, P3183, DOI 10.1103/PhysRevLett.66.3183; DAI HJ, 1993, J PHYS CHEM-US, V97, P2362, DOI 10.1021/j100112a042; ECKHARDT CJ, 1993, NATURE, V362, P614, DOI 10.1038/362614a0; EGGER M, 1990, J STRUCT BIOL, V103, P89, DOI 10.1016/1047-8477(90)90089-U; FROMMER J, 1992, ANGEW CHEM INT EDIT, V31, P1298, DOI 10.1002/anie.199212981; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; HALPERIN BI, 1978, PHYS REV LETT, V41, P121, DOI 10.1103/PhysRevLett.41.121; HALPERIN BI, 1978, PHYS REV LETT, V41, P519, DOI 10.1103/PhysRevLett.41.519; HELM CA, 1987, BIOPHYS J, V52, P381, DOI 10.1016/S0006-3495(87)83226-5; JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323; KIMURA F, 1986, LANGMUIR, V2, P96, DOI 10.1021/la00067a017; Kitaigorodskii A.I., 1961, ORGANIC CHEM CRYSTAL; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; KOSTERLI.JM, 1972, J PHYS PART C SOLID, V5, pL124, DOI 10.1088/0022-3719/5/11/002; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; MACLENNAN J, 1992, PHYS REV LETT, V69, P2082, DOI 10.1103/PhysRevLett.69.2082; MARCHETTI MC, 1990, PHYS REV B, V41, P1910, DOI 10.1103/PhysRevB.41.1910; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MEYER E, 1991, NATURE, V349, P398, DOI 10.1038/349398a0; MURRAY CA, 1987, PHYS REV LETT, V58, P1200, DOI 10.1103/PhysRevLett.58.1200; MURRAY CA, 1989, PHYS REV LETT, V62, P1643, DOI 10.1103/PhysRevLett.62.1643; MURRAY CA, 1990, PHYS REV LETT, V64, P2312, DOI 10.1103/PhysRevLett.64.2312; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; NELSON DR, 1982, PHILOS MAG A, V46, P105, DOI 10.1080/01418618208236211; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; PINDAK R, 1981, PHYS REV LETT, V46, P1135, DOI 10.1103/PhysRevLett.46.1135; PRAKASH M, 1986, CHEM PHYS LETT, V128, P354, DOI 10.1016/0009-2614(86)80376-1; QIU X, 1991, PHYS REV LETT, V67, P703, DOI 10.1103/PhysRevLett.67.703; SCHWARTZ DK, 1993, J AM CHEM SOC, V115, P7374, DOI 10.1021/ja00069a040; SCHWARTZ DK, 1993, LANGMUIR, V9, P1384, DOI 10.1021/la00029a036; SCHWARTZ DK, 1993, PHYS REV E, V47, P452, DOI 10.1103/PhysRevE.47.452; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267; SELINGER JV, 1993, PHYS REV LETT, V70, P1139, DOI 10.1103/PhysRevLett.70.1139; SIROTA EB, 1993, J CHEM PHYS, V98, P5809, DOI 10.1063/1.464874; SIROTA EB, 1992, PHYS REV LETT, V68, P492, DOI 10.1103/PhysRevLett.68.492; Strandburg KJ., 1992, BOND ORIENTATIONAL O, DOI 10.1007/978-1-4612-2812-7; UNGAR G, 1983, J PHYS CHEM-US, V87, P689, DOI 10.1021/j100227a032; VISWANATHAN R, 1994, NATURE, V368, P440, DOI 10.1038/368440a0; VISWANATHAN R, 1993, SCIENCE, V261, P449, DOI 10.1126/science.8392751; ZASADZINSKI JA, 1994, SCIENCE, V263, P1726, DOI 10.1126/science.8134836	50	53	54	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					51	54		10.1126/science.7604278	http://dx.doi.org/10.1126/science.7604278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7604278				2022-12-01	WOS:A1995RG98000027
J	YU, CL; MEYER, DJ; CAMPBELL, GS; LARNER, AC; CARTERSU, C; SCHWARTZ, J; JOVE, R				YU, CL; MEYER, DJ; CAMPBELL, GS; LARNER, AC; CARTERSU, C; SCHWARTZ, J; JOVE, R			ENHANCED DNA-BINDING ACTIVITY OF A STAT3-RELATED PROTEIN IN CELLS TRANSFORMED BY THE SRC ONCOPROTEIN	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; GENE; INDUCIBILITY; ACTIVATION; ELEMENT; KINASE; JAK	Cytokines and growth factors induce tyrosine phosphorylation of signal transducers and activators of transcription (STATs) that directly activate gene expression. Cells stably transformed by the Src oncogene tyrosine kinase were examined for STAT protein activation. Assays of electrophoretic mobility, DNA-binding specificity, and antigenicity indicated that Stat3 or a closely related STAT family member was constitutively activated by the Src oncoprotein. Induction of this DNA-binding activity was accompanied by tyrosine phosphorylation of Stat3 and correlated with Src transformation. These findings demonstrate that Src can activate STAT signaling pathways and raise the possibility that Stat3 contributes to oncogenesis by Src.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Food & Drug Administration (FDA)			Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, R01DK034171] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BHAVSAR D, COMMUNICATION; CAMPBELL GK, UNPUB; CAMPBELL GS, IN PRESS J BIOL CHEM; COCHRAN BH, UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CH, UNPUB; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	29	797	832	0	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					81	83		10.1126/science.7541555	http://dx.doi.org/10.1126/science.7541555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541555				2022-12-01	WOS:A1995RG98000038
J	ARANCIO, O; KANDEL, ER; HAWKINS, RD				ARANCIO, O; KANDEL, ER; HAWKINS, RD			ACTIVITY-DEPENDENT LONG-TERM ENHANCEMENT OF TRANSMITTER RELEASE BY PRESYNAPTIC 3',5'-CYCLIC GMP IN CULTURED HIPPOCAMPAL-NEURONS	NATURE			English	Article							NITRIC-OXIDE; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; POTENTIATION; MESSENGER; PLASTICITY; INDUCTION; CURRENTS; PATHWAY; AREA	LONG-TERM potentiation (LTP) in hippocampus is a type of synaptic plasticity that is thought to be involved in learning and memory(1). Several lines of evidence suggest that LTP involves 3',5'-cyclic GMP (cGMP), perhaps as an activity-dependent presynaptic effector of one or more retrograde messengers (refs 2-12, but see ref, 13). However, previous results are also consistent with postsynaptic effects of cGMP. This is difficult to test in hippocampal slices, but more rigorous tests are possible in dissociated cell culture(14-17). We have therefore developed a reliable method for producing N-methyl-D-aspartate (NMDA) receptor-dependent LTP at synapses between individual hippocampal pyramidal neurons in culture, We report that inhibitors of guanylyl cyclase or of cGMP-dependent protein kinase block potentiation by either tetanic stimulation or low-frequency stimulation paired with postsynaptic depolarization. Conversely, application of 8-Br-cGMP to the bath or injection of cGMP into the presynaptic neuron produces activity-dependent long-lasting potentiation, The potentiation by cGMP involves an increase in transmitter release that is in part independent of changes in the presynaptic action potential. These results support a presynaptic role for cGMP in LTP.	HOWARD HUGHES MED INST,NEW YORK,NY 10032	Howard Hughes Medical Institute	ARANCIO, O (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X				Arancio O., 1994, Society for Neuroscience Abstracts, V20, P1713; Arancio O., 1993, Society for Neuroscience Abstracts, V19, P241; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DEVENTE J, 1988, BRAIN RES, V446, P387, DOI 10.1016/0006-8993(88)90900-6; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1994, J NEUROBIOL, V25, P652, DOI 10.1002/neu.480250607; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; NEHER E, 1988, CALCIUM ION CHANNEL, P371; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZHUO M, 1994, NEUROREPORT, V5, P1033, DOI 10.1097/00001756-199405000-00004	28	264	275	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					74	80		10.1038/376074a0	http://dx.doi.org/10.1038/376074a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596438				2022-12-01	WOS:A1995RH11100065
J	BIZEBARD, T; GIGANT, B; RIGOLET, P; RASMUSSEN, B; DIAT, O; BOSECKE, P; WHARTON, SA; SKEHEL, JJ; KNOSSOW, M				BIZEBARD, T; GIGANT, B; RIGOLET, P; RASMUSSEN, B; DIAT, O; BOSECKE, P; WHARTON, SA; SKEHEL, JJ; KNOSSOW, M			STRUCTURE OF INFLUENZA-VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY	NATURE			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; FUSION; RECOGNITION; MECHANISM; RECEPTOR; MUTANT; ACID	HAEMAGGLUTININ (HA) is the influenza surface glycoprotein that interacts with infectivity-neutralizing antibodies. As a consequence of this immune pressure it is the variable virus component, which is important in antigenic drift, that results in recurrent epidemics of influenza. We have determined the crystallographic structure of a complex formed between the antigen-binding fragment (Fab) of a neutralizing antibody tend the membrane-distal domain ((HA top') of a HA subunit prepared from HA in its membrane-fusion-active conformation. A dramatic change is seen in the structure of the Fab-combining site on complex formation. Our results indicate that neutralization of infectivity by this antibody involves the inhibition of receptor binding, and demonstrate how influenza virus can maintain its conserved receptor-binding site despite the immune selective pressure for change in this region of the molecule; they also contribute to a complete description of the endosomal pH-induced fusion-active HA structure.	EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; ILL GRENOBLE,EUROPEAN MOLEC BIOL LAB,GRENOBLE OUTSTN,F-38042 GRENOBLE,FRANCE; NATL INST MED RES,MRC,DIV VIROL,LONDON NW7 1AA,ENGLAND	European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); MRC National Institute for Medical Research	BIZEBARD, T (corresponding author), UNIV PARIS SUD,BIOL STRUCT LAB,CNRS,UMR 9920,BAT 34,F-91198 GIF SUR YVETTE,FRANCE.		diat, olivier PC/B-5985-2016; Rigolet, Pascal/S-8602-2018	diat, olivier PC/0000-0003-3011-8168; Rigolet, Pascal/0000-0001-6868-4953; Gigant, Benoit/0000-0002-5946-6759				BIZEBARD T, 1994, ACTA CRYSTALLOGR D, V50, P768, DOI 10.1107/S0907444994001903; BIZEBARD T, 1990, J MOL BIOL, V216, P513, DOI 10.1016/0022-2836(90)90378-Y; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CHERFILS J, 1994, PROTEINS, V18, P8, DOI 10.1002/prot.340180104; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GRUNGER AT, 1992, XPLOR VERSION 3 1; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KNOSSOW M, 1984, NATURE, V311, P678, DOI 10.1038/311678a0; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CCP4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; RUIGROK RW, 1988, J GEN VIROL, P2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SKEHEL JJ, 1971, VIROLOGY, V44, P396, DOI 10.1016/0042-6822(71)90270-4; WARD CW, 1981, CURR TOP MICROBIOL, V94-5, P1; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513; WRIGLEY NG, 1983, VIROLOGY, P308	30	208	220	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					92	94		10.1038/376092a0	http://dx.doi.org/10.1038/376092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596443				2022-12-01	WOS:A1995RH11100069
J	BUDRENE, EO; BERG, HC				BUDRENE, EO; BERG, HC			DYNAMICS OF FORMATION OF SYMMETRICAL PATTERNS BY CHEMOTACTIC BACTERIA	NATURE			English	Article							ESCHERICHIA-COLI	MOTILE cells of Escherichia coli aggregate to form stable patterns of remarkable regularity when grown from a single point on certain substrates. Central to this self-organization is chemotaxis, the motion of bacteria along gradients of a chemical attractant that the cells themselves excrete(1). Here we show how these complex patterns develop. The long-range spatial order arises from interactions between two multicellular aggregate structures: a 'swarm ring' that expands radially, and focal aggregates that have lower mobility. Patterning occurs through alternating domination by these two sources of excreted attractant (which we identify here as aspartate). The pattern geometries vary in a systematic way, depending on how long an aggregate remains active; this depends, in turn, on the initial concentration of substrate (here, succinate).	ROWLAND INST SCI INC,CAMBRIDGE,MA 02142		BUDRENE, EO (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Ladoux, Benoit/A-9879-2013					ADLER J, 1967, J GEN MICROBIOL, V46, P175, DOI 10.1099/00221287-46-2-175; ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; BARINAGA M, 1994, SCIENCE, V266, P561, DOI 10.1126/science.7939701; BENJACOB E, 1995, NATURE, V373, P566, DOI 10.1038/373566a0; BLAT Y, 1995, J BACTERIOL, V177, P1683, DOI 10.1128/jb.177.7.1683-1691.1995; BRUNN SD, 1992, ANN ASSOC AM GEOGR, V82, P1; BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; MARCUS M, 1969, BIOCHIM BIOPHYS ACTA, V177, P314, DOI 10.1016/0304-4165(69)90141-X; Miller JH., 1972, EXPT MOL GENETICS; NEIDHARDT C, 1990, PHSYL BACTERIAL CELL, P208; NOSSAL R, 1972, EXP CELL RES, V75, P183; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1987, GENETICS, V116, P499; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOODWARD DE, 1995, BIOPHYS J, V68, P2181	16	376	376	1	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					49	53		10.1038/376049a0	http://dx.doi.org/10.1038/376049a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596432				2022-12-01	WOS:A1995RH11100058
J	FONG, GH; ROSSANT, J; GERTSENSTEIN, M; BREITMAN, ML				FONG, GH; ROSSANT, J; GERTSENSTEIN, M; BREITMAN, ML			ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM	NATURE			English	Article							GROWTH-FACTOR; MOLECULAR-CLONING; STEM-CELLS; EXPRESSION; VASCULOGENESIS; ANGIOGENESIS; FLK-1; MICE; TEK	THE vascular endothelial growth factor (VEGF) and its high-affinity binding receptors, the tyrosine kinases Flt-1 and Flk-1, are thought to be important for the development of embryonic vasculature(1-8). Here we report that Flt-1 is essential for the organization of embryonic vasculature, but is not essential for endothelial cell differentiation. Mouse embryos homozygous for a targeted mutation in the flt-1 locus, flt-1(lcz), formed endothelial cells in both embryonic and extra-embryonic regions, but assembled these cells into abnormal vascular channels and died in utero at mid-somite stages. At earlier stages, the blood islands of flt-1(lcz) homozygotes were abnormal, with angioblasts in the interior as well as on the periphery. We suggest that the Flt-1 signalling pathway may regulate normal endothelial cell-cell or cell-matrix interactions during vascular development.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BRELER G, 1992, DEVELOPMENT, V114, P521; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FINNERTY H, 1993, ONCOGENE, V8, P2293; Hogan B., 1994, MANIPULATING MOUSE E; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KORHNONEN J, 1994, ONCOGENE, V9, P995; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NODEN DM, 1989, AM REV RESPIR DIS, V149, P1097; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARK JE, 1994, J BIOL CHEM, V269, P25646; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PATAN S, 1993, ANAT EMBRYOL, V187, P121; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P622; SHIBUYA M, 1990, ONCOGENE, V5, P519; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	27	2055	2159	2	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					66	70		10.1038/376066a0	http://dx.doi.org/10.1038/376066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596436				2022-12-01	WOS:A1995RH11100063
J	HOPFIELD, JJ				HOPFIELD, JJ			PATTERN-RECOGNITION COMPUTATION USING ACTION-POTENTIAL TIMING FOR STIMULUS REPRESENTATION	NATURE			English	Article							INFERIOR COLLICULUS; INTERAURAL TIME; VISUAL-CORTEX; DELAY-LINES; BRAIN-STEM; INFORMATION; OSCILLATIONS; CIRCUIT; CELLS; BAT	A computational model is described in which the sizes of variables are represented by the explicit times at which action potentials occur, rather than by the more usual 'firing rate' of neurons. The comparison of patterns over sets of analogue variables is done by a network using different delays for different information paths. This mode of computation explains how one scheme of neuroarchitecture can be used for very different sensory modalities and seemingly different computations. The oscillations and anatomy of the mammalian olfactory systems have a simple interpretation in terms of this representation, and relate to processing in the auditory system. Single-electrode recording would plot detect such neural computing. Recognition 'units' in this style respond more like radial basis function units than elementary sigmoid un its.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	HOPFIELD, JJ (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.							ADRIAN ED, 1941, J PHYSIOL-LONDON, V100, P459; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI 10.3109/0954898X.2011.638888; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BULLOCK TH, 1993, ANNU REV NEUROSCI, V16, P1, DOI 10.1146/annurev.ne.16.030193.000245; Burgess N, 1993, ADV NEURAL INFORMATI, V5, P929; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1990, J NEUROSCI, V10, P3227; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; GIROSI F, 1990, BIOL CYBERN, V63, P169, DOI 10.1007/BF00195855; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HABERLY LB, 1985, CHEM SENSES, V10, P219, DOI 10.1093/chemse/10.2.219; HARNISCHFEGER G, 1985, J NEUROPHYSIOL, V53, P89, DOI 10.1152/jn.1985.53.1.89; HEILIGENBERG WF, 1991, NEURAL NETS ELECTRIC, P51; Herz J., 1991, INTRO THEORY NEURAL; HOSSAM O, 1994, NEURAL COMPUTAT, V6, P927; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KUWABARA N, 1993, J NEUROPHYSIOL, V69, P1713, DOI 10.1152/jn.1993.69.5.1713; LAURENT G, 1994, J NEUROSCI, V14, P2993; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; Nickell W.T., 1992, SCIENCE OLFACTION, P172; Perkel D.H., 1968, NEUROSCI RES PROGRAM, V6, P221; REICHARDT W, 1957, Z NATURFORSCH PT B, V12, P448, DOI 10.1515/znb-1957-0707; REVIAL MF, 1982, CHEM SENSES, V7, P175, DOI 10.1093/chemse/7.2.175; RODIECK RW, 1973, VERTEBRATE RETINA; Shepherd G, 1979, SYNAPTIC ORG BRAIN, P289; SHEPHERD GM, 1979, BRAIN RES, V175, P377, DOI 10.1016/0006-8993(79)91020-5; SHEPHERD GM, 1979, SYNAPTIC ORG BRAIN, P152; SILVA LR, 1991, SCIENCE, V252, P432; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; TANK DW, 1994, SCIENCE, V265, P1819, DOI 10.1126/science.265.5180.1819; UNNIKRISHNAN KP, 1991, IEEE T SIGNAL PROCES, V39, P698, DOI 10.1109/78.80888	33	812	846	3	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					33	36		10.1038/376033a0	http://dx.doi.org/10.1038/376033a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596429				2022-12-01	WOS:A1995RH11100054
J	HUBER, R; BURGGRAF, S; MAYER, T; BARNS, SM; ROSSNAGEL, P; STETTER, KO				HUBER, R; BURGGRAF, S; MAYER, T; BARNS, SM; ROSSNAGEL, P; STETTER, KO			ISOLATION OF A HYPERTHERMOPHILIC ARCHAEUM PREDICTED BY IN-SITU RNA ANALYSIS	NATURE			English	Article							SINGLE CELLS; BACTERIA; ARCHAEBACTERIA; MANIPULATION; ORGANISMS; PROBES	A variety of hyperthermophilic bacteria and archaea(1) have been isolated from high-temperature environments by plating and serial dilutions(2). However, these techniques allow only the small percentage of organisms able to form colonies, or those that are predominant within environmental samples, to be obtained in pure culture, Recently, in situ 16S ribosomal RNA analyses of samples from the Obsidian hot pool at Yellowstone National Park, Wyoming, revealed a variety of archaeal sequences, which,were all different from those of previously isolated species(3,4). This suggests substantial diversity of archaea with so far unknown morphological, physiological and biochemical features, which may play an important part within high-temperature ecosystems, Here we describe a procedure to obtain pure cultures of unknown organisms harbouring specific 16S rRNA sequences identified previously within the environment, It combines visual recognition of single cells by phylogenetic staining(5-9) and cloning by 'optical tweezers'(10,11). Our result validates polymerase chain reaction data on the existence of large archaeal communities.	UNIV REGENSBURG,ARCHAEENZENTRUM,D-93053 REGENSBURG,GERMANY; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405	University of Regensburg; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	HUBER, R (corresponding author), UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,UNIV STR 31,D-93053 REGENSBURG,GERMANY.			Burggraf, Siegfried/0000-0002-2116-0156				AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARNS SM, 1994, 94 GEN M AM SOC MICR, P253; BARNS SM, 1994, P NATL ACAD SCI USA, V9, P1609; BIOCHL E, 1995, WLD J MICRBIOL BIOTE, V11, P9; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; BURGGRAF S, 1994, APPL ENVIRON MICROB, V60, P3112, DOI 10.1128/AEM.60.9.3112-3119.1994; BURGGRAF S, 1994, APPL ENV MICORBIOL, V330, P3112; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; HUBER R, 1992, PROKARYOTES, P677; KANE MD, 1993, APPL ENVIRON MICROB, V59, P682, DOI 10.1128/AEM.59.3.682-686.1993; Stahl D.A., 1991, SEQUENCING HYBRIDIZA, P205; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; STETTER KO, 1981, ZBL BAKT MIK HYG I C, V2, P166, DOI 10.1016/S0721-9571(81)80038-5; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	19	151	162	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					57	58		10.1038/376057a0	http://dx.doi.org/10.1038/376057a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541115				2022-12-01	WOS:A1995RH11100060
J	KOLESNIKOV, SS; MARGOLSKEE, RF				KOLESNIKOV, SS; MARGOLSKEE, RF			A CYCLIC-NUCLEOTIDE-SUPPRESSIBLE CONDUCTANCE ACTIVATED BY TRANSDUCIN IN TASTE CELLS	NATURE			English	Article							ADENYLATE-CYCLASE; GATED CONDUCTANCE; RECEPTOR-CELLS; OUTER SEGMENT; PROTEIN; PHOSPHODIESTERASE; MEMBRANE; STIMULI; GMP	TASTE can be divided into four primary sensations: salty, sour, sweet and bitter, Salty and sour are directly transduced by apical channels(1-4), whereas sweet and bitter utilize cyclic nucleotide second messengers(5-11). We have shown that rod transducin is present in mammalian taste receptor cells, where it is activated by a bitter receptor and in turn activates a phosphodiesterase(12). Here we introduce into frog taste cells peptides derived from transducin's phosphodiesterase-interaction region, which cause an inward whole-cell current in a subset of cells, We find that the peptides' effects are reversibly suppressed by IBMX and forskolin, indicative of a transducin-activated phosphodiesterase. Cyclic nucleotides suppress the whole-cell current, indicating that cyclic nucleotides may regulate taste-cell conductance. IBMX modifies taste-cell responses to two taste stimuli, implicating phosphodiesterase in taste transduction. Submicromolar cyclic nucleotides directly suppress the conductance of inside-out patches derived from the taste-cell plasma membrane, independently of protein phosphorylation. The channels are unusual in that they are suppressed, rather than activated by cyclic nucleotides, We propose that transducin, via phosphodiesterase, decreases cyclic nucleotide levels to activate the cyclic-nucleotide-suppressible conductance, leading to Ca2+ influx and taste-cell depolarization.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; RUSSIAN ACAD SCI,INST CELL BIOPHYS,PUSHCHINO 142292,RUSSIA	Roche Holding; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS			Kolesnikov, Stasnislav S/C-8468-2015	Margolskee, Robert/0000-0002-9572-2887				AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; AVENET P, 1989, J MEMBRANE BIOL, V97, P223; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; CUMMINGS TA, 1993, J NEUROPHYSIOL, V70, P2326, DOI 10.1152/jn.1993.70.6.2326; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Gilbertson Timothy A., 1993, Current Opinion in Neurobiology, V3, P532, DOI 10.1016/0959-4388(93)90052-Z; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HESENKO EF, 1993, NATURE, V19, P1428; KALINOSKI DL, 1989, CHEM SENSES RECEPTOR, P85; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KOLESNIKOV SS, 1991, FEBS LETT, V290, P167, DOI 10.1016/0014-5793(91)81251-3; KURIHARA K, 1972, FEBS LETT, V27, P279, DOI 10.1016/0014-5793(72)80640-9; Margolskee Robert F., 1993, Current Opinion in Neurobiology, V3, P526, DOI 10.1016/0959-4388(93)90051-Y; MCBRIDE DW, 1991, J MEMBRANE BIOL, V124, P85, DOI 10.1007/BF01871367; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0	28	100	105	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					85	88		10.1038/376085a0	http://dx.doi.org/10.1038/376085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541117				2022-12-01	WOS:A1995RH11100067
J	NICHOLSON, DW; ALI, A; THORNBERRY, NA; VAILLANCOURT, JP; DING, CK; GALLANT, M; GAREAU, Y; GRIFFIN, PR; LABELLE, M; LAZEBNIK, YA; MUNDAY, NA; RAJU, SM; SMULSON, ME; YAMIN, TT; YU, VL; MILLER, DK				NICHOLSON, DW; ALI, A; THORNBERRY, NA; VAILLANCOURT, JP; DING, CK; GALLANT, M; GAREAU, Y; GRIFFIN, PR; LABELLE, M; LAZEBNIK, YA; MUNDAY, NA; RAJU, SM; SMULSON, ME; YAMIN, TT; YU, VL; MILLER, DK			IDENTIFICATION AND INHIBITION OF THE ICE/CED-3 PROTEASE NECESSARY FOR MAMMALIAN APOPTOSIS	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; ENDONUCLEASE; CELLS; RIBOSYLATION; SEQUENCE; ENCODES; VIRUS; GENE	The protease responsible for the cleavage of poly(ADP-ribose) polymerase and necessary for apoptosis has been purified and characterized. This enzyme, named apopain, is composed of two subunits of relative molecular mass (M(r)) 17K and 12K that are derived from a common proenzyme identified as CPP32. This proenzyme is related to interleukin-1 beta-converting enzyme (ICE) and CED-3, the product of a gene required for programmed cell death in Caenorhabditis elegans. A potent peptide aldehyde inhibitor has been developed and shown to prevent apoptotic events In vitro, suggesting that apopain/CPP32 is important for the initiation of apoptotic cell death.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK & CO INC,RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC	Merck & Company; Merck & Company; Merck & Company; Cold Spring Harbor Laboratory; Georgetown University	NICHOLSON, DW (corresponding author), MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POB 1005,POINTE CLAIRE,PQ H9R 4P8,CANADA.							AYALA JM, 1994, J IMMUNOL, V153, P2592; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; CARSON DA, 1994, LANCET, V341, P1251; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; ELLIS RE, 1991, REV CELL BIOL, V7, P663; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1995, J IMMUNOL, V154, P2321; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V76, P653; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SOLARY E, 1993, BLOOD, V81, P1359; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WESTERIK JO, 1972, J BIOL CHEM, V247, P8195; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YOSHIHAR.K, 1974, BIOCHEM BIOPH RES CO, V59, P658, DOI 10.1016/S0006-291X(74)80030-6; YOSHIHARA K, 1975, P NATL ACAD SCI USA, V72, P289, DOI 10.1073/pnas.72.1.289; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	48	3710	3860	1	91	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					37	43		10.1038/376037a0	http://dx.doi.org/10.1038/376037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596430				2022-12-01	WOS:A1995RH11100055
J	RUIZAVILA, L; MCLAUGHLIN, SK; WILDMAN, D; MCKINNON, PJ; ROBICHON, A; SPICKOFSKY, N; MARGOLSKEE, RF				RUIZAVILA, L; MCLAUGHLIN, SK; WILDMAN, D; MCKINNON, PJ; ROBICHON, A; SPICKOFSKY, N; MARGOLSKEE, RF			COUPLING OF BITTER RECEPTOR TO PHOSPHODIESTERASE THROUGH TRANSDUCIN IN TASTE RECEPTOR-CELLS	NATURE			English	Article							AMINO-ACID SEQUENCE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; ADENOSINE RECEPTOR; CDNA SEQUENCE; RHODOPSIN; PROTEOLYSIS; ACTIVATION	THE rod and cone transducins rue specific G proteins originally thought to be present only in photoreceptor cells of the vertebrate retina(1-4). Transducins convert light stimulation of photoreceptor opsins into activation of cyclic GMP phosphodiesterase (reviewed in refs. 5-7). A transducin-like G protein, gustducin, has been identified and cloned from rat taste cells(8). We report here that rod transducin is also present in vertebrate taste cells, where it specifically activates a phosphodiesterase isolated from taste tissue. Furthermore, the bitter compound denatonium in the presence of taste-ceh membranes activates transducin but not G(i). A peptide that competitively inhibits rhodopsin activation of transducing also blocks taste-cell membrane activation of transducin, arguing for the involvement of a seven-transmembrane-helix G-protein-coupled receptor. These results suggest that rod transducin tranduces bitter taste by coupling taste receptor(s) to taste-cell phosphodiesterase. Phosphodiesterase-mediated degradation of cyclic nucleotides may lead to taste-cell depolarization through the recently identified cyclic-nucleotide-suppressible conductance(10).	HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Roche Holding				robichon, alain/0000-0003-1075-9646; Margolskee, Robert/0000-0002-9572-2887; Ruiz-Avila, Luis/0000-0001-8777-1083				ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; ABE K, 1993, J BIOL CHEM, V268, P12033; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HALLIDAY KR, 1984, J BIOL CHEM, V259, P516; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NAIM M, 1991, COMP BIOCHEM PHYS B, V100, P455, DOI 10.1016/0305-0491(91)90203-P; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SCHIFFMAN SS, 1985, PHARMACOL BIOCHEM BE, V22, P195, DOI 10.1016/0091-3057(85)90377-6; SCHIFFMAN SS, 1986, PHARMACOL BIOCHEM BE, V24, P429, DOI 10.1016/0091-3057(86)90536-8; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Spickofsky Nancy, 1992, Chemical Senses, V17, P701; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; Whiteside B, 1926, J COMP NEUROL, V40, P33, DOI 10.1002/cne.900400105; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	30	176	189	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					80	85		10.1038/376080a0	http://dx.doi.org/10.1038/376080a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596440				2022-12-01	WOS:A1995RH11100066
J	SATO, TN; TOZAWA, Y; DEUTSCH, U; WOLBURGBUCHHOLZ, K; FUJIWARA, Y; GENDRONMAGUIRE, M; GRIDLEY, T; WOLBURG, H; RISAU, W; QIN, Y				SATO, TN; TOZAWA, Y; DEUTSCH, U; WOLBURGBUCHHOLZ, K; FUJIWARA, Y; GENDRONMAGUIRE, M; GRIDLEY, T; WOLBURG, H; RISAU, W; QIN, Y			DISTINCT ROLES OF THE RECEPTOR TYROSINE KINASES TIE-1 AND TIE-2 IN BLOOD-VESSEL FORMATION	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-CLONING; ANGIOGENESIS; EXPRESSION; GENES; CELLS; VASCULOGENESIS; MEMBER; DEFINE; FAMILY	TIE-1 and Tie-2 define a new class of receptor tyrosine kinases that are specifically expressed in developing vascular endothelial cells. To study the functions of Tie-1 and Tie-2 during vascular endothelial cell growth and differentiation in vivo, targeted mutations of the genes in mice were introduced by homologous recombination. Embryos deficient in Tie-1 failed to establish structural integrity of vascular endothelial cells, resulting in oedema and subsequently localized haemorrhage. However, analyses of embryos deficient in Tie-2 showed that it is important in angiogenesis, particularly for vascular network formation in endothelial cells. This result contrasts with previous reports on Tie-2 function in vasculogenesis and/or endothelial cen survival. Our in vivo analyses indicate that the structurally related receptor tyrosine kinases Tie-1 and Tie-2 have important hut distinct roles in the formation of blood vessels.	MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCHOFF INST,MOLEK ZELLBIOL ABT,D-61231 BAD NAUHEIM,GERMANY; UNIV TUBINGEN,INST PATHOL,D-72076 TUBINGEN,GERMANY	Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	SATO, TN (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110, USA.		Tozawa, Yuzuru/G-2657-2013; Tozawa, Yuzuru/AAM-9620-2020	Tozawa, Yuzuru/0000-0002-3885-1105; Deutsch, Urban/0000-0003-4265-6262				DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KALPAINEN A, 1994, CANCER RES, V54, P6571; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; OELRICHS RB, 1993, ONCOGENE, V8, P11; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QIN Y, 1995, DEV DYNAM, V202, P172, DOI 10.1002/aja.1002020209; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SUCOV HM, 1994, GENE DEV, V3, P1007; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VIRAGH S, 1981, ANAT REC, V201, P157, DOI 10.1002/ar.1092010117; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; ZIEGLER SF, 1993, ONCOGENE, V8, P663	30	1408	1500	3	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					70	74		10.1038/376070a0	http://dx.doi.org/10.1038/376070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596437				2022-12-01	WOS:A1995RH11100064
J	SHALABY, F; ROSSANT, J; YAMAGUCHI, TP; GERTSENSTEIN, M; WU, XF; BREITMAN, ML; SCHUH, AC				SHALABY, F; ROSSANT, J; YAMAGUCHI, TP; GERTSENSTEIN, M; WU, XF; BREITMAN, ML; SCHUH, AC			FAILURE OF BLOOD-ISLAND FORMATION AND VASCULOGENESIS IN FLK-1-DEFICIENT MICE	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; STEM-CELLS; MOUSE; PRECURSORS; EXPRESSION; GENE; DIFFERENTIATION; COMMITMENT; PROTEIN	THE receptor tyrosine kinase Flk-1 (ref. 1) is believed to play a pivotal role in endothelial development. Expression of the Flk-1 receptor is restricted to endothelial cells and their embryonic precursors(2-5), and is complementary to that of its ligand, vascular endothelial growth factor (VEGF)(2,3), which, is aa endothelial-specific mitogen. Highest levels of flk-1 expression are observed during embryonic vasculogenesis and angiogenesis(2-5), and dating pathological processes associated with neovascularization, such its tumour angiogenesis(7,8). Because flk-1 expression can be detected in presumptive mesodermal yolk-sac blood-island progenitors as early as 7.0 days postcoitum, Flk-1 may mark the putative common embryonic endothelial and haematopoietic precursor, the haemangioblast, and thus may also be involved in early haematopoiesis(4). Here rye report the generation of mice deficient in Flk-1 by disruption of the gene using homologous recombination in embryonic stem (ES) cells. Embryos homozygous for this mutation die in utero between 8.5 and 9.5 days post-coitum, as a result of an early defect in the development of haematopoietic and endothelial cells. Yolk-sac blood islands were absent at 7.5 days, organized blood vessels could not be observed in the embryo or yolk sac at any stage, acid haematopoietic progenitors were severely reduced. These results indicate that Flk-1 is essential for yolk-sac Mood-island formation and vasculogenesis in the mouse embryo.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,INST MED SCI,TORONTO,ON M5S 1A8,CANADA; TORONTO HOSP,DIV HAEMATOL ONCOL,TORONTO,ON M5G 2C4,CANADA; CANADIAN RED CROSS SOC,TORONTO BLOOD CTR,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; DORHONEN J, 1994, ONCOGENE, V9, P395; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, IN PRESS P NATN ACAD; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MCCLANAHAN T, 1993, BLOOD, V81, P2903; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLAUER B, 1993, CELL, V72, P1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OELRICHS RB, 1993, ONCOGENE, V8, P11; PLATE KH, 1993, CANCER RES, V53, P5822; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sambrook J., 1989, MOL CLONING LAB MANU; SHIBUYA M, 1990, ONCOGENE, V5, P519; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YOUNG PE, 1995, BLOOD, V85, P96, DOI 10.1182/blood.V85.1.96.bloodjournal85196; ZIPORI D, 1988, BLOOD, V71, P586	31	3103	3258	2	100	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					62	66		10.1038/376062a0	http://dx.doi.org/10.1038/376062a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596435				2022-12-01	WOS:A1995RH11100062
J	UMBHAUER, M; MARSHALL, CJ; MASON, CS; OLD, RW; SMITH, JC				UMBHAUER, M; MARSHALL, CJ; MASON, CS; OLD, RW; SMITH, JC			MESODERM INDUCTION IN XENOPUS CAUSED BY ACTIVATION OF MAP KINASE	NATURE			English	Article							MIDBLASTULA TRANSITION; SPEMANN ORGANIZER; RAF-1 KINASE; EXPRESSION; FGF; EMBRYOS; TRANSCRIPTION; P21RAS; NOGGIN; LAEVIS	MESODERM induction is a critical early step in vertebrate development, involving changes in gene expression and morphogenesis(1), In Xenopus, normal mesoderm formation depends on signalling through the fibroblast growth factor (FGF) tyrosine kinase receptor(2-4). One important signalling pathway from receptor tyrosine kinases involves p21(ras) (ref, 5). Ras associates with the serine kinase c-Raf-1 in a GTP-dependent manner, and this complex phosphorylates and activates MAPK/ERK kinase (MEK), a protein kinase with dual specificity, MEK then activates p42(mapk); and (at least in mammals) p44(mapk), members of the mitogen-activated protein (MAP) kinase family(6), FGF activates MAP kinase during mesoderm induction(7-9), and the use of dominant-negative constructs suggests that mesoderm induction by FGF requires both Res and Raf(10,11). However, these experiments Bo not reveal whether Ras and Raf do act through MAP kinase to induce mesoderm or whether another pathway, such as the phosphatidylinositol 3-kinase cascade(12), is involved. Here we show that expression of active forms of MEK or of MAP kinase induces ventral mesoderm of the hind elicited by FGF, Overexpression of a Xenopus MAP kinase phosphatase Mocks mesoderm induction by FGF, and causes characteristic defects in mesoderm formation in intact embryos, whereas inhibition of the P13 kinase and p70 S6 kinase pathways has no effect on mesoderm induction by FGF, FGF induces different types of mesoderm in a dose-dependent manner(13); strikingly, this is mimicked by expressing different levels of activated MEK. Together, these experiments demonstrate that activation of MAP kinases is necessary and sufficient for mesoderm formation.	INST CANC RES,CRC,CTR CELLULAR & MOLEC BIOL,LONDON SW3 6JB,ENGLAND; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Warwick	UMBHAUER, M (corresponding author), NATL INST MED RES,DIV DEV BIOL,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.			Smith, Jim/0000-0003-2413-9392; Mason, Clive/0000-0003-3179-6622; Umbhauer, Muriel/0000-0001-7419-8070				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P966; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CORNELL RA, 1994, DEVELOPMENT, V120, P453; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1990, DEVELOPMENT, V108, P229; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LABONNE C, 1994, DEVELOPMENT, V120, P463; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1993, CELLULAR INTERACTION, P181; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0	34	202	203	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					58	62		10.1038/376058a0	http://dx.doi.org/10.1038/376058a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541116				2022-12-01	WOS:A1995RH11100061
J	WANG, Y; PRIVES, C				WANG, Y; PRIVES, C			INCREASED AND ALTERED DNA-BINDING OF HUMAN P53 BY S AND G2/M BUT NOT G1 CYCLIN-DEPENDENT KINASES	NATURE			English	Article							PHOSPHORYLATION; PROTEIN; MUTANT; PROLIFERATION; REPLICATION; INHIBIT; ANTIGEN; GENES	CENTRAL to the role of p53 in cell regulation are its sequence-specific interactions with genes that control the cell cycle and apoptosis(1,2). p53 response elements contain two or more copies of a somewhat promiscuous consensus sequence: 5'-XXXC(A,T)(T, A)GYYY-3' (where X is a purine and Y is a pyrimidine) (ref, 3), The sequence-specific DNA-binding region of p53 resides in its central conserved region(4). Although this region itself is not known to he phosphorylated, the amino and carboxy termini of human p53 contain sites for phosphorylation by several protein kinases.			WANG, Y (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1990, ONCOGENE, V5, P795; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	30	326	331	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	1995	376	6535					88	91		10.1038/376088a0	http://dx.doi.org/10.1038/376088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7596441				2022-12-01	WOS:A1995RH11100068
J	WOO, D				WOO, D			APOPTOSIS AND LOSS OF RENAL TISSUE IN POLYCYSTIC KIDNEY-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-DEATH; VITRONECTIN RECEPTOR; TRANSGENIC MICE; NEOPLASIA; ATROPHY; EVENTS; MODEL; RAT	Background. Polycystic kidney disease is characterized by the enlargement of renal cysts, interstitial fibrosis, and gradual loss of normal renal tissue in association with progressive deterioration of renal function. The process causing the progressive loss of renal tissue is unknown, but it could be the result of a form of programmed cell death known as apoptosis. Methods. We assayed apoptotic DNA fragmentation in normal and polycystic kidneys biochemically by gel electrophoresis and histochemically by in situ end-labeling. A DNA-specific dye, Hoechst 33258, was used to detect morphologic apoptosis in renal samples from patients with normal kidneys, polycystic kidney disease, and other kidney diseases. Results. Apoptotic DNA fragmentation was detected in polycystic kidneys from 5 patients without renal failure and 11 patients with renal failure but not in kidneys from 12 patients with no renal disease. In situ end-labeling revealed apoptotic cells in glomeruli, in cyst walls, and in both cystic and noncystic tubules of the polycystic kidneys. No tubular apoptosis was detected in renal-biopsy specimens from five patients with IgA nephropathy, three patients with nephrosclerosis, two patients with focal glomerulosclerosis, one patient with diabetic nephropathy, six patients with acute tubular necrosis, or four patients with acute and four patients with chronic renal-transplant rejection. The capacity of polycystic kidney cells to undergo apoptosis was retained in vitro in the absence of uremia, ischemia, and other confounding pathologic conditions. Conclusions. Apoptotic loss of renal tissue may be associated with the progressive deterioration of renal function that occurs in patients with polycystic kidney disease.			WOO, D (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,DIV NEPHROL,LOS ANGELES,CA 90024, USA.				NIDDK NIH HHS [DK45663, DK40700] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045663, R01DK040700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; BASERGA R, 1968, LAB INVEST, V19, P92; CARONE FA, 1993, LAB INVEST, V68, P413; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; COLES HSR, 1993, DEVELOPMENT, V118, P777; CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; FADOK VA, 1992, J IMMUNOL, V149, P4029; FINE LG, 1989, ANNU REV PHYSIOL, V51, P19, DOI 10.1146/annurev.ph.51.030189.000315; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOBE GC, 1990, LAB INVEST, V63, P770; GOBE GC, 1987, LAB INVEST, V56, P273; GRANTHAM JJ, 1995, J CLIN INVEST, V95, P195, DOI 10.1172/JCI117638; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; HEGG O, 1966, J PATHOL BACTERIOL, V91, P311, DOI 10.1002/path.1700910204; KAMADA S, 1995, CANCER RES, V55, P354; KELLEY KA, 1991, J AM SOC NEPHROL, V2, P84; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; LEDDACOLUMBANO GM, 1989, AM J PATHOL, V135, P657; MAJNO G, 1995, AM J PATHOL, V146, P3; MIGHELI A, 1994, J NEUROPATH EXP NEUR, V53, P606, DOI 10.1097/00005072-199411000-00008; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; Sambrook J., 1989, MOL CLONING LAB MANU; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; TAKAHASHI H, 1986, J UROLOGY, V135, P1280, DOI 10.1016/S0022-5347(17)46074-5; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	41	288	304	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					18	25		10.1056/NEJM199507063330104	http://dx.doi.org/10.1056/NEJM199507063330104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776989				2022-12-01	WOS:A1995RG73500004
J	BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL				BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL			INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; HEALTH-CARE; MEDICATION	Objectives.-To assess incidence and preventability of adverse drug events (ADEs) and potential ADEs. To analyze preventable events to develop prevention strategies. Design.-Prospective cohort study. Participants.-All 4031 adult admissions to a stratified random sample of 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Units included two medical and three surgical intensive care units and four medical and two surgical general care units. Main Outcome Measures.-Adverse drug events and potential ADEs. Methods.-Incidents were detected by stimulated self-report by nurses and pharmacists and by daily review of all charts by nurse investigators. Incidents were subsequently classified by two independent reviewers as to whether they represented ADEs or potential ADEs and as to severity and preventability. Results.-Over 6 months, 247 ADEs and 194 potential ADEs were identified. Extrapolated event rates were 6.5 ADEs and 5.5 potential ADEs per 100 nonobstetrical admissions, for mean numbers per hospital per year of approximately 1900 ADEs and 1600 potential ADEs. Of all ADEs, 1% were fatal (none preventable), 12% life-threatening, 30% serious, and 57% significant. Twenty-eight percent were judged preventable. Of the life-threatening and serious ADEs, 42% were preventable, compared with 18% of significant ADEs, Errors resulting in preventable ADEs occurred most often at the stages of ordering (56%) and administration (34%); transcription (6%) and dispensing errors (4%) were less common. Errors were much more likely to be intercepted if the error occurred earlier in the process: 48% at the ordering stage vs 0% at the administration stage, Conclusion.-Adverse drug events were common and often preventable; serious ADEs were more likely to be preventable. Most resulted from errors at the ordering stage, but many also occurred at the administration stage. Prevention strategies should target both stages of the drug delivery process.	BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; APM INC, NEW YORK, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Arán, Teodoro J Martínez/A-4568-2010	Arán, Teodoro J Martínez/0000-0002-5877-3941	AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BERRY LL, 1988, AM J HOSP PHARM, V45, P1534, DOI 10.1093/ajhp/45.7.1534; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FAICH GA, 1991, ARCH INTERN MED, V151, P1645, DOI 10.1001/archinte.151.8.1645; FOLLI HL, 1987, PEDIATRICS, V79, P718; FORRESTER JW, 1971, MIT TECHNOL REV, V73, P2; FUCHSBERG A, 1978, TRIAL LAWYERS Q, V12, P9; GOSNEY M, 1984, LANCET, V2, P564; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; HODDINOTT BC, 1967, CAN MED ASSOC J, V97, P1001; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; RIND DM, 1991, P ANN S COMPUT APPL, V15, P28; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; Wan T T, 1987, QRB Qual Rev Bull, V13, P61; 1985, INJURY AM; 1991, STATXACT USER MANUAL; 1988, SAS RELEASE 6 03; 1980, MED MALPRACTICE CLOS	41	2206	2294	1	123	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					29	34		10.1001/jama.274.1.29	http://dx.doi.org/10.1001/jama.274.1.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791255				2022-12-01	WOS:A1995RG23300027
J	FEDER, HM; HUNT, MS				FEDER, HM; HUNT, MS			PITFALLS IN THE DIAGNOSIS AND TREATMENT OF LYME-DISEASE IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ERYTHEMA MIGRANS; SEROLOGIC TESTS; REFERRAL CENTER; BORRELIOSIS; DOXYCYCLINE	Objective.-To define pitfalls of diagnosis and treatment of Lyme disease in children. Design.-Case series. Setting.-A university Lyme disease clinic in a Lyme disease endemic area. Patients. A total of 146 pediatric patients (mean age, 9.9 years) referred with possible Lyme disease. Main Outcome Measures.-Of the 146 patients, 56 (38%) were overdiagnosed, 12 (8%) were underdiagnosed, and 75 (51%) were correctly diagnosed with Lyme disease. Treatment errors were made for 19 (25%) of these 75 patients. In addition, three patients (2%) with tick bites were misdiagnosed or mistreated. Frequent pitfalls included misidentifying rashes as erythema migrans, ascribing nonspecific symptoms to Lyme disease, failing to ascribe fleeting objective symptoms to Lyme disease, and inappropriate antibiotic therapy for patients with Lyme disease. Conclusions.-Errors in the diagnosis and treatment of Lyme disease in children are common.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT	University of Connecticut	FEDER, HM (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT FAMILY MED,MC 3960,FARMINGTON,CT 06030, USA.							BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; FEDER HM, 1993, PEDIATRICS, V91, P456; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; FEDER HM, 1995, J INFECT DIS, V171, P1371, DOI 10.1093/infdis/171.5.1371; FISTER RD, 1984, J CLIN MICROBIOL, V27, P2834; HALPERIN JJ, 1992, NEUROLOGY, V42, P1268, DOI 10.1212/WNL.42.7.1268; Krause P J, 1994, Adv Pediatr Infect Dis, V9, P183; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; MALANE MS, 1991, ANN INTERN MED, V114, P490, DOI 10.7326/0003-4819-114-6-490; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; 1993, MMWR-MORBID MORTAL W, V42, P345	20	26	26	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					66	68		10.1001/jama.274.1.66	http://dx.doi.org/10.1001/jama.274.1.66			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791260				2022-12-01	WOS:A1995RG23300032
J	LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M				LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M			SYSTEMS-ANALYSIS OF ADVERSE DRUG EVENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTION; FAILURES; COMPUTER; ERRORS	Objective.-To identify and evaluate the systems failures that underlie errors causing adverse drug events (ADEs) and potential ADEs. Design.-Systems analysis of events from a prospective cohort study. Participants.-All admissions to 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Main Outcome Measures.-Errors, proximal causes, and systems failures. Methods.-Errors were detected by interviews of those involved. Errors were classified according to proximal cause and underlying systems failure by multidisciplinary teams of physicians, nurses, pharmacists, and systems analysts. Results.-During this period, 334 errors were detected as the causes of 264 preventable ADEs and potential ADEs. Sixteen major systems failures were identified as the underlying causes of the errors. The most common systems failure was in the dissemination of drug knowledge, particularly to physicians, accounting for 29% of the 334 errors. Inadequate availability of patient information, such as the results of laboratory tests, was associated with 18% of errors. Seven systems failures accounted for 78% of the errors; all could be improved by better information systems. Conclusions.-Hospital personnel willingly participated in the detection and investigation of drug use errors and were able to identify underlying systems failures. The most common defects were in systems to disseminate knowledge about drugs and to make drug and patient information readily accessible at the time it is needed. Systems changes to improve dissemination and display of drug and patient data should make errors in the use of drugs less likely.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT NURSING, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; APM INC, NEW YORK, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.				AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ackoff RL., 1974, REDESIGNING FUTURE; ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bertalanffy Lv, 1968, GEN SYSTEMS THEORY; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Cook RI, 1994, HUMAN ERROR MED; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; Deming WE., 1986, OUT CRISIS; FOLLI HL, 1987, PEDIATRICS, V79, P718; Gaba D, 1994, HUMAN ERROR MED; GABA DM, 1987, ANESTHESIOLOGY, V66, P670, DOI 10.1097/00000542-198705000-00013; LANGLEY GJ, 1992, F IMPROVEMENT; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; Moray N, 1994, HUMAN ERROR MED; Norman D.A., 1988, PSYCHOL EVERYDAY THI; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Perrow C., 1984, NORMAL ACCIDENTS LIV; Rasmussen J., 1994, COGNITIVE SYSTEMS EN; REASON J, 1990, PHILOS T ROY SOC B, V327, P475, DOI 10.1098/rstb.1990.0090; Reason J., 1990, HUMAN ERROR, DOI 10.1017/cbo9781139062367; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; VANCOTT H, 1994, HUMAN ERROR MED; 1980, MED MALPRACTICE CLOS	31	1354	1408	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					35	43		10.1001/jama.1995.03530010049034	http://dx.doi.org/10.1001/jama.1995.03530010049034			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791256				2022-12-01	WOS:A1995RG23300028
J	ROSENBLOOM, AJ; PINSKY, MR; BRYANT, JL; SHIN, A; TRAN, T; WHITESIDE, T				ROSENBLOOM, AJ; PINSKY, MR; BRYANT, JL; SHIN, A; TRAN, T; WHITESIDE, T			LEUKOCYTE ACTIVATION IN THE PERIPHERAL-BLOOD OF PATIENTS WITH CIRRHOSIS OF THE LIVER AND SIRS - CORRELATION WITH SERUM INTERLEUKIN-6 LEVELS AND ORGAN DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECROSIS-FACTOR-ALPHA; SEPTIC SHOCK; UP-REGULATION; TRANSENDOTHELIAL MIGRATION; COMPLEMENT RECEPTOR-1; HYDROGEN-PEROXIDE; FLOW-CYTOMETRY; SEVERE SEPSIS; CD11B CD18; HLA-DR	Objective.-Leukocyte adhesion plays an important role in inflammation. Adhesion molecules such as CD11b on polymorphonuclear neutrophil leukocytes (PMNs) up-regulate in response to tumor necrosis factor-alpha, interleukin-8 (IL-8), and other mediators that are involved in systemic inflammatory response syndrome (SIRS). This study examined the behavior of CD11b and other membrane molecules in SIRS in relation to serum cytokines and the severity of illness. Design.-Survey study. Setting.-Liver transplantation intensive care unit at a tertiary care center. Patients.-A consecutive sample of 22 patients admitted to the liver transplantation intensive care unit for complications related to cirrhosis of the liver in the absence of other disease. Sixteen of the patients developed SIRS and multiple organ dysfunction syndrome with suspected bacterial infections. Seven control subjects were also studied. Main Outcome Measures.-Modified Goris organ failure score and Acute Physiology and Chronic Health Evaluation II score. Results.-Mean serum IL-6 levels, but not IL-1 beta or tumor necrosis factor-alpha levels, correlated with organ failure (r=0.79, P<.001). Leukocyte cell-surface markers fluctuated from day to day. The mean of several values was more stable. Mean CD11b and CD35 on PMNs correlated with serum IL-6 level (r=0.75, P<.001,and r=0.77, P<.005, respectively). Up-regulation of both CD11b and CD35 display on PMNs correlated with organ failure (r=0.74, P<.001, and r=0.71, P<.01, respectively). Polymorphonuclear neutrophil leukocyte L-selectin, CD31, and CD16 were simultaneously decreased, consistent with PMN activation. Monocytes appeared to be activated, but the pattern of surface molecule display was different. Conclusions.-In human SIRS, the circulating monocyte and PMN pools undergo alterations suggestive of leukocyte activation, including up-regulation of PMN CD11b in correlation with the serum IL-6 level and severity of organ dysfunction.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ROSENBLOOM, AJ (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT ANESTHESIOL,DIV CRIT CARE MED,200 LOTHROP ST,PITTSBURGH,PA 15213, USA.							ALBERS I, 1989, SCAND J GASTROENTERO, V24, P269, DOI 10.3109/00365528909093045; BERG O, 1989, ACTA OTO-LARYNGOL, V107, P130, DOI 10.3109/00016488909127489; BRIGHAM KL, 1991, KLIN WOCHENSCHR, V69, P1004, DOI 10.1007/BF01645147; BURCH RM, 1993, J IMMUNOL, V150, P3397; BYL B, 1993, GASTROENTEROLOGY, V104, P1492, DOI 10.1016/0016-5085(93)90361-F; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CHULUYAN HE, 1993, J CLIN INVEST, V92, P2768, DOI 10.1172/JCI116895; CREASEY AA, 1991, CIRC SHOCK, V33, P84; CROCKARD AD, 1992, CLIN IMMUNOL IMMUNOP, V65, P135, DOI 10.1016/0090-1229(92)90216-B; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIXON WJ, 1983, INTRO STATISTICAL AN, P562; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; ELSNER J, 1992, EUR J HAEMATOL, V48, P10; FABIAN TC, 1994, ANN SURG, V220, P552, DOI 10.1097/00000658-199410000-00013; GLANTZ SA, 1992, PRIMER BIOSTATISTICS, P320; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; HAMBLIN A, 1992, J IMMUNOL METHODS, V146, P219, DOI 10.1016/0022-1759(92)90231-H; HED J, 1988, SCAND J IMMUNOL, V28, P339, DOI 10.1111/j.1365-3083.1988.tb01458.x; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KUO CH, 1991, LIVER, V11, P334; LIMB GA, 1992, IMMUNOLOGY, V77, P88; LIMB GA, 1991, IMMUNOLOGY, V74, P696; LIN RY, 1993, CHEST, V104, P847, DOI 10.1378/chest.104.3.847; MAURER D, 1991, ANN HEMATOL, V62, P135, DOI 10.1007/BF01702927; MCCARTHY D, 1992, ANN RHEUM DIS, V51, P307, DOI 10.1136/ard.51.3.307; MEERSCHAERT J, 1994, J IMMUNOL, V152, P1915; MOREAU R, 1992, CRIT CARE MED, V20, P746, DOI 10.1097/00003246-199206000-00008; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Noreen EW, 1989, COMPUTER INTENSIVE M; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; OVERTON WR, 1989, CYTOMETRY, V10, P492; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; SCHLEIFFENBAUM B, 1990, J CLIN INVEST, V86, P184, DOI 10.1172/JCI114683; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; STEPHENS KE, 1988, AM REV RESPIR DIS, V138, P1300, DOI 10.1164/ajrccm/138.5.1300; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAKAHASHI M, 1994, ATHEROSCLEROSIS, V108, P73, DOI 10.1016/0021-9150(94)90038-8; TILG H, 1993, HEPATOLOGY, V18, P1132; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; WAKEFIELD CH, 1993, ARCH SURG-CHICAGO, V128, P390; WALSH CJ, 1991, SURGERY, V110, P205; WITTHAUT R, 1994, J LEUKOCYTE BIOL, V55, P105, DOI 10.1002/jlb.55.1.105; ZENTELLA A, 1991, PROG CLIN BIOL RES, V367, P9	50	143	151	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					58	65		10.1001/jama.274.1.58	http://dx.doi.org/10.1001/jama.274.1.58			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7540697				2022-12-01	WOS:A1995RG23300031
J	CLARKE, A				CLARKE, A			POPULATION SCREENING FOR GENETIC SUSCEPTIBILITY TO DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHOLESTEROL CONCENTRATION; HEALTH; HYPERCHOLESTEROLEMIA; PREVENTION	Genetic screening for susceptibility to common diseases, such as the common cancers, cardiovascular disease, and diabetes, may soon be technically feasible. Commercial interests should not be allowed to introduce such screening before proper evaluation or without adequate counselling and support. The evaluation of such testing should include psychosocial and medical outcomes and outcomes for those given low risks as well as high risks. These tests may distract attention away from environmental factors contributing to disease, for which social and political measures may be more appropriate than individualised susceptibility screening and lifestyle modification.			CLARKE, A (corresponding author), UNIV WALES COLL CARDIFF, COLL MED, DEPT MED GENET, CARDIFF CF4 4XW, S GLAM, WALES.							BACHMAN RP, 1993, AM J DIS CHILD, V147, P382, DOI 10.1001/archpedi.1993.02160280032013; BAIRD PA, 1990, PERSPECT BIOL MED, V33, P203; BERGMAN AB, 1967, NEW ENGL J MED, V276, P1008, DOI 10.1056/NEJM196705042761804; BRETT AS, 1991, AM J MED, V91, P642, DOI 10.1016/0002-9343(91)90218-M; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; COULTER A, 1994, BRIT MED J, V308, P308; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVISON C, 1989, Health Education Research, V4, P329, DOI 10.1093/her/4.3.329; DAVISON C, 1992, SOC SCI MED, V34, P675, DOI 10.1016/0277-9536(92)90195-V; GREEN J, 1993, J MED GENET, V30, P575, DOI 10.1136/jmg.30.7.575; GUSTAVSON KH, 1989, CLIN GENET, V36, P327; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HOLTZMAN NA, 1992, FASEB J, V6, P2806, DOI 10.1096/fasebj.6.10.1634043; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; LIPMANN A, 1993, MISCONCEPTIONS, V1, P39; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MCCORMICK J, 1994, LANCET, V344, P390; MULLERHILL B, 1993, NATURE, V362, P491, DOI 10.1038/362491a0; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; RAMSEY M, 1994, GENETIC COUNSELLING, P241; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; TOWNSEND P, 1990, INT J HEALTH SERV, V20, P373, DOI 10.2190/9Q6H-2KE7-X6FN-3DK8; TOWNSEND P, 1988, INEQUALITIES HLTH BL; VANDERSTEENSTRATEN IM, 1994, AM J HUM GENET, V55, P618; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WEBER JL, 1994, NAT GENET, V7, P343, DOI 10.1038/ng0794-343; WILLIAMS RR, 1988, NEW ENGL J MED, V318, P769, DOI 10.1056/NEJM198803243181208; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313; 1990, REPRODUCTION GENETIC, V3, P287	38	33	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					35	38		10.1136/bmj.311.6996.35	http://dx.doi.org/10.1136/bmj.311.6996.35			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613325	Green Published			2022-12-01	WOS:A1995RG97500026
J	EVANS, JMM; MCMAHON, AD; MCGILCHRIST, MM; WHITE, G; MURRAY, FE; MCDEVITT, DG; MACDONALD, TM				EVANS, JMM; MCMAHON, AD; MCGILCHRIST, MM; WHITE, G; MURRAY, FE; MCDEVITT, DG; MACDONALD, TM			TOPICAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND ADMISSION TO HOSPITAL FOR UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION - A RECORD LINKAGE CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the relation between topically applied non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding and perforation. Design-A case-control study with 1103 patients admitted to hospital for upper gastrointestinal bleeding or perforation between January 1990 and December 1992 (cases). Two different control groups were used, with six community controls and with two hospital controls for each case. Previous exposure to topical and oral non-steroidal antiinflammatory drugs and ulcer healing drugs was assessed. Study population-The population of 319465 people who were resident in Tayside and were registered with a Tayside general practitioner between January 1989 and October 1994. A record linkage database containing all data on hospital events and dispensed drugs between 1989 and 1992 was used for this population. Main outcome measures-Unadjusted and adjusted odds ratios of exposure in those admitted to hospital compared with controls. Results-Significant unadjusted associations were detected between all three classes of drug and upper gastrointestinal complications. The significant association detected for topical non-steroidal anti-inflammatory drugs was no longer evident in analyses which adjusted for the confounding effect of concomitant exposure to oral anti-inflammatories and ulcer healing drugs (odds ratio=1.45; 95% confidence interval 0.84 to 2.50 with community controls; 1.06; 0.60 to 1.88 with hospital controls). Conclusion-In this study topical non-steroidal anti-inflammatory drugs were not significantly associated with upper gastrointestinal bleeding and perforation after adjustment for the confounding effects of concomitant use of oral anti-inflammatories and ulcer healing drugs.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Dundee			McMahon, Alex D/C-4304-2008	MacDonald, Thomas/0000-0001-5189-6669				BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; Breslow NE., 1980, IARC SCI PUBLICATION, V32; DEAN AD, 1990, EPI INFO DATA PROCES; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; KOHLI H S, 1992, Health Bulletin (Edinburgh), V50, P14; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P223; NEWBERY R, 1992, EUR J CLIN RES, V3, P139; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; Wood S. M., 1993, Pharmaceutical Medicine (London), V7, P203; 1991, SAS P217 TECHN REP	13	125	128	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					22	26		10.1136/bmj.311.6996.22	http://dx.doi.org/10.1136/bmj.311.6996.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613317	Green Accepted, Green Published			2022-12-01	WOS:A1995RG97500020
J	FRASER, RC; FAROOQI, A; SORRIE, R				FRASER, RC; FAROOQI, A; SORRIE, R			USE OF VITAMIN-B-12 IN LEICESTERSHIRE PRACTICES - A SINGLE TOPIC AUDIT LED BY A MEDICAL AUDIT ADVISORY GROUP	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objectives-To encourage active participation of Leicestershire general practitioners and their staff in audit; to examine the use of vitamin B-12 injections and to achieve a more appropriate use. Design-Implementation of an agreed audit protocol, with central analysis and feedback of anonymous and aggregated data by a medical audit advisory group. Setting-All 147 Leicestershire practices. Main outcome measures-Participation in the complete audit cycle, comparison of actual use of vitamin B-12 injections with agreed criteria of use, and assessment of improvement in use. Results-264 general practitioners (55% of all doctors from 49% of all Leicestershire practices) completed both phases of the audit cycle, and 321 (67%) completed phase 1 only. Twenty four (16%) practices failed to participate from the outset, and a further 58 (35%) dropped out at various stages. Only 10 of the 37 singlehanded practices completed the audit, although 34 initially agreed to participate. If singlehanded practices were excluded, 56% (61) of practices completed both phases of the audit cycle. In total 1714 patients received B-12 injections. Appropriate use increased from 62% in phase 1 to 72% in phase 2 of the audit; there was a 32% reduction in the number of patients inappropriately receiving B-12 (521 to 352), and the proportion of patients receiving B-12 at the correct frequency rose from 58% to 72%. The proportion of patients in whom all the diagnostic criteria for pernicious anaemia were established before treatment with B-12 was 27% in phase 1 and 28% in phase 2. Conclusion-Our study suggests that single topic audits organised by a medical audit advisory group can encourage large numbers of general practitioners to participate and can bring about changes in behaviour resulting in improvements in standards of care. Nevertheless, advisory groups will need to devise strategies to encourage even higher levels of involvement, most particularly from singlehanded practices.			FRASER, RC (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DEPT GEN PRACTICE,LEICESTERSHIRE MED AUDIT ADVISORY GRP,LEICESTER LE5 4PW,LEICS,ENGLAND.		Farooqi, Ammad A/H-1610-2016; Farooqi, Ammad Ahmad/AAF-5325-2021					BAKER R, 1995, BRIT MED J, V311, P31, DOI 10.1136/bmj.311.6996.31; COCHRANE AL, 1971, BRIT J PREV SOC MED, V25, P147; DERRY J, 1991, BRIT MED J, V303, P1247, DOI 10.1136/bmj.303.6812.1247; ELLIS FR, 1970, PRACTITIONER, V204, P838; FRASER RC, 1983, BRIT MED J, V287, P729, DOI 10.1136/bmj.287.6394.729; HOLDEN JD, 1994, FAM PRACT, V11, P358, DOI 10.1093/fampra/11.4.358; MIDDLETON J, 1985, BRIT MED J, V290, P1254, DOI 10.1136/bmj.290.6477.1254; WEBB SJ, 1991, BRIT MED J, V302, P390, DOI 10.1136/bmj.302.6773.390; WILSON A, 1994, AUDIT TRENDS, V2, P97; 1990, DOH HCFP908 DEP HLTH	10	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					28	30		10.1136/bmj.311.6996.28	http://dx.doi.org/10.1136/bmj.311.6996.28			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613320	Green Published			2022-12-01	WOS:A1995RG97500023
J	GARATTINI, S				GARATTINI, S			CULTURAL SHIFT IN ITALY DRUG POLICY	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				GARATTINI L, 1994, PHARMACOECONOMICS, V6, P417, DOI 10.2165/00019053-199406050-00003; GARATTINI S, 1993, LANCET, V342, P1191, DOI 10.1016/0140-6736(93)92181-R	2	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					5	6		10.1016/S0140-6736(95)92647-X	http://dx.doi.org/10.1016/S0140-6736(95)92647-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF985	7603156				2022-12-01	WOS:A1995RF98500005
J	GOWDA, R; RAZVI, FM; SUMMERFIELD, GP				GOWDA, R; RAZVI, FM; SUMMERFIELD, GP			RISK OF PNEUMOCOCCAL SEPTICEMIA IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE MALIGNANCIES	BRITISH MEDICAL JOURNAL			English	Article									MIDDLESBROUGH GEN HOSP,DEPT HAEMATOL,MIDDLESBROUGH TS5 5AZ,CLEVELAND,ENGLAND									CONE L, 1964, J CLIN INVEST, V43, P2241, DOI 10.1172/JCI105098; FRIEDEN TR, 1990, JAMA-J AM MED ASSOC, V264, P1438, DOI 10.1001/jama.264.11.1438; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069; IN PRESS GUIDELINES; 1988, NEW ENGL J MED, V319, P902	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					26	27		10.1136/bmj.311.6996.26	http://dx.doi.org/10.1136/bmj.311.6996.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613318	Green Published			2022-12-01	WOS:A1995RG97500021
J	JULIUSSON, G; VITOLS, S; LILIEMARK, J				JULIUSSON, G; VITOLS, S; LILIEMARK, J			MECHANISMS BEHIND HYPOCHOLESTEROLEMIA IN HAIRY-CELL LEUKEMIA	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUKEMIA		HUDDINGE HOSP,DEPT MED,DIV CLIN HAEMATOL & ONCOL,HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT ONCOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital								HAKIMIAN D, 1991, BLOOD S1, V78, pA454; JULIUSSON G, 1992, BLOOD, V79, P888; JULIUSSON G, IN PRESS CANCER; VITOLS S, 1985, LANCET, V2, P1150; VITOLS S, 1991, CANCER CELL-MON REV, V3, P488	5	5	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					27	27		10.1136/bmj.311.6996.27	http://dx.doi.org/10.1136/bmj.311.6996.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613319	Green Published			2022-12-01	WOS:A1995RG97500022
J	KANNUS, P; HAAPASALO, H; SANKELO, M; SIEVANEN, H; PASANEN, M; HEINONEN, A; OJA, P; VUORI, I				KANNUS, P; HAAPASALO, H; SANKELO, M; SIEVANEN, H; PASANEN, M; HEINONEN, A; OJA, P; VUORI, I			EFFECT OF STARTING AGE OF PHYSICAL-ACTIVITY ON BONE MASS IN THE DOMINANT ARM OF TENNIS AND SQUASH PLAYERS	ANNALS OF INTERNAL MEDICINE			English	Article						EXERCISE; BONE DENSITY; AGE FACTORS; MENARCHE; TENNIS	X-RAY ABSORPTIOMETRY; MINERAL DENSITY; WOMEN; ADOLESCENTS; PRECISION; CHILDREN; SITES	Objective: To determine in female tennis and squash players the effect of biological age (that is, the starting age of playing relative to the age at menarche) at which tennis or squash playing was started on the difference in bone mineral content between the playing and nonplaying arms. Design: Cross-sectional study. Setting: Finnish tennis and squash federations. Participants: 105 female Finnish national-level players and 50 healthy female controls. Main Outcome Measures: Differences in bone mineral content in playing and nonplaying (dominant to nondominant) arms (proximal humerus, humeral shaft, radial shaft, and distal radius) were compared in the players and controls and among six groups of players. Players were divided into groups according to the biological age (years before or after menarche) at which their playing careers began: more than 5 years before; 3 to 5 years before; 2 to 0 years before; 1 to 5 years after; 6 to 15 years after; and more than 15 years after. Results: Compared with controls (whose mean +/- SD differences in bone mineral content were 4.6% +/- 4.6%, 3.2% +/- 2.3%, 3.2% +/- 3.8%, and 3.9% +/- 4.3% at the previously noted anatomical sites), the players had a significantly (P < 0.001) larger side-to-side difference in every measured site (15.5% +/- 8.4%, 16.2% +/- 9.8%, 8.5% +/- 6.6, and 12.5% +/- 7.1%). Among players, the group differences in bone mineral content were significant (P < 0.001 to P = 0.005), with the group means clearly decreasing with increasing starting biological age of playing. The difference was two to four times greater in the players who had started their playing careers before or at menarche (lowest mean difference in bone mineral content, 10.5% +/- 7.2%; highest difference, 23.5% +/- 7.2%) than in those who started more than 15 years after menarche (lowest difference, 2.4% +/- 4.8%; highest difference, 9.6% +/- 4.9%). Adjustment for potential confounding factors (age and height) did not change these trends. Conclusions: Bones of the playing extremity clearly benefit from active tennis and squash training, which increases their mineral mass. The benefit of playing is about two times greater if females start playing at or before menarche rather than after it. The minimal level and minimum number of years of activity necessary to produce these results, the extent to which this benefit is sustained after cessation of intensive training, and the degree to which these results can be extended to other forms of physical activity and other bone sites should be studied further.	TAMPERE RES CTR SPORTS MED, TAMPERE, FINLAND		KANNUS, P (corresponding author), UKK INST HLTH PROMOT RES, KAUPINPUISTONKATU 1, SF-33500 TAMPERE, FINLAND.		Heinonen, Ari/I-5292-2019; Heinonen, Ari/A-9199-2014	Heinonen, Ari/0000-0002-3681-9953; Heinonen, Ari/0000-0002-3681-9953				CONROY BP, 1993, MED SCI SPORT EXER, V25, P1103; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; GRIMSTON SK, 1993, MED SCI SPORT EXER, V25, P1203; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JOHNSTON CC, 1993, OSTEOPOROSIS INT, V3, pS54, DOI 10.1007/BF01621864; KANNUS P, 1994, BONE, V15, P279, DOI 10.1016/8756-3282(94)90289-5; KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem-73-6-1332; KROGER H, 1993, BONE MINER, V23, P171, DOI 10.1016/S0169-6009(08)80094-3; LU PW, 1994, J BONE MINER RES, V9, P1451; MATKOVIC V, 1994, J CLIN INVEST, V93, P799, DOI 10.1172/JCI117034; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; OTT SM, 1991, NEW ENGL J MED, V325, P1646, DOI 10.1056/NEJM199112053252310; SIEVANEN H, 1993, BONE MINER, V20, P235, DOI 10.1016/S0169-6009(08)80004-9; SIEVANEN H, 1992, J NUCL MED, V33, P1137; SLEMENDA CW, 1991, J BONE MINER RES, V6, P1227; TANNER JM, 1981, NUTR REV, V39, P43, DOI 10.1111/j.1753-4887.1981.tb06734.x; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060	18	544	549	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					27	31		10.7326/0003-4819-123-1-199507010-00003	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762910				2022-12-01	WOS:A1995RE66500004
J	LOTKE, M				LOTKE, M			SHE WONT LOOK AT ME	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Early-onset hearing impairment is a common disability in the United States. Persons with hearing loss, whether they use American Sign Language or lip-read, must look at those with whom they are speaking. Lip reading is not a reliable method of communication for most deaf persons. Reading and writing also limit the amount of communication between health care providers and deaf patients. The best way to communicate with most deaf persons is through a qualified American Sign Language interpreter. This paper discusses communication with deaf persons and ways in which health care providers and hospitals can improve their interactions with deaf patients.	STANFORD UNIV, ROBERT WOOD JOHNSON CLIN SCHOLAR PROGRAM, STANFORD, CA USA	Robert Wood Johnson Foundation (RWJF); Stanford University								[Anonymous], 1974, DEAF POPULATION US; MCEWEN E, 1988, J FAM PRACTICE, V26, P289	2	17	17	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					54	57		10.7326/0003-4819-123-1-199507010-00008	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762915				2022-12-01	WOS:A1995RE66500009
J	MARSDEN, AK; NG, GA; DALZIEL, K; COBBE, SM				MARSDEN, AK; NG, GA; DALZIEL, K; COBBE, SM			WHEN IS IT FUTILE FOR AMBULANCE PERSONNEL TO INITIATE CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							HEARTSTART-SCOTLAND PROJECT; HOSPITAL DEFIBRILLATION; DECISION-MAKING; CARDIAC-ARREST; TECHNICIANS	Objective-To determine whether patients with unexpected prehospital cardiac arrest could be identified in whom ambulance resuscitation attempts would be futile. Design-Review of ambulance and hospital records; detailed review of automated external defibrillator rhythm strips of patients in whom no shock was advised. Setting-Scottish Ambulance Service; all cardiopulmonary resuscitation attempts after cardiorespiratory arrest during 1988-94 included in the Heartstart Scotland database. Subjects-414 cardiorespiratory arrest patients with no pulse or breathing on arrival of ambulance personnel, no bystander cardiopulmonary resuscitation performed, and more than 15 minutes from time of arrest to arrival of ambulance. Patients were stratified into those with ''shockable'' and ''nonshockable'' rhythms. Main outcome measures-Return of spontaneous circulation, or survival to reach hospital alive, or survival to discharge, or all three. Results-No patient with a non-shockable rhythm who met the entry criteria for analysis survived a resuscitation attempt. Review of the defibrillator rhythm strips of these patients failed to find any case in which the tracing was deemed compatible with survival. Conclusions-On the basis that it would be inappropriate to initiate vigorous resuscitation in patients who can be identified as ''dead'' and beyond help an algorithm was prepared to guide ambulance personnel.	ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G4 0SF,LANARK,SCOTLAND	Royal Infirmary of Edinburgh	MARSDEN, AK (corresponding author), SCOTTISH AMBULANCE SERV,NATL HEADQUARTERS,EDINBURGH EH10 5UU,MIDLOTHIAN,SCOTLAND.			Ng, G. Andre/0000-0001-5965-0671				APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; JOHNSON DR, 1993, AM J EMERG MED, V11, P139, DOI 10.1016/0735-6757(93)90107-M; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; 1993, JAMA-J AM MED ASSOC, V270, P1471; 1992, JAMA-J AM MED ASSOC, V268, P2171	10	35	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					49	51		10.1136/bmj.311.6996.49	http://dx.doi.org/10.1136/bmj.311.6996.49			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613330	Green Published			2022-12-01	WOS:A1995RG97500032
J	MOCROFT, AJ; JOHNSON, MA; SABIN, CA; LIPMAN, M; ELFORD, J; EMERY, V; MORCINEK, J; YOULE, M; JANOSSY, G; LEE, CA; PHILLIPS, AN				MOCROFT, AJ; JOHNSON, MA; SABIN, CA; LIPMAN, M; ELFORD, J; EMERY, V; MORCINEK, J; YOULE, M; JANOSSY, G; LEE, CA; PHILLIPS, AN			STAGING SYSTEM FOR CLINICAL AIDS PATIENTS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NATURAL-HISTORY; SURVIVAL; LYMPHOCYTES; ZIDOVUDINE; DIAGNOSIS; MORTALITY; INFECTION; TRIALS; COHORT	Although there are wide differences in prognosis between patients with AIDS they are often thought of as a single homogeneous group. We think a simple staging system that accounts for important prognostic factors including type and number of AIDS diseases and the CD4 lymphocyte count is required. We followed 363 AIDS patients at the Royal Free Hospital and reported the occurrence of 680 AIDS-defining diseases (ADDs). We measured CD4 counts at approximately monthly intervals. Severity of AIDS diseases was defined a priori on the basis of survival in the AIDS in Europe study of 6578 AIDS patients: mild-oesophageal candidiasis, Kaposis sarcoma (cutaneous), Pneumocystis carinii pneumonia, extrapulmonary tuberculosis; severe-all other ADDs except lymphoma; very severe-lymphoma, The risk of death increased by 15% (p=0.08) for each mild condition experienced, by 89% (p<0.001) for each new severe condition and by 535% (p<0.0001) when a lymphoma developed. Estimates from the Cox model were used to derive a score reflecting the risk of death. Patient experience was divided into three categories. Patients in AIDS Grade I had an average death rate of one per 10.1 years, compared with one per 2.8 years in AIDS Grade II and one per 1.1 years in AIDS Grade III. Similar rates were seen in an independent validation study on 1230 AIDS patients at different hospital. Our grading system should be useful for patient management, clinical trial design, surveillance, and resource management.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT THORAC MED,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT VIROL,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,DEPT HAEMATOL & IMMUNOL,LONDON,ENGLAND; CHELSEA & WESTMINSTER HEALTHCARE NHS TRUST,ST STEPHENS CLIN,HIV GUM RES UNIT,LONDON,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Sabin, Caroline/C-2464-2008; Mocroft, Amanda/G-8748-2011; Mocroft, Amanda/C-1527-2008; Phillips, Andrew N/B-4427-2008; Emery, Vincent/G-8928-2013	Sabin, Caroline/0000-0001-5173-2760; Mocroft, Amanda/0000-0001-8316-1122; Phillips, Andrew N/0000-0003-2384-4807; Lipman, Marc/0000-0001-7501-4448; Emery, Vincent/0000-0001-5893-9756				BACHETTI P, 1988, J INFECT DIS, V157, P1044; BLUM S, 1994, AM J EPIDEMIOL, V139, P351, DOI 10.1093/oxfordjournals.aje.a117007; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COLFORD JM, 1994, AM J EPIDEMIOL, V139, P206, DOI 10.1093/oxfordjournals.aje.a116982; Darbyshire J, 1991, AIDS, V5 Suppl 2, pS167, DOI 10.1097/00002030-199101001-00024; ELLENBERG SS, 1992, J AM STAT ASSOC, V87, P562, DOI 10.2307/2290291; GONELLA JD, 1994, JAMA-J AM MED ASSOC, V251, P637; HANSON DL, 1993, J ACQ IMMUN DEF SYND, V6, P624; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MARASCA G, 1986, BRIT MED J, V292, P1727, DOI 10.1136/bmj.292.6537.1727; MILLS GD, 1993, AIDS, V7, P1383, DOI 10.1097/00002030-199310000-00013; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NEATON J, 1993, 9 INT C AIDS BERL; RABENECK L, 1993, ARCH INTERN MED, V153, P2749, DOI 10.1001/archinte.153.24.2749; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; 1990, SAS USERS GUIDE STAT; 1994, LANCET, V343, P871; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1992, MMWR-MORBID MORTAL W, V41, P1	26	50	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					12	17		10.1016/S0140-6736(95)92649-6	http://dx.doi.org/10.1016/S0140-6736(95)92649-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603137				2022-12-01	WOS:A1995RF98500007
J	NUYTS, GD; VANVLEM, E; THYS, J; DELEERSNIJDER, D; DHAESE, PC; ELSEVIERS, MM; DEBROE, ME				NUYTS, GD; VANVLEM, E; THYS, J; DELEERSNIJDER, D; DHAESE, PC; ELSEVIERS, MM; DEBROE, ME			NEW OCCUPATIONAL RISK-FACTORS FOR CHRONIC-RENAL-FAILURE	LANCET			English	Article							LEAD WORKERS; BODY BURDEN; CADMIUM; DISEASE; EXPOSURE; BLOOD; GLOMERULONEPHRITIS; DYSFUNCTION; POPULATION; CREATININE	Occupational pollutants may have a role in development of chronic renal failure (CRF). Most epidemiological studies have been cross-sectional, limited to certain renal diagnoses, or concentrated on early transient renal effects. In a case-control study, we examined the association between CRF and occupational exposure. Occupational histories of 272 men and women with CRF (of all types) were compared with those of 272 controls matched for age, sex, and region of residence. Exposures were assessed and degree and frequency were scored independently by three industrial hygienists unaware of case/control status, Significantly increased risk of CRF were found for exposure to lead (odds ratio 2.11 [95% CI 1.23-4.36]), copper (2.54 [1.16-5.53]), chromium (2.77 [1.21-6.33]), tin (3.72 [1.22-11.3]), mercury (5.13 [1.02-25.7]), welding fumes (2.06 [1.05-4.04]), silicon-containing compounds (2.51 [1.37-4.60]), grain dust (2.96 [1.24-7.04]), and oxygenated hydrocarbons (5.45 [1.84-16.2]). The frequencies of various occupational exposures were high among patients with diabetic nephropathy. This epidemiological study confirms previously identified risk factors and suggests that additional occupational exposures, for which there is some other experimental evidence, may be important in the development of CRF. The role of grain dust and the association between occupational exposure and diabetic nephropathy merit further investigation.	UNIV ANTWERP HOSP,DEPT NEPHROL HYPERTENS,B-2650 EDEGEM,BELGIUM; OPEL BELGIUM NV,ANTWERP,BELGIUM; APRIM,ANTWERP,BELGIUM; BRUSSELS NATL AIRPORT,SABENA SAFETY,BRUSSELS,BELGIUM	University of Antwerp			D'Haese, Patrick C/C-9599-2019	Elseviers, Monique/0000-0001-9415-6900				BOMBASSEI GJ, 1992, AM J IND MED, V21, P141, DOI 10.1002/ajim.4700210204; BROCKHAUS A, 1983, INT ARCH OCC ENV HEA, V52, P167, DOI 10.1007/BF00405420; BROWN WD, 1987, J OCCUP ENVIRON MED, V29, P877; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; DECASTO M, 1994, SCHWEIZ ARCH TIERH, V136, P111; DHAESE PC, 1991, CLIN CHEM, V37, P1583; DIEPERINK HH, 1991, TOXICOL LETT, V46, P257; DIEPERINK HH, 1991, TOXICOL LETT, V46, P1; ELSEVIERS MM, 1987, LANCET, V1, P457; EPSTEIN E, 1994, P NATL ACAD SCI USA, V96, P11; GEERLINGS W, 1991, NEPHROL DIAL TRANSPL, V6, P5; GOLDSMITH JR, 1993, AM J IND MED, V23, P873, DOI 10.1002/ajim.4700230605; HEBERT CD, 1993, FUND APPL TOXICOL, V21, P461, DOI 10.1006/faat.1993.1122; KIDO T, 1990, ARCH ENVIRON HEALTH, V45, P35, DOI 10.1080/00039896.1990.9935922; LINDER MC, 1985, NUTRITIONAL BIOCH ME, P246; NELSON NA, 1990, AM J NEPHROL, V10, P10, DOI 10.1159/000168048; NUYTS GD, 1991, NEPHROL DIAL TRANSPL, V6, P307, DOI 10.1093/ndt/6.5.307; NUYTS GD, 1993, J OCCUP ENVIRON MED, V35, P387; NUYTS GD, IN PRESS NEPHROL DIA; NYE L. J. J., 1929, Medical Journal of Australia, V2, P145; OSORIO AM, 1987, AM J KIDNEY DIS, V9, P224, DOI 10.1016/S0272-6386(87)80059-8; PORRO A, 1992, BRIT J IND MED, V49, P738; ROELS H, 1993, BRIT J IND MED, V50, P37; ROELS HA, 1989, BRIT J IND MED, V46, P755; SCHUTZ A, 1987, ARCH ENVIRON HEALTH, V42, P340, DOI 10.1080/00039896.1987.9934356; SPEIZER FE, HARRISONS PRINCIPLES, P1167; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; STENGEL B, 1992, DEC INT S PATH PATH, P24; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; WANG XR, 1994, TOXICOLOGY, V90, P93, DOI 10.1016/0300-483X(94)90208-9; YAQOOB M, IN PRESS DIABETIC ME	31	73	76	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					7	11		10.1016/S0140-6736(95)92648-8	http://dx.doi.org/10.1016/S0140-6736(95)92648-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603180				2022-12-01	WOS:A1995RF98500006
J	OREOPOULOS, DG				OREOPOULOS, DG			WITHDRAWAL FROM DIALYSIS - WHEN LETTING DIE IS BETTER THAN HELPING TO LIVE	LANCET			English	Editorial Material							ATTITUDES; DECISIONS				OREOPOULOS, DG (corresponding author), TORONTO HOSP, DIV NEPHROL, WESTERN DIV, TORONTO, ON, CANADA.							AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN LM, 1993, PSYCHOSOMATICS, V34, P395, DOI 10.1016/S0033-3182(93)71842-3; DISNEY APS, 1994, ANZDATA REPORT; KJELLSTRAND C, 1993, DEV NEPHROL, V34, P563; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; NELSON CB, 1994, J AM SOC NEPHROL, V4, P1608; OREOPOULOS DG, 1994, PERITON DIALYSIS INT, V14, P205; SCHNEIDERMAN LJ, 1994, AM J MED, V96, P110, DOI 10.1016/0002-9343(94)90130-9; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; 1993, CANADIAN ORGAN REPLA; 1995, USRDS 1995 ANN DATA, P87	12	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 1	1995	346	8966					3	4		10.1016/S0140-6736(95)92645-3	http://dx.doi.org/10.1016/S0140-6736(95)92645-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603145				2022-12-01	WOS:A1995RF98500003
J	PEARCE, MC; SHERIDAN, JW; JONES, DM; LAWRENCE, GW; MURPHY, DM; MASUTTI, B; MCCOSKER, C; DOUGLAS, V; GEORGE, D; OKEEFE, A; YOUNG, F; THOMSON, M; GORMAN, B; HANSMAN, D; HILL, PS				PEARCE, MC; SHERIDAN, JW; JONES, DM; LAWRENCE, GW; MURPHY, DM; MASUTTI, B; MCCOSKER, C; DOUGLAS, V; GEORGE, D; OKEEFE, A; YOUNG, F; THOMSON, M; GORMAN, B; HANSMAN, D; HILL, PS			CONTROL OF GROUP-C MENINGOCOCCAL DISEASE IN AUSTRALIAN ABORIGINAL CHILDREN BY MASS RIFAMPICIN CHEMOPROPHYLAXIS AND VACCINATION	LANCET			English	Article							POPULATION; CARRIAGE; VACCINES; INFANTS	An outbreak of 12 cases of meningitis, 11 caused by Neisseria meningitidis serogroup C, occurred at Doomadgee from September, 1990, to April, 1991. The incidence of meningitis was 17.55/10(3) person-years. Only children aged 1-10 years were affected. In October, 1990, or shortly thereafter, 473/509 children aged between 1 and 15 years inclusive had one dose of Mencevax AC. From the time of vaccination until April, 1991, a further eight cases occurred, six in vaccinated children. Vaccine efficacy in 1-15 year olds was calculated as 77%. Despite this, in April, 1991, the prevalence of antibody to group C polysaccharide in vaccinated children (78%) was not significantly different from that in unvaccinated children and adults. 45 nonresponders were revaccinated, and, in February, 1992, 78% had antibodies to group C polysaccharide. In April, 1991, an estimated 3.0% of the population had group C organisms, carriage being directly related to household crowding. In June, 1991, 2 months after mass prophylaxis with rifampicin, none of these individuals were carriers. In October, 1991, the carriage rate of group C organisms was 0.64%. There have been no further cases caused by the epidemic strain. Although uncrowded housing is a basic need, mass chemoprophylaxis and two doses of vaccine for children should be used in similar outbreaks.	QUEENSLAND HLTH,COMMUNICABLE DIS BRANCH,BRISBANE,QLD 4001,AUSTRALIA; AUSTRALIAN NATL UNIV,NATL CTR EPIDEMIOL & POPULAT HLTH,CANBERRA,ACT,AUSTRALIA; WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND; QUEENSLAND INST MED RES,HERSTON,QLD,AUSTRALIA; STATE HLTH LAB SERV,BRISBANE,QLD,AUSTRALIA; DOOMADGEE HOSP,ABORIGINAL HLTH PROGRAMME,DOOMADGEE,QLD,AUSTRALIA; MT ISA HOSP,MT ISA,QLD,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT MICROBIOL,ADELAIDE,SA,AUSTRALIA; UNIV QUEENSLAND,SCH MED,TROP HLTH PROGRAM,HERSTON,QLD,AUSTRALIA	Queensland Health; Australian National University; QIMR Berghofer Medical Research Institute; University of Queensland			Hill, Peter/F-2768-2010; Hill, Peter Stewart/AAL-8053-2020	Hill, Peter/0000-0001-7091-5108; Hill, Peter Stewart/0000-0001-7091-5108				ARTENSTEIN MS, 1969, NEW ENGL J MED, V281, P678, DOI 10.1056/NEJM196909182811210; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; BUTCHER R, 1986, SAMPLING ERRORS MANU; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; GREENFIELD S, 1971, J INFECT DIS, V123, P67, DOI 10.1093/infdis/123.1.67; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4; HOGUE CJR, 1983, AM J EPIDEMIOL, V118, P396, DOI 10.1093/oxfordjournals.aje.a113646; JONES DM, 1989, BRIT MED J, V298, P542, DOI 10.1136/bmj.298.6673.542; KAISER AB, 1974, J INFECT DIS, V130, P217, DOI 10.1093/infdis/130.3.217; Levy P, 1980, SAMPLING HLTH PROFES; MUMFORD RS, 1974, LANCET, V1, P1275; PELTOLA H, 1985, PEDIATRICS, V76, P91; Pizzi M, 1944, AM J PUBLIC HEALTH N, V34, P231, DOI 10.2105/AJPH.34.3.231; RAKE G, 1934, J EXP MED, V59, P533; STUART JM, 1989, BRIT MED J, V298, P569, DOI 10.1136/bmj.298.6673.569; WEIDMER CE, 1971, J INFECT DIS, V124, P172, DOI 10.1093/infdis/124.2.172	16	18	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					20	23		10.1016/S0140-6736(95)92651-8	http://dx.doi.org/10.1016/S0140-6736(95)92651-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603139				2022-12-01	WOS:A1995RF98500009
J	POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S				POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S			STROKE PATIENTS VIEWS ON THEIR ADMISSION TO HOSPITAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME	Objective-To explore which components of care were valued by patients admitted to hospital following a stroke. Design-Qualitative study using in depth interviews 10 months after the stroke. Setting-Two adjacent districts in North Thames Regional Health Authority. Subjects-82 survivors of stroke taken consecutively from a stroke register, 40 of whom agreed to be interviewed. Results-Patients reported that during the acute stage of the stroke they wanted to put their faith in experienced and trusted experts who would help them make sense of the event, take all the actions necessary to ensure survival, and provide comfort and human warmth during the crisis. In addition to being reassured by the clinical tests and practical nursing help they received, patients valued feeling cared about by the staff, In most cases patients reported that their needs were met; however, the institutional nature of the hospital sometimes obstructed the fulfilment of their needs. Conclusion-Patients have important psychosocial needs during the acute stage of the stroke, which are often met by hospital admission. Patients gained benefits from their admission over and above those measurable in terms of morbidity or function. They used a combination of criteria to evaluate their care, focusing on the process as well as the outcome of care. Researchers and clinicians should do likewise.	UNIV LONDON, ROYAL HOLLOWAY & BEDFORD NEW COLL, DEPT SOCIAL POLICY & SOCIAL SCI, EGHAM TW20 0EX, SURREY, ENGLAND	University of London; Royal Holloway University London	POUND, P (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.							Anderson R., 1992, AFTERMATH STROKE EXP; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BENSIRA Z, 1980, J HEALTH SOC BEHAV, V21, P170, DOI 10.2307/2136736; BROCKLEHURST J C, 1978, Age and Ageing, V7, P100, DOI 10.1093/ageing/7.2.100; Bury M, 1994, Health Care Anal, V2, P240, DOI 10.1007/BF02251026; CHRISTIE D, 1978, SOC SCI MED, V12, P49; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GOMPERTZ P, 1995, AGE AGEING, V24, P137, DOI 10.1093/ageing/24.2.137; HOFFMANN JE, 1974, URBAN LIFE CULT, V3, P50, DOI 10.1177/089124167400300103; Hunt SM, 1986, MEASURING HLTH STATU; ISAACS B, 1978, BRIT MED J, V2, P1640, DOI 10.1136/bmj.2.6152.1640; KAUFMAN SR, 1988, QUALITATIVE GERONTOL, P82; LUM O, 1982, CLIN GERONTOL, V1, P37; MAHONEY F I, 1965, Md State Med J, V14, P61; McKeown Thomas, 1979, ROLE MED; MULLEY G, 1978, BRIT MED J, V2, P1321, DOI 10.1136/bmj.2.6148.1321; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; Parker R., 1981, NEW LOOK PERSONAL SO, P17; Pound P, 1994, Qual Health Care, V3, P69, DOI 10.1136/qshc.3.2.69; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; WADE DT, 1987, BRIT J HOSP MED, V37, P200; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1983, LANCET, V1, P807; WADE DT, 1985, J EPIDEMIOL COMMUN H, V39, P347, DOI 10.1136/jech.39.4.347; WILLIAMS SJ, 1991, SOC SCI MED, V33, P707, DOI 10.1016/0277-9536(91)90025-8; YOUNG J, 1994, BRIT MED J, V309, P1356, DOI 10.1136/bmj.309.6965.1356	26	54	55	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					18	22		10.1136/bmj.311.6996.18	http://dx.doi.org/10.1136/bmj.311.6996.18			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613315	Green Published			2022-12-01	WOS:A1995RG97500019
J	TRIGWELL, P; HATCHER, S; JOHNSON, M; STANLEY, P; HOUSE, A				TRIGWELL, P; HATCHER, S; JOHNSON, M; STANLEY, P; HOUSE, A			ABNORMAL ILLNESS BEHAVIOR IN CHRONIC FATIGUE SYNDROME AND MULTIPLE-SCLEROSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTVIRAL FATIGUE; GUIDELINES; HEALTH	Objective-To investigate the presence of abnormal illness behaviour in patients with a diagnosis of chronic fatigue syndrome. Design-A cross sectional descriptive study using the illness behaviour questionnaire to compare illness behaviour scores and illness behaviour profiles of patients with chronic fatigue syndrome and patients with multiple sclerosis. Setting-A multidisciplinary fatigue clinic and a teaching hospital neurology outpatient clinic. Subjects-98 patients satisfying the Oxford criteria for chronic fatigue syndrome and 78 patients with a diagnosis of multiple sclerosis. Main outcome measure-Responses to the 62 item illness behaviour questionnaire. Results-90 (92%) patients in the chronic fatigue syndrome group and 70 (90%) in the multiple sclerosis group completed the illness behaviour questionnaire. Both groups had significantly high scores on the general hypochondriasis and disease conviction subscales and significantly low scores on the psychological versus somatic concern subscale, as measured in relation to normative data. There were, however, no significant differences in the subscale scores between the two groups and the two groups had identical illness behaviour profiles. Conclusion-Scores on the illness behaviour questionnaire cannot be taken as evidence that chronic fatigue syndrome is a variety of abnormal illness behaviour, because the same profile occurs in multiple sclerosis. Neither can they be taken as evidence that chronic fatigue and multiple sclerosis share an aetiology. More needs to be known about the origins of illness beliefs in chronic fatigue syndrome, especially as they are important in determining outcome.	UNIV LEEDS, LEEDS LS2 9LT, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; SEACROFT HOSP, LEEDS LS14 6UH, W YORKSHIRE, ENGLAND; GEN INFIRM, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND	University of Leeds; Saint James's University Hospital; Leeds General Infirmary	TRIGWELL, P (corresponding author), HIGH ROYDS HOSP, LEEDS LS29 6AQ, W YORKSHIRE, ENGLAND.			House, Allan/0000-0001-8721-8026				CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; FREAL JE, 1984, ARCH PHYS MED REHAB, V65, P135; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; Kleinman Arthur, 1985, CULTURE DEPRESSION S, P429; KRUPP LB, 1988, ARCH NEUROL-CHICAGO, V45, P435, DOI 10.1001/archneur.1988.00520280085020; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; Matthews WB, 1991, MCALPINES MULTIPLE S, P139; MCEVEDY CP, 1970, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.5687.11; MECHANIC D, 1962, J CHRON DIS, V15, P189, DOI 10.1016/0021-9681(62)90068-1; MURRAY M, 1991, CURRENT DEV HLTH PSY, P63; PARSONS T, 1952, SOCIALSYSTEM; PEMBERTON S, IN PRESS BRIT J OCCU; PILOWSKY I, 1969, BRIT J MED PSYCHOL, V42, P347, DOI 10.1111/j.2044-8341.1969.tb02089.x; Pilowsky I., 1983, MANUAL ILLNESS BEHAV; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1979, J NEUROL SCI, V40, P159, DOI 10.1016/0022-510X(79)90201-6; SCHWEITZER R, 1994, J PSYCHOSOM RES, V38, P41, DOI 10.1016/0022-3999(94)90007-8; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SMITH GR, 1986, ARCH INTERN MED, V146, P69, DOI 10.1001/archinte.146.1.69; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1990, RECENT ADV NEUROLOGY, V6; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; ZONDERMAN AB, 1985, HEALTH PSYCHOL, V4, P425, DOI 10.1037/0278-6133.4.5.425; 1987, DIAGNOSTIC STATISTIC	25	30	30	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					15	18		10.1136/bmj.311.6996.15	http://dx.doi.org/10.1136/bmj.311.6996.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613314	Green Published			2022-12-01	WOS:A1995RG97500018
J	WRIGHT, CJ; MUELLER, CB				WRIGHT, CJ; MUELLER, CB			SCREENING MAMMOGRAPHY AND PUBLIC-HEALTH POLICY - THE NEED FOR PERSPECTIVE	LANCET			English	Article							BREAST-CANCER DETECTION; CARCINOMA INSITU; DEATH RATES; FOLLOW-UP; MORTALITY; TRIAL; WOMEN; DURATION; GROWTH	The early trials of screening mammography, reporting 30% relative reduction in mortality from breast cancer in women over 50 years of age, led to strong professional and public demand for screening programmes. There has been little publicity about the subsequent trials showing no Significant benefit in any age group, or about the harm and costs associated with screening mammography, For women under 50, there is a reluctant consensus that screening is not beneficial, but there is increasing pressure for publicly funded programmes for older women. When analysed in terms of population benefit, the randomised controlled prospective trials showed that the numbers of women screened to achieve one less death per year ranged from 7086 (Health Insurance Plan of New York), to 63 264 (Malmo), to infinity (Canadian National Breast Screening Study). About 5% of screening mammograms are positive or suspicious, and of these 80-93% are false positives that cause much unnecessary anxiety and further procedures including surgery. False reassurance by negative mammography occurs in 10-15% of women with breast cancer that will manifest clinically within a year. Our calculations confirm others that the mean annual cost per life ''saved'' is around $1.2 million (pound 558 000). In the allocation of limited resources, public health policy on a proposed mass population intervention must be based on a critical analysis of benefits, harm, and cost. Since the benefit achieved is marginal, the harm caused is substantial, and the costs incurred are enormous, we suggest that public funding for breast cancer screening in any age group is not justifiable.	UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER,BC V6T 1W5,CANADA; MCMASTER UNIV,DEPT SURG,HAMILTON,ON L8S 4L8,CANADA	University of British Columbia; McMaster University								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR C 0225; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MUELLER CB, 1994, AM J CLIN ONCOL-CANC, V17, P86; MUELLER CB, 1975, ANN SURG, V182, P334, DOI 10.1097/00000658-197509000-00016; NORTON LW, 1988, ARCH SURG-CHICAGO, V123, P947; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; ROBERTS MM, 1990, LANCET, V335, P241; ROSEN PP, 1978, AM J SURG PATHOL, V2, P225, DOI 10.1097/00000478-197809000-00001; SCHMIDT JG, 1990, J CLIN EPIDEMIOL, V43, P215, DOI 10.1016/0895-4356(90)90002-7; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHAPIRO S, 1989, CANCER, V63, P1873, DOI 10.1002/1097-0142(19890515)63:10<1873::AID-CNCR2820631002>3.0.CO;2-6; SKRABANEK P, 1985, LANCET, V2, P316; SPRATT JA, 1993, CANCER-AM CANCER SOC, V71, P2020, DOI 10.1002/1097-0142(19930315)71:6<2020::AID-CNCR2820710616>3.0.CO;2-#; SPRATT JS, 1986, CANCER RES, V46, P970; STRAX P, 1989, CANCER, V63, P1881, DOI 10.1002/1097-0142(19890515)63:10<1881::AID-CNCR2820631003>3.0.CO;2-8; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; WRIGHT CJ, 1986, SURGERY, V100, P594; 1986, PAMPHLET 86 30 MM NO	27	71	72	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					29	32		10.1016/S0140-6736(95)92655-0	http://dx.doi.org/10.1016/S0140-6736(95)92655-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603143				2022-12-01	WOS:A1995RF98500013
J	BERTHOLD, J; BAUER, MF; SCHNEIDER, HC; KLAUS, C; DIETMEIER, K; NEUPERT, W; BRUNNER, M				BERTHOLD, J; BAUER, MF; SCHNEIDER, HC; KLAUS, C; DIETMEIER, K; NEUPERT, W; BRUNNER, M			THE MIM COMPLEX MEDIATES PREPROTEIN TRANSLOCATION ACROSS THE MITOCHONDRIAL INNER MEMBRANE AND COUPLES IT TO THE MT-HSP70/ATP DRIVING SYSTEM	CELL			English	Article							PROTEIN IMPORT MACHINERY; YEAST MITOCHONDRIA; OUTER-MEMBRANE; CONTACT SITES; IDENTIFICATION; PRECURSOR; CROSS; COMPONENT; LINKING; MPI1	We have identified a complex in mitochondria that functions as a part of the preprotein import machinery of the inner membrane (MIM complex). Two known components, MIM23 and MIM17, and two novel components, MIM33 and MIM14, were found as constituents of this complex. In the presence of a translocating chain, the outer membrane import machinery (MOM complex) and the MINI complex form translocation contact sites. On the matrix side, the MIM complex is associated with the mt-Hsp70-MIM44 system. We propose a structure of the import machinery in which the MIM complex constitutes a proteinaceous channel that accepts preproteins from the MOM complex, facilitates their reversible transmembrane movement, and mediates unidirectional transport by linkage to the ATP-dependent mt-Hsp70-MIM44 system.			BERTHOLD, J (corresponding author), UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, D-80336 MUNICH, GERMANY.			Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BROACH JR, 1983, EXPT MANIPULATION GE, P85; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DAUM G, 1982, J BIOL CHEM, V257, P3075; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HARLOW E, 1988, LABORATORY MANUAL; HIGH S, 1993, J BIOL CHEM, V268, P26745; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HOCHULI E, 1989, CHEM IND, V12, P69; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; PFANNER N, 1995, CURR BIOL, V5, P132; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; Sherman F., 1986, METHODS YEAST GENETI; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VALE RD, 1994, CELL, V78, P733, DOI 10.1016/S0092-8674(94)90402-2	41	153	153	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1085	1093		10.1016/S0092-8674(05)80013-3	http://dx.doi.org/10.1016/S0092-8674(05)80013-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600576	Bronze			2022-12-01	WOS:A1995RG91000013
J	COSO, OA; CHIARIELLO, M; YU, JC; TERAMOTO, H; CRESPO, P; XU, NG; MIKI, T; GUTKIND, JS				COSO, OA; CHIARIELLO, M; YU, JC; TERAMOTO, H; CRESPO, P; XU, NG; MIKI, T; GUTKIND, JS			THE SMALL GTP-BINDING PROTEINS RAC1 AND CDC42 REGULATE THE ACTIVITY OF THE JNK/SAPK SIGNALING PATHWAY	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SERINE THREONINE KINASE; DBL-ONCOGENE PRODUCT; MOLECULAR-CLONING; ACTIVATING PROTEINS; CELL-PROLIFERATION; PROTO-ONCOGENE; RAS; RHO; PHOSPHORYLATES	c-Jun amino-terminal kinases (JNKs) and mitogen-activated protein kinases (MAPKs) are closely related; however, they are independently regulated by a variety of environmental stimuli. Although molecules linking growth factor receptors to MAPKs have been recently identified, little is known about pathways controlling JNK activation. Here, we show that in COS-7 cells, activated Rac1 effectively stimulates MAPK but poorly induces JNK activity. In contrast, mutationally activated Rac1. and Cdc42 GTPases potently activate JNK without affecting MAPK, and oncogenic guanine nucleotide exchange factors for these Rho-like proteins selectively stimulate JNK activity. Furthermore, expression of inhibitory molecules for Rho-related GTPases and dominant negative mutants of Rac1 and Cdc42 block JNK activation by oncogenic exchange factors or after induction by inflammatory cytokines and growth factors. Taken together, these findings strongly support a critical role for Rac1 and Cdc42 in controlling the JNK signaling pathway.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COSO, OA (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892, USA.		Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Chiariello, Mario/0000-0001-8434-5177; Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1991, COLD SH Q B, V56, P237; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; UEDA T, 1990, J BIOL CHEM, V265, P9373; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAN MH, 1994, NATURE, V372, P798	52	1560	1576	2	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1137	1146		10.1016/S0092-8674(05)80018-2	http://dx.doi.org/10.1016/S0092-8674(05)80018-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600581	Bronze			2022-12-01	WOS:A1995RG91000018
J	DENT, P; JELINEK, T; MORRISON, DK; WEBER, MJ; STURGILL, TW				DENT, P; JELINEK, T; MORRISON, DK; WEBER, MJ; STURGILL, TW			REVERSAL OF RAF-1 ACTIVATION BY PURIFIED AND MEMBRANE-ASSOCIATED PROTEIN PHOSPHATASES	SCIENCE			English	Article							KINASE-ACTIVITY; PHOSPHORYLATION; CELLS; MECHANISM	The Raf-1 protein kinase participates in transduction of mitogenic signals, but its mechanisms of activation are incompletely understood. Treatment of human Raf-1 purified from insect Sf9 cells co-expressing c-H-Ras and Src(Y527F) (in which phenylalanine replaces tyrosine at residue 527) with either serine-threonine or tyrosine phosphatases resulted in enzymatic inactivation of Raf-1. Inactivation of purified Raf-1 was blocked by addition of either the 14-3-3 zeta protein or heat shock protein 90, Loading of plasma membranes from transformed cells with guanosine triphosphate (GTP) resulted in inactivation of endogenous or exogenous Raf-1; inactivation was blocked by inclusion of protein phosphatase inhibitors. These results suggest the existence of protein phosphatases in the cell membrane that are regulated by GTP and are responsible for Raf-1 inactivation.	UNIV VIRGINIA,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS INC,BASIC RES PROGRAM,FREDERICK,MD 21702	Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-46000] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline; NIGMS NIH HHS [GM47322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALLOU LM, 1986, ENZYMES, V27, P311; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DENT P, UNPUB; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HALL A, 1986, J BIOL CHEM, V261, P963; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JELINEK T, UNPUB; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MORRISON D, UNPUB; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; USUI H, 1983, J BIOL CHEM, V258, P455; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	39	186	189	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1902	1906		10.1126/science.7604263	http://dx.doi.org/10.1126/science.7604263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604263				2022-12-01	WOS:A1995RF99000039
J	DRUMMOND, JT; LI, GM; LONGLEY, MJ; MODRICH, P				DRUMMOND, JT; LI, GM; LONGLEY, MJ; MODRICH, P			ISOLATION OF AN HMSH2-P160 HETERODIMER THAT RESTORES DNA MISMATCH REPAIR TO TUMOR-CELLS	SCIENCE			English	Article							EXTRACTS; HOMOLOG; CANCER	A mismatch-binding heterodimer of hMSH2 and a 160-kilodalton polypeptide has been isolated from Hela cells by virtue of its ability to restore mismatch repair to nuclear extracts of hMSH2-deficient LoVo colorectal tumor cells. This heterodimer, designated hMutS alpha; also restores mismatch repair to extracts of alkylation-tolerant MT1 lymphoblastoid cells and HCT-15 colorectal tumor cells, which are selectively defective in the repair of base-base and single-nucleotide insertion-deletion mismatches. Because HCT-15 cells appear to be free of hMSH2 mutations, this selective repair defect is likely a result of a deficiency of the hMutS alpha 160-kilodalton subunit, and mutations in the corresponding gene may confer hypermutability and cancer predisposition.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University			Li, Guo-Min/I-5016-2014	Modrich, Paul/0000-0001-8708-9885; Li, Guo-Min/0000-0002-9842-4578	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHI NW, 1994, J BIOL CHEM, V269, P29984; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; ESHLEMAN JR, 1994, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Li G., UNPUB; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOEB LA, 1994, CANCER RES, V54, P5059; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	33	533	554	0	38	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1909	1912		10.1126/science.7604264	http://dx.doi.org/10.1126/science.7604264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604264				2022-12-01	WOS:A1995RF99000041
J	HILL, CS; WYNNE, J; TREISMAN, R				HILL, CS; WYNNE, J; TREISMAN, R			THE RHO-FAMILY GTPASES RHOA, RAC1, AND CDC42HS REGULATE TRANSCRIPTIONAL ACTIVATION BY SRF	CELL			English	Article							SERUM RESPONSE ELEMENT; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; YEAST; ACTIN; GTP; IDENTIFICATION; EXPRESSION; PROMOTER	The c-fos serum response element (SRE) forms a ternary complex with the transcription factors SRF (serum response factor) and TCF (ternary complex factor). By itself, SRF can mediate transcriptional activation induced by serum, lysophosphatidic acid, or intracellular activation of heterotrimeric G proteins. Activated forms of the Rho family GTPases RhoA, Rad, and CDC42Hs also activate transcription via SRF and act synergistically at the SRE with signals that activate TCF. Functional Rho is required for signaling to SRF by several stimuli, but not by activated CDC42Hs or Rac1. Activation of the SRF-linked signaling pathway does not correlate with activation of the MAP kinases ERK, SAPK/JNK, or MPK2/p38. Functional Rho is required for regulated activity of the c-fos promoter. These results establish SRF as a nuclear target of a novel Rho-mediated signaling pathway.	IMPERIAL CANC RES FUND,TRANSCRIPT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK				Hill, Caroline/0000-0002-8632-0480; Treisman, Richard/0000-0002-9658-0067				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; ZAMBETTI G, 1991, EXP CELL RES, V192, P93, DOI 10.1016/0014-4827(91)90162-N	49	1191	1210	0	28	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1159	1170		10.1016/S0092-8674(05)80020-0	http://dx.doi.org/10.1016/S0092-8674(05)80020-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600583	Bronze			2022-12-01	WOS:A1995RG91000020
J	JANG, JK; MESSINA, L; ERDMAN, MB; ARBEL, T; HAWLEY, RS				JANG, JK; MESSINA, L; ERDMAN, MB; ARBEL, T; HAWLEY, RS			INDUCTION OF METAPHASE ARREST IN DROSOPHILA OOCYTES BY CHIASMA-BASED KINETOCHORE TENSION	SCIENCE			English	Article							CHROMOSOMES	In normal Drosophila melanogaster oocytes, meiosis arrests at metaphase I and resumes after oocyte passage through the oviduct. Thus, metaphase arrest defines a control point in the meiotic cell cycle. Metaphase arrest only occurs in oocytes that have undergone at least one meiotic exchange. Here it Is shown that crossovers between homologs attached to the same centromere do not induce metaphase arrest. Hence, exchanges induce metaphase arrest only when they physically conjoin two separate kinetochores. Thus, the signal that mediates metaphase arrest is not the exchange event per se but the resulting tension on homologous kinetochores.	UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis				Hawley, R. Scott/0000-0002-6478-0494	NICHD NIH HHS [N01-HD-2-3144] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023144] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COURTOT C, 1992, DEVELOPMENT, V116, P405; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HAWLEY RS, 1993, DEV GENET, V13, P440; HOLM DG, 1976, GENET BIOL DROSOPHIL, P529; JANG J, UNPUB; King RC, 1970, OVARIAN DEV DROSOPHI; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MCINTOSH JR, 1991, COLD SPRING HARB SYM, V56, P613; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; REIDER CL, 1994, J CELL BIOL, V127, P1301; Sonnenblick BP, 1965, BIOLOGY DROSOPHILA, P62; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	16	48	48	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1917	1919		10.1126/science.7604267	http://dx.doi.org/10.1126/science.7604267			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604267				2022-12-01	WOS:A1995RF99000044
J	KAUFMAN, PD; KOBAYASHI, R; KESSLER, N; STILLMAN, B				KAUFMAN, PD; KOBAYASHI, R; KESSLER, N; STILLMAN, B			THE P150 AND P60 SUBUNITS OF CHROMATIN ASSEMBLY FACTOR-I - A MOLECULAR LINK BETWEEN NEWLY SYNTHESIZED HISTONES AND DNA-REPLICATION	CELL			English	Article							CELL-FREE SYSTEM; ACETYLATION; INVITRO; TRANSCRIPTION; TETRAHYMENA; PURIFICATION; COMPLEXES; MECHANISM; EXISTENCE; EXTRACTS	Chromatin assembly factor I (CAF-I) from human cell nuclei is a three-subunit protein complex that assembles histone octamers onto replicating DNA in a cell-free system. Sequences of cDNAs encoding the two largest CAF-I subunits reveal that the p150 protein contains large clusters of charged residues, whereas p60 contains WD repeats. p150 and p60 directly interact and are both required for DNA replication-dependent assembly of nucleosomes. Deletion of the p60-binding domain from the p150 protein prevents chromatin assembly. p150 and p60 form complexes with newly synthesized histones H3 and acetylated H4 in human cell extracts, suggesting that such complexes are intermediates between histone synthesis and assembly onto replicating DNA.			KAUFMAN, PD (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HARLOW E, 1988, ANTIBODIES LABORATOR; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KRUDE T, 1993, J BIOL CHEM, V268, P14432; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEVY A, 1978, CELL, V14, P259, DOI 10.1016/0092-8674(78)90112-5; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH PA, 1984, BIOCHEMISTRY-US, V23, P1576, DOI 10.1021/bi00302a036; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; TURNER BM, 1991, J CELL SCI, V99, P13; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Van Holde K.E., 1989, CHROMATIN; WOLFFE AP, 1992, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3	42	324	328	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1105	1114		10.1016/S0092-8674(05)80015-7	http://dx.doi.org/10.1016/S0092-8674(05)80015-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600578	Bronze			2022-12-01	WOS:A1995RG91000015
J	LIN, JJ; ZAKIAN, VA				LIN, JJ; ZAKIAN, VA			AN IN-VITRO ASSAY FOR SACCHAROMYCES TELOMERASE REQUIRES EST1	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; YEAST TELOMERES; PHOSPHOGLYCERATE KINASE; BINDING-PROTEIN; DNA; IDENTIFICATION; CLONING; RNA; TETRAHYMENA; CEREVISIAE	Telomerase activity was demonstrated in cell-free extracts from S. cerevisiae through the use of a PCR-based assay. As expected, this activity was eliminated by RNase or phenol treatment of the extract and was dependent on dGTP and dTTP. Telomerase was not detected in extracts prepared from cells grown far similar to 30 or more cell divisions in the absence of the EST1 product, Est1p. TLC1 RNA, which determines the sequence of telomeric DNA in vivo, was present in normal amounts in est1 Delta cells. Moreover, TLC1 RNA specifically precipitated with epitope-tagged Est1p. These data indicate that Est1p is either a subunit of yeast telomerase or an accessory protein associated with telomerase that is essential in vitro for its activity.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LIN, JJ (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Lin, Jing-Jer/G-8068-2015	LIN, JING-JER/0000-0001-8250-7398	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026938, R37GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HOLLAND MJ, 1978, BIOCHEMISTRY-US, V17, P4900, DOI 10.1021/bi00616a007; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PERKINS RE, 1983, BIOCHEM J, V211, P199, DOI 10.1042/bj2110199; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SAKAKIBARA Y, 1974, P NATL ACAD SCI USA, V71, P802, DOI 10.1073/pnas.71.3.802; Sambrook J., 1989, MOL CLONING LAB MANU; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SINGER MS, 1994, SCIENCE, V266, P387; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	52	96	99	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1127	1135		10.1016/S0092-8674(05)80017-0	http://dx.doi.org/10.1016/S0092-8674(05)80017-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600580	Bronze			2022-12-01	WOS:A1995RG91000017
J	OGG, SC; WALTER, P				OGG, SC; WALTER, P			SRP SAMPLES NASCENT CHAINS FOR THE PRESENCE OF SIGNAL SEQUENCES BY INTERACTING WITH RIBOSOMES AT A DISCRETE STEP DURING TRANSLATION ELONGATION	CELL			English	Article							PREPRO-ALPHA-FACTOR; RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CELL-GROWTH; YEAST; GENE; RNA	The signal recognition particle (SRP) binds to ribosomes that synthesize nascent chains bearing signal sequences and catalyzes their targeting to the endoplasmic reticulum membrane. In S. cerevisiae, a temperature-sensitive mutation in the SEC65 gene, encoding an SRP subunit, results in lowered levels of SRP. Growth and protein translocation defects induced by this mutation can be suppressed specifically by sublethal doses of cycloheximide but not anisomycin, each inhibitors of different steps of translation elongation. Cycloheximide also suppresses protein translocation defects caused by depletion of a different SRP subunit. We propose that reduced elongation rates in the presence of cycloheximide allow otherwise insufficient SRP to interact efficiently with ribosomes. These results are consistent with a sampling model in which SRP cycles on and off of translating ribosomes at specific steps during the elongation cycle to inspect ah nascent chains for the presence of signal sequences.			OGG, SC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Ogg, Stephen/0000-0003-4157-1654				ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; Gale E. F., 1981, MOL BASIS ANTIBIOTIC; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; ORRWEAVER TL, 1988, MOL CELL BIOL, V8, P5292, DOI 10.1128/MCB.8.12.5292; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STOCKLEIN W, 1980, CURR GENET, V1, P177, DOI 10.1007/BF00390941; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	30	87	88	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1075	1084		10.1016/S0092-8674(05)80012-1	http://dx.doi.org/10.1016/S0092-8674(05)80012-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600575	Bronze			2022-12-01	WOS:A1995RG91000012
J	PALOMBO, F; GALLINARI, P; IACCARINO, I; LETTIERI, T; HUGHES, M; DARRIGO, A; TRUONG, O; HSUAN, JJ; JIRICNY, J				PALOMBO, F; GALLINARI, P; IACCARINO, I; LETTIERI, T; HUGHES, M; DARRIGO, A; TRUONG, O; HSUAN, JJ; JIRICNY, J			GTBP, A 160-KILODALTON PROTEIN ESSENTIAL FOR MISMATCH-BINDING ACTIVITY IN HUMAN-CELLS	SCIENCE			English	Article							COLORECTAL-CANCER; GENE; MUTATIONS; CLONING; HOMOLOG; COLON	DNA mismatch recognition and binding in human cells has been thought to be mediated by the hMSH2 protein. Here it is shown that the mismatch-binding factor consists of two distinct proteins, the 100-kilodalton hMSH2 and a 160-kilodalton polypeptide, GTBP (for G/T binding protein). Sequence analysis identified GTBP as a new member of the MutS homolog family. Both proteins are required for mismatch-specific binding, a result consistent with the finding that tumor-derived cell lines devoid of either protein are also devoid of mismatch-binding activity.	IST RIC BIOL MOLEC P ANGELETTI, I-00040 POMEZIA, ITALY; UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School			Hsuan, Justin/C-8825-2009; Iaccarino, Ingram/B-9086-2015; Gallinari, Paola/ABE-8238-2021	Hsuan, Justin/0000-0001-6083-7564; Iaccarino, Ingram/0000-0001-7324-993X; Palombo, Fabio/0000-0003-0473-4901; Lettieri, Teresa/0000-0002-3363-9666				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; CHI NW, 1994, J BIOL CHEM, V269, P29984; COSTA LT, 1995, NAT GENET, V9, P10; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOUS N, SCIENCE, V268, P1915; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; UMAR A, 1994, J BIOL CHEM, V269, P14367; VOGELSTEIN B, COMMUNICATION; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	30	480	488	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1912	1914		10.1126/science.7604265	http://dx.doi.org/10.1126/science.7604265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604265				2022-12-01	WOS:A1995RF99000042
J	PAPADOPOULOS, N; NICOLAIDES, NC; LIU, B; PARSONS, R; LENGAUER, C; PALOMBO, F; DARRIGO, A; MARKOWITZ, S; WILLSON, JKV; KINZLER, KW; JIRICNY, J; VOGELSTEIN, B				PAPADOPOULOS, N; NICOLAIDES, NC; LIU, B; PARSONS, R; LENGAUER, C; PALOMBO, F; DARRIGO, A; MARKOWITZ, S; WILLSON, JKV; KINZLER, KW; JIRICNY, J; VOGELSTEIN, B			MUTATIONS OF GTBP IN GENETICALLY UNSTABLE CELLS	SCIENCE			English	Article							ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; CLONES	The molecular defects responsible for tumor cell hypermutability in humans have not yet been fully identified. Here the gene encoding a G/T mismatch-binding protein (GTBP) was localized to within 1 megabase of the related hMSH2 gene on chromosome 2 and was found to be inactivated in three hypermutable cell lines. Unlike cells defective in other mismatch repair genes, which display widespread alterations in mononucleotide, dinucleotide, and other simple repeated sequences, the GTBP-deficient cells showed alterations primarily in mononucleotide tracts. These results suggest that GTBP is important for maintaining the integrity of the human genome and document molecular defects accounting for variation in mutator phenotype.	HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; IST RIC BIOL MOLEC P ANGELETTI,I-00040 POMEZIA,ITALY; UNIV HOSP CLEVELAND,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; University Hospitals of Cleveland; Case Western Reserve University			Papadopoulos, Nickolas/K-7272-2012	Parsons, Ramon/0000-0002-6656-3514; Palombo, Fabio/0000-0003-0473-4901	NATIONAL CANCER INSTITUTE [R01CA047527, P50CA062924, R01CA035494, R37CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924, CA35494, CA47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BREUKEL C, 1991, NUCLEIC ACIDS RES, V19, P5804, DOI 10.1093/nar/19.20.5804; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GYAPAY G, 1995, NAT GENET, V7, P246; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LENGAUER C, 1992, CANCER RES, V52, P2590; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; MARRO G, IN PRESS J NAT CANCE; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, UNPUB; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	27	477	497	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1915	1917		10.1126/science.7604266	http://dx.doi.org/10.1126/science.7604266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604266				2022-12-01	WOS:A1995RF99000043
J	PARK, HW; KIM, ST; SANCAR, A; DEISENHOFER, J				PARK, HW; KIM, ST; SANCAR, A; DEISENHOFER, J			CRYSTAL-STRUCTURE OF DNA PHOTOLYASE FROM ESCHERICHIA-COLI	SCIENCE			English	Article							T4 ENDONUCLEASE-V; X-RAY-DIFFRACTION; THYMINE PHOTODIMER; ANACYSTIS-NIDULANS; ELECTRON-TRANSFER; MACROMOLECULAR CRYSTALLOGRAPHY; PYRIMIDINE DIMERS; ENERGY-TRANSFER; ACTIVE FORM; BINDING	Photolyase repairs ultraviolet (UV) damage to DNA by splitting the cyclobutane ring of the major UV photoproduct, the cis,syn-cyclobutane pyrimidine dimer (Pyr >$($) over bar Pyr). The reaction is initiated by blue light and proceeds through long-range energy transfer, single electron transfer, and enzyme catalysis by a radical mechanism. The three-dimensional crystallographic structure of DNA photolyase from Escherichia coli is presented and the atomic model was refined to an R value of 0.172 at 2.3 Angstrom resolution. The polypeptide chain of 471 amino acids is folded into an amino-terminal alpha/beta domain resembling dinucleotide binding domains and a carboxyl-terminal helical domain; a loop of 72 residues connects the domains. The light-harvesting cofactor 5,10-methenyltetrahydrofolylpolyglutamate (MTHF) binds in a cleft between the two domains. Energy transfer from MTHF to the catalytic cofactor flavin adenine dinucleotide (FAD) occurs over a distance of 16.8 Angstrom. The FAD adopts a U-shaped conformation between two helix clusters in the center of the helical domain and is accessible through a hole in the surface of this domain. Dimensions and polarity of the hole match those of a Pyr >$($) over bar Pyr dinucleotide, suggesting that the Pyr >$($) over bar Pyr ''flips out'' of the helix to fit into this hole, and that electron transfer between the flavin and the Pyr >$($) over bar Pyr occurs over van der Waals contact distance.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	PARK, HW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM31082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031082, R37GM031082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BAER ME, 1993, J BIOL CHEM, V268, P16717; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; COLONNACESARI F, 1986, J BIOL CHEM, V261, P5273; DEISENHOFER J, 1991, ANNU REV CELL BIOL, V7, P1; Forster T., 1959, Discussions of the Faraday Society, V27, P7, DOI 10.1039/df9592700007; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; HAMMALVAREZ S, 1989, J BIOL CHEM, V264, P9649; HAMMALVAREZ S, 1990, J BIOL CHEM, V265, P18656; Harm W., 1980, BIOL EFFECTS ULTRAVI; HAYES FN, 1971, J AM CHEM SOC, V93, P4940, DOI 10.1021/ja00748a065; HEELIS PF, 1990, BIOCHEMISTRY-US, V29, P5694, DOI 10.1021/bi00476a008; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; INAOKA T, 1989, J BIOL CHEM, V264, P2609; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; Kim S.O., UNPUB; KIM ST, 1991, BIOCHEMISTRY-US, V30, P11262, DOI 10.1021/bi00111a011; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KIM ST, 1992, BIOCHEMISTRY-US, V31, P11244, DOI 10.1021/bi00160a040; KIM ST, 1994, J AM CHEM SOC, V116, P3115, DOI 10.1021/ja00086a048; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Kleywegt G. J., UNPUB; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; LI YF, 1990, BIOCHEMISTRY-US, V30, P6322; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MALHOTRA K, UNPUB; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MIKI K, 1993, J MOL BIOL, V233, P167, DOI 10.1006/jmbi.1993.1492; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.bb.18.060189.001521; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; Nicholls A., 1992, GRASP GRAPHICAL REPR; OKAMURA T, 1991, J AM CHEM SOC, V113, P3143, DOI 10.1021/ja00008a050; OKAMURA T, 1994, J AM CHEM SOC, V116, P3115; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PARK HW, 1993, J MOL BIOL, V231, P1122, DOI 10.1006/jmbi.1993.1356; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; RAO SN, 1984, NUCLEIC ACIDS RES, V12, P4789, DOI 10.1093/nar/12.11.4789; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REARDON JT, UNPUB; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RUPERT CS, 1958, J GEN PHYSIOL, V41, P451, DOI 10.1085/jgp.41.3.451; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; STELGEMANN W, 1992, PROGRAM SYSTEM CRYST; STOLARSKI R, 1992, SCIENCE, V256, P342, DOI 10.1126/science.256.5055.342; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TODO T, 1994, MUTAT RES-DNA REPAIR, V315, P213, DOI 10.1016/0921-8777(94)90033-7; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YAJIMA H, 1991, NUCLEIC ACIDS RES, V19, P5359, DOI 10.1093/nar/19.19.5359; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	88	473	487	2	66	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1866	1872		10.1126/science.7604260	http://dx.doi.org/10.1126/science.7604260			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604260				2022-12-01	WOS:A1995RF99000029
J	RAHME, LG; STEVENS, EJ; WOLFORT, SF; SHAO, J; TOMPKINS, RG; AUSUBEL, FM				RAHME, LG; STEVENS, EJ; WOLFORT, SF; SHAO, J; TOMPKINS, RG; AUSUBEL, FM			COMMON VIRULENCE FACTORS FOR BACTERIAL PATHOGENICITY IN PLANTS AND ANIMALS	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; IDENTIFICATION; DETERMINANTS; RESISTANCE; SECRETION; CLONING; REGION; GENES	A Pseudomonas aeruginosa strain (UCBPP-PA14) is infectious both in an Arabidopsis thaliana leaf infiltration model and in a mouse full-thickness skin burn model. UCBPP-PA14 exhibits ecotype specificity for Arabidqosis, causing a range of symptoms from none to severe in four different ecotypes. In the mouse model, UCBPP-PA14 is as lethal as other well-studied P. aeruginosa strains. Mutations in the UCBPP-PA14 toxA, plcS, and gacA genes resulted in a significant reduction in pathogenicity in both hosts, indicating that these genes encode virulence factors required for the full expression of pathogenicity in both plants and animals.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SHRINERS BURNS INST,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital								BERKA RM, 1982, J BACTERIOL, V152, P239; BODEY GP, 1983, REV INFECT DIS, V5, P279; BURKHOLDER WALTER H., 1950, PHYTOPATH, V40, P115; CHO JJ, 1974, PHYTOPATHOLOGY, V65, P425; Crute I, 1994, ARABIDOPSIS, P705; DAVIS KR, 1991, MOL PLANT MICROBE IN, V4, P477, DOI 10.1094/MPMI-4-477; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; ELROD RP, 1942, J BACTERIOL, V46, P633; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; GAFFNEY TD, 1994, MOL PLANT MICROBE IN, V7, P455, DOI 10.1094/MPMI-7-0455; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HOLLOWAY BW, 1955, J GEN MICROBIOL, V13, P572, DOI 10.1099/00221287-13-3-572; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HUANG HC, 1993, MOL PLANT MICROBE IN, V6, P515, DOI 10.1094/MPMI-6-515; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; ISHIMOTO KS, 1989, P NATL ACAD SCI USA, V86, P1954, DOI 10.1073/pnas.86.6.1954; KOMINOS SD, 1972, APPL MICROBIOL, V24, P567, DOI 10.1128/AEM.24.4.567-570.1972; LAVILLE J, 1992, P NATL ACAD SCI USA, V89, P1562, DOI 10.1073/pnas.89.5.1562; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LORY S, 1983, GENE, V22, P95, DOI 10.1016/0378-1119(83)90068-9; LORY S, 1988, J BACTERIOL, V170, P714, DOI 10.1128/jb.170.2.714-719.1988; MEYERS BR, 1972, ANN INTERN MED, V76, P9, DOI 10.7326/0003-4819-76-1-9; OHMAN DE, 1980, INFECT IMMUN, V28, P899; OSTROFF RM, 1987, J BACTERIOL, V169, P4597, DOI 10.1128/jb.169.10.4597-4601.1987; OSTROFF RM, 1989, INFECT IMMUN, V57, P1369, DOI 10.1128/IAI.57.5.1369-1373.1989; RAHME LG, 1991, J BACTERIOL, V170, P575; RICH JJ, 1994, J BACTERIOL, V176, P7468, DOI 10.1128/JB.176.24.7468-7475.1994; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; RUBIN RA, 1987, PLASMID, V18, P84, DOI 10.1016/0147-619X(87)90081-3; Stevens Emily J., 1994, Journal of Burn Care and Rehabilitation, V15, P232, DOI 10.1097/00004630-199405000-00005; Young, 1977, PSEUDOMONAS AERUGINO, P1	33	957	994	9	140	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 30	1995	268	5219					1899	1902		10.1126/science.7604262	http://dx.doi.org/10.1126/science.7604262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7604262				2022-12-01	WOS:A1995RF99000038
J	SCHWIEBERT, EM; EGAN, ME; HWANG, TH; FULMER, SB; ALLEN, SS; CUTTING, GR; GUGGINO, WB				SCHWIEBERT, EM; EGAN, ME; HWANG, TH; FULMER, SB; ALLEN, SS; CUTTING, GR; GUGGINO, WB			CFTR REGULATES OUTWARDLY RECTIFYING CHLORIDE CHANNELS THROUGH AN AUTOCRINE MECHANISM INVOLVING ATP	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ION-TRANSPORT DEFECT; CYSTIC-FIBROSIS GENE; EPITHELIAL-CELLS; CL CHANNELS; EXTRACELLULAR ATP; PROTEIN-KINASE; ACTIVATION; IDENTIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) functions to regulate both Cl- and Na+ conductive pathways; however, the cellular mechanisms whereby CFTR acts as a conductance regulator are unknown. CFTR and outwardly rectifying Cl- channels (ORCCs) are distinct channels but are linked functionally via an unknown regulatory mechanism. We present results from whole-cell and single-channel patch-clamp recordings, short-circuit current recordings, and [gamma-P-32]ATP release assays of normal, CF, and wild-type or mutant CFTR-transfected CF airway cultured epithelial cells wherein CFTR regulates ORCCs by triggering the transport of the potent agonist, ATP, out of the cell. Once released, ATP stimulates ORCCs through a P-2U purinergic receptor-dependent signaling mechanism. Our results suggest that CFTR functions to regulate other Cl- secretory pathways in addition to itself conducting Cl-.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, CTR MED GENET, DEPT PEDIAT, BALTIMORE, MD 21287 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06520 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yale University	SCHWIEBERT, EM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA.							ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P2576; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; FULMER SB, 1995, IN PRESS P NATL ACAD, V92; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LJ, 1995, IN PRESS J CLIN INVE; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; SINGH AK, 1993, BIOPHYS J, V64, pA17; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; WELSH MJ, 1986, CLIN CHEST MED, V7, P273; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	36	584	587	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1063	1073		10.1016/S0092-8674(05)80011-X	http://dx.doi.org/10.1016/S0092-8674(05)80011-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7541313	Bronze			2022-12-01	WOS:A1995RG91000011
J	VERRIJZER, CP; CHEN, JL; YOKOMORI, K; TJIAN, R				VERRIJZER, CP; CHEN, JL; YOKOMORI, K; TJIAN, R			BINDING OF TAFS TO CORE ELEMENTS DIRECTS PROMOTER SELECTIVITY BY RNA-POLYMERASE-II	CELL			English	Article							TRANSCRIPTION FACTOR; TATA BOX; DNA-SEQUENCES; MINIMAL SET; INITIATION; GENE; COMPLEXES; PROTEIN; DOWNSTREAM	The mechanisms that govern core promoter recognition and basal transcription efficiency remain poorly understood. Here, we have assessed the potential role of TAFs and the TFIID complex in directing basal promoter function. Reconstituted transcription reactions revealed the ability of TFIID versus TBP to discriminate between distinct core promoters. A comparison of different partial TBP-TAF assemblages established that a trimeric TBP-TAF(II)250-TAF(II)150 complex is minimally required for efficient utilization of the initiator and downstream promoter elements. Depending on the promoter structure, TAFs can increase or decrease the stability of TFIID-promoter interactions. These findings suggest that TAFs play a critical role in promoter selectivity and transcription regulation through direct contacts with core promoter elements.			VERRIJZER, CP (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DYNLACHT BD, 1991, CELL, V55, P563; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; MALDONADO E, 1990, MOL CELL BIOL, V10, P653; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PARVIN JD, 1992, CELL, V68, P1153; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SMALE ST, 1990, P NATL ACAD SCI USA, V81, P4509; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	45	258	259	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					1115	1125		10.1016/S0092-8674(05)80016-9	http://dx.doi.org/10.1016/S0092-8674(05)80016-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7600579	Bronze			2022-12-01	WOS:A1995RG91000016
J	ZUNIGAPFLUCKER, JC; JIANG, D; LENARDO, MJ				ZUNIGAPFLUCKER, JC; JIANG, D; LENARDO, MJ			REQUIREMENT FOR TNF-ALPHA AND IL-1-ALPHA IN FETAL THYMOCYTE COMMITMENT AND DIFFERENTIATION	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; TUMOR-NECROSIS-FACTOR; POLYMERASE CHAIN-REACTION; CYTOKINE GENE-EXPRESSION; T-CELLS; PRECURSOR CELLS; C-KIT; INTERLEUKIN-2 RECEPTORS; IMMATURE THYMOCYTES; THYMUS DEVELOPMENT	CD25 expression occurs early in thymocyte differentiation. The mechanism of induction of CD25 before T cell receptor rearrangement and the importance of this mechanism for T cell development are unknown. In a thymus reconstitution assay, tumor necrosis factor alpha (TNF-alpha) and interleukin-1 alpha (IL-1 alpha), two cytokines produced within the thymic microenvironment, induced CD25 expression on early immature thymocytes. Either TNF-alpha or IL-1 alpha was necessary for further thymocyte maturation and CD4(+)CD8(+) differentiation. In irradiated mice reconstituted with CD117(+)CD25(+) thymocytes, commitment to the T cell lineage was marked by the loss of precursor multipotency.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Zuniga-Pflucker, Juan C/H-1295-2012	Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178				ANTICA M, 1993, J IMMUNOL, V151, P5887; BELL SE, 1991, EUR J IMMUNOL, V21, P2931, DOI 10.1002/eji.1830211206; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/s0065-2776(08)60642-2; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; HUSMANN LA, 1988, J IMMUNOL, V141, P736; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IVANOV V, 1992, INT IMMUNOL, V4, P729, DOI 10.1093/intimm/4.7.729; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MOORE NC, 1993, EUR J IMMUNOL, V23, P922, DOI 10.1002/eji.1830230424; MOORE T, 1994, J IMMUNOL, V153, P4978; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; ROTHENBERG EV, 1994, EUR J IMMUNOL, V24, P24, DOI 10.1002/eji.1830240105; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SEN J, 1994, J EXP MED, V180, P2321, DOI 10.1084/jem.180.6.2321; SHIMONKEVITZ RP, 1987, NATURE, V329, P157, DOI 10.1038/329157a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SUDA T, 1990, J IMMUNOL, V144, P3039; WATSON JD, 1989, J IMMUNOL, V143, P1215; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139; ZUNIGAPFLUCKER JC, UNPUB	45	125	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	1995	268	5219					1906	1909		10.1126/science.7541554	http://dx.doi.org/10.1126/science.7541554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7541554				2022-12-01	WOS:A1995RF99000040
J	BANFIELD, DK; LEWIS, MJ; PELHAM, HRB				BANFIELD, DK; LEWIS, MJ; PELHAM, HRB			A SNARE-LIKE PROTEIN REQUIRED FOR TRAFFIC THROUGH THE GOLGI-COMPLEX	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; YEAST GENES; APPARATUS; ER; GLYCOPROTEIN; RECEPTORS; RETRIEVAL	THE secretory pathway of eukaryotic cells comprises several distinct membrane-bound compartments which are interconnected by transport vesicles that pinch off from one membrane and fuse with the next. Targeting of these vesicles is mediated in part by interactions between integral membrane proteins on the vesicles and target organelles (soluble NSF attachment protein receptors (SNAREs)), termed v-SNAREs and t-SNAREs, respectively(1-4). SNAREs required for endoplasmic reticulum (ER)-Golgi transport and for fusion of vesicles with the plasma membrane are already known. Here we identify two yeast membrane proteins that show genetic interactions with Sed5p, which is the t-SNARE for ER-Golgi traffic(3,4). One of these membrane proteins, Sft1p, is structurally similar to the known v-SNAREs and is required for transport from an early to a later Golgi compartment. Our results indicate that a single t-SNARE can control more than one transport step, and provide the first candidate for a SNARE involved in intra-Golgi traffic.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology								BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x	20	130	133	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					806	809		10.1038/375806a0	http://dx.doi.org/10.1038/375806a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596416				2022-12-01	WOS:A1995RF98900083
J	CHITNIS, A; HENRIQUE, D; LEWIS, J; ISHHOROWICZ, D; KINTNER, C				CHITNIS, A; HENRIQUE, D; LEWIS, J; ISHHOROWICZ, D; KINTNER, C			PRIMARY NEUROGENESIS IN XENOPUS EMBRYOS REGULATED BY A HOMOLOG OF THE DROSOPHILA NEUROGENIC GENE-DELTA	NATURE			English	Article							CELL FATE; NERVOUS-SYSTEM; MOUSE NOTCH; SPINAL-CORD; EXPRESSION; PATTERN; MELANOGASTER; SERRATE; PROTEIN; XOTCH	X-Delta-1, a Xenopus homologue of the Drosophila Delta gene, is expressed in the early embryonic nervous system in scattered cells that appear to be the prospective primary neurons. Ectopic X-Delta-1 activity inhibits production of primary neurons and interference with endogenous X-Delta-1 activity results in overproduction of primary neurons. These results indicate that the X-Delta-1 protein mediates lateral inhibition delivered by prospective neurons to adjacent cells, and that commitment to a neural fate in vertebrates is regulated by Delta-Notch signalling as in Drosophila.	UNIV OXFORD, DEPT ZOOL,IMPERIAL CANC RES FUND, DEV GENET & ORGANOGENESIS LABS,DEV BIOL UNIT, OXFORD OX1 3PS, ENGLAND	University of Oxford	CHITNIS, A (corresponding author), SALK INST BIOL STUDIES, POB 85800, SAN DIEGO, CA 92186 USA.		Henrique, Domingos M/E-5460-2010; Lewis, Julian H/E-8733-2010	Henrique, Domingos M/0000-0001-8869-1894; Ish-Horowicz, David/0000-0001-5684-7129				ALRDELLI M, 1994, MECH DEVELOP, V46, P123; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; Campos-Ortega JAVH, 1985, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; DOE CQ, 1992, DEVELOPMENT, V116, P855; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GORIELY A, 1991, DEVELOPMENT, V113, P1395; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1989, NEURON, V3, P399, DOI 10.1016/0896-6273(89)90200-6; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KORZH V, 1993, DEVELOPMENT, V118, P417; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LEHMANN R, 1981, ROUX ARCH DEV BIOL, V190, P226, DOI 10.1007/BF00848307; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1994, DEVELOPMENT, V120, P2421; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROBERTS A, 1982, PHILOS T R SOC B, V296, P195, DOI 10.1098/rstb.1982.0002; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SIMPSON P, 1992, COLD SPRING HARB SYM, V57, P391, DOI 10.1101/SQB.1992.057.01.044; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	46	622	636	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					761	766		10.1038/375761a0	http://dx.doi.org/10.1038/375761a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596407				2022-12-01	WOS:A1995RF98900070
J	DAS, A; GILBERT, CD				DAS, A; GILBERT, CD			LONG-RANGE HORIZONTAL CONNECTIONS AND THEIR ROLE IN CORTICAL REORGANIZATION REVEALED BY OPTICAL-RECORDING OF CAT PRIMARY VISUAL-CORTEX	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; ORGANIZATION; NEURONS; PROJECTIONS; LESIONS; MAPS	THE cortical 'point spread' (PS) is the area of cortex activated by a minimal visual stimulus(1). Here we use the PS to explore the functional role of lateral connectivity in normal cat primary visual cortex (V1) and its involvement in topographic reorganization of cortex following retinal lesions. We compared the distributions of PSs measured with optical recording, which reflects both spiking and subthreshold activity, with those measured with extracellular electrodes, which reveal spiking activity alone. The spiking PS represented only 5% of the area of activation shown in the optical PS, indicating that the remaining 95% was probably generated by subthreshold activation. The orientation dependence of the pattern of the subthreshold activation and its close match with orientation columns suggests that long-range horizontal connections radiating from the locus of spiking activity were responsible for the observed activation. The spike PS showed anisotropies and inhomogeneities that were related to the pattern of orientation columns and indicated distortions in the representation of visual space on the cortical surface. In the reorganized cortex the spike PS expanded, approximating the extent of the optical PS seen in normal cortex, and suggesting that reorganization was mediated by an unmasking of normally subthreshold activation to suprathreshold levels. The orientation map of the reorganized cortex showed a close match to that obtained before placing the lesion, despite the large shift in topography, supporting the idea that intrinsic horizontal connections were responsible for the remapping.			DAS, A (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P659, DOI 10.1113/jphysiol.1971.sp009682; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MCILWAIN JT, 1975, J NEUROPHYSIOL, V38, P219, DOI 10.1152/jn.1975.38.2.219; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; TSO DY, 1986, J NEUROSCI, V6, P1160; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630	24	339	344	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					780	784		10.1038/375780a0	http://dx.doi.org/10.1038/375780a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596409				2022-12-01	WOS:A1995RF98900076
J	DAVIS, AP; WITTE, DP; HSIEHLI, HM; POTTER, SS; CAPECCHI, MR				DAVIS, AP; WITTE, DP; HSIEHLI, HM; POTTER, SS; CAPECCHI, MR			ABSENCE OF RADIUS AND ULNA IN MICE LACKING HOXA-11 AND HOXD-11	NATURE			English	Article							VERTEBRATE LIMB; HOMEOTIC TRANSFORMATIONS; PATTERN-FORMATION; HOX-4 GENES; EXPRESSION; EVOLUTION	MICE with targeted disruptions(1) in Hox genes have been generated to evaluate the role of the Hox complex in determining the mammalian body plan. This complex of 38 genes encodes transcription factors that specify regional information along the embryonic axes. Early in vertebrate evolution an ancestral complex shared with invertebrates was duplicated twice to give rise to the four linkage groups (Hox A, B, C and D)(2,3). As a consequence, corresponding genes on the separate linkage groups, called paralogues, are most closely related to each other. Based on sequence similarities, the Hox genes have been subdivided into 13 paralogous groups. The five most 5' groups (Hox 9-13) pattern the posterior region of the vertebrate embryo and the appendicular skeleton(4-18). Mice with individual mutations in the paralogous genes hoxa-11 and hoxd-11 have been described(15-18). By breeding these two strains together we have generated double mutants which have dramatic phenotypes not apparent in mice homozygous for the individual mutations. The radius and the ulna of the forelimb are almost entirely eliminated, the axial skeleton shows homeotic transformations, and there are severe kidney defects not present in either single mutant. The limb and axial phenotypes are quantitative: as more mutant alleles are added to the genotype, the phenotype becomes progressively more severe. The appendicular skeleton defects suggest that paralogous Hox genes function together to specify limb outgrowth and patterning along the proximodistal axis.	UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,DIV BASIC SCI RES & PATHOL,CINCINNATI,OH 45229	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati								CAPECCHI MR, 1994, SCI AM, V270, P54; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; DUBOULE D, 1994, SCIENCE, V268, P575; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FAVIER B, 1994, P NATL ACAD SCI USA, V92, P310; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; HOLLAND PWH, 1994, DEVELOPMENT, P125; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; LI HMH, 1995, DEVELOPMENT, V121, P1373; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OSTER GF, 1988, EVOLUTION, V42, P862, DOI 10.1111/j.1558-5646.1988.tb02508.x; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	29	478	490	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					791	795		10.1038/375791a0	http://dx.doi.org/10.1038/375791a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596412				2022-12-01	WOS:A1995RF98900079
J	FEHLING, HJ; KROTKOVA, A; SAINTRUF, C; VONBOEHMER, H				FEHLING, HJ; KROTKOVA, A; SAINTRUF, C; VONBOEHMER, H			CRUCIAL ROLE OF THE PRE-T-CELL RECEPTOR-ALPHA GENE IN DEVELOPMENT OF ALPHA-BETA BUT NOT GAMMA-DELTA T-CELLS	NATURE			English	Article							DEFICIENT MICE; EXPRESSION; SURFACE; CHAIN; TCR; GENERATION; THYMOCYTES; IMMATURE; ANTIGENS	T-cell precursors, the T-cell-receptor B chain is expressed before the T-cell-receptor alpha chain(1,2) and is sufficient to advance T-cell development in the absence of T-cell receptor a chains(3-7). In immature T cells, the T-cell-receptor beta protein can form disulphide-linked heterodimers with the pre-T-cell-receptor alpha chain(8,9) and associate with signal-transducing CD3 molecules(5). The recently cloned pre-T-cell-receptor alpha gene encodes a transmembrane protein that is expressed in immature but not mature T cells(9,10). Here we show that alpha beta, but not gamma delta, cell development is severely hampered in pre-T-cell-receptor alpha-gene-deficient mice, which establishes a crucial role for the pre-T-cell receptor in early thymocyte development.	INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	FEHLING, HJ (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Fehling, Hans Joerg/0000-0002-4580-1990				ALLISON JP, 1987, UCLA S MOL CELLULAR; BRUNO LEA, IN PRESS EUR J IMMUN; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FEHLING HJ, IN PRESS IMMUNOGENET; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	22	455	458	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					795	798		10.1038/375795a0	http://dx.doi.org/10.1038/375795a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596413	Green Submitted			2022-12-01	WOS:A1995RF98900080
J	FUNG, DC; BERG, HC				FUNG, DC; BERG, HC			POWERING THE FLAGELLAR MOTOR OF ESCHERICHIA-COLI WITH AN EXTERNAL VOLTAGE-SOURCE	NATURE			English	Article							BACTERIAL FLAGELLA; OPTICAL TWEEZERS; ROTATION; TORQUE; FORCE; STREPTOCOCCUS; LIGHT	ROTARY motors of bacterial flagella are driven by ions that move across the cytoplasmic membrane down an electrochemical gradient(1-4). For Escherichia coli, the ions are protons, and the maximum work per unit charge that they can do is the protonmotive force. To test whether motor efficiency is limited by proton leakage or mechanical nonlinearities, we measured torque as a function of protonmotive force. Filamentous cells were drawn into micropipettes and energized with an external voltage source. Torque was proportional to protonmotive force up to -150 mV, twice the span accessible by earlier techniques(5-9). This is consistent with a mechanism in which a fixed number of protons, working at unit efficiency, carry the motor through each revolution. We also found that individual torque-generating elements inactivate at low potentials or potentials of reverse sign. When normal potentials are restored, they reactivate sequentially.	UNIV HARTFORD, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE 02138, ENGLAND									ARMITAGE JP, 1985, BIOCHIM BIOPHYS ACTA, V806, P42, DOI 10.1016/0005-2728(85)90080-5; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; BERG HC, 1982, SYM SOC EXP BIOL, P1; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; Blair D F, 1990, Semin Cell Biol, V1, P75; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; Brown KT, 1986, ADV MICROPIPETTE TEC; CONLEY MP, 1984, J BACTERIOL, V158, P832, DOI 10.1128/JB.158.3.832-843.1984; FUNG DCY, 1994, THESIS HARVARD U CAM; ISHIHARA A, 1983, J BACTERIOL, V155, P228, DOI 10.1128/JB.155.1.228-237.1983; JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7; KAMIIKE N, 1991, BIOPHYS J, V60, P1350, DOI 10.1016/S0006-3495(91)82172-5; KASHKET ER, 1985, ANNU REV MICROBIOL, V39, P219, DOI 10.1146/annurev.mi.39.100185.001251; KATSU T, 1986, BIOCHIM BIOPHYS ACTA, V860, P608, DOI 10.1016/0005-2736(86)90560-2; KHAN S, 1983, CELL, V32, P913, DOI 10.1016/0092-8674(83)90076-4; KHAN S, 1985, J MOL BIOL, V184, P645, DOI 10.1016/0022-2836(85)90310-9; KHAN S, 1990, BIOPHYS J, V57, P779, DOI 10.1016/S0006-3495(90)82598-4; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MANSON MD, 1980, J MOL BIOL, V138, P541, DOI 10.1016/S0022-2836(80)80017-9; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; MEISTER M, 1987, BIOPHYS J, V52, P413, DOI 10.1016/S0006-3495(87)83230-7; MEISTER M, 1987, THESIS CALTECH PASAD; OVCHINNIKOV YA, 1982, PROTEINS, V5, P307; RAVID S, 1984, J BACTERIOL, V158, P222, DOI 10.1128/JB.158.1.222-230.1984; SCHUSTER SC, 1994, ANNU REV BIOPH BIOM, V23, P509, DOI 10.1146/annurev.bb.23.060194.002453	28	83	83	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					809	812		10.1038/375809a0	http://dx.doi.org/10.1038/375809a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7541114				2022-12-01	WOS:A1995RF98900084
J	GU, XN; SPITZER, NC				GU, XN; SPITZER, NC			DISTINCT ASPECTS OF NEURONAL DIFFERENTIATION ENCODED BY FREQUENCY OF SPONTANEOUS CA2+ TRANSIENTS	NATURE			English	Article							C-FOS TRANSCRIPTION; PROTEIN-KINASE-C; SPINAL NEURONS; ELECTRICAL-ACTIVITY; SIGNALING PATHWAYS; SENSORY NEURONS; CALCIUM; MIGRATION; CHANNELS; CULTURE	STIMULATION of transient increases in intracellular calcium (Ca-i(2+)) activates protein kinases(1-3), regulates transcription(4-9) and influences motility and morphology Developing neurons generate spontaneous Ca-i(2+) transients, but their role in directing neuronal differentiation and the way in which they encode information are unknown. Acre we image Ca2+ in spinal neurons throughout an extended period of early development, and find that two types of spontaneous events, spikes and waves, are expressed at distinct frequencies. Neuronal differentiation is altered when they are eliminated by preventing Ca2+ influx. Reimposing different frequency patterns of Ca2+ elevation demonstrates that natural spike activity is sufficient to promote normal neurotransmitter expression and channel maturation, whereas wave activity is sufficient to regulate neurite extension. Suppression of spontaneous Ca2+ elevations by BAPTA loaded intracellularly indicates that they are also necessary for differentiation. Ca2+ transients appear to encode information in their frequency, like action potentials, although they are 10(4) times longer in duration and less frequent, and implement an intrinsic development programme.	UNIV CALIF SAN DIEGO, CTR GENET MOLEC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	GU, XN (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.			Spitzer, Nicholas/0000-0002-3523-1103				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAHA O, 1993, J NEUROSCI, V13, P1839; CLINE HT, 1991, NEURON, V6, P259, DOI 10.1016/0896-6273(91)90361-3; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESARMENIEN MG, 1991, NEURON, V7, P797, DOI 10.1016/0896-6273(91)90282-5; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FATATIS A, 1992, GLIA, V5, P95, DOI 10.1002/glia.440050203; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FLUCHER BE, 1993, CELL MOTIL CYTOSKEL, V25, P143, DOI 10.1002/cm.970250204; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GU XN, 1994, J NEUROSCI, V14, P6325; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; HOLLIDAY J, 1990, DEV BIOL, V141, P13, DOI 10.1016/0012-1606(90)90098-4; KOCSIS JD, 1994, J NEUROBIOL, V25, P252, DOI 10.1002/neu.480250306; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHENG HZ, 1993, J NEUROSCI RES, V35, P459, DOI 10.1002/jnr.490350502; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SPITZER NC, 1993, J COMP NEUROL, V337, P168, DOI 10.1002/cne.903370111; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379	30	462	469	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					784	787		10.1038/375784a0	http://dx.doi.org/10.1038/375784a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596410				2022-12-01	WOS:A1995RF98900077
J	HENRIQUE, D; ADAM, J; MYAT, A; CHITNIS, A; LEWIS, J; ISHHOROWICZ, D				HENRIQUE, D; ADAM, J; MYAT, A; CHITNIS, A; LEWIS, J; ISHHOROWICZ, D			EXPRESSION OF A DELTA-HOMOLOG IN PROSPECTIVE NEURONS IN THE CHICK	NATURE			English	Article							NEUROGENIC GENE-DELTA; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; CELL-INTERACTIONS; SERRATE ENCODES; NOTCH; COMPLEX; PATTERN; FATE; RNA	THE product of the Delta gene, acting as ligand, and that of the Notch gene, acting as receptor, are key components in a lateral-inhibition signalling pathway that regulates the detailed patterning of many different tissues in Drosophila(1-8). During neurogenesis in particular, neural precursors, by expressing Delta, inhibit neighbouring Notch-expressing cells from becoming committed to a neural fate(5,9,10). Vertebrates are known to have several Notch genes(11-14), but their functions are unclear and their ligands hitherto unidentified. Here we identify and describe a chick Delta homologue, C-Delta-1. We show that C-Delta-1 is expressed in prospective neurons during neurogenesis, as new cells are being born and their fates decided. Our data from the chick, combined with parallel evidence from Xenopus(15), suggest that both the Delta/Notch signalling mechanism and its role in neurogenesis have been conserved in vertebrates.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,ORGANOGENESIS LAB,BIOL UNIT,OXFORD OX1 3PS,ENGLAND; SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	University of Oxford; Salk Institute	HENRIQUE, D (corresponding author), UNIV OXFORD,DEV GENET LAB,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Lewis, Julian H/E-8733-2010; Henrique, Domingos M/E-5460-2010	Henrique, Domingos M/0000-0001-8869-1894; Adam, Julie/0000-0002-7980-7151; Ish-Horowicz, David/0000-0001-5684-7129				ARTAVANISTSAKON.S, 1991, TRENDS GENET, V7, P403; BIFFO S, 1992, J HISTOCHEM CYTOCHEM, V40, P535, DOI 10.1177/40.4.1552187; Campos-Ortega Jose A., 1993, P1091; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FUJITA S, 1963, J COMP NEUROL, V120, P37, DOI 10.1002/cne.901200104; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARTIN AH, 1965, J EMBRYOL EXP MORPH, V14, P23; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; SECHRIST J, 1991, NEURON, V7, P947, DOI 10.1016/0896-6273(91)90340-6; STRAHLE U, 1994, TRENDS GENET, V10, P75, DOI 10.1016/0168-9525(94)90221-6; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931	29	928	946	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					787	790		10.1038/375787a0	http://dx.doi.org/10.1038/375787a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596411				2022-12-01	WOS:A1995RF98900078
J	LIPSHULTZ, SE; LIPSITZ, SR; MONE, SM; GOORIN, AM; SALLAN, SE; SANDERS, SP; ORAV, EJ; GELBER, RD; COLAN, SD				LIPSHULTZ, SE; LIPSITZ, SR; MONE, SM; GOORIN, AM; SALLAN, SE; SANDERS, SP; ORAV, EJ; GELBER, RD; COLAN, SD			FEMALE SEX AND HIGHER DRUG DOSE AS RISK-FACTORS FOR LATE CARDIOTOXIC EFFECTS OF DOXORUBICIN THERAPY FOR CHILDHOOD-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CONGESTIVE HEART-FAILURE; RADIONUCLIDE ANGIOGRAPHY; OSTEO-SARCOMA; FREE SURVIVAL; GENDER; ANTHRACYCLINES; CHILDREN; ECHOCARDIOGRAPHY; CARDIOMYOPATHY	Background. Late cardiotoxic effects of doxorubicin are increasingly a problem for patients who survive childhood cancer. Cardiotoxicity is often progressive, and some patients have disabling symptoms. Our objective was to identify risk factors for late cardiotoxicity. Methods. We examined echocardiograms from 120 children and adults who had received cumulative doses of 244 to 550 mg of doxorubicin per square meter of body-surface area for the treatment of acute lymphoblastic leukemia or osteogenic sarcoma in childhood, a mean of 8.1 years earlier. Measurements of blood pressure and left ventricular function, contractility (measured as the stress-velocity index), end-diastolic posterior-wall thickness, end-diastolic dimension, mass, and afterload (measured as end-systolic wall stress) were compared with sex-specific values from a cohort of 296 normal subjects. Results. All echocardiographic measurements were abnormal at follow-up a minimum of two years after the end of therapy, with more frequent and severe abnormalities in female patients. In a multivariate analysis, female sex and a higher cumulative dose of doxorubicin were associated with depressed contractility (P less than or equal to 0.001), and there was an interaction between these two variables. independent and significant associations were found between a higher rate of administration of doxorubicin and increased afterload (P less than or equal to 0.001), left ventricular dilatation, and depressed left ventricular function; between a higher cumulative dose and depressed left ventricular function (P less than or equal to 0.001); between a younger age at diagnosis and reduced left-ventricular-wall thickness and mass and increased afterload; and between a longer time since the completion of doxorubicin therapy and reduced left-ventricular-wall thickness and increased afterload (P less than or equal to 0.001). Conclusions. Female sex and a higher rate of administration of doxorubicin were independent risk factors for cardiac abnormalities after treatment with doxorubicin for childhood cancer; the prevalence and severity of abnormalities increased with longer follow-up.	CHILDRENS HOSP,DEPT HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NATIONAL CANCER INSTITUTE [P30CA006516, P01CA034183, R29CA055576, R01CA055576] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183, CA55576, CA06516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, JAMA-J AM MED ASSOC, V263, P2189, DOI 10.1001/jama.263.16.2189; ADAMI HO, 1989, JNCI-J NATL CANCER I, V81, P1640, DOI 10.1093/jnci/81.21.1640; BLEYER WA, 1990, CA-CANCER J CLIN, V40, P355, DOI 10.3322/canjclin.40.6.355; BYRNE J, 1990, JAMA-J AM MED ASSOC, V264, P1810, DOI 10.1001/jama.1990.03450140030022; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CUTHBERTSON DD, 1994, CIRCULATION S, V90, P1; EYSMANN SB, 1993, CARDIOVASCULAR HLTH, P57; FRISANCHO AR, 1974, AM J CLIN NUTR, V27, P1052, DOI 10.1093/ajcn/27.8.1052; GOLAY CC, 1993, ONCOLOGY, V7, P77; GOLAY CC, 1993, ONCOLOGY, V7, P67; GOORIN AM, 1987, J CLIN ONCOL, V5, P1178, DOI 10.1200/JCO.1987.5.8.1178; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; GOORIN AM, 1991, CLIN ORTHOP RELAT R, V270, P22; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HAUSDORF G, 1988, BRIT HEART J, V60, P309; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; HRUSHESKY WJM, 1991, CIRCULATION, V84, P697, DOI 10.1161/01.CIR.84.2.697; KLEWER SE, 1992, J AM COLL CARDIOL, V19, P394, DOI 10.1016/0735-1097(92)90497-B; KREUGER A, 1993, PEDIATR HEMAT ONCOL, V10, P297, DOI 10.3109/08880019309029501; LARSEN RL, 1992, AM J CARDIOL, V70, P73, DOI 10.1016/0002-9149(92)91393-I; LEE YTN, 1982, MED PEDIATR ONCOL, V10, P259, DOI 10.1002/mpo.2950100306; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LIPSHULTZ SE, 1992, CIRCULATION, V86, P363; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MATTHYS D, 1993, ACTA PAEDIATR, V82, P459, DOI 10.1111/j.1651-2227.1993.tb12722.x; MILLER DR, 1989, J CLIN ONCOL, V7, P316, DOI 10.1200/JCO.1989.7.3.316; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; PIAZZA E, 1981, TUMORI, V67, P533, DOI 10.1177/030089168106700604; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; SALLAN SE, 1984, SEMIN ONCOL, V11, P19; SALLAN SE, 1994, ACUTE LEUKEMIA, V4, P322; SHUB C, 1994, MAYO CLIN P, V68, P205; SILBER JH, 1993, MED PEDIATR ONCOL, V21, P477, DOI 10.1002/mpo.2950210704; SMITH MA, 1991, JNCI-J NATL CANCER I, V83, P1460, DOI 10.1093/jnci/83.20.1460; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; TANNER JM, 1975, ARCH DIS CHILD, V50, P142, DOI 10.1136/adc.50.2.142; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEESNER KM, 1991, CANCER, V68, P435, DOI 10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#; YEUNG ST, 1991, LANCET, V337, P816, DOI 10.1016/0140-6736(91)92516-5	41	557	567	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1738	1743		10.1056/NEJM199506293322602	http://dx.doi.org/10.1056/NEJM199506293322602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760889				2022-12-01	WOS:A1995RE66700002
J	MARZUK, PM; TARDIFF, K; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N; IQBAL, MI				MARZUK, PM; TARDIFF, K; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N; IQBAL, MI			FATAL INJURIES AFTER COCAINE USE AS A LEADING CAUSE OF DEATH AMONG YOUNG-ADULTS IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLICATIONS; PREVALENCE; EXCRETION; HOMICIDE; HUMANS; COUNTY; ABUSE; CRACK	Background. Cocaine intoxication can lead to fatal cardiovascular and cerebrovascular events. In addition, the neurobehavioral effects of cocaine may increase the likelihood that a user will receive violent fatal injuries. Since New York City is a center for the importation and distribution of cocaine, we sought to determine the extent of cocaine use among city residents with fatal injuries. Methods. Among a total of 14,843 residents of New York City who received fatal injuries from 1990 through 1992, we determined the proportion who had used cocaine shortly before their deaths. We also determined the population-based rates of fatal injuries that were known to follow cocaine use and the proportion of all deaths of New York City residents that was represented by these cases for each demographic stratum. For people 15 to 44 years of age, fatal injury after cocaine use was ranked with other causes of death as though it was a separate cause. Results. Cocaine use, as measured by the detection of the metabolite benzoylecgonine in urine or blood, was found in 26.7 percent of all New York City residents receiving fatal injuries; free cocaine was detected in 18.3 percent. Approximately one third of deaths after cocaine use were the result of drug intoxication, but two thirds involved traumatic injuries resulting from homicides, suicides, traffic accidents, and falls. If fatal injury after cocaine use was considered as a separate cause of death, it would rank among the five leading causes of death among those 15 to 44 years of age in New York City. Conclusions. Fatal injuries among cocaine users account for a substantial proportion of all deaths among young adults in New York City.	CORNELL UNIV, COLL MED, DEPT PSYCHIAT, EPIDEMIOL SECT, NEW YORK, NY USA; CORNELL UNIV, COLL MED, DEPT PUBL HLTH, NEW YORK, NY USA; NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA	Cornell University; Cornell University; New York University					NIDA NIH HHS [DA-06534] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; ARMITAGE P, 1987, STATISTICAL METHODS; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BASELT RC, 1983, J CHROMATOGR, V268, P502, DOI 10.1016/S0021-9673(01)95449-4; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; HAMID A, 1991, INT J ADDICT, V26, P913, DOI 10.3109/10826089109058930; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V6, P760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LIU Y, 1982, J CHROMATOGR, V248, P318; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; MARZUK P M, 1992, Journal of the American Medical Association, V267, P2635, DOI 10.1001/jama.267.19.2635; MARZUK PM, 1992, AM J PSYCHIAT, V149, P371; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; ROGERS C, 1993, J FORENSIC SCI, V38, P831; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; 1992, CP134 BUR CENS PUBL; 1993, DHHS PHS931980 RES T; 1989, DHHS PHS891260 PUBL, V1	23	75	78	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1753	1757		10.1056/NEJM199506293322606	http://dx.doi.org/10.1056/NEJM199506293322606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760893				2022-12-01	WOS:A1995RE66700006
J	ROBERTSON, MP; MILLER, SL				ROBERTSON, MP; MILLER, SL			AN EFFICIENT PREBIOTIC SYNTHESIS OF CYTOSINE AND URACIL	NATURE			English	Article							CHEMICAL EVOLUTION; PYRIMIDINES; ACIDS	In contrast to the purines(1-3), the routes that have been proposed for the prebiotic synthesis of pyrimidines from simple precursors give only low yields. Cytosine can be synthesized from cyanoacetylene and cyanate(4,5); the former precursor is produced from a spark discharge in a CH4/N-2 mixture(4,5) and is an abundant interstellar molecule(6). But this reaction requires relatively high concentrations of cyanate (>0.1 M), which are unlikely to occur in aqueous media as cyanate is hydrolysed rapidly to CO2 and NH3. An alternative route that has been explored(7) is the reaction of cyanoacetaldehyde (formed by hydrolysis of cyanoacetylene(8)) with urea. But at low concentrations of urea, this reaction produces no detectable quantities of cytosine(7). Here we show that in concentrated urea solution-such as might have been found in an evaporating lagoon or in pools on drying beaches on the early Earth-cyanoacetaldehyde reacts to form cytosine in yields of 30-50%, from which uracil can be formed by hydrolysis. These reactions provide a plausible route to the pyrimidine bases required in the RNA world(9).			ROBERTSON, MP (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.							CHITTENDEN GJF, 1976, NATURE, V263, P350, DOI 10.1038/263350a0; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; FERRIS JP, 1974, J MOL EVOL, V3, P301, DOI 10.1007/BF01796045; FERRIS JP, 1968, J MOL BIOL, V33, P693, DOI 10.1016/0022-2836(68)90314-8; FERRIS JP, 1978, J MOL EVOL, V11, P293, DOI 10.1007/BF01733839; FERRIS JP, 1970, J AM CHEM SOC, V92, P6598, DOI 10.1021/ja00725a036; GARRETT ER, 1972, J PHARM SCI, V61, P1052, DOI 10.1002/jps.2600610703; KOLB VM, 1994, J MOL EVOL, V38, P549; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; LOHRMANN R, 1972, J MOL EVOL, V1, P263, DOI 10.1007/BF01660246; LOWE CU, 1963, NATURE, V199, P219, DOI 10.1038/199219a0; Miller S. L., 1974, ORIGINS LIFE EARTH; MILLER SL, 1955, J AM CHEM SOC, V77, P2351, DOI 10.1021/ja01614a001; ORO J, 1960, BIOCHEM BIOPH RES CO, V2, P407, DOI 10.1016/0006-291X(60)90138-8; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; SANCHEZ R, 1966, SCIENCE, V153, P72, DOI 10.1126/science.153.3731.72; SANCHEZ RA, 1966, SCIENCE, V154, P784, DOI 10.1126/science.154.3750.784; SANCHEZ RA, 1968, J MOL BIOL, V38, P121, DOI 10.1016/0022-2836(68)90132-0; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; Shnidman L, 1932, J PHYS CHEM-US, V36, P1232, DOI 10.1021/j150334a013; STOKS PG, 1981, GEOCHIM COSMOCHIM AC, V45, P563, DOI 10.1016/0016-7037(81)90189-7; STOKS PG, 1979, NATURE, V282, P709, DOI 10.1038/282709a0; TESTELAND RF, 1993, RNA WORLD; TURNER BE, 1971, ASTROPHYS J, V163, pL35, DOI 10.1086/180662; WACHTERSHAUSER G, 1988, P NATL ACAD SCI USA, V85, P1134, DOI 10.1073/pnas.85.4.1134	25	185	189	2	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					772	774		10.1038/375772a0	http://dx.doi.org/10.1038/375772a0			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596408				2022-12-01	WOS:A1995RF98900073
J	SHERRINGTON, R; ROGAEV, EI; LIANG, Y; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; CHI, H; LIN, C; LI, G; HOLMAN, K; TSUDA, T; MAR, L; FONCIN, JF; BRUNI, AC; MONTESI, MP; SORBI, S; RAINERO, I; PINESSI, L; NEE, L; CHUMAKOV, I; POLLEN, D; BROOKES, A; SANSEAU, P; POLINSKY, RJ; WASCO, W; DASILVA, HAR; HAINES, JL; PERICAKVANCE, MA; TANZI, RE; ROSES, AD; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH				SHERRINGTON, R; ROGAEV, EI; LIANG, Y; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; CHI, H; LIN, C; LI, G; HOLMAN, K; TSUDA, T; MAR, L; FONCIN, JF; BRUNI, AC; MONTESI, MP; SORBI, S; RAINERO, I; PINESSI, L; NEE, L; CHUMAKOV, I; POLLEN, D; BROOKES, A; SANSEAU, P; POLINSKY, RJ; WASCO, W; DASILVA, HAR; HAINES, JL; PERICAKVANCE, MA; TANZI, RE; ROSES, AD; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH			CLONING OF A GENE BEARING MISSENSE MUTATIONS IN EARLY-ONSET FAMILIAL ALZHEIMERS-DISEASE	NATURE			English	Article							PRECURSOR PROTEIN GENE; CAENORHABDITIS-ELEGANS; HUMAN GENOME; APOLIPOPROTEIN-E; CHROMOSOME-14; IDENTIFICATION; LINKAGE; LIBRARY; ALLELE; CLONES	Some cases of Alzheimer's disease are inherited as an autosomal dominant trait. Genetic linkage studies have mapped a locus (AD3) associated with susceptibility to a very aggressive form of Alzheimer's disease to chromosome 14q24.3. We have defined a minimal cosegregating region containing the AD3 gene, and isolated at least 19 different transcripts encoded within this region. One of these transcripts (S182) corresponds to a novel gene whose product is predicted to contain multiple transmembrane domains and resembles an integral membrane protein. Five different missense mutations have been found that cosegregate with early-onset familial Alzheimer's disease. Because these changes occurred In conserved domains of this gene, and are not present in normal controls, they are likely to be causative of AD3.	UNIV TORONTO,DEPT MED NEUROL,CTR RES NEURODEGENERAT DIS,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,DIV NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA; ECOLE PRAT HAUTES ETUD,NEUROHIST LAB,F-75651 PARIS 13,FRANCE; INSERM LA SALPETRIERE,U106,F-75651 PARIS 13,FRANCE; USL 6,I-88046 LAMEZIA TERME,ITALY; CNR,UO,I-88046 LAMEZIA TERME,ITALY; UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,FLORENCE,ITALY; UNIV TURIN,DEPT NEUROL,I-10126 TURIN,ITALY; NINCDS,CLIN NEUROPHARMACOL SECT,BETHESDA,MD 20892; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; UNIV MASSACHUSETTS,MED CTR,DEPT NEUROL,WORCESTER,MA 01655; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,GENET & AGING LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; DUKE UNIV,MED CTR,BRYAN ALZHEIMERS DIS RES CTR,DURHAM,NC 27710; GLAXO GRP RES LTD,RES & DEV,MOLEC PATHOL,GREENFORD UB6 0HE,MIDDX,ENGLAND; SANDOZ PHARMACEUT CORP,SANDOZ RES INST,E HANOVER,NJ 07936; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut National de la Sante et de la Recherche Medicale (Inserm); Consiglio Nazionale delle Ricerche (CNR); University of Florence; University of Turin; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Duke University; GlaxoSmithKline; Novartis; Sandoz; University of Edinburgh			Rogaev, Evgeny/AAN-7662-2020; Haines, Jonathan/C-3374-2012; de Silva, Rohan/C-1734-2008; Tanzi, Rudolph/AAE-9622-2019; Bruni, Amalia/K-5038-2016	Haines, Jonathan/0000-0002-4351-4728; de Silva, Rohan/0000-0002-5052-5775; Tanzi, Rudolph/0000-0002-7032-1454; sorbi, sandro/0000-0002-0380-6670; Bruni, Amalia/0000-0003-3471-3343	CIHR [64309] Funding Source: Medline; Telethon [E.0010] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR)); Telethon(Fondazione Telethon)		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergamini L, 1991, Acta Neurol (Napoli), V13, P534; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CRUTS M, 1994, NEUROBIOL AGING, V15, pS129; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; ETCHEBERRIGARAY R, 1994, P NATL ACAD SCI USA, V90, P8209; FONCIN JF, 1985, REV NEUROL, V141, P194; FROMMELT P, 1991, ALZ DIS ASSOC DIS, V5, P36, DOI 10.1097/00002093-199100510-00005; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOUDSMIT J, 1981, J NEUROL SCI, V49, P78; GUSELLA JF, 1993, CELL, V72, P971; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kosik Kenneth S., 1994, P335; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LIU Q, 1995, BIOTECHNIQUES, V18, P470; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NEE LE, 1983, ARCH NEUROL-CHICAGO, V40, P203, DOI 10.1001/archneur.1983.04050040033004; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; Pollen D. A., 1993, HANNAHS HEIRS QUEST; PTACEK LJ, 1991, CELL, V67, P1021; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROGAEV EI, 1993, NEUROLOGY, V43, P2275, DOI 10.1212/WNL.43.11.2275; ROMMENS JM, 1993, HUM MOL GENET, V2, P901, DOI 10.1093/hmg/2.7.901; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SALEEBA JA, 1993, METHOD ENZYMOL, V217, P285; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1994, SCIENCE, V263, P536; STGEORGEHYSLOP PH, 1991, NATURE, V347, P194; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VAN BROECKHOVEN C, 1992, NAT GENET, V2, P335, DOI 10.1038/ng1292-335; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WONG L, 1993, NEUROSCI LETT, V152, P96, DOI 10.1016/0304-3940(93)90492-4	50	3358	3520	1	179	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					754	760		10.1038/375754a0	http://dx.doi.org/10.1038/375754a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596406				2022-12-01	WOS:A1995RF98900069
J	SLOAN, VS; CAMERON, P; PORTER, G; GAMMON, M; AMAYA, M; MELLINS, E; ZALLER, DM				SLOAN, VS; CAMERON, P; PORTER, G; GAMMON, M; AMAYA, M; MELLINS, E; ZALLER, DM			MEDIATION BY HLA-DM OF DISSOCIATION OF PEPTIDES FROM HLA-DR	NATURE			English	Article							ANTIGEN-PROCESSING MUTANT; MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; CLASS-II MOLECULES; GENES; CELLS	HUMAN leukocyte antigen (HLA)-DM is an unconventional major histocompatibility complex (MHC) class II heterodimer that is important for B-cell-mediated antigen processing and presentation to MHC class II-restricted T cells(1-12). HLA-DM is encoded by two genes, DMA and DMB, which map to the MHC class II region(1), and shares some homology with MHC class I and class II proteins(2,3). Here we define the biochemical role of HLA-DM. Recombinant soluble HLA-DM heterodimers have been purified from culture supernatants of insect cell transformants. At pH 5.0, they induce the dissociation of a subset of peptides bound to HLA-DR, including a nested set of class-II-associated invariant chain peptides (CLIP). This process liberates HLA-DR and leads to the enhanced binding of exogenous peptides.	MERCK & CO INC,RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT AUTOIMMUNE DIS RES,RAHWAY,NJ 07065; MERCK & CO INC,RES LABS,DEPT MOLEC DESIGN & DIVERS,RAHWAY,NJ 07065; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	Merck & Company; Merck & Company; Merck & Company; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia				Mellins, Elizabeth/0000-0003-2577-139X				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEMAN S, 1992, J IMMUNOL, V149, P754; DENZIN LK, 1994, IMMUNITY, V2, P595; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONJI T, 1994, J IMMUNOL, V153, P4468; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QUI Y, 1994, J CELL BIOL, V125, P595, DOI DOI 10.1083/JCB.125.3.595; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	30	497	501	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					802	806		10.1038/375802a0	http://dx.doi.org/10.1038/375802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596415				2022-12-01	WOS:A1995RF98900082
J	VANNOORT, JM; VANSECHEL, AC; BAJRAMOVIC, JJ; ELOUAGMIRI, M; POLMAN, CH; LASSMANN, H; RAVID, R				VANNOORT, JM; VANSECHEL, AC; BAJRAMOVIC, JJ; ELOUAGMIRI, M; POLMAN, CH; LASSMANN, H; RAVID, R			THE SMALL HEAT-SHOCK PROTEIN ALPHA-B-CRYSTALLIN AS CANDIDATE AUTOANTIGEN IN MULTIPLE-SCLEROSIS	NATURE			English	Article							INDIRECT FLIGHT MUSCLES; T-CELL RECEPTOR; DROSOPHILA; TISSUES; DISEASE	THE identification of key antigens in human autoimmune diseases is a crucial step towards the development of specific intervention. The autoantigen(s) relevant to multiple sclerosis (MS) probably reside in myelin of the central nervous system, the target of the disease(1). Here we examine proliferative responses of human peripheral blood T cells to the complete collection of myelin proteins fractionated by reversed-phase high-performance liquid chromatography. Myelin isolated from MS-affected brain contained a single protein fraction to which T cells from MS patients and from healthy controls showed dominant responses. This highly immunogenic protein was identified as alpha B-crystallin, a small heat-shock protein. Immunohistochemical examination of MS lesions revealed the presence of oligodendrocytes and astrocytes with raised alpha B- crystallin expression, which were not found in unaffected myelin. Our findings indicate that alpha B-crystallin serves as immunodominant myelin antigen to human T cells when expressed at the elevated levels found in active MS lesions.	FREE UNIV AMSTERDAM HOSP,DEPT NEUROL,1007 MB AMSTERDAM,NETHERLANDS; AUSTRIAN ACAD SCI,EXPTL NEUROPATHOL RES UNIT,A-1090 VIENNA,AUSTRIA; NETHERLANDS INST BRAIN RES,NETHERLANDS BRAIN BANK,1105 AZ AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Austrian Academy of Sciences; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	VANNOORT, JM (corresponding author), TNO,PREVENT & HLTH,DIV INFECT DIS & IMMUNOL,POB 2215,2301 CE LEIDEN,NETHERLANDS.		Lassmann, Hans/Z-2269-2019; Bajramovic, Jeffrey/AAF-6695-2020	Lassmann, Hans/0000-0001-8617-5052; Bajramovic, Jeffrey/0000-0002-6504-3437; van Noort, Johannes/0000-0002-9060-5921				BRUCK W, 1994, ANN NEUROL, V35, P65, DOI 10.1002/ana.410350111; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KARLIK CC, 1984, CELL, V38, P711, DOI 10.1016/0092-8674(84)90266-6; KATO K, 1992, J BIOL CHEM, V167, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; NORTON WT, 1973, J NEUROCHEM, V31, P749; OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; SALVETTI M, 1992, J AUTOIMMUN, V5, P691, DOI 10.1016/0896-8411(92)90186-T; SELMAJ K, 1991, P NATL ACAD SCI USA, V88, P6452, DOI 10.1073/pnas.88.15.6452; VANNOORT JM, 1993, J NEUROIMMUNOL, V46, P67, DOI 10.1016/0165-5728(93)90234-P; VANNOORT JM, 1994, J CHROMATOGR B, V653, P155, DOI 10.1016/0378-4347(93)E0433-Q; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	21	348	353	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					798	801		10.1038/375798a0	http://dx.doi.org/10.1038/375798a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596414				2022-12-01	WOS:A1995RF98900081
J	WEINTRAUB, SJ; CHOW, KNB; LUO, RX; ZHANG, SH; HE, S; DEAN, DC				WEINTRAUB, SJ; CHOW, KNB; LUO, RX; ZHANG, SH; HE, S; DEAN, DC			MECHANISM OF ACTIVE TRANSCRIPTIONAL REPRESSION BY THE RETINOBLASTOMA PROTEIN	NATURE			English	Article							LARGE T-ANTIGEN; GENE-PRODUCT; BINDING PROTEIN; CELL-CYCLE; C-MYC; DOMAIN; TRANSACTIVATION; PHOSPHORYLATION; EXPRESSION; PROMOTER	THE retinoblastoma tumour-suppressor protein (Rb) belongs to a family that share a motif known as the pocket. The pocket was originally identified as the region of Rb required for binding to oncoproteins from DNA tumour viruses(1,2), which disrupt the binding of Rb to the E2F family of cell-cycle transcription factors (referred to collectively here as E2F)(3). Rb switches E2F sites from positive to negative elements(4), suggesting that Rb-E2F is an active complex that blocks transcription. Here we report that Rb is selectively recruited to promoters through E2F, where it in turn inactivates surrounding transcription factors by blocking their interaction with the basal transcription complex. We suggest that this repressor activity is essential for inhibiting promoters that contain enhancers in addition to E2F sites.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	29	450	455	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 29	1995	375	6534					812	815		10.1038/375812a0	http://dx.doi.org/10.1038/375812a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7596417				2022-12-01	WOS:A1995RF98900085
J	CLARK, LR				CLARK, LR			TEEN SEX BLUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1969	1970						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783311				2022-12-01	WOS:A1995RE35400040
J	GUEST, TM; RAMANATHAN, AV; TUTEUR, PG; SCHECHTMAN, KB; LADENSON, JH; JAFFE, AS				GUEST, TM; RAMANATHAN, AV; TUTEUR, PG; SCHECHTMAN, KB; LADENSON, JH; JAFFE, AS			MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS - A FREQUENTLY UNRECOGNIZED COMPLICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREATINE-KINASE ISOENZYMES; CARDIAC TROPONIN-I; SKELETAL-MUSCLES; INTENSIVE-CARE; MB ISOENZYME; INFARCTION; SERUM; SURVIVAL; DISEASE; ASSAY	Objective.-To determine the incidence and effect of unrecognized cardiac injury in critically ill patients, Design.-Prospective, blinded, single-center study. Setting.-The medical and respiratory intensive care unit of an academic health center, Patients.-Two hundred nine patients (224 admissions), Main Outcome Measures.-Daily measurement of levels of cardiac troponin I, a sensitive, highly specific, and long-lived marker of myocardial injury, Concurrently, signs and symptoms potentially related to myocardial ischemia were tabulated by blinded investigators, All clinical evaluation and management decisions were made by the physicians responsible for the care of the patient, Results.-Thirty-two (15%) of the 209 patients had evidence of myocardial damage based on elevated levels of cardiac troponin !, Only 12 (37%) of these 32 patients were diagnosed as having acute myocardial infarction by the intensive care unit staff, Cardiac damage was unrecognized in the other 20 (63%), Unrecognized cardiac injury was more common in young patients and in blacks, Mortality in patients with myocardial injury that was recognized (42%) or unrecognized (40%) was higher than in those without myocardial injury (15%) (P<.001), Patients with cardiac injury were more frequently hypotensive (75% vs 50%; P=.007) and in need of mechanical ventilation (66% vs 27%; P<.001) and had longer intensive care unit stays (5.3 vs 3.1 days; P<.007) than patients without cardiac injury. Conclusion.-The incidence of myocardial injury defined by elevated levels of cardiac troponin I was unexpectedly high and associated with increased morbidity and mortality, Clinically it was often unrecognized.	WASHINGTON UNIV,SCH MED,DIV PULM & CRIT CARE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOSTAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JE, 1994, CLIN CHEM, V40, P1291; ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; BODOR GS, 1992, CLIN CHEM, V38, P2203; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHEITLIN MD, 1975, JAMA-J AM MED ASSOC, V231, P951, DOI 10.1001/jama.231.9.951; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; DRASNER K, 1992, PRINCIPLES CRITICAL, P959; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Girard K, 1985, Respir Care, V30, P339; GOSALAKKAL JA, 1991, SCAND J THORAC CARD, V25, P159, DOI 10.3109/14017439109098103; GRAM J, 1990, DAN MED BULL, V37, P210; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; JAFFE AS, 1984, J LAB CLIN MED, V104, P193; JULKUNEN H, 1972, ANN CHIR GYNAECOL FE, V60, P107; KUTOM AH, 1991, CHEST, V100, P571, DOI 10.1378/chest.100.2.571; LARUE C, 1993, CLIN CHEM, V39, P972; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MADIAS JE, 1973, CIRCULATION, V49, P448; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PARMLEY WW, 1976, PROG CARDIOL, V5, P19; PARRY G, 1992, CLIN CARDIOL, V15, P305, DOI 10.1002/clc.4960150416; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PINGLETON SK, 1992, PRINCIPLES CRITICAL, P599; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; SCHEINMAN MM, 1973, AM J MED, V55, P602, DOI 10.1016/0002-9343(73)90181-2; SCHNEIDER DJ, 1992, CORONARY ARTERY DIS, V3, P26, DOI 10.1097/00019501-199201000-00004; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Travis K W, 1973, Crit Care Med, V1, P235, DOI 10.1097/00003246-197309000-00001; TSUNG JS, 1986, CLIN CHEM, V32, P1568; TSUNG SH, 1981, AM J CLIN PATHOL, V75, P711, DOI 10.1093/ajcp/75.5.711; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; VAIDYA HC, 1986, CLIN CHEM, V32, P657; WILHELM A H, 1976, IRCS (International Research Communications System) Medical Science Library Compendium, V4, P418; YOUNG RKB, 1974, BRIT MED J, V1, P307, DOI 10.1136/bmj.1.5903.307	40	268	285	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1945	1949		10.1001/jama.273.24.1945	http://dx.doi.org/10.1001/jama.273.24.1945			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783306				2022-12-01	WOS:A1995RE35400032
J	IRIBARREN, C; REED, DM; BURCHFIEL, CM; DWYER, JH				IRIBARREN, C; REED, DM; BURCHFIEL, CM; DWYER, JH			SERUM TOTAL CHOLESTEROL AND MORTALITY - CONFOUNDING FACTORS AND RISK MODIFICATION IN JAPANESE-AMERICAN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FACTOR INTERVENTION TRIAL; CANCER MORTALITY; FOLLOW-UP; CARDIOVASCULAR-DISEASE; INVERSE RELATIONSHIP; PLASMA-CHOLESTEROL; HEMOSTATIC FACTORS; VITAMIN-E	Objective.-To further investigate the relationship between serum total cholesterol CTG) level and mortality due to major causes. in particular, is the elevated mortality among persons with low TC levels due to confounding conditions that both lower TC level and increase the risk of mortality, and is the association between low or high TC level and mortality homogeneous in the population or, alternatively, restricted to persons with other risk factors? Study Design.-Prospective cohort study. Setting.-Free-living population in Oahu, Hawaii. Participants.-A total of 7049 middle-aged men of Japanese ancestry. Main Outcome Measures.-Age- and risk factor-adjusted mortality due to coronary heart disease, hemorrhagic stroke, cancer, chronic obstructive pulmonary disease, nonmalignant liver disease, trauma, miscellaneous and unknown; and all causes. Results.-During 23 years of follow-up, a total of 1954 deaths were documented (38% cancer, 25% cardiovascular, and 37% other). Men with low serum TC levels (<4.66 mmol/L [<180 mg/dL]) were found to have several adverse health characteristics, including a higher prevalence of current smoking, heavy drinking, and certain gastrointestinal conditions. In an age-adjusted model, and in relation to the reference group (4.66 to 6.19 mmol/L [180 to 239 mg/dL]), those in the lowest TC group (<4.66 mmol/L [<180 mg/dL]) were at significantly higher risk of mortality due to hemorrhagic stroke (relative risk [RR], 2.41; 95% confidence interval [Ci], 1.45 to 4.00), cancer (RR, 1.41; 95% CI, 1.17 to 1.69), and all causes (RR, 1.23; 95% Cl, 1.09 to 1.38). Adjustment for confounders in multivariate analysis (and exclusion of cases with prevalent disease at baseline and deaths through year 5) did not explain the risk of fatal hemorrhagic stroke but reduced the excess risk of cancer mortality by 51% (to 1.20 from 1.41) and reduced the excess risk of all-cause mortality by 56% (to 1.10 from 1.32) in the low TC group. In addition, there were clear differences in the patterns of risk when comparing men with and without selected risk factors tie, smoking, alcohol consumption, and untreated hypertension). Conclusions.-We conclude that the excess mortality at low TC levels can be partially explained by confounding with other determinants of death and by preexisting disease at baseline, and TC-mortality associations are not homogeneous in the population. In our study, TC level was not associated with increased cancer or all-cause mortality in the absence of smoking, high alcohol consumption, and untreated hypertension.	UNIV SO CALIF,SCH MED,INST HLTH PROMOT & DIS PREVENT RES,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,INST ARTERIOSCLEROSIS RES,LOS ANGELES,CA 90033; BUCK CTR RES AGING,NOVATO,CA; NHLBI,BETHESDA,MD 20892; HONOLULU HAWAII HEART PROGRAM,HONOLULU,HI	University of Southern California; University of Southern California; Buck Institute for Research on Aging; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NHLBI NIH HHS [N01-HV-02901, N01-HC-02901] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC002901] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIKEN LS, 1991, MULTIPLE REGRESSION, P67; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BAPTISTE MS, 1992, INT J EPIDEMIOL, V21, P16, DOI 10.1093/ije/21.1.16; BELSKY JL, 1971, 1271 AT BOM CAS COMM; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BONITHONKOPP C, 1988, ATHEROSCLEROSIS, V71, P71, DOI 10.1016/0021-9150(88)90303-6; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHEN ZM, 1993, BMJ-BRIT MED J, V306, P890, DOI 10.1136/bmj.306.6882.890; Clayton D., 1992, STAT MODELS LONGITUD, P301; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; FRANK JW, 1992, J CLIN EPIDEMIOL, V45, P333, DOI 10.1016/0895-4356(92)90034-K; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Higgins M, 1992, Ann Epidemiol, V2, P69, DOI 10.1016/1047-2797(92)90039-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; ISO H, 1989, AM J EPIDEMIOL, V130, P925, DOI 10.1093/oxfordjournals.aje.a115425; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KARK JD, 1982, BRIT MED J, V284, P152, DOI 10.1136/bmj.284.6310.152; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; MARTIN MJ, 1986, LANCET, V2, P933; MEADE TW, 1985, BRIT MED J, V290, P428, DOI 10.1136/bmj.290.6466.428; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P593, DOI 10.1093/oxfordjournals.aje.a113225; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PETERSON B, 1981, JAMA-J AM MED ASSOC, V245, P2056, DOI 10.1001/jama.245.20.2056; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; ROGERS S, 1988, EUR J CLIN NUTR, V42, P197; ROSE G, 1980, LANCET, V1, P523; RUSSELLBRIEFEL R, 1985, AM J EPIDEMIOL, V122, P741, DOI 10.1093/oxfordjournals.aje.a114157; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHATZKIN A, 1987, LANCET, V2, P298; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; SINHA R, 1993, CANCER EPIDEM BIOMAR, V2, P473; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAHELIN HB, 1991, AM J EPIDEMIOL, V133, P766; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEMMERMANN GN, 1984, INT J EPIDEMIOL, V13, P299, DOI 10.1093/ije/13.3.299; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; WALD NJ, 1989, BRIT J CANCER, V59, P938; WESTLUND K, 1972, SCAND J CLIN LA S127, V30, P2; White A D, 1992, Ann Epidemiol, V2, P85, DOI 10.1016/1047-2797(92)90041-N; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YAARI S, 1981, LANCET, V1, P1011; 1988, ARCH INTERN MED, V148, P36; [No title captured]; [No title captured]; 1987, SAS STAT SOFTWARE VE	58	82	83	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1926	1932		10.1001/jama.273.24.1926	http://dx.doi.org/10.1001/jama.273.24.1926			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783302				2022-12-01	WOS:A1995RE35400028
J	JACOBER, SJ				JACOBER, SJ			EXERCISE AND HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											JACOBER, SJ (corresponding author), WAYNE STATE UNIV, SCH MED, DETROIT, MI 48202 USA.							GRASSI G, 1992, CHEST, V101, pS312, DOI 10.1378/chest.101.5.312S; STEWART KJ, 1992, PROG CARDIOVASC DIS, V35, P159, DOI 10.1016/0033-0620(92)90004-J; Tipton C M, 1991, Exerc Sport Sci Rev, V19, P447; 1993, NIH931088 NAT HEART; [No title captured]	5	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1965	1965		10.1001/jama.273.24.1965	http://dx.doi.org/10.1001/jama.273.24.1965			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783310				2022-12-01	WOS:A1995RE35400037
J	MASON, JJ; OWENS, DK; HARRIS, RA; COOKE, JP; HLATKY, MA				MASON, JJ; OWENS, DK; HARRIS, RA; COOKE, JP; HLATKY, MA			THE ROLE OF CORONARY ANGIOGRAPHY AND CORONARY REVASCULARIZATION BEFORE NONCARDIAC VASCULAR-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERY BYPASS-SURGERY; CARDIAC RISK; MYOCARDIAL-INFARCTION; GRAFT-SURGERY; CASS REGISTRY; CLINICAL-DIAGNOSIS; DISEASE; MORTALITY; DIPYRIDAMOLE; ANGIOPLASTY	Objective.-To determine whether preoperative coronary angiography and revascularization improve short-term outcomes in patients undergoing noncardiac vascular surgery. Design.-Decision analysis. Patients.-Patients undergoing elective vascular surgery who had either no angina or mild angina and a positive dipyridamole-thallium scan result. Interventions.-Three strategies were compared, The first strategy was to proceed directly to vascular surgery. The second was to perform coronary angiography, followed by selective coronary revascularization, before proceeding to vascular surgery and to cancel vascular surgery in patients with severe inoperable coronary artery disease (CAD), The third was to perform coronary angiography, followed by selective coronary revascularization, before proceeding to vascular surgery and to perform vascular surgery in patients with inoperable CAD. Main Outcome Measures.-Mortality, nonfatal myocardial infarction, stroke, uncorrected vascular disease, and cost. All outcomes were assessed within 3 months. Results.-Proceeding directly to vascular surgery led to lower morbidity and cost in the base case analysis. The coronary angiography strategy led to higher mortality if vascular surgery would proceed in patients with inoperable CAD, but led to slightly lower mortality if vascular surgery were canceled in patients with inoperable CAD. The coronary angiography strategy also led to lower mortality when vascular surgery was particularly risky. Conclusions.-Decision analysis indicates vascular surgery without preoperative coronary angiography generally leads to better outcomes. Preoperative coronary angiography should be reserved for patients whose estimated mortality from vascular surgery is substantially higher than average.	STANFORD UNIV, SCH MED, DEPT MED, DIV CARDIOVASC MED, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, PALO ALTO, CA 94304 USA; DEPT VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, PALO ALTO, CA USA	Stanford University; Stanford University				Cooke, John/0000-0003-0033-9138; Hlatky, Mark/0000-0003-4686-9441				ABRAHAM SA, 1991, PROG CARDIOVASC DIS, V34, P205, DOI 10.1016/0033-0620(91)90014-D; ALBRO PC, 1978, AM J CARDIOL, V42, P751, DOI 10.1016/0002-9149(78)90094-2; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ANDREWS TC, 1994, J VASC MED BIOL, V5, P8; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BELL MR, 1992, CIRCULATION, V86, P446, DOI 10.1161/01.CIR.86.2.446; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN KA, 1993, J AM COLL CARDIOL, V21, P325, DOI 10.1016/0735-1097(93)90670-V; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; COHEN HA, 1982, CIRCULATION, V66, P49; DAVIS K, 1979, CIRCULATION, V59, P1105, DOI 10.1161/01.CIR.59.6.1105; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DIAMOND GA, 1980, J CLIN INVEST, V65, P1210, DOI 10.1172/JCI109776; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; EAGLE KA, 1994, J AM COLL CARDIOL, V23, P1091, DOI 10.1016/0735-1097(94)90596-7; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; ELLIS SG, 1988, J AM COLL CARDIOL, V11, P211, DOI 10.1016/0735-1097(88)90082-4; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; FISHER LD, 1981, CIRCULATION, V63, P987, DOI 10.1161/01.CIR.63.5.987; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; FRANCISCO DA, 1982, CIRCULATION, V66, P370, DOI 10.1161/01.CIR.66.2.370; GERSH BJ, 1991, J AM COLL CARDIOL, V18, P203, DOI 10.1016/S0735-1097(10)80241-4; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOLDEN MA, 1990, ANN SURG, V212, P415, DOI 10.1097/00000658-199010000-00004; GOLDMAN L, 1994, NEW ENGL J MED, V330, P707, DOI 10.1056/NEJM199403103301010; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1992, JAMA-J AM MED ASSOC, V268, P3092, DOI 10.1001/jama.268.21.3092; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Hertzer N R, 1987, Ann Vasc Surg, V1, P616, DOI 10.1016/S0890-5096(06)61452-0; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HLATKY MA, 1990, CIRCULATION, V82, P208; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; JOSEPHSON MA, 1982, AM HEART J, V103, P1008, DOI 10.1016/0002-8703(82)90564-6; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P5, DOI 10.1002/ccd.1810080103; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P323, DOI 10.1002/ccd.1810080402; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; LEPPO J, 1982, CIRCULATION, V66, P649, DOI 10.1161/01.CIR.66.3.649; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARWICK TH, 1990, CLIN CARDIOL, V13, P14, DOI 10.1002/clc.4960130105; MASSIE BM, 1993, CIRCULATION, V87, P1752, DOI 10.1161/01.CIR.87.5.1752; MCFALLS EO, 1993, J AM COLL CARDIOL, V21, P1347, DOI 10.1016/0735-1097(93)90307-M; MOCK MB, 1982, CIRCULATION, V66, P562, DOI 10.1161/01.CIR.66.3.562; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; PASTERNACK PF, 1985, CIRCULATION, V72, P13; PEDERSEN TR, 1994, LANCET, V344, P1383; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RIHAL CS, 1995, CIRCULATION, V91, P46, DOI 10.1161/01.CIR.91.1.46; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; RUDDY TD, 1987, J AM COLL CARDIOL, V10, P142, DOI 10.1016/S0735-1097(87)80172-9; RYAN TJ, 1993, J AM COLL CARDIOL, V22, P2033, DOI 10.1016/0735-1097(93)90794-2; SIMONETTI I, 1991, CIRCULATION, V83, P43; SMITH LR, 1991, CIRCULATION, V84, P245; TALLEY JD, 1990, CIRCULATION, V82, P1203, DOI 10.1161/01.CIR.82.4.1203; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743; ZHU YY, 1991, AM HEART J, V121, P33, DOI 10.1016/0002-8703(91)90952-E; 1994, STAT B METROP IN JAN, P12	73	114	116	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1919	1925		10.1001/jama.273.24.1919	http://dx.doi.org/10.1001/jama.273.24.1919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783301				2022-12-01	WOS:A1995RE35400027
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V272, P1160	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RE354	7783288				2022-12-01	WOS:A1995RE35400008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SEAFOOD SAFETY HOT LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-01	WOS:A1995RE35400009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ONE-DAY COURSE ON CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-01	WOS:A1995RE35400007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TOLL-FREE NUMBER FOR LOCATING CERTIFIED MAMMOGRAPHY FACILITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V271, P179	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-01	WOS:A1995RE35400006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FAMOTIDINE APPROVED FOR OVER-THE-COUNTER USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-01	WOS:A1995RE35400005
J	VLADECK, BC				VLADECK, BC			END-STAGE RENAL-DISEASE CORE INDICATORS PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,DIV HLTH STAND & QUAL,REG OFF X,SEATTLE,WA, USA.							1994, JAMA-J AM MED ASSOC, V271, P1896	1	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1896	1896		10.1001/jama.273.24.1896	http://dx.doi.org/10.1001/jama.273.24.1896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783287				2022-12-01	WOS:A1995RE35400004
J	ALLABY, MAK				ALLABY, MAK			CONTRACEPTIVE SERVICES FOR TEENAGERS - DO WE NEED FAMILY-PLANNING CLINICS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the effectiveness of contraceptive services for teenagers is related to the balance of service provision between general practitioners and specialist family planning services. Design-Cross sectional study with routinely collected data from family planning clinics and family health services authorities and published data on births and abortions. Setting-Eight health districts in the former Oxford region. Subjects-Girls aged under 16 and women aged 16-19 who attended a contraceptive service during 1991-2 or who gave birth or had an abortion during 1990-2. Main outcome measures-Attenders at family planning clinics as a percentage of all users of contraceptive services. The conception rate:uptake of contraceptive services ratio was used as a measure of effectiveness. Results-In comparisons between districts the percentage of all users of contraceptive services who attended a clinic varied fi om 38% (95% confidence interval 28% to 48%) to 79% (72% to 86%) among 13-15 year olds and from 14% (12% to 15%) to 44% (42% to 46%) among women aged 16-19 years. The conception rate:uptake of contraceptive services ratio varied twofold in the older age group and more than threefold in the younger age group. It was lowest in districts where clinic attenders comprised a large percentage of all users of contraceptive services. Conclusion-Contraceptive services for teenagers may be more effective in districts where clinics play a large part in delivering the service, particularly for girls aged under 16.			ALLABY, MAK (corresponding author), NORTHAMPTONSHIRE HLTH AUTHOR,DEPT PUBL HLTH MED,NORTHAMPTON NN1 5DN,ENGLAND.							ALLEN I, 1991, FAMILY PLANNING PREG; IBBOTSON S, 1992, BRIT MED J, V305, P835, DOI 10.1136/bmj.305.6857.835-b; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; ROXBY M, 1992, HLTH NEEDS ASSESSMEN; SHEPHERD M, 1988, CONSUMER PREFERENCES; 1992, GUIDELINES REVIEWING; 1992, ABORTION STATISTICS; 1992, HLTH NATION STRATEGY; 1992, FM1 OFF POP CENS SUR; 1990, FM1 OFF POP CENS SUR; 1990, ABORTION STATISTICS; 1994, 37 FAC PUBL HLTH MED; 1991, ABORTION STATISTICS; 1991, FM1 OFF POP CENS SUR	14	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1641	1643		10.1136/bmj.310.6995.1641	http://dx.doi.org/10.1136/bmj.310.6995.1641			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795452	Green Published			2022-12-01	WOS:A1995RF69800024
J	BAYERDORFFER, E; NEUBAUER, A; RUDOLPH, B; THIEDE, C; LEHN, N; EIDT, S; STOLTE, M				BAYERDORFFER, E; NEUBAUER, A; RUDOLPH, B; THIEDE, C; LEHN, N; EIDT, S; STOLTE, M			REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CAMPYLOBACTER-PYLORI; STAGING CLASSIFICATION; IMMUNE-RESPONSE; MONOCLONALITY; ERADICATION; DNA	Lymphoma of gastric-mucosa-associated lymphatic tissue (MALT) type has been linked to infection with Helicobacter pylori. We investigated the effect on MALT lymphoma of eradicating H pylori infection. 33 patients with primary gastric low-grade MALT lymphoma associated with H pylori gastritis were treated with omeprazole (120 mg daily) and amoxycillin (2 . 25 g daily) for 14 days to eradicate H pylori. In addition to histology, PCR was used to examine proliferation of monoclonal B cells before treatment and during follow-up. All patients had at least two post-treatment examinations, and all became negative for H pylori, 2 after a second treatment course. On histology, 23 (70%) patients showed complete regression and 4 (12%) partial regression of lymphoma. 6 (18%) patients had no change after cure of H pylori infection. 1 was treated with chemotherapy. Of 5 treated surgically, 4 were found to have high-grade B-cell lymphoma on histology of the resected stomach and 1 a high-grade T-cell lymphoma. PCR showed complete disappearance of monoclonal B cells after cure of H pylori infection in 13 of 16 patients investigated. During median follow-up of 1 year no relapse of MALT lymphoma occurred. Low-grade primary gastric MALT lymphoma can completely regress after eradication of H pylori infection. However, longer follow-up is needed to clarify whether the remission is lasting.	FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,DEPT INTERNAL MED & HEMATOL,BERLIN,GERMANY; TECH UNIV MUNICH,INST MICROBIOL,MUNICH,GERMANY; UNIV COLOGNE,INST PATHOL,COLOGNE,GERMANY; INST PATHOL,BAYREUTH,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; University of Cologne	BAYERDORFFER, E (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81377 MUNICH,GERMANY.		Thiede, Christian/A-1417-2008; Thiede, Christian/AAS-7595-2020	Thiede, Christian/0000-0003-1241-2048				BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; CAMMAROTA G, 1995, LANCET, V345, P192, DOI 10.1016/S0140-6736(95)90195-7; CARBONE PP, 1971, CANCER RES, V31, P1860; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; EIDT S, 1994, PATHOL RES PRACT, V190, P1077, DOI 10.1016/S0344-0338(11)80904-0; HARRIS AW, 1994, LANCET, V343, P1503; HEILMANN KL, 1991, GUT, V32, P137, DOI 10.1136/gut.32.2.137; HORSTMANN M, LANCET, V3438, P94; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1994, NEW ENGL J MED, V330, P1310, DOI 10.1056/NEJM199405053301812; MARSHALL BJ, 1988, LANCET, V2, P1437; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; SAMBROOK J, 1989, MOL CLONING LANBORAT; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; STOLTE M, 1992, Z GASTROENTEROL, V29, P6; TRAINOR KJ, 1990, BLOOD, V75, P2220; WAN JH, 1990, J CLIN PATHOL, V43, P880; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WOTHERSPOON AC, LANCET, V3433, P94; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	29	816	833	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1591	1594		10.1016/S0140-6736(95)90113-2	http://dx.doi.org/10.1016/S0140-6736(95)90113-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783535				2022-12-01	WOS:A1995RE67000006
J	COCHI, SL; HULL, HF; WARD, NA				COCHI, SL; HULL, HF; WARD, NA			TO CONQUER POLIOMYELITIS FOREVER	LANCET			English	Editorial Material									WHO,EXPANDED PROGRAMME IMMUNIZAT,GENEVA,SWITZERLAND	World Health Organization	COCHI, SL (corresponding author), CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341, USA.							BART KJ, IN PRESS B WHO; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; Smith, 1990, PATENTING SUN POLIO; YANG BP, 1995, PEDIATR INFECT DIS J, V14, P308, DOI 10.1097/00006454-199504000-00011; 1994, MMWR-MORBID MORTAL W, V13, P720; 1988, GLOBAL ERADICATION P; 1995, MMWR-MORBID MORTAL W, V44, P273	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1589	1590		10.1016/S0140-6736(95)90111-6	http://dx.doi.org/10.1016/S0140-6736(95)90111-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783533				2022-12-01	WOS:A1995RE67000004
J	COYLE, A; MCGRELLIS, S				COYLE, A; MCGRELLIS, S			STRATEGIES FOR DEALING WITH PROBLEMS ASSOCIATED WITH USE OF SERVICES FOR HIV-INFECTION AND AIDS OUT OF REGION - VIEWS OF PROVIDERS AND USERS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER	Objectives-To identify reasons why people with HIV infection and AIDS living within the former South West Thames Regional Health Authority use HIV and AIDS services outside the region, and to identify strategies for dealing with the problems associated with such use. Design-Qualitative study consisting of interviews with individual subjects and focus groups. Setting-Providers of services for patients with HIV infection and AIDS in South West Thames, central London, and Brighten. Users of such services resident in South West Thames. Subjects-Thirty four South West Thames residents with HIV infection and AIDS who use or used services outside the former region; and 70 providers of services within and beyond South West Thames. Results-Principal reasons for use of services out of the region were accessibility (15) and negative appraisals of local services (14). Three main strategies for dealing with the problems of such use were suggested by providers. These entailed introducing users of services outside the region to services in their locality (16); sharing the responsibility for care between providers in specialist centres and in the person's locality (10); and involving the person's general practitioner in their care (12). These strategies were deemed acceptable by 29, 30, and 20 service users respectively. Conclusion-The reasons underlying use of services for patients with HIV infection and AIDS outside the region offer suggestions for developing services in areas with a high incidence of such use. The suggestions advanced by service providers offer an acceptable framework for dealing with the problems.			COYLE, A (corresponding author), UNIV SURREY,DEPT NURSING & MIDWIFERY,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Coyle, Adrian/0000-0002-5340-9817				ADLER M, 1993, BRIT MED J, V307, P1010, DOI 10.1136/bmj.307.6910.1010; BEARDSELL S, 1995, HIV TESTING SERVICES; COYLE A, 1993, NEED LISTEN SERVICE; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; Krueger RA., 2002, CONTRACT; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; Miles M., 2019, QUALITATIVE DATA ANA, V4th; SAUNDERS P, 1994, BRIT MED J, V308, P2, DOI 10.1136/bmj.308.6920.2; SMITH S, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-c; 1993, HIV AIDS 1992 1993 S	10	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1636	1638		10.1136/bmj.310.6995.1636	http://dx.doi.org/10.1136/bmj.310.6995.1636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795449	Green Published			2022-12-01	WOS:A1995RF69800019
J	GALLERANI, M; MANFREDINI, R; CARACCIOLO, S; SCAPOLI, C; MOLINARI, S; FERSINI, C				GALLERANI, M; MANFREDINI, R; CARACCIOLO, S; SCAPOLI, C; MOLINARI, S; FERSINI, C			SERUM-CHOLESTEROL CONCENTRATIONS IN PARASUICIDE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLASMA-CHOLESTEROL; PRIMARY PREVENTION; TERM MORTALITY; LOWERING DRUGS; MEN; TRIGLYCERIDES; POPULATION; AGGRESSION; SEROTONIN; VIOLENCE	Objective-To evaluate whether people who have committed parasuicide have low serum cholesterol concentrations. Design-Results of blood tests in subjects admitted to hospital for parasuicide compared with those of a control group of non-suicidal subjects; comparison in subgroup of parasuicide subjects of two sets of blood test results (one set from admission for parasuicide and the other from admission for some other illness). Setting-General hospital, Ferrara, Italy. Subjects-331 parasuicide subjects aged 44 (SD 21) years (109 with two sets of blood test results) and 331 controls. Main outcome measures-Serum cholesterol concentrations and possible association with parasuicide, considering sex, violence of method of parasuicide, and underlying psychiatric disorder. Results-Lower serum cholesterol concentrations (4.96 (SD 1.16) mmol/l) were found in the parasuicide subjects than in the controls (5.43 (1.30); P<0.001), regardless of sex and degree of violence of parasuicide method. Both men and women with two sets of blood test results had lower cholesterol concentrations after parsuicide. Linear regression analysis showed that the difference in cholesterol concentrations was significantly related to the length of time between the taking of the two sets of blood samples. Conclusion-The study showed low cholesterol concentrations after parasuicide. This finding agrees with previous studies, which suggest an association between low cholesterol concentration and suicide.	UNIV FERRARA, SCH MED, INST INTERNAL MED 1, FERRARA, ITALY; UNIV FERRARA, SCH MED, DEPT PSYCHOL, FERRARA, ITALY; UNIV FERRARA, DEPT BIOL, FERRARA, ITALY	University of Ferrara; University of Ferrara; University of Ferrara	GALLERANI, M (corresponding author), ST ANNA HOSP, DEPT EMERGENCY, CORSO GIOVECCA 203, I-44100 FERRARA, ITALY.		Manfredini, Roberto/N-3859-2019; Scapoli, Chiara/N-3372-2019; Manfredini, Roberto/AAJ-5442-2020; Manfredini, Roberto/A-3471-2008; Scapoli, Chiara/E-2268-2015	Manfredini, Roberto/0000-0002-8364-2601; Scapoli, Chiara/0000-0003-4058-4787; Manfredini, Roberto/0000-0002-8364-2601; Scapoli, Chiara/0000-0003-4058-4787				ALLAIN CC, 1974, CLIN CHEM, V20, P470; BOTTIGER LE, 1972, BRIT MED J, V32, P87; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; CARLSON LA, 1985, ACTA CHIR SCAND, P87; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COCCARO EF, 1989, BRIT J PSYCHIAT, V155, P52, DOI 10.1192/S0007125000291769; CUMMINGS P, 1994, ANN INTERN MED, V120, P848, DOI 10.7326/0003-4819-120-10-199405150-00006; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FOWKES FGR, 1992, LANCET, V340, P995, DOI 10.1016/0140-6736(92)93009-C; HORROBIN DF, 1989, BRIT J PSYCHIAT, V154, P882, DOI 10.1192/bjp.154.6.882b; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1992, ARCH INTERN MED, V152, P775, DOI 10.1001/archinte.152.4.775; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1988, J AM COLL CARDIOL, V12, P814, DOI 10.1016/0735-1097(88)90327-0; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PLATT S, 1992, ACTA PSYCHIAT SCAND, V85, P97, DOI 10.1111/j.1600-0447.1992.tb01451.x; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; VARTIAINEN E, 1994, BRIT MED J, V309, P445, DOI 10.1136/bmj.309.6952.445; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1989, ARCH GEN PSYCHIAT, V46, P604; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169	31	67	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 24	1995	310	6995					1632	1636		10.1136/bmj.310.6995.1632	http://dx.doi.org/10.1136/bmj.310.6995.1632			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795448	Green Published			2022-12-01	WOS:A1995RF69800018
J	KAPLAN, NM				KAPLAN, NM			ALCOHOL AND HYPERTENSION	LANCET			English	Editorial Material							BLOOD-PRESSURE; CONSUMPTION				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235, USA.							ABE H, 1994, CIRCULATION, V89, P2626, DOI 10.1161/01.CIR.89.6.2626; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; CUSHMAN WC, 1994, AM J HYPERTENS, V7, P814, DOI 10.1093/ajh/7.9.814; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Keil U, 1993, CARDIOVASC RISK FACT, V3, P189; KLAG MJ, 1993, HYPERTENSION, V22, P365, DOI 10.1161/01.HYP.22.3.365; KUPARI M, 1983, BRIT HEART J, V49, P174, DOI 10.1136/hrt.49.2.174; Lian C, 1915, B ACAD MED PARIS, V74, P525; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MAHESWARAN R, 1992, HYPERTENSION, V19, P79, DOI 10.1161/01.HYP.19.1.79; VANDONGEN R, 1994, TXB HYPERTENSION, P567; WANNAMETHEE G, 1991, J HUM HYPERTENS, V5, P59	13	35	37	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1588	1589		10.1016/S0140-6736(95)90110-8	http://dx.doi.org/10.1016/S0140-6736(95)90110-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783532				2022-12-01	WOS:A1995RE67000003
J	KATSUYA, T; KOIKE, G; YEE, TW; SHARPE, N; JACKSON, R; NORTON, R; HORIUCHI, M; PRATT, RE; DZAU, VJ; MACMAHON, S				KATSUYA, T; KOIKE, G; YEE, TW; SHARPE, N; JACKSON, R; NORTON, R; HORIUCHI, M; PRATT, RE; DZAU, VJ; MACMAHON, S			ASSOCIATION OF ANGIOTENSINOGEN GENE T235 VARIANT WITH INCREASED RISK OF CORONARY HEART-DISEASE	LANCET			English	Article							CONVERTING ENZYME; MYOCARDIAL-INFARCTION; DELETION POLYMORPHISM; CARDIOMYOPATHY; HYPERTENSION	Several genes, including some encoding components of the renin angiotensin system, are associated with the risk of cardiovascular diseases. There have been reports linking a homozygous deletion allele of the angiotensin converting enzyme (ACE) gene (DD) with an increased myocardial infarction, some variants and angiotensinogen gene with hypertension. In a case-control study of a caucasian population from New Zealand, we examined the associations with coronary heart disease (CHD) of ACE DD and of a mis-sense mutation with methionine to threonine aminoacid substitution at codon 235 in the angiotensinogen gene ( T235). We studied 422 patients (mean age 62 years, 81% male) with documented CHD (50% with myocardial infarction) and 406 controls without known CHD (frequency-matched to cases by age and sex). Risk factors for CHD were assessed by standard questionnaire, physical examination, and blood tests. Genomic DNA from leucocytes was analysed for various ACE and angiotensinogen alleles. Angiotensinogen T235 homozygotes were at significantly increased risk of CHD generally (odds ratio 1 . 7, 2p=0 . 008) and of myocardial infarction specifically (1 . 8, 2p=0 . 009). Adjustment for several risk factors increased the estimate of CHD risk associated with this allele to 2 . 6 (2p<0 . 001) and the estimate for myocardial infarction risk to 3 . 4 (2p<0 . 001). By contrast, there was no evidence of a significant increase in the risk of CHD or myocardial infarction among individuals with ACE DD. We conclude that the T235 polymorphism of the angiotensinogen gene is an independent risk factor, which carries an approximately two-fold increased risk of CHD. In this study, however, ACE DD was not associated with any detectable increase in CHD risk.	UNIV AUCKLAND,SCH MED,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; STANFORD UNIV,FALK CARDIOVASC RES CTR,DEPT MED,DIV CARDIOVASC MED,STANFORD,CA	University of Auckland; University of Auckland; Stanford University				Yee, Thomas/0000-0002-9970-3907; Jackson, Rod/0000-0001-5914-6934	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046631, R01HL035252, R01HL035610, R37HL035610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46631, HL35610, HL35252] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHN M, 1993, CLIN GENET, V44, P292; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; DZAU VJ, 1993, J HYPERTENS, V11, pS13; EVANS AE, 1994, Q J MED, V87, P211; HARRAP SB, 1994, LANCET, V344, P901, DOI 10.1016/S0140-6736(94)92262-4; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; LINDPAINTNER K, 1993, CLIN RES, V41, P216; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MIETTINEN HE, 1994, HUM GENET, V94, P189; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RUSS AP, 1993, HUM MOL GENET, V2, P609, DOI 10.1093/hmg/2.5.609; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; TIRET L, 1994, LANCET, V344, P910, DOI 10.1016/S0140-6736(94)92268-3; TIRET L, 1992, AM J HUM GENET, V51, P197; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Zhao Y, 1994, HYPERTENS RES, V17, P55	25	282	309	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1600	1603		10.1016/S0140-6736(95)90115-9	http://dx.doi.org/10.1016/S0140-6736(95)90115-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783537	Bronze			2022-12-01	WOS:A1995RE67000008
J	LEVY, JA				LEVY, JA			HIV RESEARCH - A NEED TO FOCUS ON THE RIGHT TARGET	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOCYTES; INFECTION; EFFICACY; LEUKEMIA; VACCINE; CELLS				LEVY, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							ADA G, 1992, NATURE, V359, P572, DOI 10.1038/359572a0; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; FOWKE KR, 1995, 5TH P ANN C HIV AIDS; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GARDNER MB, 1994, RETROVIRIDAE, V3, P133; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P645, DOI 10.1089/aid.1994.10.645; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUNSMANN G, 1975, VIROLOGY, V66, P327, DOI 10.1016/0042-6822(75)90203-2; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Levy JA, 1994, HIV PATHOGENESIS AID; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; MURTHY KK, 1994, 7TH P ANN M NAT COOP; PEDERSEN NC, 1993, J VET INTERN MED, V7, P34, DOI 10.1111/j.1939-1676.1993.tb03166.x; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; ROWLANDJONES S, 1993, SEMIN VIROL, V4, P83, DOI 10.1006/smvy.1993.1002; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ULRICH PP, 1989, J INFECT DIS, V160, P1; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	28	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1619	1621		10.1016/S0140-6736(95)90121-3	http://dx.doi.org/10.1016/S0140-6736(95)90121-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783542				2022-12-01	WOS:A1995RE67000014
J	PANDEY, M; GAUTAM, A; SHUKLA, VK				PANDEY, M; GAUTAM, A; SHUKLA, VK			ABO AND RH BLOOD-GROUPS IN PATIENTS WITH CHOLELITHIASIS AND CARCINOMA OF THE GALLBLADDER	BRITISH MEDICAL JOURNAL			English	Article							CANCER		BANARAS HINDU UNIV,INST MED SCI,DEPT SURG,VARANASI 221005,UTTAR PRADESH,INDIA	Banaras Hindu University (BHU)			Gautam, Amitabh/A-5636-2013; Pandey, Manoj/AAS-2315-2020	Gautam, Amitabh/0000-0002-0969-7866; Pandey, Manoj/0000-0002-1496-9846				AIRD I, 1953, BRIT MED J, V1, P799, DOI 10.1136/bmj.1.4814.799; HENDERSON J, 1993, J EPIDEMIOL COMMUN H, V47, P287, DOI 10.1136/jech.47.4.287; JUVONEN T, 1992, BRIT MED J, V305, P26, DOI 10.1136/bmj.305.6844.26; SHUKLA VK, 1985, J SURG ONCOL, V28, P32, DOI 10.1002/jso.2930280109; SLATER G, 1993, DIS COLON RECTUM, V36, P5, DOI 10.1007/BF02050293	5	27	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1639	1639		10.1136/bmj.310.6995.1639	http://dx.doi.org/10.1136/bmj.310.6995.1639			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795450	Green Published			2022-12-01	WOS:A1995RF69800021
J	PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN				PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN			PREGNANT TEENAGERS KNOWLEDGE AND USE OF EMERGENCY CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV EXETER,INST POPULAT STUDIES,EXETER EX4 6DT,DEVON,ENGLAND; UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter; University of Exeter	PEARSON, VAH (corresponding author), EXETER & N DEVON HLTH AUTHOR,SOUTHERNHAY E,EXETER EX1 1PQ,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; Bury J., 1984, TEENAGE PREGNANCY BR; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; 1992, FMI21 OFF POP CENS S	5	47	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1644	1644		10.1136/bmj.310.6995.1644	http://dx.doi.org/10.1136/bmj.310.6995.1644			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795453	Green Published			2022-12-01	WOS:A1995RF69800025
J	RICHARD, P; DELVALLE, GA; MOREAU, P; MILPIED, N; FELICE, MP; DAESCHLER, T; HAROUSSEAU, JL; RICHET, H				RICHARD, P; DELVALLE, GA; MOREAU, P; MILPIED, N; FELICE, MP; DAESCHLER, T; HAROUSSEAU, JL; RICHET, H			VIRIDANS STREPTOCOCCAL BACTEREMIA IN PATIENTS WITH NEUTROPENIA	LANCET			English	Note							MARROW TRANSPLANT RECIPIENTS; SEPTICEMIA; SEPSIS	Viridans streptococcal bacteraemia is frequent in neutropenic patients. 25 neutropenic patients with viridans streptococcal bacteraemia were compared with 64 control patients. Exposure to repeated chemotherapy or cytarabine were independent risk-factors for streptococcal bacteraemia. The use of carboxyureidopenicillins and stay in laminar-airflow rooms were protective. In a further cohort study of 49 patients, oral streptococci with the same ribotype as blood isolates were recovered from all 7 bacteraemic patients. The oral cavity is a portal of entry for viridans streptococci bacteraemia in neutropenic patients, especially after oral mucosal damage induced by repeated chemotherapy.	HOP HOTEL DIEU,FAC CHIRURG DENT,F-44035 NANTES,FRANCE; HOP HOTEL DIEU,SERV HEMATOL,F-44035 NANTES,FRANCE	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	RICHARD, P (corresponding author), HOP HOTEL DIEU,INST MED BIOL,BACTERIOL LAB A,F-44035 NANTES,FRANCE.			moreau, philippe/0000-0003-1780-8746; Milpied, Noel/0000-0002-5177-014X				BOCHUD PY, 1994, CLIN INFECT DIS, V1, P25; BOSTROM B, 1984, LANCET, V1, P1120; CLASSEN DC, 1990, AM J MED, V89, P441, DOI 10.1016/0002-9343(90)90373-L; COHEN J, 1983, LANCET, V2, P1452, DOI 10.1016/S0140-6736(83)90799-7; ELTING LS, 1994, CLIN INFECT DIS, V14, P1201; HENSLEE J, 1984, LANCET, V1, P393; MASCRET B, 1984, LANCET, V1, P1185; RINGDEN O, 1984, LANCET, V1, P744; VALTEAU D, 1991, BONE MARROW TRANSPL, V7, P415	9	80	81	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1607	1609		10.1016/S0140-6736(95)90117-5	http://dx.doi.org/10.1016/S0140-6736(95)90117-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783538				2022-12-01	WOS:A1995RE67000010
J	ROBERTS, RJ; SANDIFER, QD; EVANS, MR; NOLANFARRELL, MZ; DAVIS, PM				ROBERTS, RJ; SANDIFER, QD; EVANS, MR; NOLANFARRELL, MZ; DAVIS, PM			REASONS FOR NON-UPTAKE OF MEASLES, MUMPS, AND RUBELLA CATCH-UP IMMUNIZATION IN A MEASLES EPIDEMIC AND SIDE-EFFECTS OF THE VACCINE	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION; CHILDREN; OUTBREAK; TRANSMISSION; POPULATION; COLLEGE	Objectives-To investigate the reasons for poor uptake of immunisation (non-immunisation) and the possible side effects of measles, mumps, and rubella vaccine in a catch up immunisation campaign during a community outbreak of measles. Design-Descriptive study of reasons for non-immunisation and retrospective cohort study of side effects of the vaccine. Setting-Secondary schools in South Glamorgan. Subjects-Random cluster sample of the parents of 500 children targeted but not immunised and a randomised sample of 2866 of the children targeted. Main outcome measures-Reasons for non-immunisation; symptoms among immunised and non-immunised children. Results-Immunisation coverage of the campaign was only 43.4% (7633/17 595). The practical problems experienced included non-return of consent forms (6698/17 595), refusal of immunisation (2061/10 897 forms returned), and absence from school on day of immunisation (1203/8836 children with consent for immunisation). The most common reasons cited for non-immunisation were previous measles infection (145/232), previous immunisation against measles (78/232), and concern about side effects (55/232). Symptoms were equally common among immunised and non-immunised subjects. However, significantly more immunised boys than non-immunised boys reported fever (relative risk 2.31 (95% confidence interval 1.36 to 3.93)), rash (2.00 (1.10 to 3.64), joint symptoms (1.58; 1.05 to 2.38), and headache (1.31 (1.04 to 1.65)). Conclusions-Many of the objections raised by parents could be overcome by emphasising that primary immunisation does not necessarily confer immunity and that diagnosis of measles is unreliable. Measles, mumps, and rubella vaccine is safe in children aged 11-15.	S GLAMORGAN HLTH AUTHOR,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,S GLAM,WALES; LANSDOWNE HOSP,CARDIFF COMMUNITY HLTH CARE,CARDIFF CF1 8UL,S GLAM,WALES		ROBERTS, RJ (corresponding author), CTR COMMUNICABLE DIS SURVEILLANCE,PUBL HLTH LAB SERV,WELSH UNIT,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Morgan, Maria/D-3379-2009; Evans, Meirion/C-2990-2008	Morgan, Maria/0000-0002-5182-7222; Evans, Meirion/0000-0003-3578-1866				BARRETT G, 1993, BRIT MED J, V307, P681, DOI 10.1136/bmj.307.6905.681-b; BAXTER DN, 1990, PUBLIC HEALTH, V104, P267, DOI 10.1016/S0033-3506(05)80476-7; BENJAMIN CM, 1992, BMJ-BRIT MED J, V304, P1075, DOI 10.1136/bmj.304.6834.1075; BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; Calvert N, 1994, Commun Dis Rep CDR Rev, V4, pR70; CHEN RT, 1991, VACCINE, V9, P297, DOI 10.1016/0264-410X(91)90053-9; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; Dean A. G., 1990, EPI INFO VERSION 5 W; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HULL D, 1987, J ROY COLL PHYS LOND, V21, P28; KLEIN N, 1989, BRIT MED J, V298, P1687, DOI 10.1136/bmj.298.6689.1687; LI J, 1993, BRIT MED J, V307, P168, DOI 10.1136/bmj.307.6897.168; LOCHHEAD YJ, 1991, J ADV NURS, V16, P130, DOI 10.1111/j.1365-2648.1991.tb01616.x; LYONS R, IN PRESS EPIDEMIOL I; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MILLER C, 1989, PRACTITIONER, V223, P69; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; PELTOLA H, 1986, LANCET, V1, P939; Richardson J A, 1994, Commun Dis Rep CDR Rev, V4, pR73; SEAGER C, 1994, VACCINE, V82, P1018; SPRUANCE SL, 1977, ARTHRITIS RHEUM, V20, P741, DOI 10.1002/art.1780200216; 1994, COMMUN DIS REP CDR W, V4, P147; 1980, MMWR-MORBID MORTAL W, V29, P549; 1994, INFECTIOUS DISEASES	25	39	39	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1629	1632		10.1136/bmj.310.6995.1629	http://dx.doi.org/10.1136/bmj.310.6995.1629			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795447	Green Published			2022-12-01	WOS:A1995RF69800017
J	YOUNG, ID				YOUNG, ID			DIAGNOSING PRADER-WILLI-SYNDROME	LANCET			English	Editorial Material							ANGELMAN				YOUNG, ID (corresponding author), CITY HOSP,CLIN GENET SERV,NOTTINGHAM,ENGLAND.							DITTRICH B, 1992, HUM GENET, V90, P313; DONALDSON MDC, 1994, ARCH DIS CHILD, V70, P58, DOI 10.1136/adc.70.1.58; GILLESSENKAESBA.G, 1995, J MED GENET, V32, P88; HOLM VA, 1993, PEDIATRICS, V91, P398; LERER I, 1994, AM J MED GENET, V52, P79, DOI 10.1002/ajmg.1320520116; NICHOLLS RD, 1993, AM J MED GENET, V46, P16, DOI 10.1002/ajmg.1320460106; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; Prader A., 1956, SCHWEIZERISCHE MEDIZ, V86, P1260, DOI DOI 10.1007/978-3-642-47669-3_24; REIS A, 1994, AM J HUM GENET, V54, P741; Smith, 1982, RECOGNIZABLE PATTERN; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1590	1590		10.1016/S0140-6736(95)90112-4	http://dx.doi.org/10.1016/S0140-6736(95)90112-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783534				2022-12-01	WOS:A1995RE67000005
J	ZERR, I; BODEMER, M; RACKER, S; GROSCHE, S; POSER, S; KRETZSCHMAR, HA; WEBER, T				ZERR, I; BODEMER, M; RACKER, S; GROSCHE, S; POSER, S; KRETZSCHMAR, HA; WEBER, T			CEREBROSPINAL-FLUID CONCENTRATION OF NEURON-SPECIFIC ENOLASE IN DIAGNOSIS OF CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Note								Neuron-specific enolase (NSE) is among the biochemical markers in cerebrospinal fluid reported to be useful in the differential diagnosis of Creutzfeldt-Jakob disease from other dementing illnesses. In a group of 58 patients definite and Creutzfeldt-Jakob disease, with probable NSE concentrations (median 94 . 0, interquartile range 256 ng/mL) were significantly higher (p<0 . 001) than in 26 control patients (9 . 5, 15 . 5 ng/mL). At a cut-off of 35 ng/mL an optimum sensitivity of 80% with a specificity of 92% for the diagnosis of Creutzfeldt-Jakob disease by NSE in cerebrospinal fluid was obtained.	UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,D-37075 GOTTINGEN,GERMANY; UNIV GOTTINGEN,INST NEUROPATHOL,D-37075 GOTTINGEN,GERMANY	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen				Weber, Thomas/0000-0002-3833-6197				BROWN P, 1994, ANN NEUROL, V35, P13; JACOBI C, 1988, CLIN CHIM ACTA, V177, P49, DOI 10.1016/0009-8981(88)90306-3; JIMI T, 1992, CLIN CHIM ACTA, V11, P37; Kretzschmar H A, 1993, Arch Virol Suppl, V7, P261; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TIETJEN GE, 1990, ANN NEUROL, V28, P585, DOI 10.1002/ana.410280420; VERMUYTEN K, 1990, CLIN CHIM ACTA, V187, P69, DOI 10.1016/0009-8981(90)90332-M; WAKAYAMA Y, 1987, KLIN WOCHENSCHR, V65, P798, DOI 10.1007/BF01743256	10	150	153	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1609	1610		10.1016/S0140-6736(95)90118-3	http://dx.doi.org/10.1016/S0140-6736(95)90118-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783539				2022-12-01	WOS:A1995RE67000011
J	BARTEL, B; FINK, GR				BARTEL, B; FINK, GR			ILR1, AN AMIDOHYDROLASE THAT RELEASES ACTIVE INDOLE-3-ACETIC-ACID FROM CONJUGATES	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; RESISTANT MUTANTS; AUXIN; TISSUES; CLONING; GROWTH; YEAST	In plants, the growth regulator indole-3-acetic acid (IAA) is found both free and conjugated to a variety of amino acids, peptides, and carbohydrates. IAA conjugated to leucine has effects in Arabidopsis thaliana similar to those of free IAA. The ilr1 mutant is insensitive to exogenous IAA-Leu and was used to positionally clone the Arabidopsis ILR1 gene. ILR1 encodes a 48-kilodalton protein that cleaves IAA-amino acid conjugates in vitro and is homologous to bacterial amidohydrolase enzymes. DNA sequences similar to that of ILR1 are found in other plant species.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTEL B, UNPUB; BEDNAREK SY, 1992, PLANT MOL BIOL, V20, P133, DOI 10.1007/BF00029156; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BIALEK K, 1983, PLANT PHYSIOL, V73, P130, DOI 10.1104/pp.73.1.130; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; COHEN JD, 1988, BIOMECHANISMS REGULA, P229; Davies P. J., 1987, PLANT HORMONES THEIR; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; HANI EK, 1995, J BACTERIOL, V177, P2396, DOI 10.1128/jb.177.9.2396-2402.1995; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JAKUBOWSKA A, 1993, J PLANT PHYSIOL, V142, P61, DOI 10.1016/S0176-1617(11)80108-2; Koncz C., 1992, METHODS ARABIDOPSIS; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; MAHER EP, 1980, BIOCHEM GENET, V18, P1041, DOI 10.1007/BF00484337; MINET M, 1992, PLANT J, V2, P417; NORMANLY J, 1993, P NATL ACAD SCI USA, V90, P10355, DOI 10.1073/pnas.90.21.10355; SAKANYAN V, 1993, APPL ENVIRON MICROB, V59, P3878, DOI 10.1128/AEM.59.11.3878-3888.1993; STASINOPOULOS TC, 1990, PLANT PHYSIOL, V93, P1365, DOI 10.1104/pp.93.4.1365; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843	26	195	199	5	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1745	1748		10.1126/science.7792599	http://dx.doi.org/10.1126/science.7792599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792599				2022-12-01	WOS:A1995RE66800041
J	CASES, O; SEIF, I; GRIMSBY, J; GASPAR, P; CHEN, K; POURNIN, S; MULLER, U; AGUET, M; BABINET, C; SHIH, JC; DEMAEYER, E				CASES, O; SEIF, I; GRIMSBY, J; GASPAR, P; CHEN, K; POURNIN, S; MULLER, U; AGUET, M; BABINET, C; SHIH, JC; DEMAEYER, E			AGGRESSIVE-BEHAVIOR AND ALTERED AMOUNTS OF BRAIN-SEROTONIN AND NOREPINEPHRINE IN MICE LACKING MAOA	SCIENCE			English	Article							MONOAMINE OXIDASE-A; RAT-BRAIN; ORGANIZATION; EXPRESSION; GENES; IMMUNOCYTOCHEMISTRY; SEQUENCE; CORTEX; LIVER; MOTOR	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family. A line of transgenic mice was isolated in which transgene integration caused a deletion in the gene encoding MAOA, providing an animal model of MAOA deficiency, in pup brains, serotonin concentrations were increased up to ninefold, and serotonin-like immunoreactivity was present. in catecholaminergic neurons, In pup and adult brains, norepinephrine concentrations were increased up to twofold, and I cytoarchitectural changes were observed in the somatosensory cortex. Pup behavioral alterations, including trembling, difficulty in righting, and fearfulness were reversed by the serotonin synthesis inhibitor parachlorophenylalanine. Adults manifested a distinct behavioral syndrome, including enhanced aggression in males.	INST CURIE,CNRS,URA 1343,F-91405 ORSAY,FRANCE; UNIV SO CALIF,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; HOP LA PITIE SALPETRIERE,INSERM,U106,F-75651 PARIS,FRANCE; INST PASTEUR,CNRS,URA 361,F-75724 PARIS,FRANCE; UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Southern California; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Zurich; Roche Holding; Genentech			Gaspar, Patricia/G-8892-2011; cases, olivier/G-4882-2017	Gaspar, Patricia/0000-0003-4217-5717; cases, olivier/0000-0002-5678-7362	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085, K05MH000796] Funding Source: NIH RePORTER; NIMH NIH HHS [K05 MH 00796, R37 MH039085-23, R01 MH 37020, R37 MH 39085, R37 MH039085] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BARINAGA M, 1994, SCIENCE, V264, P1690, DOI 10.1126/science.8209247; BENEDETTI MS, 1992, DEV PHARMACOL THERAP, V18, P191, DOI 10.1159/000480622; BENNETTCLARKE CA, 1993, P NATL ACAD SCI USA, V90, P153, DOI 10.1073/pnas.90.1.153; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; BROWN SDM, 1993, MAMM GENOME, V4, pS269, DOI 10.1007/BF00360846; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, UNPUB; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CHEN ZY, 1992, GENOMICS, V14, P75, DOI 10.1016/S0888-7543(05)80286-1; COLLINS FA, 1992, AM J MED GENET, V42, P127, DOI 10.1002/ajmg.1320420126; DAMATO RJ, 1987, P NATL ACAD SCI USA, V84, P4322, DOI 10.1073/pnas.84.12.4322; GERSON SC, 1980, LIFE SCI, V27, P1435, DOI 10.1016/0024-3205(80)90368-9; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; HAEFELY WE, 1990, ADV NEUROL, V53, P505; KOIDE Y, 1984, NEUROCHEM RES, V9, P595, DOI 10.1007/BF00964506; KOLB B, 1983, CAN J PSYCHOL, V37, P211, DOI 10.1037/h0080724; KUWAHARA T, 1990, AGR BIOL CHEM TOKYO, V54, P253, DOI 10.1080/00021369.1990.10869903; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; LICHTENSTEIGER W, 1967, J NEUROCHEM, V14, P489, DOI 10.1111/j.1471-4159.1967.tb09548.x; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; Maxson Stephen C., 1992, V8, P349; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; OCHMAN H, 1988, GENETICS, V120, P621; OSTERHELDHAAS MC, 1994, DEV BRAIN RES, V77, P189, DOI 10.1016/0165-3806(94)90196-1; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RHOADES RW, 1990, J COMP NEUROL, V293, P190, DOI 10.1002/cne.902930204; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SEIF I, 1991, J VIROL, V65, P664, DOI 10.1128/JVI.65.2.664-671.1991; SHASKAN EG, 1970, J PHARMACOL EXP THER, V175, P404; STEINBUSCH HWM, 1982, CYTOCHEMICAL METHODS, P407; TSANG D, 1986, DEV NEUROSCI-BASEL, V8, P243, DOI 10.1159/000112258; WALLACE JA, 1982, BRAIN RES BULL, V9, P117, DOI 10.1016/0361-9230(82)90127-7; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WHISHAW IQ, 1981, J COMP PHYSIOL PSYCH, V95, P85, DOI 10.1037/h0077760; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WU HF, 1993, MOL PHARMACOL, V43, P888	38	931	966	0	137	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1763	1766		10.1126/science.7792602	http://dx.doi.org/10.1126/science.7792602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792602	Green Accepted			2022-12-01	WOS:A1995RE66800045
J	FRIEDMAN, AM; FISCHMANN, TO; STEITZ, TA				FRIEDMAN, AM; FISCHMANN, TO; STEITZ, TA			CRYSTAL-STRUCTURE OF LAC REPRESSOR CORE TETRAMER AND ITS IMPLICATIONS FOR DNA LOOPING	SCIENCE			English	Article							LACTOSE REPRESSOR; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; OPERATOR; SEQUENCE; OPERON; GENE; ASSOCIATION; PROMOTER	The crystal structure of the tryptic core fragment of the lac repressor of Escherichia coli (LacR) complexed with the inducer isopropyl-beta-D-thiogalactoside was determined at 2.6 Angstrom resolution. The quaternary structure consists of two dyad-symmetric dimers that are nearly parallel to each other. This structure places all four DNA binding domains of intact LacR on the same side of the tetramer, and results in a deep, V-shaped cleft between the two dimers. Each monomer contributes a carboxyl-terminal helix to an antiparallel four-helix bundle that functions as a tetramerization domain. Some of the side chains whose mutation reduce DNA binding form clusters on a surface near the amino terminus. Placing the structure of the DNA binding domain complexed with operator previously determined by nuclear magnetic resonance onto this surface results in two operators being adjacent and nearly parallel to each other. Structural considerations suggest that the two dimers of LacR may flexibly alter their relative orientation in order to bind to the known varied spacings between two operators.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520	Yale University; Howard Hughes Medical Institute; Yale University; Yale University			Friedman, Alan M/J-2696-2012; Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARRA JH, EMBO J, V12, P35; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHARLIER M, 1980, NATURE, V286, P423, DOI 10.1038/286423a0; CHEN B, 1971, NATURE-NEW BIOL, V233, P67, DOI 10.1038/newbio233067a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DANDANELL G, 1987, NATURE, V325, P823, DOI 10.1038/325823a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedman A. J., UNPUB; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOPE H, 1989, ACTA CRYSTALLOGR B, V45, P190, DOI 10.1107/S0108768188013710; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE W, 1994, NAT STRUCT BIOL, V265, P386; MAJORS J, 1975, P NATL ACAD SCI USA, V72, P4394, DOI 10.1073/pnas.72.11.4394; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MCKAY DB, 1982, J MOL BIOL, V156, P175, DOI 10.1016/0022-2836(82)90465-X; MONOD J, 1985, J MOL BIOL, V12, P88; MOWBRAY SL, 1993, J MOL BIOL, V225, P155; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; NICK H, 1985, NATURE, V313, P795, DOI 10.1038/313795a0; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OH BH, 1993, J BIOL CHEM, V268, P11348; OHSHIMA Y, 1975, J MOL BIOL, V91, P515, DOI 10.1016/0022-2836(75)90277-6; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PLATT T, 1973, J BIOL CHEM, V248, P110; PORSCHKE D, 1987, BIOPHYS CHEM, V28, P137, DOI 10.1016/0301-4622(87)80083-2; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WHITSON PA, 1987, J BIOL CHEM, V262, P14592; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	71	269	271	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1721	1727		10.1126/science.7792597	http://dx.doi.org/10.1126/science.7792597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792597				2022-12-01	WOS:A1995RE66800033
J	GOSSEN, M; FREUNDLIEB, S; BENDER, G; MULLER, G; HILLEN, W; BUJARD, H				GOSSEN, M; FREUNDLIEB, S; BENDER, G; MULLER, G; HILLEN, W; BUJARD, H			TRANSCRIPTIONAL ACTIVATION BY TETRACYCLINES IN MAMMALIAN-CELLS	SCIENCE			English	Article							GENE	A transcriptional transactivator was developed that fuses the VP16 activation domain with a mutant Tet repressor from Escherichia coli. This transactivator requires certain tetracycline (Tc) derivatives for specific DNA binding. Thus, addition of doxycycline to HeLa cells that constitutively synthesized the transactivator and that contained an appropriate, stably integrated reporter unit rapidly induced gene expression more than a thousandfold. The specificity of the Tet repressor-operator-effector interaction and the pharmacological characteristics of Tc's make this regulatory system well suited for the control of gene activities in vivo, such as in transgenic animals and possibly in gene therapy.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg	GOSSEN, M (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.		Wilson, Matthew H/K-3193-2013; Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; KISTNER A, UNPUB; MULLER G, 1995, THESIS U ERLANGEN NU; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLEICHER, 1984, P NATL ACAD SCI USA, V81, P1991; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	16	1960	2316	2	128	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1766	1769		10.1126/science.7792603	http://dx.doi.org/10.1126/science.7792603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792603				2022-12-01	WOS:A1995RE66800046
J	JIA, ZC; BARFORD, D; FLINT, AJ; TONKS, NK				JIA, ZC; BARFORD, D; FLINT, AJ; TONKS, NK			STRUCTURAL BASIS FOR PHOSPHOTYROSINE PEPTIDE RECOGNITION BY PROTEIN-TYROSINE-PHOSPHATASE 1B	SCIENCE			English	Article							HUMAN-PLACENTA; MAP KINASE; SPECIFICITY; PHOSPHORYLATION; PURIFICATION; DOMAIN; LAR	The crystal structures of a cysteine-215 --> serine mutant of protein tyrosine phosphatase 1B complexed with high-affinity peptide substrates corresponding to an autophosphorylation site of the epidermal growth factor receptor were determined. Peptide binding to the protein phosphatase was accompanied by a conformational change of a surface loop that created a phosphotyrosine recognition pocket and induced a catalytically competent form of the enzyme. The phosphotyrosine side chain is buried within the protein and anchors the peptide substrate to its binding site. Hydrogen bonds between peptide main-chain atoms and the protein contribute to binding affinity, and specific interactions of acidic residues of the peptide with basic residues on the surface of the enzyme confer sequence specificity.	UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Oxford; Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, ONCOGENE, V8, P2015; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1993, XPLOR; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JIA ZF, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; Madhusudan Elzbieta A. Trafny, 1994, Protein Science, V3, P176; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINNA LA, 1994, BBA-MOL CELL RES, V1222, P415, DOI 10.1016/0167-4889(94)90050-7; POT DA, 1992, J AM CHEM SOC, V114, P7296; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; [No title captured]	47	532	545	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1754	1758		10.1126/science.7540771	http://dx.doi.org/10.1126/science.7540771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7540771				2022-12-01	WOS:A1995RE66800043
J	LANGEN, R; CHANG, IJ; GERMANAS, JP; RICHARDS, JH; WINKLER, JR; GRAY, HB				LANGEN, R; CHANG, IJ; GERMANAS, JP; RICHARDS, JH; WINKLER, JR; GRAY, HB			ELECTRON-TUNNELING IN PROTEINS - COUPLING THROUGH A BETA-STRAND	SCIENCE			English	Article							BLUE COPPER PROTEINS; BIOLOGICAL MOLECULES; CRYSTAL-STRUCTURE; MATRIX-ELEMENTS; CYTOCHROME-C; AZURIN; PATHWAYS; RESOLUTION; SYSTEMS; MODEL	Electron coupling through a beta strand has been investigated by measurement of the intramolecular electron-transfer (ET) rates in ruthenium-modified derivatives of the beta barrel blue copper protein Pseudomonas aeruginosa azurin. Surface histidines, introduced on the methionine-121 beta strand by mutagenesis, were modified with a Ru(2,2'-bipyridine)(2)(imidazole)(2+) complex. The Cu+ to Ru3+ rate constants yielded a distance-decay constant of 1.1 per angstrom, a value close to the distance-decay constant of 1.0 per angstrom predicted for electron tunneling through an idealized beta strand. Activationless ET rate constants in combination with a tunneling-pathway analysis of the structures of azurin and cytochrome c confirm that there is a generally efficient network for coupling the internal (native) redox center to the surface of both proteins.	CALTECH,BECKMAN INST,PASADENA,CA 91125	California Institute of Technology			Winkler, Jay R/B-7372-2009	Germanas, Juris/0000-0002-1207-802X				ADMAN ET, 1981, ISRAEL J CHEM, V21, P8, DOI 10.1002/ijch.198100003; Bertini I., 1994, BIOINORGANIC CHEM; BROO A, 1991, J PHYS CHEM-US, V95, P4925, DOI 10.1021/j100166a002; CASIMIRO DR, 1993, J PHYS CHEM-US, V97, P13073, DOI 10.1021/j100152a007; CASIMIRO DR, 1993, J AM CHEM SOC, V115, P1485, DOI 10.1021/ja00057a037; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; CHANG TK, 1991, P NATL ACAD SCI USA, V88, P1325, DOI 10.1073/pnas.88.4.1325; CHRISTENSEN HEM, 1992, J PHYS CHEM-US, V96, P4451, DOI 10.1021/j100190a060; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; FARID RS, 1993, CURR OPIN STRUC BIOL, V3, P225, DOI 10.1016/S0959-440X(05)80157-5; FARVER O, 1992, J AM CHEM SOC, V114, P5764, DOI 10.1021/ja00040a043; FRIESNER RA, 1994, STRUCTURE, V2, P339, DOI 10.1016/S0969-2126(00)00035-6; GRUSCHUS JM, 1993, J PHYS CHEM-US, V97, P5581, DOI 10.1021/j100123a021; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; KARPISHIN TB, 1994, STRUCTURE, V2, P415, DOI 10.1016/S0969-2126(00)00043-5; LEE FS, 1993, J COMPUT CHEM, V14, P161, DOI 10.1002/jcc.540140205; LOWERY MD, 1992, INORG CHIM ACTA, V200, P233; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NAR H, 1992, FEBS LETT, V306, P119, DOI 10.1016/0014-5793(92)80981-L; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; ONUCHIC JN, 1991, J CHEM PHYS, V95, P1131, DOI 10.1063/1.461142; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P13078, DOI 10.1021/j100152a008; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; SIDDARTH P, 1990, J PHYS CHEM-US, V94, P8430, DOI 10.1021/j100385a015; SIDDARTH P, 1992, J PHYS CHEM-US, V96, P3213, DOI 10.1021/j100187a008; SIDDARTH PB, 1990, J PHYS CHEM-US, V94, P3213; Sigel H., 1991, METAL IONS BIOL SYST, V27; SKOURTIS SS, 1994, J PHYS CHEM-US, V98, P3379, DOI 10.1021/j100064a019; STUCHEBRUKHOV AA, 1995, J PHYS CHEM-US, V99, P7581, DOI 10.1021/j100019a044; STUDIER FW, 1990, METHODS ENZYMOLOGY; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; [No title captured]	37	324	333	0	88	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1733	1735		10.1126/science.7792598	http://dx.doi.org/10.1126/science.7792598			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792598				2022-12-01	WOS:A1995RE66800036
J	LAWRENCE, CM; RODWELL, VW; STAUFFACHER, CV				LAWRENCE, CM; RODWELL, VW; STAUFFACHER, CV			CRYSTAL-STRUCTURE OF PSEUDOMONAS-MEVALONII HMG-COA REDUCTASE AT 3.0 ANGSTROM RESOLUTION	SCIENCE			English	Article							COENZYME-A REDUCTASE; ACTIVATED PROTEIN-KINASE; AREA DETECTOR DIFFRACTOMETER; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; RAT-LIVER; CHEMICAL MODIFICATION; MEMBRANE DOMAIN; CATALYTIC SITE; CRYSTALLOGRAPHY; IDENTIFICATION	The rate-limiting step in cholesterol biosynthesis in mammals is catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a four-electron oxidoreductase that converts HMG-CoA to mevalonate. The crystal structure of HMG-CoA reductase from Pseudomonas mevalonii was determined at 3.0 angstrom resolution by multiple isomorphous replacement. The structure reveals a tightly bound dimer that brings together at the subunit interface the conserved residues implicated in substrate binding and catalysis. These dimers are packed about a threefold crystallographic axis, forming a hexamer with 23 point group symmetry. Difference Fourier studies reveal the binding sites for the substrates HMG-CoA and reduced or oxidized nicotinamide adenine dinucleotide [NAD(H)] and demonstrate that the active sites are at the dimer interfaces. The HMG-CoA is bound by a domain with an unusual fold, consisting of a central alpha helix surrounded by a triangular set of walls of beta sheets and alpha helices. The NAD(H) is bound by a domain characterized by an antiparallel beta structure that defines a class of dinucleotide-binding domains.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Lawrence, C. Martin/AAH-3420-2020	Lawrence, C. Martin/0000-0002-5398-466X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BOLLN JT, 1993, 1993 AM CRYST ASS 2; BROWN MS, 1986, SCIENCE, V232, P32; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CLARKE PR, 1990, FEBS LETT, V269, P213, DOI 10.1016/0014-5793(90)81157-J; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; DUGAN RE, 1986, BIOCHEM BIOPH RES CO, V141, P278, DOI 10.1016/S0006-291X(86)80365-5; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; ENDO A, 1992, J LIPID RES, V33, P1569; GILL JF, 1985, J BIOL CHEM, V260, P9393; GILL JF, 1984, J BACTERIOL, V160, P294, DOI 10.1128/JB.160.1.294-298.1984; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KIRTLEY ME, 1967, BIOCHEMISTRY-US, V6, P230, DOI 10.1021/bi00853a036; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE CM, 1995, ACTA CRYSTALLOGR D, V51, P386, DOI 10.1107/S0907444994009819; LESLIE GW, 1987, ASPECTS PROTEIN CRYS, P35; LOUISFLAMBERG P, 1990, BIOCHEMISTRY-US, V29, P4115, DOI 10.1021/bi00469a014; MAYER RJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P110, DOI 10.1016/0003-9861(88)90014-8; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OMKUMAR RV, 1994, J BIOL CHEM, V269, P16862; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; ROITELMAN J, 1989, J LIPID RES, V30, P97; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCALNICK DG, 1988, J BIOL CHEM, V263, P6836; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG Y, 1989, J BACTERIOL, V171, P5567, DOI 10.1128/jb.171.10.5567-5571.1989; WANG YL, 1990, J BIOL CHEM, V265, P21634; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433	46	73	78	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1758	1762		10.1126/science.7792601	http://dx.doi.org/10.1126/science.7792601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792601				2022-12-01	WOS:A1995RE66800044
J	SANES, JN; DONOGHUE, JP; THANGARAJ, V; EDELMAN, RR; WARACH, S				SANES, JN; DONOGHUE, JP; THANGARAJ, V; EDELMAN, RR; WARACH, S			SHARED NEURAL SUBSTRATES CONTROLLING HAND MOVEMENTS IN HUMAN MOTOR CORTEX	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; SUPPLEMENTARY MOTOR; VOLUNTARY MOVEMENTS; CORTICAL AREAS; ORGANIZATION; CONNECTIONS; STIMULATION; MONKEYS; ARM	Voluntary hand movements in humans involve the primary motor cortex (M1). A functional magnetic resonance imaging method that measures relative cerebral blood flow was used to identify a distributed, overlapping pattern of hand movement representation within the posterior precentral gyrus, which contains M1. The observed pattern resembles those reported in nonhuman primates and differs from a somatotopically organized plan typically used to portray human motor cortex organization. Finger and wrist movements activated a wide expanse of the posterior precentral gyrus, and representations for different finger movements overlapped each other and the wrist representation. Multiple sites of activation occurred in the precentral gyrus for all movements. The overlapping representations may mediate motor and cognitive functions requiring coordinated neural processing for finger and wrist actions rather than discrete control implied by somatotopic maps.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SANES, JN (corresponding author), BROWN UNIV, DIV BIOL & MED, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.		Warach, Steven/R-5074-2019		NIA NIH HHS [AG 10634] Funding Source: Medline; NINDS NIH HHS [NS 25074, NS 01634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS025074, R01NS025074, K08NS001634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010634] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENNETT KMB, 1994, J PHYSIOL-LONDON, V477, P291, DOI 10.1113/jphysiol.1994.sp020191; BOECKER H, 1994, BRAIN, V117, P1231, DOI 10.1093/brain/117.6.1231; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; CONSTABLE RT, 1993, MAGN RESON IMAGING, V11, P451, DOI 10.1016/0730-725X(93)90463-N; DELBER MP, 1991, EXP BRAIN RES, V84, P393; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; EDELMAN RR, 1994, RADIOLOGY, V192, P513, DOI 10.1148/radiology.192.2.8029425; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; GRAFTON ST, 1991, J NEUROPHYSIOL, V66, P735, DOI 10.1152/jn.1991.66.3.735; GRAFTON ST, 1993, EXP BRAIN RES, V95, P172; HESS G, 1994, J NEUROPHYSIOL, V71, P2543, DOI 10.1152/jn.1994.71.6.2543; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWAN HC, 1978, J NEUROPHYSIOL, V41, P1120, DOI 10.1152/jn.1978.41.5.1120; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LUKASHIN AV, 1994, P NATL ACAD SCI USA, V91, P8651, DOI 10.1073/pnas.91.18.8651; MCKIERNAN BJ, 1994, ROC NEUR ABS, V20, P983; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P137, DOI 10.1152/jn.1980.43.1.137; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; SANES JN, 1994, BEHAV BRAIN SCI, V17, P221, DOI 10.1017/S0140525X00034270; SCHAD LR, 1993, MAGN RESON IMAGING, V11, P461, DOI 10.1016/0730-725X(93)90464-O; SCHIEBER MH, 1993, SCIENCE, V261, P489, DOI 10.1126/science.8332915; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	29	367	376	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1775	1777		10.1126/science.7792606	http://dx.doi.org/10.1126/science.7792606			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792606				2022-12-01	WOS:A1995RE66800049
J	SAVITSKY, K; BARSHIRA, A; GILAD, S; ROTMAN, G; ZIV, Y; VANAGAITE, L; TAGLE, DA; SMITH, S; UZIEL, T; SFEZ, S; ASHKENAZI, M; PECKER, I; FRYDMAN, M; HARNIK, R; PATANJALI, SR; SIMMONS, A; CLINES, GA; SARTIEL, A; GATTI, RA; CHESSA, L; SANAL, O; LAVIN, MF; JASPERS, NGJ; MALCOLM, A; TAYLOR, R; ARLETT, CF; MIKI, T; WEISSMAN, SM; LOVETT, M; COLLINS, FS; SHILOH, Y				SAVITSKY, K; BARSHIRA, A; GILAD, S; ROTMAN, G; ZIV, Y; VANAGAITE, L; TAGLE, DA; SMITH, S; UZIEL, T; SFEZ, S; ASHKENAZI, M; PECKER, I; FRYDMAN, M; HARNIK, R; PATANJALI, SR; SIMMONS, A; CLINES, GA; SARTIEL, A; GATTI, RA; CHESSA, L; SANAL, O; LAVIN, MF; JASPERS, NGJ; MALCOLM, A; TAYLOR, R; ARLETT, CF; MIKI, T; WEISSMAN, SM; LOVETT, M; COLLINS, FS; SHILOH, Y			A SINGLE ATAXIA-TELANGIECTASIA GENE WITH A PRODUCT SIMILAR TO PI-3 KINASE	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; IONIZING-RADIATION; DNA-SYNTHESIS; COMPLEMENTATION ANALYSIS; CDNA SELECTION; FAMILIES; PROTEIN; CELLS; PATHWAYS; CANCERS	A gene, ATM, that is mutated in the autosomal recessive disorder ataxia telangiectasia (AT) was identified by positional cloning on chromosome 11q22-23. AT is characterized by cerebellar degeneration, immunodeficiency, chromosomal instability, cancer predisposition, radiation sensitivity, and cell cycle abnormalities. The disease is genetically heterogeneous, with four complementation groups that have been suspected to represent different genes. ATM, which has a transcript of 12 kilobases, was found to be mutated in AT patients from all complementation groups, indicating that it is probably the sole gene responsible for this disorder. A partial ATM complementary DNA clone of 5.9 kilobases encoded a putative protein that is similar to several yeast and mammalian phosphatidylinositol-3' kinases that are involved in mitogenic signal transduction, meiotic recombination, and cell cycle control. The discovery of ATM should enhance understanding of AT and related syndromes and may allow the identification of AT heterozygotes, who are at increased risk of cancer.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CHAIM SHEBA MED CTR,INST HUMAN GENET,IL-52621 TEL HASHOMER,ISRAEL; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,NEW HAVEN,CT 06536; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90095; UNIV ROMA LA SAPIENZA,DIPARTIMENTO MED SPERIMENTALE,I-00161 ROME,ITALY; HACETTEPE UNIV,FAC MED,DEPT PEDIAT,ANKARA 06100,TURKEY; QUEENSLAND INST MED RES,HERSTON,QLD 4006,AUSTRALIA; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV BIRMINGHAM,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Chaim Sheba Medical Center; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Sapienza University Rome; Hacettepe University; QIMR Berghofer Medical Research Institute; Erasmus University Rotterdam; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00882] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P101; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARR AG, UNPUB; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; Chen P., UNPUB; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DIECHA N, 1995, CELL, V80, P269; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GREEN MHL, 1987, J CELL SCI S, V6, P127; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P586; LANGE E, IN PRESS AM J HUM GE; LAVIN M, UNPUB; LAVIN MF, 1993, NATO ASI SERIES H, V77, P235; LEHMANN AR, 1982, ATAXIA TELANGIECTASI, P83; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MCCONVILLE CM, 1994, INT J RADIAT BIOL, V66, pS45, DOI 10.1080/09553009414551851; Meyn M. S., 1994, American Journal of Human Genetics, V55, pA3; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MONFAR M, 1995, MOL CELL BIOL, V15, P325; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; OSKATO R, 1993, AM J HUM GENET, V53, P1055; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PARIMOO S, 1993, NUCLEIC ACIDS RES, V21, P4422, DOI 10.1093/nar/21.18.4422; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RICHARD CW, 1993, GENOMICS, V17, P1, DOI 10.1006/geno.1993.1275; ROTMAN G, 1994, INT J RADIAT BIOL, V66, pS63, DOI 10.1080/09553009414551871; ROTMAN G, 1994, GENOMICS, V24, P234, DOI 10.1006/geno.1994.1611; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Sedgwick RP, 1991, HDB CLIN NEUROLOGY, P347; Shiloh Y., 1994, American Journal of Human Genetics, V55, pA49; SHILOH Y, IN PRESS EUR J HUM G; SHILOH Y, 1985, ATAXIA TELANGIECTASI, P111; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; UHRHAMMER N, IN PRESS AM J HUM GE; VANAGAITE L, 1995, HUM GENET, V95, P451; VANAGAITE L, UNPUB; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WEINERT TA, UNPUB; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZAMPETTIBOSSELE.F, 1981, INT J RADIAT BIOL, V39, P547; ZIV Y, 1991, GENOMICS, V9, P373, DOI 10.1016/0888-7543(91)90268-J; ZIV Y, UNPUB; ZIV Y, 1992, HUM GENET, V88, P6219; ZIV Y, IN PRESS SOMATIC CEL	68	2229	2306	0	75	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1749	1753		10.1126/science.7792600	http://dx.doi.org/10.1126/science.7792600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792600				2022-12-01	WOS:A1995RE66800042
J	TANG, WJ; GILMAN, AG				TANG, WJ; GILMAN, AG			CONSTRUCTION OF A SOLUBLE ADENYLYL-CYCLASE ACTIVATED BY G(S)ALPHA AND FORSKOLIN	SCIENCE			English	Article							GLUCOSE-TRANSPORT; ESCHERICHIA-COLI; GS-ALPHA; SITE; CAMP; RAT; ADIPOCYTES; INHIBITION	A soluble adenylyl cyclase was constructed by linkage of portions of the cytosolic domains of the mammalian type I and type II enzymes. The soluble enzyme was stimulated by both forskolin and the alpha subunit of the heterotrimeric guanine nucleotide-binding protein (G protein) G(s) (G(s) alpha). Expression of the construct complemented the catabolic defect in a strain of Escherichia coli that is deficient in adenylyl cyclase activity. The active, approximately 60-kilodalton enzyme accumulated in the cytoplasmic fraction of E. coli to yield activities in excess of 1 nanomole per minute per milligram of protein. The two sets of transmembrane helices of mammalian adenylyl cyclases are thus not necessary for the catalytic or the most characteristic regulatory activities of the enzyme. This system may be useful for both genetic and biochemical analysis of G protein-regulated adenylyl cyclases.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DESSAUER C, UNPUB; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOOST HG, 1988, MOL PHARMACOL, V33, P449; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PERLMAN RL, 1969, BIOCHEM BIOPH RES CO, V37, P151, DOI 10.1016/0006-291X(69)90893-6; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; SEAMON KB, 1983, J MED CHEM, V26, P436, DOI 10.1021/jm00357a021; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; Tang W. J., UNPUB; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WADLER S, 1988, CANCER RES, V48, P539; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507	29	148	153	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1769	1772		10.1126/science.7792604	http://dx.doi.org/10.1126/science.7792604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792604				2022-12-01	WOS:A1995RE66800047
J	BESSEN, RA; KOCISKO, DA; RAYMOND, GJ; NANDAN, S; LANSBURY, PT; CAUGHEY, B				BESSEN, RA; KOCISKO, DA; RAYMOND, GJ; NANDAN, S; LANSBURY, PT; CAUGHEY, B			NONGENETIC PROPAGATION OF STRAIN-SPECIFIC PROPERTIES OF SCRAPIE PRION PROTEIN	NATURE			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; DISEASES; BIOLOGY; MODEL; AGENT	THE infectious agents causing scrapie and other transmissible spongiform encephalopathies have been postulated to consist solely of the protease-resistant form of prion protein (PrPSc)(1-6). One unprecedented requirement of the protein-only model is that the 'inheritance' of pathogen strain differences must be mediated by stable variations in PrPSc structure(2,7,8), rather than mutations in an agent-specific nucleic acid(9). Strain differences in PrPSc structure have been described for the hyper (HY) and drowsy (DY) strains of hamster transmissible mink encephalopathy (TME)(7,8), a a scrapie-like disease originating in mink. Although HY and DY PrPSc are both post-translationally derived from the precursor prion protein (PrPc) they are cleaved at different amino-terminal sites by proteinase K (ref. 8). Here we investigate whether this strain-specific property of PrPSc is transmitted to PrPc during formation of new PrPSc. PrPSc from the HY and DY TME strains converted the protease-sensitive PrPc into two distinct sets of protease-resistant PrP products in a cell-free system. These data provide evidence that self-propagation of PrPSc polymers with distinct three-dimensional structures could be the molecular basis of scrapie strains.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BESSEN, RA (corresponding author), NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840, USA.							BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BOLTON DC, 1988, CIBA F SYMP, V135, P164; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; CASPAR DLD, 1980, BIOPHYS J, V32, P101; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	14	449	464	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					698	700		10.1038/375698a0	http://dx.doi.org/10.1038/375698a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791905				2022-12-01	WOS:A1995RE57600065
J	GONZALEZREYES, A; ELLIOTT, H; STJOHNSTON, D				GONZALEZREYES, A; ELLIOTT, H; STJOHNSTON, D			POLARIZATION OF BOTH MAJOR BODY AXES IN DROSOPHILA BY GURKEN-TORPEDO SIGNALING	NATURE			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; BICOID RNA; OOGENESIS; GENE; MELANOGASTER; OOCYTE; AXIS; LOCALIZATION; ENCODES	Anterior-posterior polarity in Drosophila arises from the movement of the oocyte to the posterior of the egg chamber, and the subsequent acquisition of posterior fate by the adjacent somatic follicle cells. We demonstrate that gurken is necessary in the oocyte and torpedo/DER in the follicle cells for the induction of posterior fate. As the gurken-torpedo/DER pathway also establishes dorsoventral polarity later in oogenesis, Drosophila uses the same germline to soma signalling pathway to determine both embryonic axes.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge	GONZALEZREYES, A (corresponding author), UNIV CAMBRIDGE,CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		Gonzalez-Reyes, Acaimo/L-1993-2014; St Johnston, Daniel/C-9568-2009	Gonzalez-Reyes, Acaimo/0000-0003-3048-0968; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1990, GENETICS, V126, P679; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chasan Rebecca, 1993, P387; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Driever Wolfgang, 1993, P301; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FASANO L, 1988, DEVELOPMENT, V104, P245; FROHNHOFER H, 1982, THESIS U TUBINGEN; FUJISUE M, 1993, DEVELOPMENT, V118, P163; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KAMMERMEYER KL, 1987, DEVELOPMENT, V100, P201; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLYMKOWSKY MW, 1994, DEV BIOL, V165, P372, DOI 10.1006/dbio.1994.1260; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; ROTH S, 1994, DEVELOPMENT, V120, P2245; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; Spradling Allan C., 1993, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; TOLIAS PP, 1990, EMBO J, V9, P1457, DOI 10.1002/j.1460-2075.1990.tb08262.x; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; YUGE M, 1990, DEVELOPMENT, V110, P1051	43	417	423	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					654	658		10.1038/375654a0	http://dx.doi.org/10.1038/375654a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791898				2022-12-01	WOS:A1995RE57600051
J	IRVING, M; ALLEN, TS; SABIDODAVID, C; CRAIK, JS; BRANDMEIER, B; KENDRICKJONES, J; CORRIE, JET; TRENTHAM, DR; GOLDMAN, YE				IRVING, M; ALLEN, TS; SABIDODAVID, C; CRAIK, JS; BRANDMEIER, B; KENDRICKJONES, J; CORRIE, JET; TRENTHAM, DR; GOLDMAN, YE			TILTING OF THE LIGHT-CHAIN REGION OF MYOSIN DURING STEP LENGTH CHANGES AND ACTIVE FORCE GENERATION IN SKELETAL-MUSCLE	NATURE			English	Article							CONTRACTING MUSCLE; MECHANICAL TRANSIENTS; FROG-MUSCLE; FIBERS; ORIENTATION; STIFFNESS; HEAD	FORCE generation and relative sliding between the myosin and actin filaments in muscle are thought to be caused by tilting of the head region of the myosin crossbridges between the filaments(1-3). Structural and spectroscopic experiments have demonstrated segmental flexibility of myosin in muscle(4-6), but have not shown a direct linkage between tilting of the myosin heads and either force generation or filament sliding. Here we use fluorescence polarization to detect changes in the orientation of the light-chain region of the head, the part most likely to tilt(5,7,8), and synchronized head movements by imposing rapid length steps(9-11). We found that the light-chain region of the myosin head tilts both during the imposed filament sliding and during the subsequent quick force recovery that is thought to signal the elementary force-generating event.	UNIV PENN,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104	University of Pennsylvania; MRC National Institute for Medical Research; MRC Laboratory Molecular Biology; University of Pennsylvania	IRVING, M (corresponding author), UNIV LONDON KINGS COLL,RANDALL INST,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGER CL, 1994, BIOPHYS J, V66, pA189; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CORRIE JET, 1994, J CHEM SOC PERK T 1, P2967, DOI 10.1039/p19940002967; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V350, P497, DOI 10.1113/jphysiol.1984.sp015215; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; GOLDMAN YE, 1987, BIOPHYS J, V52, P57, DOI 10.1016/S0006-3495(87)83188-0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1989, J PHYSIOL-LONDON, V418, pP57; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARTYN DA, 1992, J GEN PHYSIOL, V99, P795, DOI 10.1085/jgp.99.5.795; MOSS RL, 1982, J BIOL CHEM, V257, P8588; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SABIDODAVID C, 1994, BIOPHYS J, V66, P234; TANNER JW, 1992, J MOL BIOL, V223, P185, DOI 10.1016/0022-2836(92)90725-Y; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; TREGEAR RT, 1975, BIOPHYS J, V15, P455, DOI 10.1016/S0006-3495(75)85830-9; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	35	180	180	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					688	691		10.1038/375688a0	http://dx.doi.org/10.1038/375688a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791902				2022-12-01	WOS:A1995RE57600062
J	LEVITSKAYA, J; CORAM, M; LEVITSKY, V; IMREH, S; STEIGERWALDMULLEN, PM; KLEIN, G; KURILLA, MG; MASUCCI, MG				LEVITSKAYA, J; CORAM, M; LEVITSKY, V; IMREH, S; STEIGERWALDMULLEN, PM; KLEIN, G; KURILLA, MG; MASUCCI, MG			INHIBITION OF ANTIGEN-PROCESSING BY THE INTERNAL REPEAT REGION OF THE EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-1	NATURE			English	Article							LYMPHOCYTES-T; DNA-BINDING; INVIVO; RECOGNITION; EXPRESSION; SEQUENCE; EBNA-1; ESCAPE; CELLS	THE Epstein-Barr virus (EBV)-encoded nuclear antigen (EBNA1) is expressed in latently EBV-infected B lymphocytes that persist for life in healthy virus carriers(1,2) and is the only viral protein regularly detected in all malignancies associated with EBV(3,4). Major histocompatibility complex (MHC) class I-restricted, EBNA1-specific cytotoxic T lymphocyte (CTL) responses have not been demonstrated(3,5). Using recombinant vaccinia viruses encoding chimaeric proteins containing an immunodominant human leukocyte antigen A11-restricted CTL epitope, amino acids 416-424 of the EBNA4 protein(6), inserted within the intact EBNA1, or within an EBNA1 deletion mutant devoid of the internal Gly-Ala repetitive sequence, we demonstrate that the Gly-Ala repeats generate a cis-acting inhibitory signal that interferes with antigen processing and MHC class I-restricted presentation. Insertion of the Gly-Ala repeats downstream of the 416-424 epitope inhibited CTL recognition of a chimaeric EBNA4 protein. The results highlight a previously unknown mechanism of viral escape from CTL surveillance, and support the view that the resistance of cells expressing EBNA1 to rejection mediated by CTL is a critical requirement for EBV persistence and pathogenesis.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	Karolinska Institutet; University of Virginia			Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANGHAM CRM, 1986, J IMMUNOL, V137, P3973; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CHEN F, IN PRESS J VIROL; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; Clechanover A., 1994, CELL, V79, P13; DECAMPOSLIMA PO, 1994, J EXP MED, V179, P1297, DOI 10.1084/jem.179.4.1297; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LEE PY, 1993, J VIROL, V67, P4252, DOI 10.1128/JVI.67.7.4252-4263.1993; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; Rickinson A. M., 1992, NEW LOOK TUMOR IMMUN, P53; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; STEIGEWALDMULLE.PM, IN PRESS J GEN VIROL; TIEMEY RJ, 1994, J VIROL, V68, P7374; TISHON A, 1993, VIROLOGY, V195, P397, DOI 10.1006/viro.1993.1389; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421	29	638	672	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					685	688		10.1038/375685a0	http://dx.doi.org/10.1038/375685a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7540727				2022-12-01	WOS:A1995RE57600061
J	MARTIN, K; TROUCHE, D; HAGEMEIER, C; SORENSEN, TS; LATHANGUE, NB; KOUZARIDES, T				MARTIN, K; TROUCHE, D; HAGEMEIER, C; SORENSEN, TS; LATHANGUE, NB; KOUZARIDES, T			STIMULATION OF E2F1/DP1 TRANSCRIPTIONAL ACTIVITY BY MDM2 ONCOPROTEIN	NATURE			English	Article							BINDING PROTEIN; RETINOBLASTOMA PROTEIN; ACTIVATION DOMAIN; GENE-PRODUCT; P53; TRANSACTIVATION; EXPRESSION; E2F-1; COMPLEX; FORMS	THE MDM2 proto-oncogene is found amplified in a variety of tumours(1). The oncogenic capacity of the MDM2 protein is attributed to its ability to bind the p53 tumour-suppressor protein and mask its transcriptional activation potential(2,3). Here we show that MDM2 makes a functional contact with two cooperating transcription factors, E2F1 and DP1 (refs 4, 5), which are involved in S-phase progression(6). MDM2 contacts the activation domain of E2F1 using residues conserved in the activation domain of p53. However, in contrast to its repression of p53 activity, MDM2 stimulates the activation capacity of E2F1/DP1. These results indicate that MDM2 not only releases a proliferative block by silencing the tumour suppressor p53, it also positively augments proliferation by stimulating the S-phase inducing transcription factors E2F1/DP1.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND; NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	University of Cambridge; MRC National Institute for Medical Research			Trouche, Didier/B-2854-2008	Kouzarides, Tony/0000-0002-8918-4162; Trouche, Didier/0000-0003-1398-6481	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	22	446	466	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					691	694		10.1038/375691a0	http://dx.doi.org/10.1038/375691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791903				2022-12-01	WOS:A1995RE57600063
J	NOOR, MA				NOOR, MA			SPECIATION DRIVEN BY NATURAL-SELECTION IN DROSOPHILA	NATURE			English	Article							GENE FLOW; REINFORCEMENT	REINFORCEMENT is the process by which natural selection strengthens sexual isolation between incipient species, reducing the frequency of maladaptive hybridization and hence completing reproductive isolation. Although this model of speciation was once widely accepted(1,2), its plausibility(3,4) and experimental support(5-7) have been recently attacked. Here we provide an example of speciation by reinforcement, in the North American fruitfly Drosophila pseudoobscura. The results suggest that females of D. pseudoobscura evolved increased sexual isolation from their sibling species, D. persimilis, by natural selection against maladaptive hybridization.			NOOR, MA (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.			Noor, Mohamed/0000-0002-5400-4408				BROWN RGB, 1963, BEHAVIOUR, V23, P61; Butlin R., 1989, P158; BUTLIN R, 1987, TRENDS ECOL EVOL, V2, P8, DOI 10.1016/0169-5347(87)90193-5; COYNE JA, 1987, AM NAT, V129, P847, DOI 10.1086/284679; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DOBZHANSKY T, 1973, AM NAT, V107, P312, DOI 10.1086/282833; Dobzhansky T., 1935, PHILOS SCI, V2, P344, DOI DOI 10.1086/286379; Dobzhansky T, 1951, GENETICS ORIGIN SPEC; Dobzhansky T., 1975, INVERTEBRATES GENETI, P537; HOWARD DJ, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P46; Lewontin RC, 1974, GENETIC BASIS EVOLUT; MAYR E, 1946, P NATL ACAD SCI USA, V32, P128, DOI 10.1073/pnas.32.5.128; Mayr E., 1942, SYSTEMATICS ORIGIN S; Noor M.A., 1994, Drosophila Information Service, V75, P67; NOOR MA, 1995, PAN-PAC ENTOMOL, V71, P71; POWELL JR, 1983, P NATL ACAD SCI-BIOL, V80, P492, DOI 10.1073/pnas.80.2.492; SANDERSON N, 1989, EVOLUTION, V43, P1223, DOI 10.1111/j.1558-5646.1989.tb02570.x; SCHAEFFER SW, 1992, GENETICS, V132, P471; SPENCER HG, 1986, AM NAT, V128, P241, DOI 10.1086/284557; TAKAHATA N, 1984, P NATL ACAD SCI-BIOL, V81, P1764, DOI 10.1073/pnas.81.6.1764; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323	21	262	266	0	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					674	675		10.1038/375674a0	http://dx.doi.org/10.1038/375674a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791899				2022-12-01	WOS:A1995RE57600057
J	ROACH, PL; CLIFTON, IJ; FULOP, V; HARLOS, K; BARTON, GJ; HAJDU, J; ANDERSSON, I; SCHOFIELD, CJ; BALDWIN, JE				ROACH, PL; CLIFTON, IJ; FULOP, V; HARLOS, K; BARTON, GJ; HAJDU, J; ANDERSSON, I; SCHOFIELD, CJ; BALDWIN, JE			CRYSTAL-STRUCTURE OF ISOPENICILLIN N-SYNTHASE IS THE FIRST FROM A NEW STRUCTURAL FAMILY OF ENZYMES	NATURE			English	Article							X-RAY-ABSORPTION; ACTIVE-SITE; SUBSTRATE; ISOZYMES; ERRORS; MAPS	PENICILLIN antibiotics are all produced from fermentation-derived penicillins because their chemical synthesis is not commercially viable. The key step in penicillin biosynthesis, in which both the beta-lactam and thiazolidine rings of the nucleus are created, is mediated by isopenicillin N synthase (IPNS), which binds ferrous iron-and uses dioxygen as a cosubstrate, In a unique enzymatic step, with no chemical precedent, IPNS catalyses the transfer of four hydrogen atoms from its tripeptide substrate to dioxygen forming, in a single reaction, the complete bicyclic nucleus of the penicillins(1). We now report the structure of IPNS complexed with manganese, which reveals the active site is unusually buried within a 'jelly-roll' motif and lined by hydrophobic residues, and suggest hem this structure permits the process of penicillin formation. Sequence analyses indicate IPNS, 1-aminocyclopropane-1-carboxylic acid oxidase and many of the 2-oxo-acid-dependent oxygenases contain a conserved jelly-roll motif, forming a new structural family of enzymes.	UNIV OXFORD, DYSON PERRINS LAB, OXFORD OX1 3QY, ENGLAND; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT BIOL MOLEC, S-75124 UPPSALA, SWEDEN; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QY, ENGLAND; UNIV OXFORD, LAB MOLEC BIOPHYS, OXFORD OX1 3QY, ENGLAND	University of Oxford; Swedish University of Agricultural Sciences; University of Oxford; University of Oxford			Barton, Geoffrey J/C-6267-2011; Barton, Geoffrey/N-1037-2019; Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021	Barton, Geoffrey/0000-0002-9014-5355; Schofield, Christopher/0000-0002-0290-6565				BALDWIN JE, 1991, TETRAHEDRON, V47, P5991, DOI 10.1016/S0040-4020(01)86491-7; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BALDWIN JE, 1992, CHEM BETA LACTAMS, pCH1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; COWTAN K, 1994, ACTA CRYSTALLOGR D, V50, P760; Crowfoot D., 1949, The Chemistry of Penicillin, P310; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; FLOREY HW, 1949, ANTIBIOTICS, V2; FUJISHIMA Y, 1994, J MOL BIOL, V242, P712, DOI 10.1006/jmbi.1994.1622; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARSH EN, 1992, BIOCHEMISTRY-US, V31, P12648, DOI 10.1021/bi00165a015; NORRIS GE, 1994, STRUCTURE, V2, P1049, DOI 10.1016/S0969-2126(94)00108-1; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PANG CP, 1984, BIOCHEM J, V222, P789, DOI 10.1042/bj2220789; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RETEY J, 1990, ANGEW CHEM INT EDIT, V29, P355, DOI 10.1002/anie.199003551; ROACH PL, 1995, PROTEIN SCI, V4, P1007; SCOTT RA, 1992, BIOCHEMISTRY-US, V31, P4596, DOI 10.1021/bi00134a009; SRINIVASAN N, 1994, STRUCTURE, V2, P1017, DOI 10.1016/S0969-2126(94)00105-7; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; [No title captured]	30	373	386	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	1995	375	6533					700	704		10.1038/375700a0	http://dx.doi.org/10.1038/375700a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791906				2022-12-01	WOS:A1995RE57600066
J	SANCHEZGUERRERO, J; COLDITZ, GA; KARLSON, EW; HUNTER, DJ; SPEIZER, FE; LIANG, MH				SANCHEZGUERRERO, J; COLDITZ, GA; KARLSON, EW; HUNTER, DJ; SPEIZER, FE; LIANG, MH			SILICONE BREAST IMPLANTS AND THE RISK OF CONNECTIVE-TISSUE DISEASES AND SYMPTOMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; REVISED CRITERIA; WOMEN; POLYMYOSITIS; EPIDEMIOLOGY; SCLERODERMA; DERMATOMYOSITIS; CLASSIFICATION; AUGMENTATION	Background. Silicone breast implants have been linked to a variety of illnesses, the most controversial of which are connective-tissue diseases and symptoms. To study this relation, we analyzed data from 14 years of follow-up of the Nurses' Health Study cohort. Methods. Women who were free from connective-tissue disease in June 1976 were followed through May 31, 1990, before there was widespread media coverage of the possible association of breast implants and connective-tissue diseases. Information was collected through biennial and supplementary mailed questionnaires and blinded reviews of medical records with the use of standardized criteria. Relative risk, the measure of association, was defined as the incidence rate of connective-tissue disease among women with breast implants divided by the corresponding incidence rate among women without breast implants. Results. Among 87,501 women who were eligible for follow-up, 516 were confirmed as having definite connective-tissue diseases and 1183 as having breast implants (of which 876 were silicone-gel-filled, 170 saline-filled, 67 double-lumen, 14 polyurethane-coated, and 56 of unknown type). The mean (+/-SD) period of follow-up after surgery was 9.9+/-6.4 years (range, 1 month to 40.5 years). Three of the patients with definite connective-tissue disease - all had rheumatoid arthritis - had implants (one silicone-gel-filled, one saline-filled, and one double-lumen). The age-adjusted relative risk of a definite connective-tissue disease among women with any type of implant was 0.6 (95 percent confidence interval, 0.2 to 2.0), as compared with women without implants. For women with silicone-gel-filled implants, the comparable relative risk was 0.3 (95 percent confidence interval, 0 to 1.9). The relative risk of self-reported signs or symptoms of connective-tissue disease for women with implants was 1.5 (95 percent confidence interval, 0.9 to 2.4); the risk of having any 1 of 41 signs, symptoms, or laboratory features of connective-tissue disease was 0.7 (95 percent confidence interval, 0.3 to 1.6). Conclusions. In a large cohort study, we did not find an association between silicone breast implants and connective-tissue diseases, defined according to a variety of standardized criteria, or signs and symptoms of these diseases.	HARVARD UNIV,SCH MED,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,RB BRIGHAM MULTIP ARTHRIT & MUSCULOSKEL DIS CTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042630, P60AR036308] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356-08S1] Funding Source: Medline; NIAMS NIH HHS [AR42630, AR36308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P328; ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BORENSTEIN D, 1994, SEMIN ARTHRITIS RHEU, V24, P1, DOI 10.1016/0049-0172(94)90102-3; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; FESSEL WJ, 1974, ARCH INTERN MED, V134, P1027, DOI 10.1001/archinte.134.6.1027; FOX RI, 1986, SCAND J RHEUMATOL S, V61, P28; FREUNDLICH B, 1994, SEMIN ARTHRITIS RHEU, V24, P44, DOI 10.1016/0049-0172(94)90109-0; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1992, ARTHRITIS RHEUM, V35, pS65; HOCHBERG MC, 1985, ARTHRITIS RHEUM-US, V28, P80, DOI 10.1002/art.1780280113; HOCHBERG MC, 1994, ARTHRITIS RHEUM, V37, P1249; KARLSON EW, IN PRESS ANN EPIDEMI; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; STEEN V, 1988, Arthritis and Rheumatism, V31, pS57; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SYMMONS DPM, 1992, ARTHRITIS RHEUM, V35, P126; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VASEY FB, 1994, SEMIN ARTHRITIS RHEU, V24, P22, DOI 10.1016/0049-0172(94)90106-6; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; WIGLEY FM, 1992, ARTHRITIS RHEUM, V35, pS46; 1992, CAN MED ASSOC J, V147, P1141; 1993, STATA REFERENCE MANU	39	314	323	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1666	1670		10.1056/NEJM199506223322502	http://dx.doi.org/10.1056/NEJM199506223322502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760867				2022-12-01	WOS:A1995RD99600002
J	SORDINO, P; VANDERHOEVEN, F; DUBOULE, D				SORDINO, P; VANDERHOEVEN, F; DUBOULE, D			HOX GENE-EXPRESSION IN TELEOST FINS AND THE ORIGIN OF VERTEBRATE DIGITS	NATURE			English	Article							PATTERN-FORMATION; LIMB; MICE	Hox genes are essential for growth and patterning of the tetrapod limb skeleton(1-5). Mice mutant for the Hoxd-13 gene have an important delay in morphogenesis owing to reduced proliferation(2). Based on the appearance of atavisms in such mice, we suggested that modifications of Hox gene regulation may have been a source of morphological variation during the evolution of tetrapod limbs(2,6). Pectoral and pelvic fins are homologous to fore- and hindlimbs, respectively. To compare the relative importance of Hox genes during fin versus limb morphogenesis, we cloned zebrafish (Danio rerio) HoxD and HoxA complex genes and analysed their expression during fin development. The results suggest a scheme for the fin-limb transition in which the distal autopods (digits) are neomorphic structures produced by unequal proliferation of the posterior part of an ancestral appendix.	UNIV GENEVA, DEPT ZOOL & ANIM BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				duboule, denis/0000-0001-9961-2960				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; COATES M, 1991, DEV PATTERNING VERTE, P328; COATES MI, 1994, DEVELOPMENT, P169; DANE PJ, 1985, J EMBRYOL EXP MORPH, V87, P145; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; DUBOULE D, 1994, DEVELOPMENT, P135; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; GERAUDIE J, ACTA ZOOL-STOCKHOLM, V59, P85; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HOLMGREN NILS, 1952, ACTA ZOOL [STOCKHOLM], V33, P1; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; POTTHOFF T, 1993, B MAR SCI, V52, P669; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SHUBIN N, 1995, EVOL BIOL, V28, P39; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; STRAHLE U, 1993, ZEBRAFISH SCI MONITO, V2, P5; STREISINGER G, 1986, GENETICS, V112, P311; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOROGOOD P, 1991, NATO ADV SCI I A-LIF, V205, P347; TICKLE C, 1991, DEVELOPMENT, P113; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	30	277	281	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	1995	375	6533					678	681		10.1038/375678a0	http://dx.doi.org/10.1038/375678a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791900				2022-12-01	WOS:A1995RE57600059
J	XIAO, ZX; CHEN, JD; LEVINE, AJ; MODJTAHEDI, N; XING, J; SELLERS, WR; LIVINGSTON, DM				XIAO, ZX; CHEN, JD; LEVINE, AJ; MODJTAHEDI, N; XING, J; SELLERS, WR; LIVINGSTON, DM			INTERACTION BETWEEN THE RETINOBLASTOMA PROTEIN AND THE ONCOPROTEIN MDM2	NATURE			English	Article							GENE-PRODUCT; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION; COMPLEX-FORMATION; P53; TRANSACTIVATION; IDENTIFICATION; AMPLIFICATION; EXPRESSION; REPRESSION	INACTIVATION of tumour-suppressor genes leads to deregulated cell proliferation and is a key factor in human tumorigenesis. Both p53 and retinoblastoma genes are frequently mutated in human cancers(1,2), and the simultaneous inactivation of RB and p53 is frequently observed in a variety of naturally occurring human tumours(3). Furthermore, three distinct DNA tumour virus groups papovaviruses, adenoviruses and human papillomaviruses-transform cells by targeting and inactivating certain functions of both the p53 and retinoblastoma proteins(1,2). The cellular oncoprotein, Mdm2, binds to and downmodulates p53 function(4-6); its human homologue, MDM2, is amplified in certain human tumours, including sarcomas(7-9) and gliomas(10). Overproduction of Mdm2 is both tumorigenic(4) and capable of immortalizing primary rat embryo fibroblasts(11). Here we show that MDM2 interacts physically and functionally with pRB and, as with p53, inhibits pRB growth regulatory function. Therefore, both pRB and p53 can be subjected to negative regulation by the product of a single cellular proto-oncogene.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Harvard University; Harvard Medical School; Princeton University	XIAO, ZX (corresponding author), DANA FARBER CANC INST,BOSTON,MA 02115, USA.		MODJTAHEDI, Nazanine/D-4377-2017					CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDONCARDO C, 1994, CANCER RES, V54, P794; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAMEL PA, 1992, ONCOGENE, V7, P693; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	30	548	568	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					694	698		10.1038/375694a0	http://dx.doi.org/10.1038/375694a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791904				2022-12-01	WOS:A1995RE57600064
J	YUSTE, R; DENK, W				YUSTE, R; DENK, W			DENDRITIC SPINES AS BASIC FUNCTIONAL UNITS OF NEURONAL INTEGRATION	NATURE			English	Article							CALCIUM; TRANSMISSION; POTENTIATION; RESPONSES; SLICES; BRAIN	MOST excitatory synaptic connections occur on dendritic spines(1). Calcium imaging experiments have suggested that spines constitute individual calcium compartments(2,3), but recent results have challenged this idea(4,5). Using two-photon microscopy(6) to image fluorescence with high resolution in strongly scattering tissue, we measured calcium dynamics in spines from CA1 pyramidal neurons in slices of rat hippocampus. Subthreshold synaptic stimulation and spontaneous synaptic events produced calcium accumulations that were localized to isolated spines, showed stochastic failure, and were abolished by postsynaptic blockers, Single somatic spikes induced fast-peaking calcium accumulation in spines throughout the cell. Pairing of spikes with synaptic stimulation was frequently cooperative, that is, it resulted in supralinear calcium accumulations. We conclude: (1) calcium channels exist in spine heads; (2) action potentials invade the spines; (3) spines are individual calcium compartments; and (4) spines can individually detect the temporal coincidence of pre- and postsynaptic activity, and thus serve as basic functional units of neuronal integration.	AT&T BELL LABS,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P553, DOI 10.1113/jphysiol.1954.sp005128; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; Goppert-Mayer M., 1931, ANN PHYS-NEW YORK, V401, P273, DOI DOI 10.1002/ANDP.19314010303; GUTHRIE PB, 1991, NATURE, V354, P78; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1985, ELECTRICAL ACTIVITY; LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6; MAJOR G, 1993, BIOPHYS J, V65, P423, DOI 10.1016/S0006-3495(93)81037-3; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MCNAUGHTON BL, 1977, J COMP NEUROL, V175, P439, DOI 10.1002/cne.901750404; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, NATURE, V263, P529; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; SOBEL EC, 1994, SCIENCE, V263, P823, DOI 10.1126/science.263.5148.823; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; SVAASAND LO, 1983, PHOTOCHEM PHOTOBIOL, V38, P293, DOI 10.1111/j.1751-1097.1983.tb02674.x; TANK DW, IN PRESS J NEUROSCI; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	31	688	705	1	52	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					682	684		10.1038/375682a0	http://dx.doi.org/10.1038/375682a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791901				2022-12-01	WOS:A1995RE57600060
J	DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR				DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR			BLOOD-STREAM INFECTIONS ASSOCIATED WITH A NEEDLELESS INTRAVENOUS-INFUSION SYSTEM IN PATIENTS RECEIVING HOME INFUSION THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.- To determine risk factors for bloodstream infections (BSIs) in an outbreak among patients receiving home intravenous infusion therapy. Design.- Case-control and retrospective cohort studies. Setting - Home health agency. Patients.- Patients receiving home intravenous infusion therapy from Rhode Island Home Therapeutics (RIHT) from January through December 1993. Main Outcome Measure.- Development of primary BSI. Methods.- We compared patients with BSI (ie, case patients) with randomly selected noninfected RIHT patients receiving intravenous therapy, conducted a cohort study of all RIHT patients receiving intravenous therapy via a central venous catheter (CVC), and conducted a culture survey of injection cap luminal fluid. Results.- Case patients were more likely than controls to have had therapy via a CVC (11/11 vs 14/32; odds ratio [OR] undefined; P<.001) or total parenteral nutrition and intralipid therapy (TPN/IL) (9/11 vs 3/32; OR, 43.5; 95% confidence interval [CI], 4.9 to 510.0). Among RIHT patients with CVCs, risk factors for BSI were receipt of TPN/IL (9/35 vs 2/67; rate ratio [RR], 8.6; 95% CI, 2.0 to 37.7) or use of a needleless infusion system (10/41 vs 1/61; RR, 14.9; 95% CI, 2.0 to 111.8). Only the combination of both exposures was significantly associated with development of a BSI (P<.001). Luminal fluid from injection caps of needleless devices was significantly more likely to be culture positive than fluid from protected-needle devices (5/23 vs 0/18; RR undefined; P=.04). Conclusions.- Our data suggest that a needleless device used for TPN/IL was associated with increased risk of BSI when injection caps were changed every 7 days.	RHODE ISL HOME THERAPEUT,E PROVIDENCE,RI		DANZIG, LE (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.		Mahoney, William/GQB-0802-2022					BENSON JS, 1992, FDA SAFETY ALERT NEE; DEAN AG, 1991, EPIINFO VERSION 5 01; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARTNER K, 1993, AM J INFECT CONTROL, V20, P75; GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176, DOI 10.1128/CMR.6.2.176-192.1993; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P607, DOI 10.1001/jama.272.8.607; JARVIS WR, 1991, AM J MED, V91, pS101, DOI 10.1016/0002-9343(91)90352-X; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Maki DG, 1992, HOSP INFECT, P849; MENDELSON H, 1992, 33RD INT C ANT AG CH; SIMMONS BP, 1982, GUIDELINE PREVENTION; SKOLNICK R, 1993, AM J INFECT CONTROL, V21, P39, DOI 10.1016/0196-6553(93)90206-J; WILLIAMS WW, 1985, JPEN-PARENTER ENTER, V9, P735, DOI 10.1177/0148607185009006735; 1990, SAS PROCEDURES GUIDE	15	101	102	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1862	1864		10.1001/jama.273.23.1862	http://dx.doi.org/10.1001/jama.273.23.1862			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776503				2022-12-01	WOS:A1995RD11600029
J	PIMENTA, W; KORYTKOWSKI, M; MITRAKOU, A; JENSSEN, T; YKIJARVINEN, H; EVRON, W; DAILEY, G; GERICH, J				PIMENTA, W; KORYTKOWSKI, M; MITRAKOU, A; JENSSEN, T; YKIJARVINEN, H; EVRON, W; DAILEY, G; GERICH, J			PANCREATIC BETA-CELL DYSFUNCTION AS THE PRIMARY GENETIC LESION IN NIDDM - EVIDENCE FROM STUDIES IN NORMAL GLUCOSE-TOLERANT INDIVIDUALS WITH A FIRST-DEGREE NIDDM RELATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; INDUCED INSULIN RELEASE; BODY-FAT DISTRIBUTION; PIMA-INDIANS; GLYCOGEN-SYNTHASE; INCREASED RISK; ISLET FUNCTION; RESISTANCE; SENSITIVITY; SECRETION	Objective.- To test the hypothesis that insulin resistance precedes impaired insulin secretion in individuals genetically predisposed to non-insulin-dependent diabetes mellitus (NIDDM). Design.- Case-control study. Setting.- Outpatient facility of clinical research center. Participants.- One hundred volunteers of European ancestry having normal glucose tolerance, 50 with and 50 without a first-degree NIDDM relative, matched for age, sex, and degree of obesity. Main Outcome Measures.- Insulin secretion and insulin sensitivity assessed by hyperglycemic (N=100) and euglycemic-hyperinsulinemic (N=62) clamp experiments. Results.- The individuals with a first-degree NIDDM relative had reduced first-and second-phase insulin responses (mean+/-SEM, 939+/-68 vs 1209+/-82 pmol/L, and 322+/-19 vs 407+/-24 pmol/L, respectively, P=.001 and .01), but their insulin sensitivity (148+/-6 and 92+/-6 nmol . kg(-1). min(-1)/pmol . L(-1) in hyperglycemic and euglycemic clamp studies) did not differ from that of the control group (126+/-5 and 81+/-7 nmol . kg(-1). min(-1)/pmol . L(-1), in hyperglycemic and euglycemic clamp studies, P=.07 and .24, respectively). In some individuals only first- or only second-phase insulin responses were reduced. Conclusion.- In this study population, heterogeneous defects in insulin secretion were demonstrated, while defects in insulin sensitivity were not evident. We therefore conclude that since the earliest defects identified in a group genetically at high risk to develop NIDDM are those related to insulin secretion, defects in insulin secretion rather than insulin sensitivity are likely the major genetic factor predisposing to development of NIDDM.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA; UNIV ATHENS,DEPT INTERNAL MED PROPAEDEUT 2,ATHENS,GREECE; UNIV TROMSO HOSP,DEPT MED,TROMSO,NORWAY; HELSINKI UNIV,DEPT MED 2,HELSINKI,FINLAND; SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National & Kapodistrian University of Athens; UiT The Arctic University of Tromso; University Hospital of North Norway; University of Helsinki; Scripps Research Institute					NCRR NIH HHS [M501 RR00056, M501 RR00044] Funding Source: Medline; NIDDK NIH HHS [DK20411] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056, M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020411, R37DK020411] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1991, DIABETOLOGIA, V34, P483, DOI 10.1007/BF00403284; ARONOFF SL, 1977, DIABETES, V26, P827, DOI 10.2337/diabetes.26.9.827; BAK JF, 1992, DIABETOLOGIA, V35, P777; BANERJI MA, 1989, DIABETES, V38, P784, DOI 10.2337/diabetes.38.6.784; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BARNETT AH, 1981, BRIT MED J, V282, P1656, DOI 10.1136/bmj.282.6277.1656; BEARD JC, 1987, J CLIN ENDOCR METAB, V65, P59, DOI 10.1210/jcem-65-1-59; Berntorp K, 1985, Diabetes Res, V2, P151; BOBERG J, 1976, SCAND J CLIN LAB INV, V36, P145, DOI 10.3109/00365517609055241; BODEN G, 1968, J CLIN INVEST, V47, P729, DOI 10.1172/JCI105768; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BONORA E, 1984, DIABETES METAB, V10, P250; CAMPBELL PJ, 1988, METABOLISM, V37, P15, DOI 10.1016/0026-0495(88)90023-6; CARLES M, 1991, DIABETES, V40, P796; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P330, DOI 10.1530/acta.0.0550330; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; COLWELL JA, 1967, DIABETES, V16, P560, DOI 10.2337/diab.16.8.560; DAWKE H, 1968, DIABETOLOGIA, V4, P349; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EFENDIC S, 1971, METABOLISM, V20, P568, DOI 10.1016/0026-0495(71)90005-9; ELBEIN SC, 1991, DIABETES, V40, P1024, DOI 10.2337/diabetes.40.8.1024; ENSINCK J, 1976, CLIN RES, V24, pA155; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FUJITA Y, 1975, DIABETES, V24, P17, DOI 10.2337/diabetes.24.1.17; GERICH JE, 1988, BAILLIERE CLIN ENDOC, V2, P307, DOI 10.1016/S0950-351X(88)80034-X; GINSBERG H, 1981, DIABETES, V30, P739, DOI 10.2337/diab.30.9.739; GOTTLIEB MS, 1974, DIABETES, V23, P684, DOI 10.2337/diab.23.8.684; GRODSKY GM, 1965, LANCET, V1, P290; GULLI G, 1992, DIABETES, V41, P1575, DOI 10.2337/diabetes.41.12.1575; HAFFNER SM, 1986, NEW ENGL J MED, V315, P220, DOI 10.1056/NEJM198607243150403; HAMMAN RF, 1992, DIABETES METAB REV, V8, P287, DOI 10.1002/dmr.5610080402; HANDBERG A, 1993, DIABETOLOGIA, V36, P668, DOI 10.1007/BF00404079; HARRIS H, 1950, ANN EUGENIC, V15, P95; HENIKSEN J, 1994, J CLIN INVEST, V94, P1196; HO LT, 1989, DIABETIC MED, V7, P31; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; ISELIUS L, 1985, CLIN GENET, V28, P8; JACKSON WPU, 1972, LANCET, V1, P1040; JOHNSTON C, 1990, DIABETIC MED, V7, P119, DOI 10.1111/j.1464-5491.1990.tb01345.x; KALANT N, 1979, DIABETOLOGIA, V16, P365, DOI 10.1007/BF01223156; KELLER U, 1979, SCHWEIZ MED WSCHR, V109, P595; KOBBERLING J, 1990, WORLD REV NUTR DIET, P102; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; LEMIEUX S, 1992, DIABETOLOGIA, V35, P653, DOI 10.1007/BF00400258; LERNER RL, 1972, J CLIN INVEST, V51, P1624, DOI 10.1172/JCI106963; LESLIE RDG, 1988, DIABETES NUTR METAB, V3, P235; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MANDARINO L, 1984, DIABETOLOGIA, V27, P358, DOI 10.1007/BF00304850; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MITRAKOU A, 1992, J CLIN ENDOCR METAB, V75, P379, DOI 10.1210/jc.75.2.379; NESHER R, 1987, EUR J CLIN INVEST, V17, P266, DOI 10.1111/j.1365-2362.1987.tb01247.x; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; ORAHILLY SP, 1986, LANCET, V2, P360; OSEI K, 1991, DIABETES CARE, V14, P890, DOI 10.2337/diacare.14.10.890; PAULSEN EP, 1968, DIABETES, V17, P261, DOI 10.2337/diab.17.5.261; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; POZEFSKY T, 1973, J CLIN INVEST, V52, P1608, DOI 10.1172/JCI107338; PYKE DA, 1967, BRIT MED J, V4, P21, DOI 10.1136/bmj.4.5570.21; RAMACHANDRAN A, 1990, DIABETIC MED, V7, P331, DOI 10.1111/j.1464-5491.1990.tb01400.x; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICKETTS HT, 1966, DIABETES, V15, P880, DOI 10.2337/diab.15.12.880; ROJAS L, 1969, J CLIN ENDOCR METAB, V29, P1569, DOI 10.1210/jcem-29-12-1569; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; RULL AJ, 1970, DIABETES, V19, P1; SAAD MF, 1991, AM J MED, V90, P229; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; SELTZER HS, 1967, J CLIN INVEST, V46, P323, DOI 10.1172/JCI105534; SERRANORIOS M, 1970, DIABETOLOGIA, V6, P392, DOI 10.1007/BF01212071; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; SIMPSON RG, 1968, DIABETES, V17, P684, DOI 10.2337/diab.17.11.684; SIPERSTEIN MD, 1968, J CLIN INVEST, V47, P1973, DOI 10.1172/JCI105886; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SOELDNER S, 1968, DIABETES, V17, P17; SONKSEN PH, 1973, DIABETOLOGIA, V9, P426, DOI 10.1007/BF01239440; STAFFEL M, 1992, NATURE, V2, P153; TAYLOR S, 1994, DIABETES, V43, P785; TURNER RC, 1988, BAILLIERE CLIN ENDOC, V2, P327, DOI 10.1016/S0950-351X(88)80035-1; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VAAG A, 1995, J CLIN INVEST, V95, P690, DOI 10.1172/JCI117715; VIGNERI R, 1976, DIABETES, V25, P167, DOI 10.2337/diabetes.25.3.167; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WELBORN TA, 1966, LANCET, V1, P280; YKIJARVINEN H, 1990, ANN MED, V22, P197, DOI 10.3109/07853899009147269; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415; Zar JH., 1999, BIOSTAT ANAL, V4; 1985, WHO TECH REP SER, V727, P9	93	313	326	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1855	1861		10.1001/jama.273.23.1855	http://dx.doi.org/10.1001/jama.273.23.1855			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776502				2022-12-01	WOS:A1995RD11600028
J	VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE				VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE			COST OF PATIENT FOLLOW-UP AFTER POTENTIALLY CURATIVE COLORECTAL-CANCER TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE SURVEILLANCE; CARCINOMA; COLON; RESECTION; SURGERY; RECTUM; RECURRENCE; MUTATIONS	Objective.- To estimate the cost of follow-up among colorectal cancer patients treated with curative intent based on the broad spectrum of surveillance strategies suggested in the literature. Design.- Economic analysis of the costs associated with 11 separate surveillance strategies. Charge data were obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file. Setting.- Ambulatory care. Main Outcome Measures.- Medicare-allowed charges and an actual-charge proxy for 5 years of follow-up after treatment for colorectal cancer patients on a nationwide basis. Results.- Medicare-allowed charges varied widely for the 5 years of posttreatment follow-up from a low of $561 to a high of $16 492. When Medicare-allowed charges were converted to a proxy for actual charges using a conversion ratio of 1.62, the range was $910 to $26 717, a 28-fold difference in charges. Conclusions.- Charges vary extensively across follow-up strategies, with no indication that higher-cost strategies increase survival or quality of life.	DEPT VET AFFAIRS MED CTR, SURG SERV, ST LOUIS, MO USA		VIRGO, KS (corresponding author), ST LOUIS UNIV, HLTH SCI CTR, DEPT SURG, 3635 VISTA AVE, POB 15250, ST LOUIS, MO 63110 USA.		Virgo, Katherine S/AAG-3188-2021	Virgo, Katherine S/0000-0002-2069-0585				Adloff M, 1989, Chirurgie, V115, P228; ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; BEART RW, 1983, MAYO CLIN PROC, V58, P361; BERNSTAM VA, 1992, HDB GENE LEVEL DIAGN; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BUHLER H, 1984, CANCER, V54, P791, DOI 10.1002/1097-0142(19840901)54:5<791::AID-CNCR2820540502>3.0.CO;2-R; BUIE WD, 1993, GASTROINTEST ENDOSC, V3, P691; CALI RL, 1993, DIS COLON RECTUM, V36, P388, DOI 10.1007/BF02053945; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEVENEY KE, 1984, AM J SURG, V148, P717, DOI 10.1016/0002-9610(84)90423-9; FISCHER DS, 1983, FOLLOW UP CANCER HDB, P4; FISCHER DS, 1992, FOLLOW UP CANCER HDB, P34; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; JUHL G, 1990, WORLD J SURG, V14, P255, DOI 10.1007/BF01664886; KELLY CJ, 1992, CANCER-AM CANCER SOC, V70, P1397, DOI 10.1002/1097-0142(19920901)70:3+<1397::AID-CNCR2820701531>3.0.CO;2-A; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Makela J, 1992, Surg Oncol, V1, P157, DOI 10.1016/0960-7404(92)90029-K; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NAVA HR, 1982, CANCER, V49, P1043, DOI 10.1002/1097-0142(19820301)49:5<1043::AID-CNCR2820490533>3.0.CO;2-Y; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; OVASKA J, 1990, GASTROENTEROLOGY, V99, P1849; OVASKA JT, 1989, SCAND J GASTROENTERO, V24, P416, DOI 10.3109/00365528909093068; ROBERTS PJ, 1988, SCAND J GASTROENTERO, V23, P50, DOI 10.3109/00365528809096956; ROCKLIN MS, 1990, AM SURGEON, V56, P22; SAFI F, 1993, CANCER DETECT PREV, V17, P417; SANDLER RS, 1984, CANCER, V53, P193, DOI 10.1002/1097-0142(19840101)53:1<193::AID-CNCR2820530134>3.0.CO;2-V; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STEELE G, 1991, WORLD J SURG, V15, P583, DOI 10.1007/BF01789202; STEELE G, 1986, COLORECTAL CANCER; SUGARBAKER PH, 1987, SURGERY, V102, P79; TORNQVIST A, 1982, BRIT J SURG, V69, P725, DOI 10.1002/bjs.1800691213; VERNAVA AM, 1994, DIS COLON RECTUM, V37, P573, DOI 10.1007/BF02050993; VIRGO KS, IN PRESS ANN SURG ON; 1992, DIS COLON RECTUM, V35, P389; 1994, JAMA-J AM MED ASSOC, V271, P1587; 1960, CONSUMER PRICE INDEX	37	121	123	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1837	1841		10.1001/jama.273.23.1837	http://dx.doi.org/10.1001/jama.273.23.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776499				2022-12-01	WOS:A1995RD11600025
J	ARMSTRONG, DS; GRIMWOOD, K; CARZINO, R; CARLIN, JB; OLINSKY, A; PHELAN, PD				ARMSTRONG, DS; GRIMWOOD, K; CARZINO, R; CARLIN, JB; OLINSKY, A; PHELAN, PD			LOWER RESPIRATORY-INFECTION AND INFLAMMATION IN INFANTS WITH NEWLY-DIAGNOSED CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne			Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020; Grimwood, Keith/F-9334-2011	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Grimwood, Keith/0000-0003-3174-9834				ABMAN SH, 1991, J PEDIATR-US, V119, P211, DOI 10.1016/S0022-3476(05)80729-2; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; KAHN FW, 1987, J INFECT DIS, V155, P862, DOI 10.1093/infdis/155.5.862; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331	5	269	273	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1571	1572		10.1136/bmj.310.6994.1571	http://dx.doi.org/10.1136/bmj.310.6994.1571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787647	Green Published			2022-12-01	WOS:A1995RE35300021
J	BIANCHI, G; SWALES, JD				BIANCHI, G; SWALES, JD			DO WE NEED MORE ANTIHYPERTENSIVE DRUGS - LESSONS FROM THE NEW BIOLOGY	LANCET			English	Editorial Material							SODIUM SENSITIVITY; BLOOD-PRESSURE; RESISTANCE		LEICESTER ROYAL INFIRM,DEPT MED,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV MILAN,OSPED SAN RAFFAELE,CATTEDRA NEFROL,I-20127 MILAN,ITALY	University of Leicester; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele				Bianchi, Giuseppe/0000-0002-8365-3618				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; HARRAP S, 1994, LANCET, V344, P167; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; KAPLAN NM, 1994, TXB HYPERTENSION, P811; KURTZ TW, 1994, LANCET, V344, P167, DOI 10.1016/S0140-6736(94)92761-8; LINDHOLM L, 1984, ACTA MED SCAND, V21, P251; LUFT FC, 1982, AM J MED, V72, P726, DOI 10.1016/0002-9343(82)90537-X; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SWALES JD, 1994, LANCET, V344, P380; SWALES JD, 1993, J HYPERTENS       S5, V2, pS59; WEINBERGER MH, 1987, HYPERTENSION, V10, P443, DOI 10.1161/01.HYP.10.4.443; 1984, HYPERTENSION S1, V6, P198; 1991, NEW ENGL J MED, V325, P293; 1994, NAT GENET, V7, P217	14	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1555	1557		10.1016/S0140-6736(95)91094-8	http://dx.doi.org/10.1016/S0140-6736(95)91094-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791444				2022-12-01	WOS:A1995RD79000016
J	BLACK, JA; DEBELLE, GD				BLACK, JA; DEBELLE, GD			FEMALE GENITAL MUTILATION IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							CIRCUMCISION	Much has been written about female genital mutilation in Africa, but little attention has been paid to its existence in Britain. Though it has been illegal in this country since 1985, it is practised secretly or children are sent abroad to have the operation. From the social worker's point of view it is technically a form of child abuse which poses special problems. Black and Debelle review the historical background of female genital mutilation and describe its medical complications. Gallard discusses the problem in France, and Walder considers why such mutilation still continues in Britain.	S BIRMINGHAM HLTH AUTHOR,CHILDRENS SERV UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND		BLACK, JA (corresponding author), VICTORIA MILL HOUSE,WOODBRIDGE IP13 9EG,SUFFOLK,ENGLAND.							[Anonymous], 1991, CHILDREN ACT 1989; DIRIE MA, 1991, TROP DOCT, V21, P146, DOI 10.1177/004947559102100404; Dorkeno E., 1992, FEMALE GENITAL MUTIL; FAYYAD S, 1993, VOICES, P102; HEDLEY R., 1992, CHILD PROTECTION FEM; KORBIN JE, 1991, CHILD ABUSE NEGLECT, V15, P67, DOI 10.1016/0145-2134(91)90010-B; LADJALI M, 1993, BRIT MED J, V307, P460, DOI 10.1136/bmj.307.6902.460; RICHARDS T, 1993, BRIT MED J, V307, P957; SAMI IR, 1986, ANN TROP PAEDIATR, V6, P99, DOI 10.1080/02724936.1986.11748419; WEBB E, 1994, ARCH DIS CHILD, V70, P441, DOI 10.1136/adc.70.5.441; 1986, WHO CHRON, V40, P31	11	62	62	0	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1590	1592		10.1136/bmj.310.6994.1590	http://dx.doi.org/10.1136/bmj.310.6994.1590			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787654	Green Published			2022-12-01	WOS:A1995RE35300029
J	CUZICK, J; SZAREWSKI, A; TERRY, G; HO, L; HANBY, A; MADDOX, P; ANDERSON, M; KOCJAN, G; STEELE, ST; GUILLEBAUD, J				CUZICK, J; SZAREWSKI, A; TERRY, G; HO, L; HANBY, A; MADDOX, P; ANDERSON, M; KOCJAN, G; STEELE, ST; GUILLEBAUD, J			HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING	LANCET			English	Article							TYPE-16; WOMEN; DNA	Several studies have examined the role of tests for human papillomavirus (HPV) We looked at HPV testing for types 16, 18, 31, and 33 on material taken at the time of a cervical smear in 2009 eligible women having routine screening. Women with any degree of dyskaryosis or high levels of one of these HPV types were referred for colposcopy. 44% of the cervical intraepithelial neoplasia (CIN) lesions of grade 2/3 detected had negative cytology and were found only by HPV testing. A further 22% of the CIN 2/3 lesions were positive for HPV but showed only borderline or mild cytological changes. The positive predictive value of HPV testing was 42%, which was similar to that for moderate dyskaryosis. HPV types 16 and 31 were more sensitive and specific for CIN 2/3 than were types 18 or 33. However, 25% of the CIN 2/3 lesions were not detected by these four HPV tests. We suggest that HPV testing could usefully augment but not replace conventional cytology. These results should stimulate a much larger randomised trial to assess the impact of these improved CIN 2/3 detection rates on the subsequent incidence of invasive cancer.	IMPERIAL CANC RES FUND, DEPT HISTOPATHOL, LONDON WC2A 3PX, ENGLAND; UNIV NOTTINGHAM HOSP, DEPT HISTOPATHOL, NOTTINGHAM NG7 2UH, ENGLAND; UCL, SCH MED, DEPT HISTOPATHOL, LONDON W1N 8AA, ENGLAND; UCL, SCH MED, DEPT CYTOL, LONDON W1N 8AA, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND; MARGARET PYKE CTR FAMILY PLANNING & REPROD HLTH C, LONDON, ENGLAND	Cancer Research UK; University of Nottingham; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London	CUZICK, J (corresponding author), IMPERIAL CANC RES FUND, DEPT MATH STAT & EPIDEMIOL, LONDON WC2A 3PX, ENGLAND.							BAVIN PJ, 1993, BRIT J CANCER, V67, P602, DOI 10.1038/bjc.1993.110; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; HECHT JL, 1995, INT J CANCER, V60, P369, DOI 10.1002/ijc.2910600317; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Meijer C J, 1992, IARC Sci Publ, P271; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; SLATER DN, 1994, J CLIN PATHOL, V47, P27, DOI 10.1136/jcp.47.1.27; SZAREWSKI A, 1993, ACTA CYTOL, V37, P457; TERRY G, 1994, CLIN CHEM, V40, P1890; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; VANWIJNGAARDEN WJ, 1995, BRIT J OBSTET GYNAEC, V102, P137	14	289	296	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 17	1995	345	8964					1533	1536		10.1016/S0140-6736(95)91086-7	http://dx.doi.org/10.1016/S0140-6736(95)91086-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791438				2022-12-01	WOS:A1995RD79000008
J	EMMETT, PM; HEATON, KW				EMMETT, PM; HEATON, KW			IS EXTRINSIC SUGAR A VEHICLE FOR DIETARY-FAT	LANCET			English	Article							11-12-YEAR-OLD ENGLISH CHILDREN; ENERGY; QUESTIONNAIRE; WOMEN	Although many guidelines to healthy eating recommend restriction of the intake of extrinsic (refined) sugar, there are concerns that such restriction might result in an increase in the amount and the proportion of dietary fats with a consequent possible increase in the risk of cardiovascular disease. We used regression analysis to examine the determinants of fat intake in subjects from a population survey who had weighed their food for 4 days. In men (n=77) acid women (n=83), fat eaten was positively related to the intake of extrinsic sugar. When intakes were expressed as percent of calories the relation became negative. A survey in a semi-random sample of 739 men aged 40-69 yr and 976 women aged 25-69 yr showed that, in both sexes, an increase in extrinsic sugar was a linear increase in the intake of and hence of fat combined with carbohydrate. This was due mainly to a higher intake of cakes and biscuits. Foods containing sugar and fat provided an extra 12.0 g per day of fat in the men and 13.8 g per day in the women when the highest quartile of extrinsic sugar consumers were compared with the lowest quartile. We conclude that lowering the intake of extrinsic sugar is unlikely to be associated with higher fat intake. Instead extrinsic sugar may act as a vehicle for fat intake, encouraging consumption by making the fat more palatable.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary; University of Bristol			Emmett, Pauline/AAL-6815-2021	Emmett, Pauline/0000-0003-1076-4779				ADAMSON AJ, 1992, J HUM NUTR DIET, V5, P371, DOI 10.1111/j.1365-277X.1992.tb00177.x; BARKER M E, 1988, Journal of Human Nutrition and Dietetics, V1, P179, DOI 10.1111/j.1365-277X.1988.tb00187.x; BINGHAM S, 1991, P NUTR SOC, V50, pA32; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EMMETT PM, 1993, EUR J CLIN NUTR, V47, P20; GIBNEY MJ, 1980, J HUM NUTR DIET, V3, P245; Gregory F., 1990, DIETARY NUTR SURVEY; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Pryer J. A., 1994, Proceedings of the Nutrition Society, V53, p235A; RUGGGUNN AJ, 1993, J HUM NUTR DIET, V6, P419, DOI 10.1111/j.1365-277X.1993.tb00387.x; WILES SJ, 1980, J HUM NUTR, V34, P189; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1992, GOOD DIETARY PRACTIC, V3, P1; 1992, HLTH NATION STRATEGY; 1991, REPORTS HLTH SOCIAL, V41; 1989, REPORTS HLTH SOCIAL, V37	21	46	46	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1537	1540		10.1016/S0140-6736(95)91087-5	http://dx.doi.org/10.1016/S0140-6736(95)91087-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791439				2022-12-01	WOS:A1995RD79000009
J	GALE, CR; MARTYN, CN; WINTER, PD; COOPER, C				GALE, CR; MARTYN, CN; WINTER, PD; COOPER, C			VITAMIN-C AND RISK OF DEATH FROM STROKE AND CORONARY HEART-DISEASE IN COHORT OF ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-CHOLESTEROL CONCENTRATION; FOLLOW-UP; MORTALITY; CONSUMPTION; ATHEROSCLEROSIS; WHITEHALL; FRUIT; MEN	Objectives-To determine whether vitamin C status, as measured by dietary intake and plasma ascorbic acid concentration, is related to mortality from stroke and coronary heart disease in people aged 65 and over. Design-A 20 year follow up study of a cohort of randomly selected elderly people living in the community who had taken part in the 1973-4 Department of Health and Social Security nutritional survey and for whom dietary and other data had been recorded. Setting-Eight areas in Britain (five in England, two in Scotland, and one in Wales). Subjects-730 men and women who had completed a seven day dietary record and who had no history or symptoms of stroke, cerebral arteriosclerosis, or coronary heart disease when examined by a geriatrician in 1973-4. Results-Mortality from stroke was highest in those with the lowest vitamin C status. Those in the highest third of the distribution of vitamin C intake had a relative risk of 0.5 (95% confidence interval 0.3 to 0.8) compared with those in the lowest third, after adjustment for age, sex, and established cardiovascular risk factors. The relation between Vitamin C intake and stroke was independent of social class and other dietary variables. A similar gradient in risk was present for plasma ascorbic acid concentrations. No association was found between vitamin C status and risk of death from coronary heart disease. Conclusion-In elderly people vitamin C concentration, whether measured by dietary intake or plasma concentration of ascorbic acid, is strongly related to subsequent risk of death from stroke but not from coronary heart disease.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton			Gale, Catharine R/B-1653-2012					ACHESON RM, 1983, LANCET, V1, P1191; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARMSTRONG BK, 1975, J CHRON DIS, V28, P455, DOI 10.1016/0021-9681(75)90056-9; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; JAJICH CL, 1984, JAMA-J AM MED ASSOC, V252, P2831, DOI 10.1001/jama.252.20.2831; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MANSON JE, 1992, CIRCULATION, V85, P865; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Roe JH, 1943, J BIOL CHEM, V147, P399; ROSE G, 1980, LANCET, V1, P523; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHIPLEY MJ, 1991, BRIT MED J, V303, P89, DOI 10.1136/bmj.303.6794.89; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WINAWER SJ, 1990, JAMA-J AM MED ASSOC, V263, P2083, DOI 10.1001/jama.263.15.2083; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	22	231	238	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1563	1566		10.1136/bmj.310.6994.1563	http://dx.doi.org/10.1136/bmj.310.6994.1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787644	Green Published, Green Submitted			2022-12-01	WOS:A1995RE35300018
J	GALLARD, C				GALLARD, C			FEMALE GENITAL MUTILATION IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article											GALLARD, C (corresponding author), FRENCH FAMILY PLANNING ASSOC,4 IRENEE SQ,F-75011 PARIS,FRANCE.							HOSKEN F, 1994, LIVRE IMAGES UNIVERS; 1993, MUTILATIONS SEXUELLE; EXCISION SA PRESENCE	3	25	25	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1592	1593		10.1136/bmj.310.6994.1592	http://dx.doi.org/10.1136/bmj.310.6994.1592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787655	Green Published			2022-12-01	WOS:A1995RE35300030
J	GOLDBERG, S; SAVAGE, MP; FISCHMAN, DL				GOLDBERG, S; SAVAGE, MP; FISCHMAN, DL			CORONARY-ARTERY STENTS	LANCET			English	Editorial Material							ANGIOPLASTY; OCCLUSION				GOLDBERG, S (corresponding author), JEFFERSON MED COLL,PHILADELPHIA,PA 19107, USA.							COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DEFEYTER PJ, 1992, AM HEART J, V123, P1633, DOI 10.1016/0002-8703(92)90818-G; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; HERRMANN HC, 1992, CIRCULATION, V86, P812, DOI 10.1161/01.CIR.86.3.812; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SRIDHAR K, 1994, CIRCULATION, V90, P1; SUTTON JM, 1994, CIRCULATION, V89, P1126, DOI 10.1161/01.CIR.89.3.1126; WALLER BF, 1989, J AM COLL CARDIOL, V13, P969, DOI 10.1016/0735-1097(89)90248-9	12	7	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1523	1524		10.1016/S0140-6736(95)91083-2	http://dx.doi.org/10.1016/S0140-6736(95)91083-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791436	Bronze			2022-12-01	WOS:A1995RD79000005
J	HARDEN, PN; GEDDES, C; ROWE, PA; MCILROY, JH; BOULTONJONES, M; RODGER, RSC; JUNOR, BJR; BRIGGS, JD; CONNELL, JMC; JARDINE, AG				HARDEN, PN; GEDDES, C; ROWE, PA; MCILROY, JH; BOULTONJONES, M; RODGER, RSC; JUNOR, BJR; BRIGGS, JD; CONNELL, JMC; JARDINE, AG			POLYMORPHISMS IN ANGIOTENSIN-CONVERTING-ENZYME GENE AND PROGRESSION OF IGA NEPHROPATHY	LANCET			English	Note							QUESTIONNAIRE; SUGARS; WOMEN	We have investigated the influence of the functional insertion (I) and deletion (D) polymorphism in intron 16 of the gene for angiotensin-converting enzyme (ACE) in a retrospective study of 100 patients with IgA nephropathy. There was no difference in genotype frequency compared with normal subjects. However, patients homozygous for the D allele tended to present at an earlier age (medians: DD, 33; ID, 34; II, 42 years) and to require renal replacement therapy at a younger age (medians 37, 42, and 48 years, respectively). The rate of progression was significantly worse in patients homozygous for the D allele. The DD genotype is associated with increased severity of disease in patients with IgA nephropathy.	WESTERN INFIRM & ASSOCIATED HOSP,RENAL UNIT,GLASGOW,LANARK,SCOTLAND; ROYAL INFIRM,RENAL UNIT,GLASGOW,LANARK,SCOTLAND; ROYAL INFIRM,DEPT CLIN BIOCHEM,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT MED,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow			Jardine, Alan/L-5770-2019	Jardine, Alan/0000-0001-5815-9370				ADAMSON AJ, 1980, J HUM NUTRDIET, V5, P371; BARKER M E, 1988, Journal of Human Nutrition and Dietetics, V1, P179, DOI 10.1111/j.1365-277X.1988.tb00187.x; BINGHAM S, 1991, P NUTR SOC, V50, pA32; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EMMETT PM, 1993, EUR J CLIN NUTR, V47, P20; GIBNEY MJ, 1980, J HUM NUTR DIET, V3, P245; Gregory F., 1990, DIETARY NUTR SURVEY; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Pryer J. A., 1994, Proceedings of the Nutrition Society, V53, p235A; RUGGGUNN AJ, 1993, J HUM NUTR DIET, V6, P419, DOI 10.1111/j.1365-277X.1993.tb00387.x; WILES SJ, 1980, J HUM NUTR, V34, P189; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1992, GOOD DIETARY PRACTIC, V3, P1; 1992, HLTH NATION STRATEGY; 1991, REPORTS HLTH SOCIAL, V41; 1989, REPORTS HLTH SOCIAL, V37	21	225	232	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1540	1542		10.1016/S0140-6736(95)91088-3	http://dx.doi.org/10.1016/S0140-6736(95)91088-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791440				2022-12-01	WOS:A1995RD79000010
J	KHAW, KT; WOODHOUSE, P				KHAW, KT; WOODHOUSE, P			INTERRELATION OF VITAMIN-C, INFECTION, HEMOSTATIC FACTORS, AND CARDIOVASCULAR-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; SEASONAL-VARIATION; E CONSUMPTION; RISK FACTOR; MORTALITY; STROKE; POPULATION; PREVENTION; FIBRINOGEN	Objective-To examine the hypothesis that the increase in fibrinogen concentration and respiratory infections in winter is related to seasonal variations in vitamin C status (assessed with serum ascorbate concentration). Design-Longitudinal study of individuals seen at intervals of two months over one year. Setting-Cambridge. Subjects-96 men and women aged 65-74 years living in their own homes. Main outcome measures-Haemostatic factors fibrinogen and factor VIIC; acute phase proteins; respiratory symptoms; respiratory function. Results-Mean dietary intake of vitamin C varied from about 65 mg/24 h in winter to 90 mg/24 h in summer; mean serum ascorbate concentration ranged from 50 mu mol/l in winter to 60 mu mol/l in summer. Serum ascorbate concentration was strongly inversely related to haemostatic factors fibrinogen and factor VIIC as well as to acute phase proteins but not to self reported respiratory symptoms or neutrophil count. Serum ascorbate concentration was also related positively to forced expiratory volume in one second. An increase in dietary vitamin C of 60 mg daily (about one orange) was associated with a decrease in fibrinogen concentrations of 0.15 g/l, equivalent (according to prospective studies) to a decline of approximately 10% in risk of ischaemic heart disease. Conclusion-High intake of vitamin C has been suggested as being protective both for respiratory infection and for cardiovascular disease. These findings support the hypothesis that vitamin C may protect against cardiovascular disease through an effect on haemostatic factors at least partly through the response to infection; this may have implications both for our understanding of the pathogenetic mechanisms in respiratory and cardiovascular disease and for the prevention of such conditions.			KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.		Khaw, Kay-Tee/AAZ-3209-2021					AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALEXANDER RW, 1994, NEW ENGL J MED, V331, P468, DOI 10.1056/NEJM199408183310709; BLOCK G, 1991, AM J CLIN NUTR, V53, pS270, DOI 10.1093/ajcn/53.1.270S; CALVIN J, 1986, ANN CLIN BIOCHEM, V23, P206, DOI 10.1177/000456328602300212; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Curwen M., 1991, HLTH TRENDS, V22, P169; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN M, 1994, AM J EPIDEMIOL, V139, pS47; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; GREGORY J, 1990, DIETARY NUTRITIONAL, P126; HEMILA H, 1992, BRIT J NUTR, V67, P3, DOI 10.1079/BJN19920004; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; Nyyssonen K., 1994, European Heart Journal, V15, P168; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Pauling L., 1970, VITAMIN C COMMON COL; QIZILBASH N, 1991, BRIT MED J, V303, P605, DOI 10.1136/bmj.303.6803.605; RAO CR, 1973, LINEAR STATISTICAL I, P418; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STRACHAN DP, 1992, J EPIDEMIOL COMMUN H, V46, P66, DOI 10.1136/jech.46.1.66; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; VOLLSET SE, 1983, LANCET, V2, P742; VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILSONT W, 1993, AM J EPIDEMIOL, V137, P292; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	38	90	91	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1559	1563		10.1136/bmj.310.6994.1559	http://dx.doi.org/10.1136/bmj.310.6994.1559			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787643	Green Published			2022-12-01	WOS:A1995RE35300017
J	KUIPERS, EJ; UYTERLINDE, AM; PENA, AS; ROOSENDAAL, R; PALS, G; NELIS, GF; FESTEN, HPM; MEUWISSEN, SGM				KUIPERS, EJ; UYTERLINDE, AM; PENA, AS; ROOSENDAAL, R; PALS, G; NELIS, GF; FESTEN, HPM; MEUWISSEN, SGM			LONG-TERM SEQUELAE OF HELICOBACTER-PYLORI GASTRITIS	LANCET			English	Article							FOLLOW-UP; CANCER-EPIDEMIOLOGY; INFECTION; CARCINOMA; RISK; CAMPYLOBACTER; POPULATION; ATROPHY; AGE	Chronic Helicobacter pylori gastritis has been put forward as a risk factor for development of gastric mucosal atrophy and gastric cancer. The purpose of our study was to investigate the long-term effects of H pylori gastritis on the gastric mucosa. We prospectively studied 49 subjects negative for H pylori and 58 positive subjects for a mean follow-up of 11.5 years (range 10-13 years). Serum samples were obtained at the initial and follow-up visits for determination of H pylori IgG antibodies. Gastroscopies with biopsy sampling were done in all patients at both visits. Biopsy specimens were used for assessment of H pylori infection and histology. Development of atrophic gastritis and intestinal metaplasia occurred in 2 (4%) uninfected and 16 (28%) infected subjects. Regression of atrophy was noted in 4 (7%) infected subjects. Development of atrophic gastritis and intestinal metaplasia was significantly associated with H pylori infection (p=0.0014; odds ratio 9.0, 95% Cl 1.9-41.3). The proportion of atrophic gastritis in the Study population showed an annual increase of 1.15% (0.5-1.8%). We conclude that H pylori infection is a significant risk factor for development of atrophic gastritis and intestinal metaplasia. Our findings support strongly the causative role of this infection in gastric carcinogenesis.	FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT CLIN MICROBIOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT HUMAN GENET,1007 MB AMSTERDAM,NETHERLANDS; SOPHIA HOSP,DEPT GASTROENTEROL,ZWOLLE,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	KUIPERS, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.		Pals, Gerard/A-5198-2011; Kuipers, Ernst J/H-3293-2019; Beales, Ian/M-5161-2014	Kuipers, Ernst J/0000-0002-0633-3098; Beales, Ian/0000-0003-1923-3237; Pals, Gerard/0000-0003-4091-7115				[Anonymous], 1994, IARC MONOGR EVAL CAR, V61, P1; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; CORREA P, 1975, LANCET, V2, P58; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1992, CANCER RES, V52, P6735; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GENTA RM, 1993, MODERN PATHOL, V6, P288; IHAMAKI T, 1985, SCAND J GASTROENTERO, V20, P485, DOI 10.3109/00365528509089685; KATELARIS PH, 1993, GUT, V34, P1032, DOI 10.1136/gut.34.8.1032; KUIPERS EJ, 1993, LANCET, V342, P328, DOI 10.1016/0140-6736(93)91473-Y; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SIPPONEN P, 1984, BRIT J CANCER, V49, P521, DOI 10.1038/bjc.1984.80; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; VILLAKO K, 1991, SCAND J GASTROENTERO, V26, P135, DOI 10.3109/00365529109104000; WARREN JR, 1983, LANCET, V1, P1273	23	665	684	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1525	1528		10.1016/S0140-6736(95)91084-0	http://dx.doi.org/10.1016/S0140-6736(95)91084-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791437				2022-12-01	WOS:A1995RD79000006
J	OCONNOR, N				OCONNOR, N			NEW CLASSIFICATION FOR LYMPHOMAS	LANCET			English	Editorial Material											OCONNOR, N (corresponding author), ROYAL SHREWSBURY HOSP NHS TRUST,SHREWSBURY,SALOP,ENGLAND.							[Anonymous], 1982, CANCER, V49, P2112; [Anonymous], 1975, BRIT J HAEMATOL, DOI DOI 10.1111/J.1365-2141.1975.TB00911.X; CHAN JKC, 1994, HISTOPATHOLOGY, V25, P517, DOI 10.1111/j.1365-2559.1994.tb01371.x; CHAN JKC, IN PRESS AM J CLIN P; HARRIS NL, 1994, BLOOD, V84, P1361; KAY HEM, 1974, LANCET, V2, P586; Lennert K, 1992, HISTOPATHOLOGY NON H; LUKES RJ, 1966, CANCER RES, V26, P1311; MACLENNAN KA, 1989, CANCER-AM CANCER SOC, V64, P1686, DOI 10.1002/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I; OCONNOR NTJ, 1987, J PATHOL, V151, P185, DOI 10.1002/path.1711510305; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1521	1522		10.1016/S0140-6736(95)91081-6	http://dx.doi.org/10.1016/S0140-6736(95)91081-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791434				2022-12-01	WOS:A1995RD79000003
J	RADFORD, CF; BACON, AS; DART, JKG; MINASSIAN, DC				RADFORD, CF; BACON, AS; DART, JKG; MINASSIAN, DC			RISK-FACTORS FOR ACANTHAMOEBA-KERATITIS IN CONTACT-LENS USERS - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							MICROBIAL-CONTAMINATION; WEARERS	Objective-To investigate reasons for an increase in cases of Acanthamoeba keratitis related to contact lenses. Design-Case-control study. Cases were contact lens related acanthamoeba keratitis patients treated between 1 September 1989 and 31 August 1992. Controls were lens users without lens related disease who presented as new patients to the casualty department from 1 March 1992 to 31 August 1992. All subjects completed a questionnaire detailing lens use and hygiene practices. Setting-Eye hospital. Subjects-35 cases with acanthamoeba keratitis and 378 controls. Main outcome measures-Relative risks comparing different contact lens types, socioeconomic classification, age, sex, lens use, lens wearing experience, hygiene compliance, and hygiene systems. Results-The crude relative risk for developing acanthamoeba keratitis with the use of daily wear disposable lenses was 49.45 (95% confidence interval 6.53 to 2227; P < 0.001) compared with conventional soft lenses (the referent). Multivariable analysis showed that this increased risk could be largely attributed to lack of disinfection (relative risk 55.86 (10 to 302); P < 0.001) and use of chlorine based disinfection (14.63 (2.8 to 76); P = 0.001) compared with other chemical systems (the referent). None of the other outcome measures showed a significant association. Conclusions-Both failure to disinfect daily wear soft contact lenses and the use of chlorine release lens disinfection systems, which have little protective effect against the organism, are major risk factors for acanthamoeba keratitis. These risks have been particularly common in disposable lens use. Over 80% of acanthamoeba keratitis could be avoided by the use of lens. disinfection systems that are effective against the organism.	MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND; INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London			Dart, John Kenneth/GZM-7807-2022					BACON AS, 1993, EYE, V7, P719, DOI 10.1038/eye.1993.168; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DARK JK, 1991, LANCET, V338, P650; DEVONSHIRE P, 1993, BRIT J OPHTHALMOL, V77, P41, DOI 10.1136/bjo.77.1.41; DONZIS PB, 1989, AM J OPHTHALMOL, V108, P53, DOI 10.1016/S0002-9394(14)73260-X; Efron N, 1992, INT CONTACT LENS CLI, V19, P8; HELTON D O, 1991, CLAO Journal, V17, P59; KILVINGTON S, 1990, J APPL BACTERIOL, V68, P519, DOI 10.1111/j.1365-2672.1990.tb02904.x; LARKIN DFP, 1990, BRIT J OPHTHALMOL, V74, P133, DOI 10.1136/bjo.74.3.133; LOWE R, 1992, CLAO Journal, V18, P34; MATTHEWS TD, 1992, ARCH OPHTHALMOL-CHIC, V110, P1559, DOI 10.1001/archopht.1992.01080230059020; MINARIK L, 1989, CLAO Journal, V15, P185; Radford CF, 1993, J BRIT CONTACT LENS, V16, P105; Rosenthal R. A., 1992, J BRIT CONTACT LENS, V15, P81; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SEAL D, 1992, BRIT J OPHTHALMOL, V76, P424, DOI 10.1136/bjo.76.7.424; Seal D. V., 1992, Pharmaceutical Journal, V248, P717; SHARMA S, 1990, ARCH OPHTHALMOL-CHIC, V108, P676, DOI 10.1001/archopht.1990.01070070062035; Stapleton Fiona, 1993, CLAO (Contact Lens Association of Ophthalmologists) Journal, V19, P204; STEHRGREEN JK, 1987, JAMA-J AM MED ASSOC, V258, P57, DOI 10.1001/jama.258.1.57; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; 1982, NOTES APPLICATIONS P, P23; 1990, STANDARD OCCUPATIONA	24	103	105	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1567	1570		10.1136/bmj.310.6994.1567	http://dx.doi.org/10.1136/bmj.310.6994.1567			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787645	Green Published			2022-12-01	WOS:A1995RE35300019
J	SCOFIELD, RH; KURIEN, B; GROSS, T; WARREN, WL; HARLEY, JB				SCOFIELD, RH; KURIEN, B; GROSS, T; WARREN, WL; HARLEY, JB			HLA-B27 BINDING OF PEPTIDE FROM ITS OWN SEQUENCE AND SIMILAR PEPTIDES FROM BACTERIA - IMPLICATIONS FOR SPONDYLOARTHROPATHIES	LANCET			English	Note							ANKYLOSING-SPONDYLITIS; REACTIVE ARTHRITIS; MOLECULAR MIMICRY; B27	The spondyloarthropathies are associated by an unknown mechanism with HLA-B27 and certain bacteria. HLA-B27 shares sequence with proteins from enteric bacteria. The B*2705 sequence contains a nonapeptide, LRRYLENGK, predicted to bind in the binding cleft of B27. Some nonapeptides from enteric organisms that share sequence with this nonapeptide of B27 also bind B27. These observations suggest an unappreciated mechanism for autoimmunity that may operate in the B27-associated spondyloarthropathies involving peptides bound to and derived from histocompatibility alleles.	UNIV OKLAHOMA,HLTH SCI CTR,COLL MED,DEPT MED,OKLAHOMA CITY,OK; USA,DEPT VET AFFAIRS MED CTR,OKLAHOMA CITY,OK	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	SCOFIELD, RH (corresponding author), OKLAHOMA MED RES FDN,ARTHRITIS & IMMUNOL PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.		Kurien, Biji T/C-2392-2008; Scofield, Robert Hal/AEJ-8314-2022	Kurien, Biji T/0000-0002-7877-6859; 				BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; CALIN A, 1989, TXB RHEUMATOLOGY, P1023; HAMMER M, 1990, ARTHRITIS RHEUM, V33, P1795, DOI 10.1002/art.1780331206; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; PARKER KC, 1992, J BIOL CHEM, V267, P5451; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; SCOFIELD RH, 1993, P NATL ACAD SCI USA, V90, P9330, DOI 10.1073/pnas.90.20.9330; TERASAKI PI, 1981, ARTHRITIS RHEUM, V30, P353; WILLIAMS RC, 1992, SCAND J RHEUMATOL, V21, P105, DOI 10.3109/03009749209095079	10	90	92	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1542	1544		10.1016/S0140-6736(95)91089-1	http://dx.doi.org/10.1016/S0140-6736(95)91089-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791441				2022-12-01	WOS:A1995RD79000011
J	SPENCER, I; UNWIN, N; PLEDGER, G				SPENCER, I; UNWIN, N; PLEDGER, G			HOSPITAL INVESTIGATION OF MEN AND WOMEN TREATED FOR ANGINA	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK				Unwin, Nigel/0000-0002-1368-1648				CAMPEAU L, 1975, CIRCULATION, V54, P522; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; PETTICREW M, 1994, BRIT MED J, V306, P1164; Rose G.A., 1982, CARDIOVASCULAR SURVE	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1576	1576		10.1136/bmj.310.6994.1576	http://dx.doi.org/10.1136/bmj.310.6994.1576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787649	Green Published			2022-12-01	WOS:A1995RE35300024
J	THOMAS, JM				THOMAS, JM			GROIN STRAIN VERSUS OCCULT HERNIA - UNCOMFORTABLE ALTERNATIVES OR INCOMPATIBLE RIVALS	LANCET			English	Editorial Material							INGUINAL SURGERY; PAIN				THOMAS, JM (corresponding author), WATFORD DIST GEN HOSP,WATFORD,HERTS,ENGLAND.							ASHBY EC, 1977, ANN ROY COLL SURG, V59, P242; ASHBY EC, 1994, BRIT J SURG, V81, P1632, DOI 10.1002/bjs.1800811123; Carnett J., 1926, SURG GYNECOL OBSTET, P625; Cyriax EF, 1919, PRACTITIONER, V102, P314; EKBERG O, 1988, SPORTS MED, V6, P56, DOI 10.2165/00007256-198806010-00006; GALLEGOS NC, 1990, BRIT J SURG, V77, P1167, DOI 10.1002/bjs.1800771026; MALYCHA P, 1992, AUST NZ J SURG, V62, P123; POLGLASE AL, 1991, MED J AUSTRALIA, V155, P674, DOI 10.5694/j.1326-5377.1991.tb93958.x; Renstrom P, 1980, Br J Sports Med, V14, P30; SCOTT EM, 1993, GUT, V34, P1006, DOI 10.1136/gut.34.7.1006; SMEDBERG SGG, 1985, AM J SURG, V149, P378, DOI 10.1016/S0002-9610(85)80112-4; THOMSON H, 1977, LANCET, V2, P1053; UPPINGTON J, 1988, HOSP PRACT, V23, P37; Zimmerman G, 1988, Aust Fam Physician, V17, P1046	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1522	1523		10.1016/S0140-6736(95)91082-4	http://dx.doi.org/10.1016/S0140-6736(95)91082-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791435				2022-12-01	WOS:A1995RD79000004
J	VINGERLING, JR; DIELEMANS, I; WITTEMAN, JCM; HOFMAN, A; GROBBEE, DE; DEJONG, PTVM				VINGERLING, JR; DIELEMANS, I; WITTEMAN, JCM; HOFMAN, A; GROBBEE, DE; DEJONG, PTVM			MACULAR DEGENERATION AND EARLY MENOPAUSE - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							RISK; DISEASE; WOMEN		ERASMUS UNIV ROTTERDAM,SCH MED,DEPT OPHTHALMOL,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT BIOSTAT & EPIDEMIOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; PALMER JR, 1992, AM J EPIDEMIOL, V136, P408, DOI 10.1093/oxfordjournals.aje.a116513; WITTEMAN JCM, 1989, BRIT MED J, V298, P642, DOI 10.1136/bmj.298.6674.642; 1992, ARCH OPHTHALMOL-CHIC, V110, P1701	5	61	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1570	1571		10.1136/bmj.310.6994.1570	http://dx.doi.org/10.1136/bmj.310.6994.1570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787646	Green Submitted, Green Published			2022-12-01	WOS:A1995RE35300020
J	WALDER, R				WALDER, R			WHY THE PROBLEM CONTINUES IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article											WALDER, R (corresponding author), REGENTS COLL,INT PLANNED PARENTHOOD FEDERAT,REGENTS PK,LONDON NW1 4NS,ENGLAND.								0	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1593	1594		10.1136/bmj.310.6994.1593	http://dx.doi.org/10.1136/bmj.310.6994.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787656	Green Published			2022-12-01	WOS:A1995RE35300031
J	BEACH, ME; HAWKINS, RD; OSMAN, M; KANDEL, ER; MAYFORD, M				BEACH, ME; HAWKINS, RD; OSMAN, M; KANDEL, ER; MAYFORD, M			IMPAIRMENT OF SPATIAL BUT NOT CONTEXTUAL MEMORY IN CAMKII MUTANT MICE WITH A SELECTIVE LOSS OF HIPPOCAMPAL LTP IN THE RANGE OF THE THETA-FREQUENCY	CELL			English	Article							LONG-TERM POTENTIATION; RADIAL MAZE; PLACE NAVIGATION; RATS; BEHAVIOR; NEURONS; RHYTHM; AREA; CA1; STIMULATION	We assessed hippocampal-dependent memory in mice with a Ca2+-independent form of CaMKII generated by the introduction of an aspartate at amino acid 286. The CaMKII-Asp-286 mice show normal LTP at high frequency stimulation, but in the 5-10 Hz range, they show a shift in the frequency-response curve favoring LTD. This range of frequencies is similar to the theta rhythm, which is associated with exploration in rodents. Using the Barnes maze to assess spatial memory, we found the transgenic mice could not learn to navigate to a specific location using spatial cues. In contrast, one line of transgenic mice performed normally in contextual fear conditioning, a task that is also hippocampal dependent. This dissociation between spatial and contextual memory suggests that even though both require the hippocampus, they may be mediated by different synaptic mechanisms.			BEACH, ME (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Mayford, Mark/0000-0002-9001-5024	NIMH NIH HHS [MH50733] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ARAI A, 1992, BRAIN RES, V598, P173, DOI 10.1016/0006-8993(92)90181-8; AUER RN, 1989, J NEUROSCI, V9, P1641; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEARMF, 1994, CURR OPIN NEUROBIOL, V4, P389; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BLAND BH, 1988, BRAIN RES, V447, P364, DOI 10.1016/0006-8993(88)91141-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; CAREW TJ, 1973, SCIENCE, V182, P1158, DOI 10.1126/science.182.4117.1158; COSTALL B, 1989, PHARMACOL BIOCHEM BE, V32, P777, DOI 10.1016/0091-3057(89)90033-6; DALE RHI, 1986, BEHAV BRAIN RES, V19, P17, DOI 10.1016/0166-4328(86)90043-4; DAVIS HP, 1990, SYMP MED H, V23, P477; DAVIS S, 1992, J NEUROSCI, V12, P21; DEVAN BD, 1992, PSYCHOBIOLOGY, V20, P120; DEVENPORT LD, 1988, BEHAV NEUROSCI, V102, P489; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; FANSELOW MS, 1980, PAVLOVIAN J BIOL SCI, V15, P177; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HEBB DO, 1949, ORG BEHAVIOR; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; KANDEL ER, 1968, PHYSIOL REV, V48, P65, DOI 10.1152/physrev.1968.48.1.65; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LEUNG LWS, 1991, BRAIN RES, V553, P261, DOI 10.1016/0006-8993(91)90834-I; MACVICAR BA, 1989, J PHYSIOL-LONDON, V417, P197, DOI 10.1113/jphysiol.1989.sp017797; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MULLER RU, 1991, BRAIN SPACE, P297; O'Keefe J, 1993, Curr Opin Neurobiol, V3, P917, DOI 10.1016/0959-4388(93)90163-S; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; Olton D., 1978, COGNITIVE PROCESS, P341; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHACTER DL, 1994, MEMORY SYYSTEMS; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHAPIRO ML, 1992, BEHAV NEUROSCI, V106, P604, DOI 10.1037/0735-7044.106.4.604; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMYTHE JW, 1992, NEUROSCI BIOBEHAV R, V16, P289, DOI 10.1016/S0149-7634(05)80203-9; SPARKS PD, 1995, BEHAV NEUROSCI, V109, P184; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STADDON JER, 1983, ADAPTIVE BEHAVIOR LE, P378; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; SUTHERLAND RJ, 1984, CAN J PSYCHOL, V38, P322, DOI 10.1037/h0080832; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WATTS J, 1981, PHYSIOL BEHAV, V26, P845, DOI 10.1016/0031-9384(81)90108-6; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; YOERG SI, 1982, ANIM LEARN BEHAV, V10, P530, DOI 10.3758/BF03212295; ZOLADEK L, 1978, ANIM LEARN BEHAV, V6, P77, DOI 10.3758/BF03212006; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	61	354	366	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 16	1995	81	6					905	915		10.1016/0092-8674(95)90010-1	http://dx.doi.org/10.1016/0092-8674(95)90010-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781067	Bronze			2022-12-01	WOS:A1995RD76800011
J	BOUJRAD, N; OGWUEGBU, SO; GARNIER, M; LEE, CH; MARTIN, BM; PAPADOPOULOS, V				BOUJRAD, N; OGWUEGBU, SO; GARNIER, M; LEE, CH; MARTIN, BM; PAPADOPOULOS, V			IDENTIFICATION OF A STIMULATOR OF STEROID-HORMONE SYNTHESIS ISOLATED FROM TESTIS	SCIENCE			English	Article							LEYDIG-CELL STEROIDOGENESIS; RAT SERTOLI CELLS; TISSUE INHIBITOR; SEMINIFEROUS TUBULES; MATRIX METALLOPROTEINASES; TESTICULAR FUNCTION; GRANULOSA-CELLS; INVITRO; PROTEIN; PURIFICATION	Gonadal steroidogenesis is regulated by pituitary gonadotropins and a locally produced, unidentified factor. A 70-kilodalton (kD) protein complex secreted from rat Serloli cells was isolated. The complex, composed of 28- and 38-kD proteins, stimulated steroidogenesis by Leydig cells and ovarian granulosa cells in a dose-dependent and adenosine 3',5'-monophosphate-independent manner. The follicle-stimulating hormone-induced 28-kD protein appeared to be responsible for the bioactivity, but the 38-kD protein was indispensable for maximal activity. The 28- and 38-kD proteins were shown to be identical to the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the proenzyme form of cathepsin L, respectively. Thus, a TIMP-1-procathepsin L complex is a potent activator of steroidogenesis and may regulate steroid concentrations and, thus, germ cell development in both males and females.	GEORGETOWN UNIV, MED CTR, DEPT CELL BIOL, WASHINGTON, DC 20007 USA; NIMH, CLIN NEUROSCI BRANCH, MOLEC NEUROGENET SECT, BETHESDA, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Papadopoulos, Vassilios/AAI-2613-2019; BOUJRAD, Noureddine/L-1367-2015	Papadopoulos, Vassilios/0000-0002-1183-8568; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024633] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01031, HD24633] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOKI A, 1978, BIOL REPROD, V19, P144, DOI 10.1095/biolreprod19.1.144; BENAHMED M, 1985, AM J PHYSIOL, V248, pE176, DOI 10.1152/ajpendo.1985.248.2.E176; BENNETT B, 1992, J IMMUNOL METHODS, V153, P31, DOI 10.1016/0022-1759(92)90302-A; BENZEEV A, 1987, DIFFERENTIATION, V34, P222, DOI 10.1111/j.1432-0436.1987.tb00070.x; BERGH A, 1982, INT J ANDROL, V5, P325, DOI 10.1111/j.1365-2605.1982.tb00261.x; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; CHEN YDI, 1976, P SOC EXP BIOL MED, V153, P473; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEKRETSER DM, 1987, INT REV CYTOL, V109, P89, DOI 10.1016/S0074-7696(08)61720-9; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DYM M, 1991, ENDOCRINOLOGY, V128, P1167, DOI 10.1210/endo-128-2-1167; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; Gamier M., 1994, MOL PHARM, V45, P201; GROTJAN HE, 1982, ANN NY ACAD SCI, V383, P456, DOI 10.1111/j.1749-6632.1982.tb23198.x; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HSUEH AJW, 1984, J CLIN ENDOCR METAB, V15, P117; JANSZ GF, 1990, J ANDROL, V11, P131; JOHNSON BH, 1971, SCIENCE, V173, P635, DOI 10.1126/science.173.3997.635; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; Kane S E, 1990, Semin Cancer Biol, V1, P127; KERR JB, 1985, ENDOCRINOLOGY, V116, P2592, DOI 10.1210/endo-116-6-2592; KRETSER DMD, 1979, ENDOCRINOLOGY, V105, P135, DOI 10.1210/endo-105-1-135; MANN JS, 1991, ENDOCRINOLOGY, V128, P1825, DOI 10.1210/endo-128-4-1825; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MELSERT R, 1988, MOL CELL ENDOCRINOL, V59, P221, DOI 10.1016/0303-7207(88)90107-4; MELSERT R, 1967, J ENDOCRINOL, V115, pR17; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONODA M, 1991, MOL CELL ENDOCRINOL, V77, P207, DOI 10.1016/0303-7207(91)90076-5; PAPADOPOULOS V, 1985, FEBS LETT, V188, P312, DOI 10.1016/0014-5793(85)80393-8; PAPADOPOULOS V, 1987, J ENDOCRINOL, V114, P459, DOI 10.1677/joe.0.1140459; PAPADOPOULOS V, 1991, J CLIN ENDOCR METAB, V72, P1332, DOI 10.1210/jcem-72-6-1332; PAPADOPOULOS V, UNPUB; PARVINEN M, 1984, MOL CELL ENDOCRINOL, V37, P331, DOI 10.1016/0303-7207(84)90103-5; RICH KA, 1979, MOL CELL ENDOCRINOL, V13, P123, DOI 10.1016/0303-7207(79)90013-3; RISBRIDGER GP, 1986, J REPROD FERTIL, V77, P239, DOI 10.1530/jrf.0.0770239; RISBRIDGER GP, 1981, ENDOCRINOLOGY, V109, P1234, DOI 10.1210/endo-109-4-1234; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; SAEZ JM, 1987, J STEROID BIOCHEM, V27, P317, DOI 10.1016/0022-4731(87)90323-2; Setchell B.P., 1978, THE MAMMALIAN TESTIS; SHARPE RM, 1984, MOL CELL ENDOCRINOL, V37, P159, DOI 10.1016/0303-7207(84)90048-0; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SMITH GW, 1994, ENDOCRINOLOGY, V134, P344, DOI 10.1210/en.134.1.344; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TEERDS KJ, 1989, J ENDOCRINOL, V120, P97, DOI 10.1677/joe.0.1200097; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VERHOEVEN G, 1986, J STEROID BIOCHEM, V25, P393, DOI 10.1016/0022-4731(86)90252-9; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHU C, 1991, BIOL REPROD, V45, P334, DOI 10.1095/biolreprod45.2.334	50	144	154	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1609	1612		10.1126/science.7777858	http://dx.doi.org/10.1126/science.7777858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777858				2022-12-01	WOS:A1995RD45900035
J	DATTA, A; JINKSROBERTSON, S				DATTA, A; JINKSROBERTSON, S			ASSOCIATION OF INCREASED SPONTANEOUS MUTATION-RATES WITH HIGH-LEVELS OF TRANSCRIPTION IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED MUTAGENESIS; GENE; RAD6; RECOMBINATION; DISRUPTION; RADIATION; STRAINS; CELLS; CONSTRUCTION	Complex processes such as transcription, replication, repair, and recombination require changes in chromatin structure and the interactions of numerous trans-acting factors with DNA sequences, raising the possibility that these processes may be interrelated. Here the effect of transcription on the rate of spontaneous mutation in the yeast Saccharomyces cerevisiae was examined. With the use of a lys2 frameshift allele under the control of a highly inducible promoter, the rate of spontaneous reversion was shown to increase when the mutant gene was highly transcribed. Thus, transcriptionally active DNA and enhanced spontaneous mutation rates are associated in yeast.	EMORY UNIV, GRAD PROGRAM BIOCHEM & MOLEC BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT BIOL, ATLANTA, GA 30322 USA	Emory University; Emory University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038464, R29GM038464] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BALBINDER E, 1970, GENETICS, V66, P31; BARTLETT JD, 1991, MUTAT RES, V255, P247, DOI 10.1016/0921-8777(91)90028-N; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CHATTOO BB, 1979, GENETICS, V93, P51; Datta A., UNPUB; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FOX MS, 1994, EXPERIENTIA, V50, P253, DOI 10.1007/BF01924008; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GANGLOFF S, 1994, EXPERIENTIA, V50, P261, DOI 10.1007/BF01924009; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HERMAN RK, 1971, J BACTERIOL, V106, P543, DOI 10.1128/JB.106.2.543-550.1971; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KOMBERG RD, 1992, ANN REV CELL BIOL, V8, P563; KOROGODIN VI, 1991, YEAST, V7, P105, DOI 10.1002/yea.320070204; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; LAWRENCE CW, 1976, GENETICS, V82, P207; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Luria SE, 1943, GENETICS, V28, P491; MELAMED C, 1992, MOL CELL BIOL, V12, P1613, DOI 10.1128/MCB.12.4.1613; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; PLATT T, 1984, MOL CELL BIOL, V4, P994, DOI 10.1128/MCB.4.5.994; PRAKASH L, 1976, GENETICS, V83, P285; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QUAH SK, 1980, GENETICS, V96, P819; RATTRAY AJ, 1994, GENETICS, V138, P587; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVIC DJ, 1972, MOL GEN GENET, V118, P45, DOI 10.1007/BF02428331; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STEELE DF, 1992, GENETICS, V132, P9; STEELE DF, 1991, GENETICS, V127, P53; STRATHEM JN, IN PRESS GENETICS; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; VONBORSTEL RC, 1971, GENETICS, V69, P17; WARTERS RL, 1987, MUTAT RES, V180, P21, DOI 10.1016/0027-5107(87)90063-7; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	50	207	212	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1616	1619		10.1126/science.7777859	http://dx.doi.org/10.1126/science.7777859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777859				2022-12-01	WOS:A1995RD45900037
J	FINLAY, BL; DARLINGTON, RB				FINLAY, BL; DARLINGTON, RB			LINKED REGULARITIES IN THE DEVELOPMENT AND EVOLUTION OF MAMMALIAN BRAINS	SCIENCE			English	Article							POSSUM TRICHOSURUS-VULPECULA; ANTERIOR OLFACTORY NUCLEUS; LATERAL GENICULATE-NUCLEUS; GANGLION-CELL LAYER; REELER MUTANT MICE; RHESUS-MONKEY; AUTORADIOGRAPHIC ANALYSIS; VISUAL-CORTEX; NEURON ORIGIN; THYMIDINE-H-3 AUTORADIOGRAPHY	Analysis of data collected on 131 species of primates, bats, and insectivores showed that the sizes of brain components, from medulla to forebrain, are highly predictable from absolute brain size by a nonlinear function. The order of neurogenesis was found to be highly conserved across a wide range of mammals and to correlate with the relative enlargement of structures as brain size increases, with disproportionately large growth occurring in late-generated structures. Because the order of neurogenesis is conserved, the most likely brain alteration resulting from selection for any behavioral ability may be a coordinated enlargement of the entire nonolfactory brain.			FINLAY, BL (corresponding author), CORNELL UNIV,DEPT PSYCHOL,URIS HALL,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019245] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19245] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1981, EXP BRAIN RES, V42, P411; ALTMAN J, 1981, EXP BRAIN RES, V42, P424; ALTMAN J, 1978, J COMP NEUROL, V182, P945, DOI 10.1002/cne.901820511; ALTMAN J, 1980, J COMP NEUROL, V194, P877, DOI 10.1002/cne.901940410; ALTMAN J, 1980, J COMP NEUROL, V194, P1, DOI 10.1002/cne.901940102; ALTMAN J, 1980, J COMP NEUROL, V194, P905, DOI 10.1002/cne.901940411; ALTMAN J, 1978, J COMP NEUROL, V179, P23, DOI 10.1002/cne.901790104; ALTMAN J, 1978, J COMP NEUROL, V179, P49, DOI 10.1002/cne.901790105; ALTMAN J, 1978, J COMP NEUROL, V188, P455; ALTMAN J, 1980, J COMP NEUROL, V198, P677; ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; ANGEVINE JB, 1974, ANAT REC, V178, P300; ANGEVINE JB, 1964, ANAT REC, V148, P255; BARON G, 1988, J HIRNFORSCH, V29, P509; Bayer S.A., 1991, NEOCORTICAL DEV, V1; BAYER SA, 1979, J COMP NEUROL, V183, P89, DOI 10.1002/cne.901830108; BAYER SA, 1983, EXP BRAIN RES, V50, P329; BAYER SA, 1986, INT J DEV NEUROSCI, V4, P225, DOI 10.1016/0736-5748(86)90062-6; BAYER SA, 1980, J COMP NEUROL, V194, P845, DOI 10.1002/cne.901940409; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BRAND S, 1980, NEUROSCIENCE, V5, P2125, DOI 10.1016/0306-4522(80)90128-1; BRAND S, 1979, NEUROSCIENCE, V4, P767, DOI 10.1016/0306-4522(79)90005-8; BRANDSTATTER R, 1990, BRAIN BEHAV EVOLUT, V35, P195, DOI 10.1159/000115867; BRUNJES PC, 1989, NEUROSCI LETT, V107, P114, DOI 10.1016/0304-3940(89)90801-X; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CAVINESS VS, 1982, DEV BRAIN RES, V4, P293, DOI 10.1016/0165-3806(82)90141-9; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; COOPER ML, 1981, J COMP NEUROL, V202, P309; CREPS ES, 1974, J COMP NEUROL, V157, P139, DOI 10.1002/cne.901570204; CREPS ES, 1974, J COMP NEUROL, V157, P161, DOI 10.1002/cne.901570205; CROSSLAND WJ, 1982, DEV BRAIN RES, V5, P99, DOI 10.1016/0165-3806(82)90117-1; DAVIS FC, 1990, BRAIN RES, V519, P192, DOI 10.1016/0006-8993(90)90077-O; DEHAY C, 1993, NATURE, V366, P464, DOI 10.1038/366464a0; DELONG GR, 1962, J COMP NEUROL, V118, P205, DOI 10.1002/cne.901180207; DEVOOGD TJ, 1993, P ROY SOC B-BIOL SCI, V254, P75, DOI 10.1098/rspb.1993.0129; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Erwin, 1988, COMP PRIMATE BIOL, V4, P1; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GOULD BB, 1981, EXP BRAIN RES, V44, P195; Gould S.J., 1977, ONTOGENY PHYLOGENY; HICKEY TL, 1984, J COMP NEUROL, V228, P186, DOI 10.1002/cne.902280205; HINDS JW, 1968, J COMP NEUROL, V134, P287, DOI 10.1002/cne.901340304; HOFMAN MA, 1985, BRAIN BEHAV EVOLUT, V27, P28, DOI 10.1159/000118718; HOFMAN MA, 1989, PROG NEUROBIOL, V32, P137, DOI 10.1016/0301-0082(89)90013-0; JERISON HJ, 1991, NATO ADV SCI I A-LIF, V200, P5; Jerison HJ., 1973, EVOLUTION BRAIN INTE, DOI 10.4324/9781315787107-3; JOHNSTON AM, 1966, ANAT REC, V154, P163; KIMBLE J, 1994, SCIENCE, V266, P577, DOI 10.1126/science.7939710; KORDOWER JH, 1992, DEV BRAIN RES, V68, P9, DOI 10.1016/0165-3806(92)90242-O; KORDOWER JH, 1990, J COMP NEUROL, V291, P637, DOI 10.1002/cne.902910410; KOSTOVIC I, 1980, J NEUROCYTOL, V9, P219, DOI 10.1007/BF01205159; KREBS JR, 1990, PHILOS T R SOC LON B, V329, P161; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LEVITT P, 1984, SCIENCE, V223, P299, DOI 10.1126/science.6199842; LEVITT P, 1979, SOC NEUR ABSTR, V5, P341; LEVITT P, 1986, NEUROBIOLOGY DOWN SY, P195; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1985, J NEUROSCI, V5, P1062; MARCHAND R, 1986, NEUROSCIENCE, V17, P573, DOI 10.1016/0306-4522(86)90031-X; MCCONNELL JA, 1975, ANAT REC, V181, P418; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; NOTTEBOHM F, 1981, BRAIN RES, V213, P99, DOI 10.1016/0006-8993(81)91250-6; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; NUSSLEINVOLHARD C, 1994, SCIENCE, V266, P572, DOI 10.1126/science.7939708; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; PIERCE ET, 1970, ANAT REC, V166, P388; PIERCE ET, 1970, J COMP NEUROL, V131, P27; PIERCE ET, 1967, J COMP NEUROL, V126, P219; Polley E.H., 1989, P3; PURVES D, 1994, P NATL ACAD SCI USA, V91, P5030, DOI 10.1073/pnas.91.11.5030; RAKIC P, 1981, J COMP NEUROL, V196, P99, DOI 10.1002/cne.901960109; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1977, J COMP NEUROL, V176, P23, DOI 10.1002/cne.901760103; REEP RL, 1990, BRAIN BEHAV EVOLUT, V35, P185, DOI 10.1159/000115866; REESE BE, 1992, NEUROSCIENCE, V46, P419, DOI 10.1016/0306-4522(92)90062-7; REHKAMPER G, 1991, BRAIN BEHAV EVOLUT, V37, P125, DOI 10.1159/000114353; SANDERSON KJ, 1990, BRAIN BEHAV EVOLUT, V35, P339, DOI 10.1159/000115879; SANDERSON KJ, 1990, BRAIN BEHAV EVOLUT, V35, P325, DOI 10.1159/000115878; SCHWERDTFEGER WK, 1984, ANAT EMBRYOL, V170, P11, DOI 10.1007/BF00319453; Sengelaub D.R., 1989, Advances in Comparative and Environmental Physiology, V3, P239; SENGELAUB DR, 1986, J COMP NEUROL, V246, P527, DOI 10.1002/cne.902460409; SHERRY DF, 1992, TRENDS NEUROSCI, V15, P298, DOI 10.1016/0166-2236(92)90080-R; SIDMAN RL, 1962, ANAT REC, V142, P327; Sidman RL, 1961, STRUCTURE EYE, P487; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; STEPHAN H, 1981, FOLIA PRIMATOL, V35, P1, DOI 10.1159/000155963; TABER E, 1963, ANAT REC, V145, P291; UZMAN LL, 1960, J COMP NEUROL, V114, P137; WOO TU, 1990, CEREB CORTEX, V1, P433; WYSS JM, 1985, DEV BRAIN RES, V21, P89, DOI 10.1016/0165-3806(85)90026-4	96	862	870	2	141	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1578	1584		10.1126/science.7777856	http://dx.doi.org/10.1126/science.7777856			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777856				2022-12-01	WOS:A1995RD45900026
J	JUNG, M; ZHANG, Y; LEE, S; DRITSCHILO, A				JUNG, M; ZHANG, Y; LEE, S; DRITSCHILO, A			CORRECTION OF RADIATION SENSITIVITY IN ATAXIA-TELANGIECTASIA CELLS BY A TRUNCATED I-KAPPA-B-ALPHA	SCIENCE			English	Article							INHIBITOR; GENE; RADIOSENSITIVITY; LOCALIZATION; FIBROBLASTS; EXPRESSION; PLASMIDS; SURVIVAL	Cells from patients with ataxia telangiectasia (AT) are hypersensitive to ionizing radiation and are defective in the regulation of DNA synthesis. A complementary DNA that corrects the radiation sensitivity and DNA synthesis defects in fibroblasts from an AT group D patient was isolated by expression cloning and shown to encode a truncated form of I kappa B-alpha, an inhibitor of the nuclear factor kappa B (NF-kappa B) transcriptional activator. The parental AT fibroblasts expressed large amounts of the I kappa B-alpha transcript and showed constitutive activation of NF-kappa B. The AT fibroblasts transfected with the truncated I kappa B-alpha expressed normal amounts of the I kappa B-alpha transcript and showed regulated activation of NF-kappa B. These results suggest that aberrant regulation of NF-kappa B and I kappa B-alpha contribute to the cellular defect in AT.	GEORGETOWN UNIV, SCH MED, DEPT RADIAT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NCI NIH HHS [CA45408, R29 CA63023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, R29CA063023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BODER E, 1985, ATAXIA TELANGIECTASI, P1; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIRT B, 1967, J MOL BIOL, V26, P265; HOPGOOD R, 1992, BIOTECHNIQUES, V13, P82; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; Jung M, 1992, PCR Methods Appl, V1, P171; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; LEA DE, 1962, ACTIONS RAD LIVING C, P74; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; SALEHI Z, 1991, EXP BIOL M, P377; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	31	171	177	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1619	1621		10.1126/science.7777860	http://dx.doi.org/10.1126/science.7777860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777860				2022-12-01	WOS:A1995RD45900038
J	KELLEY, RL; SOLOVYEVA, I; LYMAN, LM; RICHMAN, R; SOLOVYEV, V; KURODA, MI				KELLEY, RL; SOLOVYEVA, I; LYMAN, LM; RICHMAN, R; SOLOVYEV, V; KURODA, MI			EXPRESSION OF MSL-2 CAUSES ASSEMBLY OF DOSAGE COMPENSATION REGULATORS ON THE X-CHROMOSOMES AND FEMALE LETHALITY IN DROSOPHILA	CELL			English	Article							SEX-SPECIFIC LETHALS; GENE-PRODUCT; SPLICE-SITE; SEQUENCE SIMILARITY; MELANOGASTER; PROTEIN; RNA; MUTATIONS; BINDING; TRANSCRIPTION	Male-specific lethal-2 (msl-2) is a RING finger protein that is required for X chromosome dosage compensation in Drosophila males. Consistent with the formation of a dosage compensation protein complex, msl-2 colocalizes with the other MSL proteins on the male X chromosome and coimmunoprecipitates with msl-1 from male larval extracts. Ectopic expression of msl-2 in females results in the appearance of the other MSL dosage compensation regulators on the female X chromosomes and decreased female viability. We suggest that msl-2 RNA is the primary target of Sxl regulation in the dosage compensation pathway and present a speculative model for the regulation of two distinct modes of dosage compensation by Sxl.			KELLEY, RL (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOWARD HUGHES MED INST,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Solovyev, Victor/C-4614-2013	Solovyev, Victor/0000-0001-8885-493X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045744, R37GM045744] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45744] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BENZ WK, 1988, GENETICS, V118, P461; BERNSTEIN M, 1994, GENETICS, V136, P1051; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CRONMILLER C, 1994, MOL GENETICS SEX DET, P172; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GERGEN JP, 1987, GENETICS, V117, P477; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HIEBERT JC, 1994, GENETICS, V136, P913; HILFIKER A, 1994, EMBO J, V15, P3542; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KARPEN GH, 1988, GENE DEV, V2, P1745, DOI 10.1101/gad.2.12b.1745; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; OKUNO T, 1984, JPN J GENET, V59, P237, DOI 10.1266/jjg.59.237; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SKRIPSKY T, 1982, DEV BIOL, V94, P153, DOI 10.1016/0012-1606(82)90078-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UENOYAMA T, 1984, JPN J GENET, V59, P335, DOI 10.1266/jjg.59.335; UENOYAMA T, 1982, GENETICS, V102, P233; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; ZHOU S, 1995, IN PRESS EMBO J	53	253	259	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					867	877		10.1016/0092-8674(95)90007-1	http://dx.doi.org/10.1016/0092-8674(95)90007-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781064	Bronze			2022-12-01	WOS:A1995RD76800008
J	LOCKSHON, D; ZWEIFEL, SG; FREEMANCOOK, LL; LORIMER, HE; BREWER, BJ; FANGMAN, WL				LOCKSHON, D; ZWEIFEL, SG; FREEMANCOOK, LL; LORIMER, HE; BREWER, BJ; FANGMAN, WL			A ROLE FOR RECOMBINATION JUNCTIONS IN THE SEGREGATION OF MITOCHONDRIAL-DNA IN YEAST	CELL			English	Article							CRUCIFORM CUTTING ENDONUCLEASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; REPLICATION; GENOME; LOCALIZATION; PLASMIDS; MUTANTS; ORIGINS; GENE	In S. cerevisiae, mitochondrial DNA (mtDNA) molecules, in spite of their high copy number, segregate as if there were a small number of heritable units. The rapid segregation of mitochondrial genomes can be analyzed using mtDNA deletion variants. These small, amplified genomes segregate preferentially from mixed zygotes relative to wild-type mtDNA. This segregation advantage is abolished by mutations in a gene, MGT1, that encodes a recombination junction-resolving enzyme. We show here that resolvase deficiency causes a larger proportion of molecules to be linked together by recombination junctions, resulting in the aggregation of mtDNA into a small number of cytological structures. This change in mtDNA structure can account far the increased mitotic loss of mtDNA and the altered pattern of mtDNA segregation from zygotes. We propose that the level of unresolved recombination junctions influences the number of heritable units of mtDNA.	UNIV WASHINGTON, DEPT GENET SK50, SEATTLE, WA 98195 USA; CARLETON COLL, DEPT BIOL, NORTHFIELD, MN 55057 USA	University of Washington; University of Washington Seattle; Carleton College	LOCKSHON, D (corresponding author), UNIV WASHINGTON, DEPT PATHOL SM30, SEATTLE, WA 98195 USA.				NIA NIH HHS [AG11435] Funding Source: Medline; NIGMS NIH HHS [GM43847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R15AG011435] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERLIN V, 1991, METHOD ENZYMOL, V194, P774; BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480; BIRKY CW, 1982, MITOCHONDRIAL GENES, P279; BLANC H, 1984, GENE, V30, P47, DOI 10.1016/0378-1119(84)90104-5; BLANC H, 1980, P NATL ACAD SCI-BIOL, V77, P3942, DOI 10.1073/pnas.77.7.3942; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; DEZAMAROCZY M, 1981, NATURE, V292, P75, DOI 10.1038/292075a0; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; EVANS DH, 1988, J MOL BIOL, V201, P69, DOI 10.1016/0022-2836(88)90439-1; EZEKIEL UR, 1993, MOL GEN GENET, V240, P414, DOI 10.1007/BF00280395; FANGMAN WL, 1989, MOL CELL BIOL, V9, P1917, DOI 10.1128/MCB.9.5.1917; FANGMAN WL, 1978, NUCLEIC ACIDS RES, V5, P653, DOI 10.1093/nar/5.3.653; FRIEDMAN KL, 1995, IN PRESS METH ENZYMO, V262; GINGOLD EB, 1988, DIVISION SEGREGATION, P149; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; MARINI JC, 1980, J BIOL CHEM, V255, P4976; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OOI BG, 1986, CURR GENET, V10, P713, DOI 10.1007/BF00405093; PISKUR J, 1994, PLASMID, V31, P229, DOI 10.1006/plas.1994.1025; SENA EP, 1986, MOL GEN GENET, V202, P421, DOI 10.1007/BF00333272; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Williamson D H, 1979, Methods Enzymol, V56, P728; WILLIAMSON D H, 1977, P1; WILLIAMSON DH, 1974, MOL GEN GENET, V131, P193, DOI 10.1007/BF00267959; WILLIAMSON DH, 1976, GENETICS BIOGENESIS, P117; ZWEIFEL SG, 1991, GENETICS, V128, P214	30	148	149	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 16	1995	81	6					947	955		10.1016/0092-8674(95)90014-4	http://dx.doi.org/10.1016/0092-8674(95)90014-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781070	Bronze			2022-12-01	WOS:A1995RD76800015
J	MALGAROLI, A; TING, AE; WENDLAND, B; BERGAMASCHI, A; VILLA, A; TSIEN, RW; SCHELLER, RH				MALGAROLI, A; TING, AE; WENDLAND, B; BERGAMASCHI, A; VILLA, A; TSIEN, RW; SCHELLER, RH			PRESYNAPTIC COMPONENT OF LONG-TERM POTENTIATION VISUALIZED AT INDIVIDUAL HIPPOCAMPAL SYNAPSES	SCIENCE			English	Article							FROG NEUROMUSCULAR-JUNCTION; MINIATURE SYNAPTIC CURRENTS; RELEASE; ENHANCEMENT; PROBABILITY; INDUCTION; TRANSMISSION; MECHANISM; FREQUENCY; NEURONS	Long-term potentiation has previously been studied with electrophysiological techniques that do not readily separate presynaptic and postsynaptic contributions. Changes in exocytotic-endocytotic cycling have now been monitored at synapses between cultured rat hippocampal neurons by measuring the differential uptake of antibodies that recognize the intraluminal domain of the synaptic vesicle protein synaptotagmin. Vesicular cycling increased markedly during glutamate-induced long-term potentiation. The degree of potentiation was heterogeneous, appearing greater at synapses at which the initial extent of vesicular turnover was low. Thus, changes in presynaptic activity were visualized directly and the spatial distribution of potentiation could be determined at the level of single synaptic boutons.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; UNIV MILAN,DIPARTIMENTO FARMACOL,I-20132 MILAN,ITALY	Howard Hughes Medical Institute; Stanford University; University of Milan	MALGAROLI, A (corresponding author), SCI INST SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY.		Bergamaschi, Andrea/AAN-3705-2020; Malgaroli, Antonio/I-5090-2013; Villa, Antonello/B-4781-2012	Malgaroli, Antonio/0000-0003-3758-7477; Ting, Anthony/0000-0002-5058-9576	Telethon [D.016] Funding Source: Medline	Telethon(Fondazione Telethon)		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LEVTOV A, 1980, J PHYSIOL-LONDON, V309, P247, DOI 10.1113/jphysiol.1980.sp013507; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LYNCH MA, 1986, BRAIN RES, V369, P405, DOI 10.1016/0006-8993(86)90561-5; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Matteoli M, 1991, Curr Opin Neurobiol, V1, P91, DOI 10.1016/0959-4388(91)90015-Y; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MELDOLESI J, 1988, CURR TOP MEMBR TRANS, V32, P139; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299; ZHENG W, 1991, MOL PHARMACOL, V40, P734	37	148	148	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1624	1628		10.1126/science.7777862	http://dx.doi.org/10.1126/science.7777862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777862				2022-12-01	WOS:A1995RD45900040
J	MANTYH, PW; DEMASTER, E; MALHOTRA, A; GHILARDI, JR; ROGERS, SD; MANTYH, CR; LIU, HT; BASBAUM, AI; VIGNA, SR; MAGGIO, JE; SIMONE, DA				MANTYH, PW; DEMASTER, E; MALHOTRA, A; GHILARDI, JR; ROGERS, SD; MANTYH, CR; LIU, HT; BASBAUM, AI; VIGNA, SR; MAGGIO, JE; SIMONE, DA			RECEPTOR ENDOCYTOSIS AND DENDRITE RESHAPING IN SPINAL NEURONS AFTER SOMATOSENSORY STIMULATION	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTORS; EXCITATORY AMINO-ACIDS; PRIMARY SENSORY NEURONS; SUBSTANCE-P RECEPTORS; INTRADERMAL INJECTION; GUINEA-PIG; CORD; RAT; CAT; LOCALIZATION	In vivo somatosensory stimuli evoked the release of substance P from primary afferent neurons that terminate in the spinal cord and stimulated endocytosis of substance P receptors in rat spinal cord neurons. The distal dendrites that showed substance P receptor internalization underwent morphological reorganization, changing from a tubular structure to one characterized by swollen varicosities connected by thin segments. This internalization and dendritic structural reorganization provided a specific image of neurons activated by substance P. Thus receptor internalization can drive reversible structural changes in central nervous system neurons in vivo. Both of these processes may be involved in neuronal plasticity.	UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Minnesota System; University of Minnesota Twin Cities; Duke University; Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	MANTYH, PW (corresponding author), VET ADM MED CTR, MOLEC NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.		mantyh, christopher/AAJ-9140-2021		NINDS NIH HHS [NS21445, NS14627, NS23970] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS021445, R37NS023970, R01NS014627, P50NS021445, R01NS023970] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIGOT D, 1990, NEUROSCI LETT, V111, P275, DOI 10.1016/0304-3940(90)90274-D; BIGOT D, 1991, NEUROSCI LETT, V131, P21, DOI 10.1016/0304-3940(91)90328-Q; BIGOT D, 1991, EUR J NEUROSCI, V3, P551, DOI 10.1111/j.1460-9568.1991.tb00842.x; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRELJE TC, 1989, DIABETES, V38, P808, DOI 10.2337/diabetes.38.6.808; BREWER GJ, 1989, NEUROSCI LETT, V99, P268, DOI 10.1016/0304-3940(89)90458-8; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CASTEL MN, 1992, NEUROSCIENCE, V50, P269, DOI 10.1016/0306-4522(92)90422-X; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DALSGAARD CJ, 1984, NEUROSCI LETT, V51, P139, DOI 10.1016/0304-3940(84)90275-1; DUBNER R, 1991, PAIN RES CLIN MANAGE, V5, P263; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; JACK J, 1979, NEUROSCIENCES 4TH ST, P423; KATZ B, 1966, NERVE MUSCLE SYNAPSE, P12; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MANTYH PW, 1995, J NEUROSCI, V15, P152; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MANTYH PW, 1985, BRAIN RES, V332, P315, DOI 10.1016/0006-8993(85)90600-6; MANTYH PW, UNPUB; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; SIMONE DA, 1987, BRAIN RES, V418, P201, DOI 10.1016/0006-8993(87)90982-6; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; SJODIN L, 1980, ACTA PHYSIOL SCAND, V109, P97, DOI 10.1111/j.1748-1716.1980.tb06570.x; VIGNA SR, 1994, J NEUROSCI, V14, P834; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WILCOX GL, 1988, ANN NY ACAD SCI, V525, P228, DOI 10.1111/j.1749-6632.1988.tb38608.x; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; YASHPAL K, 1990, BRAIN RES, V506, P259, DOI 10.1016/0006-8993(90)91260-N	39	419	421	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1629	1632		10.1126/science.7539937	http://dx.doi.org/10.1126/science.7539937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7539937				2022-12-01	WOS:A1995RD45900041
J	MAYFORD, M; WANG, J; KANDEL, ER; ODELL, TJ				MAYFORD, M; WANG, J; KANDEL, ER; ODELL, TJ			CAMKII REGULATES THE FREQUENCY-RESPONSE FUNCTION OF HIPPOCAMPAL SYNAPSES FOR THE PRODUCTION OF BOTH LTD AND LTP	CELL			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; SQUID GIANT SYNAPSE; II MUTANT MICE; VISUAL-CORTEX; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; NEUROTRANSMITTER RELEASE; AREA CA1; CALMODULIN	To investigate the function of the autophosphorylated form of CaMKII in synaptic plasticity, we generated transgenic mice that express a kinase that is Ca2+ independent as a result of a point mutation of Thr-286 to aspartate, which mimics autophosphorylation. Mice expressing the mutant form of the kinase show an increased level of Ca2+-independent CaMKII activity similar to that seen following LTP. The mice nevertheless exhibit normal LTP in response to stimulation at 100 Hz. However, at lower frequencies, in the range of 1-10 Hz, there is a systematic shift in the size and direction of the resulting synaptic change in the transgenic animals that favors LTD. The regulation of this frequency-response function by Ca2+-independent CaMKII activity seems to account for two previously unexplained synaptic phenomena, the relative loss of LTD in adult animals compared with juveniles and the enhanced capability for depression of facilitated synapses.			MAYFORD, M (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Mayford, Mark/0000-0002-9001-5024	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIMH NIH HHS [MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BACH ME, 1995, CELL, V81; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEAR MF, 1990, J NEUROSCI, V10, P909; BEARMF, 1994, CURR OPIN NEUROBIOL, V4, P389; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CLINE HT, 1990, J NEUROSCI, V10, P1197; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GOODMAN CS, 1993, NEURON S, V10, P77; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HEBB DO, 1949, ORG BEHAVIOR; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1989, J NEUROSCI, V9, P2020; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; O'Dell T J, 1994, Learn Mem, V1, P129; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHATZ CJ, 1928, SCIENCE, V242, P87; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SUNYER T, 1990, P NATL ACAD SCI USA, V87, P278, DOI 10.1073/pnas.87.1.278; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	61	431	459	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					891	904		10.1016/0092-8674(95)90009-8	http://dx.doi.org/10.1016/0092-8674(95)90009-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781066	hybrid			2022-12-01	WOS:A1995RD76800010
J	MORSE, D; SALOIS, P; MARKOVIC, P; HASTINGS, JW				MORSE, D; SALOIS, P; MARKOVIC, P; HASTINGS, JW			A NUCLEAR-ENCODED FORM-II RUBISCO IN DINOFLAGELLATES	SCIENCE			English	Article							CHLOROPHYLL-B; EVOLUTION; CARBOXYLASE; ORIGINS; PLASTIDS; PROTEINS; PHYLOGENIES; GENE	The chloroplasts of most dinoflagellates are unusual in that they are surrounded by three membranes and contain the carotenoid peridinin. The ribulose-1,5-bisphosphate carboxylase-oxygenase (RuBisCO) in dinoflagellate chloroplasts was found here to also be unusual. Unlike other eukaryotes, dinoflagellates containing peridinin use a form of RuBisCO (form II) previously found only in some species of proteobacteria. Furthermore, this RuBisCO is not encoded in the chloroplast DNA, as is the case in other organisms, but is encoded by the nuclear DNA. The unusual nature of this enzyme and location of its gene support the idea that dinoflagellate chloroplasts may have had a distinctive evolutionary origin.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	MORSE, D (corresponding author), UNIV MONTREAL,INST RECH BIOL VEGETALE,MONTREAL,PQ H1X 2B2,CANADA.			Morse, David/0000-0003-4131-4367	NIGMS NIH HHS [2R01-GM-19536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ASSALI NE, 1991, PLANT MOL BIOL, V17, P853, DOI 10.1007/BF00037066; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORUZZI G, 1983, J BIOL CHEM, V258, P1399; GIBSON JL, 1977, J BIOL CHEM, V252, P943; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; INNI SM, 1990, PCR PROTOCOLS; KANEVSKI I, 1994, P NATL ACAD SCI USA, V91, P1969, DOI 10.1073/pnas.91.5.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAEMMLI UK, 1974, NATURE, V227, P680; LOEBLICH AR, 1976, J PROTOZOOL, V23, P13, DOI 10.1111/j.1550-7408.1976.tb05241.x; MACHABEE S, 1994, PLANT MOL BIOL, V25, P23, DOI 10.1007/BF00024195; MARTIN W, 1992, J MOL EVOL, V35, P385, DOI 10.1007/BF00171817; MILOS P, 1990, NATURWISSENSCHAFTEN, V77, P87, DOI 10.1007/BF01131782; MORDEN CW, 1992, BIOSYSTEMS, V28, P75, DOI 10.1016/0303-2647(92)90010-V; MORDEN CW, 1991, J MOL EVOL, V32, P379, DOI 10.1007/BF02101278; MORSE DC, UNPUB; NARANG F, 1984, MOL GEN GENET, V193, P220; RAVEN PH, 1970, SCIENCE, V169, P641, DOI 10.1126/science.169.3946.641; RITLAND K, 1987, American Naturalist, V130, pS74, DOI 10.1086/284693; SCHULER M, METHODS PLANT MOL BI; TANGEN K, 1981, Journal of Plankton Research, V3, P389, DOI 10.1093/plankt/3.3.389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE MM, 1987, J PHYCOL, V23, P382, DOI 10.1111/j.1529-8817.1987.tb04148.x; WILCOX LW, 1985, SCIENCE, V227, P192, DOI 10.1126/science.227.4683.192; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	208	220	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1622	1624		10.1126/science.7777861	http://dx.doi.org/10.1126/science.7777861			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777861				2022-12-01	WOS:A1995RD45900039
J	PEPPELENBOSCH, MP; QIU, RG; DEVRIESSMITS, AMM; TERTOOLEN, LGJ; DELAAT, SW; MCCORMICK, F; HALL, A; SYMONS, MH; BOS, JL				PEPPELENBOSCH, MP; QIU, RG; DEVRIESSMITS, AMM; TERTOOLEN, LGJ; DELAAT, SW; MCCORMICK, F; HALL, A; SYMONS, MH; BOS, JL			RAC MEDIATES GROWTH FACTOR-INDUCED ARACHIDONIC-ACID RELEASE	CELL			English	Article							SIGNAL-REGULATED KINASE-2; RHO GENE-PRODUCT; PROTEIN; ACTIN; PHOSPHOLIPASE-A2; ACTIVATION; P21RAS; CELLS; IDENTIFICATION; FIBROBLASTS	Growth factor-induced stress fiber formation involves signal transduction through Rac and Rho proteins and production of leukotrienes from arachidonic acid metabolism. In exploring the relationship between these pathways, we found that Rac is essential for EGF-induced arachidonic acid production and subsequent generation of leukotrienes and that Rac V12, a constitutively activated mutant of Rac, generates leukotrienes in a growth factor-independent manner. Leukotrienes generated by EGF or Rac V12 are necessary and sufficient for stress fiber formation. Furthermore, leukotriene-dependent stress fiber formation requires Rho proteins. We have therefore identified elements of a pathway from growth factor receptors that includes Rac, arachidonic acid production, arachidonic acid metabolism to leukotrienes, and leukotriene-dependent Rho activation. This appears to be the major pathway by which Rac influences Rho-dependent cytoskeleton rearrangements.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS; ONYX PHARMACEUT, RICHMOND, CA 94806 USA; NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS; UCL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of London; University College London; University of London; University College London				Peppelenbosch, Maikel/0000-0001-9112-6028				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BRETCHER A, 1989, J CELL BIOL, V64, P573; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOLDBERG H, 1994, BIOCHEM BIOPH RES CO, V198, P220, DOI 10.1006/bbrc.1994.1031; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HABETS GGM, 1994, CELL, V77, P539; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NOBES CD, 1995, J CELL SCI, V108, P225; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; WARNER LC, 1993, ONCOGENE, V8, P3249; XU XX, 1994, J BIOL CHEM, V269, P31693	34	197	198	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 16	1995	81	6					849	856		10.1016/0092-8674(95)90005-5	http://dx.doi.org/10.1016/0092-8674(95)90005-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781062	Bronze			2022-12-01	WOS:A1995RD76800006
J	RANGANATHAN, R; STEVENS, CF				RANGANATHAN, R; STEVENS, CF			ARRESTIN BINDING DETERMINES THE RATE OF INACTIVATION OF THE G-PROTEIN-COUPLED RECEPTOR RHODOPSIN IN-VIVO	CELL			English	Article							LIGHT-INDUCED PHOSPHORYLATION; 48-KDA PROTEIN; DROSOPHILA PHOTORECEPTOR; PHOTOEXCITED RHODOPSIN; RETINAL RODS; INVIVO; DESENSITIZATION; KINASE; DEACTIVATION; ACTIVATION	G protein-coupled receptor inactivation is a crucial feature of cellular signaling systems; this process determines the catalytic lifetime of the activated receptor and is necessary for response termination. Although previous work has indicated a class of models in which several sequential steps are required for receptor inactivation, the rate-limiting event is still unclear. In this paper, we develop a theory that describes the kinetics of inactivation of the G protein-coupled receptor rhodopsin based on the rate of arrestin binding and test the theory using a combination of genetic and electrophysiological techniques in Drosophila photoreceptors. The theory quantitatively describes the inactivation kinetics of activated rhodopsin in vivo and can be independently tested with molecular and spectroscopic data. The results demonstrate that the rate of arrestin binding determines the kinetics of receptor inactivation in vivo and thus is the event that controls signal amplification at the first step of this G protein-coupled transduction cascade.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	RANGANATHAN, R (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; Dartnall H. J. A., 1972, HDB SENSORY PHYSIOLO, V7, P122; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Goodeve CF, 1938, PROC R SOC LON SER-A, V166, P0342, DOI 10.1098/rspa.1938.0097; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; MAKINO CL, 1991, J PHYSIOL-LONDON, V442, P761, DOI 10.1113/jphysiol.1991.sp018818; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1984, SCIENCE, V223, P184, DOI 10.1126/science.6419348; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RANGANATHAN R, 1991, ANN REV NEUROL, V18, P283; RICHARD EA, 1992, NATURE, V356, P336, DOI 10.1038/356336a0; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHWEMER J, 1984, J COMP PHYSIOL, V154, P535, DOI 10.1007/BF00610167; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAMOTO K, 1983, BIOPHYS STRUCT MECH, V9, P259, DOI 10.1007/BF00535661	29	49	50	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					841	848		10.1016/0092-8674(95)90004-7	http://dx.doi.org/10.1016/0092-8674(95)90004-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781061	Bronze			2022-12-01	WOS:A1995RD76800005
J	REBAY, I; RUBIN, GM				REBAY, I; RUBIN, GM			YAN FUNCTIONS AS A GENERAL INHIBITOR OF DIFFERENTIATION AND IS NEGATIVELY REGULATED BY ACTIVATION OF THE RAS1/MAPK PATHWAY	CELL			English	Article							PROTEIN-KINASE; NUCLEAR-LOCALIZATION; SEVENLESS PROTEIN; DROSOPHILA; NOTCH; EXPRESSION; SEQUENCE; RECEPTOR; DOMAIN; EYE	Drosophila yan has been postulated to act as an antagonist of the proneural signal mediated by the sevenless/Ras1/MAPK pathway. We have mutagenized the eight MAPK phosphorylation consensus sites of yan and examined the effects of overexpressing the mutant protein in transgenic flies and transfected S2 cultured cells. Our results suggest that phosphorylation by MAPK affects the stability and subcellular localization of yan, resulting in rapid down-regulation of yan activity. Furthermore, MAPK-mediated down-regulation of yan function appears to be critical for the proper differentiation of both neuronal and nonneuronal tissues throughout development, suggesting that yan is an essential component of a general timing mechanism controlling the competence of a cell to respond to inductive signals.			REBAY, I (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; HAY BA, 1994, DEVELOPMENT, V120, P2121; JANCKNECHT R, 1993, EMBO J, V12, P5097; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WOLFF T, 1991, DEVELOPMENT, V113, P825; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	29	285	285	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					857	866		10.1016/0092-8674(95)90006-3	http://dx.doi.org/10.1016/0092-8674(95)90006-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781063	Bronze			2022-12-01	WOS:A1995RD76800007
J	RISCH, N; ZHANG, HP				RISCH, N; ZHANG, HP			EXTREME DISCORDANT SIB PAIRS FOR MAPPING QUANTITATIVE TRAIT LOCI IN HUMANS	SCIENCE			English	Article							LINKAGE	Analysis of differences between siblings (sib pair analysis) is a standard method of genetic linkage analysis for mapping quantitative trait loci, such as those contributing to hypertension and obesity, in humans. In traditional designs, pairs are selected at random or with one sib having an extreme trait value. The majority of such pairs provide little power to detect linkage; only pairs that are concordant for high values, low values, or extremely discordant pairs (for example, one in the top 10 percent and the other in the bottom 10 percent of the distribution) provide substantial power. Focus on discordant pairs can reduce the amount of genotyping necessary over conventional designs by 10- to 40-fold.	YALE UNIV,SCH MED,DEPT GENET,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520	Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030712] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00348] Funding Source: Medline; NICHD NIH HHS [HD30712] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; BLACKWELDER WC, 1982, COMMUN STAT A-THEOR, V11, P449, DOI 10.1080/03610928208828250; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CARDON LR, 1994, AM J HUM GENET, V55, P825; CAREY G, 1991, AM J HUM GENET, V49, P786; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVIES JL, 1994, NATURE, V371, P161; Falconer D. S., 1989, Introduction to quantitative genetics.; FULKER DW, 1991, READ WRIT, V3, P299, DOI 10.1007/BF00354964; FULKER DW, 1994, AM J HUM GENET, V54, P1092; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; GOLDGAR DE, 1990, AM J HUM GENET, V47, P957; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; LANDER ES, 1989, GENETICS, V121, P185; OLSON JM, 1993, GENET EPIDEMIOL, V10, P87, DOI 10.1002/gepi.1370100202; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, UNPUB	17	456	464	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1584	1589		10.1126/science.7777857	http://dx.doi.org/10.1126/science.7777857			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RD459	7777857				2022-12-01	WOS:A1995RD45900027
J	ROTH, S; NEUMANSILBERBERG, FS; BARCELO, G; SCHUPBACH, T				ROTH, S; NEUMANSILBERBERG, FS; BARCELO, G; SCHUPBACH, T			CORNICHON AND THE EGF RECEPTOR SIGNALING PROCESS ARE NECESSARY FOR BOTH ANTERIOR-POSTERIOR AND DORSAL-VENTRAL PATTERN-FORMATION IN DROSOPHILA	CELL			English	Article							FAINT-LITTLE-BALL; DORSOVENTRAL PATTERN; BICOID RNA; FEMALE GERMLINE; TGF-ALPHA; OOGENESIS; GENE; LOCALIZATION; MELANOGASTER; HOMOLOG	In Drosophila, the dorsal-ventral polarity of the egg chamber depends on the localization of the oocyte nucleus and the gurken RNA to the dorsal-anterior corner of the oocyte. Gurken protein presumably acts as a ligand for the Drosophila EGF receptor (torpedo/DER) expressed in the somatic follicle cells surrounding the oocyte. cornichon is a gene required in the germline for dorsal-ventral signaling, cornichon, gurken, and torpedo also function in an earlier signaling event that establishes posterior follicle cell fates and specifies the anterior-posterior polarity of the egg chamber. Mutations in all three genes prevent the formation of a correctly polarized microtubule cytoskeleton required for proper localization of the anterior and posterior determinants bicoid and oskar and for the asymmetric positioning of the oocyte nucleus.			ROTH, S (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,SPEMANNSTR 35-LL,D-72076 TUBINGEN,GERMANY.		Roth, Siegfried/E-8241-2010	Roth, Siegfried/0000-0001-5772-3558	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; CAROLL SB, 1985, CELL, V43, P47; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; EPHRUSSI A, 1991, CELL, V66, P23; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOCH EA, 1983, CELL TISSUE RES, V228, P21; KYTE J, 1982, J MOL BIOL, V157, P133; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lehmann Ruth, 1995, Seminars in Developmental Biology, V6, P25, DOI 10.1016/S1044-5781(06)80082-4; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Maniatis T, 1989, DECONTAMINATION DILU; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Spradling Allan C., 1993, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Thummel C., 1992, DROS INFORM SERV, V71, P150; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wieschaus E., 1986, P199	52	417	426	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					967	978		10.1016/0092-8674(95)90016-0	http://dx.doi.org/10.1016/0092-8674(95)90016-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7540118	Bronze			2022-12-01	WOS:A1995RD76800017
J	TANENHAUS, MK; SPIVEYKNOWLTON, MJ; EBERHARD, KM; SEDIVY, JC				TANENHAUS, MK; SPIVEYKNOWLTON, MJ; EBERHARD, KM; SEDIVY, JC			INTEGRATION OF VISUAL AND LINGUISTIC INFORMATION IN SPOKEN LANGUAGE COMPREHENSION	SCIENCE			English	Article							PERCEPTION	Psycholinguists have commonly assumed that as a spoken linguistic message unfolds over time, it is initially structured by a syntactic processing module that is encapsulated from information provided by other perceptual and cognitive systems. To test the effects of relevant visual context on the rapid mental processes that accompany spoken language comprehension, eye movements were recorded with a head-mounted eye-tracking system while subjects followed instructions to manipulate real objects. Visual context influenced spoken word recognition and mediated syntactic processing, even during the earliest moments of language processing.	UNIV ROCHESTER, DEPT LINGUIST, ROCHESTER, NY 14627 USA	University of Rochester	TANENHAUS, MK (corresponding author), UNIV ROCHESTER, DEPT BRAIN & COGNIT SCI, 601 ELMWOOD AVE, ROCHESTER, NY 14627 USA.		Eberhard, Kathleen M/A-2542-2014; Eberhard, Kathleen/B-4346-2008; Galantucci, Bruno/E-5770-2010	Eberhard, Kathleen/0000-0002-0764-4541; 	NCRR NIH HHS [1-P41-RR09283] Funding Source: Medline; NICHD NIH HHS [HD27206] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD027206] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR009283] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTMANN G, 1988, COGNITION, V30, P191, DOI 10.1016/0010-0277(88)90020-0; BALLARD DH, 1995, J COGNITIVE NEUROSCI, V7, P66, DOI 10.1162/jocn.1995.7.1.66; BRITT MA, 1994, J MEM LANG, V33, P251, DOI 10.1006/jmla.1994.1013; Chomsky N., 1965, ASPECTS THEORY SYNTA; CLARK H, 1994, ARENAS LANGUAGE USE; Crain S., 1985, NATURAL LANGUAGE PAR, P320, DOI DOI 10.1017/CBO9780511597855.011; FERREIRA F, 1986, J MEM LANG, V25, P348, DOI 10.1016/0749-596X(86)90006-9; Fodor J. A., 1983, MODULARITY MIND; FRAZIER L, 1987, ATTENTION PERFORM, P559; Jackendoff R., 1992, LANGUAGES MIND; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MACDONALD MC, 1994, PSYCHOL REV, V101, P676, DOI 10.1037/0033-295X.101.4.676; MARSLENWILSON WD, 1975, SCIENCE, V189, P226, DOI 10.1126/science.189.4198.226; MATIN E, 1993, PERCEPT PSYCHOPHYS, V53, P372, DOI 10.3758/BF03206780; MCCLELLAND JL, 1987, ATTENTION PERFORM, P3; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Pinker S, 2007, LANGUAGE INSTINCT MI; Pollard C., 1993, HEAD DRIVEN PHRASE S; SPIVEYKNOWLTON M, IN PRESS COGNITION; TANENHAUS M, IN PRESS HDB COGNITI; WILSON WM, 1973, NATURE, V244, P522, DOI 10.1038/244522a0	21	1485	1513	7	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1632	1634		10.1126/science.7777863	http://dx.doi.org/10.1126/science.7777863			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RD459	7777863				2022-12-01	WOS:A1995RD45900042
J	TRAVERS, K; MBOUP, S; MARLINK, R; GUEYENDIAYE, A; SIBY, T; THIOR, I; TRAORE, I; DIENGSARR, A; SANKALE, JL; MULLINS, C; NDOYE, I; HSIEH, CC; ESSEX, M; KANKI, P				TRAVERS, K; MBOUP, S; MARLINK, R; GUEYENDIAYE, A; SIBY, T; THIOR, I; TRAORE, I; DIENGSARR, A; SANKALE, JL; MULLINS, C; NDOYE, I; HSIEH, CC; ESSEX, M; KANKI, P			NATURAL PROTECTION AGAINST HIV-1 INFECTION PROVIDED BY HIV-2	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD8+ T-CELLS; WEST-AFRICA; NEUTRALIZING ANTIBODIES; VERTICAL TRANSMISSION; CROSS-NEUTRALIZATION; HIV-2-INFECTED CELLS; TYPE-2 HIV-2; IVORY-COAST; AIDS	Significant differences have been observed in the rates of transmission and disease development in human immunodeficiency virus (HIV) types 1 and 2. Because many HIV-2-infected people remain asymptomatic for prolonged periods, the hypothesis that HIV-2 might protect against subsequent infection by HIV-1 was considered. During a 9-year period in Dakar, Senegal, the seroincidence of both HIV types was measured in a cohort of commercial sex workers. Despite a higher incidence of other sexually transmitted diseases (STDs), HIV-2-infected women had a lower incidence of HIV-1 than did HIV-seronegative women, with a relative risk of 0.32 (P = 0.008). An understanding of the cross-protective mechanisms involved may be directly relevant to HIV-1 vaccine development.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; UNIV CHEIKH ANTA DIOP, VIROL & BACTERIOL LAB, DAKAR, SENEGAL; INST SOCIAL HYG, DAKAR, SENEGAL; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar; Harvard University; Harvard T.H. Chan School of Public Health				Travers, Karin/0000-0002-9097-1710	NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39805] Funding Source: Medline; PHS HHS [P01 A1 30795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; Arya Suresh K., 1994, AIDS Research and Human Retroviruses, V10, pS158; BARIN F, 1985, LANCET, V2, P1387; BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160; BOTTIGER B, 1990, J VIROL, V64, P3492; BOTTIGER B, 1989, AIDS RES HUM RETROV, V5, P525, DOI 10.1089/aid.1989.5.525; Breslow NE., 1987, STATISTICAL METHODS, P1; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1989, LANCET, V2, P408; DENIS F, 1987, LANCET, V1, P408; DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671; EVANS LA, 1988, LANCET, V2, P1389; GRANKVIST O, 1990, AIDS, V5, P286; GUEYENDIAYE A, 1993, AIDS, V7, P481; HART AR, 1990, VIROLOGY, V177, P1, DOI 10.1016/0042-6822(90)90454-Y; HORSBURGH CR, 1988, TRANSFUSION, V28, P92; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KANKI PJ, 1990, ADV AP BIOT, V7, P255; KANKI PJ, 1987, SCIENCE, V236, P827, DOI 10.1126/science.3033826; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; Kanki PJ, 1994, AIDS S1, V8, pS85; KANNAGI M, 1990, J VIROL, V64, P3399, DOI 10.1128/JVI.64.7.3399-3406.1990; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LEGUERN M, 1992, P NATL ACAD SCI USA, V89, P363, DOI 10.1073/pnas.89.1.363; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NORLEY SG, 1990, J IMMUNOL, V145, P1700; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; ROBERTGUROFF M, 1992, J VIROL, V66, P3602, DOI 10.1128/JVI.66.6.3602-3608.1992; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; SIMMOND P, 1992, J VIROL, V64, P864; SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480; TRAVERS K, UNPUB; VONDALNOK GK, 1993, ARCH VIROL, V131, P419, DOI 10.1007/BF01378642; VONGEGERFELT A, 1993, AIDS RES HUM RETROV, V9, P883, DOI 10.1089/aid.1993.9.883; WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X; WEIR SS, 1994, AIDS, V8, P1605, DOI 10.1097/00002030-199411000-00013	41	176	180	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1612	1615		10.1126/science.7539936	http://dx.doi.org/10.1126/science.7539936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7539936				2022-12-01	WOS:A1995RD45900036
J	VANGENT, DC; MCBLANE, JF; RAMSDEN, DA; SADOFSKY, MJ; HESSE, JE; GELLERT, M				VANGENT, DC; MCBLANE, JF; RAMSDEN, DA; SADOFSKY, MJ; HESSE, JE; GELLERT, M			INITIATION OF V(D)J RECOMBINATION IN A CELL-FREE SYSTEM	CELL			English	Article							RAG-1; GENES; MICE; DNA	Cells performing V(D)J recombination make specific cuts in DNA at recombination signal sequences. Here, we show that nuclear extracts of pre-a cell lines carry out this specific cleavage. The products of cleavage are the same as found previously in thymocytes: full-length, blunt, 5'-phosphorylated signal ends, and covalently sealed (hairpin) coding ends. A complete signal sequence is required. Recombinant RAG1 protein greatly increases activity and complements an inactive extract from a RAG1 (-/-) pre-a cell line. When the extracts are fractionated, cleavage activity correlates with the presence of RAG2 protein. These results suggest that RAG1 and RAG2 are components of the V(D)J recombinase.			VANGENT, DC (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.			Ramsden, Dale/0000-0003-1575-4748; Sadofsky, Moshe/0000-0002-6893-629X				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GELLERT M, 1992, ANNU REV GENET, V22, P425; HARLOW E, 1988, ANTIBODIES LABORATOR; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; O'Reilly DR., 1994, BACULOVIRUS EXPRESSI; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	27	253	256	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					925	934		10.1016/0092-8674(95)90012-8	http://dx.doi.org/10.1016/0092-8674(95)90012-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781069	Bronze, Green Published			2022-12-01	WOS:A1995RD76800013
J	ZHANG, GG; KAZANIETZ, MG; BLUMBERG, PM; HURLEY, JH				ZHANG, GG; KAZANIETZ, MG; BLUMBERG, PM; HURLEY, JH			CRYSTAL-STRUCTURE OF THE CYS2 ACTIVATOR-BINDING DOMAIN OF PROTEIN-KINASE C-DELTA IN COMPLEX WITH PHORBOL ESTER	CELL			English	Article							PROGRAM; REFINEMENT; ZINC	Protein kinase Cs (PKCs) are a ubiquitous family of regulatory enzymes that associate with membranes and are activated by diacylglycerol or tumor-promoting agonists such as phorbol esters. The structure of the second activator-binding domain of PKC delta has been determined in complex with phorbol 13-acetate, which binds in a groove between two pulled-apart beta strands at the tip of the domain. The C3, C4, and C20 phorbol oxygens form hydrogen bonds with mai n-chain groups whose orientation is controlled by a set of highly conserved residues. Phorbol binding caps the groove and forms a contiguous hydrophobic surface covering one-third of the domain, explaining how the activator promotes insertion of PKC into membranes.	NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, MOLEC MECHANISMS TUMOR PROMOT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; Hecker E., 1978, CARCINOGENESIS, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; Rando RR, 1992, PROTEIN KINASE C CUR, P41; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P11, DOI 10.1107/S0907444993008224; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90	23	593	601	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					917	924		10.1016/0092-8674(95)90011-X	http://dx.doi.org/10.1016/0092-8674(95)90011-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781068	Bronze			2022-12-01	WOS:A1995RD76800012
J	ZHAO, K; HART, CM; LAEMMLI, UK				ZHAO, K; HART, CM; LAEMMLI, UK			VISUALIZATION OF CHROMOSOMAL DOMAINS WITH BOUNDARY ELEMENT-ASSOCIATED FACTOR BEAF-32	CELL			English	Article							SCAFFOLD-ATTACHED REGIONS; PROTEIN-DNA INTERACTIONS; BETA-GLOBIN GENE; DROSOPHILA-MELANOGASTER; RNA-POLYMERASE; HEAT-SHOCK; REGULATORY SEQUENCES; IN-VIVO; EXPRESSION; CELLS	We have purified two proteins from Drosophila that bind to the scs' boundary element of the hsp70 domain at locus 87A7. Their palindromic binding sites (CGATA-TATCG) symmetrically abut the previously mapped hypersensitive site of scs'. We have cloned a cDNA for one of these proteins, BEAF-32 (boundary element-associated factor of 32 kDa). It encodes a novel protein that is bound to scs' but not scs in vivo. Immunostaining localizes BEAF to hundreds of interbands and many puff boundaries on polytene chromosomes, suggesting that a chromosomal domain consists of a band (or puff) and part of the flanking interbands. Enhancer blocking assays implicate the palindromic binding site in boundary function. The lack of enhancer blocking in transiently transfected cells suggests an involvement of chromatin, nuclear structure, or both in boundary function.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA,SWITZERLAND	University of Geneva	ZHAO, K (corresponding author), UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA,SWITZERLAND.		Hart, Craig/B-4832-2016	Hart, Craig/0000-0002-9870-991X; Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ASHBURNER M, 1989, DROSOPHILA LABORATOR, P51; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DUBENDORFER A, 1986, INSECT BIOCHEM, V16, P645, DOI 10.1016/0020-1790(86)90007-7; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; FARKAS G, 1992, NUCLEIC ACIDS RES, V20, P2604, DOI 10.1093/nar/20.10.2604; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HELLER RA, 1986, J BIOL CHEM, V261, P8063; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JAMRICH M, 1977, P NATL ACAD SCI USA, V74, P2079, DOI 10.1073/pnas.74.5.2079; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; RIDDIHOUGH G, 1986, EMBO J, V5, P1653, DOI 10.1002/j.1460-2075.1986.tb04408.x; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; RYKOWSKI MC, 1988, CELL, V54, P461, DOI 10.1016/0092-8674(88)90067-0; Sambrook J., 1989, MOL CLONING LAB MANU; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TTSUKIYAMA T, 1994, NATURE, V367, P525; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VAZQUEZ J, 1994, EMBO J, V13, P5984, DOI 10.1002/j.1460-2075.1994.tb06944.x; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	44	268	278	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					879	889		10.1016/0092-8674(95)90008-X	http://dx.doi.org/10.1016/0092-8674(95)90008-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781065	Bronze, Green Published			2022-12-01	WOS:A1995RD76800009
J	CASANO, AA				CASANO, AA			REIMBURSEMENT OVER THE ATLANTIC	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CASANO, AA (corresponding author), ALBANY MED CTR, A38, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					957	958		10.7326/0003-4819-122-12-199506150-00012	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755234				2022-12-01	WOS:A1995RC27000012
J	COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE				COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE			THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; SEX-HORMONES; MORTALITY; WEIGHT; EPIDEMIOLOGY; PROGESTOGENS; SURVEILLANCE; HEIGHT	Background. The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. Methods. To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breastcancer. Results. The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. Conclusions. The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women, The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40956] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LILIENFELD AM, 1956, CANCER, V9, P927, DOI 10.1002/1097-0142(195609/10)9:5<927::AID-CNCR2820090510>3.0.CO;2-3; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; MORRISON AS, 1979, AM J EPIDEMIOL, V109, P709, DOI 10.1093/oxfordjournals.aje.a112734; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSE DP, 1977, OBSTET GYNECOL, V49, P80; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P2438; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; 1991, ORAL CONTRACEPTIVES	33	1283	1328	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1589	1593		10.1056/NEJM199506153322401	http://dx.doi.org/10.1056/NEJM199506153322401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753136				2022-12-01	WOS:A1995RC19200001
J	CRAIG, AM; WYBORSKI, RJ; BANKER, G				CRAIG, AM; WYBORSKI, RJ; BANKER, G			PREFERENTIAL ADDITION OF NEWLY SYNTHESIZED MEMBRANE-PROTEIN AT AXONAL GROWTH CONES	NATURE			English	Article							SIMPLEX VIRUS AMPLICON; HIPPOCAMPAL-NEURONS; POLARITY ORIENTATION; PLASMA-MEMBRANE; GROWING AXONS; BREFELDIN-A; CULTURE; MICROTUBULES; DIFFUSION; MOVEMENT	THE addition of plasma membrane proteins to a growing axon could occur by preferential insertion at the tip (the growth cone), by uniform insertion along the axon, or by insertion at the cell body and bulk flow along the axon. To differentiate between these possibilities we used a defective herpesvirus vector to express an exogenous protein, the lymphocyte transmembrane protein CD8 alpha, in cultured rat hippocampal neurons. The newly synthesized protein first appeared on the axonal surface almost exclusively at the growth cone. Preferential addition at the growth cone was also observed in minor processes (immature dendrites), but not in mature dendrites. Over several hours, CD8 alpha reached a uniform distribution over the entire neuronal surface, presumably by diffusion within the membrane and possibly endocytic recycling. As well as providing materials for axonal growth, the selective addition of membrane vesicles at the growth cone may contribute to the polarized distribution of axonal surface molecules(1).	UNIV VIRGINIA,SCH MED,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908; PARKE DAVIS RES,DEPT BIOTECHNOL,ANN ARBOR,MI 48106	University of Virginia; Pfizer			Craig, Ann Marie/M-2054-2014					BAAS PW, 1989, J CELL BIOL, V109, P3085, DOI 10.1083/jcb.109.6.3085; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1990, CELL, V62, P62; FELDMAN EL, 1981, J NEUROBIOL, V12, P591, DOI 10.1002/neu.480120607; FUTERMAN AH, 1993, NATURE, V362, P119, DOI 10.1038/362119a0; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOSLIN K, 1991, CULTURING NERVE CELL, P207; GRIFFIN JW, 1981, J CELL BIOL, V88, P205, DOI 10.1083/jcb.88.1.205; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KAPLITT M G, 1991, Molecular and Cellular Neuroscience, V2, P320, DOI 10.1016/1044-7431(91)90062-S; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KODA LY, 1976, J NEUROBIOL, V7, P157, DOI 10.1002/neu.480070208; KWONG AD, 1985, VIROLOGY, V142, P421, DOI 10.1016/0042-6822(85)90351-4; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; PFENNINGER KH, 1981, J CELL BIOL, V89, P547, DOI 10.1083/jcb.89.3.547; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; ROIZMAN B, 1990, VIROLOGY, V2, P1795; SMALL RK, 1984, J CELL BIOL, V98, P1434, DOI 10.1083/jcb.98.4.1434; SPAETE RR, 1982, CELL, V30, P295, DOI 10.1016/0092-8674(82)90035-6	26	154	155	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					592	594		10.1038/375592a0	http://dx.doi.org/10.1038/375592a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791876				2022-12-01	WOS:A1995RD28700052
J	CUENOUD, B; SZOSTAK, JW				CUENOUD, B; SZOSTAK, JW			A DNA METALLOENZYME WITH DNA-LIGASE ACTIVITY	NATURE			English	Article							HUMAN THROMBIN; RNA; BINDING; APTAMER; SELECTION; MOLECULES; INVITRO	SINGLE-STRANDED DNA can fold into well-defined sequence-dependent tertiary structures that specifically bind a variety of target molecules(1-10), raising the possibility that some folded single-stranded DNAs might exhibit catalytic activities similar to those of ribozymes and protein enzymes. Derivatives of the hammerhead ribozyme that contain a majority of deoxyribonucleotides retain the ability to cleave RNA(11), and a 'deoxyribozyme' was generated by leaving all essential ribonucleotides of the hammerhead on the RNA 'substrate'(12). Recently in vitro selection has been used to isolate a DNA sequence that shows Pb2+-dependent RNA-cleaving activity(13). Here we report the isolation by in vitro selection(14-17) of a small single-stranded DNA that is a Zn2+/Cu2+-dependent metalloenzyme. The enzyme catalyses the formation of a new phosphodiester bond by the condensation of the 5'-hydroxyl of one oligodeoxynucleotide and a 3'-phosphorimidazolide on another oligodeoxynucleotide, and shows multiple turnover ligation.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; CHARTRAND P, 1994, RNA PROCESSING, V77; CHU BCF, 1986, NUCLEIC ACIDS RES, V14, P5591, DOI 10.1093/nar/14.14.5591; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; Fersht A., 1985, ENZYME STRUCTURE MEC; HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; ORGEL LE, 1994, SCI AM, V271, P77, DOI 10.1038/scientificamerican1094-76; PABORSKY LR, 1993, J BIOL CHEM, V268, P20808; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; PAN T, 1994, BIOCHEMISTRY-US, V33, P9561, DOI 10.1021/bi00198a023; PERREAULT JP, 1989, EUR J BIOCHEM, V186, P87, DOI 10.1111/j.1432-1033.1989.tb15181.x; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; SHABAROVA ZA, 1988, BIOCHIMIE, V70, P1323, DOI 10.1016/0300-9084(88)90003-X; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; Trotman-Dickenson AF., 1973, COMPREHENSIVE INORGA; WANG KY, 1993, BIOCHEMISTRY-US, V32, P11285, DOI 10.1021/bi00093a004; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356	30	342	370	7	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	1995	375	6532					611	614		10.1038/375611a0	http://dx.doi.org/10.1038/375611a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791880				2022-12-01	WOS:A1995RD28700057
J	FAIRMAN, WA; VANDENBERG, RJ; ARRIZA, JL; KAVANAUGH, MP; AMARA, SG				FAIRMAN, WA; VANDENBERG, RJ; ARRIZA, JL; KAVANAUGH, MP; AMARA, SG			AN EXCITATORY AMINO-ACID TRANSPORTER WITH PROPERTIES OF A LIGAND-GATED CHLORIDE CHANNEL	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; GLUTAMATE TRANSPORTER; RAT-BRAIN; ASPARTATE TRANSPORTER; EXPRESSION; CALCIUM; SALAMANDER; BLOCKERS; RECEPTOR; CLONING	EXCITATORY amino-acid transporters (EAATs) in the central nervous system maintain extracellular glutamate concentrations below excitotoxic levels and may limit the activation of glutamate receptors. Here we report the cloning of a novel human aspartate/glutamate transporter, EAAT4, which is expressed predominantly in the cerebellum. The transport activity encoded by EAAT4 has high apparent affinity for L-aspartate and L-glutamate, and has a pharmacological profile consistent with previously described cerebellar transport activities. In Xenopus oocytes expressing EAAT4, L-aspartate and L-glutamate elicited a current predominantly carried by chloride ions. This chloride conductance was not blocked by components that block endogenous oocyte chloride channels. Thus EAAT4 combines the re-uptake of neurotransmitter with a mechanism for increasing chloride permeability, both of which could regulate excitatory neurotransmission.	OREGON HLTH SCI UNIV,HOWARD HUGHES MED INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University			Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814; Amara, Susan/0000-0001-8914-1106				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; COYLE JT, 1985, J NEUROSCI RES, V16, P491; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, P783; ELIASOF S, 1993, J NEUROSCI, V13, P402; FLETCHER EJ, 1991, J NEUROCHEM, V57, P911, DOI 10.1111/j.1471-4159.1991.tb08237.x; GREGER R, 1990, METHOD ENZYMOL, V191, P793; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PIN JP, 1984, FEBS LETT, V175, P31, DOI 10.1016/0014-5793(84)80563-3; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROBINSON MB, 1993, J NEUROCHEM, V60, P167, DOI 10.1111/j.1471-4159.1993.tb05835.x; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, IN PRESS NEURON; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WI G, 1992, PFLUGERS ARCH, V420, P227; ZACZEK R, 1987, NEUROPHARMACOLOGY, V26, P281, DOI 10.1016/0028-3908(87)90179-1	30	978	996	1	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					599	603		10.1038/375599a0	http://dx.doi.org/10.1038/375599a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791878				2022-12-01	WOS:A1995RD28700054
J	KELCE, WR; STONE, CR; LAWS, SC; GRAY, LE; KEMPPAINEN, JA; WILSON, EM				KELCE, WR; STONE, CR; LAWS, SC; GRAY, LE; KEMPPAINEN, JA; WILSON, EM			PERSISTENT DDT METABOLITE P,P'-DDE IS A POTENT ANDROGEN RECEPTOR ANTAGONIST	NATURE			English	Article							ESTROGENIC ACTIVITY; RAT; BINDING; PROSTATE; ANALOGS	THE increase in the number of reports of abnormalities in male sex development in wildlife and humans coincided with the introduction of 'oestrogenic' chemicals such as DDT (1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane) into the environment, Although these phenotypic alterations are thought to be mediated by the oestrogen receptor, they are also consistent with inhibition of androgen receptor-mediated events, Here we report that the major and persistent DDT metabolite, p,p'-DDE (1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene), has little ability to bind the oestrogen receptor, but inhibits androgen binding to the androgen receptor, androgen-induced transcriptional activity, and androgen action in developing, pubertal and adult male rats, The results suggest that abnormalities in male sex development induced by p,p'-DDE and related environmental chemicals may be mediated at the level of the androgen receptor.	UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	KELCE, WR (corresponding author), US EPA,HLTH EFFECTS RES LAB,DIV DEV TOXICOL,REPROD TOXICOL BRANCH,RES TRIANGLE PK,NC 27711, USA.			gray jr, leon earl/0000-0002-1111-4754				BITMAN J, 1970, J AGR FOOD CHEM, V18, P1108, DOI 10.1021/jf60172a019; BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CLEMENS LG, 1978, HORM BEHAV, V10, P40, DOI 10.1016/0018-506X(78)90023-5; CURLEY A, 1969, ARCH ENVIRON HEALTH, V19, P628, DOI 10.1080/00039896.1969.10666901; DURNBERGER H, 1980, CELL, V19, P465, DOI 10.1016/0092-8674(80)90521-8; Dustman E H, 1969, Ann N Y Acad Sci, V160, P162, DOI 10.1111/j.1749-6632.1969.tb15828.x; GELLERT RJ, 1972, ENDOCRINOLOGY, V91, P1095, DOI 10.1210/endo-91-4-1095; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; KELCE W R, 1988, Steroids, V52, P217, DOI 10.1016/0039-128X(88)90005-0; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; KUPFER D, 1975, Critical Reviews in Toxicology, V4, P83; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; MORGAN DP, 1971, ARCH ENVIRON HEALTH, V22, P301, DOI 10.1080/00039896.1971.10665848; NELSON J A, 1978, Journal of Toxicology and Environmental Health, V4, P325; NELSON JA, 1974, BIOCHEM PHARMACOL, V23, P447, DOI 10.1016/0006-2952(74)90436-5; Neumann F, 1970, Recent Prog Horm Res, V26, P337; PAGE MJ, 1982, MOL CELL ENDOCRINOL, V27, P343, DOI 10.1016/0303-7207(82)90099-5; ROBISON AK, 1985, J TOXICOL ENV HEALTH, V16, P493, DOI 10.1080/15287398509530758; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STONE CR, 1995, J ANDROL S, V16, P42; WELCH RM, 1969, TOXICOL APPL PHARM, V14, P358, DOI 10.1016/0041-008X(69)90117-3; WILSON EM, 1976, J BIOL CHEM, V251, P5620; WOOLLEY DE, 1971, TOXICOL APPL PHARM, V18, P907, DOI 10.1016/0041-008X(71)90238-9; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	29	1256	1316	11	187	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					581	585		10.1038/375581a0	http://dx.doi.org/10.1038/375581a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791873				2022-12-01	WOS:A1995RD28700049
J	LI, C; ULLRICH, B; ZHANG, JZ; ANDERSON, RGW; BROSE, N; SUDHOF, TC				LI, C; ULLRICH, B; ZHANG, JZ; ANDERSON, RGW; BROSE, N; SUDHOF, TC			CA2+-DEPENDENT AND CA2+-INDEPENDENT ACTIVITIES OF NEURAL AND NONNEURAL SYNAPTOTAGMINS	NATURE			English	Article							NEUROTRANSMITTER RELEASE; PROTEIN; FUSION; SYNTAXIN; BINDING; DOCKING	SYNAPTOTAGMINS (Syts) are brain-specific Ca2+/phospholipid-binding proteins(1-5). In hippocampal synapses, Syt I is essential for fast Ca2+-dependent synaptic vesicle exocytosis but not for Ca2+-independent exocytosis(3). In vertebrates and invertebrates(6-9), Syt may therefore participate in Ca2+-dependent synaptic membrane fusion, either by serving as the Ca2+ sensor in the last step of fast Ca2+-triggered neurotransmitter release, or by collaborating with an additional Ca2+ sensor. While Syt I binds Ca2+ (refs 10, 11), its phospholipid binding is triggered at lower calcium concentrations (EC(50)=3-6 mu M) than those required for exocytosis(12). Furthermore, Syts bind clathrin-AP2 with high affinity, indicating that they may play a general role in endocytosis(4,5) rather than being confined to a specialized function in regulated exocytosis(3). Here me resolve this apparent contradiction by describing four Syts, three of which (Syt VI, VII and VIII) are widely expressed in non-neural tissues. All Syts tested share a common domain structure, with a cytoplasmic region composed of two C-2 domains that interacts with clathrin-AP2 (K-d=0.1-1.0 nM) and with neural and non-neural syntaxins. The first C-2 domains of Syt I, II, III, V and VII, but not of IV, VI or VIII, bind phospholipids with a similar Ca2+-concentration dependence (EC(50)=3-6 mu M). The same C-2 domains also bind syntaxin as a function of Ca2+ but the Ca2+-concentration dependence of Syt I, II, and V (>200 mu M) differs from that of Syt III and VII (<10 mu M), Syts therefore appear to be ubiquitous proteins with a role in exocytosis mediated by syntaxin binding. The Ca2+ levels needed to trigger syntaxin binding by the different Syts suggest that they play distinct roles in membrane fusion; the level required by Syt I approximates those required for synaptic exocytosis.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P51; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.neuro.17.1.219; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PERIN MS, 1994, J BIOL CHEM, V266, P623; Sambrook J., 1989, MOL CLONING LAB MANU; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH U, 1994, NEURON, V13, P1281; YOSHIDA A, 1992, J BIOL CHEM, V267, P25925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	30	548	563	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					594	599		10.1038/375594a0	http://dx.doi.org/10.1038/375594a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791877				2022-12-01	WOS:A1995RD28700053
J	MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C				MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C			RATIONAL DESIGN OF AROMATIC POLYKETIDE NATURAL-PRODUCTS BY RECOMBINANT ASSEMBLY OF ENZYMATIC SUBUNITS	NATURE			English	Article							STREPTOMYCES-COELICOLOR A3(2); NUCLEOTIDE-SEQUENCE; ENGINEERED BIOSYNTHESIS; HYBRID ANTIBIOTICS; DEDUCED FUNCTION; SYNTHASE GENE; ACTINORHODIN; GLAUCESCENS; CLUSTER	Recent advances in understanding of bacterial aromatic polyketide biosynthesis allow the development of a set of design rules for the rational manipulation of chain synthesis, reduction of keto groups and early cyclization steps by genetic engineering. The concept of rational design is illustrated by the preparation of Streptomyces strains that produce two new polyketides by expression of combinations of appropriate enzymatic subunits from naturally occurring polyketide synthases. The potential for generating molecular diversity within this class of molecules by genetic engineering is enormous.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; JOHN INNES CTR,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND	Stanford University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				Khosla, Chaitan/0000-0001-6529-495X				AOYAMA T, 1992, J ANTIBIOT, V45, P1767, DOI 10.7164/antibiotics.45.1767; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; CARTER GT, 1989, J ORG CHEM, V54, P4321, DOI 10.1021/jo00279a018; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, BIOCHEMISTRY-US, V33, P9321, DOI 10.1021/bi00197a036; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; GRIFFIN DA, 1984, J CHEM SOC PERK T 1, P1035, DOI 10.1039/p19840001035; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.micro.47.1.875; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, IN PRESS J AM CHEM S; O'Hagan D., 1991, POLYKETIDE METABOLIT; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TOKIWA Y, 1992, J AM CHEM SOC, V114, P4107, DOI 10.1021/ja00037a011; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	32	238	249	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					549	554		10.1038/375549a0	http://dx.doi.org/10.1038/375549a0			6	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791871				2022-12-01	WOS:A1995RD28700041
J	MEEHAN, TP; HENNEN, J; RADFORD, MJ; PETRILLO, MK; ELSTEIN, P; BALLARD, DJ				MEEHAN, TP; HENNEN, J; RADFORD, MJ; PETRILLO, MK; ELSTEIN, P; BALLARD, DJ			PROCESS AND OUTCOME OF CARE FOR ACUTE MYOCARDIAL-INFARCTION AMONG MEDICARE BENEFICIARIES IN CONNECTICUT - A QUALITY IMPROVEMENT DEMONSTRATION PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To evaluate the feasibility of linking claims-based pattern analysis with medical record review in the assessment of quality of hospital care among Medicare beneficiaries with acute myocardial infarction. Design: An analysis of risk-adjusted mortality after hospital admission for acute myocardial infarction using the regression model from the Health Care Financing Administration for predicting mortality rates. Hospital records for 300 patients admitted for myocardial infarction were abstracted to evaluate the accuracy of diagnostic coding and the adequacy of claims data-based risk adjustment and to assess process measures of quality care. Setting: Six Connecticut hospitals in the pilot study of the Medicare Hospital information Project. Patients: Medicare beneficiaries 65 years of age or older who were hospitalized with a primary diagnosis of acute myocardial infarction from 1989 to 1991. Main Outcome Measures: Principal diagnosis code verification rates for acute myocardial infarction; observed mortality rates at 30 and 365 days; 30-day standardized mortality ratios; and utilization rates for thrombolytic agents, aspirin, and beta-blockers. Results: The coding of acute myocardial infarction diagnosis had an overall accuracy of 96%. Little change was noted in relative mortality ratio hospital rank order after the exclusion of 13 patients who did not fulfill criteria for acute myocardial infarction and after additional risk adjustment with Killip class data. Utilization rates for therapies among eligible patients were as follows: aspirin, 73%; beta-blockers, 41%; and thrombolytic agents, 43%. The use of thrombolytic agents was associated with a lower 30-day mortality; the use of thrombolytic agents, aspirin, and beta-blockers was related to lower mortality rates at 1 year after discharge; and the use of these three therapies was lower in the two hospitals with the highest risk-adjusted mortality. Conclusions: Medicare principal diagnosis codes for acute myocardial infarction were accurate in the six study hospitals. Therapies that have been endorsed by clinicians in Connecticut were underused in elderly patients. Pattern analysis of Medicare claims data can be useful as a quality-of-care screening tool; however, additional clinical information is required to stimulate quality improvement efforts within hospitals.	EMORY UNIV, CTR CLIN EVALUAT SCI, DECATUR, GA 30030 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT 06457 USA; KERR L WHITE INST HLTH SERV RES, DECATUR, GA USA; UNIV CONNECTICUT, SCH MED, FARMINGTON, CT USA; US HLTH CARE FINANCING ADM, OFF PROGRAM ASSESSMENT & INFORMAT, BALTIMORE, MD 21207 USA	Emory University; University of Connecticut			Ballard, David J/H-1062-2018	Radford, Martha/0000-0001-7503-9557				BALLARD DJ, 1994, HEALTH SERV RES, V28, P771; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Corn R F, 1981, Inquiry, V18, P351; COX DR, 1972, J R STAT SOC B, V34, P187; DEMLO LK, 1978, MED CARE, V16, P995, DOI 10.1097/00005650-197812000-00003; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Feldman S E, 1993, Med Care Rev, V50, P123, DOI 10.1177/107755879305000202; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; Hayes R P, 1994, Med Care Rev, V51, P39, DOI 10.1177/107755879405100103; HAYES RP, 1994, CLIN PERFORMANCE QUA, V2, P233; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KRAKAUER H, 1991, STAT MED, V10, P521, DOI 10.1002/sim.4780100405; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NASH DB, 1992, JAMA-J AM MED ASSOC, V268, P917, DOI 10.1001/jama.268.7.917; SULLIVAN LW, 1992, MEDICARE HOSPITAL S, V55	19	57	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					928	936		10.7326/0003-4819-122-12-199506150-00007	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RC270	7755229				2022-12-01	WOS:A1995RC27000007
J	MUKHOPADHYAY, D; TSIOKAS, L; ZHOU, XM; FOSTER, D; BRUGGE, JS; SUKHATME, VP				MUKHOPADHYAY, D; TSIOKAS, L; ZHOU, XM; FOSTER, D; BRUGGE, JS; SUKHATME, VP			HYPOXIC INDUCTION OF HUMAN VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION THROUGH C-SRC ACTIVATION	NATURE			English	Article							PROTEIN-TYROSINE KINASE; OVEREXPRESSED PP60C-SRC; CELL-TRANSFORMATION; ANGIOGENESIS; GENE; PHOSPHORYLATION; FAMILY	ANGIOGENESIS the formation of new microvasculature by capillary sprouting, is crucial for tumour development(1). Hypoxic regions of solid tumours produce the powerful and directly acting angiogenic protein VEGF/VPF (vascular endothelial growth factor/vascular permeability factor)(2-6). We now investigate the signal transduction pathway involved in hypoxic induction of VEGF expression. Hypoxia is known to induce a tyrosine kinase cascade that results in the activation of nitrogen-fixation genes in Rhizobium meliloti(7), and activation of tyrosine kinases is critical in signalling triggered by growth factors and ultraviolet light. We show here that genistein, an inhibitor of protein tyrosine kinases blocks VEGF induction. Hypoxia increases the kinase activity of pp60(c-src) and its phosphorylation on tyrosine 416 but does not activate Fyn or Yes. Expression of either a dominant-negative mutant form of c-Src or of Raf-1 markedly reduces VEGF induction. VEGF induction by hypoxia in c-src(-) cells is impaired, although there is a compensatory activation of Fyn. Our results provide an insight into hypoxia-triggered intracellular signalling, define VEGF as a new downstream target for c-Src, and suggest a role for c-Src in promoting angiogenesis.	BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; CUNY HUNTER COLL, NEW YORK, NY 10018 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Takeda Oncology; City University of New York (CUNY) System; Hunter College (CUNY)			Sukhatme, Vikas/W-2776-2019	Tsiokas, Leonidas/0000-0002-3659-1813				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BREIER G, 1992, DEVELOPMENT, V114, P521; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CHENG HC, 1992, J BIOL CHEM, V267, P9248; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOONG AC, 1994, CANCER RES, V54, P5273; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMAS JE, 1993, ONCOGENE, V8, P2521; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852	28	540	558	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 15	1995	375	6532					577	581		10.1038/375577a0	http://dx.doi.org/10.1038/375577a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7540725				2022-12-01	WOS:A1995RD28700048
J	NASSAR, M; HORN, G; HERRMANN, C; SCHERER, A; MCCORMICK, F; WITTINGHOFER, A				NASSAR, M; HORN, G; HERRMANN, C; SCHERER, A; MCCORMICK, F; WITTINGHOFER, A			THE 2.2-ANGSTROM CRYSTAL-STRUCTURE OF THE RAS-BINDING DOMAIN OF THE SERINE THREONINE KINASE C-RAF1 IN COMPLEX WITH RAP1A AND A GTP ANALOG	NATURE			English	Article							RAS-P21 GTPASE; GENE-PRODUCT; HA-RAS; PROTEIN; TARGET; RAF-1; RECOGNITION; INHIBITION; RESOLUTION; HYDROLYSIS	The X-ray crystal structure of the complex between the Ras-related protein Rap1A in the GTP-analogue (GppNHp) form and the pas-binding domain (RED) of the Ras effector molecule c-Raf1, a ser/Thr-specific protein kinase, has been solved to a resolution of 2.2 Angstrom. It shows that RED has the ubiquitin superfold and that the structure of Rap1A is very similar to that of Ras. The interaction between the two proteins is mediated by an apparent central antiparallel beta-sheet formed by strands B1-B2 from RED and strands beta 2-beta 3 from Rap1A. Complex formation is mediated by main-chain and side-chain interactions of the so-called effector residues in the switch I region of Rap1A.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69119 HEIDELBERG,GERMANY; ONYX PHARMACEUT,RICHMOND,CA 94806	Max Planck Society	NASSAR, M (corresponding author), MAX PLANCK INST MOLEK PHYSIOL,STRUKTURELLE BIOL ABT,POSTFACH 102664,D-44026 DORTMUND,GERMANY.							AMOR JC, 1994, NATURE, V372, P704; Barnard D, 1995, ONCOGENE, V10, P1283; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1993, XPLOR VERSION 3 1; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COOK S, 1993, EMBO J, V12, P3485; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P1; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	547	562	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					554	560		10.1038/375554a0	http://dx.doi.org/10.1038/375554a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791872				2022-12-01	WOS:A1995RD28700042
J	NOWAK, MA; MAY, RM; PHILLIPS, RE; ROWLANDJONES, S; LALLOO, DG; MCADAM, S; KLENERMAN, P; KOPPE, B; SIGMUND, K; BANGHAM, CRM; MCMICHAEL, AJ				NOWAK, MA; MAY, RM; PHILLIPS, RE; ROWLANDJONES, S; LALLOO, DG; MCADAM, S; KLENERMAN, P; KOPPE, B; SIGMUND, K; BANGHAM, CRM; MCMICHAEL, AJ			ANTIGENIC OSCILLATIONS AND SHIFTING IMMUNODOMINANCE IN HIV-1 INFECTIONS	NATURE			English	Article							T-CELL DETERMINANTS; LYMPHOCYTES-T; SELECTION; VIRUS; RECOGNITION; RESPONSES; DOMINANCE; PEPTIDES; GENES	A TYPICAL protein antigen contains several epitopes that can be recognized by cytotoxic T lymphocytes (CTL), but in a characteristic antiviral immune response in vivo, CTL recognize only a small number of these potential epitopes, sometimes only one(1,2), this phenomenon is known as immunodominance(1-10). Antigenic variation within CTL epitopes has been demonstrated for the human immunodeficiency virus HIV-1 (ref. 11) and other viruses(12-17) and such 'antigenic escape' may be responsible for viral persistence. Here we develop a new mathematical model that deals with the interaction between CTL and multiple epitopes of a genetically variable pathogen, acid show that the nonlinear competition among CTL responses against different epitopes can explain immunodominance. This model suggests that an antigenically homogeneous pathogen population tends to induce a dominant response against a single epitope, whereas a heterogeneous pathogen population can stimulate complicated fluctuating responses against multiple epitopes. Antigenic variation in the immunodominant epitope can shift responses to weaker epitopes and thereby reduce immunological control of the pathogen population. These ideas are consistent with detailed longitudinal studies of CTL responses in HIV-1 infected patients. For vaccine design, the model suggests that the major response should be directed against conserved epitopes even if they are subdominant.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; UNIV VIENNA,INST MATH,A-1090 VIENNA,AUSTRIA	University of Oxford; University of Vienna	NOWAK, MA (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Nowak, Martin A/A-6977-2008	klenerman, paul/0000-0003-4307-9161; Lalloo, David/0000-0001-7680-2200; Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; BANGHAM CRM, 1989, T CELLS, P281; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CAMPOSLIMA P, 1993, SCIENCE, V260, P98; Carpenter S., 1990, Applied Virology Research, V2, P99; Gegin Cem, 1992, Journal of Immunology, V149, P3331; HILL AB, 1993, IMMUNOL REV, V133, P75, DOI 10.1111/j.1600-065X.1993.tb01510.x; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LIU ZR, 1993, J IMMUNOL, V151, P1852; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOWAK M, 1993, AIDS, V7, pS3, DOI 10.1097/00002030-199301001-00002; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, IN PRESS J THEOR BIO; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; ZINKERNAGEL RM, 1978, J EXP MED, V148, P592, DOI 10.1084/jem.148.2.592	28	306	311	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					606	611		10.1038/375606a0	http://dx.doi.org/10.1038/375606a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791879				2022-12-01	WOS:A1995RD28700056
J	PINET, V; VERGELLI, M; MARTIN, R; BAKKE, O; LONG, EO				PINET, V; VERGELLI, M; MARTIN, R; BAKKE, O; LONG, EO			ANTIGEN PRESENTATION MEDIATED BY RECYCLING OF SURFACE HLA-DR MOLECULES	NATURE			English	Article							CLASS-II MOLECULES; INVARIANT-CHAIN; PROTEIN-SYNTHESIS; MHC MOLECULES; MICE LACKING; LIVING CELLS; ENDOCYTOSIS; PEPTIDES; EXPRESSION; IA	CLASS II histocompatibility molecules associate with peptides derived from antigens that are processed in endocytic compartments. Antigen presentation to class II-restricted T cells generally requires newly synthesized class II molecules(1), associated invariant chain(2,3), and HLA-DM(4,5). Exceptions to these rules have been reported(6-10), but without description of an underlying mechanism. Here we show that presentation of immunodominant epitopes in the haemagglutinin protein of influenza virus and in myelin basic protein correlates,vith recycling of surface KLA-DR molecules. Truncation of either one of the alpha or beta cytoplasmic tails virtually eliminated internalization of HLA-DR molecules and presentation of haemagglutinin from inactive virus particles. In contrast, the invariant chain-dependent presentation of matrix antigen from the same virus particles was unaffected by these truncations. Thus HLA-DR cytoplasmic tails are not required for the conventional presentation pathway, but jointly contribute a signal for an alternative pathway involving internalization of HLA-DR molecules.	NIAID,IMMUNOGENET LAB,ROCKVILLE,MD 20852; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; UNIV OSLO,DEPT BIOL,N-0316 OSLO,NORWAY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Oslo			Long, Eric O/G-5475-2011; PINET, Valérie/G-6085-2012	Long, Eric O/0000-0002-7793-3728; PINET, Valérie/0000-0002-4044-6440; Bakke, Oddmund/0000-0003-4843-7626				ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIS JE, 1990, J IMMUNOL, V144, P990; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HARDING CV, 1989, J IMMUNOL, V142, P12; KAKIUCHI T, 1990, J IMMUNOL, V145, P1653; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LONG EO, 1994, J IMMUNOL, V153, P1487; MARTIN R, 1992, J IMMUNOL, V148, P1359; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NABAVI N, 1989, J IMMUNOL, V142, P1444; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PINET V, 1994, J IMMUNOL, V152, P4852; RADKA SF, 1984, HUM IMMUNOL, V10, P177, DOI 10.1016/0198-8859(84)90038-7; REID PA, 1992, IMMUNOLOGY, V77, P539; RICCIO P, 1994, NEUROREPORT, V5, P689, DOI 10.1097/00001756-199402000-00007; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STPIERRE Y, 1989, J IMMUNOL, V143, P808; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z	30	241	243	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					603	606		10.1038/375603a0	http://dx.doi.org/10.1038/375603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7540726				2022-12-01	WOS:A1995RD28700055
J	POWERS, NL; SALVI, RJ; WANG, J; SPONGR, V; QIU, CX				POWERS, NL; SALVI, RJ; WANG, J; SPONGR, V; QIU, CX			ELEVATION OF AUDITORY-THRESHOLDS BY SPONTANEOUS COCHLEAR OSCILLATIONS	NATURE			English	Article							SPONTANEOUS OTOACOUSTIC EMISSIONS; OUTER HAIR-CELLS; ACOUSTIC EMISSIONS; EAR CANALS; NERVE; RESPONSES; FREQUENCY; PATTERNS	THE inner ear sometimes acts as a robust sound generator, continuously broadcasting sounds (spontaneous otoacoustic emissions) which can be intense enough to be heard by other individuals standing nearby(1-4). Paradoxically, most individuals are unaware of the sounds generated within their ears, Two hypotheses could explain this paradox: (1) the spontaneous emissions may not be transmitted to the central nervous system; or (2) the spontaneous emission produces a continuous, high rate of neural activity, which, like the natural pattern of spontaneous activity, is ignored by the central nervous system. Here we demonstrate that high-intensity spontaneous otoacoustic emissions can vigorously activate auditory nerve fibres in mammals (Chinchilla laniger). This 'internal biological noise' creates a 'line busy' signal that significantly degrades a neuron's ability to respond to sound and results in a hearing loss completely different from that caused by damage to sensory cells(1,4).	SUNY BUFFALO,DEPT COMMUNICAT DISORDERS & SCI,HEARING RES LAB,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Wang, Jian/0000-0003-3633-6799				ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CLARK WW, 1984, HEARING RES, V16, P299, DOI 10.1016/0378-5955(84)90119-9; DALLOS P, 1976, J ACOUST SOC AM, V60, P510, DOI 10.1121/1.381086; DIELER R, 1991, J NEUROCYTOL, V20, P637, DOI 10.1007/BF01187066; ELDREDGE DH, 1981, J ACOUST SOC AM, V69, P1091, DOI 10.1121/1.385688; EVANS EF, 1981, TINNITUS, P108; FROYMOVICH O, 1995, J ACOUST SOC AM, V97, P3021, DOI 10.1121/1.411867; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; Kiang N.Y.-S., 1965, DISCHARGE PATTERNS S; Kiang NY, 1970, SENSORINEURAL HEARIN, P241, DOI DOI 10.1002/9780470719756.CH15; Liberman M. C., 1986, BASIC APPL ASPECTS N, P163; LIBERMAN MC, 1982, SCIENCE, V217, P1239; LONSBURYMARTIN BL, 1990, ANN OTO RHINOL LARYN, V99, P15, DOI 10.1177/00034894900990S502; MCFADDEN D, 1984, J ACOUST SOC AM, V76, P443, DOI 10.1121/1.391585; NEDZELNITSKY V, 1980, J ACOUST SOC AM, V68, P1676, DOI 10.1121/1.385200; POWERS NL, 1991, THESIS SUNY BUFFALO; RUGGERO MA, 1984, HEARING RES, V13, P293, DOI 10.1016/0378-5955(84)90083-2; SACHS MB, 1968, J ACOUST SOC AM, V43, P1120, DOI 10.1121/1.1910947; SALVI R, 1982, NEW PERSPECTIVES NOI, P165; SCHMIEDT RA, 1980, J NEUROPHYSIOL, V43, P1367, DOI 10.1152/jn.1980.43.5.1367; SINEX DG, 1984, HEARING RES, V13, P285, DOI 10.1016/0378-5955(84)90082-0; SINEX DG, 1986, J NEUROPHYSIOL, V56, P1763, DOI 10.1152/jn.1986.56.6.1763; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; SUBRAMANIAM M, 1994, HEARING RES, V74, P204, DOI 10.1016/0378-5955(94)90188-0; WILSON JP, 1980, HEARING RES, V2, P233, DOI 10.1016/0378-5955(80)90060-X; WILSON JP, 1981, TINNITUS, P82; ZUREK PM, 1982, J ACOUST SOC AM, V72, P774, DOI 10.1121/1.388258; ZUREK PM, 1981, J ACOUST SOC AM, V70, P446, DOI 10.1121/1.386787; ZUREK PM, 1981, J ACOUST SOC AM, V69, P514, DOI 10.1121/1.385481	30	33	33	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					585	587		10.1038/375585a0	http://dx.doi.org/10.1038/375585a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791874				2022-12-01	WOS:A1995RD28700050
J	SHER, GD; GINDER, GD; LITTLE, J; YANG, SY; DOVER, GJ; OLIVIERI, NF				SHER, GD; GINDER, GD; LITTLE, J; YANG, SY; DOVER, GJ; OLIVIERI, NF			EXTENDED THERAPY WITH INTRAVENOUS ARGININE BUTYRATE IN PATIENTS WITH BETA-HEMOGLOBINOPATHIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICKLE-CELL-ANEMIA; GLOBIN GENE-EXPRESSION; INCREASED FETAL HEMOGLOBIN; ADULT ERYTHROID-CELLS; HYDROXYUREA INDUCTION; DIABETIC MOTHERS; SODIUM-BUTYRATE; F PRODUCTION; DISEASE; 5-AZACYTIDINE	Background. Enhanced production of fetal hemoglobin lessens the severity of beta-thalassemia and sickle cell disease, Intravenous infusion of arginine butyrate can increase the number of reticulocytes containing fetal_hemoglobin in patients with these disorders, and it has induced a substantial increase in hemoglobin in one patient with thalassemia. We therefore tested the efficacy of this agent in patients with beta-hemoglobinopathies. Methods. We treated 10 patients with severe beta-thalassemia or sickle cell disease with arginine butyrate at an initial dose of 500 mg per kilogram of body weight per day (final dose, 2000 mg per kilogram per day), 6 days per week, for a mean (+/-SD) of 10+/-1.2 weeks (range, 9 to 13). A hematologic response was defined as an increase in the hemoglobin concentration of at least 2 g per deciliter in patients with thalassemia and as a twofold increase in fetal hemoglobin in patients with sickle cell disease. Results. There were increases in gamma-globin messenger RNA and in reticulocytes containing fetal hemoglobin, but no increases in hemoglobin, in the patients with thalassemia, A small, unsustained increase in fetal hemoglobin was observed in two patients with sickle cell disease, Drug toxicity was minimal at standard doses. One patient had a grand mat seizure after inadvertently receiving 2000 mg of arginine butyrate per kilogram over a period of six hours. Conclusions. Ten weeks of intravenous arginine butyrate did not produce a hematologic response in 10 patients with either severe beta-thalassemia or sickle cell disease.	HOSP SICK CHILDREN,HAEMOGLOBINOPATHY PROGRAM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University			Olivieri, Nancy/AAI-2250-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029902, R01DK029902] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29902] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARD H, 1985, PEDIATRICS, V75, P1143; BRITTENHAM GM, 1985, BLOOD, V65, P183; CAO A, 1994, BLOOD REV, V8, P1, DOI 10.1016/0268-960X(94)90002-7; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1987, BLOOD, V69, P109; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Constantoulakis P, 1989, Prog Clin Biol Res, V316B, P351; CONSTANTOULAKIS P, 1991, BLOOD, V77, P1326; DESFORGES JF, 1993, NEW ENGL J MED, V329, P1038, DOI 10.1056/NEJM199309303291413; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; DOVER GJ, 1994, BLOOD, V84, P339; DOVER GJ, 1978, BLOOD, V52, P664; DOVER GJ, 1992, SEMIN ONCOL, V19, P61; DOVER GJ, 1985, BLOOD, V66, P527; FIBACH E, 1993, BLOOD, V82, P2203, DOI 10.1182/blood.V82.7.2203.bloodjournal8272203; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1983, BLOOD, V62, P370; LITTLE J, 1994, CLIN RES, V42, pA238; LITTLE JA, 1995, BLOOD, V85, P1712, DOI 10.1182/blood.V85.7.1712.bloodjournal8571712; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; MILLER BA, 1986, BLOOD, V67, P104; NATHAN DG, 1990, ANN NY ACAD SCI, V612, P179; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PACE B, 1994, BLOOD, V84, P4344, DOI 10.1182/blood.V84.12.4344.bloodjournal84124344; PAPAYANNOPOULOU T, 1984, SCIENCE, V224, P617, DOI 10.1126/science.6200940; PEMBREY ME, 1978, BRIT J HAEMATOL, V40, P415, DOI 10.1111/j.1365-2141.1978.tb05813.x; PERRINE RP, 1972, LANCET, V2, P1163; PERRINE SP, 1989, BLOOD, V74, P454; PERRINE SP, 1988, P NATL ACAD SCI USA, V85, P8540, DOI 10.1073/pnas.85.22.8540; PERRINE SP, 1987, BIOCHEM BIOPH RES CO, V148, P694, DOI 10.1016/0006-291X(87)90932-6; PERRINE SP, 1985, NEW ENGL J MED, V312, P334, DOI 10.1056/NEJM198502073120602; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RODGERS GP, 1992, SEMIN ONCOL, V19, P67; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503; VICHINSKY EP, 1994, BLOOD, V83, P1124; WAYE JS, 1991, BLOOD, V77, P1100; WEATHERALL DJ, 1981, THALASSEMIA SYNDROME, P148; WOOD WG, 1980, BRIT J HAEMATOL, V45, P431, DOI 10.1111/j.1365-2141.1980.tb07163.x	47	133	143	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1606	1610		10.1056/NEJM199506153322404	http://dx.doi.org/10.1056/NEJM199506153322404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753139				2022-12-01	WOS:A1995RC19200004
J	SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA				SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA			EFFECT OF A PRIOR-AUTHORIZATION REQUIREMENT ON THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS BY MEDICAID PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAYMENT; THERAPY	Background. Prior authorization - mandatory advance approval for the use of expensive medications - is now the primary method by which Medicaid programs control expenditures for drugs. However, whether this policy reduces expenditures for specific drugs without causing the unwanted substitution of other drugs or medical services has been largely unstudied. We evaluated the effects of a prior-authorization policy involving nongeneric nonsteroidal antiinflammatory drugs (NSAIDs) in the Medicaid program in Tennessee. Methods. We compared monthly Medicaid expenditures that were potentially affected by the policy change during the year before and the two years after its implementation. We studied prescriptions for NSAIDs, other analgesic or antiinflammatory drugs, and psychotropic drugs, as well as outpatient services and inpatient admissions for the management of pain or inflammation. Results. At the midpoint of the base-line year, 495,821 people were enrolled in Medicaid. During that year, mean annualized Medicaid expenditures for NSAID prescriptions amounted to $22.41. Expenditures decreased by 53 percent (95 percent confidence interval, 48 to 57 percent) during the next two years, for an estimated savings of $12.8 million. The reduction in expenditures resulted from the increased use of generic NSAIDs, as well as from a 19 percent decrease in overall NSAID use (95 percent confidence interval, 13 to 25 percent). There was no concomitant increase in Medicaid expenditures for other medical care. Regular users of nongeneric NSAIDs, those most affected by the policy change, had similar reductions in NSAID expenditures and use, with no increase in expenditures for other medical care. Conclusions. Prior-authorization requirements may be highly cost effective with regard to expenditures for NSAIDs, drugs that have very similar efficacy and safety but substantial variation in cost.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,NASHVILLE,TN 37212; TENNESSEE STATE DEPT HLTH,BUR TENNCARE,NASHVILLE,TN	Vanderbilt University; Vanderbilt University; Tennessee Department Health	SMALLEY, WE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,A-1124 MCN,NASHVILLE,TN 37232, USA.			Sullivan, Lisa/0000-0003-0726-7149	AHRQ HHS [HS07768] Funding Source: Medline; FDA HHS [FD-U-0000073] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007768] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); FDA HHS; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BATCHLOR EE, 1992, OSTEOARTHRITIS DIAGN, P465; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Gondek K, 1994, Health Care Financ Rev, V15, P1; OLIN BR, 1992, DRUG FACTS COMP; POLLARD MR, 1991, HEALTH AFFAIR, V10, P196, DOI 10.1377/hlthaff.10.2.196; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; TOMITA DK, 1988, PB89143325; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; 1980, INT CLASSIFICATION D; 1993, DRUG EVALUATIONS ANN; 1992, STAT B, V73, P25; 1994, SOCIAL SECURITY B AN, P325	20	137	137	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1612	1617		10.1056/NEJM199506153322406	http://dx.doi.org/10.1056/NEJM199506153322406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753141	Bronze			2022-12-01	WOS:A1995RC19200006
J	TEMPLETON, GL; ILLING, LA; YOUNG, L; CAVE, MD; STEAD, WW; BATES, JH				TEMPLETON, GL; ILLING, LA; YOUNG, L; CAVE, MD; STEAD, WW; BATES, JH			RISK FOR TRANSMISSION OF MYCOBACTERIUM-TUBERCULOSIS AT THE BEDSIDE AND DURING AUTOPSY	ANNALS OF INTERNAL MEDICINE			English	Note								Objective: To emphasize the differing infectious potentials of a patient with tuberculosis. Setting: Hospital ward and autopsy room. Design: An epidemiologic investigation of tuberculin skin test conversions in a clinical setting and during autopsy when results of tuberculin tests done before exposure were available for all participants. Measurements: Tuberculin skin test results after the discovery of tuberculosis exposure from a patient with unsuspected tuberculosis for comparison with the test results before exposure; culture of sputum and autopsy material for Mycobacterium tuberculosis; and DNA fingerprinting of organisms. Intervention: Preventive therapy for persons with skin test conversion. Results: None of the 40 skin test-negative health care workers caring for the patient for 3 weeks on an open medical ward showed a skin test conversion, even though they had not used respiratory precautions. By contrast, among personnel present during the 3-hour autopsy, the test results of all five nonreactors converted from negative to positive (mean reaction, 24 mm). Two of these persons had a positive sputum culture 8 weeks later. The DNA fingerprints of all three isolates were identical. Conclusions: A patient who did not transmit tuberculosis before death released a prodigious number of tubercle bacilli during autopsy.	UNIV ARKANSAS, COLL MED, LITTLE ROCK, AR 72204 USA; ARKANSAS STATE DEPT HLTH, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	TEMPLETON, GL (corresponding author), JOHN L MCCLELLAN MEM VET ADM HOSP, 4300 W 7TH ST, LITTLE ROCK, AR 72205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001136] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 01136] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759; HEDVALL ERIK, 1940, AMER REV TUBERC, V41, P770; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; KOHN GJ, 1992, DIAGN MICR INFEC DIS, V15, P527, DOI 10.1016/0732-8893(92)90103-Z; MEADE GM, 1948, AM REV TUBERC PULM, V58, P675; MORRIS SI, 1946, AM REV TUBERC PULM, V54, P140; NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1; OSLER W, 1892, PRINCIPLES PRACTICE, P198; REID DD, 1957, BMJ-BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5035.10; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; RILEY RL, 1961, AIRBORNE INFECTION, P91; SLOAN R. A., 1942, New York State Journal of Medicine, V42, P133	17	90	92	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					922	925		10.7326/0003-4819-122-12-199506150-00005	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755227				2022-12-01	WOS:A1995RC27000005
J	ZHONG, Y				ZHONG, Y			MEDIATION OF PACAP-LIKE NEUROPEPTIDE TRANSMISSION BY COACTIVATION OF RAS/RAF AND CAMP SIGNAL-TRANSDUCTION PATHWAYS IN DROSOPHILA	NATURE			English	Article							PROTEIN-TYROSINE KINASE; ADENYLATE-CYCLASE; RECEPTOR; RUTABAGA; CURRENTS; GENE; RAS1	MUCH work on the signal transduction mechanisms underlying neurotransmission has been directed towards studying the roles of the cyclic AMP and phosphoinositide pathways1-3. Upon ligand binding, the transmitter receptors interact with heterotrimeric G proteins, allowing G(alpha) and G(beta gamma) subunits to disengage(2,3). The free G(alpha) then modulates the activity of adenylyl cyclase and phospholipase C1-3. It has been suggested that the G(beta gamma), complex which is activated through muscarinic or neuropeptide receptors can stimulate mitogen-activated protein kinase (MAPK) via activation of the small guanine-nucleotide-binding protein Ras(4,5). Sequential activation of the intermediates in the Ras/Raf serine-threonine protein kinase/MAPK kinase/MAPK/transcription factor pathway has emerged as a central mechanism for controlling cell proliferation and differentiation in yeast, worms, fruitflies and mammals(6-11). Here we show, by analysis of Drosophila mutants, that synaptic current and modulation of K+ current, triggered by a pituitary adenylyl cyclase-activating polypeptide-like neuropeptide(12), are mediated by coactivation of the Ras/Raf and Rutabaga-adenylyl cyclase pathways. Thus the Ras/Raf pathway also appears to be essential for G-protein-coupled neurotransmission.			ZHONG, Y (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Zhong, Yi/0000-0002-7927-5976; Zhong, Yi/0000-0001-7810-9899				ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hille B., 1992, IONIC CHANNELS EXCIT; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUMANSILBERBER, 1984, CELL, V0037; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; YATANI A, 1991, CELL, V61, P769; ZHAO ML, 1995, J NEUROSCI, V15, P1406; ZHONG Y, 1993, J NEUROGENET, V9, P15, DOI 10.3109/01677069309167273; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	30	97	98	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					588	592		10.1038/375588a0	http://dx.doi.org/10.1038/375588a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791875				2022-12-01	WOS:A1995RD28700051
J	ANNEST, JL; MERCY, JA; GIBSON, DR; RYAN, GW				ANNEST, JL; MERCY, JA; GIBSON, DR; RYAN, GW			NATIONAL ESTIMATES OF NONFATAL FIREARM-RELATED INJURIES - BEYOND THE TIP OF THE ICEBERG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; HOMICIDE; HOME	Objective.-To describe the magnitude and characteristics of nonfatal firearm-related injuries treated in hospital emergency departments in the United States and to compare nonfatal injury rates with firearm-related fatality rates. Design.-Data were obtained from medical records for all firearm-related injury cases identified using the National Electronic Injury Surveillance System (NEISS) from June 1, 1992, through May 31, 1993. Setting.-NEISS comprises 91 hospitals that are a stratified probability sample of all hospitals in the United States and its territories that have at least six beds and provide 24-hour emergency service. Main Outcome Measures.-Numbers and population rates for nonfatal and fatal firearm-related injuries. Results.-An estimated 99 025 (95% confidence interval [CI], 56 325 to 141 725) persons (or 38.6 per 100 000 population; 95% CI, 22.0 to 55.2) were treated for nonfatal firearm-related injuries in US hospital emergency departments during the study period. The rate of nonfatal firearm-related injuries treated was 2.6 (95% CI, 1.5 to 3.7) times the national rate of fatal firearm-related injuries for 1992. Conclusions.-Nonfatal firearm-related injuries contribute substantially to the overall public health burden of firearm-related injuries. NEISS can be useful to monitor the number of nonfatal firearm-related injuries in the United States. A national surveillance system is needed to provide uniform data on firearm-related injury morbidity and mortality for use in research and prevention efforts.			ANNEST, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT & PROGRAMMING K59,ATLANTA,GA 30341, USA.							ASKRANT AP, 1968, ACCIDENTS HOMICIDE; BRICK M, 1992, STATISTICAL EVALUATI; BURT CW, 1995, ADVANCE DATA VITAL H, V261, P1; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; COOK PJ, 1985, J QUANTITATIVE CRIMI, V0001; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1994, ADV DATA VITAL HLTH, V242, P1; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KOCHANEK KD, 1994, MONTHLY VITAL STAT S, V43, P56; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARKER D, 1988, CPSCC871144 US CONS; RAND MR, 1994, NCJ147003 US DEP JUS, P1; Rice DP, 1989, COST INJURY US REPOR; SALTZMAN LE, 1992, JAMA-J AM MED ASSOC, V267, P3043, DOI 10.1001/jama.267.22.3043; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; WINTEMUTE G, 1993, JAMA-J AM MED ASSOC, V269, P2213, DOI 10.1001/jama.1993.03500170043026; WRIGHT JD, 1981, WEAPONS CRIME VIOLEN, P293; ZWERLING C, 1993, AM J PREV MED, V3, P1; 1976, VITAL HLTH STAT 10, V105; 1991, MMWR-MORBID MORTAL W, V43, P609; 1964, VITAL HLTH STAT 10, V6; 1994, NATIONAL ELECTRONIC; 1994, MMWR-MORBID MORTAL W, V43, P37; 1993, NATIONAL ELECTRONIC; 1994, TIP ICEBERG WEAPON I, P5	28	227	227	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1749	1754		10.1001/jama.273.22.1749	http://dx.doi.org/10.1001/jama.273.22.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769767				2022-12-01	WOS:A1995RB80000026
J	DOWELL, SF; TOKO, A; SITA, C; PIARROUX, R; DUERR, A; WOODRUFF, BA				DOWELL, SF; TOKO, A; SITA, C; PIARROUX, R; DUERR, A; WOODRUFF, BA			HEALTH AND NUTRITION IN CENTERS FOR UNACCOMPANIED REFUGEE CHILDREN - EXPERIENCE FROM THE 1994 RWANDAN REFUGEE CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY		MED MONDE, MARSEILLE, FRANCE; UN, CHILDRENS FUND, KINSHASA, DEM REP CONGO		DOWELL, SF (corresponding author), CTR DIS CONTROL & PREVENT, RESP & ENTER VIRUSES BRANCH, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.			piarroux, renaud/0000-0002-4151-4134				[Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRERE B, 1994, ENQUETE DEMOGRAPHIQU; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; Williamson J, 1988, UNACCOMPANIED CHILDR; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1992, GUIDELINES CHOLERA C; 1995, LANCET, V348, P339; 1994, MMWR-MORBID MORTAL W, V43, P701; 1992, MMWR MORB MORTAL WKL, V41; 1994, STANDARDS PROTECTION; 1983, MEASURING CHANGE NUT	15	19	19	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1802	1806		10.1001/jama.273.22.1802	http://dx.doi.org/10.1001/jama.273.22.1802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769778				2022-12-01	WOS:A1995RB80000037
J	KIZER, KW; VASSAR, MJ; HARRY, RL; LAYTON, KD				KIZER, KW; VASSAR, MJ; HARRY, RL; LAYTON, KD			HOSPITALIZATION CHARGES, COSTS AND INCOME FOR FIREARM-RELATED INJURIES AT A UNIVERSITY TRAUMA CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To quantify the actual cost of inpatient medical care for firearm-related injuries at a university trauma center. Design.-Retrospective Case Series of all hospital admissions for firearm-related injuries for the 3 years 1990 through 1992. Total inpatient financial data Were examined by means of a recently instituted cost-accounting methodology. Setting.-Level trauma Center at a university hospital that provides trauma care and tertiary care to 3.7 million residents of 23 Counties. Patients.-A total of 787 consecutive patients were admitted to the hospital with firearm-related injuries information from the trauma registry and hospital finance records were linked for 750 (95%) of these patients. Main Outcome Measures.-Total inpatient hospital charges, costs, revenues, and net income according to payer source. Results.-Men aged 15 to 44 years accounted for 77% of patients with firearm-related injuries. The overall mean and median hospital charges per admission were $52 271 and $28 033, respectively, whereas the overall mean and median hospital costs per admission were $13 794 and $7964, respectively. The net income per patient ranged from an average loss of $6980 for each patient having no insurance to an average profit of $28 557 for each patient with a health maintenance organization contract the losses sustained on nonsponsored and Medicaid patients were more than offset by net income from patients having private health insurance, Medicare or other insurance coverage such that there was an average profit of $5809 per admission for a firearm-related injury. Concluslons.-Treatment of firearm-related injuries produces net income for this University trauma center by virtue of the cost shifting built into its pricing structure. if data from this institution ate extrapolated to the nation, then the actual cost of providing medical care for firearm-related injuries in the United States in 1995 is projected to be $4.0 billion. The majority of this cost will be paid indirectly by private health insurance.	UNIV CALIF DAVIS,SCH MED,DEPT COMMUNITY & INT HLTH,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DIV EMERGENCY MED & CLIN TOXICOL,DAVIS,CA 95616; UNIV CALIF DAVIS,MED CTR,FINANCIAL SERV ADM,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,MED CTR,TRAUMA PROGRAM,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					[Anonymous], 1988, INT CLASSIFICATION D; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1989, DETERMINING INJURY S; 1990, TRANSITION 1 SOFTWAR; 1994, MMWR-MORBID MORTAL W, V43, P37; 1991, TRAUMA CARE LIFESAVI	18	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1768	1773		10.1001/jama.273.22.1768	http://dx.doi.org/10.1001/jama.273.22.1768			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769771				2022-12-01	WOS:A1995RB80000030
J	SOSIN, DM; SNIEZEK, JE; WAXWELLER, RJ				SOSIN, DM; SNIEZEK, JE; WAXWELLER, RJ			TRENDS IN DEATH ASSOCIATED WITH TRAUMATIC BRAIN INJURY, 1979 THROUGH 1992 - SUCCESS AND FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; HEAD-INJURY	Objective.-To report updated national trends in traumatic brain injury deaths from 1979 through 1992. Design.-Retrospective analysis of Multiple Cause-of-Death Public Use Data Tapes from the National Center for Health Statistics. All deaths associated with traumatic brain injury were identified, the underlying causes of death were categorized, and the annual rates were calculated per 100 000 US residents. Patients.-Residents of the United States who died with traumatic brain injury from 1979 through 1992. Results.-An average of 52 000 US residents die each year with traumatic brain injuries. The brain injury-associated death rate declined 22% from 24.6 per 100 000 US residents in 1979 to 19.3 per 100 000 US residents in 1992. Firearm-related rates increased 13% from 1984 through 1992, undermining a 25% decline in motor vehicle-related rates for the same period. Firearms surpassed motor vehicles as the largest single cause of death associated with traumatic brain injury in 1990. Conclusions.-These data highlight the success of efforts to prevent traumatic brain injury due to motor vehicles and failure to prevent such injuries due to firearms. The increasing importance of penetrating injury has important implications for research, treatment, and prevention of traumatic brain injury in the United States.			SOSIN, DM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.							FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1994, FIREARM MOTOR VEHICL; GRAHAM J, 1992, POSITION PAPERS 3RD; IRWIN R, 1970, INTERCENSAL POPULATI; Kraus JF, 1993, HEAD INJURY, P1; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76, DOI DOI 10.1097/00001199-199106000-00010; Mercy J. A., 1993, HLTH AFFAIRS     WIN, P7; Nelson David E., 1993, Morbidity and Mortality Weekly Report, V42, P29; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; 1994, MMWR-MORBID MORTAL W, V43, P37; 1993, CURRENT POPULATI P25, V1095; 1994, DOT HS808022 US DEP; 1977, MANUAL INT CLASSIFIC	14	273	279	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1778	1780		10.1001/jama.273.22.1778	http://dx.doi.org/10.1001/jama.273.22.1778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769773				2022-12-01	WOS:A1995RB80000032
J	ADAMI, J; FRISCH, M; YUEN, J; GLIMELIUS, B; MELBYE, M				ADAMI, J; FRISCH, M; YUEN, J; GLIMELIUS, B; MELBYE, M			EVIDENCE OF AN ASSOCIATION BETWEEN NON-HODGKINS-LYMPHOMA AND SKIN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							TRANSPLANT RECIPIENTS; UV-RADIATION; TIME TRENDS; RISK; MECHANISMS	Objective-To investigate a possible Link between exposure to ultraviolet light and the almost epidemic increase in non-Hodgkin's lymphoma worldwide. Because ultraviolet light is known to cause skin cancers, the association between non-Hodgkin's lymphoma and skin cancer was studied. Design-Secondary occurrence of either malignant melanoma or squamous cell skin cancer in cohorts of patients with a first diagnosis of either non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, and vice versa, were studied. Expected numbers of subsequent cancers were calculated by sex, age, and period specific national incidence rates multiplied by the person years under observation in the cohorts. Setting-Denmark (1943-89) and Sweden (1958-89). Subjects-Four population based cohorts identified in the nationwide cancer registries (34641 people with non-Hodgkin's lymphoma, 17400 with chronic lymphocytic leukaemia, 34989 with malignant melanoma, 25980 with squamous cell skin cancer). A total of 562085 person years were accrued for the analysis. Main outcome measures-The ratios of observed to expected cancers (the standardised incidence ratio) served as a measure of the relative risk. Results-The relative risk for developing squamous cell skin cancer was 5.5 (95% confidence interval 4.6 to 6.6) among patients with non-Hodgkin's lymphoma and 8.6 (7.2 to 10.3) among patients with chronic lymphocytic leukaemia. The relative risks remained high over more than IS years of follow up. Relative risks for malignant melanoma were 2.4 (1.8 to 3.2) for patients with non-Hodgkin's lymphoma and 3.1 (2.1 to 4.4) for patients with chronic lymphocytic leukaemia. After aquamous cell skin cancer had been diagnosed there was a twofold excess risk for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. By contrast, in each of the cohorts the general cancer risks excluding skin and lymphoproliferative malignancies were close to the expected. Conclusions-The occurrence of non-Hodgkin's lymphoma and skin cancer are strongly associated; this supports the hypothesis that the secular increase in exposure to ultraviolet light may have contributed to the increasing incidence of non-Hodgkin's lymphoma in recent decades	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK; UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN	Aarhus University; Statens Serum Institut; Uppsala University; Uppsala University Hospital	ADAMI, J (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN.		Yuen, Jonathan/AAI-2035-2021; Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Yuen, Jonathan/0000-0003-2944-9226; melbye, mads/0000-0001-8264-6785				BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BRESLOW N, 1987, STAT METHODS CANC RE, V2, P71; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CASABONA J, 1991, INT J CANCER, V47, P49, DOI 10.1002/ijc.2910470110; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; COBEMAN M, 1985, ANN INTERN MED, V103, P140; DEVESA SS, 1992, CANCER RES, V52, pS5432; EBBESEN P, 1981, J NATL CANCER I, V67, P1077; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; HAKULINEN T, 1985, AM J MED, V78, P29, DOI 10.1016/0002-9343(85)90242-6; HARTGE P, 1992, CANCER RES, V52, pS5566; HERSEY P, 1983, LANCET, V1, P545; HERSEY P, 1983, J IMMUNOL, V31, P171; HOOVER R, 1973, LANCET, V2, P55; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; Kripke M L, 1981, Adv Cancer Res, V34, P69, DOI 10.1016/S0065-230X(08)60239-0; KRIPKE ML, 1990, J NATL CANCER I, V82, P1392, DOI 10.1093/jnci/82.17.1392; Lee JAH, 1982, CANC EPIDEMIOLOGY PR, P984; LENNERT K, 1978, HDB SPEZIELLEN PA 3B, V1, P84; MAGRATH I, 1992, CANCER RES, V52, pS5529; MARTINSSON U, 1992, ACTA ONCOL, V31, P275, DOI 10.3109/02841869209108173; MARTINSSON U, 1989, EUR J HAEMATOL, V43, P332; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OSTERLIND A, 1991, Current Opinion in Oncology, V3, P355; PARKIN DM, 1993, INT J CANCER, V54, P594; PENN I, 1988, CANCER DETECT PREV, V12, P39; POTTER M, 1992, CANCER RES, V52, pS5522; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SHAPIRO RS, 1988, BLOOD, V71, P1234; STORM HH, 1992, CANCER INCIDENCE DEN; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I; 1993, CANCER INCIDENCE SWE; 1992, IARC MONOGRAPHS EVAL, V55, P73	36	212	213	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1491	1495		10.1136/bmj.310.6993.1491	http://dx.doi.org/10.1136/bmj.310.6993.1491			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787593	Green Published			2022-12-01	WOS:A1995RD28500018
J	MOLLER, H; MELLEMKJAER, L; MCLAUGHLIN, JK; OLSEN, JH				MOLLER, H; MELLEMKJAER, L; MCLAUGHLIN, JK; OLSEN, JH			OCCURRENCE OF DIFFERENT CANCERS IN PATIENTS WITH PARKINSONS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							MELANOMA		DANISH CANC SOC,DIV CANC EPIDEMIOL,COPENHAGEN,DENMARK; NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892	Danish Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOLLER, H (corresponding author), INT AGCY RES CANC,F-69372 LYON,FRANCE.			Olsen, Jorgen Helge/0000-0001-9633-5662; Moller, Henrik/0000-0001-8200-5929				GRANDINETTI A, 1994, AM J EPIDEMIOL, V139, P1129, DOI 10.1093/oxfordjournals.aje.a116960; GRENHOFF J, 1989, BRIT J ADDICT, V84, P477; JANSSON B, 1985, ANN NEUROL, V17, P505, DOI 10.1002/ana.410170514; KOCHAR AS, 1985, AM J MED, V79, P119, DOI 10.1016/0002-9343(85)90555-8; WICK MM, 1977, CANCER RES, V37, P2123	5	79	81	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1500	1501		10.1136/bmj.310.6993.1500	http://dx.doi.org/10.1136/bmj.310.6993.1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787596	Green Published			2022-12-01	WOS:A1995RD28500021
J	NEED, AG; WISHART, JM; SCOPACASA, F; HOROWITZ, M; MORRIS, HA; NORDIN, BEC				NEED, AG; WISHART, JM; SCOPACASA, F; HOROWITZ, M; MORRIS, HA; NORDIN, BEC			EFFECT OF PHYSICAL-ACTIVITY ON FEMORAL BONE-DENSITY IN MEN	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ADELAIDE HOSP,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5001,AUSTRALIA	Royal Adelaide Hospital; University of Adelaide	NEED, AG (corresponding author), INST MED & VET SCI,DIV CLIN BIOCHEM,ADELAIDE,SA 5000,AUSTRALIA.		Morris, Howard A/G-4564-2010; Morris, Howard/L-6272-2019					MCARDLE WD, 1986, EXERCISE PHYSL ENERG, P642; SLEMENDA CW, 1993, BONE MINER, V20, P125, DOI 10.1016/S0169-6009(08)80021-9; SNOWHARTER C, 1992, J BONE MINER RES, V7, P1291; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WISHART JM, IN PRESS CLIN ENDOCR	5	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1501	1502		10.1136/bmj.310.6993.1501	http://dx.doi.org/10.1136/bmj.310.6993.1501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787597	Green Published			2022-12-01	WOS:A1995RD28500022
J	PHILP, I; MCKEE, KJ; MELDRUM, P; BALLINGER, BR; GILHOOLY, MLM; GORDON, DS; MUTCH, WJ; WHITTICK, JE				PHILP, I; MCKEE, KJ; MELDRUM, P; BALLINGER, BR; GILHOOLY, MLM; GORDON, DS; MUTCH, WJ; WHITTICK, JE			COMMUNITY CARE FOR DEMENTED AND NONDEMENTED ELDERLY PEOPLE - A COMPARISON STUDY OF FINANCIAL BURDEN, SERVICE USE, AND UNMET NEEDS IN FAMILY SUPPORTERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure and compare perceived financial burden, use of services, and perceived unmet service needs of supporters of demented and non-demented elderly people. Design-Comparison study of age and sex matched demented and non-demented elderly people and their supporters. Setting-25 primary health care teams in Dundee. Subjects-114 community resident elderly (age over 65) people with dementia, 114 age and sex matched comparators, and the main informal supporter of each elderly person. Main outcome measures-Carers' perceptions of financial impact of looking after an old person, service use (from a list of locally available services), unmet service needs, and needs for three types of generic service (help with supervision, housework, or personal care). Results-Financial impact was low, except for extra household expense in the dementia group. There was significantly greater use of mainstream domiciliary and day care services in the dementia group. Dementia was nevertheless associated with a high level of unmet need, mainly for more mainstream support and help with supervision of the elderly person. Conclusion-Supervisory care for demented elderly people should be further developed within an expanded domiciliary service to meet supporters needs.	ROYAL VICTORIA HOSP,DEPT GERIATR MED,DUNDEE,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,AGING & HLTH SECT,DUNDEE DD1 9SY,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN,SCOTLAND; ROYAL DUNDEE LIFF HOSP,DUNDEE,SCOTLAND; UNIV GLASGOW,BEHAV SCI GRP,GLASGOW G61 1BD,LANARK,SCOTLAND; BANGOR DIST GEN HOSP,LOTHIAN,SCOTLAND	University of Dundee; University of Aberdeen; University of Glasgow			Gilhooly, Mary/A-6330-2014	Gilhooly, Mary/0000-0003-0504-3619; philp, ian/0000-0002-3972-6496				[Anonymous], 1981, GROWING OLDER; ARIE T, 1986, BRIT MED BULL, V42, P91, DOI 10.1093/oxfordjournals.bmb.a072105; BOND J, 1980, BRIT J PSYCHIAT, V157, P221; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; GILHOOLY MLM, 1984, BRIT J MED PSYCHOL, V57, P35, DOI 10.1111/j.2044-8341.1984.tb01578.x; GRAD J, 1986, BRIT J PSYCHIAT, V114, P265; HAY JW, 1987, AM J PUBLIC HEALTH, V77, P1169, DOI 10.2105/AJPH.77.9.1169; HOWELLS J, 1990, Medical Science Research, V18, P843; HUANG LF, 1985, PUBLIC HLTH REP, V130, P3; LEVIN E, 1989, FAMILIES SERVICES CO; MACLENNAN WJ, 1984, BRIT MED J, V288, P701, DOI 10.1136/bmj.288.6418.701; PATTIE AH, 1979, CLIFTOTT ASSESSMENT; PHILP I, 1992, Health Bulletin (Edinburgh), V50, P296; PHILP I, 1988, J ROY COLL GEN PRACT, V38, P153; POULSHOCK SW, 1984, J GERONTOL, V39, P230, DOI 10.1093/geronj/39.2.230; Sheldon F, 1982, Age Ageing, V11, P184, DOI 10.1093/ageing/11.3.184; TONER H, 1985, DEMENTIA RES INNOVAT, P28; WEST P, 1984, SOC SCI MED, V18, P287, DOI 10.1016/0277-9536(84)90117-5; WHITTICK JE, 1988, BRIT J CLIN PSYCHOL, V27, P167, DOI 10.1111/j.2044-8260.1988.tb00765.x; WHITTICK JE, 1993, THESIS U GLASGOW GLA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92; 1987, REPORT MRC ALZHEIMER; 1980, SCOTTISH HLTH AUTHOR	23	63	64	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1503	1506		10.1136/bmj.310.6993.1503	http://dx.doi.org/10.1136/bmj.310.6993.1503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD285	7787599	Green Published			2022-12-01	WOS:A1995RD28500024
J	RAFFLE, AE; ALDEN, B; MACKENZIE, EFD				RAFFLE, AE; ALDEN, B; MACKENZIE, EFD			DETECTION RATES FOR ABNORMAL CERVICAL SMEARS - WHAT ARE WE SCREENING FOR	LANCET			English	Article							CARCINOMA INSITU; MORTALITY; CANCER; TRENDS; DNA	We analysed rates of detection for smear abnormalities in 255 000 women served by the Bristol screening programme. The programme began in 1966 with the aim of eradicating the 30-40 deaths each year in Bristol from cervical cancer. Organisation has been good and population uptake has been high for the past 15 years. Records were computerised in 1977. During the 1988 to 1993 screening round, 225 974 women were tested. New smear abnormalities were found in 15 551, of whom nearly 6000 were referred for colposcopy. These numbers are excessively high in comparison with the incidence of the malignancy we are trying to prevent. The effect of screening on death rates in Bristol is too small to detect. Our conclusion is that despite good organisation of the service, much of our effort in Bristol is devoted to limiting the harm done to healthy women and to protecting our staff from litigation as cases of serious disease continue to occur. The real lesson from 30 years' cervical screening is that no matter how obvious the predicted benefit may seem for any screening test, introduction should never take place without adequate prior evaluation of both positive and negative effects in controlled trials.	UNITED BRISTOL HEALTHCARE TRUST,DEPT INFORMAT TECHNOL,BRISTOL,AVON,ENGLAND; SOUTHMEAD HLTH SERV TRUST,BRISTOL,AVON,ENGLAND		RAFFLE, AE (corresponding author), BRISTOL & DIST HLTH AUTHOR,10 DIGHTON ST,BRISTOL BS2 8EE,AVON,ENGLAND.							ADELSTEIN AM, 1971, BRIT J PREV SOC MED, V25, P186; ANDERSON CM, 1994, BRIT MED J, V309, P953, DOI 10.1136/bmj.309.6959.953a; AUSTOKER J, 1994, CANCER CERVIX UTERI; BUCKLEY CH, 1994, J CLIN PATHOL, V47, P481; CREASMAN WT, 1972, OBSTET GYNECOL, V39, P373; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DUNCAN ID, 1993, GUIDELINES CLIN PRAC; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; MACGREGOR JE, 1994, BMJ-BRIT MED J, V308, P1407, DOI 10.1136/bmj.308.6941.1407; MACGREGOR JE, 1978, LANCET, V2, P774; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PARTINGTON CK, 1991, CANCER, V67, P3104, DOI 10.1002/1097-0142(19910615)67:12<3104::AID-CNCR2820671227>3.0.CO;2-L; SASIENI P, 1991, LANCET, V338, P818, DOI 10.1016/0140-6736(91)90701-P; SIGURDSSON K, 1991, INT J CANCER, V48, P523, DOI 10.1002/ijc.2910480408; 1965, REPORT MED OFFICER H; 1994, REPORT 1ST 5 YEARS N	18	111	111	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1469	1473		10.1016/S0140-6736(95)91036-0	http://dx.doi.org/10.1016/S0140-6736(95)91036-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769901				2022-12-01	WOS:A1995RC18900008
J	WYATT, J; BEARD, D; GRAY, A; BUSUTTIL, A; ROBERTSON, C				WYATT, J; BEARD, D; GRAY, A; BUSUTTIL, A; ROBERTSON, C			THE TIME OF DEATH AFTER TRAUMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL EDINBURGH & ASSOCIATED HOSP,DIRECTORATE ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,FORENS MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; TRUNKEY DD, 1983, SCI AM, V249, P20; 1988, REPORT WORKING PARTY; 1994, EMERGENCY HEALTHCARE; 1992, HLTH NATION, P102	5	39	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1502	1502		10.1136/bmj.310.6993.1502	http://dx.doi.org/10.1136/bmj.310.6993.1502			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787598	Green Published			2022-12-01	WOS:A1995RD28500023
J	ZUCKERMAN, AJ				ZUCKERMAN, AJ			THE NEW GB HEPATITIS VIRUSES	LANCET			English	Editorial Material											ZUCKERMAN, AJ (corresponding author), ROYAL FREE HOSP,SCH MED,WHO,COLLABORATING CTR REFERENCE & RES VIRAL DIS,LONDON,ENGLAND.							DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; PARKS WP, 1969, J INFECT DIS, V120, P539, DOI 10.1093/infdis/120.5.539; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, IN PRESS P NATL ACAD	5	51	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1453	1454		10.1016/S0140-6736(95)91032-8	http://dx.doi.org/10.1016/S0140-6736(95)91032-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769898				2022-12-01	WOS:A1995RC18900004
J	CARRINGTON, WA; LYNCH, RM; MOORE, EDW; ISENBERG, G; FOGARTY, KE; FREDRIC, FS				CARRINGTON, WA; LYNCH, RM; MOORE, EDW; ISENBERG, G; FOGARTY, KE; FREDRIC, FS			SUPERRESOLUTION 3-DIMENSIONAL IMAGES OF FLUORESCENCE IN CELLS WITH MINIMAL LIGHT EXPOSURE	SCIENCE			English	Article							SMOOTH-MUSCLE; MICROSCOPY; NUCLEUS	Fluorescent probes offer insight into the highly localized and rapid molecular events that underlie cell function. However, methods are required that can efficiently transform the limited signals from such probes into high-resolution images. An algorithm has now been developed that produces highly accurate images of fluorescent probe distribution inside cells with minimal light exposure and a conventional light microscope. This method provides resolution nearly four times greater than that currently available from any fluorescence microscope and was used to study several biological problems.	UNIV ARIZONA, DEPT PHYSIOL, TUCSON, AZ 85724 USA; UNIV BRITISH COLUMBIA, DEPT PHYSIOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV HALLE WITTENBERG, FAK MED, JULIUS BERNSTEIN INST PHYSIOL, DEPT PHYSIOL, D-06097 HALLE, GERMANY	University of Arizona; University of British Columbia; Martin Luther University Halle Wittenberg	CARRINGTON, WA (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, BIOMED IMAGING GRP, WORCESTER, MA 01605 USA.			Moore, Edwin DW/0000-0001-7519-5592				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BOYDE A, 1985, SCIENCE, V230, P1270, DOI 10.1126/science.4071051; BRAKENHOFF GJ, 1985, NATURE, V317, P748, DOI 10.1038/317748a0; BRENNER M, 1994, AM LAB, V26, P14; BUTLER JP, 1981, SIAM J NUMER ANAL, V18, P381, DOI 10.1137/0718025; CARRINGTON W, 1987, 13TH P ANN NE BIOENG, P108; CARRINGTON WA, 1990, P SOC PHOTO-OPT INS, V1205, P72, DOI 10.1117/12.17785; CARRINGTON WA, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P151; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CARRINGTON WA, 1992, THESIS WASHINGTON U; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; COLEMAN R, 1987, J MICROSC-OXFORD, V153, P233; CONCHELLO JA, 1994, SPIE P, V2302, P369; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FAY FS, 1986, OPTICAL METHODS CELL, P51; FRISKENGIBSON S, 1989, J OPT SOC AM A, V6, P9; GASBJERG PK, 1994, BIOPHYS J, V66, pA274; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GROETSCH CW, 1984, RES NOTES MATH, V107; GUERRERO A, 1993, BIOPHYS J, V64, pA153; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; Hanson K. M., 1987, IMAGE RECOVERY THEOR, P79; HELL S, 1993, J MICROSC-OXFORD, V169, P391, DOI 10.1111/j.1365-2818.1993.tb03315.x; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; IINO M, 1987, BIOCHEM BIOPH RES CO, V142, P47, DOI 10.1016/0006-291X(87)90449-9; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOSHY M, 1990, SOC PHOTO OPT INSTRU, V1205, P64; KRISHNAMURTHY V, 1992, SPIE, V1660, P95; Lanni F., 1993, Bioimaging, V1, P187, DOI 10.1002/1361-6374(199312)1:4<187::AID-BIO1>3.3.CO;2-G; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; LYNCH R M, 1991, Biophysical Journal, V59, p157A; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TELLA LL, 1985, THESIS WORCESTER POL; Tikhonov A.N., 1977, SIAM REV, V32, P491, DOI DOI 10.1137/1021044; TUFT R A, 1992, Biophysical Journal, V61, pA34; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WILSON JE, 1988, MICROCOMPARTMENTATIO, P172	42	285	298	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1483	1487		10.1126/science.7770772	http://dx.doi.org/10.1126/science.7770772			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770772				2022-12-01	WOS:A1995RC19000036
J	CORTES, J; WIESMANN, KEH; ROBERTS, GA; BROWN, MJB; STAUNTON, J; LEADLAY, PF				CORTES, J; WIESMANN, KEH; ROBERTS, GA; BROWN, MJB; STAUNTON, J; LEADLAY, PF			REPOSITIONING OF A DOMAIN IN A MODULAR POLYKETIDE SYNTHASE TO PROMOTE SPECIFIC CHAIN CLEAVAGE	SCIENCE			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BIOSYNTHESIS; GENES; ORGANIZATION; EXPRESSION; CLUSTER	Macrocyclic polyketides exhibit an impressive range of medically useful activities, and there is great interest in manipulating the genes that govern their synthesis. The 6-deoxyerythronolide B synthase (DEBS) of Saccharopolyspora erythraea, which synthesizes the aglycone core of the antibiotic erythromycin A, has been modified by repositioning of a chain-terminating cyclase domain to the carboxyl-terminus of DEBS1, the multienzyme that catalyzes the first two rounds of polyketide chain extension. The resulting mutant markedly accelerates formation of the predicted triketide lactone, compared to a control in which the repositioned domain is inactive. Repositioning of the cyclase should be generally useful for redirecting polyketide synthesis to obtain polyketides of specified chain lengths.	UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT ORGAN CHEM,CAMBRIDGE CB2 1EW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge				Roberts, Gareth/0000-0002-3726-390X; Leadlay, Peter/0000-0002-3247-509X; Cortes, Jesus/0000-0002-2475-6983				APARICIO JF, 1994, J BIOL CHEM, V269, P8524; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; CAFFREY P, 1991, EUR J BIOCHEM, V195, P823, DOI 10.1111/j.1432-1033.1991.tb15771.x; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CUTTER A, UNPUB; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; KANEDA T, 1962, J BIOL CHEM, V237, P322; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KAO CM, 1994, J BIOL CHEM, V265, P509; LEADLAY PF, 1993, BIOCHEM SOC T, V21, P218, DOI 10.1042/bst0210218; MACNEIL DJ, 1992, GENE, V115, P97; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; ROBERTS GB, UNPUB; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; STAUNTON J, 1991, ANGEW CHEM INT EDIT, V30, P1302, DOI 10.1002/anie.199113021; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994	25	226	248	1	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1487	1489		10.1126/science.7770773	http://dx.doi.org/10.1126/science.7770773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770773				2022-12-01	WOS:A1995RC19000037
J	CRAVATT, BF; PROSPEROGARCIA, O; SIUZDAK, G; GILULA, NB; HENRIKSEN, SJ; BOGER, DL; LERNER, RA				CRAVATT, BF; PROSPEROGARCIA, O; SIUZDAK, G; GILULA, NB; HENRIKSEN, SJ; BOGER, DL; LERNER, RA			CHEMICAL CHARACTERIZATION OF A FAMILY OF BRAIN LIPIDS THAT INDUCE SLEEP	SCIENCE			English	Article							FATTY-ACID AMIDES	A molecule isolated from the cerebrospinal fluid of sleep-deprived cats has been chemically characterized and identified as cis-9,10-octadecenoamide. Other fatty acid primary amides in addition to cis-9,10-octadecenoamide were identified as natural constituents of the cerebrospinal fluid of cat, rat, and human, indicating that these compounds compose a distinct family of brain lipids. Synthetic cis-9,10-octadecenoamide induced physiological sleep when injected into rats. Together, these results suggest that fatty acid primary amides may represent a previously unrecognized class of biological signaling molecules.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Siuzdak, Gary/0000-0002-4749-0014	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR07273-01] Funding Source: Medline; NIDA NIH HHS [R01 DA015648] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARAFAT ES, 1989, LIFE SCI, V45, P1679, DOI 10.1016/0024-3205(89)90278-6; CHRISTIE WW, 1973, LIPID ANAL, P128; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; GENARD S, 1991, B SOC CHIM FR, P397; INOUE S, 1989, BIOL SLEEP SUBSTANCE; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; LERNER RA, 1994, P NATL ACAD SCI USA, V91, P9505, DOI 10.1073/pnas.91.20.9505; PRIVETT OS, 1966, PROGR CHEMISTRY FATS, V9, P91; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHOENENBERGER GA, 1984, EUR NEUROL, V23, P321, DOI 10.1159/000115711; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z	14	535	565	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1506	1509		10.1126/science.7770779	http://dx.doi.org/10.1126/science.7770779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770779				2022-12-01	WOS:A1995RC19000043
J	DENHAAN, JMM; SHERMAN, NE; BLOKLAND, E; HUCZKO, E; KONING, F; DRIJFHOUT, JW; SKIPPER, J; SHABANOWITZ, J; HUNT, DF; ENGELHARD, VH; GOULMY, E				DENHAAN, JMM; SHERMAN, NE; BLOKLAND, E; HUCZKO, E; KONING, F; DRIJFHOUT, JW; SKIPPER, J; SHABANOWITZ, J; HUNT, DF; ENGELHARD, VH; GOULMY, E			IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; MARROW TRANSPLANTATION; MASS-SPECTROMETRY; TISSUE DISTRIBUTION; UNRELATED DONORS; PEPTIDES; HLA; CELLS; PROTEIN; BETA-2-MICROGLOBULIN	Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.	UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Virginia; University of Virginia; University of Virginia; University of Virginia			Drijfhout, Jan Wouter/ABA-6318-2021; Hunt, Donald F/I-6936-2012; den Haan, Joke MM/A-4281-2010	Drijfhout, Jan Wouter/0000-0003-4808-5296; Hunt, Donald F/0000-0003-2815-6368; den Haan, Joke MM/0000-0002-4421-6917; Koning, Frits/0000-0002-4007-5715; Sherman, Nicholas/0000-0003-3206-3113; Engelhard, Victor/0000-0002-1741-0925	NIAID NIH HHS [AI20963, AI33993] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020963, R01AI033993, R37AI033993, R01AI020963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEATTY PG, 1989, GRAFT VERSUS HOST DI, P415; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BORTIN MM, 1991, TRANSPLANT P, V23, P61; BORTIN MM, 1970, TRANSPLANTATION, V9, P571, DOI 10.1097/00007890-197006000-00006; CHEN Y, 1994, J IMMUNOL, V152, P2874; COUDRIER E, 1992, FEBS LETT, V307, P87, DOI 10.1016/0014-5793(92)80907-X; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1993, EUR J IMMUNOL, V23, P614, DOI 10.1002/eji.1830230305; DENHAAN JMM, UNPUB; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRANKSSON L, 1993, EUR J IMMUNOL, V23, P2606, DOI 10.1002/eji.1830231034; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; GOULMY E, UNPUB; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; IRSCHICK EU, 1992, BLOOD, V79, P1622; KURTZ ME, 1985, J IMMUNOL, V135, P2847; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; MOOSEKER M, 1993, CURR BIOL, V3, P245, DOI 10.1016/0960-9822(93)90346-P; NIEDERWIESER D, 1993, BLOOD, V81, P2200; PERARNAU B, 1990, NATURE, V346, P751, DOI 10.1038/346751a0; RAMMENSEE HG, 1986, NATURE, V319, P502, DOI 10.1038/319502a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUPPERT J, 1993, CELL, V74, P829; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; SEKIMATA M, 1992, INT IMMUNOL, V4, P301, DOI 10.1093/intimm/4.2.301; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TSOI MS, 1983, TRANSPLANT P, V15, P1484; TSOI MS, 1980, J IMMUNOL, V125, P2258; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANDERHARST D, 1994, BLOOD, V84, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0	44	327	350	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1476	1480		10.1126/science.7539551	http://dx.doi.org/10.1126/science.7539551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539551	Green Submitted			2022-12-01	WOS:A1995RC19000034
J	FUNAKOSHI, H; BELLUARDO, N; ARENAS, E; YAMAMOTO, Y; CASABONA, A; PERSSON, H; IBANEZ, CF				FUNAKOSHI, H; BELLUARDO, N; ARENAS, E; YAMAMOTO, Y; CASABONA, A; PERSSON, H; IBANEZ, CF			MUSCLE-DERIVED NEUROTROPHIN-4 AS AN ACTIVITY-DEPENDENT TROPHIC SIGNAL FOR ADULT MOTOR-NEURONS	SCIENCE			English	Article							NEUROMUSCULAR-JUNCTIONS; POSTNATAL-DEVELOPMENT; MESSENGER-RNA; CELL-DEATH; NERVE; BRAIN; EXPRESSION; RECEPTORS; SURVIVAL; INVIVO	The production of neurotrophin-4 (NT-4) in rat skeletal muscle was found to depend on muscle activity. The amounts of NT-4 messenger RNA present decreased after blockade of neuromuscular transmission with alpha-bungarotoxin and increased during postnatal development and after electrical stimulation in a dose-dependent manner. NT-4 immunoreactivity was detected in slow, type I muscle fibers. Intramuscular administration of NT-4 induced sprouting of intact adult motor nerves. Thus, muscle-derived NT-4 acted as an activity-dependent neurotrophic signal for growth and remodeling of about motor-neuron innervation. NT-4 may thus be partly responsible for the effects of exercise and electrical stimulation on neuromuscular performance.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,INST WOMAN & CHILD HLTH,S-17177 STOCKHOLM,SWEDEN; UNIV CATANIA,INST FISIOL HUMANA,CATANIA,ITALY	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Catania			Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577; Casabona, Antonino/0000-0003-0180-4695				BALICEGORDON RJ, 1990, J NEUROSCI, V10, P894; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRADLEY WG, 1983, ANN NEUROL, V14, P267, DOI 10.1002/ana.410140304; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CONNOLD AL, 1986, DEV BRAIN RES, V28, P99, DOI 10.1016/0165-3806(86)90069-6; CONNOLD AL, 1994, NEUROSCIENCE, V63, P327, DOI 10.1016/0306-4522(94)90027-2; CONNOR EA, 1994, J NEUROBIOL, V25, P722, DOI 10.1002/neu.480250611; CZEH G, 1978, J PHYSIOL-LONDON, V281, P239, DOI 10.1113/jphysiol.1978.sp012419; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; DESCHENES MR, 1993, J NEUROCYTOL, V22, P603, DOI 10.1007/BF01181487; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; Funakoshi H., UNPUB; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1983, NATURE, V302, P609, DOI 10.1038/302609a0; HOPKINS WG, 1981, J NEUROCYTOL, V10, P537, DOI 10.1007/BF01262589; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; KAPLAN DB, COMMUNICATION; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LANDMESSER L, 1992, J NEUROBIOL, V23, P1131, DOI 10.1002/neu.480230906; LIND A, 1991, J HISTOCHEM CYTOCHEM, V39, P589, DOI 10.1177/39.5.1826695; MUNSAT TL, 1976, ARCH NEUROL-CHICAGO, V33, P608, DOI 10.1001/archneur.1976.00500090014004; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PERSSON H, 1993, CURR OPIN NEUROL NEU, V6, P11; PIEHL F, 1994, NEUROREPORT, V5, P697, DOI 10.1097/00001756-199402000-00009; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; WAERHAUG O, 1992, ANAT EMBRYOL, V185, P115; WERNIG A, 1991, J NEUROCYTOL, V20, P903, DOI 10.1007/BF01190468; WERNIG A, 1986, PROG NEUROBIOL, V27, P251, DOI 10.1016/0301-0082(86)90023-7; WIGSTON DJ, 1989, J NEUROSCI, V9, P639; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	38	305	324	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1495	1499		10.1126/science.7770776	http://dx.doi.org/10.1126/science.7770776			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770776				2022-12-01	WOS:A1995RC19000040
J	GARGAS, A; DEPRIEST, PT; GRUBE, M; TEHLER, A				GARGAS, A; DEPRIEST, PT; GRUBE, M; TEHLER, A			MULTIPLE ORIGINS OF LICHEN SYMBIOSES IN FUNGI SUGGESTED BY SSU RDNA PHYLOGENY	SCIENCE			English	Article							CLADISTIC OUTLINE	Phylogenetic hypotheses provide a context for examining the evolution of heterotrophic lifestyles. The lichen lifestyle, which is the symbiotic association of fungi with algae, is found in various representatives of Dicaryomycotina, both Ascomycetes and Basidiomycetes. A highly resolved parsimony analysis of small subunit ribosomal DNA (SSU rDNA) sequences suggests at least five independent origins of the lichen habit in disparate groups of Ascomycetes and Basidiomycetes. Because lichen associations arose from parasitic, mycorrhizal, or free-living saprobic fungi, neither mutualism nor parasitism should be construed as endpoints in symbiont evolution.	GRAZ UNIV,INST BOT,A-8010 GRAZ,AUSTRIA; UNIV STOCKHOLM,INST BOT,S-10691 STOCKHOLM,SWEDEN	University of Graz; Stockholm University	GARGAS, A (corresponding author), SMITHSONIAN INST,NATL MUSEUM NAT HIST,DEPT BOT,NHB-166,WASHINGTON,DC 20560, USA.		DePriest, Paula T./K-6633-2015	DePriest, Paula T./0000-0002-6079-7870; Grube, Martin/0000-0001-6940-5282				Ahmadjian V, 1983, ALGAL SYMBIOSIS, P147; Ahmadjian V., 1967, LICHEN SYMBIOSIS; BERBEE ML, 1992, MOL BIOL EVOL, V9, P278; BLACKWELL M, 1994, MYCOLOGIA, V86, P1, DOI 10.2307/3760716; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; Caullery M., 1952, PARASITISM SYMBIOSIS; De Bary A, 1879, ERSCHEINUNG SYMBIOSE; ERIKSSON OE, 1993, SYST ASCOMYCETUM, V12, P52; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FUTUYAMA DJ, 1991, GENES ECOLOGY, P139; GARGAS A, 1995, EXP MYCOL, V19, P7, DOI 10.1006/emyc.1995.1002; Hawksworth D.L., 1982, J HATTORI BOT LAB, V52, P323; Hawksworth David L., 1994, Cryptogamic Botany, V4, P117; HAWKSWORTH DL, 1978, ESSAYS PLANT TAXONOM, P122; Henssen A, 1973, LICHENES; HONEGGER R, 1991, ANNU REV PLANT PHYS, V42, P553, DOI 10.1146/annurev.arplant.42.1.553; Kappen Ludger, 1994, Cryptogamic Botany, V4, P193; Landvik Sara, 1993, Systema Ascomycetum, V11, P107; Margulis L., 1988, 5 KINGDOMS ILLUSTRAT; NISHIDA H, 1993, MOL BIOL EVOL, V10, P431; Oberwinkler F., 1984, NOVA HEDWIGIA S, V79, P739; POELT J, 1958, PLANTA, V51, P288, DOI 10.1007/BF02125723; Rambold G., 1992, BIBLIOTHECA LICHENOL, V48, P1; SAENZ GS, 1994, MYCOLOGIA, V86, P212, DOI 10.2307/3760639; SPATAFORA JW, 1993, MYCOLOGIA, V85, P912, DOI 10.2307/3760674; SWANN EC, 1993, MYCOLOGIA, V85, P923, DOI 10.2307/3760675; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TEHLER A, 1990, CAN J BOT, V68, P2458, DOI 10.1139/b90-312; TEHLER A, 1988, CLADISTICS, V4, P227, DOI 10.1111/j.1096-0031.1988.tb00474.x; Tucker S. C., 1991, TROPICAL LICHENS THE, P171; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WIRTH V, 1995, FLECHTEN BADEN WURTL, P137	32	245	251	2	63	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1492	1495		10.1126/science.7770775	http://dx.doi.org/10.1126/science.7770775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770775				2022-12-01	WOS:A1995RC19000039
J	JEANLOZ, R; MITCHELL, DL; SPRAGUE, AL; DEPATER, I				JEANLOZ, R; MITCHELL, DL; SPRAGUE, AL; DEPATER, I			EVIDENCE FOR A BASALT-FREE SURFACE ON MERCURY AND IMPLICATIONS FOR INTERNAL HEAT	SCIENCE			English	Article							THERMAL EVOLUTION; ATMOSPHERE; POTASSIUM; MANTLE; PLANETS; SODIUM	Microwave and mid-infrared observations reveal that Mercury's surface contains less FeO + TiO2 and at least as much feldspar as the lunar highlands. The results are compatible with the high albedo (brightness) of Mercury's surface at visible wavelengths in suggesting a rock and soil composition that is devoid of basalt, the primary differentiate of terrestrial mantles. The occurrence of a basalt-free, highly differentiated crust is in accord with recent models of the planet's thermal evolution and suggests that Mercury has retained a hot interior as a result of a combination of inefficient mantle convection and minimal volcanic heat loss.	CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; UNIV CALIF BERKELEY,DEPT ASTRON,BERKELEY,CA 94720	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona; University of California System; University of California Berkeley	JEANLOZ, R (corresponding author), UNIV CALIF BERKELEY,DEPT GEOL & GEOPHYS,BERKELEY,CA 94720, USA.							BENZ W, 1988, ICARUS, V74, P516, DOI 10.1016/0019-1035(88)90118-2; CAMERON AGW, 1988, MERCURY, P692; CAMPBELL MJ, 1969, J GEOPHYS RES, V74, P5867, DOI 10.1029/JB074i025p05867; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GRIEVE RA, 1993, METEORITICS, V28, P602; GRIEVE RAF, 1992, METEORITICS, V27, P526, DOI 10.1111/j.1945-5100.1992.tb01074.x; Heiken G.H., 1991, LUNAR SOURCEBOOK; Hunten D.M., 1988, MERCURY ATMOSPHERE, P562; HYNDMAN DW, 1982, PETROLOGY IGNEOUS ME; JEANLOZ R, 1986, ANNU REV EARTH PL SC, V14, P377, DOI 10.1146/annurev.ea.14.050186.002113; KILLEN RM, 1991, SCIENCE, V252, P974, DOI 10.1126/science.252.5008.974; LEDLOW MJ, 1992, ASTROPHYS J, V384, P640, DOI 10.1086/170906; Lewis J.S., 1988, MERCURY, P651; Lissauer J. J., 1993, PROTOSTARS PLANETS, VIII, P1061; Melosh H. J., 1988, MERCURY, P374; MITCHELL DL, 1994, ICARUS, V110, P2, DOI 10.1006/icar.1994.1105; NESS NF, 1979, PHYS EARTH PLANET IN, V20, P209, DOI 10.1016/0031-9201(79)90044-X; NESS NF, 1975, J GEOPHYS RES-SPACE, V80, P2708, DOI 10.1029/JA080i019p02708; NESS NF, 1978, SPACE SCI REV, V21, P527; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1990, SCIENCE, V248, P835, DOI 10.1126/science.248.4957.835; POTTER AE, 1986, ICARUS, V67, P336, DOI 10.1016/0019-1035(86)90113-2; Ringwood A. E., 1975, COMPOSITION PETROLOG; ROEDER PL, 1970, CONTRIB MINERAL PETR, V29, P275, DOI 10.1007/BF00371276; Schubert G., 1988, MERCURY, P429; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; SOLOMON SC, 1978, GEOPHYS RES LETT, V5, P461, DOI 10.1029/GL005i006p00461; SPOHN T, 1991, ICARUS, V90, P222, DOI 10.1016/0019-1035(91)90103-Z; SPRAGUE AL, 1994, ICARUS, V109, P156, DOI 10.1006/icar.1994.1083; SPRAGUE AL, 1990, SCIENCE, V249, P1140, DOI 10.1126/science.249.4973.1140; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; STOLPER E, 1981, J GEOPHYS RES, V86, P6261, DOI 10.1029/JB086iB07p06261; STROM RG, 1989, MERCURY ELUSIVE PLAN; STROM RG, 1984, NASA, P13; Taylor SR, 1992, SOLAR SYSTEM EVOLUTI; TONKS WB, 1992, ICARUS, V109, P326; TYLER AL, 1988, GEOPHYS RES LETT, V15, P808, DOI 10.1029/GL015i008p00808; Veverka J., 1988, MERCURY, P37; Vilas F, 1988, MERCURY, P651; VILAS F, 1988, MERCURY, P59; VONHIPPEL AR, 1952, DIELECTRIC MATERIALS; Wasson J.T., 1988, MERCURY, P622; Wetherill G. W., 1988, MERCURY, P670; Yoder H. S. J., 1976, GENERATION BASALTIC; 1981, BASALTIC VOLCANISM T	45	68	68	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1455	1457		10.1126/science.7770770	http://dx.doi.org/10.1126/science.7770770			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770770				2022-12-01	WOS:A1995RC19000027
J	KOENIG, HL; SCHUMACHER, M; FERZAZ, B; DOTHI, AN; RESSOUCHES, A; GUENNOUN, R; JUNGTESTAS, I; ROBEL, P; AKWA, Y; BAULIEU, EE				KOENIG, HL; SCHUMACHER, M; FERZAZ, B; DOTHI, AN; RESSOUCHES, A; GUENNOUN, R; JUNGTESTAS, I; ROBEL, P; AKWA, Y; BAULIEU, EE			PROGESTERONE SYNTHESIS AND MYELIN FORMATION BY SCHWANN-CELLS	SCIENCE			English	Article							NEUROACTIVE STEROIDS; SCIATIC-NERVES; TREMBLER MOUSE; BASAL LAMINA; NEUROSTEROIDS; BRAIN; PREGNENOLONE; DIFFERENTIATION; PHOSPHOLIPIDS; REGENERATION	Progesterone is shown here to be produced from pregnenolone by Schwann cells in peripheral nerves, After cryolesion of the sciatic nerve in male mice, axons regenerate and become myelinated. Blocking either the local synthesis or the receptor-mediated action of progesterone impaired remyelination. Administration of progesterone or its precursor, pregnenolone, to the lesion site increased the extent of myelin sheath formation. Myelination of axons was also increased when progesterone was added to cultures of rat dorsal root ganglia. These observations indicate a role for locally produced progesterone in myelination, demonstrate that progesterone is not simply a sex steroid, and suggest a new therapeutic approach to promote myelin repair.	INSERM,U33,HORMONES LAB,F-94276 LE KREMLIN BICETR,FRANCE; UNIV BORDEAUX 1,DEV NEUROBIOL LAB,F-33405 TALENCE,FRANCE; COLL FRANCE,CNRS,U1115,F-75231 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Universite Paris Cite			Akwa, Yvette/I-5223-2018; Messier, Claude/A-2322-2008; Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Akwa, Yvette/0000-0003-2181-4612; Messier, Claude/0000-0002-4791-1763; Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371				AKWA Y, 1993, CR ACAD SCI III-VIE, V316, P410; AKWA Y, 1993, J CELL BIOL, V121, P135, DOI 10.1083/jcb.121.1.135; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Baulieu E.E., 1981, STEROID HORMONE REGU, P3; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BIZZOZERO OA, 1991, J BIOL CHEM, V266, P17092; BOLIN LM, 1993, J CELL BIOL, V123, P237, DOI 10.1083/jcb.123.1.237; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHADWICK D, 1990, CIBA F S, V153; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; DROZ B, 1981, BRAIN RES, V219, P57, DOI 10.1016/0006-8993(81)90267-5; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FERZAZ B, 1989, CR ACAD SCI III-VIE, V309, P377; FUXE K, 1981, STEROID HORMONE REGU; GUENNOUN R, IN PRESS MOL BRAIN R; HILDEBRAND C, 1994, PROG NEUROBIOL, V43, P85, DOI 10.1016/0301-0082(94)90010-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JUNGTESTAS I, 1994, J STEROID BIOCHEM, V48, P145, DOI 10.1016/0960-0760(94)90261-5; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; Kleitman N, 1991, CULTURING NERVE CELL, P337; KOENIG H, UNPUB; LEGOASCOGNE C, 1987, SCIENCE, V237, P1212, DOI 10.1126/science.3306919; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MCEWEN BS, 1991, TRENDS ENDOCRIN MET, V2, P62, DOI 10.1016/1043-2760(91)90042-L; MELLON SH, 1994, J CLIN ENDOCR METAB, V78, P1003, DOI 10.1210/jc.78.5.1003; MORFIN R, 1992, P NATL ACAD SCI USA, V89, P6790, DOI 10.1073/pnas.89.15.6790; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; RAISINGHANI KH, 1968, ACTA ENDOCRINOL-COP, V57, P393; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TOEWS AD, 1988, J NEUROSCI, V8, P593; VERDI JM, 1990, J BIOL CHEM, V265, P20314	37	402	414	0	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1500	1503		10.1126/science.7770777	http://dx.doi.org/10.1126/science.7770777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770777				2022-12-01	WOS:A1995RC19000041
J	MAINEN, ZF; SEJNOWSKI, TJ				MAINEN, ZF; SEJNOWSKI, TJ			RELIABILITY OF SPIKE TIMING IN NEOCORTICAL NEURONS	SCIENCE			English	Article							CAT VISUAL-CORTEX; SINGLE NEURONS; RESPONSES; MONKEY; VARIABILITY; STIMULUS; PATTERNS; CELLS; BRAIN; TRANSMISSION	It is not known whether the variability of neural activity in the cerebral cortex carries information or reflects noisy underlying mechanisms. In an examination of the reliability of spike generation using recordings from neurons in rat neocortical slices, the precision of spike timing was found to depend on stimulus transients. Constant stimuli led to imprecise spike trains, whereas stimuli with fluctuations resembling synaptic activity produced spike trains with timing reproducible to less than 1 millisecond. These data suggest a low intrinsic noise level in spike generation, which could allow cortical neurons to accurately transform synaptic input into spike sequences, supporting a possible role for spike timing in the processing of cortical information by the neocortex.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MAINEN, ZF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Sejnowski, Terrence/AAV-5558-2021	Mainen, Zachary/0000-0001-7913-9109				Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; ADRIAN ED, 1926, J PHYSIOL-LONDON, V61, P47; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BAIR W, 1994, SOC NEUR ABSTR, V20, P1229; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BARLOW HB, 1963, KYBERNETIK, V2, P1, DOI 10.1007/BF00292103; BERGMAN H, 1993, J NEUROPHYSIOL, V70, P1629; BRYANT HL, 1976, J PHYSIOL-LONDON, V260, P279, DOI 10.1113/jphysiol.1976.sp011516; BULLOCK TH, 1970, J GEN PHYSIOL, V55, P565, DOI 10.1085/jgp.55.5.565; Burns BD, 1968, UNCERTAIN NERVOUS SY; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; CARR CE, 1990, J NEUROSCI, V10, P3227; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FERSTER D, 1992, J NEUROSCI, V12, P1262; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KORENBERG MJ, 1989, J NEUROPHYSIOL, V61, P1110, DOI 10.1152/jn.1989.61.6.1110; KRUGER J, 1991, TRENDS NEUROSCI, V14, P282, DOI 10.1016/0166-2236(91)90138-K; LASS Y, 1975, BIOL CYBERN, V19, P61, DOI 10.1007/BF00364102; LESTIENNE R, 1987, BRAIN RES, V437, P214, DOI 10.1016/0006-8993(87)91638-6; LEVINE MW, 1988, VISUAL NEUROSCI, V1, P31, DOI 10.1017/S0952523800001000; MacKAY DONALD M., 1952, BULL MATH BIOPHYS, V14, P127, DOI 10.1007/BF02477711; MAINEN ZF, UNPUB; MALNEN ZF, UNPUB; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; NODA H, 1970, BRAIN RES, V18, P513, DOI 10.1016/0006-8993(70)90134-4; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; PECHER C, 1939, ARCH INTERN PHYSIOL, V49, P129; PHILLIPS JR, 1992, J NEUROSCI, V12, P827; Rice SO, 1954, SELECTED PAPERS NOIS, P133; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHREINER RC, 1978, J NEUROPHYSIOL, V41, P338, DOI 10.1152/jn.1978.41.2.338; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STEIN RB, 1967, BIOPHYS J, V7, P797, DOI 10.1016/S0006-3495(67)86623-2; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUGA N, 1990, COLD SH Q B, V55, P585; THOMSON AM, 1993, J NEUROPHYSIOL, V70, P2354, DOI 10.1152/jn.1993.70.6.2354; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; TOMKO GJ, 1974, BRAIN RES, V79, P405, DOI 10.1016/0006-8993(74)90438-7; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; WERNER G, 1963, J NEUROPHYSIOL, V26, P958, DOI 10.1152/jn.1963.26.6.958; WHITSEL BL, 1977, J NEUROPHYSIOL, V40, P589, DOI 10.1152/jn.1977.40.3.589; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	55	1427	1441	2	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1503	1506		10.1126/science.7770778	http://dx.doi.org/10.1126/science.7770778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770778				2022-12-01	WOS:A1995RC19000042
J	MARINO, JP; GREGORIAN, RS; CSANKOVSZKI, G; CROTHERS, DM				MARINO, JP; GREGORIAN, RS; CSANKOVSZKI, G; CROTHERS, DM			BENT HELIX FORMATION BETWEEN RNA HAIRPINS WITH COMPLEMENTARY LOOPS	SCIENCE			English	Article							COLE1 PLASMID REPLICATION; ROP ROM PROTEIN; NMR-SPECTROSCOPY; ANTISENSE RNA; SPIN-ECHO; TAR RNA; BINDING; CONFORMATION; PSEUDOKNOTS; POLYMERASE	The initial interaction between the CoIE1 plasmid specific transcripts RNA I and RNA II, which function as antisense regulators of plasmid replication, comprises a transient complex between complementary loops found within the RNA secondary structures. Multidimensional heteronuclear magnetic resonance spectroscopy was used to characterize complexes formed between model RNA hairpins having seven nucleotide complementary loops. Seven base pairs are formed in the loop-loop helix, with continuous helical stacking of the loop residues on the 3' side of their helical stems. A sharp bend in the loop-loop helix, documented by gel electrophoresis, narrows the major groove and allows bridging of the phosphodiester backbones across the major groove in order to close the hairpin loops at their 5'-ends. The bend is further enhanced by the binding of Rom, a ColE1 encoded protein that regulates replication.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06511 USA	Yale University				Csankovszki, Gyorgyi/0000-0001-5918-034X	NIGMS NIH HHS [GM 21966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021966, R37GM021966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BANNER DW, 1983, MECHANISMS DNA REPLI, P327; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASCONE PJ, 1993, SCIENCE, V260, P801, DOI 10.1126/science.8484119; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; EBERLE W, 1991, Journal of Biomolecular NMR, V1, P71, DOI 10.1007/BF01874570; EBERLE W, 1990, BIOCHEMISTRY-US, V29, P7402, DOI 10.1021/bi00484a007; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; GREGORIAN RS, IN PRESS J MOL BIOL; GREGORIAN RS, 1994, THESIS YALE U; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1993, NATURE, V356, P512; LEFFERS H, 1987, J MOL BIOL, V195, P43, DOI 10.1016/0022-2836(87)90326-3; LEGAULT P, 1994, J MAGN RESON SER B, V103, P82, DOI 10.1006/jmrb.1994.1012; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MARINO JP, 1995, THESIS YALE U; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUESING M, 1984, GENE, V31, P155, DOI 10.1016/0378-1119(84)90206-3; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PUGLISI JD, 1991, ACCOUNTS CHEM RES, V24, P152, DOI 10.1021/ar00005a005; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; SAENGER W, 1988, PRINCIPLES NUCLEIC A; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; SZEWCZAK AA, 1993, FEBS LETT, V327, P261, DOI 10.1016/0014-5793(93)81000-P; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; TOMIZAWA J, 1990, J MOL BIOL, V212, P695, DOI 10.1016/0022-2836(90)90231-A; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P; WYATT JR, 1993, RNA WORLD, P465	47	113	114	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1448	1454		10.1126/science.7539549	http://dx.doi.org/10.1126/science.7539549			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539549				2022-12-01	WOS:A1995RC19000026
J	STRATER, N; KLABUNDE, T; TUCKER, P; WITZEL, H; KREBS, B				STRATER, N; KLABUNDE, T; TUCKER, P; WITZEL, H; KREBS, B			CRYSTAL-STRUCTURE OF A PURPLE ACID-PHOSPHATASE CONTAINING A DINUCLEAR FE(III)-ZN(II) ACTIVE-SITE	SCIENCE			English	Article							REACTION-MECHANISM; BOVINE SPLEEN; PROTEIN; UTEROFERRIN; CATALYZES	Kidney bean purple acid phosphatase (KBPAP) is an Fe(III)-Zn(II) metalloenzyme resembling the mammalian Fe(III)-Fe(II) purple acid phosphatases. The structure of the homodimeric III-kilodalton KBPAP was determined at a resolution of 2.9 angstroms. The enzyme contains two domains in each subunit. The active site is located in the carboxyl-terminal terminal domain at the carboxy end of two sandwiched beta alpha beta alpha beta motifs. The two metal ions are 3.1 angstroms apart and bridged monodentately by Asp(164) The iron is further coordinated by Tyr(167), His(325), and Asp(135), and the zinc by His(286), His(323), and Asn(201). The active-site structure is consistent with previous proposals regarding the mechanism of phosphate ester hydrolysis involving nucleophilic attack on the phosphate group by an Fe(III)coordinated hydroxide ion.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV MUNSTER, INST BIOCHEM, D-48149 MUNSTER, GERMANY	European Molecular Biology Laboratory (EMBL); University of Munster	STRATER, N (corresponding author), UNIV MUNSTER, INST ANORGAN CHEM, D-48149 MUNSTER, GERMANY.		Krebs, Bernt/B-9068-2011; Strater, Norbert/P-4856-2018	Strater, Norbert/0000-0002-2001-0500				AQUINO MAS, 1994, J CHEM SOC DALTON, P429, DOI 10.1039/dt9940000429; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1993, XPLOR VERSION 3 1 MA; DIETRICH M, 1991, EUR J BIOCHEM, V199, P105, DOI 10.1111/j.1432-1033.1991.tb16097.x; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; HAYMAN AR, 1994, J BIOL CHEM, V269, P1294; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; HOLZ RC, 1992, J AM CHEM SOC, V114, P4434, DOI 10.1021/ja00037a079; Jones T.A., 1992, MOL REPLACEMENT; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUZLARICH SM, 1986, INORG CHEM, V25, P2781, DOI 10.1021/ic00236a025; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KLABUNDE T, 1994, EUR J BIOCHEM, V226, P369, DOI 10.1111/j.1432-1033.1994.tb20061.x; KLEYWEGT GJ, IN PRESS ACTA CRYS D; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PRIGGEMEYER S, 1995, INORG CHEM, V34, P1445, DOI 10.1021/ic00110a024; QUE L, 1990, PROG INORG CHEM, V38, P97; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STAHL B, 1994, EUR J BIOCHEM, V220, P321, DOI 10.1111/j.1432-1033.1994.tb18628.x; STRATER N, 1992, J MOL BIOL, V224, P511, DOI 10.1016/0022-2836(92)91012-E; SUERBAUM H, 1993, EUR J BIOCHEM, V214, P313, DOI 10.1111/j.1432-1033.1993.tb17926.x; TRUE AE, 1993, J AM CHEM SOC, V115, P4246, DOI 10.1021/ja00063a047; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P5263, DOI 10.1021/bi00138a004	28	404	413	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1489	1492		10.1126/science.7770774	http://dx.doi.org/10.1126/science.7770774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770774				2022-12-01	WOS:A1995RC19000038
J	SUZUKI, H; KUNDIG, TM; FURLONGER, C; WAKEHAM, A; TIMMS, E; MATSUYAMA, T; SCHMITS, R; SIMARD, JJL; OHASHI, PS; GRIESSER, H; TANIGUCHI, T; PAIGE, CJ; MAK, TW				SUZUKI, H; KUNDIG, TM; FURLONGER, C; WAKEHAM, A; TIMMS, E; MATSUYAMA, T; SCHMITS, R; SIMARD, JJL; OHASHI, PS; GRIESSER, H; TANIGUCHI, T; PAIGE, CJ; MAK, TW			DEREGULATED T-CELL ACTIVATION AND AUTOIMMUNITY IN MICE LACKING INTERLEUKIN-2 RECEPTOR-BETA	SCIENCE			English	Article							IL-2 RECEPTOR; MOLECULAR-CLONING; HUMAN NEUTROPHILS; LYMPHOCYTE-T; GAMMA-CHAIN; EXPRESSION; GENE; P75; SUBSETS; CDNAS	In mice lacking the interleukin-2 receptor beta chain (lL-2R beta), T cells were shown to be spontaneously activated, resulting in exhaustive differentiation of B cells into plasma cells and the appearance of high serum concentrations of immunoglobulins G1 and E as well as autoantibodies that cause hemolytic anemia. Marked infiltrative granulocytopoiesis was also apparent, and the animals died after about 12 weeks. Depletion of CD4(+) T cells in mutant mice rescued B cells without reversion of granulocyte abnormalities. T cells did not proliferate in response to polyclonal activators, nor could antigen-specific immune responses be elicited. Thus, IL-2R beta is required to keep the activation programs of T cells under control, to maintain homeostasis, and to prevent autoimmunity.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT IMMUNOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,WELLESLEY HOSP,RES INST,TORONTO,ON M4Y 1J3,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M4X 1K9,CANADA; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Osaka University				Ohashi, Pamela S./0000-0003-2915-9317				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BEGLEY CG, 1990, LEUKEMIA RES, V14, P263, DOI 10.1016/0145-2126(90)90134-U; CHARAN S, 1986, J VIROL, V57, P1139, DOI 10.1128/JVI.57.3.1139-1144.1986; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DJEU JY, 1993, J IMMUNOL, V150, P960; ESPINOZADELGADO I, 1990, J EXP MED, V171, P1821, DOI 10.1084/jem.171.5.1821; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JENKINSON EJ, 1994, CURR OPIN IMMUNOL, V6, P293, DOI 10.1016/0952-7915(94)90104-X; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG WP, 1994, J EXP MED, V180, P959; MATSUYAMA T, 1992, CELL, V75, P1; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NISHIKAWA K, 1990, INT IMMUNOL, V2, P481, DOI 10.1093/intimm/2.6.481; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; STARKEY PM, 1991, IMMUNOLOGY, V73, P64; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKEUCHI Y, 1992, EUR J IMMUNOL, V22, P2929, DOI 10.1002/eji.1830221126; TANAKA K, 1993, J IMMUNOL, V151, P748; TANAKA K, 1994, CELL IMMUNOL, V153, P401; TANAKA T, 1992, INT IMMUNOL, V4, P487, DOI 10.1093/intimm/4.4.487; TORIBIO ML, 1989, NATURE, V342, P82, DOI 10.1038/342082a0; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WEI S, 1993, J IMMUNOL, V150, P1979; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZOLA H, 1991, IMMUNOLOGY, V72, P167	35	727	741	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1472	1476		10.1126/science.7770771	http://dx.doi.org/10.1126/science.7770771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770771				2022-12-01	WOS:A1995RC19000033
J	TYCKO, R; BARRETT, SE; DABBAGH, G; PFEIFFER, LN; WEST, KW				TYCKO, R; BARRETT, SE; DABBAGH, G; PFEIFFER, LN; WEST, KW			ELECTRONIC STATES IN GALLIUM-ARSENIDE QUANTUM-WELLS PROBED BY OPTICALLY PUMPED NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPIN-LATTICE RELAXATION; FIELD DEPENDENCE; GAS; DIFFUSION; ENERGIES	An optical pumping technique was used to enhance and localize nuclear magnetic resonance (NMR) signals from an n-doped GaAs/Al0.1Ga0.9As multiple quantum well structure, permitting direct radio-frequency measurements of gallium-71 NMR spectra and nuclear spin-lattice relaxation rates (1/T-1) as functions of temperature (1.6 K < T < 4.2 K) and the Landau level filling factor (0.66 < nu < 1.76). The measurements reveal effects of electron-electron interactions on the energy levels and spin states of the two-dimensional electron system confined in the GaAs wells. Minima in 1/T-1 at nu approximate to 1 and nu approximate to 2/3 indicate energy gaps for electronic excitations in both integer and fractional quantum Hall states. Rapid, temperature-independent relaxation at intermediate v values indicates a manifold of low-lying electronic states with mixed spin polarizations.	AT&T BELL LABS,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs			Barrett, Sean E/F-1274-2015	Barrett, Sean E/0000-0002-0498-2027				ANTONIOU D, 1991, PHYS REV B, V43, P11686, DOI 10.1103/PhysRevB.43.11686; BARRETT SE, 1994, PHYS REV LETT, V72, P1368, DOI 10.1103/PhysRevLett.72.1368; BARRETT SE, IN PRESS PHYS REV LE; BERG A, 1990, PHYS REV LETT, V64, P2563, DOI 10.1103/PhysRevLett.64.2563; BOEBINGER GS, 1985, PHYS REV LETT, V55, P1606, DOI 10.1103/PhysRevLett.55.1606; BURATTO SK, 1992, J VAC SCI TECHNOL B, V10, P1740, DOI 10.1116/1.586233; BURATTO SK, 1991, PHYS REV B, V44, P9035, DOI 10.1103/PhysRevB.44.9035; DEVREESE JT, 1987, PHYSICS 2 DIMENSIONA; EISENSTEIN JP, 1990, SCIENCE, V248, P1510, DOI 10.1126/science.248.4962.1510; EISENSTEIN JP, 1994, SCIENCE, V266, P1199; FERTIG HA, 1994, PHYS REV B, V50, P11018, DOI 10.1103/PhysRevB.50.11018; FLINN GP, 1990, SEMICOND SCI TECH, V5, P533, DOI 10.1088/0268-1242/5/6/012; FURNEAUX JE, 1989, PHYS REV LETT, V63, P1098, DOI 10.1103/PhysRevLett.63.1098; IORDANSKII SV, 1991, PHYS REV B, V44, P6554, DOI 10.1103/PhysRevB.44.6554; KALEVICH VK, 1990, JETP LETT+, V52, P349; KIM JH, 1994, PHYS REV B, V49, P16777, DOI 10.1103/PhysRevB.49.16777; KRAPF M, 1991, SOLID STATE COMMUN, V78, P459, DOI 10.1016/0038-1098(91)90704-Y; LAMPEL G, 1968, PHYS REV LETT, V20, P491, DOI 10.1103/PhysRevLett.20.491; MARTINDALE JA, 1992, PHYS REV LETT, V68, P702, DOI 10.1103/PhysRevLett.68.702; OVCHINNIKOV YN, 1994, JETP LETT+, V59, P569; PAGET D, 1977, PHYS REV B, V15, P5780, DOI 10.1103/PhysRevB.15.5780; RICHARDSON SL, 1986, PHYS REV B, V33, P1177, DOI 10.1103/PhysRevB.33.1177; SONDHI SL, 1993, PHYS REV B, V47, P16419, DOI 10.1103/PhysRevB.47.16419; SUTER D, 1985, PHYS REV B, V32, P5608, DOI 10.1103/PhysRevB.32.5608; TYCKO R, 1991, SCIENCE, V253, P884, DOI 10.1126/science.253.5022.884; TYCKO R, 1992, ISRAEL J CHEM, V32, P179; TYCKO R, 1993, J PHYS CHEM SOLIDS, V54, P1713, DOI 10.1016/0022-3697(93)90286-Z; WALSTEDT RE, 1990, SCIENCE, V248, P1082, DOI 10.1126/science.248.4959.1082; WEISBUCH C, 1991, QUANTUM SEMICONDUCTO, P123; Winter J., 1971, MAGNETIC RESONANCE M	30	246	247	1	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1460	1463		10.1126/science.7539550	http://dx.doi.org/10.1126/science.7539550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539550				2022-12-01	WOS:A1995RC19000029
J	BRYANT, H; BRASHER, P				BRYANT, H; BRASHER, P			BREAST IMPLANTS AND BREAST-CANCER - REANALYSIS OF A LINKAGE STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP	Background. In 1992, Berkel and colleagues reported in the Journal the results of their study of the potential association of breast augmentation and breast cancer. The study reported that women who had breast augmentation had a significantly lower subsequent risk of breast cancer (P<0.01) than the general population, with a standardized incidence ratio of 0.48 overall. Assuming a 10-year induction period (that is, assuming that cancers found within 10 years of the augmentation might have been the result of a process begun before surgery and therefore should not be considered), the reported standardized incidence ratio was 0.16. Problems were later identified involving some of the study methods. This paper reports a second analysis of these data. Methods. We used a data set from Alberta Health Care to identify eligible women with bilateral breast augmentation. Using a combination of deterministic and probabilistic methods, we linked this data set to the Alberta Cancer Registry to identify subsequent breast cancers that developed during the study period. Multiple estimates of standardized incidence ratios were calculated on the basis of differing study-eligibility dates, induction periods, and types of breast-cancer (invasive only or invasive plus in situ). Results. The reanalysis found substantial differences in the numbers of person-years at risk, resulting in higher standardized incidence ratios than in the original analysis. The final ratios for all breast cancers, with October 1, 1973, used as the starting date of the study, were 0.76 (95 percent confidence interval, 0.55 to 1.02), 0.85 (95 percent confidence interval, 0.58 to 1.19), and 0.68 (95 percent confidence interval, 0.32 to 1.25) for induction periods of 0, 5, and 10 years, respectively. None of these standardized incidence ratios were significantly different from 1. Conclusions. On the basis of this reanalysis, the incidence of breast cancer among the women who had breast augmentation could not be said to be either significantly higher or lower than that among the general population over the period during which this cohort was followed.			BRYANT, H (corresponding author), ALBERTA CANC BOARD,DIV EPIDEMIOL PREVENT & SCREENING,1040 7TH AVE SW,SUITE 120,CALGARY,AB T2P 3G9,CANADA.							BAILAR JC, 1964, BIOMETRICS, V20, P639; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; BRYANT H, 1994, NEW ENGL J MED, V330, P293, DOI 10.1056/NEJM199401273300419; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; WAJDA A, 1992, LINKPRO USERS MANUAL; 1993, STATISTICS CANADA	7	87	88	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1535	1539		10.1056/NEJM199506083322302	http://dx.doi.org/10.1056/NEJM199506083322302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739707				2022-12-01	WOS:A1995RB19600002
J	CANDELIERE, GA; GLORIEUX, FH; PRUDHOMME, J; STARNAUD, R				CANDELIERE, GA; GLORIEUX, FH; PRUDHOMME, J; STARNAUD, R			INCREASED EXPRESSION OF THE C-FOS PROTOONCOGENE IN BONE FROM PATIENTS WITH FIBROUS DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCCUNE-ALBRIGHT SYNDROME; STIMULATORY G-PROTEIN; TRANSGENIC MICE; ADENYLYL CYCLASE; TUMORS; CELLS; PROTOONCOGENE; TRANSCRIPTION; CALCITRIOL; MUTATIONS	Background. Fibrous dysplasia is characterized by intense marrow fibrosis and increased rates of bone turnover. The lesions of fibrous dysplasia resemble those described in the long bones of transgenic mice overexpressing the c-fos proto-oncogene. Activating mutations in the a subunit of the stimulatory guanine-nucleotide-binding protein (G(s) alpha) linked to adenylate cyclase have recently been described in bone cells from patients with the McCune-Albright syndrome and fibrous dysplasia. Methods. We used in situ hybridization to determine the level of expression of c-fos in bone-biopsy specimens from two normal subjects, eight patients with fibrous dysplasia, and six patients with other bone disorders characterized by high rates of bone turnover. The probe used corresponded to the fourth exon of the c-fos gene. Results. High levels of c-fos expression were detected in the bone lesions from all eight patients with fibrous dysplasia. No expression of c-fos was detected in bone specimens from the normal subjects or from specimens of normal bone obtained from patients with fibrous dysplasia. The cells that expressed c-fos in the dysplastic lesions were fibroblastic and populated the marrow space. A very low level of c-fos expression was detected in the biopsy specimens from the patients with other bone diseases. One patient with polyostotic fibrous dysplasia and one patient with the McCune-Albright syndrome were tested for the previously described G(s) alpha gene mutations and were found to express these mutations in bone. Conclusions. Increased expression of the c-fos proto-oncogene, presumably a consequence of increased adenylate cyclase activity, may be important in the pathogenesis of the bone lesions in patients with fibrous dysplasia.	MCGILL UNIV,SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 2T5,CANADA	McGill University; McGill University; McGill University								Abate C, 1990, Semin Cancer Biol, V1, P19; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COLE DEC, 1983, AM J MED GENET, V14, P725, DOI 10.1002/ajmg.1320140414; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750; WALLACH S, 1991, Current Opinion in Rheumatology, V3, P472, DOI 10.1097/00002281-199106000-00022; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATKINS S, 1989, CURRENT PROTOCOLS MO; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WU JX, 1990, ONCOGENE, V5, P989; YABUT SM, 1988, CLIN ORTHOP RELAT R, V228, P281; ZELLER R, 1989, CURRENT PROTOCOLS MO	27	115	118	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1546	1551		10.1056/NEJM199506083322304	http://dx.doi.org/10.1056/NEJM199506083322304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739708	Bronze			2022-12-01	WOS:A1995RB19600004
J	CHIARA, MD; REED, R				CHIARA, MD; REED, R			A 2-STEP MECHANISM FOR 5' AND 3' SPLICE-SITE PAIRING	NATURE			English	Article							MESSENGER-RNA PRECURSORS; ACTIVE-SITE; U6 SNRNA; SELECTION; SEQUENCES; INVITRO	A FUNDAMENTAL question in the splicing of precursor messenger RNA is how the 5' and 3' splice sites are recognized and paired during the splicing reaction. It has been proposed that spliceosome assembly in metazoan pre-mRNAs can be initiated through interaction between the 3' splice site and specific sequence elements on the downstream exon (an exonic enhancer or a 5' splice site)(1). Pairing of the intronic 5' and 3' splice sites occurs subsequently. We report here that 5' and 3' splice sites located on separate synthetic pre-mRNA substrates can be efficiently trans-spliced if the 3' trans-splicing substrate contains these downstream sequence elements. Moreover, selection of the trans 5' splice site can occur after the second pre-spliceosomal complex A has assembled on the 3' trans-splicing substrate. Thus our data demonstrate that 5' and 3' splice-site pairing in metazoans can occur in two distinct steps.			CHIARA, MD (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Chiara, María Dolores/AAG-5765-2019	Chiara, María Dolores/0000-0002-1112-1583				DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUO HC, 1992, SCIENCE, V251, P1045; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WOLFF T, 1994, P NATL ACAD SCI USA, V91, P903, DOI 10.1073/pnas.91.3.903	17	93	97	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					510	513		10.1038/375510a0	http://dx.doi.org/10.1038/375510a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777062				2022-12-01	WOS:A1995RC18800054
J	FLOR, H; ELBERT, T; KNECHT, S; WIENBRUCH, C; PANTEV, C; BIRBAUMER, N; LARBIG, W; TAUB, E				FLOR, H; ELBERT, T; KNECHT, S; WIENBRUCH, C; PANTEV, C; BIRBAUMER, N; LARBIG, W; TAUB, E			PHANTOM-LIMB PAIN AS A PERCEPTUAL CORRELATE OF CORTICAL REORGANIZATION FOLLOWING ARM AMPUTATION	NATURE			English	Article							CORTEX	ALTHOUGH phantom-limb pain is a frequent consequence of the amputation of an extremity, little is known about its origin(1-4). On the basis of the demonstration of substantial plasticity of the somatosensory cortex after amputation(5) or somatosensory deafferentation in adult monkeys(6), it has been suggested that cortical reorganization could account for some non-painful phantom-limb phenomena in amputees and that cortical reorganization has an adaptive (that is, pain-preventing) function(2,5,7,8). Theoretical and empirical work on chronic back pain(9,10) has revealed a positive relationship between the amount of cortical alteration and the magnitude of pain, so we predicted that cortical reorganization and phantom-limb pain should be positively related. Using non-invasive neuromagnetic imaging techniques to determine cortical reorganization in humans(11-13), we report a very strong direct relationship (r = 0.93) between the amount of cortical reorganization and the magnitude of phantom limb pain (but not non-painful phantom phenomena) experienced after arm amputation. These data indicate that phantom-limb pain is related to, and may be a consequence of, plastic changes in primary somatosensory cortex.	UNIV KONSTANZ,DEPT PSYCHOL,D-78434 CONSTANCE,GERMANY; UNIV MUNSTER,DEPT NEUROL,D-48129 MUNSTER,GERMANY; UNIV MUNSTER,INST EXPTL AUDIOL,D-48129 MUNSTER,GERMANY; UNIV TUBINGEN,INST MED PSYCHOL & BEHAV NEUROBIOL,D-72074 TUBINGEN,GERMANY; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294	University of Konstanz; University of Munster; University of Munster; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Alabama System; University of Alabama Birmingham	FLOR, H (corresponding author), HUMBOLDT UNIV BERLIN,DEPT PSYCHOL,HAUSVOGTEIPL 5-7,D-10117 BERLIN,GERMANY.		Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939; Birbaumer, Niels/0000-0002-6786-5127; Flor, Herta/0000-0003-4809-5398; Knecht, Stefan/0000-0003-1056-9228				CALFORD MB, 1991, P ROY SOC B-BIOL SCI, V243, P269, DOI 10.1098/rspb.1991.0041; Casey K., 1991, PAIN CENTRAL NERVOUS; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Flor H, 1990, Schmerz, V4, P82, DOI 10.1007/BF02527839; FLOR H, 1994, AM PAIN SOC J, V3, P1187; FLOR H, IN PRESS RECENT ADV; GEISSNER E, IN PRESS SCHMERZEMPF; Gilbert C D, 1993, Curr Opin Neurobiol, V3, P100, DOI 10.1016/0959-4388(93)90042-W; Jensen TS., 1994, TXB PAIN, P651; KATZ J, 1992, CAN J PSYCHIAT, V37, P282, DOI 10.1177/070674379203700502; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; LUND JP, 1994, SCIENCE, V265, P546, DOI 10.1126/science.8036500; LUTKENHONER B, IN PRESS BRAIN TOPOG; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1989, CAN PSYCHOL, V30, P1, DOI 10.1037/h0079793; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; WILLIS WD, 1994, 7TH P WORLD C PAIN, P301; YANG TT, 1994, NATURE, V368, P592, DOI 10.1038/368592b0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	24	1248	1279	1	183	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					482	484		10.1038/375482a0	http://dx.doi.org/10.1038/375482a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777055	Green Submitted			2022-12-01	WOS:A1995RC18800046
J	JUST, I; SELZER, J; WILM, M; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K				JUST, I; SELZER, J; WILM, M; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K			GLUCOSYLATION OF RHO-PROTEINS BY CLOSTRIDIUM-DIFFICILE TOXIN-B	NATURE			English	Article							TRIPHOSPHATE CONFORMATION; MECHANISM; P21	TOXIN A and B, the major virulence factors of Clostridium difficile, are the causative agents of antibiotic-associated pseudomembranous colitis. In cultured cell lines their potent cytotoxicity results from their ability to induce disaggregation of the microfilament cytoskeleton(1,2). Toxin B acts on the low-molecular-mass GTPase RhoA(3,4), which is involved in the regulation of the actin cytoskeleton. We report here that toxin B catalyses the incorporation of up to one mole of glucose per mole of RhoA at the amino acid threonine at position 37. The modification was identified and localized by tandem electrospray mass spectrometry. UDP-glucose selectively serves as cosubstrate for the monoglucosylation reaction catalysed by toxin B. Microinjection of RhoA previously glucosylated by toxin B into monolayer cells caused disaggregation of actin filaments, indicating a dominant-negative activity of glucosylated RhoA.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST MED MIKROBIOL,D-55101 MAINZ,GERMANY	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022; Mann, Matthias/A-3454-2013	Aktories, Klaus/0000-0002-5397-0436; Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1994, J CELL SCI, V107, P1653; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SELF AJ, 1993, ONCOGENE, V8, P655; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	12	854	878	1	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					500	503		10.1038/375500a0	http://dx.doi.org/10.1038/375500a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777059				2022-12-01	WOS:A1995RC18800051
J	KANNO, K; SASAKI, S; HIRATA, Y; ISHIKAWA, S; FUSHIMI, K; NAKANISHI, S; BICHET, DG; MARUMO, F				KANNO, K; SASAKI, S; HIRATA, Y; ISHIKAWA, S; FUSHIMI, K; NAKANISHI, S; BICHET, DG; MARUMO, F			URINARY-EXCRETION OF AQUAPORIN-2 IN PATIENTS WITH DIABETES-INSIPIDUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY COLLECTING TUBULE; WATER CHANNEL; RECEPTOR GENE; RAT-KIDNEY; VASOPRESSIN; MUTATIONS; CELLS; PERMEABILITY; ENDOSOMES	Background. Urine-concentrating ability is regulated by vasopressin. Recently, the specific water-channel protein of the renal collecting duct, known as aquaporin-2, was cloned. However, it is not certain whether this molecule is responsive to vasopressin. Methods. We measured the urinary excretion of aquaporin-2 and its response to vasopressin in 11 normal subjects and 9 patients with central or nephrogenic diabetes insipidus. The urine samples were collected during periods of dehydration and hydration and after the administration of vasopressin. Urine samples were analyzed for aquaporin-2 by the Western blot assay and immunogold labeling, and the amount of aquaporin-2 was determined by radioimmunoassay. Results. Aquaporin-2 was detectable in the urine in both soluble and membrane-bound forms. In the five normal subjects tested, the mean (+/-SE) urinary excretion of aquaporin-2 was 11.2+/-2.2 pmol per milligram of creatinine after a period of dehydration, and it decreased to 3.9+/-1.9 pmol per milligram of creatinine (P=0.03) during the second hour after a period of hydration. In the six other normal subjects, an infusion of desmopressin (1-desamino-8-D-arginine vasopressin) increased the urinary excretion of aquaporin-2 from 0.8+/-0.3 to 11.2+/-1.6 pmol per milligram of creatinine (P<0.001). The five patients with central diabetes insipidus also had increases in urinary excretion of aquaporin-2 in response to the administration of vasopressin, but the four patients with X-linked or non-X-linked nephrogenic diabetes insipidus did not. Conclusions. Aquaporin-2 is detectable in the urine, and changes in the urinary excretion of this protein can be used as an index of the action of vasopressin on the kidney.	TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; JICHI MED SCH,DEPT ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI,JAPAN; JT INC,CENT PHARMACEUT RES INST,PHARMACEUT BASIC RES LABS,KANAGAWA,JAPAN; UNIV MONTREAL,HOP SACRE COEUR,CTR RECH,MONTREAL,PQ,CANADA	Tokyo Medical & Dental University (TMDU); Jichi Medical University; Universite de Montreal			Nakanishi, Setsuko/G-5871-2015	Nakanishi, Setsuko/0000-0003-4909-2113				AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; BICHET DG, 1993, J CLIN INVEST, V92, P1262, DOI 10.1172/JCI116698; BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; LANGLEY JM, 1991, AM J MED GENET, V38, P90, DOI 10.1002/ajmg.1320380120; Lonergan Michele, 1993, Journal of the American Society of Nephrology, V4, P264; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SASAKI S, 1994, J CLIN INVEST, V94, P216; SHI LB, 1990, J GEN PHYSIOL, V96, P789, DOI 10.1085/jgp.96.4.789; UCHIDA S, 1994, J BIOL CHEM, V269, P23451; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x	29	237	244	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1540	1545		10.1056/NEJM199506083322303	http://dx.doi.org/10.1056/NEJM199506083322303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7537863	Bronze			2022-12-01	WOS:A1995RB19600003
J	KIEFHABER, T; LABHARDT, AM; BALDWIN, RL				KIEFHABER, T; LABHARDT, AM; BALDWIN, RL			DIRECT NMR EVIDENCE FOR AN INTERMEDIATE PRECEDING THE RATE-LIMITING STEP IN THE UNFOLDING OF RIBONUCLEASE-A	NATURE			English	Article							STRUCTURAL CHARACTERIZATION; TRANSITION-STATE; PROTEIN; LYSOZYME	IT is commonly believed that there are no detectable intermediates in the kinetic unfolding reactions of small proteins(1-6). If such intermediates could be found, they would give important information about the nature of the transition state for unfolding, which is thought to occur close to the native state. We report here that one-dimensional proton magnetic resonance spectra recorded during the unfolding of ribonuclease A provide direct evidence for at least one unfolding intermediate in which side chains are free to rotate. This intermediate appears to be a 'dry molten globule' of the kind hypothesized by Shakhnovich and Finkelstein(7).	F HOFFMANN LA ROCHE & CO LTD,PHARMA RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305	Roche Holding; Stanford University	KIEFHABER, T (corresponding author), UNIV BASEL,BIOCTR,BIOPHYS CHEM ABT,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		Kiefhaber, Thomas/A-3028-2010					CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; CHEN XW, 1994, BIOCHEMISTRY-US, V33, P6356, DOI 10.1021/bi00186a040; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P2657, DOI 10.1073/pnas.92.7.2657; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P12930; PITITSYN GB, 1992, PROTEIN FOLDING, P243; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; ROBERTSON AD, 1989, BIOCHEMISTRY-US, V28, P5930, DOI 10.1021/bi00440a033; Schmid Franz X., 1992, P197; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SERRANO L, 1992, J MOL BIOL, V224, P805, DOI 10.1016/0022-2836(92)90563-Y; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; VANDAEL H, 1993, BIOCHEMISTRY-US, V32, P11886, DOI 10.1021/bi00095a018; Wuthrich K., 1986, NMR PROTEINS NUCL AC	17	146	146	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					513	515		10.1038/375513a0	http://dx.doi.org/10.1038/375513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777063				2022-12-01	WOS:A1995RC18800055
J	KOH, J; ENDERS, GH; DYNLACHT, BD; HARLOW, E				KOH, J; ENDERS, GH; DYNLACHT, BD; HARLOW, E			TUMOR-DERIVED P16 ALLELES ENCODING PROTEINS DEFECTIVE IN CELL-CYCLE INHIBITION	NATURE			English	Article							RETINOBLASTOMA PROTEIN	THE cyclin-dependent kinase inhibitor p16 is a candidate tumour-suppressor protein that maps to a genomic locus strongly associated with familial melanoma and other tumour types(1-3). Screening of primary tumours and linkage analysis of familial melanoma pedigrees have identified many potential mutations in p16, but the functional significance of these sequence variants has remained unclear(1,3-9). We report here that p16 can act as a potent and specific inhibitor of progression through the G1 phase of the cell cycle, and we demonstrate that several tumour-derived alleles of p16 encode functionally compromised proteins. The ability of p16 to arrest cell-cycle progression generally correlates with inhibition of cyclin D1/Cdk4 kinase activity irt vitro, with two exceptions among the alleles tested. In vivo, the presence of functional retinoblastoma protein appears to be necessary but may not be sufficient to confer full sensitivity to p16-mediated growth arrest. Our results provide support for the notion that p16 is an important cell-cycle regulator whose inactivation contributes to the outgrowth of human tumours.	MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	KOH, J (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BLDG 149, 13TH ST, BOSTON, MA 02129 USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORI T, 1994, CANCER RES, V54, P3396; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	27	530	548	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					506	510		10.1038/375506a0	http://dx.doi.org/10.1038/375506a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777061				2022-12-01	WOS:A1995RC18800053
J	LANYI, JK				LANYI, JK			BACTERIORHODOPSIN AS A MODEL FOR PROTON PUMPS	NATURE			English	Article							CYTOCHROME-C-OXIDASE; X-RAY-DIFFRACTION; STRUCTURAL-CHANGES; MECHANISM; PHOTOCYCLE; TRANSPORT; ENERGY; INTERMEDIATE; ACTIVATION; PROTEINS	According to a long-standing hypothesis, membrane pumps function by flip-flopping between two protein conformations that allow alternative access of the ion binding site to the two membrane surfaces. Site-specific mutagenesis, time-resolved spectroscopy and X-ray diffraction confirm this mechanism for bacteriorhodopsin, and implicate change of electrostatic interaction at the active site as the trigger for the global protein conformation change during the proton transport cycle.			LANYI, JK (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.		Ueno, Hiroshi/C-3301-2009; Lanyi, Janos/C-3808-2011					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMES JB, 1990, BIOCHEMISTRY-US, V29, P7181, DOI 10.1021/bi00483a005; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; BRZEZINSKI P, 1986, P NATL ACAD SCI USA, V83, P4282, DOI 10.1073/pnas.83.12.4282; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COPELAND RA, 1989, ANNU REV PHYS CHEM, V40, P671; FILLINGAME RH, 1994, BACTERIA, V12, P345; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GRABER P, 1994, BBA-BIOENERGETICS, V1187, P171, DOI 10.1016/0005-2728(94)90105-8; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LAUBINGER W, 1994, BIOCHEMISTRY-US, V29, P5458; MALMSTROM BG, 1993, ACCOUNTS CHEM RES, V26, P332, DOI 10.1021/ar00030a006; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OPRIAN DD, 1993, J BIOENERG BIOMEMBR, V24, P211; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; STRADER CD, 1994, DEV BIOCHEM, V63, P101; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VALPUESTA JM, 1990, J MOL BIOL, V214, P237, DOI 10.1016/0022-2836(90)90158-I; VARO G, 1992, BIOCHEMISTRY-US, V30, P5016; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WIKSTROM M, 1979, BIOCHIM BIOPHYS ACTA, V549, P177, DOI 10.1016/0304-4173(79)90014-4; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010; ZIMANYI L, 1992, BIOCHEMISTRY-US, V3, P8535; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046	50	133	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					461	463		10.1038/375461a0	http://dx.doi.org/10.1038/375461a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777054				2022-12-01	WOS:A1995RC18800039
J	LUKAS, J; PARRY, D; AAGAARD, L; MANN, DJ; BARTKOVA, J; STRAUSS, M; PETERS, G; BARTEK, J				LUKAS, J; PARRY, D; AAGAARD, L; MANN, DJ; BARTKOVA, J; STRAUSS, M; PETERS, G; BARTEK, J			RETINOBLASTOMA-PROTEIN-DEPENDENT CELL-CYCLE INHIBITION BY THE TUMOR-SUPPRESSOR P16	NATURE			English	Article							GENE; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; G(1); D1	D-TYPE cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle(1-6) by phosphorylating the retinoblastoma protein (RB)(7,8). The activities of Cdk4 and Cdk6 are constrained by inhibitors(9-12) such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb--/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.	DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN 0,DENMARK; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MAX PLANCK GESELL,D-13122 BERLIN,GERMANY	Danish Cancer Society; Cancer Research UK; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, IN PRESS ONCOGENE; LUKAS J, 1994, J ONCOGENE, V9, P707; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, CANCER RES, V54, P5816; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	26	863	888	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					503	506		10.1038/375503a0	http://dx.doi.org/10.1038/375503a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777060				2022-12-01	WOS:A1995RC18800052
J	PIERIBONE, VA; SHUPLIAKOV, O; BRODIN, L; HILFIKERROTHENFLUH, S; CZERNIK, AJ; GREENGARD, P				PIERIBONE, VA; SHUPLIAKOV, O; BRODIN, L; HILFIKERROTHENFLUH, S; CZERNIK, AJ; GREENGARD, P			DISTINCT POOLS OF SYNAPTIC VESICLES IN NEUROTRANSMITTER RELEASE	NATURE			English	Article							SYNAPSIN-I; SHORT-TERM; PROTEIN; PHOSPHOPROTEINS; SYNAPTOTAGMIN; PLASTICITY; NEURONS	NERVE terminals are unique among cellular secretory systems in that they can sustain vesicular release at a high rate. Although little is known about the mechanisms that account for the distinctive features of neurotransmitter release, it can be assumed that neuron-specific proteins are involved. One such protein family, the synapsins, are believed to regulate neurotransmitter release through phosphorylation-dependent interactions with synaptic vesicles and cytoskeletal elements(1). Here we show that clusters of vesicles at synaptic release sites are composed of two pools, a distal pool containing synapsin and a proximal pool devoid of synapsin and located adjacent to the presynaptic membrane. Presynaptic injection of synapsin antibodies resulted in the loss of the distal pool, without any apparent effect on the proximal pool. Depletion of this distal pool,vas associated with a marked depression of neurotransmitter release evoked by high-frequency (18-20 Hz) but not by low-frequency (0.2 Hz) stimulation. Thus the availability of the synapsin-associated pool of vesicles seems to be required to sustain release of neurotransmitter in response to high-frequency bursts of impulses.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	PIERIBONE, VA (corresponding author), ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Hilfiker, Sabine N/L-6369-2014; Shupliakov, Oleg/R-9148-2016	Hilfiker, Sabine N/0000-0002-5167-7682; Shupliakov, Oleg/0000-0001-5352-6848; Pieribone, Vincent/0000-0002-5836-5454				ATWOOD HL, 1986, INT REV NEUROBIOL, V28, P275, DOI 10.1016/S0074-7742(08)60111-7; BENFENATI F, 1993, J CELL BIOL, V123, P1845, DOI 10.1083/jcb.123.6.1845; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRODIN L, 1994, J NEUROPHYSIOL, V72, P592, DOI 10.1152/jn.1994.72.2.592; BRODIN L, 1994, ADV SEC MESS PHOSPH, V29, P205; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCHANAN JT, 1992, BIOL CYBERN, V67, P123, DOI 10.1007/BF00201019; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROVAINEN CM, 1979, PHYSIOL REV, V59, P1007, DOI 10.1152/physrev.1979.59.4.1007; RUBENSTEIN JL, 1993, SYNAPSE, V13, P161, DOI 10.1002/syn.890130207; SHUPLIAKOV O, 1995, EUR J NEUROSCI, V7, P1111, DOI 10.1111/j.1460-9568.1995.tb01099.x; SHUPLIAKOV O, 1992, J NEUROSCI, V12, P3789; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WICKELGREN WO, 1985, J NEUROSCI, V5, P1188	24	423	429	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					493	497		10.1038/375493a0	http://dx.doi.org/10.1038/375493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777058				2022-12-01	WOS:A1995RC18800049
J	ROSAHL, TW; SPILLANE, D; MISSLER, M; HERZ, J; SELIG, DK; WOLFF, JR; HAMMER, RE; MALENKA, RC; SUDHOF, TC				ROSAHL, TW; SPILLANE, D; MISSLER, M; HERZ, J; SELIG, DK; WOLFF, JR; HAMMER, RE; MALENKA, RC; SUDHOF, TC			ESSENTIAL FUNCTIONS OF SYNAPSIN-I AND SYNAPSIN-II IN SYNAPTIC VESICLE REGULATION	NATURE			English	Article							PROTEIN; PHOSPHOPROTEINS; ASSOCIATION; PLASTICITY; ACTIN; MICE	SYNAPTIC vesicles are coated by synapsins, phosphoproteins that account for 9% of the vesicle protein(1-3). To analyse the functions of these proteins, we have studied knockout mice lacking either synapsin I, synapsin II, or both. Mice lacking synapsins are viable and fertile with no gross anatomical abnormalities, but experience seizures with a frequency proportional to the number of mutant alleles. Synapsin-II and double knockouts, but not synapsin-I knockouts, exhibit decreased post-tetanic potentiation and severe synaptic depression upon repetitive stimulation. Intrinsic synaptic-vesicle membrane proteins, but not peripheral membrane proteins or other synaptic proteins, are slightly decreased in individual knockouts and more severely reduced in double knockouts, as is the number of synaptic vesicles. Thus synapsins are not required for neurite outgrowth, synaptogenesis or the basic mechanics of synaptic vesicle traffic, but are essential for accelerating this traffic during repetitive stimulation. The phenotype of the synapsin knockouts could be explained either by deficient recruitment of synaptic vesicles to the active zone, or by impaired maturation of vesicles at the active zone, both of which could lead to a secondary destabilization of synaptic vesicles.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; GOTHENBURG UNIV, ZENTRUM ANAT, D-37075 GOTTINGEN, GERMANY	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Missler, Markus/0000-0001-8008-984X				ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; GEPPERT M, 1994, EMBO J, V13, P3720, DOI 10.1002/j.1460-2075.1994.tb06681.x; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Imaizumi K, 1959, EXP ANIM TOKYO, V8, P6; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MISSLER M, 1993, J COMP NEUROL, V333, P53, DOI 10.1002/cne.903330105; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; Robertson E. J, 1987, TERATOCARCINOMAS EMB, P71; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUSAKOV DA, 1991, NEUROSCI LETT, V131, P156, DOI 10.1016/0304-3940(91)90602-P; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINER JP, 1987, J BIOL CHEM, V262, P905; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Weibel E, 1979, STEREOLOGICAL METHOD; WOOLSON RF, 1987, STATISTICAL METHODS, P344; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	24	605	612	2	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					488	493		10.1038/375488a0	http://dx.doi.org/10.1038/375488a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777057				2022-12-01	WOS:A1995RC18800048
J	WESTENDORP, MO; FRANK, R; OCHSENBAUER, C; STRICKER, K; DHEIN, J; WALCZAK, H; DEBATIN, KM; KRAMMER, PH				WESTENDORP, MO; FRANK, R; OCHSENBAUER, C; STRICKER, K; DHEIN, J; WALCZAK, H; DEBATIN, KM; KRAMMER, PH			SENSITIZATION OF T-CELLS TO CD95-MEDIATED APOPTOSIS BY HIV-1 TAT AND GP120	NATURE			English	Article							MONOCLONAL-ANTIBODY; INFECTION; AIDS; PROTEIN; CD4	THE depletion of CD4(+) T cells in AIDS is correlated with high turnover of the human immunodeficiency virus HIV-1(1,2) acid associated with apoptosis(3-5). The molecular mechanism of apoptosis in HIV infection, however, is largely unknown, T-cell apoptosis might be affected by viral proteins such as HIV-1 Tat(6-9) and gp120 (refs 10, 11). T-cell-receptor (TCR)-induced apoptosis was recently shown to involve the CD95 (APO-1/Fas) receptor(12). We show here that HIV-1 Tat strongly sensitizes TCR- and CD4(gp120)-induced apoptosis by upregulation of CD95 ligand expression. Concentrations of Tat found to be effective in cultures of HIV-1-infected cells were also observed in sera from HIV-1-infected individuals. Taken together, our results indicate that HIV-1 Tat and gp120 accelerate CD95-mediated, activation-induced T-cell apoptosis, a mechanism that may contribute to CD4(+) T-cell depletion(5,13,14) in AIDS.	GERMAN CANC RES CTR, TUMORIMMUNOL PROGRAM, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, CTR BIOL MOLEC, W-6900 HEIDELBERG, GERMANY; UNIV HEIDELBERG, CHILDRENS HOSP, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg			Debatin, Klaus-Michael/J-9704-2014; Walczak, Henning/AAV-2214-2020	Debatin, Klaus-Michael/0000-0002-8397-1886; Walczak, Henning/0000-0002-6312-4591; Dhein, Jens/0000-0002-7200-2967				AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DEBATIN KM, 1994, BLOOD, V83, P3101, DOI 10.1182/blood.V83.10.3101a.3101a; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gougeon M L, 1995, Cell Death Differ, V2, P1; HAIGWOOD NL, 1990, VACCINES 90, P313; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KRAFT M, 1995, PEPTIDES 1994, P349; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LU YY, 1994, J VIROL, V68, P390, DOI 10.1128/JVI.68.1.390-399.1994; OYAIZU N, 1993, BLOOD, V82, P3392; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCANDELLA CJ, 1993, AIDS RES HUM RETROV, V9, P1233, DOI 10.1089/aid.1993.9.1233; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZAULI G, 1993, CANCER RES, V53, P4481	30	878	904	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					497	500		10.1038/375497a0	http://dx.doi.org/10.1038/375497a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7539892				2022-12-01	WOS:A1995RC18800050
J	WINKLER, J; SUHR, ST; GAGE, FH; THAL, LJ; FISHER, LJ				WINKLER, J; SUHR, ST; GAGE, FH; THAL, LJ; FISHER, LJ			ESSENTIAL ROLE OF NEOCORTICAL ACETYLCHOLINE IN SPATIAL MEMORY	NATURE			English	Article							NUCLEUS BASALIS MAGNOCELLULARIS; EXCITOTOXIC LESIONS; CHOLINERGIC SYSTEM; SENILE DEMENTIA; IBOTENIC ACID; FOREBRAIN; RATS; NEURONS; ACETYLTRANSFERASE; PHYSOSTIGMINE	THE cholinergic system plays a crucial role in learning and memory. Lesions of cholinergic nuclei(1-4), pharmacological manipulations of cholinergic systems(5-8), intracerebral transplantation of fetal tissue(9-11) and anatomical changes in cholinergic pathways during ageing(12-14) have all been correlated with altered cognitive behaviour. However, it has not been proved that regional acetylcholine is causally required for learning and memory. Here we describe how we achieved a permanent and selective impairment of learning and memory by damaging the nucleus basalis magnocellularis, a nucleus that provides the major cholinergic innervation of the neocortex(15,16), in adult rats. To test the hypothesis that acetylcholine is essential for restoration of cognitive function, we implanted genetically modified cells that produce acetylcholine(17) into denervated neocortical target regions. After grafting, rats with increased neocortical acetylcholine levels showed a significant improvement in a spatial navigation task. Acetylcholine is thus not only necessary for learning and memory, as previously argued, but its presence within the neocortex is also sufficient to ameliorate learning deficits and restore memory following damage to the nucleus basalis.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; VET AFFAIRS MED CTR,DEPT NEUROL,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ALKON DL, 1991, BRAIN RES REV, V16, P193, DOI 10.1016/0165-0173(91)90005-S; ARENDT T, 1989, NEUROSCIENCE, V33, P435, DOI 10.1016/0306-4522(89)90397-7; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOEGMAN RJ, 1992, NEUROSCIENCE, V51, P129, DOI 10.1016/0306-4522(92)90477-J; CONNOR DJ, 1991, BRAIN RES, V555, P84, DOI 10.1016/0006-8993(91)90863-Q; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DUNNETT SB, 1985, NEUROSCIENCE, V16, P787, DOI 10.1016/0306-4522(85)90094-6; DUNNETT SB, 1991, TRENDS NEUROSCI, V14, P494, DOI 10.1016/0166-2236(91)90061-X; FIBIGER HC, 1982, BRAIN RES REV, V4, P327, DOI 10.1016/0165-0173(82)90011-X; FISHER LJ, 1993, J NEUROCHEM, V61, P1323, DOI 10.1111/j.1471-4159.1993.tb13625.x; FREED WJ, 1990, EXP NEUROL, V110, P139, DOI 10.1016/0014-4886(90)90026-O; GAGE FH, 1986, J NEUROSCI, V6, P2837; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GIROD R, IN PRESS J NEUROSCI; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; MANDEL RJ, 1988, PSYCHOPHARMACOLOGY, V96, P421, DOI 10.1007/BF00216074; MANDEL RJ, 1989, BEHAV BRAIN RES, V31, P221, DOI 10.1016/0166-4328(89)90004-1; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MUIR JL, 1993, BEHAV BRAIN RES, V57, P123, DOI 10.1016/0166-4328(93)90128-D; MURRAY CL, 1985, NEUROSCIENCE, V14, P1025, DOI 10.1016/0306-4522(85)90273-8; NILSSON OG, 1987, EXP BRAIN RES, V67, P195, DOI 10.1007/BF00269466; PAGE KJ, 1991, NEUROSCIENCE, V43, P457, DOI 10.1016/0306-4522(91)90308-B; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd ed; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341	29	246	255	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					484	487		10.1038/375484a0	http://dx.doi.org/10.1038/375484a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777056				2022-12-01	WOS:A1995RC18800047
J	BRANDSTATER, ME				BRANDSTATER, ME			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BRANDSTATER, ME (corresponding author), LOMA LINDA UNIV,LOMA LINDA,CA 92350, USA.							AGRE JC, 1991, ARCH PHYS MED REHAB, V72, P923, DOI 10.1016/0003-9993(91)90013-9; BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; BACH JR, 1992, ARCH PHYS MED REHAB, V73, P934; BORGSTEIN J, 1993, J HEAD TRAUMA REHAB, V8, P103; BOYESON MG, 1994, J HEAD TRAUMA REHAB, V9, P78, DOI 10.1097/00001199-199409000-00007; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hamilton BB., 1987, REHABILITATION OUTCO, P137; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Saal J A, 1990, Orthop Rev, V19, P691; SAAL JS, 1990, SPINE, V15, P674, DOI 10.1097/00007632-199007000-00011; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; [No title captured]; B HLTH INSURANCE ASS, V287	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1710	1712		10.1001/jama.273.21.1710	http://dx.doi.org/10.1001/jama.273.21.1710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752431				2022-12-01	WOS:A1995RB09700039
J	FRANKLIN, JE				FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FRANKLIN, JE (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.							BOHN MJ, 1994, AM J ADDICTION, V3, P91; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; HASIN D, 1994, ALCOHOL CLIN EXP RES, V18, P1348, DOI 10.1111/j.1530-0277.1994.tb01435.x; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P898; LEVIN ED, 1994, J CLIN PSYCHOPHARM, V14, P41; MUELLER TI, 1994, AM J PSYCHIAT, V151, P701; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P1723; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; TIIHONEN J, 1994, AM J PSYCHIAT, V151, P1505; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; 1987, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC	15	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1656	1657		10.1001/jama.273.21.1656	http://dx.doi.org/10.1001/jama.273.21.1656			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752401				2022-12-01	WOS:A1995RB09700009
J	HARDY, MA; SUNG, RS				HARDY, MA; SUNG, RS			TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HARDY, MA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.							BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; CANTAROVICH D, 1994, TRANSPLANTATION, V57, P198, DOI 10.1097/00007890-199401001-00007; COLE EH, 1994, TRANSPLANTATION, V57, P60, DOI 10.1097/00007890-199401000-00012; DUNN SP, 1994, TRANSPLANTATION, V57, P544; GRIFFITH BP, 1994, TRANSPLANTATION, V57, P848, DOI 10.1097/00007890-199403270-00013; HRIEIK DE, 1994, TRANSPLANTATION, V57, P979; LASKOW DA, 1994, TRANSPLANTATION, V57, P640, DOI 10.1097/00007890-199402270-00030; LO CM, 1994, TRANSPLANTATION, V58, P543, DOI 10.1097/00007890-199409150-00003; MCDANIEL DO, 1994, TRANSPLANTATION, V57, P852, DOI 10.1097/00007890-199403270-00014; MEISER BM, 1994, TRANSPLANTATION, V57, P563; MONTAGNINO G, 1994, TRANSPLANTATION, V58, P149, DOI 10.1097/00007890-199405820-00005; NIKAEIN A, 1994, TRANSPLANTATION, V58, P786, DOI 10.1097/00007890-199410150-00006; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; TAKEMOTO S, 1994, NEW ENGL J MED, V331, P760, DOI 10.1056/NEJM199409223311202; YANDZA T, 1994, TRANSPLANTATION, V58, P46, DOI 10.1097/00007890-199407000-00009; 1994, NEW ENGL J MED, V331, P1110	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1723	1725						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752438				2022-12-01	WOS:A1995RB09700046
J	KANE, RL; KANE, RA				KANE, RL; KANE, RA			LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATIONS; NURSING-HOME; SERVICES				KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455, USA.							ARRAS J, 1995, BRINGING HOSPITAL HO; EUSTIS NN, 1992, GENERATIONS, V16, P17; HARRINGTON C, 1993, GERONTOLOGIST, V33, P790, DOI 10.1093/geront/33.6.790; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; Kane RA, 1993, ASSISTED LIVING US N; KANE RL, 1992, GERONTOLOGIST, V32, P771, DOI 10.1093/geront/32.6.771; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1990, GERONTOLOGIST, V30, P291, DOI 10.1093/geront/30.3.291; KANE RL, 1994, GERONTOLOGIST, V34, P598, DOI 10.1093/geront/34.5.598; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; MANTON KG, 1994, MED CARE, V32, P277, DOI 10.1097/00005650-199403000-00007; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; NEWCOMER R, 1990, GERONTOLOGIST, V30, P86, DOI 10.1093/geront/30.1.86; NEWCOMER R, 1990, HEALTH SERV RES, V25, P425; SIMONRUSINOWITZ L, 1993, GERONTOLOGIST, V33, P159, DOI 10.1093/geront/33.2.159; 1994, GAOHEHE94167 US GEN; 1994, GAOHEHS9526 US GEN A	17	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1690	1691		10.1001/jama.273.21.1690	http://dx.doi.org/10.1001/jama.273.21.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752419				2022-12-01	WOS:A1995RB09700027
J	PINGLETON, SK				PINGLETON, SK			PULMONARY AND CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASTHMA; DEATH; RISK				PINGLETON, SK (corresponding author), UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103, USA.							[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1994, JAMA-J AM MED ASSOC, V271, P1412; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAAHTELA T, 1993, NEW ENGL J MED, V331, P700; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; MALFMO NA, 1991, NEW ENGL J MED, V321, P285; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SLY MS, 1994, ANN ALLERGY, V73, P259; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; 1989, NATIONAL HEART LUNG; 1991, 913042 US DEP HLTH H	19	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1717	1718						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752434				2022-12-01	WOS:A1995RB09700042
J	RUSSELL, RM				RUSSELL, RM			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-FATTY-ACIDS; WOMEN				RUSSELL, RM (corresponding author), TUFTS UNIV,JEAN MAYER HUMAN NUTR RES CTR AGING,BOSTON,MA 02111, USA.							ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; GOLDSTEIN DJ, 1994, AM J CLIN NUTR, V60, P647, DOI 10.1093/ajcn/60.5.647; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; GREENBERG RE, 1994, NEW ENGL J MED, V331, P141; KUCAMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; 1994, DIABETES CARE, V17, P519; 1994, STATEMENT T FATTY AC, P1; 1994, JAMA-J AM MED ASSOC, V272, P1942; 1994, NEW ENGL J MED, V330, P1029	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1699	1700						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752424				2022-12-01	WOS:A1995RB09700032
J	BENNICKE, K; CONRAD, C; SABROE, S; SORENSEN, HT				BENNICKE, K; CONRAD, C; SABROE, S; SORENSEN, HT			CIGARETTE-SMOKING AND BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate cigarette smoking in relation to the risk of breast cancer. Design-interviews with women referred for mammography. Setting-Hjorring District Hospital, a public, population based hospital in Denmark. Subjects-3240 women aged 15-99 years referred for mammography during 1 June 1989 to 1 November 1991. Main outcome measures-Smoking, parity, age, reason for referral, breast cancer. Results-In a multiple logistic regression analysis adjusted for six variables a pronounced increased risk of breast cancer was found in women who had smoked for over 20 years, and this was significant in women who had smoked for over 30 years (odds ratio 1.6, 95% confidence interval 1.1 to 2.3). The median age of women with breast cancer was 59 (range 31-81) years for smokers and 67 (38-92) years for nonsmokers. The difference of eight years between the median ages was significant (P<0.01). Conclusion-Smoking may increase the risk of breast cancer after 30 years of smoking.	HJORRING DIST HOSP,DEPT RADIOL,DK-9800 HJORRING,DENMARK; AARHUS UNIV,DEPT EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,STENO INST PUBL HLTH,DANISH EPIDEMIOL SCI CTR,AARHUS,DENMARK	Aarhus University; Aarhus University			Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040				BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; HIATT RA, 1986, JNCI-J NATL CANCER I, V76, P833; Hosmer D, 2013, APPL LOGISTIC REGRES; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KRALL EA, 1989, AM J PUBLIC HEALTH, V79, P200, DOI 10.2105/AJPH.79.2.200; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; Osler M, 1992, DANSKERNES RYGEVANER; PALMER JR, 1993, EPIDEMIOL REV, V5, P145; PETRAKIS NL, 1980, CANCER RES, V40, P188; ROTH HD, 1994, J CLIN EPIDEMIOL, V47, P207, DOI 10.1016/0895-4356(94)90026-4; VOGT TM, 1977, AM J PUBLIC HEALTH, V67, P545, DOI 10.2105/AJPH.67.6.545	12	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1431	1433		10.1136/bmj.310.6992.1431	http://dx.doi.org/10.1136/bmj.310.6992.1431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613275	Green Published			2022-12-01	WOS:A1995RC10500015
J	BRAHAMS, D				BRAHAMS, D			CLARIFICATION OF THE EGGSHELL SKULL DOCTRINE	LANCET			English	Editorial Material																		1994, LANCET, V343, P1217	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1430	1430		10.1016/S0140-6736(95)92614-3	http://dx.doi.org/10.1016/S0140-6736(95)92614-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760618	Bronze			2022-12-01	WOS:A1995RB44100025
J	BRUGGER, P; MARKTL, W; HEROLD, M				BRUGGER, P; MARKTL, W; HEROLD, M			IMPAIRED NOCTURNAL SECRETION OF MELATONIN IN CORONARY HEART-DISEASE	LANCET			English	Note								Patients with coronary heart disease have increased nocturnal urinary noradrenaline. Because melatonin suppresses sympathetic activity, we measured serum melatonin concentrations at night (0200 h) in 15 patients with coronary heart disease. Melatonin was significantly lower in the patients than in 10 healthy controls (median 7.8 [interquartile range 6.5-11.8] vs 36.2 [32.2-42.5] pg/mL, p<0.0001). Thus, impaired nocturnal secretion of melatonin is associated with coronary heart disease. Patients disease nocturnal noradrenaline.	UNIV VIENNA, DEPT PHYSIOL, VIENNA, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	University of Vienna; University of Innsbruck	BRUGGER, P (corresponding author), INST CARDIOVASC DIAGNOSIS & THERAPY, IMBERGSTR 22, A-5020 SALZBURG, AUSTRIA.							Arendt J., 1985, Pineal Research Reviews, V3, P161; AXELROD J, 1981, J NEUROSURG, V55, P669, DOI 10.3171/jns.1981.55.5.0669; BRUGGER P, 1990, WIEN MED WOCHENSCHR, V14, P375; DOLLINS AB, 1993, PHYSIOL BEHAV, V53, P153, DOI 10.1016/0031-9384(93)90024-A; LYNCH HJ, 1975, SCIENCE, V187, P168; MAHATA SK, 1991, J COMP PHYSIOL B, V161, P81, DOI 10.1007/BF00258750; SHAFI S, 1989, PROC R SOC SER B-BIO, V235, P289, DOI 10.1098/rspb.1989.0001; VAUGHAN GM, 1979, NEUROSCI LETT, V14, P81, DOI 10.1016/0304-3940(79)95348-5; VISWANATHAN M, 1986, LIFE SCI, V38, P73, DOI 10.1016/0024-3205(86)90277-8	9	165	171	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 3	1995	345	8962					1408	1408		10.1016/S0140-6736(95)92600-3	http://dx.doi.org/10.1016/S0140-6736(95)92600-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760612				2022-12-01	WOS:A1995RB44100012
J	HOOGERBRUGGE, PM; BROUWER, OF; BORDIGONI, P; RINGDEN, O; KAPAUN, P; ORTEGA, JJ; OMEARA, A; CORNU, G; SOUILLET, G; FRAPPAZ, D; BLANCHE, S; FISCHER, A				HOOGERBRUGGE, PM; BROUWER, OF; BORDIGONI, P; RINGDEN, O; KAPAUN, P; ORTEGA, JJ; OMEARA, A; CORNU, G; SOUILLET, G; FRAPPAZ, D; BLANCHE, S; FISCHER, A			ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LYSOSOMAL STORAGE DISEASES	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; GAUCHER DISEASE; MICE	Patients with lysosomal storage disorders have visceral, skeletal, and neurological abnormalities and a limited life expectancy. Bone marrow transplantation has been used to correct the metabolic defects and leads to metabolic improvements in most patients However, the long-term effect of such therapy is uncertain. We analysed the data from 63 patients transplanted for lysosomal storage diseases. The transplant-related mortality was 10% if an HLA-identical sibling marrow donor was available (n=40) and 20-25% if mismatched tissue was used. Data on the effect of bone transplantation on biochemical and clinical variables were available in 29 of the 63. 28 had a follow-up duration of 1.0-10.2 years; 1 patient died of disease progression in the first year after stable engraftment. 13 patients who had severe neurological symptoms at the time of transplantation showed disease progression. Engraftment of bone marrow in 5 patients with non-neuronopathic Gaucher's disease led to complete disappearance of symptoms. 11 patients had skeletal symptoms because of various mucopolysaccharidoses (MPSs). There was stabilisation of the skeletal lesions during the observation period of 1.4-6.4 years, but none of the patients showed significant regression of the skeletal symptoms. The visceral features (hepatosplenomegaly, cardiac hypertrophy, and upper airway obstruction) in these patients abated after transplantation. We could not evaluate the biochemical and clinical variables in 34 patients because of graft rejection, transplant-related mortality, or follow-up of less than 1 year. There were significant beneficial effects of bone marrow transplantation in patients with non-neuronopathic Gaucher's disease, Stabilisation of disease was observed in patients with MPS-I and MPS-II; this potential benefit needs to be confirmed by longer follow-up, Bone marow transplantation was not effective if severe neurological symptoms were already present at the time of transplantation.	UNIV LEIDEN HOSP, DIV GENE THERAPY, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT NEUROL, LEIDEN, NETHERLANDS; HOP ENFANTS, SERV PEDIAT 2, NANCY, FRANCE; UNIV HOSP BRUSSELS, BRUSSELS, BELGIUM; UNIV HAMBURG, HOSP EPPENDORF, HAMBURG, GERMANY; HOSP INFANTIL VAN HEBRON, BARCELONA, SPAIN; OUR LADYS HOSP SICK CHILDREN, DUBLIN, IRELAND; HOP DEBROUSSE, LYON, FRANCE; HOP NORD ST ETIENNE, SERV PEDIAT, ST ETIENNE, FRANCE; HOP NECKER ENFANTS MALAD, PARIS, FRANCE; HUDDINGE HOSP, FRANCE & BMT UNIT, S-14186 HUDDINGE, SWEDEN	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); CHU de Nancy; University Hospital Brussels; University of Hamburg; Hospital Universitari Vall d'Hebron; Our Ladys Children Hospital Crumlin; CHU Lyon; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	HOOGERBRUGGE, PM (corresponding author), UNIV LEIDEN HOSP, DEPT PEDIAT, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Hoogerbrugge, Peter M./H-8049-2014					Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BARRANGER JA, 1984, NEW ENGL J MED, V311, P1629, DOI 10.1056/NEJM198412203112509; BARRANGER JA, 1984, MOL BASIS LYSOSOMAL, P1; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BAYEVER E, 1992, J INHERIT METAB DIS, V15, P919, DOI 10.1007/BF01800234; BAYEVER E, 1985, LANCET, V2, P471; GALE RP, 1978, SCIENCE, V192, P1016; GREENFIELD JG, 1963, GREENFIELDS NEUROPAT, P475; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HOBBS JR, 1987, LANCET, V1, P1111; HOOGERBRUGGE PM, 1987, TRANSPLANTATION, V43, P609, DOI 10.1097/00007890-198705000-00001; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; HOOGERBRUGGE PM, 1989, BONE MARROW TRANSPL, P331; HOPWOOD JJ, 1993, J INHERIT METAB DIS, V16, P1024, DOI 10.1007/BF00711520; Hugh-Jones K, 1986, Birth Defects Orig Artic Ser, V22, P25; KOLODNY EH, 1989, METABOLIC BASIS INHE, P1721; KRIVIT W, 1984, NEW ENGL J MED, V311, P1606, DOI 10.1056/NEJM198412203112504; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; KRIVIT W, 1991, TREATMENT GENETIC DI, P203; Krivit W., 1989, BONE MARROW TRANSPL, P367; OLSEN I, 1983, NATURE, V306, P75, DOI 10.1038/306075a0; RINGDEN O, 1988, TRANSPLANTATION, V46, P66, DOI 10.1097/00007890-198807000-00011; RINGDEN O, 1990, TRANSPL P, V22, P198; SAKIYAMA T, 1983, BIOCHEM BIOPH RES CO, V113, P605, DOI 10.1016/0006-291X(83)91769-2; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; SHULL RM, 1987, J CLIN INVEST, V79, P435, DOI 10.1172/JCI112830; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; TAYLOR RM, 1987, TRANSPLANT P, V19, P2730; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TSAI P, 1992, PEDIATR RES, V31, P503, DOI 10.1203/00006450-199205000-00019; VELLODI A, 1992, J INHERIT METAB DIS, V15, P911, DOI 10.1007/BF01800232; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970; WHITLEY CB, 1993, AM J MED GENET, V46, P209, DOI 10.1002/ajmg.1320460222	33	207	220	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 3	1995	345	8962					1398	1402		10.1016/S0140-6736(95)92597-X	http://dx.doi.org/10.1016/S0140-6736(95)92597-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760610				2022-12-01	WOS:A1995RB44100009
J	MCNICHOLL, BP; LEE, J				MCNICHOLL, BP; LEE, J			PATIENTS WITH MAJOR TRAUMA WHO DO NOT USE EMERGENCY AMBULANCES	BRITISH MEDICAL JOURNAL			English	Article							FIELD TRIAGE				MCNICHOLL, BP (corresponding author), ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND.							KNUDSON P, 1988, J TRAUMA, V28, P602, DOI 10.1097/00005373-198805000-00006; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; WEST JG, 1986, J TRAUMA, V26, P655	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1442	1442		10.1136/bmj.310.6992.1442	http://dx.doi.org/10.1136/bmj.310.6992.1442			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613278	Green Published			2022-12-01	WOS:A1995RC10500019
J	REUL, J; WEIS, J; JUNG, A; WILLMES, K; THRON, A				REUL, J; WEIS, J; JUNG, A; WILLMES, K; THRON, A			CENTRAL-NERVOUS-SYSTEM LESIONS AND CERVICAL DISC HERNIATIONS IN AMATEUR DIVERS	LANCET			English	Article								Permanent neuropsychological changes such as memory disturbances and depression have been found in professional divers, even in those who have never had decompression sickness. The changes are probably the result of intravascular gas bubbles insufficient to cause acute symptoms. We examined amateur divers with long histories of self-contained underwater breathing apparatus diving by magnetic resonance imaging and compared them with normal controls. Hyperintense lesions of the subcortical cerebral white matter and degenerative changes of the cervical disks were significantly more common in the divers. 27 of 52 divers had a total of 86 focal hyperintensities versus 10 of 50 controls with 14 focal hyperintensities (p<0.01). 32 divers had at least one degenerated intravertebral disc versus 9 controls (P<0.0001). These results suggest that amateur divers are at risk of accumulating lesions in the central nervous system and in cartilage.	RHEIN WESTFAL TH AACHEN,DEPT NEURORADIOL,AACHEN,GERMANY; RHEIN WESTFAL TH AACHEN,DEPT NEUROPATHOL,AACHEN,GERMANY; RHEIN WESTFAL TH AACHEN,DEPT NEUROL,AACHEN,GERMANY	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University			Willmes, Klaus F/A-1268-2014; Weis, Joachim/G-1984-2014	Willmes, Klaus F/0000-0002-9012-0553; Weis, Joachim/0000-0003-3280-6773				BADDLEY A, 1983, LONG TERM NEUROLOGIC, P165; EDMONDS C, 1985, 9TH P INT S UND HYP; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; NIX WA, 1980, DEUT MED WOCHENSCHR, V105, P302, DOI 10.1055/s-2008-1070654; PALMER AC, 1992, NEUROPATH APPL NEURO, V18, P113, DOI 10.1111/j.1365-2990.1992.tb00773.x; PALMER AC, 1987, LANCET, V2, P1365; POLKINGHORNE PJ, 1988, LANCET, V2, P1381; RINCK PA, 1991, JMRI-J MAGN RESON IM, V1, P293, DOI 10.1002/jmri.1880010306; SMYTH E, 1985, NEW SCI, V1439, P8; TODNEM K, 1991, ELECTROEN CLIN NEURO, V79, P322, DOI 10.1016/0013-4694(91)90127-P; TODNEM K, 1991, BRIT J IND MED, V48, P258; VAERNES RJ, 1982, AVIAT SPACE ENVIR MD, V53, P803; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003	13	88	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1403	1405		10.1016/S0140-6736(95)92598-8	http://dx.doi.org/10.1016/S0140-6736(95)92598-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760611				2022-12-01	WOS:A1995RB44100010
J	RIGBY, R				RIGBY, R			OUT OF CONTROL	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1475	1475		10.1136/bmj.310.6992.1475	http://dx.doi.org/10.1136/bmj.310.6992.1475			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613305	Green Published			2022-12-01	WOS:A1995RC10500073
J	VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W				VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W			TRANSMISSION OF HIV IN DIALYSIS CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BENZALKONIUM CHLORIDE; HEMODIALYSIS; PREVALENCE; BLOOD	In August, 1993, 13 dialysis patients at one dialysis centre. in Colombia, South America, were found to be HIV positive, and this prompted an epidemiological investigation. We carried out a cohort study of all dialysis centre patients during January, 1992 to December, 1993 (epidemic period) to determine risk factors for HIV seroconversion. Haemodialysis and medical records were reviewed, dialysis centre staff and surviving patients were interviewed, and dialysis practices were observed. Stored sera from all dialysis centre patients were tested for HIV antibody. 12 (52%) of 23 patients tested positive for HIV antibody by enzyme immunoassay and western blot during the epidemic period. Of the 23 tested, 9 (39%) converted from HIV antibody negative to positive (seroconverters) and 10 (44%) remained HIV negative (seronegatives). The HIV seroconversion rate was higher among patients dialysed at the centre while a new patient, who was HIV seropositive, was dialysed there (90% vs 0%; p<0.01), or when the dialysis centre reprocessed access needles, dialysers, and bloodlines (60% vs 0%). While 2 of 9 HIV seroconverters had had sex with prostitutes, none had received unscreened blood products or had other HIV risk factors. No surgical or dental procedures were associated with HIV seroconversion. Dialysers were reprocessed separately with 5% formaldehyde and were labelled for use on the same patient. Access needles were reprocessed by soaking them in a common container with a low-level disinfectant, benzalkonium chloride; 4 pairs of needles were placed in one pan creating the potential for cross-contamination or use of one patient's needles on another patient. HIV transmission at the dialysis centre was confirmed, Improperly reprocessed patient-care equipment, most probably access needles, is the likely mechanism of transmission. This outbreak was discovered by accident and similar transmission may be occurring in many other countries where low-level disinfectants are used to sterilise critical patient-care equipment.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,INVEST & PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; COLOMBIAN FIELD EPIDEMIOL TRAINING PROGRAM,BOGOTA,COLOMBIA; NATL INST HLTH,BOGOTA,COLOMBIA; IND UNIV SANTANDER,SCH MED,SANTANDER,SPAIN	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Velandia-Gonzalez, Martha/0000-0002-7636-3604				ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P652; ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P701; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; BURCHOVSKY G, 1988, 4TH INT C AIDS STOCK; CHANT K, 1994, LANCET, V342, P1548; CHIRGWIN K, 1989, AIDS, V3, P731, DOI 10.1097/00002030-198911000-00007; DEAN AG, 1991, EPI INFO VERSION 5 0; DYER E, 1993, BRIT MED J, V307, P584; FAVERO MS, 1989, ASPECTS RENAL CARE, P55; FAVERO MS, 1991, MANUAL CLIN MICROBIO, P183; Favero MS, 1992, HOSPITAL INFECTIONS, P375; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; KASLOW RA, 1976, JAMA-J AM MED ASSOC, V236, P2407, DOI 10.1001/jama.236.21.2407; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARCUS R, 1991, AM J MED, V90, P614, DOI 10.1016/S0002-9343(05)80014-2; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; NAKASHIMA AK, 1987, J CLIN MICROBIOL, V25, P1014, DOI 10.1128/JCM.25.6.1014-1018.1987; NAUS JI, 1965, J AM STAT ASSOC, V60, P532, DOI 10.2307/2282688; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PLOTT RT, 1990, ARCH DERMATOL, V126, P1441, DOI 10.1001/archderm.126.11.1441; POKROVSKY VV, 1988, 5TH INT C AIDS STOCK; RENGITO B, 1995, 7 C PAN AM INF CART; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Tokars J I, 1994, ASAIO J, V40, P1020, DOI 10.1097/00002480-199410000-00021; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; WAINBERG MA, 1990, J CLIN MICROBIOL, V28, P156, DOI 10.1128/JCM.28.1.156-158.1990; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; 1992, MMWR-MORBID MORTAL W, V41, P823; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, REC PRACT REUSE HEMO; 1992, MMWR-MORBID MORTAL W, V41, P344; 1992, MMWR-MORBID MORTAL W, V41, P575	32	51	51	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1417	1422		10.1016/S0140-6736(95)92603-8	http://dx.doi.org/10.1016/S0140-6736(95)92603-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760615				2022-12-01	WOS:A1995RB44100015
J	AULD, VJ; FETTER, RD; BROADIE, K; GOODMAN, CS				AULD, VJ; FETTER, RD; BROADIE, K; GOODMAN, CS			GLIOTACTIN, A NOVEL TRANSMEMBRANE PROTEIN ON PERIPHERAL GLIA, IS REQUIRED TO FORM THE BLOOD-NERVE BARRIER IN DROSOPHILA	CELL			English	Article							CELL-ADHESION; MOLECULAR-GENETICS; SERINE ESTERASES; RUTHENIUM RED; MELANOGASTER; GLYCOPROTEIN; EXPRESSION; MUSCLES; CLONING; AXON	Peripheral glia help ensure that motor and sensory axons are bathed in the appropriate ionic and biochemical environment. In Drosophila, peripheral glia help shield these axons against the high K+ concentration of the hemolymph, which would largely abolish their excitability. Here, we describe the molecular genetic analysis of gliotactin, a novel transmembrane protein that is transiently expressed on peripheral glia and that is required for the formation of the peripheral blood-nerve barrier, In gliotactin mutant embryos, the peripheral glia develop normally in many respects, except that ultrastructurally and physiologically they do not form a complete blood-nerve barrier. As a result, peripheral motor axons are exposed to the high K+ hemolymph, action potentials fail to propagate, and the embryos are nearly paralyzed.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, DIV NEUROBIOL, BERKELEY, CA 94720 USA; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Cambridge				Auld, Vanessa/0000-0003-3976-9186	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATWOOD HL, 1993, J NEUROBIOL, V24, P1008, DOI 10.1002/neu.480240803; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BATE M, 1990, DEVELOPMENT, V110, P791; BROADIE KS, 1993, J NEUROSCI, V13, P144; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Doyle JP, 1993, CURR OPIN CELL BIOL, V5, P779, DOI 10.1016/0955-0674(93)90025-L; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GRENNINGLOH G, 1990, COLD SPRING HARB SYM, V55, P327; GROSSMAN Y, 1979, J PHYSIOL-LONDON, V295, P307, DOI 10.1113/jphysiol.1979.sp012970; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KOCSIS JD, 1983, J PHYSIOL-LONDON, V334, P225, DOI 10.1113/jphysiol.1983.sp014491; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; LANE NJ, 1975, J CELL SCI, V18, P179; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; LONG RM, 1991, LIFE SCI, V48, P43; LUFT JH, 1971, ANAT RECORD, V171, P369, DOI 10.1002/ar.1091710303; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; Maniatis T., 1982, MOL CLONING; Manning Gerards, 1993, P609; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; ROBERTSON HM, 1988, GENETICS, V118, P461; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Treherne J.E., 1972, Advances Insect Physiol, V9, P257, DOI 10.1016/S0065-2806(08)60278-7; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	39	223	228	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					757	767		10.1016/0092-8674(95)90537-5	http://dx.doi.org/10.1016/0092-8674(95)90537-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7539719	Bronze			2022-12-01	WOS:A1995RB96100014
J	BOLDUC, JM; DYER, DH; SCOTT, WG; SINGER, P; SWEET, RM; KOSHLAND, DE; STODDARD, BL				BOLDUC, JM; DYER, DH; SCOTT, WG; SINGER, P; SWEET, RM; KOSHLAND, DE; STODDARD, BL			MUTAGENESIS AND LAUE STRUCTURES OF ENZYME INTERMEDIATES - ISOCITRATE DEHYDROGENASE	SCIENCE			English	Article							X-RAY CRYSTALLOGRAPHY; PROTEIN CRYSTALLOGRAPHY; DIFFRACTION; TIME; MECHANISM; PHOTOGRAPHS; HYDROLYSIS; BINDING	Site-directed mutagenesis and Laue diffraction data to 2.5 Angstrom resolution were used to solve the structures of two sequential intermediates formed during the catalytic actions of isocitrate dehydrogenase. Both intermediates are distinct from the enzyme-substrate and enzyme-product complexes. Mutation of key catalytic residues changed the rate determining steps so that protein and substrate intermediates within the overall reaction pathway could be visualized.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; BROOKHAVEN NATL LABS,DEPT BIOL STRUCT,UPTON,NY 11973; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	MRC Laboratory Molecular Biology; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Berkeley	BOLDUC, JM (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM STRUCT BIOL,DIV BASIC SCI,1124 COLUMBIA ST A3-023,SEATTLE,WA 98104, USA.			Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [GM49857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOW DM, 1992, PHILOS T ROY SOC A, V340, P311, DOI 10.1098/rsta.1992.0069; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; DEAN AM, 1992, BIOCHEMISTRY-US, V132, P9302; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GETZOFF ED, 1993, NUCL INSTRUM METH B, V79, P249, DOI 10.1016/0168-583X(93)95337-5; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; HAJDU J, 1987, NATURE, V329, P178, DOI 10.1038/329178a0; HELLIWELL JR, 1989, J APPL CRYSTALLOGR, V22, P483, DOI 10.1107/S0021889889006564; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JOHNSON LN, 1992, PROTEIN SCI, V1, P1237, DOI 10.1002/pro.5560011002; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; OCHOA S, 1948, J BIOL CHEM, V174, P115; PETSKO GA, 1992, PHILOS T ROY SOC A, V340, P323, DOI 10.1098/rsta.1992.0070; PLAUT G, 1963, ENZYMES, P112; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; SCHEIDIG AJ, 1994, ACTA CRYSTALLOGR D, V50, P512, DOI 10.1107/S090744499301443X; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; STODDARD BL, 1991, P NATL ACAD SCI USA, V88, P5503, DOI 10.1073/pnas.88.13.5503; STODDARD BL, 1992, BIOCHEMISTRY-US, V32, P9310; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; WALSH C, 1979, ENZYMATIC REACTION M, P344	24	112	116	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1312	1318		10.1126/science.7761851	http://dx.doi.org/10.1126/science.7761851			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761851	Green Submitted			2022-12-01	WOS:A1995RB19800028
J	COLLINS, K; KOBAYASHI, R; GREIDER, CW				COLLINS, K; KOBAYASHI, R; GREIDER, CW			PURIFICATION OF TETRAHYMENA TELOMERASE AND CLONING OF GENES ENCODING THE 2 PROTEIN-COMPONENTS OF THE ENZYME	CELL			English	Article							RNA; ELONGATION; SENESCENCE; SEQUENCES; ELEMENTS; MOTIFS; DNA	Telomerase is a ribonucleoprotein DNA polymerase that catalyzes the de novo synthesis of telomeric simple sequence repeats. We describe the purification of telomerase and the cloning of cDNAs encoding two protein subunits from the ciliate Tetrahymena. Two proteins of 80 and 95 kDa copurified and coimmunoprecipitated with telomerase activity and the previously identified Tetrahymena telomerase RNA. The p95 subunit specifically cross-linked to a radiolabeled telomeric DNA primer, while the p80 subunit specifically bound to radiolabeled telomerase RNA. At the primary sequence level, the two telomerase proteins share only limited homologies with other polymerases and polymerase accessory factors.			COLLINS, K (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Greider, Carol/0000-0002-5494-8126	NIGMS NIH HHS [GM43080] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043080] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; BHATTACHARYYA A, 1994, EMBO J, V13, P5721, DOI 10.1002/j.1460-2075.1994.tb06910.x; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CHERRY JM, 1985, CELL, V43, P747, DOI 10.1016/0092-8674(85)90248-X; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; HARLEY CB, 1994, COLD SPRING HARB SYM, V66, P1; HARRINGTON L, 1995, J BIOL CHEM, V270, P8893, DOI 10.1074/jbc.270.15.8893; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MAIZELS N, 1993, RNA WORLD, P577; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Sambrook J., 1989, MOL CLONING LAB MANU; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; TAKEMASA T, 1989, J BIOL CHEM, P19293; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	37	241	265	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					677	686		10.1016/0092-8674(95)90529-4	http://dx.doi.org/10.1016/0092-8674(95)90529-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774009	Bronze			2022-12-01	WOS:A1995RB96100006
J	ERICSON, J; MUHR, J; PLACZEK, M; LINTS, T; JESSELL, TM; EDLUND, T				ERICSON, J; MUHR, J; PLACZEK, M; LINTS, T; JESSELL, TM; EDLUND, T			SONIC HEDGEHOG INDUCES THE DIFFERENTIATION OF VENTRAL FOREBRAIN NEURONS - A COMMON SIGNAL FOR VENTRAL PATTERNING WITHIN THE NEURAL-TUBE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; CELL PATTERN; PROTEIN ISL-1; CHICK-EMBRYO; EXPRESSION; NOTOCHORD; INDUCTION; HOMEODOMAIN; HOMEOBOX	The vertebrate hedgehog-related gene Sonic hedgehog (Shh) is expressed in ventral domains along the entire rostrocaudal length of the neural tube, including the forebrain. We show here that SHH induces the differentiation of ventral neuronal cell types in explants derived from prospective forebrain regions of the neural plate. Neurons induced in explants derived from both diencephalic and telencephalic levels of the neural plate express the LIM homeodomain protein Isl-1, and these neurons possess distinct identities that match those of the ventral neurons generated in these two subdivisions of the forebrain in vivo. A single inducing molecule, SHH, therefore appears to mediate the induction of distinct ventral neuronal cell types along the entire rostrocaudal extent of the embryonic central nervous system.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	MRC National Institute for Medical Research; Columbia University; Howard Hughes Medical Institute; Columbia University	ERICSON, J (corresponding author), UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN.		Lints, Thierry/K-4408-2012; Placzek, Marysia/E-6172-2010	Ericson, Johan/0000-0002-8019-7127; Placzek, Marysia/0000-0002-4106-9229	NINDS NIH HHS [NS-33245, NS-30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245, P01NS030532] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BARTH KA, 1995, IN PRESS DEVELOPMENT, V121; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; JESSELL TM, 1992, HARVEY LECT, V86, P87; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROACH FC, 1945, J EXP ZOOL, V99, P53, DOI 10.1002/jez.1400990203; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; SIMON H, 1994, J NEUROBIOL, V25, P1129, DOI 10.1002/neu.480250908; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TANABE Y, 1995, IN PRESS CURR BIOL; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	454	476	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					747	756		10.1016/0092-8674(95)90536-7	http://dx.doi.org/10.1016/0092-8674(95)90536-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774016	Bronze			2022-12-01	WOS:A1995RB96100013
J	FORMAN, BM; GOODE, E; CHEN, J; ORO, AE; BRADLEY, DJ; PERLMANN, T; NOONAN, DJ; BURKA, LT; MCMORRIS, T; LAMPH, WW; EVANS, RM; WEINBERGER, C				FORMAN, BM; GOODE, E; CHEN, J; ORO, AE; BRADLEY, DJ; PERLMANN, T; NOONAN, DJ; BURKA, LT; MCMORRIS, T; LAMPH, WW; EVANS, RM; WEINBERGER, C			IDENTIFICATION OF A NUCLEAR RECEPTOR THAT IS ACTIVATED BY FARNESOL METABOLITES	CELL			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE; ECDYSONE RECEPTOR; RXR-BETA; ACID; MEVALONATE; PROTEIN; HETERODIMERIZATION; ULTRASPIRACLE; SUPERFAMILY	Nuclear hormone receptors comprise a superfamily of ligand-modulated transcription factors that mediate the transcriptional activities of steroids, retinoids, and thyroid hormones. A growing number of related proteins have been identified that possess the structural features of hormone receptors, but that lack known ligands, Known as orphan receptors, these proteins represent targets for novel signaling molecules. We have isolated a mammalian orphan receptor that forms a heterodimeric complex with the retinoid X receptor. A screen of candidate ligands identified farnesol and related metabolites as effective activators of this complex. Farnesol metabolites are generated intracellularly and are required for the synthesis of cholesterol, bile acids, steroids, retinoids, and farnesylated proteins. Intermediary metabolites have been recognized as transcriptional regulators in bacteria and yeast. Our results now suggest that metabolite-controlled intracellular signaling systems are utilized by higher organisms.	SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; NIEHS,RECEPTOR BIOL GRP,RES TRIANGLE PK,NC 27709; NIEHS,REPROD & DEV TOXICOL LAB,ORGAN CHEM GRP,RES TRIANGLE PK,NC 27709; NIH,CELL BIOL LAB,BETHESDA,MD 20892; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40506; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121	Howard Hughes Medical Institute; Salk Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; University of Kentucky; University of California System; University of California San Diego; Ligand Pharmaceuticals	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES,GENE EXPRESS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BROWN MS, 1980, J LIPID RES, V21, P505; EDMOND J, 1976, SCIENCE, V193, P154, DOI 10.1126/science.935865; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMEZ R, 1993, BIOCHEM J, V289, P25, DOI 10.1042/bj2890025; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KIM CM, 1992, J BIOL CHEM, V267, P23113; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KULKARNI YS, 1987, J ORG CHEM, V52, P1568, DOI 10.1021/jo00384a035; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEID M, 1992, CELL, V71; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MOORE D D, 1990, New Biologist, V2, P100; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIGHETTI M, 1976, J BIOL CHEM, V251, P2716; Rilling H. C., 1985, STEROLS BILE ACIDS, P1; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; TNTONOZ P, 1994, CELL, V79, P1147; TOMKINS GM, 1975, SCIENCE, V189, P760, DOI 10.1126/science.169570; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILEY MH, 1977, J BIOL CHEM, V252, P548; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	45	923	1042	1	49	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					687	693		10.1016/0092-8674(95)90530-8	http://dx.doi.org/10.1016/0092-8674(95)90530-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774010	Bronze			2022-12-01	WOS:A1995RB96100007
J	FRANKE, TF; YANG, SI; CHAN, TO; DATTA, K; KAZLAUSKAS, A; MORRISON, DK; KAPLAN, DR; TSICHLIS, PN				FRANKE, TF; YANG, SI; CHAN, TO; DATTA, K; KAZLAUSKAS, A; MORRISON, DK; KAPLAN, DR; TSICHLIS, PN			THE PROTEIN-KINASE ENCODED BY THE AKT PROTOONCOGENE IS A TARGET OF THE PDGF-ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE	CELL			English	Article							POLYMERASE CHAIN-REACTION; GROWTH-FACTOR; C-AKT; V-AKT; REGION; EXPRESSION; RECEPTORS; MICE	The serine/threonine protein kinase encoded by the Akt proto-oncogene is catalytically inactive in serum-starved primary and immortalized fibroblasts. Here we show that Akt and the Akt-related kinase AKT2 are activated by PDGF. The activation was rapid and specific, and it was abrogated by mutations in the Akt Pleckstrin homology (PH) domain. The Akt activation was also shown to depend on PDGFR beta tyrosines Y740 and Y751, which bind phosphatidylinositol 3-kinase (Pl 3-kinase) upon phosphorylation. Moreover, Akt activation was blocked by the Pl 3-kinase-specific inhibitor wortmannin and the dominant inhibitory N17Ras. Conversely, Akt activity was induced following the addition of phosphatidylinositol-3-phosphate to Akt immunoprecipitates from serum-starved cells in vitro, These results identify Akt as a novel target of Pl 3-kinase and suggest that the Akt PH domain may be a mediator of Pl 3-kinase signaling.	NCI, FREDERICK CANC RES FACIL & DEV CTR, ABL BASIC RES PROGRAM, EUKARYOT SIGNAL TRANSDUCT SECT, FREDERICK, MD 21702 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Jewish Health	FRANKE, TF (corresponding author), FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA.			Chan, Tung/0000-0001-6574-9555	NATIONAL CANCER INSTITUTE [R01CA038047, R29CA055063, R01CA057436] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55063, R01-CA57436, R01-CA38047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; FRANKE TF, 1994, ONCOGENE, V9, P141; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POWIS G, 1994, CANCER RES, V54, P2419; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STILES CD, 1979, J CELL PHYSIOL, V99, P395, DOI 10.1002/jcp.1040990314; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	31	1811	1864	2	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					727	736		10.1016/0092-8674(95)90534-0	http://dx.doi.org/10.1016/0092-8674(95)90534-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774014	Bronze			2022-12-01	WOS:A1995RB96100011
J	FULLER, SD; BERRIMAN, JA; BUTCHER, SJ; GOWEN, BE				FULLER, SD; BERRIMAN, JA; BUTCHER, SJ; GOWEN, BE			LOW PH INDUCES SWIVELING OF THE GLYCOPROTEIN HETERODIMERS IN THE SEMLIKI-FOREST VIRUS SPIKE COMPLEX	CELL			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; SINDBIS VIRUS; ELECTRON-MICROGRAPHS; INFLUENZA-VIRUS; FUSION PROCESS; PROTEIN; ENVELOPE; RECONSTRUCTION; MECHANISM; CELLS	Time-resolved cryoelectron microscopy reveals the first step in the conformational changes that enable membrane fusion in Semliki Forest virus. The neutral pH structure reveals a central cavity within the spike complex, plate-like extensions forming a layer above the membrane, and the paths of the paired transmembrane domains connecting the trimeric spikes and pentamer-hexamer clustered capsid subunits. Low pH treatment results in centrifugal movement of E2, the receptor-binding subunit, centripetal movement of E1 to narrow the central cavity initiating the formation of an E1 trimer, and the extension of the E1 fusion sequence toward the target membrane.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	FULLER, SD (corresponding author), EUROPEAN MOLEC BIOL LAB,STRUCT BIOL PROGRAMME,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Butcher, Sarah J/H-5579-2012	Butcher, Sarah/0000-0001-7060-5871	NIGMS NIH HHS [GM41449] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1994, STRUCTURE, V2, P907, DOI 10.1016/S0969-2126(94)00091-3; BERRIMAN J, 1994, ULTRAMICROSCOPY, V156, P241; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHENG RH, 1995, CELL, V80, P621; DUBUISSON J, 1993, J VIROL, V67, P3363, DOI 10.1128/JVI.67.6.3363-3374.1993; FULLER S, 1994, STRUCTURE, V2, P903, DOI 10.1016/S0969-2126(94)00090-5; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GAROFF H, 1980, NATURE, V288, P221; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; JAIN SK, 1991, J BIOL CHEM, V266, P5756; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; Kielian M, 1986, TOGAVIRIDAE FLAVIVIR, P91; KIELIAN N, 1994, ADV VIRUS RES, V45, P113; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; LOBIGS M, 1990, J VIROL, V64, P4346, DOI 10.1128/JVI.64.9.4346-4355.1990; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; SALMINEN A, 1992, J CELL BIOL, V116, P349, DOI 10.1083/jcb.116.2.349; SCHLESINGER MJ, 1986, TOGAVIRIDAE FLAVIVIR, P21; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Singh I., 1992, SEMIN VIROL, V3, P511; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STEWART PL, 1993, EMBO J, V72, P2589; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; TUCKER PC, 1991, J VIROL, V65, P1551, DOI 10.1128/JVI.65.3.1551-1557.1991; VENIENBRYAN C, 1994, J MOL BIOL, V236, P572, DOI 10.1006/jmbi.1994.1166; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VOGEL RH, 1988, ULTRAMICROSCOPY, V25, P223, DOI 10.1016/0304-3991(88)90017-4; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WHITE J, 1980, J CELL BIOL, V87, P264, DOI 10.1083/jcb.87.1.264; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	36	119	119	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					715	725		10.1016/0092-8674(95)90533-2	http://dx.doi.org/10.1016/0092-8674(95)90533-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774013	Bronze			2022-12-01	WOS:A1995RB96100010
J	GRIEDER, NC; NELLEN, D; BURKE, R; BASLER, K; AFFOLTER, M				GRIEDER, NC; NELLEN, D; BURKE, R; BASLER, K; AFFOLTER, M			SCHNURRI IS REQUIRED FOR DROSOPHILA DPP SIGNALING AND ENCODES A ZINC-FINGER PROTEIN SIMILAR TO THE MAMMALIAN TRANSCRIPTION FACTOR PRDII-BF1	CELL			English	Article							DECAPENTAPLEGIC GENE; GERM LAYERS; BINDING PROTEIN; LARVAL CUTICLE; ZYGOTIC LOCI; BETA FAMILY; PATTERN; EMBRYO; MELANOGASTER; EXPRESSION	Cytokines of the TGF beta superfamily regulate many aspects of cellular function by activating receptor complexes consisting of two distantly related serine/threonine kinases. Previous studies have indicated that Drosophila dpp uses similar signaling complexes and strictly requires the punt and thick veins receptors to transduce the signal across the membrane. Here, we show that the schnurri (shn) gene is required for many aspects of dpp signaling, Genetic epistasis experiments indicate that shn functions downstream of the dpp signal and its receptors. The shn gene encodes a large protein similar to a family of mammalian zinc finger transcription factors. The shn protein might therefore act as a nuclear target in the dpp signaling pathway directly regulating the expression of dpp-responsive genes.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich	GRIEDER, NC (corresponding author), UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016; Burke, Richard/0000-0003-0086-0767				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JACKSON PD, 1994, DEV DYNAM, V199, P28, DOI 10.1002/aja.1001990104; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NOMURA N, 1991, J BIOL CHEM, V266, P8590; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROOP DR, 1978, CELL, V15, P671, DOI 10.1016/0092-8674(78)90035-1; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SEGAL D, 1985, GENETICS, V109, P119; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; TREMML G, 1992, DEVELOPMENT, V116, P447; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; ZECCA M, 1995, IN PRESS DEVELOPMENT	49	168	173	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					791	800		10.1016/0092-8674(95)90540-5	http://dx.doi.org/10.1016/0092-8674(95)90540-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774018	Bronze, Green Accepted			2022-12-01	WOS:A1995RB96100017
J	KIMURA, Y; YAHARA, I; LINDQUIST, S				KIMURA, Y; YAHARA, I; LINDQUIST, S			ROLE OF THE PROTEIN CHAPERONE YDJ1 IN ESTABLISHING HSP90-MEDIATED SIGNAL-TRANSDUCTION PATHWAYS	SCIENCE			English	Article							HEAT-SHOCK PROTEIN; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; YEAST HOMOLOG; HSP90; KINASE; TEMPERATURES; COMPLEXES; BINDING; GROWTH	The substrate-specific protein chaperone Hsp90 (heat shock protein 90) from Saccharomyces cerevisiae functions in diverse signal transduction pathways. A mutation in YDJ1, a member of the DnaJ chaperone family, was recovered in a synthetic-lethal screen with Hsp90 mutants. in an otherwise wild-type background, the ydj1 mutation exerted strong and specific effects an three Hsp90 substrates, derepressing two (the estrogen and glucocorticoid receptors) and reducing the function of the third (the tyrosine kinase p60(v-src)). Analysis of one of these substrates, the glucocorticoid receptor, indicated that Ydj1 exerts its effects through physical interaction with Hsp90 substrates.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Tokyo Metropolitan Institute of Medical Science			Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753				ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOHEN SP, UNPUB; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CAPLAN A, COMMUNICATION; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHANG H, UNPUB; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CUTTFORTH T, 1994, CELL, V77, P1027; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1994, J BIOL CHEM, V263, P24989; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; KIMURA Y, UNPUB; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NATHAN DF, UNPUB; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	34	218	226	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1362	1365		10.1126/science.7761857	http://dx.doi.org/10.1126/science.7761857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761857				2022-12-01	WOS:A1995RB19800042
J	KOCH, WJ; ROCKMAN, HA; SAMAMA, P; HAMILTON, RA; BOND, RA; MILANO, CA; LEFKOWITZ, RJ				KOCH, WJ; ROCKMAN, HA; SAMAMA, P; HAMILTON, RA; BOND, RA; MILANO, CA; LEFKOWITZ, RJ			CARDIAC-FUNCTION IN MICE OVEREXPRESSING THE BETA-ADRENERGIC-RECEPTOR KINASE OR A BETA-ARK INHIBITOR	SCIENCE			English	Article							BETA-2-ADRENERGIC RECEPTORS; GAMMA-SUBUNITS; G-PROTEINS; BINDING; DESENSITIZATION; PATHWAYS; LIGAND; HEART	Transgenic mice were created with cardiac-specific overexpression of the beta-adrenergic receptor kinase-1 (beta ARK1) or a beta ARK inhibitor. Animals overexpressing beta ARK1 demonstrated attenuation of isoproterenol-stimulated left ventricular contractility in vivo, dampening of myocardial adenylyl cyclase activity, and reduced functional coupling of beta-adrenergic receptors. Conversely, mice expressing the beta ARK inhibitor displayed enhanced cardiac contractility in vivo with or without isoproterenol. These animals demonstrate the important role of beta ARK in modulating in vivo myocardial function. Because increased amounts of beta ARK1 and diminished cardiac beta-adrenergic responsiveness characterize heart failure, these animals may provide experimental models to study the role of beta ARK in heart disease.	DUKE UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,DEPT SURG,DURHAM,NC 27710; UNIV HOUSTON,DEPT PHARMACOL & PHARMACEUT SCI,HOUSTON,TX 77204	Duke University; Howard Hughes Medical Institute; Duke University; University of Houston System; University of Houston	KOCH, WJ (corresponding author), DUKE UNIV,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021		NATIONAL CANCER INSTITUTE [F32CA009350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NCI NIH HHS [5F32-CA09350] Funding Source: Medline; NHLBI NIH HHS [HL-16037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEAN A, 1980, J BIOL CHEM, V255, P7106; FREEDMAN NJ, UNPUB; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLESE J, 1992, NATURE, V359, P149; KENT RS, 1980, MOL PHARMACOL, V17, P14; KOCH W, UNPUB; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; ROCKMAN HA, UNPUB; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454	30	619	642	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1350	1353		10.1126/science.7761854	http://dx.doi.org/10.1126/science.7761854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761854				2022-12-01	WOS:A1995RB19800039
J	KUNDIG, TM; BACHMANN, MF; DIPAOLO, C; SIMARD, JJL; BATTEGAY, M; LOTHER, H; GESSNER, A; KUHLCKE, K; OHASHI, PS; HENGARTNER, H; ZINKERNAGEL, RM				KUNDIG, TM; BACHMANN, MF; DIPAOLO, C; SIMARD, JJL; BATTEGAY, M; LOTHER, H; GESSNER, A; KUHLCKE, K; OHASHI, PS; HENGARTNER, H; ZINKERNAGEL, RM			FIBROBLASTS AS EFFICIENT ANTIGEN-PRESENTING CELLS IN LYMPHOID ORGANS	SCIENCE			English	Article							CD8+ T-CELLS; INTERCELLULAR-ADHESION MOLECULE-1; FOOTPAD SWELLING REACTION; TUMOR-CELLS; LYMPHOCYTIC CHORIOMENINGITIS; ANTITUMOR IMMUNITY; TRANSGENIC MICE; GENE-TRANSFER; INVIVO; EXPRESSION	Only so-called ''professional'' antigen-presenting cells (APCs) of hematopoietic origin are believed capable of inducing T lymphocyte responses. However, fibroblasts transfected with viral proteins directly induced antiviral cytotoxic T lymphocyte responses in vivo, without involvement of host APCs. Fibroblasts induced T cells only in the milieu of lymphoid organs. Thus, antigen localization affects self-nonself discrimination and cell-based vaccine strategies.	ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M4X 1K9, CANADA; ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M4X 1K9, CANADA; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, W-2000 HAMBURG, GERMANY	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Heinrich Pette Institute; University of Hamburg	KUNDIG, TM (corresponding author), UNIV ZURICH, INST EXPTL IMMUNOL, SCHMELZBERGSTR 12, CH-8091 ZURICH, SWITZERLAND.			Ohashi, Pamela S./0000-0003-2915-9317				BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; Barker CF, 1967, TRANSPLANTATION, V5, P962; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COLOMBO MP, 1991, J EXP MED, V173, P889, DOI 10.1084/jem.173.4.889; CROFT M, 1994, CURR OPIN IMMUNOL, V6, P431, DOI 10.1016/0952-7915(94)90123-6; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; Deichman G I, 1969, Adv Cancer Res, V12, P101, DOI 10.1016/S0065-230X(08)60329-2; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DIPAOLO C, THESIS U ZURICH; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FAUSTMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P3864, DOI 10.1073/pnas.81.12.3864; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FREY JR, 1957, INT ARCH ALLER A IMM, V11, P81, DOI 10.1159/000228405; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GESSNER A, 1993, THESIS U HAMBURG; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GUERDER S, 1994, IMMUNITY, V1, P155; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HARLAN DM, 1994, P NATL ACAD SCI USA, V91, P3137, DOI 10.1073/pnas.91.8.3137; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KLEIN G, 1978, MANIPULATION IMMUNE, P339; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LAFFERTY KJ, 1977, IMMUNOL REV, V35, P231, DOI 10.1111/j.1600-065X.1977.tb00241.x; LANE P, 1993, IMMUNOLOGY, V80, P56; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; LEIST TP, 1987, J IMMUNOL, V138, P2278; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; MATZINGER P, 1977, CELL IMMUNOL, V33, P92, DOI 10.1016/0008-8749(77)90137-X; NISHIHARA K, 1988, CANCER RES, V48, P4730; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLD LJ, 1964, ANNU REV MED, V15, P167, DOI 10.1146/annurev.me.15.020164.001123; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PORGADOR A, 1992, CANCER RES, V52, P3679; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SIU G, 1989, J IMMUNOL, V143, P3813; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; TAHARA H, 1994, CANCER RES, V54, P182; TALMAGE DW, 1976, SCIENCE, V191, P385, DOI 10.1126/science.1082167; TANAKA K, 1988, MOL CELL BIOL, V8, P1857, DOI 10.1128/MCB.8.4.1857; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WACHTEL SS, 1972, J EXP MED, V135, P388, DOI 10.1084/jem.135.2.388; WACHTEL SS, 1971, J EXP MED, V133, P921, DOI 10.1084/jem.133.4.921; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125; ZINKERNAGEL RM, 1993, IMMUNOL REV, V133, P199, DOI 10.1111/j.1600-065X.1993.tb01517.x	65	263	273	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	1995	268	5215					1343	1347		10.1126/science.7761853	http://dx.doi.org/10.1126/science.7761853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761853				2022-12-01	WOS:A1995RB19800037
J	LIANG, C; WEINREICH, M; STILLMAN, B				LIANG, C; WEINREICH, M; STILLMAN, B			ORC AND CDC6P INTERACT AND DETERMINE THE FREQUENCY OF INITIATION OF DNA-REPLICATION IN THE GENOME	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEIN; GENE; CHROMOSOMES; NUCLEAR; MUTANTS; LOCALIZATION	The origin recognition complex (ORC) binds replicators in the yeast S. cerevisiae in a manner consistent with it being an initiator protein for DNA replication. Two-dimensional (2D) gel techniques were used to examine directly initiation of chromosomal DNA replication in temperature-sensitive orc mutants. Unlike in wild-type cells, in orc2-1 and orc5-1 mutant cells, only a subset of replicators formed active origins of DNA replication at the permissive temperature. At the restrictive temperature, the number of active replicators was diminished further. Using a genetic screen, CDC6 was identified as a multicopy suppressor of orc5-1. 2D gel and biochemical analyses demonstrated that Cdc6p interacted functionally and physically with ORC. We suggest that ORC and Cdc6p form a prereplication complex at individual replicators and therefore cooperate to determine the frequency of initiation of DNA replication in the genome.			LIANG, C (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Weinreich, Michael/D-2310-2014	Stillman, Bruce/0000-0002-9453-4091	NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLON S, 1995, P NATL ACAD SCI USA, V92, P2514; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DOWELL JFX, 1994, SCIENCE, V265, P1243; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cellbio.7.1.375; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GUTHRIE C, 1991, METH ENZYMOL, V194; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARTWELL LH, 1985, GENETICS, V110, P381; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1993, GENE DEV, V7, P1072, DOI 10.1101/gad.7.6.1072; LOO S, 1995, IN PRESS MOL BIOL CE; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PALMER RE, 1990, GENETICS, V125, P763; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROSE MD, 1990, METHODS YEAST GENETI; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V12, P19; STILLMAN B, 1993, NATURE, V366, P506, DOI 10.1038/366506a0; STILLMAN B, 1994, J BIOL CHEM, V269, P7074; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23352	53	307	313	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					667	676		10.1016/0092-8674(95)90528-6	http://dx.doi.org/10.1016/0092-8674(95)90528-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774008	Bronze			2022-12-01	WOS:A1995RB96100005
J	NASIR, J; FLORESCO, SB; OKUSKY, JR; DIEWERT, VM; RICHMAN, JM; ZEISLER, J; BOROWSKI, A; MARTH, JD; PHILLIPS, AG; HAYDEN, MR				NASIR, J; FLORESCO, SB; OKUSKY, JR; DIEWERT, VM; RICHMAN, JM; ZEISLER, J; BOROWSKI, A; MARTH, JD; PHILLIPS, AG; HAYDEN, MR			TARGETED DISRUPTION OF THE HUNTINGTONS-DISEASE GENE RESULTS IN EMBRYONIC LETHALITY AND BEHAVIORAL AND MORPHOLOGICAL-CHANGES IN HETEROZYGOTES	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; EXPRESSION; TISSUES	Huntington's disease (HD) is an incurable neuropsychiatric disease associated with CAG repeat expansion within a widely expressed gene that causes selective neuronal death. To understand its normal function, we have created a targeted disruption in exon 5 of Hdh (Hdh(ex5)), the murine homolog of the HD gene. Homozygotes die before embryonic day 8.5, initiate gastrulation, but do not proceed to the formation of somites or to organogenesis, Mice heterozygous for the Hdh(ex5) mutation display increased motor activity and cognitive deficits. Neuropathological assessment of two heterozygous mice shows significant neuronal loss in the subthalamic nucleus. These studies show that the HD gene is essential for postimplantation development and that it may play an important role in normal functioning of the basal ganglia.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT PSYCHOL, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT CLIN DENT SCI, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, CTR MOLEC MED & THERAPEUT, VANCOUVER, BC V6T 1Z4, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia			Richman, Joy/AAD-9445-2020; Floresco, Stan B/F-8160-2012; Hayden, Michael R/D-8581-2011; Richman, Joy M./C-3111-2018	Richman, Joy/0000-0002-1409-8163; Floresco, Stan B/0000-0002-5633-243X; Hayden, Michael R/0000-0001-5159-1419; Richman, Joy M./0000-0002-1409-8163; Nasir, Jamal/0000-0001-6378-5616				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; CARPENTER MB, 1950, J COMP NEUROL, V92, P293, DOI 10.1002/cne.900920303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; DUNNETT SB, 1981, BEHAV BRAIN RES, V2, P189, DOI 10.1016/0166-4328(81)90055-3; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Harper PS, 1991, HUNTINGTONS DISEASE; Hayden MR, 1981, HUNTINGTONS CHOREA; Hogan B., 1986, MANIPULATING MOUSE E; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; LANGE H, 1976, J NEUROL SCI, V28, P401, DOI 10.1016/0022-510X(76)90114-3; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MYERS RH, 1989, AM J HUM GENET, V45, P615; NASIR J, 1994, GENOMICS, V22, P198, DOI 10.1006/geno.1994.1361; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; Sambrook J., 1989, MOL CLONING LAB MANU; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WHITTIER JR, 1947, ARCH NEURO PSYCHIATR, V58, P672, DOI 10.1001/archneurpsyc.1947.02300350022002; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	37	626	644	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					811	823		10.1016/0092-8674(95)90542-1	http://dx.doi.org/10.1016/0092-8674(95)90542-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774020	Bronze			2022-12-01	WOS:A1995RB96100019
J	NICOLELIS, MAL; BACCALA, LA; LIN, RCS; CHAPIN, JK				NICOLELIS, MAL; BACCALA, LA; LIN, RCS; CHAPIN, JK			SENSORIMOTOR ENCODING BY SYNCHRONOUS NEURAL ENSEMBLE ACTIVITY AT MULTIPLE LEVELS OF THE SOMATOSENSORY SYSTEM	SCIENCE			English	Article							SOMATIC SENSORY TRANSMISSION; MOTOR CORTEX STIMULATION; AWAKE RATS; AFFERENT MODULATION; RECEPTIVE-FIELDS; PARIETAL RHYTHMS; DIRECT RESPONSES; SINGLE NEURONS; SI-CORTEX; MOVEMENT	Neural ensemble processing of sensorimotor information during behavior was investigated by simultaneously recording up to 48 single neurons at multiple relays of the rat trigeminal somatosensory system. Cortical, thalamic, and brainstem neurons exhibited widespread 7- to 12-hertz synchronous oscillations, which began during attentive immobility and reliably predicted the imminent onset of rhythmic whisker twitching. Each oscillatory cycle began as a traveling wave of neural activity in the cortex that then spread to the thalamus. Just before the onset of rhythmic whisker twitching, the oscillations spread to the spinal trigeminal brainstem complex. Thereafter, the oscillations at all levels were synchronous with whisker protraction. Neural structures manifesting these rhythms also exhibited distributed spatiotemporal patterns of neuronal ensemble activity in response to tactile stimulation, thus, multilevel synchronous activity in this system may encode not only sensory information but also the onset and temporal domain of tactile exploratory movements.	MED COLL PENN, DEPT ANAT & NEUROBIOL, PHILADELPHIA, PA 19102 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; UNIV PENN, DEPT ELECT ENGN, PHILADELPHIA, PA 19104 USA; UNIV SAO PAULO, DEPT ELECTR ENGN, BR-05508 SAO PAULO, BRAZIL	Drexel University; Drexel University; University of Pennsylvania; Universidade de Sao Paulo			Baccala, Luiz Antonio/A-3370-2008	Baccala, Luiz Antonio/0000-0002-2668-6747	NIDCR NIH HHS [DE11121-01] Funding Source: Medline; NINDS NIH HHS [NS-29161, NS-26722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026722, R01NS029161] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P211, DOI 10.1002/cne.903030204; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BUZSAKI G, 1991, NEUROSCIENCE, V41, P351, DOI 10.1016/0306-4522(91)90332-I; CARVELL GE, 1990, J NEUROSCI, V10, P2638; CHAPIN JK, 1982, EXP NEUROL, V78, P654, DOI 10.1016/0014-4886(82)90082-6; CHAPIN JK, 1986, EXP BRAIN RES, V62, P549; CHAPIN JK, 1982, EXP NEUROL, V78, P670, DOI 10.1016/0014-4886(82)90083-8; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; COULTER JD, 1974, J NEUROPHYSIOL, V37, P831, DOI 10.1152/jn.1974.37.5.831; DIAMOND IT, 1969, SCIENCE, V164, P251, DOI 10.1126/science.164.3877.251; ERICKSON RP, 1968, PSYCHOL REV, V75, P447, DOI 10.1037/h0026752; FREEMAN WJ, 1987, BEHAV NEUROSCI, V101, P393, DOI 10.1037/0735-7044.101.3.393; Freeman WJ, 1975, MASS ACTION NERVOUS; GASTAUT MH, 1952, REV NEUROL, V87, P176; HOPFIELD JJ, 1986, SCIENCE, V233, P625, DOI 10.1126/science.3755256; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; KAAS JH, 1990, HUMAN NERVOUS SYSTEM, P813; KRISTEVAFEIGE R, 1993, NEUROREPORT, V4, P1291, DOI 10.1097/00001756-199309150-00001; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; LIN RCS, 1993, SOC NEUR ABSTR, V19, P106; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON RJ, 1984, BRAIN RES, V304, P143, DOI 10.1016/0006-8993(84)90870-9; Nicolelis M. A. L., 1994, Society for Neuroscience Abstracts, V20, P125; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; NICOLELIS MAL, 1993, P NATL ACAD SCI USA, V90, P2212, DOI 10.1073/pnas.90.6.2212; NICOLELIS MAL, 1994, J NEUROSCI, V14, P3511; ROUGEUL A, 1979, ELECTROEN CLIN NEURO, V46, P310, DOI 10.1016/0013-4694(79)90205-0; SALMELIN R, 1994, NEUROSCIENCE, V60, P537, DOI 10.1016/0306-4522(94)90263-1; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; SHERMAN SM, 1990, SYNAPTIC ORG BRAIN, P246; SHIN HC, 1990, NEUROSCI LETT, V108, P116, DOI 10.1016/0304-3940(90)90716-M; SHIN HC, 1990, BRAIN RES BULL, V24, P257; SHIN HC, 1989, BRAIN RES BULL, V22, P245, DOI 10.1016/0361-9230(89)90049-X; SOMPOLINSKY H, 1991, PHYS REV A, V43, P6990, DOI 10.1103/PhysRevA.43.6990; Steriade M, 1990, THALAMIC OSCILLATION	39	450	464	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	1995	268	5215					1353	1358		10.1126/science.7761855	http://dx.doi.org/10.1126/science.7761855			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761855				2022-12-01	WOS:A1995RB19800040
J	OKADA, Y; YAMAZAKI, H; SEKINEAIZAWA, Y; HIROKAWA, N				OKADA, Y; YAMAZAKI, H; SEKINEAIZAWA, Y; HIROKAWA, N			THE NEURON-SPECIFIC KINESIN SUPERFAMILY PROTEIN KIF1A IS A UNIQUE MONOMERIC MOTOR FOR ANTEROGRADE AXONAL-TRANSPORT OF SYNAPTIC VESICLE PRECURSORS	CELL			English	Article							HEAVY-CHAIN; MONOCLONAL-ANTIBODY; MEMBRANOUS ORGANELLES; SECRETORY VESICLES; C-ELEGANS; IDENTIFICATION; SYNAPTOPHYSIN; MICROTUBULES; DOMAINS; GLYCOPROTEIN	Axonal transport has been intensively examined as a good model for studying the mechanism of organelle transport in cells, but it is still unclear how different types of membrane organelles are transported through the nerve axon. To elucidate the function of this mechanism, we have cloned KIF1A, a novel neuron-specific kinesin superfamily motor that was discovered to be a monomeric, globular molecule and that had the fastest reported anterograde motor activity (1.2 mu m/s). To identify its cargo, membranous organelles were isolated from the axon. KIF1A was associated with organelles that contained synaptic vesicle proteins such as synaptotagmin, synaptophysin, and Rab3A. However, this organelle did not contain SV2, another synaptic vesicle protein, nor did it contain presynaptic membrane proteins, such as syntaxin 1A or SNAP-25, or other known anterograde motor proteins, such as kinesin and KIF3. Thus, we suggest that the membrane proteins are sorted into different classes of transport organelles in the cell body and are transported by their specific motor proteins through the axon.	UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN	University of Tokyo			Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1993, NEUROSCI RES, V18, P1, DOI 10.1016/0168-0102(93)90099-C; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOYT MA, 1993, GENETICS, V135, P35; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; HUANG TG, 1994, J BIOL CHEM, V269, P16502; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALIK F, 1994, P NATL ACAD SCI USA, V91, P4584, DOI 10.1073/pnas.91.10.4584; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OBATA K, 1986, BRAIN RES, V375, P37, DOI 10.1016/0006-8993(86)90956-X; OKADA Y, 1995, J NEUROSCI, V15, P3053; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PESAVENTO PA, 1994, J CELL BIOL, V127, P1041, DOI 10.1083/jcb.127.4.1041; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; SATO YR, 1992, J BIOL CHEM, V267, P23930; SCHMIDLE T, 1991, BIOCHIM BIOPHYS ACTA, V1060, P251, DOI 10.1016/S0005-2728(05)80314-7; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	58	482	492	3	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					769	780		10.1016/0092-8674(95)90538-3	http://dx.doi.org/10.1016/0092-8674(95)90538-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7539720	Bronze			2022-12-01	WOS:A1995RB96100015
J	RIEUXLAUCAT, F; LEDEIST, F; HIVROZ, C; ROBERTS, IAG; DEBATIN, KM; FISCHER, A; DEVILLARTAY, JP				RIEUXLAUCAT, F; LEDEIST, F; HIVROZ, C; ROBERTS, IAG; DEBATIN, KM; FISCHER, A; DEVILLARTAY, JP			MUTATIONS IN FAS ASSOCIATED WITH HUMAN LYMPHOPROLIFERATIVE SYNDROME AND AUTOIMMUNITY	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; SURFACE ANTIGEN; APOPTOSIS; MICE; LPR	Fas (also known as Apo1 and CD95) is a cell surface receptor involved in apoptotic cell death. Fas expression and function were analyzed in three children (including two siblings) with a lymphoproliferative syndrome, two of whom also had autoimmune disorders. A targe deletion in the gene encoding Fas and no detectable cell surface expression characterized the most affected patient. Clinical manifestations in the two related patients were less severe: Fas-mediated apoptosis was impaired and a deletion within the intracytoplasmic domain was detected. These findings illustrate the crucial regulatory role of Fas and may provide a molecular basis for some autoimmune diseases in humans.	HOP NECKER ENFANTS MALAD,INSERM,U429,F-75743 PARIS 15,FRANCE; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND; UNIV HEIDELBERG,CHILDRENS HOSP,HAEMATOL SECT,D-69120 HEIDELBERG,GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Ruprecht Karls University Heidelberg			Rieux-Laucat, Frédéric/A-7916-2017; Debatin, Klaus-Michael/J-9704-2014; Hivroz, Claire/H-2711-2014; de Villartay, jean pierre/H-9353-2017	Rieux-Laucat, Frédéric/0000-0001-7858-7866; Debatin, Klaus-Michael/0000-0002-8397-1886; Hivroz, Claire/0000-0002-6794-2890; de Villartay, jean pierre/0000-0001-5987-0463				COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KRAMMER P H, 1992, Current Biology, V2, P383, DOI 10.1016/0960-9822(92)90084-N; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LANDOLFI MMT, 1993, J IMMUNOL, V151, P1086; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; RIEUXLAUCAT F, 1993, EUR J IMMUNOL, V23, P928, DOI 10.1002/eji.1830230425; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	17	1113	1145	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1347	1349		10.1126/science.7539157	http://dx.doi.org/10.1126/science.7539157			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7539157				2022-12-01	WOS:A1995RB19800038
J	ROITBERG, A; GERBER, RB; ELBER, R; RATNER, MA				ROITBERG, A; GERBER, RB; ELBER, R; RATNER, MA			ANHARMONIC WAVE-FUNCTIONS OF PROTEINS - QUANTUM SELF-CONSISTENT-FIELD CALCULATIONS OF BPTI	SCIENCE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NEUTRON-SCATTERING ANALYSIS; VIBRATIONAL-STATES; NORMAL-MODES; DYNAMICS; MYOGLOBIN; LYSOZYME; ENERGY	The harmonic approximation for the potential energy of proteins is known to be inadequate for the calculation of many protein properties. To study the effect of anharmonic terms on protein vibrations, the anharmonic wave functions for the ground state and low-lying excited states of the bovine pancreatic trypsin inhibitor (BPTI) were calculated. The results suggest that anharmonic treatments are essential for protein vibrational spectroscopy. The calculation uses the Vibrational self-consistent field approximation, which includes anharmonicity and interaction among modes in a mean-field sense. Properties obtained include the quantum coordinate fluctuations, zero-point energies, and the vibrational absorption spectrum.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA; HEBREW UNIV JERUSALEM, DEPT PHYS CHEM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, FRITZ HABER INST, IL-91904 JERUSALEM, ISRAEL; UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA	Northwestern University; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Roitberg, Adrian E/A-2378-2009					AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BOWMAN JM, 1978, J CHEM PHYS, V68, P608, DOI 10.1063/1.435782; BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1986, BIOPOLYMERS, V25, P1767, DOI 10.1002/bip.360250916; CUSACK S, 1988, J MOL BIOL, V202, P903, DOI 10.1016/0022-2836(88)90566-9; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELBER R, IN PRESS COMPUT PHYS; GERBER RB, 1988, ADV CHEM PHYS, V70, P97, DOI 10.1002/9780470141199.ch4; GO N, 1983, P NATL ACAD SCI-BIOL, V80, P3696, DOI 10.1073/pnas.80.12.3696; HORN TR, 1989, J CHEM PHYS, V91, P1813, DOI 10.1063/1.457086; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; LAANE J, 1994, ANNU REV PHYS CHEM, V45, P179; LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X; LEVY RM, 1984, J PHYS CHEM-US, V88, P4233, DOI 10.1021/j150663a009; NESBITT DJ, 1994, ANNU REV PHYS CHEM, V45, P367; NISHIKAWA T, 1987, PROTEINS, V2, P308, DOI 10.1002/prot.340020407; QIAN WL, 1994, BIOPOLYMERS, V34, P1377, DOI 10.1002/bip.360341009; RATNER MA, 1986, J PHYS CHEM-US, V90, P20, DOI 10.1021/j100273a008; ROMANOWSKI H, 1985, J CHEM PHYS, V82, P4155, DOI 10.1063/1.448858; SMITH J, 1990, J CHEM PHYS, V93, P2974, DOI 10.1063/1.458885; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	23	116	119	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1319	1322		10.1126/science.7539156	http://dx.doi.org/10.1126/science.7539156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7539156				2022-12-01	WOS:A1995RB19800029
J	SCHNITZLER, GR; BRISCOE, C; BROWN, JM; FIRTEL, RA				SCHNITZLER, GR; BRISCOE, C; BROWN, JM; FIRTEL, RA			SERPENTINE CAMP RECEPTORS MAY ACT THROUGH A G-PROTEIN-INDEPENDENT PATHWAY TO INDUCE POSTAGGREGATIVE DEVELOPMENT IN DICTYOSTELIUM	CELL			English	Article							MOLECULAR-GENETIC-ANALYSIS; CYCLIC-AMP; SIGNAL-TRANSDUCTION; MULTICELLULAR DEVELOPMENT; CELL-DIFFERENTIATION; KINASE ACTIVATION; PRESTALK GENE; EXPRESSION; DISCOIDEUM; SUBUNITS	The transcription factor G box-binding factor (GBF) is required for the developmental switch between aggregative and postaggregative gene expression, cell-type differentiation, and morphogenesis. We show that constitutive expression of GBF allows ectopic expression of postaggregative genes, but only in response to exogenous cAMP. GBF activation requires the serpentine cAMP receptors required for aggregation, but not the coupled G alpha 2 or the GP subunit, suggesting a novel signaling pathway. in response to high cAMP, g alpha 2-null cells can bypass the aggregation stage, expressing cell type-specific genes and forming fruiting bodies. Our results demonstrate that the same receptors regulate aggregation and cell-type differentiation, but via distinct pathways depending upon whether the receptor perceives a pulsatile or sustained signal.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego								ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BERKS M, 1990, DEVELOPMENT, V110, P977; BLUMBERG DD, 1988, DEV GENET, V9, P359, DOI 10.1002/dvg.1020090417; BLUMBERG DD, 1989, DIFFERENTIATION, V41, P14, DOI 10.1111/j.1432-0436.1989.tb00727.x; CARREL F, 1994, MOL BIOL CELL, V5, P7, DOI 10.1091/mbc.5.1.7; CECCARELLI A, 1992, DEV BIOL, V152, P188, DOI 10.1016/0012-1606(92)90169-H; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CUBITT AB, 1992, COLD SPRING HARB SYM, V57, P177, DOI 10.1101/SQB.1992.057.01.023; DATTA S, 1988, GENE DEV, V2, P294, DOI 10.1101/gad.2.3.294; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DHARMAWARDHANE S, 1994, DEVELOPMENT, V120, P3549; DYNES JL, 1994, GENE DEV, V8, P948, DOI 10.1101/gad.8.8.948; FOSNAUGH KL, 1993, DEV BIOL, V157, P38, DOI 10.1006/dbio.1993.1110; GOMER RH, 1985, COLD SPRING HARB SYM, V50, P801, DOI 10.1101/SQB.1985.050.01.098; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; HJORTH AL, 1990, GENE DEV, V4, P419, DOI 10.1101/gad.4.3.419; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JERMYN KA, 1987, DEVELOPMENT, V100, P745; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; Kay Robert R., 1992, Current Opinion in Cell Biology, V4, P934, DOI 10.1016/0955-0674(92)90121-R; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KUBOHARA Y, 1994, FASEB J, V11, P869; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUMAGAI A, 1988, COLD SPRING HARB SYM, V2, P675; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V259, P14123; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; MILNE JLS, 1995, IN PRESS J BIOL CHEM; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; OYAMA M, 1986, P NATL ACAD SCI USA, V83, P4819, DOI 10.1073/pnas.83.13.4819; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; PEARS CJ, 1987, EMBO J, V6, P195, DOI 10.1002/j.1460-2075.1987.tb04738.x; POWELLCOFFMAN JA, 1994, MOL CELL BIOL, V14, P5840, DOI 10.1128/MCB.14.9.5840; SARAN S, 1994, FEBS LETT, V337, P43, DOI 10.1016/0014-5793(94)80626-8; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SCHAAP P, 1985, EXP CELL RES, V159, P388, DOI 10.1016/S0014-4827(85)80012-4; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SCHNITZLER GR, 1994, GENE DEV, V8, P502, DOI 10.1101/gad.8.4.502; SEGALL J, 1995, IN PRESS J CELL BIOL; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TOWN C, 1978, DEV BIOL, V63, P412, DOI 10.1016/0012-1606(78)90145-8; Williams JG, 1991, CURR OPIN GENET DEV, V1, P358, DOI 10.1016/S0959-437X(05)80300-4; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, IN PRESS J CELL BIOL	59	55	56	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					737	745		10.1016/0092-8674(95)90535-9	http://dx.doi.org/10.1016/0092-8674(95)90535-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774015	Bronze			2022-12-01	WOS:A1995RB96100012
J	SHIVDASANI, RA; ROSENBLATT, MF; ZUCKERFRANKLIN, D; JACKSON, CW; HUNT, P; SARIS, CJM; ORKIN, SH				SHIVDASANI, RA; ROSENBLATT, MF; ZUCKERFRANKLIN, D; JACKSON, CW; HUNT, P; SARIS, CJM; ORKIN, SH			TRANSCRIPTION FACTOR NF-E2 IS REQUIRED FOR PLATELET FORMATION INDEPENDENT OF THE ACTIONS OF THROMBOPOIETIN/MGDF IN MEGAKARYOCYTE DEVELOPMENT	CELL			English	Article							DOMINANT CONTROL REGION; TARGETED MUTATION; BINDING PROTEINS; GENE; EXPRESSION; CELLS; MOUSE; LINEAGES; MARROW; GROWTH	Despite the importance of blood platelets in health and disease, the mechanisms regulating their formation within megakaryocytes are unknown. We generated mice lacking the hematopoietic subunit (p45) of the heterodimeric erythroid transcription factor NF-E2. Unexpectedly, NF-E2(-/-) mice lack circulating platelets and die of hemorrhage; their megakaryocytes show no cytoplasmic platelet formation. Though platelets are absent, serum levels of the growth factor thrombopoietin/MGDF are not elevated above controls. Nonetheless, NF-E2(-/-) megakaryocytes proliferate in vivo in response to thrombopoietin administration. Thus, as an essential factor for megakaryocyte maturation and platelet production, NF-ES must regulate critical target genes independent of the action of thrombopoietin. These findings provide insight into the genetic analysis of megakaryocyte maturation and thrombopoiesis.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA USA; CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; NYU, MED CTR, DEPT MED, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DIV EXPTL HEMATOL, MEMPHIS, TN 38105 USA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; New York University; St Jude Children's Research Hospital; Amgen	SHIVDASANI, RA (corresponding author), DANA FARBER CANC INST, DIV MED ONCOL, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051290, U01HL142103, R01HL042103] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42103, HL51290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BECKSTEAD JH, 1986, BLOOD, V67, P285; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BLOCK KL, 1994, BLOOD, V84, P3385; BRETONGORIUS J, 1981, BRIT J HAEMATOL, V47, P635, DOI 10.1111/j.1365-2141.1981.tb02693.x; BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; BURSTEIN SA, 1995, WILLIAMS HEMATOLOGY, P1149; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHOI ES, 1995, BLOOD, V85, P402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KUTER DJ, 1994, BLOOD, V84, P1464; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVINE RF, 1976, J CELL BIOL, V69, P159, DOI 10.1083/jcb.69.1.159; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lind S.E., 1995, BLOOD PRINCIPLES PRA, P949; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MAZUR EM, 1981, J CLIN INVEST, V68, P733, DOI 10.1172/JCI110309; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIURA M, 1988, EXP HEMATOL, V16, P139; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ODELL TT, 1968, BLOOD, V32, P102, DOI 10.1182/blood.V32.1.102.102; OGAWA M, 1989, HEMATOL ONCOL CLIN N, V3, P453, DOI 10.1016/S0889-8588(18)30541-0; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAULUS JM, 1970, BLOOD-J HEMATOL, V35, P298, DOI 10.1182/blood.V35.3.298.298; PETERS LL, 1990, BLOOD, V76, P745; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROBERTSON EJ, 1987, TERATOCARCIOMAS EMBR; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; SWANK RT, 1993, BLOOD, V81, P2626; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZUCKERFRANKLIN D, 1984, J CELL BIOL, V99, P390, DOI 10.1083/jcb.99.2.390; ZUCKERFRANKLIN D, 1989, ATLAS BLOOD CELLS FU, P621	65	601	616	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 2	1995	81	5					695	704		10.1016/0092-8674(95)90531-6	http://dx.doi.org/10.1016/0092-8674(95)90531-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774011	hybrid			2022-12-01	WOS:A1995RB96100008
J	TEWARI, M; QUAN, LT; OROURKE, K; DESNOYERS, S; ZENG, Z; BEIDLER, DR; POIRIER, GG; SALVESEN, GS; DIXIT, VM				TEWARI, M; QUAN, LT; OROURKE, K; DESNOYERS, S; ZENG, Z; BEIDLER, DR; POIRIER, GG; SALVESEN, GS; DIXIT, VM			YAMA/CPP32-BETA, A MAMMALIAN HOMOLOG OF CED-3, IS A CRMA-INHIBITABLE PROTEASE THAT CLEAVES THE DEATH SUBSTRATE POLY(ADP-RIBOSE) POLYMERASE	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CELL-DEATH; C-ELEGANS; ALPHA-1-PROTEINASE INHIBITOR; GENE CED-3; INDUCTION; APOPTOSIS; ENCODES	Although the mechanism of mammalian apoptosis has not been elucidated, a protease of the CED-3/ICE family is anticipated to be a component of the death machinery. Several lines of evidence predict that this protease cleaves the death substrate poly(ADP-ribose) polymerase (PARP) to a specific 85 kDa form observed during apoptosis, is inhibitable by the CrmA protein, and is distinct from ICE, We cloned a ced-3/ICE-related gene, designated Yama, that encodes a protein identical to CPP32 beta. Purified Yama was a zymogen that, when activated, cleaved PARP to generate the 85 kDa apoptotic fragment. Cleavage of PARP by Yama was inhibited by CrmA but not by an inactive point mutant of CrmA. Furthermore, CrmA blocked cleavage of PARP in cells undergoing apoptosis. We propose that Yama may represent an effector component of the mammalian cell death pathway and suggest that CrmA blocks apoptosis by inhibiting Yama.	UNIV MICHIGAN,SCH MED,GRAD PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; CHU LAVAL,RES CTR,MOLEC ENDOCRINOL LAB,POLY ADPRIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,ST FOY,PQ G1V 4G2,CANADA	University of Michigan System; University of Michigan; Duke University; Laval University; Laval University	TEWARI, M (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424	NCI NIH HHS [CA64803] Funding Source: Medline; NHLBI NIH HHS [HL07517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HU HM, 1994, J BIOL CHEM, V269, P30069; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOMIYAMA T, 1994, TECHNIQUES PROTEIN C, V5, P305; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RON D, 1992, BIOTECHNIQUES, V13, P866; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SHAO HN, 1994, J BIOL CHEM, V269, P26606; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	38	2288	2358	2	32	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					801	809		10.1016/0092-8674(95)90541-3	http://dx.doi.org/10.1016/0092-8674(95)90541-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774019	Bronze			2022-12-01	WOS:A1995RB96100018
J	VANDIJK, MR; WATERS, AP; JANSE, CJ				VANDIJK, MR; WATERS, AP; JANSE, CJ			STABLE TRANSFECTION OF MALARIA PARASITE BLOOD STAGES	SCIENCE			English	Article							PLASMODIUM-BERGHEI; TRYPANOSOMA-BRUCEI; HOMOLOGOUS RECOMBINATION; PYRIMETHAMINE RESISTANCE; TOXOPLASMA-GONDII; GENE REPLACEMENT; TRANSFORMATION; EXPRESSION; FALCIPARUM; MUTATIONS	Genetic manipulation of malaria parasites would revolutionize the study of this group of pathogens and have implications for vaccine and drug development. This report describes the stable, drug-selectable genetic transformation of the clinically relevant intracellular blood stages of a malaria parasite. A plasmid transfection vector carrying the gene locus that encodes a drug-resistant form of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from the rodent malaria parasite Plasmodium berghei was constructed. Derivatives of this vector were introduced into merozoites of P. berghei by electroporation, and parasites were selected for successful transformation in the rodent host on the basis of resistance to pyrimethamine. The plasmids were present in a circular, unrearranged form that replicated episomally to an observed maximum of 15 copies per cell in drug-resistant populations.	LEIDEN UNIV,DEPT PARASITOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205				BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; COWMAN AF, 1990, MOL BIOCHEM PARASIT, V42, P21, DOI 10.1016/0166-6851(90)90109-Y; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; DONALD RGK, 1993, MOL BIOCHEM PARASIT, V63, P243; DORE E, 1990, MOL CELL BIOL, V10, P2423, DOI 10.1128/MCB.10.5.2423; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; JANSE CJ, 1989, INT J PARASITOL, V19, P509, DOI 10.1016/0020-7519(89)90080-5; JANSE CJ, 1984, INT J PARASITOL, V14, P317, DOI 10.1016/0020-7519(84)90083-3; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; JANSE CJ, 1994, METHOD CELL BIOL, V42, P296; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LONG CA, 1993, CURR OPIN IMMUNOL, V5, P548, DOI 10.1016/0952-7915(93)90036-R; MONS B, 1985, PARASITOLOGY, V91, P423, DOI 10.1017/S0031182000062673; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; TANAKA M, 1990, MOL BIOCHEM PARASIT, V39, P127, DOI 10.1016/0166-6851(90)90015-E; TENASBROEK ALMA, 1993, MOL BIOCHEM PARASIT, V59, P133, DOI 10.1016/0166-6851(93)90014-O; VANDIJK MR, 1994, MOL BIOCHEM PARASIT, V68, P167, DOI 10.1016/0166-6851(94)00163-4; VANDIJK MR, UNPUB; VINKENOOG R, IN PRESS MOL BIOCH P; WU Y, 1995, P NATL ACAD SCI USA, V91, P973	29	192	197	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1358	1362		10.1126/science.7761856	http://dx.doi.org/10.1126/science.7761856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761856				2022-12-01	WOS:A1995RB19800041
J	WERNER, MH; RUTH, JR; GRONENBORN, AM; CLORE, GM				WERNER, MH; RUTH, JR; GRONENBORN, AM; CLORE, GM			MOLECULAR-BASIS OF HUMAN 46X,Y SEX REVERSAL REVEALED FROM THE 3-DIMENSIONAL SOLUTION STRUCTURE OF THE HUMAN SRY-DNA COMPLEX	CELL			English	Article							HMG BOX; BINDING DOMAIN; MINOR-GROOVE; XY FEMALES; NUCLEOPROTEIN STRUCTURES; DETERMINING REGION; DETERMINING LOCUS; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; PROTEINS	The solution structure of the specific complex between the high mobility group (HMG) domain of SRY (hSRY-HMG), the protein encoded by the human testis-determining gene, and its DNA target site in the promoter of the Mullerian inhibitory substance gene has been determined by multidimensional NMR spectroscopy. hSRY-HMG has a twisted L shape that presents a concave surface (made up of three helices and the N- and C-terminal strands) to the DNA for sequence-specific recognition. Binding of hSRY-HMG to its specific target site occurs exclusively in the minor groove and induces a large conformational change in the DNA. The DNA in the complex has an overall 70 degrees-80 degrees bend and is helically unwound relative to classical A- and B-DNA. The structure of the complex reveals the origin of sequence-specific binding within the HMG-1/HMG-2 family and provides a framework for understanding the effects of point mutations that cause 46X, Y sex reversal at the atomic level.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				AFFARA NA, 1993, HUM MOL GENET, V2, P785, DOI 10.1093/hmg/2.6.785; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRAUN A, 1993, AM J HUM GENET, V52, P578; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T, 1993, XPLOR MANUAL VERSION; BRUNGER AT, 1993, AVS XPLOR USERS MANU; CLORE GM, 1994, PROTEIN SCI, V3, P372; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DECASTRO E, 1992, VISP ONE ZERO USERS; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GUSTAFSON ML, 1994, ANNU REV MED, V45, P505, DOI 10.1146/annurev.med.45.1.505; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; Nicholls A.J., 1993, GRASP MANUAL; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1993, PROTEIN-STRUCT FUNCT, V17, P295; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TAJIMA T, 1994, HUM MOL GENET, V3, P1187, DOI 10.1093/hmg/3.7.1187; THIAN R, 1994, CELL, V77, P5; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	49	407	413	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					705	714		10.1016/0092-8674(95)90532-4	http://dx.doi.org/10.1016/0092-8674(95)90532-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774012	Bronze			2022-12-01	WOS:A1995RB96100009
J	BOURGUET, W; RUFF, M; CHAMBON, P; GRONEMEYER, H; MORAS, D				BOURGUET, W; RUFF, M; CHAMBON, P; GRONEMEYER, H; MORAS, D			CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA	NATURE			English	Article							STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; TRANSCRIPTIONAL ACTIVATION; ECDYSONE RECEPTOR; IDENTIFICATION; SUPERFAMILY; HETERODIMER; MUTATION	The crystal structure of the human retinoid-X receptor RXR-alpha ligand-binding domain reveals a previously undiscovered fold of an antiparallel alpha-helical sandwich, packed as dimeric units. Two helices and one loop form the homodimerization surface, and hydrophobic heptad repeats participate in stabilizing the fold. The existence of a ligand-binding pocket is proposed that would allow 9-cis retinoic acid to interact with different functional modules, including the AF-2 activating domain. Several lines of evidence indicate that the overall structure is a prototype fold of ligand-binding domains of nuclear receptors.	UNIV STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Bourguet, William/I-5569-2013; Gronemeyer, Hinrich/AAH-5575-2019; Bourguet, William/Y-6600-2019; ruff, marc/J-3011-2013; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016	Bourguet, William/0000-0002-0643-7719; Gronemeyer, Hinrich/0000-0001-9454-2449; Bourguet, William/0000-0002-0643-7719; ruff, marc/0000-0001-5451-6377; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				AMEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAMBON P, 1994, CELL BIOL, V5, P115; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V90, P1293; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARD T, 1990, SCIENCE, V248, P157; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, IN PRESS EMBO J; LEE MS, 1993, SCIENCE, V269, P1117; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SCHILTZ M, 1994, J APPL CRYSTALLOGR, V27, P950, DOI 10.1107/S0021889894005923; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WRENN CK, 1993, J BIOL CHEM, V268, P24089; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	50	1007	1043	6	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					377	382		10.1038/375377a0	http://dx.doi.org/10.1038/375377a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760929				2022-12-01	WOS:A1995RB10100045
J	CHILLON, M; CASALS, T; MERCIER, B; BASSAS, L; LISSENS, W; SILBER, S; ROMEY, MC; RUIZROMERO, J; VERLINGUE, C; CLAUSTRES, M; NUNES, V; FEREC, C; ESTIVILL, X				CHILLON, M; CASALS, T; MERCIER, B; BASSAS, L; LISSENS, W; SILBER, S; ROMEY, MC; RUIZROMERO, J; VERLINGUE, C; CLAUSTRES, M; NUNES, V; FEREC, C; ESTIVILL, X			MUTATIONS IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH CONGENITAL ABSENCE OF THE VAS-DEFERENS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGULATOR CFTR GENE; MESSENGER-RNA TRANSCRIPTS; HUMAN FETAL TISSUES; BILATERAL ABSENCE; CONDUCTANCE; EXPRESSION; IDENTIFICATION; DNA; FORM; MEN	Background. Congenital bilateral absence of the vas deferens (CBAVD) is a form of male infertility in which mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been identified. The molecular basis of CBAVD is not completely understood. Although patients with cystic fibrosis have mutations in both copies of the CFTR gene, most patients with CBAVD have mutations in only one copy of the gene. Methods. To investigate CBAVD at the molecular level, we have characterized the mutations in the CFTR gene in 102 patients with this condition. None had clinical manifestations of cystic fibrosis. We also analyzed a DNA variant (the 5T allele) in a noncoding region of CFTR that causes reduced levels of the normal CFTR protein. Parents of patients with cystic fibrosis, patients with types of infertility other than CBAVD, and normal subjects were studied as controls. Results. Nineteen of the 102 patients with CBAVD had mutations in both copies of the CFTR gene, and none of them had the 5T allele. Fifty-four patients had a mutation in one copy of CFTR, and 34 of them (63 percent) had the 5T allele in the other CFTR gene. In 29 patients no CFTR mutations were found, but 7 of them (24 percent) had the 5T allele. In contrast, the frequency of this allele in the general population was about 5 percent. Conclusions. Most patients with CBAVD have mutations in the CFTR gene. The combination of the 5T allele in one copy of the CFTR gene with a cystic fibrosis mutation in the other copy is the most common cause of CBAVD. The 5T allele mutation has a wide range of clinical presentations, occurring in patients with CBAVD or moderate forms of cystic fibrosis and in fertile men.	HOSP DURAN & REYNALS, CANC RES INST, DEPT MOLEC GENET, E-08907 LHOSPITALET DE LLOBREGAT, SPAIN; UNIV HOSP BREST, INST BIOGENET, BREST, FRANCE; FDN PUIGVERT, INST UROL NEPHROL MED GENET, DEPT ANDROL, BARCELONA, SPAIN; ST LUKES HOSP, DEPT UROL & MICROSURG, ST LOUIS, MO USA; FREE UNIV BRUSSELS, DEPT MED GENET, BRUSSELS, BELGIUM; INST BIOL, BIOCHIM GENET LAB, MONTPELLIER, FRANCE; HOSP CLIN BARCELONA, GENET SERV, BARCELONA, SPAIN	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; CHU Brest; Universite de Bretagne Occidentale; Fundacio Puigvert; Saint Luke's Hospital - Missouri; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Barcelona; Hospital Clinic de Barcelona			Ferec, Claude/ABG-9699-2020; Lissens, Willy/B-2892-2013; Nunes, Virginia/AAD-1014-2019; Estivill, Xavier/A-3125-2013; ROMEY-CHATELAIN, Marie-Catherine/A-9623-2008; Chillon, Miguel/A-2466-2009	Ferec, Claude/0000-0002-2325-0710; Lissens, Willy/0000-0003-3875-9955; Nunes, Virginia/0000-0002-5747-9310; Estivill, Xavier/0000-0002-0723-2256; Chillon, Miguel/0000-0003-0840-2111				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; AUDREZET MP, 1993, HUM MOL GENET, V2, P496, DOI 10.1093/hmg/2.4.496-a; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; CASALS T, 1995, HUM GENET, V95, P205; CHILLON M, 1994, HUM GENET, V93, P447; CHILLON M, 1995, AM J HUM GENET, V56, P623; CHILLON M, 1994, HUM MUTAT, V3, P223, DOI 10.1002/humu.1380030308; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; CULARD JF, 1994, HUM GENET, V93, P467; CUPPENS H, 1994, HUM MOL GENET, V3, P607, DOI 10.1093/hmg/3.4.607; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DORK T, 1994, HUM GENET, V93, P67; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GERVAIS R, 1993, NEW ENGL J MED, V328, P446, DOI 10.1056/NEJM199302113280619; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; JEQUIER AM, 1985, J ANDROL, V6, P15; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; LEAR JD, 1989, SCIENCE, V245, P1437; MERCIER B, 1995, AM J HUM GENET, V56, P272; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; OSBORNE LR, 1993, HUM MOL GENET, V2, P1990; RIORDAN JR, 1989, SCIENCE, V245, P1066; SLOMSKI R, 1992, HUM GENET, V89, P615; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; TIZZANO EF, 1993, HUM MOL GENET, V2, P219, DOI 10.1093/hmg/2.3.219; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	36	715	740	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1475	1480		10.1056/NEJM199506013322204	http://dx.doi.org/10.1056/NEJM199506013322204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739684	Green Published			2022-12-01	WOS:A1995RA14000004
J	CHONG, JPJ; MAHBUBANI, HM; KHOO, CY; BLOW, JJ				CHONG, JPJ; MAHBUBANI, HM; KHOO, CY; BLOW, JJ			PURIFICATION OF AN MCM-CONTAINING COMPLEXES A COMPONENT OF THE DNA-REPLICATION LICENSING SYSTEM	NATURE			English	Article							CELL-FREE-EXTRACTS; SUBCELLULAR-LOCALIZATION; YEAST; CYCLE; INITIATION; PROTEIN; FAMILY; NUCLEI	REPLICATION licensing factor (RLF) ensures that eukaryotic chromosomal DNA is replicated exactly once in each cell cycle(1-4). On exit from metaphase, RLF is activated and binds to or modifies chromatin. This modification (the 'licence') is required for subsequent DNA replication; the licence is also inactivated in the process of replication. Active RLF is not imported into the nucleus, so further DNA replication cannot occur until the DNA is relicensed by passage throught mitosis. We have developed an assay to purify RLF from Xenopus eggs(4). Activity resolves into two components, RLF-M and RLF-B, both of which are required for licensing, RLF-M has been purified to apparent homogeneity: it consists of three polypeptides, one of which is a Xenopus homologue of the yeast MCM3 protein. Xenopus Mcm3 associates with chomatin in G1 and is removed during replication, consistent with its being a component of the RLF system.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND				Chong, James/AAC-4957-2019; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Chong, James/0000-0001-9447-7421	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; CREVEL G, 1991, EMBO J, V10, P4361, DOI 10.1002/j.1460-2075.1991.tb05014.x; DEROEPER A, 1977, NATURE, V265, P469, DOI 10.1038/265469a0; FORSBURG SL, 1994, J CELL SCI, V107, P2779; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KUBOTA Y, IN PRESS CELL; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAITI AK, 1992, J MOL BIOL, V224, P545, DOI 10.1016/0022-2836(92)90543-S; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; SHIVJI MKK, 1994, J CURR BIOL, V4, P1062; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	319	321	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 1	1995	375	6530					418	421		10.1038/375418a0	http://dx.doi.org/10.1038/375418a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760937				2022-12-01	WOS:A1995RB10100057
J	FRUH, K; AHN, K; DJABALLAH, H; SEMPE, P; VANENDERT, PM; TAMPE, R; PETERSON, PA; YANG, Y				FRUH, K; AHN, K; DJABALLAH, H; SEMPE, P; VANENDERT, PM; TAMPE, R; PETERSON, PA; YANG, Y			A VIRAL INHIBITOR OF PEPTIDE TRANSPORTERS FOR ANTIGEN PRESENTATION	NATURE			English	Article							ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; MHC; COMPLEX; TRANSLOCATION; MOLECULES; GOLGI	CYTOTOXIC T lymphocytes lyse target cells after T-cell-receptor-mediated recognition of class I major histocompatibility complex molecules presenting peptides(1). Antigenic peptides are generated in the cytoplasm by proteasomes(2) and translocated into the lumen of the endoplasmic reticulum (ER) by peptide transporters (TAP)3-6. Herpes simplex virus (HSV) expresses a cytoplasmic protein, ICP47, which seems to interfere with such immune surveillance by mediating retention of 'empty' class I molecules in the ER(7,8). BY expressing ICP47 in HeLa cells under an inducible promoter(9), we show that ICP47 efficiently inhibits peptide transport across the ER membrane such that nascent class I molecules fail to acquire antigenic peptides. This inhibition was overcome by transfecting murine TAP. Further, we demonstrate that ICP47 colocalizes and physically associates with TAP within the cell, Inhibition of peptide translocation by a viral protein indicates a previously undocumented potential mechanism for viral immune evasion.	HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE; MAX PLANCK INST BIOCHEM, STRUKT BIOL ABT, D-82152 MARTINSRIED, GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society	FRUH, K (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Tampe, Robert/H-2953-2015	Tampe, Robert/0000-0002-0403-2160; Djaballah, Hakim/0000-0002-6039-0181; van Endert, Peter/0000-0003-3782-0750; Frueh, Klaus/0000-0001-8014-3877				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HILL AB, 1994, J IMMUNOL, V152, P2736; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P342; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; YANG Y, 1992, J BIOL CHEM, V267, P11669; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	22	525	539	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					415	418		10.1038/375415a0	http://dx.doi.org/10.1038/375415a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760936				2022-12-01	WOS:A1995RB10100056
J	HERTZMAN, PA; CLAUW, DJ; KAUFMAN, LD; VARGA, J; SILVER, RM; THACKER, HL; MEASE, P; ESPINOZA, LR; PINCUS, T				HERTZMAN, PA; CLAUW, DJ; KAUFMAN, LD; VARGA, J; SILVER, RM; THACKER, HL; MEASE, P; ESPINOZA, LR; PINCUS, T			THE EOSINOPHILIA-MYALGIA-SYNDROME - STATUS OF 205 PATIENTS AND RESULTS OF TREATMENT 2 YEARS AFTER ONSET	ANNALS OF INTERNAL MEDICINE			English	Review							TOXIC OIL SYNDROME; RHEUMATOID-ARTHRITIS; FOLLOW-UP; TRYPTOPHAN; INGESTION; FASCIITIS	Objective: To describe the course of the eosinophilia-myalgia syndrome during a 2-year period. Design: 15 physicians completed a structured review;form to describe symptoms, physical findings, laboratory data, and responses to treatments in 205 patients with the eosinophilia-myalgia syndrome at the onset of illness and after 18 to 24 months of follow-up. Setting: 15 university and private clinical practice settings. Patients: 205 patients for whom follow-up data were available and who met four criteria at diagnosis: eosinophil count of 1000 cells/mm(3) or greater; presence of fasciitis, peripheral neuropathy, polyradiculopathy, interstitial pulmonary disease, pulmonary hypertension, or myocardial involvement; history of L-tryptophan consumption; and absence of other conditions that could account for these findings. Intervention: Empirical interventions by the physicians. Measurements: Symptoms, physical findings, laboratory test results, biopsy findings, radiographic reports, therapeutic interventions, and responses to these interventions. Results: After 18 to 24 months, all symptoms except cognitive changes were reported to have improved in most patients. Nearly all physical findings were also reported to have improved or resolved in most patients; only peripheral neuropathy was unchanged. No evidence of ongoing inflammatory disease was reported. Prednisone was reported to be helpful in 79% of patients who received it during the acute phase of the syndrome. No other treatment was reported to be consistently beneficial. Conclusions: 18 to 24 months after the onset of illness, most symptoms and physical findings in most patients with the eosinophilia-myalgia syndrome resolved or improved. Cognitive changes were reported to be worse in 32% of patients. Prednisone was helpful in the acute phase of illness. No treatment was clearly valuable in management of the later phase of the syndrome.	VANDERBILT UNIV, SCH MED, DEPT MED, DIV RHEUMATOL & IMMUNOL, NASHVILLE, TN 37232 USA; LOS ALAMOS MED CTR, LOS ALAMOS, NM 87544 USA; GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; SUNY STONY BROOK, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, STONY BROOK, NY 11794 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; MINOR & JAMES MED CTR, SEATTLE, WA 98104 USA; LOUISIANA STATE UNIV, MED CTR, NEW ORLEANS, LA USA	Vanderbilt University; Georgetown University; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Jefferson University; Medical University of South Carolina; Cleveland Clinic Foundation; Louisiana State University System					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R18AR021393] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 21393] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; ALONSORUIZ A, 1993, MEDICINE, V72, P285, DOI 10.1097/00005792-199309000-00001; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; CULPEPPER RC, 1991, ANN INTERN MED, V115, P437, DOI 10.7326/0003-4819-115-6-437; DUFFY J, 1992, HOSP PRACT, V27, P65; FREUNDLICH B, 1990, ANN INTERN MED, V112, P758, DOI 10.7326/0003-4819-112-10-758; GUADINO EA, 1995, IN PRESS NEUROPSYCHI; HERTZMAN P A, 1991, Arthritis and Rheumatism, V34, pS131; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HERTZMAN PA, 1993, ARTHRITIS RHEUM, V36, pS115; HERTZMAN PA, 1991, J RHEUMATOL, V18, P867; HERTZMAN PA, 1995, J RHEUMATOL, V22, P161; HERTZMAN PA, 1993, J RHEUMATOL, V20, P1707; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KAUFMAN LD, 1994, RHEUM DIS CLIN N AM, V20, P973; KAUFMAN LD, 1994, ARTHRITIS RHEUM-US, V37, P84, DOI 10.1002/art.1780370112; KAUFMAN LD, 1995, J RHEUMATOL, V22, P282; KILBOURNE EM, 1991, J AM COLL CARDIOL, V18, P711, DOI 10.1016/0735-1097(91)90794-A; KILBOURNE EM, 1992, EPIDEMIOL REV, V14, P16, DOI 10.1093/oxfordjournals.epirev.a036085; KRUPP LB, 1993, NEUROLOGY, V43, P931, DOI 10.1212/WNL.43.5.931; PHILEN RM, 1991, ARCH INTERN MED, V151, P533, DOI 10.1001/archinte.151.3.533; PHILEN RM, 1993, SEMIN ARTHRITIS RHEU, V23, P104, DOI 10.1016/S0049-0172(05)80017-4; PINCUS T, 1992, J RHEUMATOL, V19, P1874; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; PINCUS T, 1989, ANN INTERN MED, V110, P259, DOI 10.7326/0003-4819-110-4-259; SACK KE, 1992, SOUTHERN MED J, V85, P878, DOI 10.1097/00007611-199209000-00005; SILVER RM, 1991, ARCH DERMATOL, V127, P1214, DOI 10.1001/archderm.127.8.1214; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; THACKER HL, 1991, CLEV CLIN J MED, V58, P400, DOI 10.3949/ccjm.58.5.400; VARGA J, 1991, J RHEUMATOL, V18, P259; WOLFE F, 1991, J RHEUMATOL, V18, P643; 1989, MMWR MORBMORTAL WKLY, V38, P765; 1990, JAMA-J AM MED ASSOC, V263, P633	33	30	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					851	855		10.7326/0003-4819-122-11-199506010-00008	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741371				2022-12-01	WOS:A1995RA13900008
J	HILL, A; JUGOVIC, P; YORK, I; RUSS, G; BENNINK, J; YEWDELL, J; PLOEGH, H; JOHNSON, D				HILL, A; JUGOVIC, P; YORK, I; RUSS, G; BENNINK, J; YEWDELL, J; PLOEGH, H; JOHNSON, D			HERPES-SIMPLEX VIRUS TURNS OFF THE TAP TO EVADE HOST IMMUNITY	NATURE			English	Article							PEPTIDE TRANSLOCATION; ENDOPLASMIC-RETICULUM; TRANSPORTER; CHAINS; CONSTRUCTION; EXPRESSION; MOLECULES; VARIANTS; HEAVY	MANY viruses have evolved mechanisms to avoid detection by the host immune system, Herpes simplex virus (HSV) expresses an immediate early protein, ICP47, which blocks presentation of viral peptides to MHC class I-restricted cells(1). The properties of the newly synthesized class I molecules in HSV-infected cells resemble those of cell lines deficient in the transporter associated with antigen processing (TAP) in that class I molecules are retained in the endoplasmic reticulum(1,2), and the heavy chain and beta(2)-microglubulin subunits dissociate in detergent extracts but the complex can be stabilized by peptides(1). We show here that ICP47 binds to TAP and prevents peptide translocation into the endoplasmic reticulum.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 325,CANADA; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HILL, A (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		York, Ian/X-9351-2019; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	York, Ian/0000-0002-3478-3344; 				ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; COUPAR BEH, 1988, GENE, V68, P1, DOI 10.1016/0378-1119(88)90593-8; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; CROMME FV, 1994, J EXP MED, V170, P335; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HEEMELS MT, 1995, REV BIOCH, V64, P463; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILL AB, 1994, J IMMUNOL, V152, P3736; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAVROMARANAZOS P, 1986, J VIROL, V60, P807, DOI 10.1128/JVI.60.2.807-812.1986; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; ROESLE J, 1994, J EXP MED, V180, P1591; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1994, P NATL ACAD SCI USA, V91, P13004, DOI 10.1073/pnas.91.26.13004; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	29	729	744	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					411	415		10.1038/375411a0	http://dx.doi.org/10.1038/375411a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760935				2022-12-01	WOS:A1995RB10100055
J	KIM, JS; KIM, Y; MARTI, K; KERRIDGE, JF				KIM, JS; KIM, Y; MARTI, K; KERRIDGE, JF			NITROGEN ISOTOPE ABUNDANCES IN THE RECENT SOLAR-WIND	NATURE			English	Article								ALTHOUGH lunar crystalline rocks are essentially devoid of nitrogen, the same is not true of the lunar regolith. The nitrogen contents of individual regolith samples (which can be as high as 0.012% by mass) correlate strongly with abundances of noble gases known to be implanted in the lunar surface by solar radiation, indicating that lunar regolith nitrogen is also predominantly of solar origin(1). The large variability in N-15/N-14 ratios measured in different regolith samples may thus reflect long-term changes in tbe isotopic composition of the solar radiation(1). But attempts to explain these variations have been hampered by the lack of any firm constraint on N-15/N-14 in, the present solar wind. Here we report measurements of nitrogen isotopes from two lunar samples that have had simple (and relatively recent) exposure histories. We find that nitrogen implanted in the lunar surface during the past 10(5) to 5 x 10(7) years has a N-15/N-14 ratio approximately 40 parts per thousand higher than that in the terrestrial atmosphere, which is substantially lower than most previous estimates(2,3). This isotopic signature probably represents the best measure of N-15/N-14 in, the present-day solar wind.	UNIV CALIF SAN DIEGO,DEPT CHEM 0317,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BECKER RH, 1994, METEORITICS, V29, P724, DOI 10.1111/j.1945-5100.1994.tb00790.x; BECKER RH, 1975, 6TH P LUN SCI C, P2131; BECKER RH, 1976, 7TH P LUN SCI C, P441; BECKER RH, 1977, P LUNAR PLANET SCI C, P3685; Cameron A., 1982, ESSAYS NUCL ASTROPHY, P23; FRICK U, 1988, 18TH P LUN PLAN SCI, P87; GEISS J, 1982, GEOCHIM COSMOCHIM AC, V46, P529, DOI 10.1016/0016-7037(82)90156-9; Geiss J., 1991, SUN TIME, P98; HEYMANN D, 1975, MOON PLANETS, V13, P81, DOI 10.1007/BF00567509; KERIDGE JF, 1980, ANCIENT SUN, P475; KERRIDGE JF, 1993, REV GEOPHYS, V31, P423, DOI 10.1029/93RG01953; KERRIDGE JF, 1975, SCIENCE, V188, P162, DOI 10.1126/science.188.4184.162; KERRIDGE JF, 1991, 21ST P LUN PLAN SCI, P301; KIM Y, 1992, LUNAR PLANET SCI, V23, P693; KOHL CP, 1978, P LUNAR PLANET SCI C, P2299; MARTI K, 1973, 4TH LUN SCI C, P2037; NORRIS SJ, 1983, 14TH P LUN PLAN SCI; RAO MN, 1958, GEOCHIM COSMOCHIM AC, V58, P4231; RAY J, 1982, LUNAR PLANET; WIELER R, IN PRESS ASTROPHYS J; YANIV A, 1981, ASTROPHYS J, V247, pL143, DOI 10.1086/183609; Yuhas, 1973, P LUNAR PLANET SCI C, P1957	23	20	20	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					383	385		10.1038/375383a0	http://dx.doi.org/10.1038/375383a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760930				2022-12-01	WOS:A1995RB10100046
J	KORF, B				KORF, B			MOLECULAR MEDICINE - MOLECULAR DIAGNOSIS .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											KORF, B (corresponding author), CHILDRENS HOSP,DIV GENET,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							COOPER DN, 1993, HUM GENET, V92, P211	1	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1499	1502		10.1056/NEJM199506013322208	http://dx.doi.org/10.1056/NEJM199506013322208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739688				2022-12-01	WOS:A1995RA14000008
J	LENNON, VA; KRYZER, TJ; GRIESMANN, GE; OSUILLEABHAIN, PE; WINDEBANK, AJ; WOPPMANN, A; MILJANICH, GP; LAMBERT, EH				LENNON, VA; KRYZER, TJ; GRIESMANN, GE; OSUILLEABHAIN, PE; WINDEBANK, AJ; WOPPMANN, A; MILJANICH, GP; LAMBERT, EH			CALCIUM-CHANNEL ANTIBODIES IN THE LAMBERT-EATON SYNDROME AND OTHER PARANEOPLASTIC SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CARCINOMA; AMYOTROPHIC-LATERAL-SCLEROSIS; MYASTHENIC SYNDROME ANTIGEN; ACETYLCHOLINE-RECEPTORS; CA2+ CHANNELS; IGG; AUTOANTIBODIES; PROTEIN; ACTIVATION; RI	Background. Voltage-gated calcium channels in small-cell lung carcinomas may initiate autoimmunity in the paraneoplastic neuromuscular disorder Lambert-Eaton syndrome. The calcium-channel subtype that is responsible is not known. Methods. We compared the effects of antagonists of L-type, N-type, and P/Q-type neuronal calcium channels on the depolarization-dependent influx of calcium-45 in cultured carcinoma cells. Serum samples from patients with various disorders were tested for reactivity with P/Q-type channels solubilized from carcinoma and cerebellar membranes and N-type channels from cerebral cortex. Results. P/Q-type calcium-channel antagonists were the most potent inhibitors of depolarization-induced Ca-45 influx in cultured small-cell carcinoma cell lines. Anti-P/Q-type calcium-channel antibodies were found in serum from all 32 patients with the Lambert-Eaton syndrome and a diagnosis of cancer and in 91 percent of the 33 patients with the Lambert-Eaton syndrome without cancer. Anti-N-type calcium-channel antibodies were found in 49 percent of the 65 patients with the Lambert-Eaton syndrome. Lower titers of anti-P/Q-type and anti-N-type calcium-channel antibodies were found in 54 percent of 70 patients with a paraneoplastic encephalomyeloneuropathic complication of lung, ovarian, or breast carcinoma, 24 percent of 90 patients with cancer but no evident neurologic complications, 23 percent of 78 patients with sporadic amyotrophic lateral sclerosis, and less than 3 percent of 69 patients with myasthenia gravis, epilepsy, or scleroderma. Conclusions. The high frequency of P/Q-type calcium-channel antibodies found in patients with the Lambert-Eaton syndrome implies that antibodies of this specificity have a role in the presynaptic pathophysiology of this disorder.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55905; NEUREX CORP,MENLO PK,CA	Mayo Clinic; Mayo Clinic; Mayo Clinic				O'Suilleabhain, Padraig/0000-0002-2981-4791	NCI NIH HHS [CA-37343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CODIGNOLA A, 1993, J BIOL CHEM, V268, P26240; CUNNINGHAM JM, 1985, J NEUROCHEM, V45, P159, DOI 10.1111/j.1471-4159.1985.tb05488.x; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; FUKUNAGA H, 1983, P NATL ACAD SCI-BIOL, V80, P7636, DOI 10.1073/pnas.80.24.7636; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KIERS L, 1991, MAYO CLIN PROC, V66, P1209, DOI 10.1016/S0025-6196(12)62471-9; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LAMBERT EH, 1988, MUSCLE NERVE, V11, P1133, DOI 10.1002/mus.880111105; Lennon V, 1994, HDB MYASTHENIA GRAVI, P149; LENNON V A, 1990, Annals of Neurology, V28, P281; Lennon V. A., 1993, Society for Neuroscience Abstracts, V19, P1753; LENNON VA, 1994, NEUROLOGY, V44, P2236, DOI 10.1212/WNL.44.12.2236; LENNON VA, 1994, NEUROLOGY, V44, P2412, DOI 10.1212/WNL.44.12.2412; LENNON VA, 1989, MAYO CLIN PROC, V64, P1498, DOI 10.1016/S0025-6196(12)65705-X; LENNON VA, 1994, MUSCLE NERVE       S, V1, pS22; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEYS K, 1991, ANN NEUROL, V29, P307, DOI 10.1002/ana.410290313; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P11743, DOI 10.1073/pnas.90.24.11743; LOOSER P, 1980, SCHWEIZ MED WSCHR, V110, P1342; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; MCCANN FV, 1981, SCIENCE, V212, P1155, DOI 10.1126/science.6262914; Oguro-Okano M., 1993, Society for Neuroscience Abstracts, V19, P1755; OGUROOKANO M, 1992, MAYO CLIN PROC, V67, P1150, DOI 10.1016/S0025-6196(12)61144-6; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OSUILLEABHAIN PE, 1994, NEUROLOGY, V44, pA157; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROSENFELD MR, 1993, ANN NEUROL, V33, P113, DOI 10.1002/ana.410330126; SHER E, 1989, LANCET, V2, P640; SHER E, 1991, FASEB J, V5, P2677, DOI 10.1096/fasebj.5.12.1655547; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TRIGGLE DJ, 1989, TRENDS PHARMACOL SCI, V10, P507, DOI 10.1016/0165-6147(89)90051-5; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P330; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS CL, 1990, J BIOL CHEM, V265, P1443; WILLIAMS CL, 1991, CELL REGUL, V2, P373, DOI 10.1091/mbc.2.5.373; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	41	425	439	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1467	1474		10.1056/NEJM199506013322203	http://dx.doi.org/10.1056/NEJM199506013322203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739683				2022-12-01	WOS:A1995RA14000003
J	LIAO, DZ; HESSLER, NA; MALINOW, R				LIAO, DZ; HESSLER, NA; MALINOW, R			ACTIVATION OF POSTSYNAPTICALLY SILENT SYNAPSES DURING PAIRING-INDUCED LTP IN CA1 REGION OF HIPPOCAMPAL SLICE	NATURE			English	Article							LONG-TERM POTENTIATION; PRESYNAPTIC ENHANCEMENT; SYNAPTIC CURRENTS; NMDA RECEPTORS; EXPRESSION; RELEASE; PROBABILITY; MECHANISMS; RESPONSES; INDUCTION	LONG-TERM potentiation (LTP) is an enhancement of synaptic strength that can be produced by pairing of presynaptic activity with postsynaptic depolarization(1). LTP in the hippocampus has been extensively studied as a cellular model of learning and memory, but the nature of the underlying synaptic modification remains elusive, partly because our knowledge of central synapses is still limited(2,3). One proposal(4,5) is that the modification is postsynaptic, and that synapses expressing only NMDA (N-methyl-D-aspartate) receptors before potentiation are induced by LTP to express functional AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate) receptors. Here we report that a high proportion of synapses in hippocampal area CAI transmit with NMDA receptors but not AMPA receptors, making these synapses effectively non-functional at normal resting potentials. These silent synapses acquire AMPA-type responses following LTP induction, Our findings challenge the view(6-10) that LTP in CA1 involves a presynaptic modification, and suggest instead a simple postsynaptic mechanism for both induction and expression of LTP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA; UNIV IOWA,NEUROSCI PROGRAM,IOWA CITY,IA	Cold Spring Harbor Laboratory; University of Iowa; University of Iowa			hessler, neal/A-7328-2010		NIMH NIH HHS [R29MH49159] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH049159] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AZTELY F, 1992, EUR J NEUROSCI, V4, P681; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DAVIES SN, 1989, NATURE, V330, P500; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TSIEN RW, 1990, COLD SPRING HARB SYM, V55, P147; VORONIN LL, 1993, NEUROSCIENCE, V56, P275, DOI 10.1016/0306-4522(93)90332-A; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WU LG, 1994, J NEUROSCI, V14, P645; XIE XP, 1992, J NEUROPHYSIOL, V67, P1009, DOI 10.1152/jn.1992.67.4.1009	30	1031	1056	1	51	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					400	404		10.1038/375400a0	http://dx.doi.org/10.1038/375400a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760933				2022-12-01	WOS:A1995RB10100052
J	LIU, GS; TSIEN, RW				LIU, GS; TSIEN, RW			PROPERTIES OF SYNAPTIC TRANSMISSION AT SINGLE HIPPOCAMPAL SYNAPTIC BOUTONS	NATURE			English	Article							LONG-TERM POTENTIATION; QUANTAL ANALYSIS; SLICES; CURRENTS; NEURONS; VARIABILITY; MINIATURE; SYNAPSES	SYNAPTIC transmission between individual presynaptic terminals and postsynaptic dendrites is a fundamental element of communication among central nervous system neurons. Yet little is known about evoked neurotransmission at the level of single presynaptic boutons(1-5). Here we describe key functional characteristics of individual presynaptic boutons of hippocampal neurons in culture. Excitatory postsynaptic currents (e.p.s.cs) were evoked by localized application of elevated K+/Ca2+ solution to single functional boutons, visually identified by staining with the vital dye FM1-43 (refs 6, 7). Frequent repetitive stimulation produced a decline in the incidence of e.p.s.cs as the pool of releasable vesicles was exhausted; typically, recovery proceeded with a time constant of about 40 s (23 degrees C), and involved a vesicular pool capable of generating about 90 e.p.s.cs without recycling. At individual synapses, synaptic currents were broadly distributed in amplitude(1), but this distribution was remarkably similar at multiple synapses on a given postsynaptic neuron. The average size of synaptic currents and of responses to focal glutamate application varied fourfold across different cells, decreasing markedly with increasingly dense synaptic innervation. This raises the possibility of a very effective mechanism for coordinating synaptic strength at multiple sites throughout the dendritic tree.	STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University								BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; HORRIGAN FT, 1994, J NEURON, V13, P1119; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KATZ B, 1967, J PHYSIOL-LONDON, V189, P535, DOI 10.1113/jphysiol.1967.sp008183; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LAVIDIS NA, 1992, J PHYSIOL-LONDON, V454, P9, DOI 10.1113/jphysiol.1992.sp019252; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2	22	253	257	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					404	408		10.1038/375404a0	http://dx.doi.org/10.1038/375404a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760934				2022-12-01	WOS:A1995RB10100053
J	MADINE, MA; KHOO, CY; MILLS, AD; LASKEY, RA				MADINE, MA; KHOO, CY; MILLS, AD; LASKEY, RA			MCM3 COMPLEX REQUIRED FOR CELL-CYCLE REGULATION OF DNA-REPLICATION IN VERTEBRATE CELLS	NATURE			English	Article							LICENSING FACTOR; XENOPUS EGGS; YEAST; INITIATION; PROTEINS; NUCLEI; LOCALIZATION; EXTRACT; GENES	AN intact nuclear membrane restricts DNA replication to only one round in each cell cycle, apparently by excluding an essential replication-licensing factor throughout interphase(1-5). A family of related yeast replication proteins, MCM2, 3 and 5 (also called, after cell-division cycle, CDC46), resemble licensing factor, entering the nucleus only during mitosis(6-8). We have cloned a Xenopus homologue of MCM3 (XMCM3) and raised antibodies against expressed protein, Immunodepletion of Xenopus egg extracts removes a complex of MCM2, 3 and 5 homologues and inhibits replication of Xenopus sperm nuclei or permeable G2 HeLa nuclei. However, G1 HeLa nuclei still replicate efficiently. Mock-depleted extracts replicate all three templates. XMCM3 accumulates in nuclei before replication but anti-XMCM3 staining decreases during replication. These results can explain why replicated nuclei are unable to reinitiate replication in a single cell cycle.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	MADINE, MA (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KUBOTA Y, 1995, IN PRSS CELL; LEMAIRE P, 1993, CR ACAD SCI III-VIE, V316, P938; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MANIATIS T, 1991, MOL CLONING; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	241	243	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					421	424		10.1038/375421a0	http://dx.doi.org/10.1038/375421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760938				2022-12-01	WOS:A1995RB10100058
J	MARRS, KA; ALFENITO, MR; LLOYD, AM; WALBOT, V				MARRS, KA; ALFENITO, MR; LLOYD, AM; WALBOT, V			A GLUTATHIONE-S-TRANSFERASE INVOLVED IN VACUOLAR TRANSFER ENCODED BY THE MAIZE GENE BRONZE-2	NATURE			English	Article							CONJUGATE EXPORT PUMP; STRUCTURAL-ANALYSIS; ZEA-MAYS; TOBACCO; PROTOPLASTS; ARABIDOPSIS; EXPRESSION; MEMBRANE; PROTEIN; FAMILY	GLUTATHIONE S-transferases (GSTs) are enzymes that detoxify heterocyclic compounds (xenobiotics) by covalently linking glutathione to the substrate, forming a glutathione S-conjugate(1,2). A glutathione pump in the vacuolar membrane of barley actively sequesters herbicide-glutathione S-conjugates; glutathionation allows recognition and entry of the conjugates into vacuoles(3). The protein encoded by the Bronze-2 gene in maize performs the last genetically defined step in anthocyanin biosynthesis, resulting in the deposition of red and purple pigments in the vacuoles of maize tissues(4). We show here that Bz2 encodes a GST with activity in maize, transformed Arabidopsis thaliana plants and Escherichia coli. We demonstrate that anthocyanins extracted from maize protoplasts expressing BZ2 are conjugated with glutathione, and that vanadate, a known inhibitor of the glutathione pump(3) in plant vacuolar membranes, inhibits the accumulation of anthocyanins in the vacuole. These results provide a biochemical function for BZ2, and suggest a common mechanism for the ability of plants to sequester structurally similar but functionally diverse molecules in the vacuole.			MARRS, KA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279				BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Coe E. H. Jr., 1988, Corn and corn improvement. Third edition., P81; CZAMECKA E, 1988, MOL CELL BIOL, V8, P113; DROOG FNJ, 1993, PLANT MOL BIOL, V21, P965, DOI 10.1007/BF00023595; DUDLER R, 1991, MOL PLANT MICROBE IN, V4, P14, DOI 10.1094/MPMI-4-014; GOFF SA, 1990, EMBO J, V9, P2517, DOI 10.1002/j.1460-2075.1990.tb07431.x; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; Harborne J. B. M. T. J. M. H., 1975, FLAVONOIDS; HARBORNE JB, 1986, PHYTOCHEMISTRY, V25, P1887, DOI 10.1016/S0031-9422(00)81168-1; HARBORNE JB, 1987, PHYTOCHEMISTRY, V26, P2417, DOI 10.1016/S0031-9422(00)84738-X; IRZYK GP, 1982, PLANT PHYSIOL, V102, P803; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; LAMOUREUX GL, 1983, PESTICIDE CHEM HUMAN, P295; LAMOUREUX GL, 1981, SULFUR PESTICIDE ACT, P133; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; Mannervik B, 1981, Methods Enzymol, V77, P231; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; NASH J, 1993, PLANT PHYSIOL, V100, P464; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PILUKA S, 1994, J BIOL CHEM, V269, P27566; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SCHMITZ G, 1992, MOL GEN GENET, V233, P269, DOI 10.1007/BF00587588; SHAH DM, 1986, PLANT MOL BIOL, V6, P203, DOI 10.1007/BF00015226; TAKAHASHI Y, 1991, PLANT J, V1, P327, DOI 10.1046/j.1365-313X.1991.t01-2-00999.x; TAYLOR JL, 1990, MOL PLANT MICROBE IN, V3, P72; TIMMERMAN KP, 1989, PHYSIOL PLANTARUM, V77, P465, DOI 10.1111/j.1399-3054.1989.tb05668.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071; WALBOT V, 1994, MAYDICA, V39, P19	30	444	501	5	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					397	400		10.1038/375397a0	http://dx.doi.org/10.1038/375397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760932				2022-12-01	WOS:A1995RB10100051
J	MEHARG, AA; OSBORN, D				MEHARG, AA; OSBORN, D			DIOXINS RELEASED FROM CHEMICAL ACCIDENTS	NATURE			English	Editorial Material							POLYCHLORINATED DIBENZOFURANS; CHLORINATED DIOXINS; COMBUSTION; FURANS				MEHARG, AA (corresponding author), INST TERR ECOL,HUNTINGDON PE17 2LS,CAMBS,ENGLAND.		Meharg, Andrew Alexander/F-8182-2014	Meharg, Andrew Alexander/0000-0003-2019-0449				BERTAZZI PA, 1991, SCI TOTAL ENVIRON, V106, P5, DOI 10.1016/0048-9697(91)90016-8; BUSER HR, 1985, ENVIRON HEALTH PERSP, V60, P259, DOI 10.2307/3429969; CATTABENI F, 1985, NATO C SERIES 1, V11; CHANG R, 1989, CHEMOSPHERE, V19, P481, DOI 10.1016/0045-6535(89)90355-X; CHRISTMANN W, 1990, CHEMOSPHERE, V19, P387; DAO MJ, 1992, J HAZARD MATER, V9, P61; FERNANDEZSALGUE.P, 1995, SCIENCE NEW YORK N Y, V0268; FUNCKE W, 1988, STAUB REINHALT LUFT, V48, P393; HARRAD SJ, 1992, SCI TOTAL ENVIRON, V126, P89, DOI 10.1016/0048-9697(92)90486-C; Hay Alastair, 1982, CHEM SCYTHE LESSONS; HORVATH A, 1995, ENVIRON SCI TECHNOL, V29, pA86, DOI 10.1021/es00002a003; HUTZINGER O, 1985, ENVIRON HEALTH PERSP, V60, P3, DOI 10.2307/3429939; JACOBUS EM, 1993, ENV TOXIC CHEM, V12, P1549; KOESTER CJ, 1992, ENVIRON SCI TECHNOL, V26, P1375, DOI 10.1021/es00031a015; MEHARG AA, 1994, TOXICOL ECOTOXICOL N, V1, P117; NARANG AS, 1991, CHEMOSPHERE, V22, P1029, DOI 10.1016/0045-6535(91)90304-V; PHANEUF D, 1995, ARCH ENVIRON CON TOX, V28, P145, DOI 10.1007/BF00217609; RAPPE C, 1991, BANBURY REPORT, V35; THEISEN J, 1989, CHEMOSPHERE, V19, P423, DOI 10.1016/0045-6535(89)90346-9; 1989, WHO INT PROGRAMME CH, V88; 1994, ACCIDENTS DO HAPPEN; 1995, ENVIRON SCI TECHNOL, V29, pA24	22	64	65	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					353	354		10.1038/375353a0	http://dx.doi.org/10.1038/375353a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760923				2022-12-01	WOS:A1995RB10100022
J	NOGALES, E; WOLF, SG; KHAN, IA; LUDUENA, RF; DOWNING, KH				NOGALES, E; WOLF, SG; KHAN, IA; LUDUENA, RF; DOWNING, KH			STRUCTURE OF TUBULIN AT 6.5 ANGSTROM AND LOCATION OF THE TAXOL-BINDING SITE	NATURE			English	Article							MICROTUBULE ASSEMBLY INVITRO; ZINC-INDUCED SHEETS; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; BETA-TUBULIN; GUANOSINE 5'-TRIPHOSPHATE; PURPLE MEMBRANE; LOW RESOLUTION; CROSS-LINKING; COLCHICINE	TUBULIN, the major component of microtubules, is a heterodimer of two chains, alpha and beta(1), both of relative molecular mass 50,000 (M(r) 50K) and sith 40-50% identity. The isotypic variety(2) and conformational flexibility of tubulin have so far made it impossible to obtain crystals for X-ray work(3). Structural knowledge of tubulin has been limited to about 20 Angstrom from X-ray diffraction of oriented microtubules(4), and from electron microscopy of microtubules and zinc-induced crystalline sheets in negative stain(5,6). The sheets consist of protofilaments similar to those in microtubules but associated in an antiparallel arrangement(7) and their two-dimensional character is ideal for high-resolution electron microscopy(8,9). Here we present a three-dimensional reconstruction of tubulin to 6.5 Angstrom resolution, obtained by electron crystallography of zinc-induced two-dimensional crystals of the protein, The alpha- and beta-subunits appear topologically similar, in agreement with their sequence homology(10). Several features can be defined in terms of secondary structure. An apparent alpha-helical portion, adjacent to both interdimer and inter-protofilament contacts, is tentatively attributed to a segment near the carboxy terminus of the protein. We can assign the alpha- and beta-subunits on the basis of projection studies of the binding of taxol*, which show one taxol site per tubulin heterodimer, in agreement with the known stoichiometry of taxol in microtubules(11). These studies indicate that taxol affects the interaction between protofilaments; to our knowledge, this is the first time that a ligand-binding site has been visualized in the tubulin molecule.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	NOGALES, E (corresponding author), LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720, USA.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; AMOS LA, 1974, MICROTUBULES, P1; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BURNS RG, 1993, MICROTUBULES, P3; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; COMBEAU C, 1994, BIOCHEMISTRY-US, V33, P6676, DOI 10.1021/bi00187a038; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DOWNING KH, 1991, SCIENCE, V251, P53, DOI 10.1126/science.1846047; DOWNING KH, 1992, J STRUCT BIOL, V109, P152, DOI 10.1016/1047-8477(92)90046-D; DOWNING KH, 1992, ULTRAMICROSCOPY, V46, P199, DOI 10.1016/0304-3991(92)90015-C; DYE RB, 1993, J BIOL CHEM, V288, P6847; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUSER JE, 1986, J CELL BIOL, V103, P2209, DOI 10.1083/jcb.103.6.2209; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KUHLBRANDT W, 1991, NATURE, V350, P130; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUMAR N, 1981, J BIOL CHEM, V250, P10435; LOBERT S, 1991, ARCH BIOCHEM BIOPHYS, V290, P93, DOI 10.1016/0003-9861(91)90595-A; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; LUDUENA RF, 1993, MOL BIOL CELL, V44, P445; MANDELKOW E, 1977, P NATL ACAD SCI USA, V74, P3370, DOI 10.1073/pnas.74.8.3370; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MARGOLIS RL, 1980, BIOCHEMISTRY-US, V19, P5550, DOI 10.1021/bi00565a014; NOGALES E, IN PRESS J STRUCT BI; PALANIVELU P, 1982, J BIOL CHEM, V257, P6311; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROWINSKY EK, 1993, CANCER SURV, V17, P283; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TAMM LK, 1979, J MOL BIOL, V130, P473, DOI 10.1016/0022-2836(79)90435-2; TRACHTENBERG S, 1987, J MOL BIOL, V195, P581, DOI 10.1016/0022-2836(87)90184-7; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; WOLF SG, 1994, J STRUCT BIOL, V111, P190	45	318	323	2	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					424	427		10.1038/375424a0	http://dx.doi.org/10.1038/375424a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760939				2022-12-01	WOS:A1995RB10100059
J	SCHROEDER, PL; FILLER, SJ; RAMIREZ, B; LAZARCHIK, DA; VAEZI, MF; RICHTER, JE				SCHROEDER, PL; FILLER, SJ; RAMIREZ, B; LAZARCHIK, DA; VAEZI, MF; RICHTER, JE			DENTAL EROSION AND ACID REFLUX DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						DENTAL ENAMEL; GASTROESOPHAGEAL REFLUX; DENTIN; GASTRIC ACID	GASTROESOPHAGEAL REFLUX; ANOREXIA-NERVOSA; HIATUS-HERNIA; BULIMIA; MANIFESTATIONS; COMPLICATIONS; ASSOCIATION; VOLUNTEERS; POPULATION; ENAMEL	Objective: To determine the relation between gastroesophageal reflux disease and dental erosion using ambulatory 24-hour esophageal pH testing. Design: Cross-sectional observational study. Setting: Tertiary referral center. Patients: The dental group consisted of 12 patients with idiopathic dental erosion who were identified by dentists and screened for gastroesophageal reflux disease using 24-hour pH testing. The gastroenterology group consisted of 30 patients who had 24-hour pH testing in the esophageal laboratory and who were referred for dental evaluation (10 did not have reflux, 10 had distal reflux, and 10 had proximal reflux). Measurements: 24-hour esophageal pH monitoring using a pH probe in the distal and proximal esophagus; Complete dental examination with particular attention to the presence and severity of dental erosion; plaque; gingival damage; and decayed, missing, and filled teeth. Analysis of saliva for pH, flow rates, buffering capacity, and calcium and phosphorus levels. Standardized questionnaire to ascertain possible causes of dental erosion and presence of reflux symptoms. Results: Ten of the 12 patients in the dental group (83% [95% Cl, 52% to 98%]) had gastroesophageal reflux on esophageal pH monitoring. Nine had distal and 7 had proximal reflux. Seven had reflux in the upright position only, 1 had reflux in the supine position only, and 2 had both upright and supine reflux. No saliva abnormalities were found. Ten patients had typical symptoms of gastroesophageal reflux, but dietary or mechanical problems that may have been causing dental erosion were not identified. In the gastroenterology group, upright reflux was seen in 5 of the 10 patients with distal reflux and in all 10 patients with proximal reflux. In addition, 40% of patients in the gastroenterology group (12 of 30) had dental erosion (4 of the 10 with distal reflux [40%], 7 of the 10 with proximal reflux [70%], and only 1 of the 10 without reflux [10%]; P = 0.02 for those with reflux compared with those without reflux). The cumulative dental erosion score correlated with proximal upright reflux when all 24 study patients with erosion were analyzed (r = 0.55 [P < 0.01]); this correlation was even stronger in the subgroup of 12 patients with abnormal amounts of proximal upright reflux (r = 0.84 [P = 0.001]). Conclusion: Dental erosion is a common finding in patients with gastroesophageal reflux disease and should be considered an atypical manifestation of this disease.	UNIV ALABAMA, DIV GASTROENTEROL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								Allan D N, 1969, Br Dent J, V126, P311; ASHER C, 1987, BRIT DENT J, V162, P384, DOI 10.1038/sj.bdj.4806141; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16; CATE HJT, 1968, BRIT J IND MED, V25, P249; CENTERWALL BS, 1986, AM J EPIDEMIOL, V123, P641, DOI 10.1093/oxfordjournals.aje.a114283; DAWES C, 1970, J DENT RES, V49, P1263, DOI 10.1177/00220345700490061501; DESCHNER WK, 1989, AM J GASTROENTEROL, V84, P1; DREWNOWSKI A, 1988, AM J PSYCHIAT, V145, P753; DUCOLONE A, 1987, AM REV RESPIR DIS, V135, P327; ECCLES JD, 1974, J DENT, V2, P153, DOI 10.1016/0300-5712(74)90044-X; ECCLES JD, 1978, LANCET, V2, P479; FRASER D, 1987, FUNDAMENTALS CLIN CH, P721; FRASER D, 1987, FUNDAMENTALS CLIN CH, P716; HELLSTROM I, 1977, SCAND J DENT RES, V85, P71; HOWDEN GF, 1971, BRIT DENT J, V131, P455, DOI 10.1038/sj.bdj.4802772; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; JACOB P, 1991, GASTROENTEROLOGY, V100, P305, DOI 10.1016/0016-5085(91)90196-R; JARVINEN V, 1988, ORAL SURG ORAL MED O, V65, P298, DOI 10.1016/0030-4220(88)90113-2; JARVINEN V, 1992, CARIES RES, V26, P391; JONES RRH, 1989, J DENT RES, V68, P1275, DOI 10.1177/00220345890680081201; KAHRILAS PJ, 1987, GASTROENTEROLOGY, V92, P466, DOI 10.1016/0016-5085(87)90143-0; KATZMAN MA, 1984, INT J EAT DISORDER, V3, P53; KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1; KRASSE B, 1985, CARIES RISK, P41; LEVINE RS, 1973, J DENT, V2, P85, DOI 10.1016/S0300-5712(73)80025-9; LOC J, 1963, ACTA ODONTOL SCAND, V21, P532; LUSSI A, 1991, COMMUNITY DENT ORAL, V19, P286, DOI 10.1111/j.1600-0528.1991.tb00169.x; LYNCH JB, 1947, BRIT J IND MED, V4, P84; MALCOLM D, 1961, BRIT J IND MED, V18, P63; Mandel I D, 1977, J Dent Guid Counc Handicap, V16, P3; MILOSEVIC A, 1989, BRIT DENT J, V167, P66, DOI 10.1038/sj.bdj.4806915; MYLLARNIEMI H, 1985, ANN SURG, V202, P159, DOI 10.1097/00000658-198508000-00004; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; PETERSEN PE, 1991, COMMUNITY DENT ORAL, V19, P104, DOI 10.1111/j.1600-0528.1991.tb00121.x; PINDBORG JJ, 1970, PATHOLOGY DENT HARD, P312; RICHTER JE, 1992, DIGEST DIS SCI, V37, P849, DOI 10.1007/BF01300382; RICHTER JE, 1987, DIGEST DIS SCI, V32, P583, DOI 10.1007/BF01296157; ROBERTS MW, 1987, J AM DENT ASSOC, V115, P407, DOI 10.14219/jada.archive.1987.0262; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968; SINCLAIR JW, 1991, AMBULATORY ESOPHAGEA, P23; SOGNNAES RF, 1972, J AM DENT ASSOC, V84, P571, DOI 10.14219/jada.archive.1972.0116; SREEBNY LM, 1988, DIAGNOSIS COMPENDIUM, V9, P569; SUDDICK RP, 1980, BIOL BASIS DENTAL CA, P132; TAYLOR G, 1992, J DENT CHILD, V59, P182; TUOMINEN M, 1989, SCAND J WORK ENV HEA, V15, P335, DOI 10.5271/sjweh.1841; WOLTGENS J H M, 1985, Clinical Preventive Dentistry, V7, P8; ZIPKIN I, 1949, J DENT RES, V28, P613, DOI 10.1177/00220345490280061301	48	115	121	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					809	815		10.7326/0003-4819-122-11-199506010-00001	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741364				2022-12-01	WOS:A1995RA13900001
J	SICHERI, F; YANG, DSC				SICHERI, F; YANG, DSC			ICE-BINDING STRUCTURE AND MECHANISM OF AN ANTIFREEZE PROTEIN FROM WINTER FLOUNDER	NATURE			English	Article							MOLECULAR-DYNAMICS; GLOBULAR-PROTEINS; ALPHA-HELICES; POLYPEPTIDE; ADSORPTION	ANTIFREEZE proteins provide fish with protection against the freezing effect of polar environments by binding to ice surfaces and inhibiting growth of ice crystals. We present the X-ray crystal structure at 1.5 Angstrom resolution of a lone alpha-helical antifreeze protein from winter flounder, which provides a detailed look at its ice-binding features. These consist of four repeated ice-binding motifs, the side chains of which are inherently rigid or restrained by pairwise side-chain interactions to form a flat binding surface. Elaborate amino- and carboxy-terminal cap structures are also present, which explain the protein's rich alpha-helical content in solution. We propose an ice-binding model that accounts for the binding specificity of the antifreeze protein along the [01 (1) over bar 2] axes of the {20 (2) over bar 1} ice planes(1).	MCMASTER UNIV,FAC HLTH SCI,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; VET ADM MED CTR,BIOCRYSTALLOG LAB,PITTSBURGH,PA 15240	McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Sicheri, Frank/F-8856-2013					ANANTHANARAYANA.VS, 1977, BIOCHEM BIOPH RES CO, V74, P685; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1987, INTEGRATION CONTROL, P299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN H, 1993, PROTEIN ENG, V6, P19, DOI 10.1093/protein/6.1.19; KNIGHT CA, 1993, BIOPHYS J, V64, P252, DOI 10.1016/S0006-3495(93)81361-4; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LAL M, 1993, J FARADAY DISCUSS, V95, P299; MADURA JD, 1994, J AM CHEM SOC, V116, P417, DOI 10.1021/ja00080a066; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; PIELA L, 1987, BIOPOLYMERS, V26, P1273, DOI 10.1002/bip.360260805; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; THANKI N, 1988, J MOL BIOL, V202, P637, DOI 10.1016/0022-2836(88)90292-6; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1986, J MOL BIOL, V189, P725, DOI 10.1016/0022-2836(86)90504-8; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	23	325	346	5	115	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					427	431		10.1038/375427a0	http://dx.doi.org/10.1038/375427a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760940	Green Submitted			2022-12-01	WOS:A1995RB10100060
J	STEWART, JD; BENKOVIC, SJ				STEWART, JD; BENKOVIC, SJ			TRANSITION-STATE STABILIZATION AS A MEASURE OF THE EFFICIENCY OF ANTIBODY CATALYSIS	NATURE			English	Article							HYDROLYSIS; SUBSTRATE	THERE are now about 60 examples of reactions that have been successfully catalysed by monoclonal antibodies(1-3). Not surprisingly, many of the early examples involved reactions that were already favoured kinetically (such as carbonate and ester hydrolysis). But it has since been shown that antibodies can also accelerate reaction pathways that are normally disfavoured kinetically (by at least a few kcal mol(-1))(4-7). Here we use transition-state theory to provide a quantitative analysis of the scope and limitations of antibody catalysis. We show that the observed rate accelerations can be predicted from the ratio of equilibrium binding constants of the reaction substrate and the transition-state analogue used to raise the antibody. This scheme allows us to rationalize the product selectivity displayed in antibody catalysis of disfavoured reactions, to predict the degree of rate acceleration that catalytic antibodies may ultimately afford, and to highlight some differences between the way that they and enzymes catalyse reactions.	PENN STATE UNIV,DEPT CHEM,UNIVERSITY PK,PA 16801	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	STEWART, JD (corresponding author), UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611, USA.							ASHLEY JA, 1993, J AM CHEM SOC, V115, P2515, DOI 10.1021/ja00059a061; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; CAMPBELL DA, 1994, J AM CHEM SOC, V116, P2165, DOI 10.1021/ja00084a075; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; COCHRAN AG, 1990, SCIENCE, V240, P781; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; GIBBS RA, 1992, J AM CHEM SOC, V114, P3528, DOI 10.1021/ja00035a057; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; IVERSON BL, 1990, J AM CHEM SOC, V112, P5320, DOI 10.1021/ja00169a044; IWABUCHI Y, 1994, J AM CHEM SOC, V116, P771, DOI 10.1021/ja00081a049; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JACOBS JW, 1991, BIO-TECHNOL, V9, P258, DOI 10.1038/nbt0391-258; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; MARTIN MT, 1991, BIOCHEMISTRY-US, V30, P9757, DOI 10.1021/bi00104a027; NA J, 1993, J AM CHEM SOC, V115, P8453, DOI 10.1021/ja00071a067; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; POSNER B, 1994, TRENDS BIOCHEM SCI, V19, P145, DOI 10.1016/0968-0004(94)90273-9; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; STEWART JD, 1994, P NATL ACAD SCI USA, V91, P7404, DOI 10.1073/pnas.91.16.7404; STEWART JD, 1993, ACCOUNTS CHEM RES, V26, P396, DOI 10.1021/ar00032a002; STEWART JD, 1993, CHEM SOC REV, V22, P213, DOI 10.1039/cs9932200213; STEWART JD, 1994, BIOCHEMISTRY-US, V33, P1991; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415	39	105	108	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					388	391		10.1038/375388a0	http://dx.doi.org/10.1038/375388a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760931				2022-12-01	WOS:A1995RB10100048
J	TANZI, RE				TANZI, RE			CLINICAL IMPLICATIONS OF BASIC RESEARCH - A PROMISING ANIMAL-MODEL OF ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TANZI, RE (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02129, USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454				GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290	3	10	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1512	1513		10.1056/NEJM199506013322212	http://dx.doi.org/10.1056/NEJM199506013322212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739692				2022-12-01	WOS:A1995RA14000012
J	TONG, MJ; ELFARRA, NS; REIKES, AR; CO, RL				TONG, MJ; ELFARRA, NS; REIKES, AR; CO, RL			CLINICAL OUTCOMES AFTER TRANSFUSION-ASSOCIATED HEPATITIS-C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; NON-B-HEPATITIS; POSTTRANSFUSION HEPATITIS; NON-A; FOLLOW-UP; VIRUS	Background. The extent of serious complications in people who have acquired chronic hepatitis C after a blood transfusion is unclear. Methods. We studied 131 patients with chronic posttransfusion hepatitis C who were referred to our center between February 1980 and June 1994. Eighty-two other patients were excluded because they had multiple transfusions, hemophilia, intravenous drug use, human immunodeficiency virus infection, hepatitis B infection, hemochromatosis, or alcoholic liver disease. Liver biopsies were performed in 101 patients; biopsies were not performed in the other 30 patients, all with signs of cirrhosis, because the results of coagulation tests were abnormal. Results. The mean age of the patients was 57 years (range, 21 to 81) at the time of our initial evaluation. The mean age at the time of the blood transfusion was 35 years (range, 1 to 76). The mean duration of follow-up after presentation to us was 3.9 years (range, 1 to 15). Eighty-eight of the patients (67.2 percent) initially had fatigue, and 89 (67.9 percent) had hepatomegaly. Twenty-seven patients (20.6 percent) initially had chronic hepatitis, 30 (22.9 percent) had chronic active hepatitis, 67 (51.1 percent) had cirrhosis, and 7 (5.3 percent) had hepatocellular carcinoma. Hepatocellular carcinoma developed in an additional seven patients an average of 36 months (range, 7 to 121) after the initial visit. During follow-up, 20 patients (15.3 percent) died: 8 from complications of cirrhosis (1 after a liver transplantation); 11 from hepatocellular carcinoma; and 1, with chronic active hepatitis, from pneumonia. Conclusions. in a group of patients seen at a referral center, chronic post-transfusion hepatitis C was a progressive disease and, in some patients, led to death from either liver failure or hepatocellular carcinoma.			TONG, MJ (corresponding author), HUNTINGTON MEM HOSP, CTR LIVER, 744 FAIRMOUNT AVE, PASADENA, CA 91105 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BOYER JL, 1976, GASTROENTEROLOGY, V70, P1161; CHIEN DY, 1993, J GASTROEN HEPATOL, V8, pS33; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1002/hep.1840140603; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; LUDWIG J, 1993, GASTROENTEROLOGY, V105, P274, DOI 10.1016/0016-5085(93)90037-D; MATTSSON L, 1988, LIVER, V8, P184; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; TONG MJ, 1994, WESTERN J MED, V160, P133; TONG MJ, 1987, HEPATOLOGY, V7, P713, DOI 10.1002/hep.1840070416; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9	13	1022	1054	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1463	1466		10.1056/NEJM199506013322202	http://dx.doi.org/10.1056/NEJM199506013322202			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739682				2022-12-01	WOS:A1995RA14000002
J	WEI, XQ; CHARLES, IG; SMITH, A; URE, J; FENG, CJ; HUANG, FP; XU, DM; MULLER, W; MONCADA, S; LIEW, FY				WEI, XQ; CHARLES, IG; SMITH, A; URE, J; FENG, CJ; HUANG, FP; XU, DM; MULLER, W; MONCADA, S; LIEW, FY			ALTERED IMMUNE-RESPONSES IN MICE LACKING INDUCIBLE NITRIC-OXIDE SYNTHASE	NATURE			English	Article							L-ARGININE; INFECTION; CYTOKINE	NITRIC oxide (NO) is important in many biological functions(1-5). It is generated from L-arginine by the enzyme NO synthase (NOS), The cytokine-inducible NOS (iNOS) is activated by several immunological stimuli, leading to the production of large quantities of NO which can be cytotoxic(6). To define the biological role of iNOS further, we generated iNOS mutant mice. These are viable, fertile and without evident histopathological abnormalities, However, in contrast to wild-type and heterozygous mice, which are highly resistant to the protozoa parasite Leishmania major infection, mutant mice are uniformly susceptible, The infected mutant mice developed a significantly stronger Th1 type of immune response than the wild-type or heterozygous mice, The mutant mice showed reduced nonspecific inflammatory response to carrageenin, and were resistant to lipopolysaccharide-induced mortality.	UNIV GLASGOW, DEPT IMMUNOL, GLASGOW G11 6NT, LANARK, SCOTLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND; UNIV EDINBURGH, CTR GENOME RES, GENE TARGETING LAB, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Glasgow; GlaxoSmithKline; Wellcome Research Laboratories; University of Edinburgh; University of Cologne			Xu, Damo/A-8212-2011; Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Smith, Austin/0000-0002-3029-4682	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; EFRON DT, 1991, SURGERY, V110, P327; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; HIBBS JB, 1990, INT CONGR SER, V897, P189; JAMES SL, 1990, PARASITOL TODAY, V6, P303, DOI 10.1016/0169-4758(90)90261-2; JENKINS DC, IN PRESS P NATN ACAD; LIEW FY, 1991, IMMUNOL TODAY, pA17; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRALAYI MD, 1994, INT IMMUN, V6, P931; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VOULDOUKIS I, IN PRESS P NATN ACAD; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; XU D, 1995, IMMUNOLOGY, V85, P1	21	1096	1136	3	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					408	411		10.1038/375408a0	http://dx.doi.org/10.1038/375408a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7539113				2022-12-01	WOS:A1995RB10100054
J	WHITE, N; COHEN, S				WHITE, N; COHEN, S			TRADEMARKS MUST NOT GO GENERIC	NATURE			English	Editorial Material											WHITE, N (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.							1995, NATURE, V373, P370; 1995, NATURE, V374, P208	2	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					432	432		10.1038/375432a0	http://dx.doi.org/10.1038/375432a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760941	Bronze			2022-12-01	WOS:A1995RB10100063
J	WONG, F; SNIDERMAN, K; LIU, P; ALLIDINA, Y; SHERMAN, M; BLENDIS, L				WONG, F; SNIDERMAN, K; LIU, P; ALLIDINA, Y; SHERMAN, M; BLENDIS, L			TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT - EFFECTS ON HEMODYNAMICS AND SODIUM HOMEOSTASIS IN CIRRHOSIS AND REFRACTORY ASCITES	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODYNAMICS; SODIUM; ASCITES; LIVER CIRRHOSIS; PORTOSYSTEMIC SHUNT, SURGICAL	PORTAL-HYPERTENSION; ELECTROCHEMICAL DETECTION; SYSTEMIC HEMODYNAMICS; RENAL SODIUM; NITRIC-OXIDE; TIPS; PLASMA; CATECHOLAMINES; RETENTION; RENIN	Objective: To assess the effects of transjugular intrahepatic portosystemic shunt (TIPS) on systemic and renal hemodynamics, neurohumoral factors, and sodium homeostasis in patients with cirrhosis and refractory ascites. Design: Prospective study with 1-year follow-up. Setting: Tertiary referral center and university-affiliated hospital. Patients: 7 patients with cirrhosis and refractory ascites had metabolic studies done while receiving a 22 mmol/d sodium, 1 L/d fluid diet. Intervention: TIPS insertion. Measurements: Urinary sodium excretion, systemic and renal hemodynamics, hormonal profile, and central blood volume were measured before, at day 1 after, and at 1 month after TIPS insertion. Results: Immediately after TIPS insertion, mean corrected sinusoid pressure decreased from 18.2 +/- 2.2 mm Hg to 7.7 +/- 1.3 mm Hg (P < 0.001); mean cardiac output increased from 6.83 +/- 0.68 L/min to 8.62 L/min (P = 0.005); and mean systemic Vascular resistance decreased from 1018 +/- 103 dyne.s.cm(-5) to 762 +/- 46 dyne.s.cm(-5) (P = 0.011). Mean plasma renin activity, serum aldosterone levels, and 24-hour urinary sodium excretion (5.8 +/- 0.7 mmol/d before TIPS insertion compared with 6.0 a 1.8 mmol/d 1 day after insertion) were unchanged; mean elevated plasma norepinephrine levels significantly increased. By 1 month after insertion, mean proximal tubular reabsorption of sodium had decreased, and this had led to a mean natriuresis of 15.1 +/- 3.1 mmol/d (P = 0.02 compared with baseline), which was associated with a decrease in plasma renin activity and aldosterone levels to within the normal range. Conclusions: Our results suggest that natriuresis associated with TIPS is delayed and occurs in the presence of increased systemic vasodilatation at 1 month after insertion and that TIPS insertion should not be done in any patients with refractory ascites without careful attention to cardiac and renal status. However, in carefully selected patients, TIPS is a safe and effective means of managing refractory ascites.	TORONTO HOSP, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								AZOULAY D, 1994, HEPATOLOGY, V19, P129, DOI 10.1016/0270-9139(94)90063-9; BOER WH, 1987, EUR J CLIN INVEST, V17, P442, DOI 10.1111/j.1365-2362.1987.tb01140.x; BOSCH J, 1980, GASTROENTEROLOGY, V78, P92; BRUN C, 1951, J LAB CLIN MED, V37, P955; BURCHELL AR, 1968, ANN SURG, V168, P655, DOI 10.1097/00000658-196810000-00012; CAMPBELL V, 1982, HEPATOLOGY, V2, P54; CHENG KH, 1994, EUR J GASTROEN HEPAT, V6, P749, DOI 10.1097/00042737-199408000-00020; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1002/hep.1840170125; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; FERRAL H, 1993, RADIOLOGY, V189, P795, DOI 10.1148/radiology.189.3.8234706; GOODMAN JM, 1992, CAN J CARDIOL, V8, P363; GORDON FD, 1994, GASTROENTEROLOGY, V106, pA900; HUONKER M, 1993, HEPATOLOGY, V18, pA281, DOI 10.1016/0270-9139(93)92647-I; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LANG F, 1991, HEPATOLOGY, V14, P590, DOI 10.1016/0270-9139(91)90043-U; LEVY M, 1987, AM J PHYSIOL, V253, pF664, DOI 10.1152/ajprenal.1987.253.4.F664; LOTTERER E, 1993, HEPATOLOGY, V18, pA102, DOI 10.1016/0270-9139(93)91938-O; MORALI GA, 1992, J HEPATOL, V16, P249, DOI 10.1016/S0168-8278(05)80128-X; PAK JM, 1994, J HEPATOL, V20, P825, DOI 10.1016/S0168-8278(05)80156-4; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POMIERLAYRARGUE G, 1993, HEPATOLOGY, V18, pA103; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RECTOR WG, 1990, HEPATOLOGY, V12, P455, DOI 10.1002/hep.1840120302; RECTOR WG, 1986, LIVER, V6, P221; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHROEDER ET, 1979, KIDNEY INT, V15, P54, DOI 10.1038/ki.1979.8; THOMAS SH, 1991, DIGEST DIS SCI, V36, P1243, DOI 10.1007/BF01307516; THOMSEN K, 1969, PFLUG ARCH EUR J PHY, V308, P180, DOI 10.1007/BF00587025; TOBE SW, 1993, AM J KIDNEY DIS, V21, P472, DOI 10.1016/S0272-6386(12)80392-1; TOMINAGA T, 1988, LIFE SCI, V42, P1861, DOI 10.1016/0024-3205(88)90025-2; TONG L, 1993, GASTROENTEROLOGY, V104, pA1009; WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204; WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009-8981(84)90162-1; WENSING G, 1990, HEPATOLOGY, V12, P13, DOI 10.1002/hep.1840120104; WONG F, 1993, HEPATOLOGY, V18, P519, DOI 10.1016/0270-9139(93)90350-V; WONG F, 1994, HEPATOLOGY, V20, P873, DOI 10.1002/hep.1840200415; WONG F, 1995, HEPATOLOGY, V21, P717; WONG F, 1994, HEPATOLOGY, V19, P312	41	181	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					816	822		10.7326/0003-4819-122-11-199506010-00002	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741365				2022-12-01	WOS:A1995RA13900002
J	ALMOND, N; KENT, K; CRANAGE, M; RUD, E; CLARKE, B; STOTT, EJ				ALMOND, N; KENT, K; CRANAGE, M; RUD, E; CLARKE, B; STOTT, EJ			PROTECTION BY ATTENUATED SIMIAN IMMUNODEFICIENCY VIRUS IN MACAQUES AGAINST CHALLENGE WITH VIRUS-INFECTED CELLS	LANCET			English	Note							SIV INFECTION; NEF GENE	A vaccine against AIDS will probably have to protect against challenge both by viable virus-infected cells and by cell-free virus. Eight cynomolgus macaques infected with attenuated simian immunodeficiency virus (SIV) were challenged (four each) with cell-free and cell-associated SIV, All were protected, whereas eight controls were all infected after challenge. These findings show that live-attenuated vaccine can confer protection against SIV in macaques, Extrapolation to human beings will require extensive evaluation of the safety of attenuated retroviruses. Alternatively, the mechanism of this potent protection must be understood and reproduced by less hazardous means.	CTR APPL MICROBIOL & RES,SALISBURY,WILTS,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; HLTH CANADA,LAB CTR DIS CONTROL,BUR HIV AIDS,OTTAWA,ON,CANADA	GlaxoSmithKline; Wellcome Research Laboratories; Health Canada	ALMOND, N (corresponding author), NATL INST BIOL STAND & CONTROLS,BLANCHE LANE S MIMMS,POTTERS BAR EN6 3QG,HERTS,ENGLAND.		Rud, Erling/P-5359-2016	Rud, Erling/0000-0001-8615-0277; Almond, Neil/0000-0001-6105-0616	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KENT K, 1995, AIDS RES HUM RETROV, V10, P189; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; MILLS KHG, 1992, J MED PRIMATOL, V21, P50; MITCHELL T, 1992, J VIROL, V66, P5696, DOI 10.1128/JVI.66.9.5696-5702.1992; ROSE J, 1995, J VIROL METHODS, V57, P229; RUD EW, 1994, J GEN VIROL, V75, P529, DOI 10.1099/0022-1317-75-3-529; SABIN AB, 1992, P NATL ACAD SCI USA, V89, P8852, DOI 10.1073/pnas.89.18.8852; STOTT EJ, 1991, 6EME C CENT GARD PAR, P261	10	211	213	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1342	1344		10.1016/S0140-6736(95)92540-6	http://dx.doi.org/10.1016/S0140-6736(95)92540-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752758				2022-12-01	WOS:A1995RA14800011
J	AOKI, K; KAJIURA, S; MATSUMOTO, Y; OGASAWARA, M; OKADA, S; YAGAMI, Y; GLEICHER, N				AOKI, K; KAJIURA, S; MATSUMOTO, Y; OGASAWARA, M; OKADA, S; YAGAMI, Y; GLEICHER, N			PRECONCEPTIONAL NATURAL-KILLER-CELL ACTIVITY AS A PREDICTOR OF MISCARRIAGE	LANCET			English	Note							PREGNANCY	There is no immunological test for the prospective identification of alloimmune causes of miscarriage. We investigated whether activity of natural killer cells was predictive of subsequent abortion in women who had had unexplained recurrent abortions and had received no treatment. 24 women with high preconceptional NK activity, defined as mean plus 1 SD of NK activity of 47 controls, had a significantly higher abortion rate in the next pregnancy than 44 women with normal levels of NK activity (71 vs 20%; relative risk 3.5; 95% CI 1.8-6.5), The preconceptional evaluation of NK activity in women with recurrent miscarriages may thus be predictive of the risk of pregnancy loss at the next conception,	CTR HUMAN REPROD,CHICAGO,IL; FDN REPROD MED,CHICAGO,IL		AOKI, K (corresponding author), NAGOYA CITY UNIV,SCH MED,DEPT OBSTET & GYNAECOL,NAGOYA,AICHI 467,JAPAN.							BULMER JN, 1991, HUM REPROD, V6, P791, DOI 10.1093/oxfordjournals.humrep.a137430; CLARK DA, 1994, CELL IMMUNOL, V154, P143, DOI 10.1006/cimm.1994.1064; COULAM CB, 1992, AM J OBSTET GYNECOL, V167, P1844, DOI 10.1016/0002-9378(92)91785-9; HIGUCHI K, 1995, AM J REPROD IMMUNOL, V33, P221, DOI 10.1111/j.1600-0897.1995.tb00888.x; KING A, 1990, CELL IMMUNOL, V129, P435, DOI 10.1016/0008-8749(90)90219-H; MAKIDA R, 1991, LANCET, V338, P579, DOI 10.1016/0140-6736(91)91153-L; TARTOF D, 1984, CLIN EXP IMMUNOL, V57, P502; TODER V, 1984, J CLIN LAB IMMUNOL, V14, P129; 1994, AM J REPROD IMMUNOL, V32, P55	9	262	271	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1340	1342		10.1016/S0140-6736(95)92539-2	http://dx.doi.org/10.1016/S0140-6736(95)92539-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752757				2022-12-01	WOS:A1995RA14800010
J	EVANS, MR				EVANS, MR			CHILDREN WHO MISS IMMUNIZATION - IMPLICATIONS FOR ELIMINATING MEASLES	BRITISH MEDICAL JOURNAL			English	Article											EVANS, MR (corresponding author), S GLAMORGAN HLTH AUTHOR,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				ERDMAN DD, 1994, J MED VIROL, V41, P44; MILLER E, 1994, BRIT MED J, V309, P1102, DOI 10.1136/bmj.309.6962.1102; RAMSAY N, 1994, COMMUN DIS REP CDR R, V4, P141; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; WHITE JM, 1994, COMMUN DIS REP CDR R, V4, P129	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1367	1368		10.1136/bmj.310.6991.1367	http://dx.doi.org/10.1136/bmj.310.6991.1367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787540	Green Published			2022-12-01	WOS:A1995RB00500023
J	FAIRWEATHERTAIT, SJ; FOX, TE; MALLILLIN, A				FAIRWEATHERTAIT, SJ; FOX, TE; MALLILLIN, A			BALTI CURRIES AND IRON	BRITISH MEDICAL JOURNAL			English	Article							FOOD				FAIRWEATHERTAIT, SJ (corresponding author), INST FOOD RES,NORWICH LAB,NORWICH NR4 7UA,NORFOLK,ENGLAND.		Fairweather-Tait, Susan J/K-4251-2012	Fairweather-Tait, Susan/0000-0002-1413-5569				BRITTIN HC, 1986, J AM DIET ASSOC, V86, P897; FAIRWEATHERTAIT SJ, 1990, BRIT J NUTR, V64, P547, DOI 10.1079/BJN19900054; Gregory F., 1990, DIETARY NUTR SURVEY; MARTINEZ FE, 1986, NUTR RES, V6, P421, DOI 10.1016/S0271-5317(86)80183-X	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1368	1368		10.1136/bmj.310.6991.1368	http://dx.doi.org/10.1136/bmj.310.6991.1368			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787541	Green Published			2022-12-01	WOS:A1995RB00500024
J	HOPTON, JL; DLUGOLECKA, M				HOPTON, JL; DLUGOLECKA, M			NEED AND DEMAND FOR PRIMARY HEALTH-CARE - A COMPARATIVE SURVEY APPROACH	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; RESOURCE-ALLOCATION; PUBLIC-HEALTH; RAWP; NHS	Objective-To develop general practice profiles of needs and demand for primary health care. Design-Postal survey of a stratified random sample of 3478 people registered with five general practices. Data from a single practice were compared with data from the remaining four to identify areas of comparative need. Setting-Five general practices in Lothian. Main outcome measures-Differences between the single practice and the comparison practices in terms of social and economic circumstances, limiting long term illness, specific ongoing conditions, minor illness or symptoms, psychosocial problems, discussion of lifestyle, associated use of services. Results-Respondents from the single practice reported higher rates than those in the four comparison practices of ongoing mental health and respiratory problems and use of antidepressants, tranquillisers, or sleeping tablets. Although rates of limiting long term illness and other specific ongoing conditions were comparable, the rates of minor illness or symptoms and psychosocial difficulties were higher in the single practice. Respondents from the single practice were more likely to consult frequently, to have contacted the practice out of normal working hours, and to have discussed psychosocial difficulties with a general practitioner. For any specific ongoing condition or ''minor'' illness, respondents from the single practice were no more likely to consult. Conclusions-A comparative survey approach is a useful method of developing an understanding of patterns of need and demand among general practice populations. It has the potential to inform planning within individual general practices and the process of commissioning among general practices within a given area.	LOTHIAN HLTH,EDINBURGH,MIDLOTHIAN,SCOTLAND		HOPTON, JL (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ABRAMSON J H, 1988, Public Health Reviews, V16, P35; ASHTON J, 1990, PUBLIC HEALTH, V104, P387, DOI 10.1016/S0033-3506(05)80082-4; BLAXTER M, 1985, Q J SOC AFF, V1, P131; Bradshaw J, 1972, PROBLEMS PROGR MED C, P71; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; DONABEDIAN A, 1973, ASPECTS MED CARE ADM; GAFFY JP, 1994, BRIT MED J, V308, P391; HAM C, 1992, 30 U BIRM HLTH SERV; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; HOPTON JL, 1992, BRIT J GEN PRACT, V42, P236; Howie J G, 1972, J R Coll Gen Pract, V22, P310; HOWIE JGR, IN PRESS BR J GEN PR; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KEVELL PT, 1990, SOC SCI MED, V30, P701; KNOX EG, 1978, J EPIDEMIOL COMMUN H, V32, P3, DOI 10.1136/jech.32.1.3; MAGI M, 1981, SOCIOLOGY HLTH ILLNE, V25, P49; MAYS N, 1989, COMMUNITY MED, V11, P173; MAYS N, 1987, BRIT MED J, V295, P703, DOI 10.1136/bmj.295.6600.703; MCDOWELL I, 1976, INT J EPIDEMIOL, V6, P247; MORLEY V, 1993, BMJ-BRIT MED J, V306, P112, DOI 10.1136/bmj.306.6870.112; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; STONE DH, 1987, J ROY COLL GEN PRACT, V37, P218; TOLLMAN S, 1991, SOC SCI MED, V32, P633, DOI 10.1016/0277-9536(91)90142-Y; TUDORHART J, 1984, BRIT MED J, V288, P1670; 1992, LOCAL VOICES; 1989, 1990 CONTRACT GENERA	28	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1369	1373		10.1136/bmj.310.6991.1369	http://dx.doi.org/10.1136/bmj.310.6991.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB005	7787542	Green Published			2022-12-01	WOS:A1995RB00500025
J	MCKENDRY, RJR				MCKENDRY, RJR			IS RHEUMATOID-ARTHRITIS CAUSED BY AN INFECTION	LANCET			English	Editorial Material							MINOCYCLINE; TETRACYCLINES; INHIBITION				MCKENDRY, RJR (corresponding author), UNIV OTTAWA,FAC MED,RHEUMAT DIS UNIT,OTTAWA,ON,CANADA.							BAGNALL A W, 1957, Can Med Assoc J, V77, P182; BREEDVELD FC, 1990, J RHEUMATOL, V17, P43; ENNIS RS, 1972, ARTHRITIS RHEUM, V15, P108; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; Forestier J, 1935, J LAB CLIN MED, V20, P827; FREEDMAN A, 1952, LANCET, V2, P231; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; KLOPPENBURG M, 1995, J RHEUMATOL, V22, P611; KLOPPENBURG M, 1992, BR J RHEUMATOL, V31, pS41; Lande K, 1927, MUNCH MED WSCHR, V74, P1132; LANGEVITZ P, 1992, J RHEUMATOL, V19, P1502; MATSUURA T, 1992, LANCET, V340, P1553, DOI 10.1016/0140-6736(92)92810-3; NIP LH, 1993, J PERIODONTAL RES, V28, P379, DOI 10.1111/j.1600-0765.1993.tb01082.x; OLSER W, 1920, PRINCIPLES PRACTICE, P1126; PRUZANSKI W, 1992, BIOCHEM PHARMACOL, V44, P1165, DOI 10.1016/0006-2952(92)90381-R; STANDFORD HC, 1990, MANDELL DOUGLAS BENN, P306; TAYLORROBINSON D, 1992, LANCET, V340, P81, DOI 10.1016/0140-6736(92)90399-N; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001	19	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1319	1320		10.1016/S0140-6736(95)92533-3	http://dx.doi.org/10.1016/S0140-6736(95)92533-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752751				2022-12-01	WOS:A1995RA14800004
J	RADY, PL; YEN, A; ROLLEFSON, JL; ORENGO, I; BRUCE, S; HUGHES, TK; TYRING, SK				RADY, PL; YEN, A; ROLLEFSON, JL; ORENGO, I; BRUCE, S; HUGHES, TK; TYRING, SK			HERPESVIRUS-LIKE DNA-SEQUENCES IN NON-KAPOSIS SARCOMA SKIN-LESIONS OF TRANSPLANT PATIENTS	LANCET			English	Note								Herpesvirus-like DNA sequences (KSHV) have been reported to be associated with various forms of Kaposi's sarcoma (KS). To determine if KSHV was associated with other proliferative skin lesions from non-AIDS immunocompromised patients, 33 shin lesions (basal cell carcinomas, squamous cell carcinomas, actinic keratoses, verruca vulgaris, atypical squamous proliferations, and seborrhoeic keratosis) from 4 organ-transplant patients receiving immunosuppressive therapy were tested for KSHV by PCR. KSHV sequences were detected in 82% of these skin lesions. Our results suggest that KSHV is associated with lesions other than KS in non-AIDS immunocompromised patients, and may also be involved in the pathogenesis of the various forms of proliferative skin lesions from organ-transplant patients.	UNIV TEXAS,MED BRANCH,DEPT IMMUNOL MICROBIOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine			RADY, PETER/AAA-4481-2021					Brash DE, 1991, P NATL ACAD SCI USA, V101, P24; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; HUANG YQ, 1995, LANCET, V45, P759; MCGREGOR JM, 1994, J AM ACAD DERMATOL, V30, P701, DOI 10.1016/S0190-9622(08)81498-3; RADY P, 1992, CANCER RES, V52, P3804; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	9	201	206	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1339	1340						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752756				2022-12-01	WOS:A1995RA14800009
J	TONKIN, SL; DAVIS, SL; GUNN, TR				TONKIN, SL; DAVIS, SL; GUNN, TR			NASAL ROUTE FOR INFANT RESUSCITATION BY MOTHERS	LANCET			English	Article							AIRWAY	In infants under 6 months of age air normally enters the trachea by the nose because the tongue fills the oral cavity, and the oral route is open only when the infant is making muscular efforts such as crying or gasping. The present recommendation for infant resuscitation is for the resuscitator's mouth to cover the mouth and nose of the baby. We set out to test whether this recommendation is feasible. We measured the dimensions of the faces of 28 babies aged between 2 and 4 months (the age when resuscitation is most often needed) and of the mouths of 25 of their mothers. Only 2 mothers would have been able to cover with their mouths the nose and closed mouth of 2 babies (not their own). The mannequins often used to teach adults to resuscitate infants are misleading because they present a wide open mouth, thus implying that that is the preferred route. We recommend that the nasal route of air entry be taught to parents for resuscitation of babies who have stopped breathing.	UNIV AUCKLAND,AUCKLAND,NEW ZEALAND	University of Auckland	TONKIN, SL (corresponding author), NEW ZEALAND COT DEATH ASSOC,POB 28-177,AUCKLAND,NEW ZEALAND.							GUNN TR, 1989, PEDIATRICS, V84, P73; SIEBERT J R, 1991, Pediatric Pathology, V11, P813; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1988, NEW ZEAL MED J, V101, P261; WILSON SL, 1980, J APPL PHYSIOL, V48, P500, DOI 10.1152/jappl.1980.48.3.500; 1992, JAMA-J AM MED ASSOC, V268, P2184; 1994, PUBLIC HLTH COMMISSI	7	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1353	1354		10.1016/S0140-6736(95)92543-0	http://dx.doi.org/10.1016/S0140-6736(95)92543-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752760				2022-12-01	WOS:A1995RA14800014
J	WESSELY, S; CHALDER, T; HIRSCH, S; PAWLIKOWSKA, T; WALLACE, P; WRIGHT, DJM				WESSELY, S; CHALDER, T; HIRSCH, S; PAWLIKOWSKA, T; WALLACE, P; WRIGHT, DJM			POSTINFECTIOUS FATIGUE - PROSPECTIVE COHORT STUDY IN PRIMARY-CARE	LANCET			English	Article							POSTVIRAL FATIGUE; VIRUS; POPULATION; SYMPTOMS; ANTIBODY; SIGNS	The idea that chronic fatigue has an infectious origin has become popular, but the main evidence for such an association has come from retrospective case-control studies, which are subject to ascertainment bias. We report a prospective study of the outcome of clinically diagnosed infections in patients presenting to UK general practitioners. Questionnaires assessing fatigue and psychiatric morbidity were sent to all patients aged 18-45 years in the study practices. The prevalence of chronic fatigue and chronic fatigue syndrome was then ascertained among 1199 people aged 18-45 who presented to the general practitioners with symptomatic infections and in 1167 people who attended the surgeries for other reasons, 84% were followed up at 6 months. 9.9% of cases and 11.7% of controls reported chronic fatigue (odds ratio 1.0 [95% CI 0.6-1.1]). There were no differences in the proportions who met various criteria for chronic fatigue syndrome. No effect of infection was noted when we excluded subjects who reported fatigue or psychological morbidity at the baseline screening. The strongest independent predictors of postinfectious fatigue were fatigue assessed before presentation with clinical infection (3.0 [1.9-4.7]) and psychological distress before presentation (1.8 [1.2-2.9]) and at presentation with the acute infection (1.8 [1.1-2.8]). There was no effect of sex or social class. Our study shows no evidence that common infective episodes in primary care are related to the onset of chronic fatigue or chronic fatigue syndrome.	INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND; CHARING CROSS HOSP,SCH MED,DEPT PSYCHIAT,LONDON,ENGLAND; CHARING CROSS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND; THE SURGERY,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE,LONDON,ENGLAND	University of London; King's College London; Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	WESSELY, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PSYCHOL MED,DENMARK HILL,LONDON SE5 9RS,ENGLAND.		Wessely, Simon C/A-8713-2008; Chalder, Trudie/A-5717-2011	Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BUTLER S, 1961, J NEUROL NEUROSUR PS, V54, P153; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CHALDER T, 1990, THESIS CITY U LONDON; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; Cox B.D., 1987, HLTH LIFESTYLE SURVE; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOLDENBERG D L, 1989, Journal of Rheumatology, V16, P91; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HELLINGER WC, 1988, JAMA-J AM MED ASSOC, V260, P971; Hinds G. M. E., 1993, P R COLL PHYSICIANS, V23, P10; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; IMBODEN JB, 1961, ARCH INTERN MED, V108, P393, DOI 10.1001/archinte.1961.03620090065008; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; POWELL R, 1990, J PSYCHOSOM RES, V34, P665, DOI 10.1016/0022-3999(90)90111-G; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; Ware J. E., 1992, MEASURING FUNCTIONIN, P277; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1991, BRIT MED BULL, V47, P919, DOI 10.1093/oxfordjournals.bmb.a072521; WHITE P, IN PRESS PSYCHOL MED; WITTENBORN J, 1979, ARCH GEN PSYCHIAT, V84, P118; [No title captured]	29	140	140	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1333	1338		10.1016/S0140-6736(95)92537-6	http://dx.doi.org/10.1016/S0140-6736(95)92537-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752755				2022-12-01	WOS:A1995RA14800008
J	CHEN, JQ; DEVIVO, M; DINGUS, J; HARRY, A; LI, JR; SUI, JL; CARTY, DJ; BLANK, JL; EXTON, JH; STOFFEL, RH; INGLESE, J; LEFKOWITZ, RJ; LOGOTHETIS, DE; HILDEBRANDT, JD; IYENGAR, R				CHEN, JQ; DEVIVO, M; DINGUS, J; HARRY, A; LI, JR; SUI, JL; CARTY, DJ; BLANK, JL; EXTON, JH; STOFFEL, RH; INGLESE, J; LEFKOWITZ, RJ; LOGOTHETIS, DE; HILDEBRANDT, JD; IYENGAR, R			A REGION OF ADENYLYL-CYCLASE-2 CRITICAL FOR REGULATION BY G-PROTEIN BETA-GAMMA-SUBUNITS	SCIENCE			English	Article							MUSCARINIC K+-CHANNEL; ALPHA-SUBUNIT; BINDING; SITE; STIMULATION; ACTIVATION; CLONING; BRAIN	Receptor-mediated activation of heterotrimeric guanine nucleotide-binding proteins (G proteins) results in the dissociation of alpha from beta gamma subunits, thereby allowing both to regulate effecters. Little is known about the regions of effecters required for recognition of G beta gamma. A peptide encoding residues 956 to 982 of adenylyl cyclase 2 specifically blocked G beta gamma stimulation of adenylyl cyclase 2, phospholipase C-beta 3, potassium channels, and beta-adrenergic receptor kinase as well as inhibition of calmodulin-stimulated adenylyl cyclases, but had no effect on interactions between G beta gamma and G alpha(o). Substitutions in this peptide identified a functionally important motif, Gln-X-X-G lu-Arg, that is also conserved in regions of potassium channels and beta-adrenergic receptor kinases that participate in G beta gamma interactions, Thus, the region defined by residues 956 to 982 of adenylyl cyclase 2 may contain determinants important for receiving signals from G beta gamma.	CUNY,MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL,CHARLESTON,SC 29425; CUNY,MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL,NASHVILLE,TN 37232; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Medical University of South Carolina; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021		NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-37219, DK-38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, R01DK037219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC J, 1991, J BIOL CHEM, V261, P14939; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BLANK JL, 1994, METHOD ENZYMOL, V238, P237; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PREMONT RT, 1993, ENDOCRINOLOGY, V131, P2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9808; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON PA, 1994, J BIOL CHEM, V269, P28893	33	221	228	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1166	1169		10.1126/science.7761832	http://dx.doi.org/10.1126/science.7761832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761832				2022-12-01	WOS:A1995RA60400034
J	DORIT, RL; AKASHI, H; GILBERT, W				DORIT, RL; AKASHI, H; GILBERT, W			ABSENCE OF POLYMORPHISM AT THE ZFY LOCUS ON THE HUMAN Y-CHROMOSOME	SCIENCE			English	Article							TESTIS-DETERMINING FACTOR; HUMAN MITOCHONDRIAL-DNA; GENE-CLUSTER; SEQUENCES; POPULATIONS; HAPLOTYPES; EVOLUTION; PATTERNS; PROTEIN; TISSUES	DNA polymorphism in the Y chromosome, examined at a 729-base pair intron located immediately upstream of the ZFY zinc-finger exon, revealed no sequence Variation in a worldwide sample of 38 human males. This finding cannot be explained by global constraint on the intron sequence, because interspecific comparisons with other nonhuman primates revealed phylogenetically informative sequence changes. The invariance likely results from either a recent selective sweep, a recent origin for modern Homo sapiens, recurrent male population bottlenecks, or historically small effective male population sizes. A coalescence model predicts an expected time to a most recent common ancestral male lineage of 270,000 years (95 percent confidence limits: 0 to 800,000 years).	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637; HARVARD UNIV,CAMBRIDGE,MA 02138	University of Chicago; Harvard University	DORIT, RL (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037997] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONARAKIS SE, 1988, HUM GENET, V80, P265, DOI 10.1007/BF01790095; AVRAMOPOULOS D, 1993, GENOMICS, V15, P98, DOI 10.1006/geno.1993.1015; AYALA FJ, 1994, P NATLA CAD SCI US, V91, P6786; BERRY AJ, 1991, GENETICS, V129, P1111; CHAKRAVARTI A, 1986, P NATL ACAD SCI USA, V83, P1045, DOI 10.1073/pnas.83.4.1045; CHAKRAVARTI A, 1984, P NATL ACAD SCI-BIOL, V81, P6085, DOI 10.1073/pnas.81.19.6085; CHAKRAVARTI A, 1981, AM J HUM GENET, V33, pA134; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; FRAYER DW, 1993, AM ANTHROPOL, V95, P14, DOI 10.1525/aa.1993.95.1.02a00020; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; HASEGAWA M, 1989, J HUM EVOL, V18, P461, DOI 10.1016/0047-2484(89)90075-4; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HUDSON RR, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P23; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KREITMAN M, 1991, GENETICS, V127, P565; LAU YFC, 1989, AM J HUM GENET, V45, P942; LI WH, 1991, GENETICS, V129, P513; LUCOTTE G, 1985, NUCLEIC ACIDS RES, V13, P8285, DOI 10.1093/nar/13.22.8285; LUCOTTE G, 1988, HUMAN REVOLUTION BEH, P39; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; MATTESON KJ, 1985, HUM GENET, V69, P263, DOI 10.1007/BF00293037; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; NAGAMINE CM, 1990, GENE DEV, V4, P63, DOI 10.1101/gad.4.1.63; NGO KY, 1986, AM J HUM GENET, V38, P407; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; ROEWER L, 1992, HUM GENET, V89, P389; SCHENIDERGADICK.A, 1989, CELL, V57, P1247; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SPRUDLE AB, 1991, AM J HUM GENET, V50, P107; SPURDLE AB, 1994, AM J HUM GENET, V54, P319; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; SU H, 1992, MOL REPROD DEV, V33, P252, DOI 10.1002/mrd.1080330304; TORRONI A, 1990, ANN HUM GENET, V54, P287; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62	37	168	171	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1183	1185		10.1126/science.7761836	http://dx.doi.org/10.1126/science.7761836			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761836				2022-12-01	WOS:A1995RA60400039
J	HINTON, GE; DAYAN, P; FREY, BJ; NEAL, RM				HINTON, GE; DAYAN, P; FREY, BJ; NEAL, RM			THE WAKE-SLEEP ALGORITHM FOR UNSUPERVISED NEURAL NETWORKS	SCIENCE			English	Article								An unsupervised learning algorithm for a multilayer network of stochastic neurons is described. Bottom-up ''recognition'' connections convert the input into representations in successive hidden layers, and top-down ''generative'' connections reconstruct the representation in one layer from the representation in the layer above. In the ''wake'' phase, neurons are driven by recognition connections, and generative connections are adapted to increase the probability that they would reconstruct the correct activity vector in the layer below. In the ''sleep'' phase, neurons are driven by generative connections, and recognition connections are adapted to increase the probability that they would produce the correct activity vector in the layer above.			HINTON, GE (corresponding author), UNIV TORONTO, DEPT COMP SCI, 6 KINGS COLL RD, TORONTO, ON M5S 1A4, CANADA.			Dayan, Peter/0000-0003-3476-1839				Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; CARPENTER GA, 1987, COMPUT VISION GRAPH, V37, P54, DOI 10.1016/S0734-189X(87)80014-2; DAYAN P, IN PRESS NEURAL COMP; GRENANDER U, 1976, LECTURES PATTERN THE; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; Hinton G., 1994, ADV NEURAL INFORM PR, V6, P3; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; KAWATO M, 1993, NETWORK-COMP NEURAL, V4, P415, DOI 10.1088/0954-898X/4/4/001; MUMFORD D, 1994, LARGE SCALE NEURONAL, P125; RISSANEN J, 1989, STOCHASTIC COMPLEXIT; ULLMAN S, 1994, LARGE SCALE THEORIES, P257	11	518	570	2	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1158	1161		10.1126/science.7761831	http://dx.doi.org/10.1126/science.7761831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761831				2022-12-01	WOS:A1995RA60400031
J	KANG, CH; CHAN, R; BERGER, I; LOCKSHIN, C; GREEN, L; GOLD, L; RICH, A				KANG, CH; CHAN, R; BERGER, I; LOCKSHIN, C; GREEN, L; GOLD, L; RICH, A			CRYSTAL-STRUCTURE OF THE T4 REGA TRANSLATIONAL REGULATOR PROTEIN AT 1.9-ANGSTROM RESOLUTION	SCIENCE			English	Article							BACTERIOPHAGE-T4; REPRESSOR; BINDING	The translational regulator protein regA is encoded by the T4 bacteriophage and binds to a region of messenger RNA (mRNA) that includes the initiator codon, RegA is unusual in that it represses the translation of about 35 early T4 mRNAs but does not affect nearly 200 other mRNAs. The crystal structure of regA was determined at 1.9 Angstrom resolution; the protein was shown to have an alpha-helical core and two regions with antiparallel beta sheets. One of these beta sheets has four antiparallel strands and has some sequence homology to RNP-1 and RNP-2, which are believed to be RNA-binding motifs and are found in a number of known RNA-binding proteins. Structurally guided mutants may help to uncover the basis for this variety of RNA interaction.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HANNOVER MED SCH,DEPT BIOPHYS CHEM,D-30623 HANNOVER,GERMANY; NEXAGEN INC,BOULDER,CO 80302; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80302	Massachusetts Institute of Technology (MIT); Hannover Medical School; University of Colorado System; University of Colorado Boulder				Berger, Imre/0000-0001-7518-9045				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, XPLOR; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAVARELLI J, 1991, NATURE, V352, P181; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLER ES, 1985, J BIOL CHEM, V260, P3053; MILLER ES, 1994, MOL BIOL BACTERIOP T, V4, P193; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; STEIGMANN W, 1982, PROTEIN PACKAGE CRYS; TROJANOWSKA M, 1984, NUCLEIC ACIDS RES, V12, P5979, DOI 10.1093/nar/12.15.5979; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WEBSTERKR, 1992, J BIOL CHEM, V267, P26097; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	21	21	22	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1170	1173		10.1126/science.7761833	http://dx.doi.org/10.1126/science.7761833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761833				2022-12-01	WOS:A1995RA60400035
J	KATZ, JD; BENOIST, C; MATHIS, D				KATZ, JD; BENOIST, C; MATHIS, D			T-HELPER CELL SUBSETS IN INSULIN-DEPENDENT DIABETES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NOD MICE; INTERFERON-GAMMA; LEISHMANIA-MAJOR; TRANSGENIC MICE; CD4+; ANTIBODY; RECEPTOR; INTERLEUKIN-4; DESTRUCTION	It has been proposed that the development of insulin-dependent diabetes is controlled by the T helper 1 (T(H)1) versus T(H)2 phenotype of autoreactive T-H cells: T(H)1 cells would promote diabetes, whereas, T(H)2 cells would actually protect from disease. This proposition was tested by establishing cultures of T(H)1 and T(H)2 cells that express and identical diabetogenic T cell receptor and comparing their ability to initiate disease in neonatal nonobese diabetic mice. T(H)1-like cells actively promoted diabetes; T(H)2-like cells invaded the islets but did not provoke disease-neither did they provide substantial protection.	UNIV STRASBOURG 1, INST GENET & BIOL MOLEC & CELLULAIRE, CNRS, INSERM, F-67404 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Katz, Jonathan/0000-0002-9864-2268				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ALZONA M, 1994, J IMMUNOL, V153, P2861; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BRADLEY BJ, 1992, DIABETES, V41, P1603, DOI 10.2337/diabetes.41.12.1603; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DARDENNE M, 1989, EUR J IMMUNOL, V19, P889, DOI 10.1002/eji.1830190516; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; DUNCAN DD, 1994, EUR J IMMUNOL, V24, P2506, DOI 10.1002/eji.1830241037; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303; HARADA M, 1986, EXP ANIM TOKYO, V35, P501, DOI 10.1538/expanim1978.35.4_501; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, INT IMMUNOL, V5, P371; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KATZ JE, UNPUB; KOIKE T, 1987, DIABETES, V36, P539, DOI 10.2337/diabetes.36.4.539; LAGOO AS, 1994, EUR J IMMUNOL, V24, P3087, DOI 10.1002/eji.1830241226; LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241; LEE MS, 1994, J CLIN INVEST, V93, P1332, DOI 10.1172/JCI117092; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MAKINO S, 1986, EXP ANIM TOKYO, V35, P495, DOI 10.1538/expanim1978.35.4_495; MILLER BJ, 1988, J IMMUNOL, V140, P52; MIYAZAKI A, 1985, CLIN EXP IMMUNOL, V60, P622; MORI Y, 1986, DIABETOLOGIA, V29, P244, DOI 10.1007/BF00454884; MORITANI M, 1994, INT IMMUNOL, V6, P1927, DOI 10.1093/intimm/6.12.1927; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NANDA NK, 1994, INT IMMUNOL, V6, P731, DOI 10.1093/intimm/6.5.731; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PUKEL C, 1988, DIABETES, V37, P133, DOI 10.2337/diabetes.37.1.133; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHMITT E, 1994, EUR J IMMUNOL, V24, P343, DOI 10.1002/eji.1830240211; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SCOTT P, 1993, CURR OPIN IMMUNOL, V5, P391, DOI 10.1016/0952-7915(93)90058-Z; SEDER RA, 1995, J EXP MED, V181, P5, DOI 10.1084/jem.181.1.5; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEMPEP, 1991, EUR J IMMUNOL, V21, P1663; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; VOLLMER S, 1994, EUR J IMMUNOL, V24, P2377, DOI 10.1002/eji.1830241018; WANG Y, 1991, P NATL ACAD SCI USA, V88, P527, DOI 10.1073/pnas.88.2.527; WOGENSEN L, 1994, J EXP MED, V179, P1379, DOI 10.1084/jem.179.4.1379	60	523	544	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1185	1188		10.1126/science.7761837	http://dx.doi.org/10.1126/science.7761837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761837				2022-12-01	WOS:A1995RA60400040
J	KAUFFMANNZEH, A; THOMAS, GMH; BALL, A; PROSSER, S; CUNNINGHAM, E; COCKCROFT, S; HSUAN, JJ				KAUFFMANNZEH, A; THOMAS, GMH; BALL, A; PROSSER, S; CUNNINGHAM, E; COCKCROFT, S; HSUAN, JJ			REQUIREMENT FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN EPIDERMAL GROWTH-FACTOR SIGNALING	SCIENCE			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; EGF RECEPTOR; A431 CELLS; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANES; BINDING-SITE; BOVINE BRAIN; KINASE	Stimulation of phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis is a widespread mechanism for receptor-mediated signaling in eukaryotes. Cytosolic phosphatidylinositol transfer protein (PITP) is necessary for guanosine triphosphate (GTP)-dependent hydrolysis of PIP2 by phospholipase C-beta (PLC-beta), but the role of PITP is unclear. Stimulation of phospholipase C-gamma (PLC-gamma) in A431 human epidermoid carcinoma cells treated with epidermal growth factor (EGF) required PITP. Stimulation of PI-4 kinase in cells treated with EGF also required PITP. Coprecipitation studies revealed an EGF-dependent association of PITP with the EGF receptor, with PI-4 kinase, and with PLC-gamma.	UCL, SCH MED, LUDWIG INST CANC RES, PROT BIOCHEM GRP, LONDON W1P 8BT, ENGLAND; UCL, DEPT PHYSIOL, LONDON WC1E 6JJ, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London			Hsuan, Justin/C-8825-2009; Cockcroft, Shamshad/F-9480-2011	Hsuan, Justin/0000-0001-6083-7564; Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Cunningham E. S., UNPUB; DOWNES CP, 1993, CURR BIOL, V3, P794; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KAUFFMANNZEH A, UNPUB; KIM JW, 1990, J BIOL CHEM, V265, P3940; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHERMOLY MJ, 1983, BRAIN RES, V268, P197, DOI 10.1016/0006-8993(83)90410-9; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1992, J BIOL CHEM, V267, P8672; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VANPARIDON PA, 1988, BIOCHIM BIOPHYS ACTA, V943, P76, DOI 10.1016/0005-2736(88)90348-3; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.bi.60.070191.000445	40	149	157	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1188	1190		10.1126/science.7761838	http://dx.doi.org/10.1126/science.7761838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761838				2022-12-01	WOS:A1995RA60400041
J	KAVANAUGH, WM; TURCK, CW; WILLIAMS, LT				KAVANAUGH, WM; TURCK, CW; WILLIAMS, LT			PTB DOMAIN BINDING TO SIGNALING PROTEINS THROUGH A SEQUENCE MOTIF CONTAINING PHOSPHOTYROSINE	SCIENCE			English	Article							SRC SH2 DOMAIN; RECEPTOR; KINASE; AUTOPHOSPHORYLATION; IDENTIFICATION; SITES	Src homology 2 (SH2) domains mediate assembly of signaling complexes by binding specifically to tyrosine-phosphorylated proteins. A phosphotyrosine binding (PTB) domain has been identified which also binds specifically to tyrosine-phosphorylated targets, but is structurally different from SH2 domains, Expression cloning was used to identify targets of PTB domains. PTB domains bound to phosphotyrosine within a sequence motif, asparagine-X(1)-X(2)-phosphotyrosine (where X represents any amino acid), that is found in many signaling proteins and is not recognized by SH2 domains. Mutational studies indicated that high affinity binding of PTB domains may require a specific conformation of the motif.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NHLBI NIH HHS [K11 HL02714, R01 HL 32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, UNPUB; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Summers MD, 1987, MANUAL METHODS BACUL; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	223	229	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1177	1179		10.1126/science.7539155	http://dx.doi.org/10.1126/science.7539155			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7539155				2022-12-01	WOS:A1995RA60400037
J	SINGH, R; VALCARCEL, J; GREEN, MR				SINGH, R; VALCARCEL, J; GREEN, MR			DISTINCT BINDING SPECIFICITIES AND FUNCTIONS OF HIGHER EUKARYOTIC POLYPYRIMIDINE TRACT-BINDING PROTEINS	SCIENCE			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR U2AF; CIS-ACTING ELEMENTS; SEX-LETHAL; PREMESSENGER RNA; TRANSFORMER GENE; DROSOPHILA; SITE; EXON; CLONING	In higher eukaryotes, the polypyrimidine-tract (Py-tract) adjacent to the 3' splice site is recognized by several proteins, including the essential splicing factor U2AF(65), the splicing regulator Sex-lethal (Sxl), and polypyrimidine tract-binding protein (PTB), whose function is unknown. Iterative in vitro genetic selection was used to show that these proteins have distinct sequence preferences. The uridine-rich degenerate sequences selected by U2AF(65) are similar to those present in the diverse array of natural metazoan Py-tracts. In contrast, the Sxl-consensus is a highly specific sequence, which can help explain the ability of Sxl to regulate splicing of transformer pre-mRNA and autoregulate splicing of its own pre-mRNA. The PTB-consensus is not a typical Py-tract; it can be found in certain alternatively spliced pre-mRNAs that undergo negative regulation. Here it is shown that PTB can regulate alternative splicing by selectively repressing 3' splice sites that contain a PTB-binding site.			SINGH, R (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KANAAR R, 1993, SCIENCE, V262, P569, DOI 10.1126/science.7692602; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; MAYEDA A, 1994, SCIENCE, V265, P1706; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOOREMJ, 1993, RNA WORLD, P1; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; ONEIL MT, 1992, GENETICS, V131, P113; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SAIKI R. K., 1990, PCR PROTOCOLS GUIDE, P13; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SOSNOWSKI BA, 1994, DEV BIOL, V161, P302, DOI 10.1006/dbio.1994.1030; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655	50	467	474	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1173	1176		10.1126/science.7761834	http://dx.doi.org/10.1126/science.7761834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761834				2022-12-01	WOS:A1995RA60400036
J	WALLACE, L; BERNATH, P; LIVINGSTON, W; HINKLE, K; BUSLER, J; GUO, BJ; ZHANG, KQ				WALLACE, L; BERNATH, P; LIVINGSTON, W; HINKLE, K; BUSLER, J; GUO, BJ; ZHANG, KQ			WATER ON THE SUN	SCIENCE			English	Article							HYDROGEN FLAME SPECTRA; RO-VIBRATIONAL LEVELS; MILLIMETER-WAVE; H2O; MOLECULES; CM-1	High-resolution infrared spectra of sunspot umbrae have been recorded with the 1-meter Fourier transform spectrometer on Kitt Peak. The spectra contain a very large number of water absorption features originating on the sun. These lines have been assigned to the pure rotation and the vibration-rotation transitions of hot water by comparison with high-temperature laboratory emission spectra.	UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA; KITT PEAK NATL OBSERV, NATL OPT ASTRON OBSERV, TUCSON, AZ 85726 USA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA; NATL OPT ASTRON OBSERV, NATL SOLAR OBSERV, TUCSON, AZ 85726 USA; UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA	University of Waterloo; National Optical Astronomy Observatory; University of Arizona; National Optical Astronomy Observatory; University of Waterloo			Bernath, Peter F/B-6567-2012	Bernath, Peter F/0000-0002-1255-396X				ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; AMANO T, 1991, CHEM PHYS LETT, V182, P93, DOI 10.1016/0009-2614(91)80109-B; BRAY RJ, 1979, SUNSPOTS, P107; CAMPBELL JC, UNPUB; CAMYPEYRET C, 1977, MOL PHYS, V33, P1641, DOI 10.1080/00268977700101361; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; GELLER M, 1992, NASA REF PUBL, V1224, P92; GLENAR DA, 1985, J MOL SPECTROSC, V111, P403, DOI 10.1016/0022-2852(85)90015-3; HALL DNB, 1972, ASTROPHYS J, V175, pL95, DOI 10.1086/180993; HALL DNB, 1970, THESIS HARVARD U; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; JORGENSEN UG, 1993, J MOL SPECTROSC, V161, P219, DOI 10.1006/jmsp.1993.1228; KLEINMANN SG, 1986, ASTROPHYS J SUPPL S, V62, P501, DOI 10.1086/191149; LEBLANC RB, 1994, J MOL SPECTROSC, V164, P574, DOI 10.1006/jmsp.1994.1100; LIEBERT J, 1994, MOL STELLAR ENV, P62; LIVINGSTON W, 1991, NATURE, V350, P45, DOI 10.1038/350045a0; PEARSON JC, 1991, ASTROPHYS J, V379, pL41, DOI 10.1086/186149; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; POLYANSKY OL, 1994, J CHEM PHYS, V101, P7651, DOI 10.1063/1.468258; POLYANSKY OL, 1985, J MOL SPECTROSC, V112, P79, DOI 10.1016/0022-2852(85)90193-6; SINHA K, 1991, P ASTRON SOC AUST, V9, P32, DOI 10.1017/S1323358000024814; SPINARD H, 1969, ANNU REV ASTRON ASTR, V7, P249, DOI 10.1146/annurev.aa.07.090169.001341; TOTH RA, 1994, APPL OPTICS, V33, P4851, DOI 10.1364/AO.33.004851; TSUJI T, IN PRESS ELEMENTARY; TYUTEREV VG, 1992, J MOL SPECTROSC, V151, P97, DOI 10.1016/0022-2852(92)90009-D; WALLACE L, 1992, 92001 NAT OPT ASTR O; WALLACE L, 1994, 199401 NAT OPT ASTR	28	111	113	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1155	1158		10.1126/science.7761830	http://dx.doi.org/10.1126/science.7761830			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761830				2022-12-01	WOS:A1995RA60400030
J	WIRTZ, E; CLAYTON, C				WIRTZ, E; CLAYTON, C			INDUCIBLE GENE-EXPRESSION IN TRYPANOSOMES MEDIATED BY A PROKARYOTIC REPRESSOR	SCIENCE			English	Article							RNA-POLYMERASE-I; AMANITIN-RESISTANT TRANSCRIPTION; TN10-ENCODED TET-REPRESSOR; PROTEIN-CODING GENES; COLI LAC REPRESSOR; CAMV 35S PROMOTER; REPETITIVE PROTEIN; HOMOLOGOUS RECOMBINATION; DISCONTINUOUS TRANSCRIPTION; DEVELOPMENTAL REGULATION	An inducible expression system was developed for the protozoan parasite Trypanosoma brucei. Transgenic trypanosomes expressing the tetracycline repressor of Escherichia coli exhibited inducer (tetracycline)-dependent expression of chromosomally integrated reporter genes under the control of a procyclic acidic repetitive protein (PARP) promoter bearing a fet operator. Reporter expression could be controlled over a range of four orders of magnitude in response to tetracycline concentration, a degree of regulation that exceeds those exhibited by other eukaryotic repression-based systems. The tet repressor-controlled PARP promoter should be a valuable tool for the study of trypanosome biochemistry, pathogenicity, and cell and molecular biology.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Clayton, Christine/K-7700-2019	Clayton, Christine/0000-0002-6384-0731				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; ANZ L, 1994, MOL CELL BIOL, V14, P5804; Beverley S. M., 1993, PROTOCOLS MOL PARASI, P333; BEVERLEY SM, UNPUB; BONIN A, 1994, THESIS U HEIDELBERG; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CLAYTON CE, 1992, PROGR NUCLEIC ACID R, P37; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; EID JE, 1991, GENE DEV, V5, P2024, DOI 10.1101/gad.5.11.2024; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; FLASPOHLER J, UNPUB; GATZ C, 1991, MOL GEN GENET, V227, P229, DOI 10.1007/BF00259675; GATZ C, 1988, P NATL ACAD SCI USA, V85, P1394, DOI 10.1073/pnas.85.5.1394; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEINS L, 1992, MOL GEN GENET, V232, P328, DOI 10.1007/BF00280013; Hillen W., 1989, TOPICS MOL STRUCTURA, V10, P143; HU MCT, 1991, GENE, V99, P141, DOI 10.1016/0378-1119(91)90120-Z; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; KONIG E, 1989, NUCLEIC ACIDS RES, V17, P8727, DOI 10.1093/nar/17.21.8727; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEE MGS, 1991, GENE, V105, P255, DOI 10.1016/0378-1119(91)90159-9; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NILSEN TW, 1994, SCIENCE, V264, P1868, DOI 10.1126/science.7912006; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; PAYS E, 1992, SOC GENERL MICROBIOL, V50, P127; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1986, CELL, V47, P479, DOI 10.1016/0092-8674(86)90608-2; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	54	195	201	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1179	1183		10.1126/science.7761835	http://dx.doi.org/10.1126/science.7761835			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761835				2022-12-01	WOS:A1995RA60400038
J	CRAIR, MC; MALENKA, RC				CRAIR, MC; MALENKA, RC			A CRITICAL PERIOD FOR LONG-TERM POTENTIATION AT THALAMOCORTICAL SYNAPSES	NATURE			English	Article							DEPENDENT SYNAPTIC PLASTICITY; NMDA RECEPTOR CHANNEL; VISUAL-CORTEX; SOMATOSENSORY CORTEX; BARREL CORTEX; MECHANISMS; TRANSMISSION; RESPONSES; PATTERNS; CURRENTS	IN mammalian development, the refinement of topographical projections from the thalamus to the cortex is thought to arise through an activity-dependent process in which thalamic axons compete for cortical targets(1,2). In support of this view, if activity is altered during a critical period in early development, normal connectivity is disrupted(1,2). It has been proposed that synaptic connections are strengthened during development by correlated pre- and postsynaptic activity(3,4), and a likely mechanism for this process would be N-methyl-D-aspartate (NMDA) receptor-dependent long-term potentiation (LTP)(5,6). However, the evidence that LTP is involved in normal development remains inconclusive. We have examined LTP in the thalamocortical synapses that form whisker barrels in rat somatosensory cortex (S1). We report here that the period during which LTP can be induced matches closely the critical period during which the barrels can be modified by sensory perturbations. Moreover, the loss of susceptibility to LTP with age is accompanied by a decrease in NMDA receptor-mediated synaptic currents. These findings provide compelling evidence that LTP is important for the development of cortical circuitry.	UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CRAIR, MC (corresponding author), UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA.							AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; FOX K, 1992, J NEUROSCI, V12, P1826; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KILLACKEY HP, 1975, BRAIN RES, V86, P469, DOI 10.1016/0006-8993(75)90897-5; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	29	578	589	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					325	328		10.1038/375325a0	http://dx.doi.org/10.1038/375325a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753197				2022-12-01	WOS:A1995RA03000053
J	KIRKWOOD, A; LEE, HK; BEAR, MF				KIRKWOOD, A; LEE, HK; BEAR, MF			COREGULATION OF LONG-TERM POTENTIATION AND EXPERIENCE-DEPENDENT SYNAPTIC PLASTICITY IN VISUAL-CORTEX BY AGE AND EXPERIENCE	NATURE			English	Article							D-ASPARTATE RECEPTORS; MONOCULAR DEPRIVATION; SLICE PREPARATION; SENSITIVE PERIOD; STRIATE CORTEX; RAT; KITTENS; SUSCEPTIBILITY; HIPPOCAMPUS; NEOCORTEX	LONG-TERM potentiation (LTP) is a lasting enhancement of excitatory synaptic transmission that follows specific patterns of electrical stimulation(1). Although the mechanism of LTP has been intensively studied, particularly in the hippocampus, its significance for normal brain function remains unproven. It has been proposed that LTP-like mechanisms may contribute to naturally occurring, experience-dependent synaptic modifications in the visual cortex(2-8). The formation of normal binocular connections within the, visual cortex: requires simultaneous input from both eyes during a postnatal critical period(9-12) that can be delayed by rearing animals in complete darkness(13,14). To explore the role of LTP in this experience-dependent maturation process, we induced LTP in visual cortical slices taken at different ages from light-reared and dark-reared rats. Susceptibility to LTP coincides with the critical period and, like the critical period, can be prolonged by rearing animals in darkness. These findings support the hypothesis that LTP reflects a normal mechanism of experience-dependent synaptic modification in the developing mammalian brain.	BROWN UNIV, INST BRAIN & NEURAL SYST, PROVIDENCE, RI 02912 USA	Brown University	KIRKWOOD, A (corresponding author), BROWN UNIV, DEPT NEUROSCI, HOWARD HUGHES MED INST, PROVIDENCE, RI 02912 USA.			Lee, Hey-Kyoung/0000-0002-5554-983X; Bear, Mark/0000-0002-9903-2541				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1992, J NEUROPHYSIOL, V67, P1; BERRY RL, 1989, BRAIN RES, V481, P221, DOI 10.1016/0006-8993(89)90797-X; BERRY RL, 1993, BRAIN RES, V628, P99, DOI 10.1016/0006-8993(93)90943-H; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KIMURA F, 1989, J PHYSIOL-LONDON, V414, P125, DOI 10.1113/jphysiol.1989.sp017680; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KOMATSU Y, 1981, NEUROSCI LETT, V26, P269, DOI 10.1016/0304-3940(81)90144-0; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; LUHMANN HJ, 1990, DEV BRAIN RES, V54, P287, DOI 10.1016/0165-3806(90)90152-O; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PERKINS AT, 1988, BRAIN RES, V439, P222; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6	30	358	364	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					328	331		10.1038/375328a0	http://dx.doi.org/10.1038/375328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753198				2022-12-01	WOS:A1995RA03000054
J	LOTAN, R; XU, XC; LIPPMAN, SM; RO, JY; LEE, JS; LEE, JJ; HONG, WK				LOTAN, R; XU, XC; LIPPMAN, SM; RO, JY; LEE, JS; LEE, JJ; HONG, WK			SUPPRESSION OF RETINOIC ACID RECEPTOR-BETA IN PREMALIGNANT ORAL LESIONS AND ITS UP-REGULATION BY ISOTRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; MESSENGER-RNA LEVELS; HUMAN LUNG-CANCER; NUCLEAR RECEPTORS; VITAMIN-A; EXPRESSION; LINES; KERATINOCYTES; KERATIN-19; TISSUES	Background. Retinoids are effective in the treatment and prevention of certain human cancers. Most of their actions are thought to result from changes in gene expression mediated by nuclear retinoic acid receptors and retinoid X receptors. We conducted a study to determine whether the expression of these receptors was altered in premalignant oral lesions and, if so, whether their expression could be restored by treatment with isotretinoin. Methods. We performed in situ hybridization of retinoic acid receptors and retinoid X receptors using antisense riboprobes in specimens of oral mucosa from 7 normal subjects and specimens of premalignant oral lesions from 52 patients before treatment with isotretinoin and from 39 of the 52 patients after three months of treatment. Results. All the normal specimens expressed retinoic acid receptor-beta messenger RNA (mRNA). In contrast, retinoic acid receptor-beta mRNA was detected in only 21 of the 52 premalignant oral lesions (P = 0.003). Thirty-five of the 39 specimens available for evaluation after treatment expressed retinoic acid receptor-beta mRNA (P<0.001). All normal and premalignant specimens expressed similar levels of mRNA for retinoic acid receptor-alpha and retinoic acid receptor-gamma and the three types of retinoid X receptors, alpha, beta, and gamma. The levels of retinoic acid receptor-beta mRNA increased in the specimens from 18 of the 22 patients who had responses to isotretinoin and in 8 of the 17 specimens from the patients without responses (P = 0.04). Conclusions. The expression of retinoic acid receptor-beta mRNA is selectively lost in premalignant oral lesions and can be restored by treatment with isotretinoin. Restoration of the expression of retinoic acid receptor-beta mRNA is associated with a clinical response. Retinoic acid receptor-beta may have a role in mediating the response to retinoids and may be a useful intermediate biologic marker in trials of these agents for the prevention of oral carcinogenesis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT PATHOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	LOTAN, R (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL 108, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019	Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X	NATIONAL CANCER INSTITUTE [U01CA046303, P01CA052051] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 52051, CA46303] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHIESA F, 1992, ORAL ONCOL, V28B, P97; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FRANGIONI JV, 1994, J CELL SCI, V107, P827; GEBERT, 1992, ONCOGENE, V7, P821; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; HARNISH DC, 1990, DIFFERENTIATION, V45, P103, DOI 10.1111/j.1432-0436.1990.tb00463.x; Hong Waun Ki, 1994, P597; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KRUYT FAE, 1993, MOL ENDOCRINOL, V7, P604, DOI 10.1210/me.7.4.604; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; LIPPMAN SM, 1994, J CLIN ONCOL, V12, P851, DOI 10.1200/JCO.1994.12.4.851; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; Mangelsdorf David J., 1994, P319; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; MIQUEL C, 1992, MOL BIOL REP, V17, P35; MORRISSKAY G, 1992, CANCER SURV, V14, P181; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Woolson R. F, 1987, STATISTICAL METHODS; XU XC, 1994, DIAGN MOL PATHOL, V3, P122, DOI 10.1097/00019606-199406000-00009; XU XC, 1994, CANCER RES, V54, P3580	43	369	372	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1405	1410		10.1056/NEJM199505253322103	http://dx.doi.org/10.1056/NEJM199505253322103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723796	Bronze			2022-12-01	WOS:A1995QY94100003
J	MARSH, K; FORSTER, D; WARUIRU, C; MWANGI, I; WINSTANLEY, M; MARSH, V; NEWTON, C; WINSTANLEY, P; WARN, P; PESHU, N; PASVOL, G; SNOW, R				MARSH, K; FORSTER, D; WARUIRU, C; MWANGI, I; WINSTANLEY, M; MARSH, V; NEWTON, C; WINSTANLEY, P; WARN, P; PESHU, N; PASVOL, G; SNOW, R			INDICATORS OF LIFE-THREATENING MALARIA IN AFRICAN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL MALARIA; CLINICAL-FEATURES; FALCIPARUM-MALARIA	Background. About 90 percent of the deaths from malaria are in African children, but criteria to guide the recognition and management of severe malaria have not been validated in them. Methods. We conducted a prospective study of all children admitted to the pediatric ward of a Kenyan district hospital with a primary diagnosis of malaria. We calculated the frequency and mortality rate for each of the clinical and laboratory criteria in the current World Health Organization (WHO) definition of severe malaria, and then used logistic-regression analysis to identify the variables with the greatest prognostic value. Results. We studied 1844 children (mean age, 26.4 months) with a primary diagnosis of malaria, Not included were 18 children who died on arrival and 4 who died of other causes. The mortality rate was 3.5 percent (95 percent confidence interval, 2.7 to 4.3 percent), and 84 percent of the deaths occurred within 24 hours of admission. Logistic-regression analysis identified four key prognostic indicators: impaired consciousness (relative risk, 3.3; 95 percent confidence interval, 1.6 to 7.0), respiratory distress (relative risk, 3.9; 95 percent confidence interval, 2.0 to 7.7), hypoglycemia (relative risk, 3.3; 95 percent confidence interval, 1.6 to 6.7), and jaundice (relative risk, 2.6; 95 percent confidence interval, 1.1 to 6.3). Of the 64 children who died, 54 were among those with impaired consciousness (n = 336; case fatality rate, 11.9 percent) or respiratory distress (n = 251; case fatality rate, 13.9 percent), or both. Hence, this simple bedside index identified 84.4 percent of the fatal cases, as compared with the 79.7 percent identified by the current WHO criteria. Conclusions. In African children with malaria, the presence of impaired consciousness or respiratory distress can identify those at high risk for death.	JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND	University of Oxford; University of Oxford	MARSH, K (corresponding author), KENYA GOVT MED RES CTR, CLIN RES CTR, KILIFI UNIT, POB 230, KILIFI, KENYA.		Newton, Charles RJC/B-7578-2014; Snow, Robert William/AFR-1436-2022; Pasvol, Geoffrey/B-7113-2009; Newton, Charles/C-6222-2009	Newton, Charles RJC/0000-0002-6999-5507; Snow, Robert William/0000-0003-3725-6088; Marsh, Vicki/0000-0002-5178-4250	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MOLYNEUX ME, 1989, J ROY SOC MED, V82, P35; MOLYNEUX ME, 1989, Q J MED, V71, P441; NEWTON CRJC, 1990, LANCET, V335, P472, DOI 10.1016/0140-6736(90)90703-8; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; PASVOL G, 1991, AM J TROP MED HYG, V45, P702, DOI 10.4269/ajtmh.1991.45.702; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; TAYLOR TE, 1993, Q J MED, V86, P99; WARRELL DA, 1987, PARASITOLOGY, V94, pS53, DOI 10.1017/S0031182000085826; White N. J., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P55; 1993, 1993 WORLD BANK WORL; [No title captured]	15	779	791	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1399	1404		10.1056/NEJM199505253322102	http://dx.doi.org/10.1056/NEJM199505253322102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723795				2022-12-01	WOS:A1995QY94100002
J	MARTI, E; BUMCROT, DA; TAKADA, R; MCMAHON, AP				MARTI, E; BUMCROT, DA; TAKADA, R; MCMAHON, AP			REQUIREMENT OF 19K FORM OF SONIC HEDGEHOG FOR INDUCTION OF DISTINCT VENTRAL CELL-TYPES IN CNS EXPLANTS	NATURE			English	Article							POLARITY GENE HEDGEHOG; FLOOR PLATE; DROSOPHILA; TRANSCRIPTION; NOTOCHORD; PATTERN; EMBRYO; SYSTEM	THE identity and patterning of ventral cell types in the vertebrate central nervous system depends on cell interactions(1). For example, induction of a specialized population of ventral midline cells, the Boor plate, appears to require contact-mediated signalling by the underlying notochord, whereas diffusible signals from the notochord and floor plate can induce ventrolaterally positioned motor neurons. Sonic hedgehog (Shh), a vertebrate hedgehog-family member, is processed to generate two peptides (M(r) 19K and 26/27K) which are secreted by both of these organizing centres(2,30). Moreover, experiments in a variety of vertebrate embryos(3-5), and in neural explants in vitro(5), indicate that Shh can mediate floor-plate induction. Here we have applied recombinant Shh peptides to neural explants in serum-free conditions. High concentrations of Shh bound to a matrix induce floor plate and motor neurons, and addition of Shh to the medium leads to dose-dependent induction of motor neurons. All inducing activity resides in a highly conserved amino-terminal peptide (M(r) 19K). Moreover, antibodies that specifically recognize this peptide block induction of motor neurons by the notochord. We propose that Shh acts as a morphogen to induce distinct ventral cell types in the vertebrate central nervous system.			MARTI, E (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		MARTI, ELISA/K-7814-2014; McMahon, Andrew P/ABE-7520-2020	MARTI, ELISA/0000-0001-5839-7133; Takada, Ritsuko/0000-0002-1615-056X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fietz MJ, 1994, DEVELOPMENT S, V120, P43; FIETZ MJ, IN PRESS CURR BIOL; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARTI E, IN PRESS DEVELOPMENT; MOHLER J, 1988, GENETICS, V120, P1061; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	30	421	450	0	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					322	325		10.1038/375322a0	http://dx.doi.org/10.1038/375322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753196				2022-12-01	WOS:A1995RA03000052
J	MICHIELS, F; HABETS, GGM; STAM, JC; VANDERKAMMEN, RA; COLLARD, JG				MICHIELS, F; HABETS, GGM; STAM, JC; VANDERKAMMEN, RA; COLLARD, JG			A ROLE FOR RAC IN TIAM1-INDUCED MEMBRANE RUFFLING AND INVASION	NATURE			English	Article							GTP-BINDING-PROTEIN; ONCOGENE PRODUCT; RHO GDI; EXCHANGE; TRANSFECTION; CELLS; GENE	RHO-LIKE GTPases have been implicated in the regulation of the actin cytoskeleton which controls the morphology, adhesion and motility of cells(1-3). Like Ras proteins, they become activated when bound GDP is exchanged for GTP, a process catalysed by GDP-dissociation stimulator (GDS) proteins(4). Several GDS proteins specific for Rho-like GTPases have been identified(5-8). Most of these contain a conserved catalytic domain, the DBL-homology (DH) domain(9), and activate Cdc42 or Rho but not Rac(5-8). We have isolated the invasion-inducing Tiam1 gene, which also encodes a protein with a DH domain(10). Here we show that Tiam1 is a GDS protein for Rho-like GTPases in vitro. In fibroblasts, Tiam1 induces a similar phenotype as constitutively activated (V12)Rac1, including membrane ruffling, and this is inhibited by dominant negative (N17)Rac1. Moreover, T-lymphoma cells expressing V12Rac1 become invasive, indicating that the Tiam1-Rac signalling pathway could be operating in the invasion and metastasis of tumour cells.	NETHERLANDS CANC INST, DIV CELL BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COLLARD JG, 1987, CANCER RES, V47, P754; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HORLI Y, 1994, EMBO J, V13, P4776; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	26	508	521	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					338	340		10.1038/375338a0	http://dx.doi.org/10.1038/375338a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753201				2022-12-01	WOS:A1995RA03000057
J	NUEZ, B; MICHALOVICH, D; BYGRAVE, A; PLOEMACHER, R; GROSVELD, F				NUEZ, B; MICHALOVICH, D; BYGRAVE, A; PLOEMACHER, R; GROSVELD, F			DEFECTIVE HEMATOPOIESIS IN FETAL LIVER RESULTING FROM INACTIVATION OF THE EKLF GENE	NATURE			English	Article							BETA-GLOBIN GENE; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; PROMOTER ELEMENT; STEM-CELLS; EXPRESSION; MUTATIONS; SEQUENCE; DISTAL	ERYTHROID Kruppel-like factor (EKLF) was originally isolated from erythroid cell RNA by differential screening and shown to be erythroid-specific, although a low level of EKLF was found in mast cell lines(1,2). EKLF contains three zinc-fingers homologous to those found in the Kruppel family of transcription factors, Because it binds the sequence CCACACCCT, EKLF may affect erythroid development as a result of its ability to bind to the CAC box in the promoter of the beta-globin gene(1,2). Mutation of this element leads to reduced beta-globin expression(3-5) and it appears to mediate the effect of the globin locus control region on the promoter(6). Here we inactivate the EKLF gene through insertion of a lacZ reporter gene by homologous recombination in embryonic stem (ES) cells. Heterozygous EKLF(+/-) mice show that the reporter gene is expressed in a developmentally specific manner in all types of erythroblasts in the fetal liver and adult bone marrow. Homozygous EKLF(-/-) mice appear normal during the embryonic stage of haematopoiesis in the yolk sac, but develop a fatal anaemia during early fetal life when haematopoiesis has switched to the fetal liver. Enucleated erythrocytes are formed but these do not contain the proper amount of haemoglobin. We conclude that the transcription factor EKLF is essential for the final steps of definitive erythropoiesis in fetal liver.	ERASMUS UNIV ROTTERDAM, DEPT HAEMATOL, 3015 GE ROTTERDAM, NETHERLANDS; NATL INST MED RES, DEPT GENE STRUCT & EXPRESS, LONDON NW7 1AA, ENGLAND	Erasmus University Rotterdam; MRC National Institute for Medical Research	NUEZ, B (corresponding author), ERASMUS UNIV ROTTERDAM, MGC DEPT CELL BIOL & GENET, DR MOLEWATERPLEIN 50, 3015 GE ROTTERDAM, NETHERLANDS.			Michalovich, David/0000-0003-4452-5776				ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELEOUET JF, 1993, EUR J BIOCHEM, V272, P763; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EPPERLY BR, 1994, GENE, V131, P249; FENG WC, 1994, J BIOL CHEM, V269, P1492; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KULOZIK AE, 1991, BLOOD, V77, P2054; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PLOEMACHER RE, 1993, LEUKEMIA, V7, P1374; Robertson E. J., 1987, TERATOCARCINOMAS EMB; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WONG PMC, 1983, BLOOD, V62, P1280	23	470	484	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					316	318		10.1038/375316a0	http://dx.doi.org/10.1038/375316a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753194	Green Submitted			2022-12-01	WOS:A1995RA03000050
J	PERKINS, AC; SHARPE, AH; ORKIN, SH				PERKINS, AC; SHARPE, AH; ORKIN, SH			LETHAL BETA-THALASSEMIA IN MICE LACKING THE ERYTHROID CACCC-TRANSCRIPTION FACTOR EKLF	NATURE			English	Article							HUMAN GAMMA-GLOBIN; TARGETED MUTATION; MAMMALIAN-CELLS; TRANSGENIC MICE; FACTOR GATA-1; GENE; BINDING; EXPRESSION; EXTRACTION; PROMOTER	GLOBIN genes are regulated in a tissue-specific and developmental stage-specific manner, with the beta-globin gene being the last to be activated in the beta-gene cluster(1). CACCC-nucleotide sequences, which bind multiple nuclear proteins, including ubiquitously expressed Sp1 and erythroid Kruppel-like factor (EKLF), are among the cis-regulatory sequences critical for transcription of globin and non-globin erythroid-expressed genes(2-5). To determine the function of EKLF in vivo, we created mice deficient in EKLF by gene targeting(6). These embryos die of anaemia during fetal liver erythropoiesis and show the molecular and haematological features of beta-globin deficiency, found in beta-thalassaemia. Although it is expressed at all stages, EKLF is not required for yolk sac erythropoiesis, erythroid commitment or expression of other potential target genes. Its stage-specific and beta-globin-gene-specific requirement suggests that EKLF may facilitate completion of the fetal-to-adult (haemoglobin gamma to beta) switch in humans.	CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Perkins, Andrew/AAJ-9696-2020; Perkins, Andrew/X-4180-2019; Brugnara, Carlo/A-8041-2010; Perkins, Andrew C/M-3216-2014	Perkins, Andrew/0000-0003-3644-7093; Brugnara, Carlo/0000-0001-8192-8713; Perkins, Andrew C/0000-0003-3644-7093				ALTER BP, 1982, HEMOGLOBIN, V6, P517, DOI 10.3109/03630268209083764; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONAGH KT, 1992, HEMATOLOGY INFANCY C; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PORCHER C, 1991, J BIOL CHEM, V266, P10562; Sambrook J., 1989, MOL CLONING LAB MANU; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; THIEN SL, 1993, BLOOD, V82, P961; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	29	518	530	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					318	322						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753195				2022-12-01	WOS:A1995RA03000051
J	PULENDRAN, B; KANNOURAKIS, G; NOURI, S; SMITH, KGC; NOSSAL, GJV				PULENDRAN, B; KANNOURAKIS, G; NOURI, S; SMITH, KGC; NOSSAL, GJV			SOLUBLE-ANTIGEN CAN CAUSE ENHANCED APOPTOSIS OF GERMINAL-CENTER B-CELLS	NATURE			English	Article							IMMUNE-RESPONSE; AFFINITY MATURATION; SOMATIC MUTATION; C57BL-6 MICE; DEATH; CENTERS; LYMPHOCYTES; REPERTOIRE; ANTIBODIES; PROTEIN	GERMINAL centres are dynamic microenvironments of B-lymphocyte differentiation, which develop in secondary lymphoid tissues during immune responses(1-3). Within germinal centres, activated B lymphocytes proliferate and point mutations are rapidly introduced into the genes encoding their immunoglobulin receptor(4-10). As a result, new specificities of B cells are created, including those with a heightened capacity to bind the immunizing antigen(4-11). Immunoglobulin gene mutation can also lead to reactivity to self antigens(12-14). It has been suggested that any newly formed self-reactive B cells are eliminated within the germinal centre in order to avoid autoimmunity(15,16). Here we present evidence that antigen-specific, high-affinity, germinal-centre B cells are rapidly killed by apoptosis in sits when they encounter soluble antigen. The effect seems to act directly on the B cells, rather than through helper T cells. Furthermore, the apoptosis is unique to germinal-centre cells, and is only incompletely impeded by constitutive expression of the proto-oncogene bcl-2. This phenomenon may reflect clonal deletion of self-reactive B cells within germinal centres.	ROYAL MELBOURNE HOSP, DEPT NEPHROL, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL CHILDRENS HOSP, LARCH CANC RES UNIT, PARKVILLE, VIC 3052, AUSTRALIA	Royal Melbourne Hospital; Royal Children's Hospital Melbourne	PULENDRAN, B (corresponding author), WALTER & ELIZA HALL INST MED RES, PO ROYAL MELBOURNE HOSP, MELBOURNE, VIC 3050, AUSTRALIA.		Pulendran, Bali/AAW-9550-2021	Pulendran, Bali/0000-0001-6517-4333; Smith, Kenneth/0000-0003-3829-4326				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; DIAMOND B, 1992, A REV IMMUN, V10, P737; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HERZENBERG LA, 1980, J EXP MED, V151, P1071, DOI 10.1084/jem.151.5.1071; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MACLENNAN ICM, 1990, CURR TOP MICROBIOL I, V159, P138; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; NAKAYAMA KI, 1993, SCIENCE, V261, P1548; NISITANI S, 1993, J EXP MED, V178, P1247, DOI 10.1084/jem.178.4.1247; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Theofilopoulos A N, 1979, Adv Immunol, V28, P89; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VELS DJ, 1993, J CELL, V75, P229	31	277	282	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					331	334		10.1038/375331a0	http://dx.doi.org/10.1038/375331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753199				2022-12-01	WOS:A1995RA03000055
J	REY, FA; HEINZ, FX; MANDL, C; KUNZ, C; HARRISON, SC				REY, FA; HEINZ, FX; MANDL, C; KUNZ, C; HARRISON, SC			THE ENVELOPE GLYCOPROTEIN FROM TICK-BORNE ENCEPHALITIS-VIRUS AT 2 ANGSTROM RESOLUTION	NATURE			English	Article							WEST NILE FLAVIVIRUS; PROTEIN-E; NUCLEOTIDE-SEQUENCE; RESISTANT MUTANTS; INFLUENZA-VIRUS; NEUROVIRULENCE; EXPRESSION; MICE; SELECTION; VIRULENCE	The crystallographically determined structure of a soluble fragment from the major envelope protein of a flavivirus reveals an unusual architecture. The flat, elongated dimer extends in a direction that would be parallel to the viral membrane. Residues that influence binding of monoclonal antibodies lie on the outward-facing surface of the protein. The clustering of mutations that affect virulence in various flaviviruses indicates a possible receptor binding site and, together with other mutational and biochemical data, suggests a picture for the fusion-activating, conformational change triggered by low pH.	HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA; UNIV VIENNA, INST VIROL, A-1095 VIENNA, AUSTRIA	Harvard University; Howard Hughes Medical Institute; University of Vienna	REY, FA (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		Rey, Felix/B-6497-2012	Rey, Felix/0000-0002-9953-7988				ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; BLUM M, 1990, THESIS HARVARD U; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1016/S0022-2836(84)71582-8; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GAO GF, 1994, J GEN VIROL, V75, P609, DOI 10.1099/0022-1317-75-3-609; GUIRAKHOO F, 1993, VIROLOGY, V194, P219, DOI 10.1006/viro.1993.1252; GUIRAKHOO F, 1991, J GEN VIROL, V72, P1323, DOI 10.1099/0022-1317-72-6-1323; GUIRAKHOO F, 1992, VIROLOGY, V191, P921, DOI 10.1016/0042-6822(92)90267-S; HASEGAWA H, 1992, VIROLOGY, V191, P158, DOI 10.1016/0042-6822(92)90177-Q; HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013; HEINZ FX, 1986, ADV VIRUS RES, V31, P103, DOI 10.1016/S0065-3527(08)60263-8; HEINZ FX, 1991, J VIROL, V65, P5579, DOI 10.1128/JVI.65.10.5579-5583.1991; HEINZ FX, 1990, IMMUNOCHEMISTRY VIRU, V2, P289; HOLZMANN H, 1995, ARCH VIROL, V140, P213, DOI 10.1007/BF01309857; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWANO H, 1993, J VIROL, V67, P6567, DOI 10.1128/JVI.67.11.6567-6575.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS JA, 1993, VIROLOGY, V197, P216, DOI 10.1006/viro.1993.1582; LOBIGS M, 1990, VIROLOGY, V176, P587, DOI 10.1016/0042-6822(90)90029-Q; MANDL CW, 1989, J VIROL, V63, P564, DOI 10.1128/JVI.63.2.564-571.1989; MANDL CW, 1988, VIROLOGY, V166, P197, DOI 10.1016/0042-6822(88)90161-4; Monath T.P., 1990, VIROLOGY, P763; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOWAK T, 1987, VIROLOGY, V156, P127, DOI 10.1016/0042-6822(87)90443-0; PLETNEV AG, 1993, J VIROL, V67, P4956, DOI 10.1128/JVI.67.8.4956-4963.1993; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROEHRIG JT, 1989, VIROLOGY, V171, P49, DOI 10.1016/0042-6822(89)90509-6; ROEHRIG JT, 1990, VIROLOGY, V177, P668, DOI 10.1016/0042-6822(90)90532-V; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SUMIYOSHI H, 1987, VIROLOGY, V161, P497, DOI 10.1016/0042-6822(87)90144-9; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	44	1152	1259	1	63	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					291	298		10.1038/375291a0	http://dx.doi.org/10.1038/375291a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753193				2022-12-01	WOS:A1995RA03000042
J	SHOKAT, KM; GOODNOW, CC				SHOKAT, KM; GOODNOW, CC			ANTIGEN-INDUCED B-CELL DEATH AND ELIMINATION DURING GERMINAL-CENTER IMMUNE-RESPONSES	NATURE			English	Article							SOMATIC MUTATION; ANTIBODY; EXPRESSION; CENTERS; SPECIFICITY; GENERATION; SELECTION; LYSOZYME; PROTEINS; CHAIN	DURING an immune response, hypermutation of immunoglobulin genes in B cells proliferating within germinal centres (GCs) generates variant antibodies that react with higher affinity against either foreign or self antigens(1-9). Several experiments suggest that self-reactive B cells may be censored at this stage of the immune response(10-12), but the rarity of these cells and the dynamic nature of GC reactions have prevented direct analysis. We have developed a new approach to visualize the fate of antigen-specific B cells during GC reactions by seeding an ongoing immune response with lysozyme-specific B cells from immunoglobulin-gene transgenic animals. Administration of soluble antigen at the peak of the GC response rapidly eliminates lysozyme-specific GC B cells in two waves of apoptosis, one within the GC and a second in cells that have redistributed to lymphoid zones that are rich in T cells. Elimination of these cells is inhibited by constitutive expression of the follicular lymphoma proto-oncogene bcl-2. These findings reveal censoring steps that may normally prevent affinity maturation of autoantibodies to systemic autoantigens, and might be used by pathogenic microorganisms or in clinical strategies to interfere with antibody responses.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DINTZIS HM, 1992, P NATL ACAD SCI USA, V89, P1113, DOI 10.1073/pnas.89.3.1113; GAMMON G, 1987, IMMUNOL REV, V98, P53; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LAGASSE E, 1992, BLOOD, V79, P1907; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PRAGER EM, 1971, J BIOL CHEM, V246, P523; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	29	333	340	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					334	338		10.1038/375334a0	http://dx.doi.org/10.1038/375334a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753200				2022-12-01	WOS:A1995RA03000056
J	TAPLIN, ME; BUBLEY, GJ; SHUSTER, TD; FRANTZ, ME; SPOONER, AE; OGATA, GK; KEER, HN; BALK, SP				TAPLIN, ME; BUBLEY, GJ; SHUSTER, TD; FRANTZ, ME; SPOONER, AE; OGATA, GK; KEER, HN; BALK, SP			MUTATION OF THE ANDROGEN-RECEPTOR GENE IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STEROID BINDING; EXPRESSION; ACID; SEQUENCE; CELLS; IDENTIFICATION; INSENSITIVITY; DEFINITION; TRIALS; DOMAIN	Background. Metastatic prostate cancer is a leading cause of cancer-related death in men. The rate of response to androgen ablation is high, but most patients relapse as a result of the outgrowth of androgen-independent tumor cells. The androgen receptor, which binds testosterone and stimulates the transcription of androgen-responsive genes, regulates the growth of prostate cells. We analyzed the androgen-receptor genes from samples of metastatic androgen-independent prostate cancers to determine whether mutations in the gene have a role in androgen independence. Methods. Complementary DNA was synthesized from metastatic prostate cancers in 10 patients with androgen-independent prostate cancer, and the expression of the androgen-receptor gene was estimated by amplification with the polymerase chain reaction. Exons B through H of the gene were cloned, and mutations were identified by DNA sequencing. The functional effects of the mutations were assessed in cells transfected with mutant genes. Results. All androgen-independent tumors expressed high levels of androgen-receptor gene transcripts, relative to the levels expressed by an androgen-independent prostate-cancer cell line (LNCaP). Point mutations in the androgen-receptor gene were identified in metastatic cells from 5 of the 10 patients examined. One mutation was in the same codon as the mutation found previously in the androgen-independent prostate-cancer cell line. The mutations were not detected in the primary tumors from two of the patients. Functional studies of two of the mutant androgen receptors demonstrated that they could be activated by progesterone and estrogen. Conclusions. Most metastatic androgen-independent prostate cancers express high levels of androgen-receptor gene transcripts. Mutations in androgen-receptor genes are not uncommon and may provide a selective growth advantage after androgen ablation.	BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; UNIV MASSACHUSETTS,MED CTR,DEPT MED,DIV ONCOL,WORCESTER,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA051438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007516] Funding Source: NIH RePORTER; NCI NIH HHS [R-29 CA51438] Funding Source: Medline; NHLBI NIH HHS [HL07516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P127; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Dawson N A, 1993, Oncology (Williston Park), V7, P17; DAWSON NA, 1993, ONCOLOGY, V7, P2; Dawson NA, 1993, ONCOLOGY, V7, P17; DEBELLIS A, 1992, MOL ENDOCRINOL, V6, P1909, DOI 10.1210/me.6.11.1909; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KARNIK PS, 1994, CANCER RES, V54, P349; LUBAHN DB, 1990, P NATL ACAD SCI USA, V87, P4411; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RISSTALPERS C, 1993, BIOCHEM BIOPH RES CO, V196, P173, DOI 10.1006/bbrc.1993.2231; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANTINTEREN H, 1993, CANCER-AM CANCER SOC, V72, P3847, DOI 10.1002/1097-0142(19931215)72:12+<3847::AID-CNCR2820721716>3.0.CO;2-J; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1	39	975	1025	1	38	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1393	1398		10.1056/NEJM199505253322101	http://dx.doi.org/10.1056/NEJM199505253322101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723794				2022-12-01	WOS:A1995QY94100001
J	COOPER, JR				COOPER, JR			INCLUDING NARCOTIC ADDICTION TREATMENT IN AN OFFICE-BASED PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							METHADONE-MAINTENANCE				COOPER, JR (corresponding author), NIDA,DIV CLIN SERV & RES,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							Ball J. C., 1991, EFFECTIVENESS METHAD; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234; GRAHAM LA, 1994, NOV NAT I DRUG AB ME; MOLINARI SP, 1994, J LAW MED ETHICS, V22, P231, DOI 10.1111/j.1748-720X.1994.tb01300.x; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; PAYTE JT, 1994, 25TH AM SOC ADD MED; 1970, L91513 PUB; 1974, L93281 PUB; 1994, DEV ANTIADDICTION ME; 1984, L98473 PUB; 1995, FEDERAL REGULATION M	12	27	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1619	1620		10.1001/jama.273.20.1619	http://dx.doi.org/10.1001/jama.273.20.1619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745777				2022-12-01	WOS:A1995QY54100031
J	BERRY, SM; LECOLIER, B; SMITH, RS; BERCAU, G; DOMBROWSKI, MP; PUDER, KS; KITHIER, K; BIDAT, L; JOHNSON, MP; COTTON, DB				BERRY, SM; LECOLIER, B; SMITH, RS; BERCAU, G; DOMBROWSKI, MP; PUDER, KS; KITHIER, K; BIDAT, L; JOHNSON, MP; COTTON, DB			PREDICTIVE VALUE OF FETAL SERUM BETA(2)-MICROGLOBULIN FOR NEONATAL RENAL-FUNCTION	LANCET			English	Note							BETA2-MICROGLOBULIN; MATURATION; INDEX	When fetal urinary-tract malformations (UTM) are discovered, management is based on the prediction of postnatal renal function, currently made by fetal urinary biochemistry and sonography, Serum beta(2)-microglobulin has been used postnatally to estimate renal function and does not cross the placenta. We investigated the relation between fetal serum beta(2)-microglobulin and renal function by comparing 64 unaffected fetuses and 15 fetuses with UTM. A beta(2)-microglobulin above a 5.6 mg/L cut-off gave cross-validated sensitivity of 88.9%, specificity of 98.6%, a positive predictive value of 88.9%, and a negative predictive value of 97.1% for our cohort study.	WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT OBSTET & GYNAECOL,DIV REPROD GENET,DETROIT,MI 48201; WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT PATHOL,DETROIT,MI 48201; HOP NOTRE DAME DE BON SECOURS,CTR PRENATAL DIAG,PARIS,FRANCE	Wayne State University; Wayne State University	BERRY, SM (corresponding author), WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT OBSTET & GYNAECOL,DIV MATERNAL FETAL MED,DETROIT,MI 48201, USA.							ASSADI FK, 1985, KIDNEY INT, V28, P153, DOI 10.1038/ki.1985.135; EUGENE M, 1994, AM J OBSTET GYNECOL, V170, P595, DOI 10.1016/S0002-9378(94)70235-7; GLICK PL, 1985, J PEDIATR SURG, V20, P376, DOI 10.1016/S0022-3468(85)80223-2; KITHIER K, 1974, CLIN CHIM ACTA, V52, P293, DOI 10.1016/0009-8981(74)90113-2; LIVERA LN, 1989, BRIT MED J, V298, P1421, DOI 10.1136/bmj.298.6685.1421; NICOLAIDES K H, 1992, Fetal Diagnosis and Therapy, V7, P1; NICOLINI U, 1992, BRIT J OBSTET GYNAEC, V99, P46, DOI 10.1111/j.1471-0528.1992.tb14391.x; NOLTE S, 1991, PEDIATR NEPHROL, V5, P573, DOI 10.1007/BF00856641; ONASSON LE, 1974, ACTA OBSTET GYNAECOL, V53, P48; WIBELL L, 1973, NEPHRON, V10, P320, DOI 10.1159/000180203	10	54	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1277	1278		10.1016/S0140-6736(95)90928-1	http://dx.doi.org/10.1016/S0140-6736(95)90928-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746060				2022-12-01	WOS:A1995QY93300012
J	CARLEN, PL; GORDON, M				CARLEN, PL; GORDON, M			CARDIOPULMONARY-RESUSCITATION AND NEUROLOGICAL COMPLICATIONS IN THE ELDERLY	LANCET			English	Editorial Material									UNIV TORONTO,BAYCREST CTR GERIATR CARE,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Baycrest	CARLEN, PL (corresponding author), TORONTO HOSP,RES INST,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA.		Carlen, Peter Louis/GLN-7260-2022	Carlen, Peter/0000-0002-3339-8102				BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEDELL SE, 1983, NEW ENGL J MED, V309, P570; DATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; GORDON M, 1995, CARDIOL ELDER, V3, P53; JOHNSTON MV, 1994, NEUROBIOL AGING, V15, P235, DOI 10.1016/0197-4580(94)90119-8; KHACHATURIAN ZS, 1987, NEUROBIOL AGING, V8, P345, DOI 10.1016/0197-4580(87)90073-X; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P	16	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1253	1254		10.1016/S0140-6736(95)90919-2	http://dx.doi.org/10.1016/S0140-6736(95)90919-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746051				2022-12-01	WOS:A1995QY93300003
J	HAYASHI, N; ITO, I; YANAGISAWA, A; KATO, Y; NAKAMORI, S; IMAOKA, S; WATANABE, H; OGAWA, M; NAKAMURA, Y				HAYASHI, N; ITO, I; YANAGISAWA, A; KATO, Y; NAKAMORI, S; IMAOKA, S; WATANABE, H; OGAWA, M; NAKAMURA, Y			GENETIC DIAGNOSIS OF LYMPH-NODE METASTASIS IN COLORECTAL-CANCER	LANCET			English	Article							SOMATIC MUTATIONS; APC GENE; TUMORS; OCCUR	If a regional lymph node taken during surgery for colorectal cancer is found to be free of tumour on histological examination this is taken to be a good sign. However, conventional staining may not be sensitive enough. Mutant-allele-specific amplification (MASA) is a technique that can detect, at the level of an individual cell, micrometastases to lymph nodes that are histologically diagnosed as negative. To examine the prognostic significance of such genetically detectable tumour cells we screened 120 colorectal cancers from patients who had no histologically detectable lymph-node metastasis at the time of surgery for mutations in K-ras (codons 12, 13, and 61) or p53 (exons 5-8). Somatic mutations were identified by MASA in 71 tumours, We next examined preserved tissues from corresponding regional lymph nodes, using MASA to look for the specific mutation found in the primary. Of 37 patients with genetically positive lymph nodes 27 had had a tumour recurrence within 5 years of surgery; none of the 34 patients who were MASA negative for lymph node metastasis had had a recurrence. Genetic diagnosis of lymph node metastasis may be a useful prognostic factor in colorectal cancer, and it could also serve as a selective marker for intensive postoperative adjuvant chemotherapy.	INST CANC RES,DEPT BIOCHEM,TOKYO,JAPAN; INST CANC RES,DEPT PATHOL,TOKYO,JAPAN; CTR ADULT DIS,DEPT SURG ONCOL,OSAKA 537,JAPAN; NIIGATA UNIV,SCH MED,DEPT PATHOL 1,NIIGATA 95021,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT SURG 2,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,MOLEC MED LAB,MINATO KU,TOKYO 108,JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Niigata University; Kumamoto University; University of Tokyo								BAKER SJ, 1990, CANCER RES, V50, P7717; BOS JL, 1989, CANCER RES, V49, P4682; BRODSKY JT, 1992, CANCER-AM CANCER SOC, V69, P322, DOI 10.1002/1097-0142(19920115)69:2<322::AID-CNCR2820690208>3.0.CO;2-B; COHEN AM, 1991, CANCER, V67, P1859, DOI 10.1002/1097-0142(19910401)67:7<1859::AID-CNCR2820670707>3.0.CO;2-A; HAYASHI N, 1994, CANCER RES, V54, P3853; KRONBORG O, 1993, EUR J CANCER, V29A, P575, DOI 10.1016/S0959-8049(05)80155-8; KUNE GA, 1990, DIS COLON RECTUM, V33, P938, DOI 10.1007/BF02139103; LEVINE AJ, 1991, NATURE, V358, P453; LOSI L, 1992, EUR J CANCER, V28A, P1115, DOI 10.1016/0959-8049(92)90468-H; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; PURDIE CA, 1991, AM J PATHOL, V138, P807; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209	16	272	285	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1257	1259		10.1016/S0140-6736(95)90922-2	http://dx.doi.org/10.1016/S0140-6736(95)90922-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746054				2022-12-01	WOS:A1995QY93300006
J	KOOPMANS, PP				KOOPMANS, PP			REGISTRATION OF DRUGS FOR TREATING CANCER AND HIV-INFECTION - A PLEA TO CARRY OUT PHASE-3 TRIALS BEFORE ADMISSION TO THE MARKET	BRITISH MEDICAL JOURNAL			English	Article							CHEMOTHERAPY; THERAPY; QUALITY; AIDS; LIFE	Drugs for cancer and HIV infection tend to be admitted to the market on the basis of results from phase 2 trials. Assessing the benefit-risk balance with phase 2 trials often is difficult-the effect of the drug is usually temporary; the correlation between response or improvement of clinical measurements and the patient's wellbeing is often poor; and the side effects of drugs for these fatal diseases are serious. Therefore, although sometimes difficult to conduct, comparative trials that use standard treatment, placebos, or best supportive care remain the corner-stone for reliably assessing the benefit-risk balance.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT CLIN PHARMACOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	KOOPMANS, PP (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DEPT MED,DIV GEN INTERNAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Koopmans, Peter/O-9276-2015					ATZPODIEN J, 1990, LANCET, V335, P1509, DOI 10.1016/0140-6736(90)93039-R; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BOYD KM, 1992, BRIT MED J, V305, P699; BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; GROOPMAN JE, 1989, ANN INTERN MED, V110, P335, DOI 10.7326/0003-4819-110-5-335; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; LAGAKOS SW, 1992, ANN INTERN MED, V116, P599, DOI 10.7326/0003-4819-116-7-599; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P54; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SILVERMAN WA, 1994, LANCET, V343, P1585; SOUQUET PJ, 1993, LANCET, V342, P19; TOBIAS JS, 1994, BRIT MED J, V308, P961, DOI 10.1136/bmj.308.6934.961; TRIMBLE EL, 1993, J CLIN ONCOL, V11, P2405, DOI 10.1200/JCO.1993.11.12.2405; TWYCROSS R, 1992, BRIT MED J, V305, P969, DOI 10.1136/bmj.305.6860.969; WALSH TD, 1988, BRIT MED J, V296, P477, DOI 10.1136/bmj.296.6620.477; 1994, LANCET, V343, P871	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1305	1306		10.1136/bmj.310.6990.1305	http://dx.doi.org/10.1136/bmj.310.6990.1305			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773046	Green Published, Green Submitted			2022-12-01	WOS:A1995QZ86000026
J	LEGUENNO, B; FORMENTRY, P; WYERS, M; GOUNON, P; WALKER, F; BOESCH, C				LEGUENNO, B; FORMENTRY, P; WYERS, M; GOUNON, P; WALKER, F; BOESCH, C			ISOLATION AND PARTIAL CHARACTERIZATION OF A NEW STRAIN OF EBOLA VIRUS	LANCET			English	Article							ZAIRE; SUDAN	We have isolated a new strain of Ebola virus from a nonfatal human case infected during the autopsy of a wild chimpanzee in the Cote-d'lvoire. The wild troop to which this animal belonged has been decimated by outbreaks of haemorrhagic syndromes. This is the first time that a human infection has been connected to naturally-infected monkeys in Africa. Data from the long-term survey of this troop of chimpanzees could answer questions about the natural reservoir of the Ebola virus.	LAB CENT PATHOL ANIM,BINGERVILLE,COTE IVOIRE; ECOLE NATL VET,HISTOPATHOL ANIM LAB,F-44087 NANTES 30,FRANCE; INST PASTEUR,SERV MICROSCOPIE ELECTR,F-75724 PARIS 15,FRANCE; CHU BICHAT,HISTOPATHOL LAB,F-75877 PARIS 18,FRANCE; UNIV BASEL,INST ZOOL,CH-4051 BASEL,SWITZERLAND; CTR SUISSE RECH SCI,ABIDJAN,COTE IVOIRE	Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Basel	LEGUENNO, B (corresponding author), INST PASTEUR,WHO,COLLABORATING CTR ARBOVIRUSES & HAEMORRHAG FEVERS,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							[Anonymous], 1978, Bull World Health Organ, V56, P271; [Anonymous], 1978, Bull World Health Organ, V56, P247; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BOESCH C, 1989, AM J PHYS ANTHROPOL, V78, P547, DOI 10.1002/ajpa.1330780410; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541; HEYMANN DL, 1980, J INFECT DIS, V142, P372, DOI 10.1093/infdis/142.3.372; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON ED, 1993, T ROY SOC TROP MED H, V87, P536, DOI 10.1016/0035-9203(93)90077-4; JOHNSON KM, 1981, J INFECT DIS, V143, P749, DOI 10.1093/infdis/143.5.749; JOHNSON KM, 1977, LANCET, V1, P569; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; MCCORMICK JB, 1983, J INFECT DIS, V147, P264, DOI 10.1093/infdis/147.2.264; MURPHY F, 1978, PATHOLOGY EBOLA VIRU	14	268	289	1	46	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1271	1274		10.1016/S0140-6736(95)90925-7	http://dx.doi.org/10.1016/S0140-6736(95)90925-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746057				2022-12-01	WOS:A1995QY93300009
J	MANTZOROS, CS; GEORGIADIS, EI; TRICHOPOULOS, D				MANTZOROS, CS; GEORGIADIS, EI; TRICHOPOULOS, D			CONTRIBUTION OF DIHYDROTESTOSTERONE TO MALE SEXUAL-BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							TESTOSTERONE; MEN	Objective-To document the relative importance of endogenous sex steroids in modulating the frequency of orgasms, the dominant aspect of sexual behaviour in healthy eugonadal men. Design-Measurement of adrenal and testicular sex steroids in a sample of army recruits and study of their relation to frequency of orgasms ascertained by questionnaire after potential confounding variables were controlled for. Setting-Military campus and military hospital laboratories in Athens, Greece. Subjects-92 consecutively enrolled healthy male recruits aged 18-22 years. Main outcome measures-Weekly number of orgasms. Serum concentrations of testosterone, dehydroepiandrosterone sulphate, dihydrotestosterone, oestradiol, oestrone, Delta-4-androstenedione, and sex hormone binding globulin. Results-Serum dihydrotestosterone concentration was the only independent hormonal predictor of the frequency of orgasms; an increase in concentration of 1.36 nmol/l (about 2 SD) corresponded to an average increase of one orgasm a week. Conclusions-Differences in concentrations of circulating dihydrotestosterone within the normal range may represent a major predictor of sexual activity in healthy young men.	MIL HOSP 401,ENDOCRINE UNIT,ATHENS,GREECE; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02215	Harvard University; Harvard T.H. Chan School of Public Health			Mantzoros, Christos/Y-2902-2019					ANDERSON RA, 1992, J CLIN ENDOCR METAB, V75, P1503, DOI 10.1210/jc.75.6.1503; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V78, P711, DOI 10.1210/jc.78.3.711; BANCROFT J, 1980, CLIN OBSTET GYNAECOL, V7, P253; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; KNUSSMANN R, 1986, ARCH SEX BEHAV, V15, P429, DOI 10.1007/BF01543113; KRAEMER HC, 1976, ARCH SEX BEHAV, V5, P125, DOI 10.1007/BF01541869; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; TSITOURAS PD, 1987, ENDOCRIN METAB CLIN, V16, P1045, DOI 10.1016/S0889-8529(18)30458-4; WEINBAUER GF, 1990, ACTA ENDOCRINOL-COP, V122, P432, DOI 10.1530/acta.0.1220432	9	69	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1289	1291		10.1136/bmj.310.6990.1289	http://dx.doi.org/10.1136/bmj.310.6990.1289			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773040	Green Published			2022-12-01	WOS:A1995QZ86000018
J	MOOSA, AA; QUORTUM, HA; IBRAHIM, MD				MOOSA, AA; QUORTUM, HA; IBRAHIM, MD			RAPID DIAGNOSIS OF BACTERIAL-MENINGITIS WITH REAGENT STRIPS	LANCET			English	Article								Laboratory examination of cerebrospinal fluid (CSF) is not available in many parts of the world, and without knowledge of CSF glucose, protein, and cells, a diagnosis of meningitis may be missed. Testing CSF with urine reagent strips that measure glucose and protein has given variable results. We tested CSF samples from 234 children with suspected meningitis for glucose, protein, and leucocytes with Combur9 reagent strips. The results were compared with those obtained from the laboratory and also interpreted as indicating bacterial or viral meningitis. There was good agreement between the strip and laboratory method of estimating CSF glucose, protein, and leucocytes. All but 4 of the cases of meningitis were correctly identified by the strip method (sensitivity 97%). 2 (2.9%) of 69 cases of bacterial meningitis were judged by an independent observer to be viral, and 2 (3.3%) of 60 cases of viral meningitis as normal. No normal CSF was diagnosed as meningitis (specificity 100%). The results indicate that Combur9 reagent strips can distinguish normal from infected CSF and are of value in the diagnosis of meningitis.	FARWANIYA HOSP,MINIST PUBL HLTH,KUWAIT,KUWAIT		MOOSA, AA (corresponding author), KUWAIT UNIV,FAC MED,DEPT PAEDIAT,POB 24923,SAFAT 13110,KUWAIT.							FEINBLOO.RI, 1969, J PEDIATR, V74, P615, DOI 10.1016/S0022-3476(69)80047-8; MULLER PD, 1987, ANN TROP PAEDIATR, V7, P287, DOI 10.1080/02724936.1987.11748527; SCHWARTZ RP, 1971, J PEDIATR-US, V78, P677, DOI 10.1016/S0022-3476(71)80474-2	3	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1290	1291		10.1016/S0140-6736(95)90931-1	http://dx.doi.org/10.1016/S0140-6736(95)90931-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746063				2022-12-01	WOS:A1995QY93300015
J	OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE				OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE			10-YEAR CEREBROVASCULAR MORBIDITY AND MORTALITY IN 68-YEAR-OLD MEN WITH ASYMPTOMATIC CAROTID STENOSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; ARTERY ATHEROSCLEROSIS; RISK-FACTORS; STROKE; POPULATION; PREVALENCE; BRUITS	Objective-To study the natural course of carotid artery stenosis detected by ultrasonography. Design-Prospective cohort study. Baseline examination in 1982-3 included ultrasound examination of carotid arteries, measurement of ankle-brachial blood pressure index, and detection of atrial fibrillation by 24 hour ambulatory electrocardiography. Setting-Malmo, a city in southern Sweden with 230 000 inhabitants. Subjects-470 men aged 68 years randomly selected hom the population. Main outcome measures-Incidence of stroke and transient ischaemic attack and all cause mortality during 10 years of follow up in relation to carotid stenosis, leg artery disease (ankle-brachial blood pressure index below 0.9), and atrial fibrillation. Results-Fifty men had a stroke; six of these were haemorrhagic. Another 11 had a transient ischaemic attack. Eighteen of the men with carotid stenosis (21.6 events/1000 person years) and 43 of the men with normal carotid arteries (14.8 events/1000 person years) had a stroke or transient ischaemic attack (P = 0.188). Men with atrial fibrillation had an increased rate of cerebrovascular events (36.7/1000 person years (P = 0.048). The highest rate was found in men with asymptomatic disease of the leg arteries (38.6/1000 person years) (P < 0.001). The increased risk of stroke or transient ischaemic attack in this group remained after multivariate analysis (relative risk 2.0; 95% confidence interval 1.1 to 3.7). Conclusions-In this cohort carotid stenosis was not associated with an increased risk of stroke. Part of this lack of association was explained by the high mortality from ischaemic heart disease in men with severe stenosis. Twenty seven of the 61 cerebrovascular events, however, occurred in men who had normal carotid arteries, normal ankle pressure, and no atrial fibrillation.	LUND UNIV, MALMO GEN HOSP, DEPT CLIN PHYSIOL, S-21401 MALMO, SWEDEN	Lund University	OGREN, M (corresponding author), LUND UNIV, MALMO GEN HOSP, DEPT COMMUNITY HLTH SCI, S-21401 MALMO, SWEDEN.							ANDERSON S, 1980, STATISTICAL METHODS; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CARTER SA, 1968, CIRCULATION, V37, P624, DOI 10.1161/01.CIR.37.4.624; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; COX DR, 1972, J R STAT SOC B, V34, P187; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; Criqui M H, 1991, Drugs, V42 Suppl 5, P16; CULLEN SJ, 1983, CIRCULATION, V68, P83; DYKEN ML, 1984, STROKE, V15, P1105; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; GUNDERSEN J, 1972, ACTA CHIR SCAND S426, V26; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; ISACSSON SO, 1972, ACTA MED SCANDI S537, V192; JANZON L, 1981, CIRCULATION, V63, P1339, DOI 10.1161/01.CIR.63.6.1339; JUNGQUIST G, 1986, CLIN PHYSIOL, V6, P319, DOI 10.1111/j.1475-097X.1986.tb00237.x; JUNGQUIST G, 1989, STROKE, V20, P1327, DOI 10.1161/01.STR.20.10.1327; JUULMOLLER S, 1991, J INTERN MED, V230, P143, DOI 10.1111/j.1365-2796.1991.tb00422.x; LANDI G, 1992, LANCET, V339, P402, DOI 10.1016/0140-6736(92)90086-I; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SUTTON KC, 1987, STROKE, V18, P817, DOI 10.1161/01.STR.18.5.817; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	23	62	63	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	1995	310	6990					1294	1298		10.1136/bmj.310.6990.1294	http://dx.doi.org/10.1136/bmj.310.6990.1294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773042	Green Published			2022-12-01	WOS:A1995QZ86000020
J	SAINSBURY, R; HAWARD, B; RIDER, L; JOHNSTON, C; ROUND, C				SAINSBURY, R; HAWARD, B; RIDER, L; JOHNSTON, C; ROUND, C			INFLUENCE OF CLINICIAN WORKLOAD AND PATTERNS OF TREATMENT ON SURVIVAL FROM BREAST-CANCER	LANCET			English	Article								Chemotherapy and hormone therapy prolong disease-free and overall survival for patients with breast cancer in the clinical-trial setting, but it is not clear if this translates into a benefit on a population basis. It is also not clear if surgical caseload has any influence on survival. We used cancer-registry data from 12 861 patients with breast cancer treated in Yorkshire, UK, between 1979 and 1988, and found that patients of surgeons with higher rates of usage of chemotherapy and hormone therapy (regional mean usage 9.3%, range 0-46%) had prolonged survival. There was considerable variation in survival of breast cancer patients between surgeons, but their rate of use of chemotherapy and hormone therapy explained about 26% of this survival variation. Had the practice of the surgeons with the better outcomes been used by all treating clinicians, 5-year survival would have increased by about 4-5%, Examination of differences in survival as a function of consultant caseload demonstrated poorer results amongst those surgeons treating less than 30 new cases of breast cancer per year (risk ratio [95% CI] for treating >30 compared with <10=0.85 [0.77-0.93]). We recommend that patients with breast cancer be dealt with only by clinicians who see more than 30 new cases per year and who have a full range of treatment options available within a multidisciplinary setting.	COOKRIDGE HOSP,YORKSHIRE CANC ORG,DEPT CANC STUDIES,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND; COOKRIDGE HOSP,YORKSHIRE CANC ORG,CLIN TRIALS & RES UNIT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND; COOKRIDGE HOSP,YORKSHIRE CANC ORG,YORKSHIRE CANC REGISTRY,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND	Cookridge Hospital; Cookridge Hospital; University of Leeds; Cookridge Hospital	SAINSBURY, R (corresponding author), ROYAL INFIRM,DEPT SURG,HUDDERSFIELD HD3 3EA,W YORKSHIRE,ENGLAND.							BERINO F, IN PRESS IARC SCI PU, V132; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS S, 1987, JNCI-J NATL CANCER I, V78, P471; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; HENDERSON R, 1955, STAT MED, V14, P161; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MATTHEWS HR, 1986, BRIT J SURG, V73, P621; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MORPHET C, 1992, INTERPRETATION SMALL, P62; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; 1994, CONSULTATIVE DOCUMEN; 1995, MACMILLAN DIRECTORY; 1995, PROVISION BREAST SER	17	309	310	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1265	1270		10.1016/S0140-6736(95)90924-9	http://dx.doi.org/10.1016/S0140-6736(95)90924-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746056				2022-12-01	WOS:A1995QY93300008
J	SEN, D; OSBORNE, K				SEN, D; OSBORNE, K			GENERAL-PRACTITIONERS KNOWLEDGE OF NOTIFIABLE, REPORTABLE, AND PRESCRIBED DISEASES	BRITISH MEDICAL JOURNAL			English	Article									HLTH & SAFETY EXECUT,EPIDEMIOL & MED STAT UNIT,BOOTLE L20 3QZ,MERSEYSIDE,ENGLAND		SEN, D (corresponding author), HLTH & SAFETY EXECUT,MERSEYSIDE & CHESHIRE AREA OFF,BOOTLE L20 3PG,MERSEYSIDE,ENGLAND.							BOILLAT MA, 1994, OCCUP MED-OXFORD, V44, P123, DOI 10.1093/occmed/44.3.123; 1991, N12 BEN AG LEAFL; 1992, COMPENDIUM HLTH STAT; 1986, HSR23 OFF SAF EC	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1299	1299		10.1136/bmj.310.6990.1299	http://dx.doi.org/10.1136/bmj.310.6990.1299			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773043	Green Published			2022-12-01	WOS:A1995QZ86000021
J	STENTON, SC; SANDHU, PS; HENDRICK, DJ				STENTON, SC; SANDHU, PS; HENDRICK, DJ			INDUSTRIAL INJURY BENEFIT FOR OCCUPATIONAL ASTHMA IN NORTH-EAST OF ENGLAND	BRITISH MEDICAL JOURNAL			English	Article									NEWCASTLE GEN HOSP,REG UNIT OCCUPAT LUNG DIS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	STENTON, SC (corresponding author), NEWCASTLE GEN HOSP,CHEST UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.							CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; LUCMALO J, 1991, AM REV RESPIR DIS, V143, P528; MEREDITH SK, 1994, OCCUP MED-OXFORD, V44, P183, DOI 10.1093/occmed/44.4.183; 1989, NI226 DEP HLTH SOC S	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1299	1300		10.1136/bmj.310.6990.1299a	http://dx.doi.org/10.1136/bmj.310.6990.1299a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773044	Green Published			2022-12-01	WOS:A1995QZ86000022
J	TENNANT, A; FEAR, J; PICKERING, A; HILLMAN, M; CUTTS, A; CHAMBERLAIN, MA				TENNANT, A; FEAR, J; PICKERING, A; HILLMAN, M; CUTTS, A; CHAMBERLAIN, MA			PREVALENCE OF KNEE PROBLEMS IN THE POPULATION AGED 55 YEARS AND OVER - IDENTIFYING THE NEED FOR KNEE ARTHROPLASTY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OSTEOARTHRITIS; GUIDELINES; ARTHRITIS; HIP	Objective-To determine the prevalence of knee problems in people aged 55 years and over and identify those who should be considered for knee arthroplasty. Design-Postal survey; questionnaires were sent to a multistage stratified probability sample of residents of North Yorkshire Health Authority aged 55 and over. Setting-A health district with a population of 210 000 aged 55 and over. Results-An initial four page postal questionnaire produced an 86% response rate among 18 827 eligible patients. A subsequent detailed questionnaire sent to 1277 patients with knee problems (with a response rate of 78%) then determined the prevalence of severe pain and severe disability. Pain and disability consistent with the need to consider arthroplasty was found in 20.4/1000 (95% confidence interval 18.0 to 23.1); of these, 4.1 (2.7 to 5.8)/1000 had extreme disability. Age and sex specific rates in men who might benefit from arthroplasty were, in those aged 55-64, 12.9 (8.4 to 19.0)/1000; aged 65-74, 12.1 (7.4 to 18.4)/1000; aged 75 and over, 20.3 (12.9 to 30.5)/ 1000. In women aged 55-64 the rates were 12.9 (8.6 to 18.7)/1000; aged 65-74, 19.6 (13.9 to 26.7)/1000; aged 75 years and over, 42.6 (34.3 to 52.4)/1000. Conclusions-Total knee replacement has until recently been considered unreliable and often seen as a last resort for many with severe knee problems. Advances in prosthesis design and surgical and anaesthetic techniques have transformed this procedure into a reliable option with a potential for reducing disability and dependency in a large number of people in the community. Understandably, the prevalence pool of those who may benefit is large; health authorities and, increasingly, general practitioners should consider purchasing more total knee replacement surgery to offer real choice to those in need.	N YORKSHIRE HLTH, PUBL HLTH MED, YORK YO1 1PE, N YORKSHIRE, ENGLAND		TENNANT, A (corresponding author), UNIV LEEDS, RES SCH MED, RHEUMATOL & REHABIL RES UNIV, LEEDS LS2 9NZ, W YORKSHIRE, ENGLAND.							COOPER C, 1994, ANN RHEUM DIS, V53, P90, DOI 10.1136/ard.53.2.90; CROFT P, 1992, SCAND J WORK ENV HEA, V18, P59, DOI 10.5271/sjweh.1608; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; HARRIS AI, 1971, SAMPLE SURVEYS LOCAL; Harris Amelia I, 1971, HANDICAPPED IMPAIRED; KIRWAN JR, 1994, BRIT J RHEUMATOL, V33, P357; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MARTIN J, 1988, OPCS1 SURV DIS GREAT; RAND JA, 1991, J BONE JOINT SURG AM, V73A, P397, DOI 10.2106/00004623-199173030-00011; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; SCOTT DL, 1993, J ROY COLL PHYS LOND, V27, P391; STEVENS A, 1994, HLTH NEEDS ASSESSMEN, V1; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P81, DOI 10.1136/jech.45.1.81; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILKIN D, 1992, HOSPITAL REFERRALS, P76; WILLIAMS MH, 1994, HLTH CARE NEEDS ASSE, V1, P448; 1971, SERVICES HANDICAPPED	19	80	81	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	1995	310	6990					1291	1293		10.1136/bmj.310.6990.1291	http://dx.doi.org/10.1136/bmj.310.6990.1291			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773041	Green Published			2022-12-01	WOS:A1995QZ86000019
J	TRACEY, I; SCOTT, RB; THOMPSON, CH; DUNN, JF; BARNES, PRJ; STYLES, P; KEMP, GJ; RAE, CD; PIKE, M; RADDA, GK				TRACEY, I; SCOTT, RB; THOMPSON, CH; DUNN, JF; BARNES, PRJ; STYLES, P; KEMP, GJ; RAE, CD; PIKE, M; RADDA, GK			BRAIN ABNORMALITIES IN DUCHENNE MUSCULAR-DYSTROPHY - P-31 MAGNETIC-RESONANCE SPECTROSCOPY AND NEUROPSYCHOLOGICAL STUDY	LANCET			English	Article							MUSCLE; IMPAIRMENT; METABOLISM; SKELETAL; NEURONS; CELLS	Duchenne muscular dystrophy (DMD) is one of a range of muscular dystrophies caused by abnormalities of the short arm of the X chromosome (Xp21), which often cause mental retardation in addition to progressive muscular weakness. Normal dystrophin expression is lacking in both skeletal muscle and brain of affected subjects. Phosphorus-Si magnetic resonance spectroscopy has shown several abnormalities in skeletal muscle in DMD. We looked for similar abnormalities in brain in patients with DMD and related the findings to neuropsychological test results. We studied by magnetic resonance spectroscopy 19 boys (aged 76-167 months) diagnosed as having DMD and 19 control boys of similar age (87-135 months). intelligence quotient (IQ) was assessed with the Wechsler Intelligence Scale for children. The DMD patients had significantly higher values than the controls in the brain ratios of inorganic phosphate to adenosine triphosphate (mean 0.53 [SD 0.21] vs 0.36 [0.09], p=0.003), to phosphomonoesters (0.40 [0.07] vs 0.29 [0.07], p=0.0001), and to phosphocreatine (0.44 [0.10] vs 0.37 [0.08], p=0.02). There were significant differences between the DMD patients and the controls in full-scale IQ (76 [16] vs 101 [16], p=0.0001), performance IQ (78 [17] vs 94 [14], p=0.003), and verbal IQ (78 [17] vs 106 [17], p=0.0001). These altered metabolite ratios parallel the findings in dystrophic muscle and suggest bioenergetic similarities in tissues that lack dystrophin.	OXFORD RADCLIFFE HOSP,MRC,BIOCHEM & CLIN MAGNET RESONANCE UNIT,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; RADCLIFFE INFIRM NHS TRUST,DEPT NEUROSURG,RUSSELL CAIRNS UNIT,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; University of Oxford			Kemp, Graham J/A-7540-2008; Thompson, Campbell/E-2885-2010; Rae, Caroline/B-7537-2008	Kemp, Graham J/0000-0002-8324-9666; Thompson, Campbell/0000-0002-5164-3327; Rae, Caroline/0000-0003-0673-8084; Tracey, Irene/0000-0003-4134-6115	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALQUDAH AA, 1990, PEDIATR NEUROL, V6, P57, DOI 10.1016/0887-8994(90)90081-B; ARCHIBALD K C, 1959, Arch Phys Med Rehabil, V40, P150; BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61; BATTOCLETTI JH, 1979, MED BIOL ENG COMPUT, V17, P183, DOI 10.1007/BF02440927; Blake Derek J., 1994, Trends in Cell Biology, V4, P19, DOI 10.1016/0962-8924(94)90034-5; BULLFIELD G, 1984, P NATL ACAD SCI USA, V81, P1189; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805; DUNN JF, 1993, P ROY SOC B-BIOL SCI, V251, P201, DOI 10.1098/rspb.1993.0030; DUNN JF, 1991, BIOCHIM BIOPHYS ACTA, V1096, P115, DOI 10.1016/0925-4439(91)90048-E; DUNN JF, 1991, J NEUROL SCI, V103, P226, DOI 10.1016/0022-510X(91)90168-7; DUNN JF, 1993, J NEUROL SCI, V114, P76, DOI 10.1016/0022-510X(93)90052-Z; ERVASTI JM, 1992, CELL, V66, P1121; HODGSON SV, 1992, NEUROMUSCULAR DISORD, V2, P269, DOI 10.1016/0960-8966(92)90059-F; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; HOPF FW, 1992, BRAIN RES, V578, P49; JAGADHA V, 1988, PEDIATR NEUROL, V4, P87, DOI 10.1016/0887-8994(88)90047-1; KARAGAN NJ, 1979, PSYCHOL BULL, V86, P250; KEMP GJ, 1993, J NEUROL SCI, V116, P201, DOI 10.1016/0022-510X(93)90326-T; KIM TW, 1992, P NATL ACAD SCI USA, V89, P11642, DOI 10.1073/pnas.89.23.11642; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; MONACO AP, 1985, NATURE, V318, P842; Muntoni F, 1991, Neuromuscul Disord, V1, P121, DOI 10.1016/0960-8966(91)90059-2; ROSMAN NP, 1970, NEUROLOGY, V20, P324; SANCHEZ V, 1988, BIOPHYS J, V53, P438; SOLLEE ND, 1985, J CLIN EXP NEUROPSYC, V7, P486, DOI 10.1080/01688638508401280; TRACEY I, 1992, 11TH P ANN M SOC MAG, V2, P2125; WHELAN TB, 1987, DEV MED CHILD NEUROL, V29, P212; YOSHIOKA M, 1980, ARCH DIS CHILD, V55, P589, DOI 10.1136/adc.55.8.589	30	46	48	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1260	1264		10.1016/S0140-6736(95)90923-0	http://dx.doi.org/10.1016/S0140-6736(95)90923-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746055				2022-12-01	WOS:A1995QY93300007
J	WARLOW, C				WARLOW, C			ENDARTERECTOMY FOR ASYMPTOMATIC CAROTID STENOSIS	LANCET			English	Editorial Material							POPULATION; PREVALENCE; BRUIT				WARLOW, C (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP NHS TRUST,DEPT CLIN NEUROSCI,EDINBURGH,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1992, Mayo Clin Proc, V67, P513; CLAGETT GP, 1984, SURGERY, V96, P823; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; LAGNEAU P, 1993, J MAL VASCUL, V18, P209; MEISSNER I, 1987, JAMA-J AM MED ASSOC, V258, P2704; MITCHELL J R, 1962, Br Med J, V1, P1293; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RICCI S, 1991, CEREBROVASC DIS, V1, P16, DOI 10.1159/000108810; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; WIEBERS DO, 1990, STROKE, V21, P984, DOI 10.1161/01.STR.21.7.984; 1991, LANCET, V337, P1235; 1995, JAMA-J AM MED ASSOC, V273, P1421; 1995, LANCET, V345, P209; 1991, STROKE, V22, P1229; 1993, MANAGEMENT PATIENTS; 1991, NEW ENGL J MED, V325, P445	19	67	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1254	1255		10.1016/S0140-6736(95)90920-6	http://dx.doi.org/10.1016/S0140-6736(95)90920-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746052				2022-12-01	WOS:A1995QY93300004
J	CANNELL, MB; CHENG, H; LEDERER, WJ				CANNELL, MB; CHENG, H; LEDERER, WJ			THE CONTROL OF CALCIUM-RELEASE IN HEART-MUSCLE	SCIENCE			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; RAT VENTRICULAR MYOCYTES; CA-2+ RELEASE; SKELETAL-MUSCLE; CONTRACTION; ACTIVATION; RYANODINE; CHANNEL; TRANSIENTS; CELLS	The control of calcium release from intracellular stores (the sarcoplasmic reticulum) in cardiac muscle was examined with the use of a confocal microscope and voltage clamp techniques. Depolarization evoked graded calcium release by altering the extent of spatial and temporal summation of elementary calcium release events called ''calcium sparks.'' These evoked sparks were triggered by local L-type calcium channel currents in a stochastic manner, were similar at different potentials, and resembled spontaneous calcium sparks. Once triggered, the calcium release from the sarcoplasmic reticulum during a calcium spark was independent of the duration of the triggering calcium influx. These results were used to develop a unifying model for cardiac excitation-contraction coupling that explains the large (but paradoxically stable) amplification of the trigger calcium influx by a combination of digital and analog behavior.	ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND; UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	St Georges University London; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010	Heping, Cheng/0000-0002-9604-6702; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036974, R37HL036974, R01HL025675] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25675, HL36974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALKE CW, 1994, J PHYSIOL-LONDON, V474, P447, DOI 10.1113/jphysiol.1994.sp020036; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; CALLEWAERT G, 1988, P NATIONAL ACADEMY S, V82, P2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG H, 1994, AM J PHYSIOL, V428, P415; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERGUSON DG, 1984, J CELL BIOL, V99, P1735, DOI 10.1083/jcb.99.5.1735; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; ROSE WC, 1992, J PHYSIOL-LONDON, V456, P267, DOI 10.1113/jphysiol.1992.sp019336; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TRAFFORD AW, 1993, PFLUG ARCH EUR J PHY, V425, P181, DOI 10.1007/BF00374521; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037	31	502	512	0	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1045	1049		10.1126/science.7754384	http://dx.doi.org/10.1126/science.7754384			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754384				2022-12-01	WOS:A1995QY93400040
J	CANO, RJ; BORUCKI, MK				CANO, RJ; BORUCKI, MK			REVIVAL AND IDENTIFICATION OF BACTERIAL-SPORES IN 25-MILLION-YEAR-OLD TO 40-MILLION-YEAR-OLD DOMINICAN AMBER	SCIENCE			English	Article							LARVAL PROVISIONS; APIS-MELLIFERA; GENUS BACILLUS; STINGLESS BEE; SOLITARY BEES; MICROORGANISMS; POLLEN; MICROBIOLOGY; HONEY; DNA	A bacterial spore was revived, cultured, and identified from the abdominal contents of extinct bees preserved for 25 to 40 million years in buried Dominican amber. Rigorous surface decontamination of the amber and aseptic procedures were used during the recovery of the bacterium. Several lines of evidence indicated that the isolated bacterium was of ancient origin and not an extant contaminant. The characteristic enzymatic, biochemical, and 16S ribosomal DNA profiles indicated that the ancient bacterium is most closely related to extant Bacillus sphaericus.			CANO, RJ (corresponding author), CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,SAN LUIS OBISPO,CA 93407, USA.							CANO RJ, 1994, APPL ENVIRON MICROB, V60, P2164, DOI 10.1128/AEM.60.6.2164-2167.1994; CANO RJ, 1993, NATURE, V363, P536, DOI 10.1038/363536a0; CANO RJ, 1993, BIOTECHNIQUES, V15, P8; Claus D., 1986, BERGEYS MANUAL SYSTE; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GEST H, 1987, MICROBIOL SCI, V4, P69; GILLIAM M, 1978, APIDOLOGIE, V9, P213, DOI 10.1051/apido:19780305; GILLIAM M, 1990, APIDOLOGIE, V21, P89, DOI 10.1051/apido:19900201; GILLIAM M, 1985, BIOTROPICA, V17, P28, DOI 10.2307/2388374; GILLIAM M, 1979, APIDOLOGIE, V10, P269, DOI 10.1051/apido:19790304; GILLIAM M, 1976, J INVERTEBR PATHOL, V28, P275, DOI 10.1016/0022-2011(76)90137-3; GILLIAM M, 1984, APIDOLOGIE, V15, P1, DOI 10.1051/apido:19840101; GILLIAM M, 1990, APIDOLOGIE, V21, P99, DOI 10.1051/apido:19900202; GILLIAM M, 1988, MICROBIOS, V55, P95; GILLIAM M, 1991, J INVERTEBR PATHOL, V58, P286, DOI 10.1016/0022-2011(91)90077-4; Gordon RE, 1973, THE GENUS BACILLUS; GOUY M, 1990, RIBOSOME; KENNEDY MJ, 1994, MICROBIOL-SGM, V140, P2513, DOI 10.1099/00221287-140-10-2513; Li W-H., 1991, FUNDAMENTALS MOL EVO; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACHADO J O, 1971, Ciencia e Cultura (Sao Paulo), V23, P625; MORAN NA, 1993, P ROY SOC B-BIOL SCI, V253, P167, DOI 10.1098/rspb.1993.0098; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; Poinar G.O., 1992, LIFE AMBER; POTTS M, 1994, MICROBIOL REV, V58, P755, DOI 10.1128/MMBR.58.4.755-805.1994; Roubik D.W., 1990, ECOLOGY NATURAL HIST, V1st ed., P526, DOI [10.1126/science.248.4958.1026, DOI 10.1126/SCIENCE.248.4958.1026]; SEAWARD MRD, 1976, NATURE, V261, P407, DOI 10.1038/261407a0; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; SETLOW P, 1993, APPL BACTERIOL S S, V76, pS49; WILLE ALVARO, 1964, REV BIOL TROP, V12, P187; WOESE CR, 1991, EVOLUTION MOL LEVEL	32	371	405	0	109	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1060	1064		10.1126/science.7538699	http://dx.doi.org/10.1126/science.7538699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7538699				2022-12-01	WOS:A1995QY93400044
J	CHINNAIYAN, AM; OROURKE, K; TEWARI, M; DIXIT, VM				CHINNAIYAN, AM; OROURKE, K; TEWARI, M; DIXIT, VM			FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CELL-DEATH; MONOCLONAL-ANTIBODY; GENE CED-3; ANTIGEN; INHIBITOR; INDUCTION; RECEPTOR; ENCODES	Using the cytoplasmic domain of Pas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Pas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8. FADD contains a death domain homologous to the death domains of Pas and TNFR-1. A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Pas, suggesting a death domain to death domain interaction. Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Pas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme; These findings suggest that FADD may play an important role in the proximal signal transduction of Fas.			CHINNAIYAN, AM (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				BAGLIONI C, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; HARPER JW, 1993, CELL, V75, P805; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HU HM, 1994, J BIOL CHEM, V369, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RON D, 1992, BIOTECHNIQUES, V13, P866; RON D, 1992, BIOTECHNIQUES, V14, P221; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU; SONG HY, 1994, J BIOL CHEM, V269, P22492; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	2044	2151	4	64	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					505	512		10.1016/0092-8674(95)90071-3	http://dx.doi.org/10.1016/0092-8674(95)90071-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538907	Bronze			2022-12-01	WOS:A1995QZ71000007
J	COLAMARINO, SA; TESSIERLAVIGNE, M				COLAMARINO, SA; TESSIERLAVIGNE, M			THE AXONAL CHEMOATTRACTANT NETRIN-1 IS ALSO A CHEMOREPELLENT FOR TROCHLEAR MOTOR AXONS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD; C-ELEGANS; NEURITE OUTGROWTH; GUIDES CELL; NEURONS; RAT; OCULOMOTOR; EXPRESSION; GUIDANCE	Extending axons are guided in part by diffusible chemoattractants that lure them to their targets and by diffusible chemorepellents that keep them away from nontarget regions. Floor plate cells at the ventral midline of the neural tube express a diffusible chemoattractant, netrin-1, that attracts a group of ventrally directed axons. Here we report that floor plate cells also have a long-range repulsive effect on a set of axons, trochlear motor axons, that grow dorsally away from the floor plate in vivo. COS cells secreting recombinant netrin-1 mimic this effect, suggesting that netrin-1 is a bifunctional guidance cue that simultaneously attracts some axons to the floor plate while steering others away. This bifunctionality of netrin-1 in vertebrates mirrors the dual actions of UNC-6, a C. elegans homolog of netrin-1, which is involved in guiding both dorsal and ventral migrations in the nematode.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, DEV BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, NEUROSCI PROGRAM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	COLAMARINO, SA (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA.							ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; CHEDOTAL A, 1995, EUR J NEUROSCI, V7, P198, DOI 10.1111/j.1460-9568.1995.tb01056.x; COWAN WM, 1967, J EXP ZOOL, V164, P267, DOI 10.1002/jez.1401640210; DEROUICHE A, 1994, J COMP NEUROL, V341, P340, DOI 10.1002/cne.903410305; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FRITZSCH B, 1993, DEV BRAIN RES, V74, P122, DOI 10.1016/0165-3806(93)90091-N; FRITZSCH B, 1990, NEUROSCI LETT, V114, P129, DOI 10.1016/0304-3940(90)90060-M; FRITZSCH B, 1988, CELL TISSUE RES, V252, P223; FRITZSCH B, 1995, IN PRESS J NEUROBIOL; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUTHRIE S, 1995, IN PRESS NEURON, V14; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATESZ C, 1990, NEUROSCI LETT, V116, P1, DOI 10.1016/0304-3940(90)90376-K; MATTHES D, 1985, CELL, V81, P631; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MURPHY EH, 1990, J COMP NEUROL, V295, P685; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PRINCE JT, 1992, DEV BRAIN RES, V68, P193, DOI 10.1016/0165-3806(92)90061-Z; PUELLES L, 1977, ANAT EMBRYOL, V150, P187, DOI 10.1007/BF00316650; RAMONYCAJAL S, 1892, CELLULE, V9, P119; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINCLAIR JOHN G., 1958, TEXAS REPTS BIOL AND MED, V16, P253; SOHAL GS, 1985, J COMP NEUROL, V239, P227, DOI 10.1002/cne.902390209; SOHAL GS, 1977, EXP NEUROL, V56, P227, DOI 10.1016/0014-4886(77)90152-2; SOHAL GS, 1991, J COMP NEUROL, V304, P187, DOI 10.1002/cne.903040204; SOHAL GS, 1991, J NEUROSCI, V23, P10; SONNTAG R, 1987, NEUROSCI LETT, V77, P143, DOI 10.1016/0304-3940(87)90576-3; Szekely G, 1993, Adv Anat Embryol Cell Biol, V128, P1; TAMADA A, 1995, IN PRESS NEURON, V14; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WEHRLE B, 1990, DEVELOPMENT, V110, P401; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	50	492	505	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					621	629		10.1016/0092-8674(95)90083-7	http://dx.doi.org/10.1016/0092-8674(95)90083-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758116	Bronze			2022-12-01	WOS:A1995QZ71000019
J	FORMAN, BM; UMESONO, K; CHEN, J; EVANS, RM				FORMAN, BM; UMESONO, K; CHEN, J; EVANS, RM			UNIQUE RESPONSE PATHWAYS ARE ESTABLISHED BY ALLOSTERIC INTERACTIONS AMONG NUCLEAR HORMONE RECEPTORS	CELL			English	Article							RETINOID-X-RECEPTOR; TATA-BINDING PROTEIN; THYROID-HORMONE; DNA-BINDING; TRANSCRIPTION FACTOR; ACID RECEPTORS; AUXILIARY PROTEIN; ORPHAN RECEPTORS; MAMMALIAN-CELLS; GENE-EXPRESSION	Heterodimerization is a common paradigm among eukaryotic transcription factors. The 9-cis retinoic acid receptor (RXR) serves as a common heterodimerization partner for several nuclear receptors, including the thyroid hormone receptor (T(3)R) and retinoic acid receptor (RAR). This raises the question as to whether these complexes possess dual hormonal responsiveness. We devised a strategy to examine the transcriptional properties of each receptor individually or when tethered to a heterodimeric partner. We find that the intrinsic binding properties of RXR are masked in T(3)R-RXR and RAR-RXR heterodimers. In contrast, RXR is active as a non-DNA-binding cofactor with the NGFI-B/Nurr1 orphan receptors. Heterodimerization of RXR with constitutively active NGFI-B/Nurr1 creates a novel hormone-dependent complex. These findings suggest that allosteric interactions among heterodimers create complexes with unique properties. We suggest that allostery is a critical feature underlying the generation of diversity in hormone response networks.	HOWARD HUGHES MED INST, GENE EXPRESS LAB, SAN DIEGO, CA 92037 USA	Howard Hughes Medical Institute	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES, SAN DIEGO, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	566	591	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					541	550		10.1016/0092-8674(95)90075-6	http://dx.doi.org/10.1016/0092-8674(95)90075-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758108	Bronze			2022-12-01	WOS:A1995QZ71000011
J	FUNG, PA; GAERTIG, J; GOROVSKY, MA; HALLBERG, RL				FUNG, PA; GAERTIG, J; GOROVSKY, MA; HALLBERG, RL			REQUIREMENT OF A SMALL CYTOPLASMIC RNA FOR THE ESTABLISHMENT OF THERMOTOLERANCE	SCIENCE			English	Article							HEAT-SHOCK RESPONSE; III-TRANSCRIBED RNA; TETRAHYMENA-THERMOPHILA; PROTEIN-SYNTHESIS	Thermotolerance is an inducible state that endows cells with an enhanced resistance to thermal killing. Heat shock proteins are believed, and in a few instances have been shown, to be the agents conferring this resistance. The role of a small cytoplasmic RNA (G8 RNA) in developing thermotolerance in Tetrahymena thermophila was investigated by creating a strain devoid of all functional G8 genes. These G8 null cells mounted an apparently normal heat shock response, but they were unable to establish thermotolerance.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	Syracuse University; University of Rochester			Gaertig, Jacek/F-1553-2010		NIGMS NIH HHS [GM26973, GM46302] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046302, R01GM026973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FUNG PA, UNPUB; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG JA, 1994, P NATL ACAD SCI USA, V91, P9196; HALLBERG EM, 1992, NUCLEIC ACIDS RES, V20, P912, DOI 10.1093/nar/20.4.912; HALLBERG EM, UNPUB; HALLBERG RL, 1981, CELL, V26, P47, DOI 10.1016/0092-8674(81)90032-5; HALLBERG RL, 1984, MOL CELL BIOL, V4, P2170, DOI 10.1128/MCB.4.10.2170; HALLBERG RL, 1985, MOL CELL BIOL, V5, P2061, DOI 10.1128/MCB.5.8.2061; HALLBERG RL, 1986, MOL CELL BIOL, V6, P2267, DOI 10.1128/MCB.6.6.2267; HALLBERG RL, 1989, STRESS INDUCED PROTE, P107; HALLBERG RL, 1983, MOL CELL BIOL, V3, P502; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KRAUS KW, 1987, P NATL ACAD SCI USA, V84, P383, DOI 10.1073/pnas.84.2.383; KRAUS KW, 1986, MOL CELL BIOL, V6, P3854, DOI 10.1128/MCB.6.11.3854; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MCMULLIN TW, 1986, MOL CELL BIOL, V6, P2527, DOI 10.1128/MCB.6.7.2527; NOVER L., 1991, HEAT SHOCK RESPONSE; Parsell DA, 1994, BIOL HEAT SHOCK PROT; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365	21	18	18	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1036	1039		10.1126/science.7754381	http://dx.doi.org/10.1126/science.7754381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754381				2022-12-01	WOS:A1995QY93400037
J	GACY, AM; GOELLNER, G; JURANIC, N; MACURA, S; MCMURRAY, CT				GACY, AM; GOELLNER, G; JURANIC, N; MACURA, S; MCMURRAY, CT			TRINUCLEOTIDE REPEATS THAT EXPAND IN HUMAN-DISEASE FORM HAIRPIN STRUCTURES IN-VITRO	CELL			English	Article							HUNTINGTONS-DISEASE; MISMATCH REPAIR; BASE PAIR; DNA; MUTATIONS; SEQUENCE; CANCER; DUPLEX; LENGTH; GENES	We show that repeating units from all reported disease genes are capable of forming hairpins of common structure and threshold stability, The threshold stability is roughly -50 kcal per hairpin and is influenced by the flanking sequence of the gene, Hairpin stability has two components, sequence and length; only DNA of select sequences and the correct length can form hairpins of threshold energy. There is a correlation among the ability to form hairpins of threshold stability, the sequence selectivity of expansion, and the length dependence of expansion. Additionally, hairpin formation provides a potential structural basis for the constancy of the CCG region of the Huntington's disease gene in individuals and explains the stabilizing effects of AGG interruptions in FMR1 alleles.	MAYO CLIN & MAYO GRAD SCH MED,DEPT PHARMACOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO GRAD SCH MED,MOLEC NEUROSCI PROGRAM,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	GACY, AM (corresponding author), MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BAXTER SM, 1993, BIOCHEMISTRY-US, V32, P8702, DOI 10.1021/bi00084a042; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; GAO XL, 1987, J BIOL CHEM, V262, P16973; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; HAN J, 1994, NUCLEIC ACIDS RES, V22, P1735, DOI 10.1093/nar/22.9.1735; HARAYAMA S, 1991, J BACTERIOL, V173, P7540, DOI 10.1128/jb.173.23.7540-7548.1991; HIRST MC, 1994, HUM MOL GENET, V9, P1553; HOELZEL AR, 1994, J MOL EVOL, V39, P191; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P100, DOI 10.1021/bi00401a017; KOHWI Y, 1993, NUCLEIC ACIDS RES, V21, P5651; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3218, DOI 10.1021/bi00309a016; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P9373; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; RENTEPERIS D, 1993, NUCLEIC ACIDS RES, V9, P133; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; RUBINSZTEIN DC, 1993, HUM MOL GENET, V2, P1713, DOI 10.1093/hmg/2.10.1713; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SNOW K, 1993, AM J HUM GENET, V53, P1217; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	41	496	507	0	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					533	540						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758107				2022-12-01	WOS:A1995QZ71000010
J	GEISS, J; GLOECKLER, G; VONSTEIGER, R; BALSIGER, H; FISK, LA; GALVIN, AB; IPAVICH, FM; LIVI, S; MCKENZIE, JF; OGILVIE, KW; WILKEN, B				GEISS, J; GLOECKLER, G; VONSTEIGER, R; BALSIGER, H; FISK, LA; GALVIN, AB; IPAVICH, FM; LIVI, S; MCKENZIE, JF; OGILVIE, KW; WILKEN, B			THE SOUTHERN HIGH-SPEED STREAM - RESULTS FROM THE SWICS INSTRUMENT ON ULYSSES	SCIENCE			English	Article							POLAR CORONAL HOLE; SOLAR-WIND; MINOR IONS; IONIZATION EQUILIBRIUM; ABUNDANCES; SKYLAB; STATE	The high-speed solar wind streaming from the southern coronal hole was remarkably uniform and steady and was confined by a sharp boundary that extended to the corona and chromosphere. Charge state measurements indicate that the electron temperature in this coronal hole reached a maximum;of about 1.5 million kelvin within 3 solar radii of the sun. This result, combined with the observed lack of depletion of heavy elements, suggests that an additional source of momentum is required to accelerate the polar wind.	UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV MARYLAND,DEPT PHYS,COLLEGE PK,MD 20742; MAX PLANCK INST AERON,D-37189 KATLENBURG DUHM,GERMANY; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771	University of Michigan System; University of Michigan; University System of Maryland; University of Maryland College Park; Max Planck Society; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	GEISS, J (corresponding author), UNIV BERN,INST PHYS,CH-3012 BERN,SWITZERLAND.		von Steiger, Rudolf/F-6822-2011; Galvin, Antoinette/A-6114-2013; Livi, Stefano/H-5348-2012	von Steiger, Rudolf/0000-0002-3350-0023; 				[Anonymous], 1989, AIP C, DOI DOI 10.1063/1.37985; ARNAUD M, 1992, ASTROPHYS J, V398, P394, DOI 10.1086/171864; Arnaud M., 1985, Astronomy & Astrophysics Supplement Series, V60, P425; BAME SJ, 1977, J GEOPHYS RES-SPACE, V82, P1487, DOI 10.1029/JA082i010p01487; BOCHSLER P, 1983, NASA CP2280 C PUBL, P613; BOCHSLER P, 1992, SOLAR WIND SEVEN, V3, P323; BURGI A, 1986, SOL PHYS, V103, P347, DOI 10.1007/BF00147835; BURGI A, 1987, J GEOPHYS RES, V92, P1057, DOI 10.1029/JA092iA02p01057; GEISS J, 1994, PHILOS T R SOC A, V349, P213, DOI 10.1098/rsta.1994.0126; GEISS J, 1995, SPACE SCI REV, V72, P49, DOI 10.1007/BF00768753; GEISS J, 1985, RAPPORTS ISOTOPIQUES, P213; GLOECKLER G, 1992, ASTRON ASTROPHYS SUP, V92, P267; GLOECKLER G, 1989, EOS T AGU, V70, P424; GOSLING JT, 1995, SPACE SCI REV, V72, P99, DOI 10.1007/BF00768761; HOLLWEG JV, 1981, J GEOPHYS RES-SPACE, V86, P8899, DOI 10.1029/JA086iA11p08899; HOLLWEG JV, 1986, J GEOPHYS RES-SPACE, V91, P4111, DOI 10.1029/JA091iA04p04111; HOLLWEG JV, 1978, REV GEOPHYS, V16, P689, DOI 10.1029/RG016i004p00689; HUBER MCE, 1974, ASTROPHYS J, V194, pL115, DOI 10.1086/181682; HUNDHAUSEN AJ, 1968, J GEOPHYS RES, V73, P5485, DOI 10.1029/JA073i017p05485; LALLEMENT R, 1986, J GEOPHYS RES, V91, P6751, DOI 10.1029/JA091iA06p06751; MARSDEN RG, 1986, SUN HELIOSPHERE 3 DI, P173; MCKENZIE JF, 1979, ASTROPHYS SPACE SCI, V64, P183, DOI 10.1007/BF00640041; MEYER JP, 1993, ADV SPACE RES, V13, P377, DOI 10.1016/0273-1177(93)90509-A; MUNRO RH, 1977, ASTROPHYS J, V213, P874, DOI 10.1086/155220; NOLTE JT, 1977, SOL PHYS, V51, P459, DOI 10.1007/BF00216379; OWOCKI SP, 1983, ASTROPHYS J, V275, P354, DOI 10.1086/161538; SHULL JM, 1982, ASTROPHYS J SUPPL S, V48, P95, DOI 10.1086/190769; TOUSEY R, 1973, SOL PHYS, V33, P265; VONSTEIGER R, 1989, ASTRON ASTROPHYS, V225, P222; VONSTEIGER R, 1992, ASTROPHYS J, V389, P791, DOI 10.1086/171252; WIELER R, 1993, LUNAR PLANET SCI, V24, P1519; WITHBROE GL, 1971, SOL PHYS, V21, P271	32	216	217	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1033	1036		10.1126/science.7754380	http://dx.doi.org/10.1126/science.7754380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754380				2022-12-01	WOS:A1995QY93400036
J	GROTE, E; HAO, JC; BENNETT, MK; KELLY, RB				GROTE, E; HAO, JC; BENNETT, MK; KELLY, RB			A TARGETING SIGNAL IN VAMP REGULATING TRANSPORT TO SYNAPTIC VESICLES	CELL			English	Article							MEMBRANE-PROTEIN; RAT-BRAIN; SYNAPTOPHYSIN; FUSION; SYNAPTOBREVIN; GENES; BIOGENESIS; RECEPTORS; TETANUS; PATHWAY	VAMP is a synaptic vesicle membrane protein required for fusion. Synaptic vesicle targeting was measured for mutants of an epitope-tagged form of VAMP in transfected PC12 cells. A signal within a predicted amphipathic alpha helix is essential for targeting to synaptic vesicles. Cellubrevin, a nonneural VAMP homolog, contains this signal and is also targeted to synaptic vesicles. Amino acid substitutions within the synaptic vesicle targeting signal either enhance or inhibit sorting of VAMP to synaptic vesicles, but do not affect the ability of VAMP to form complexes with syntaxin and SNAP-25.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GROTE, E (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK33937, DK09878] Funding Source: Medline; NIGMS NIH HHS [GM51313] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009878, R01DK033937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051313] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HOLTZMAN E, 1971, SCIENCE, V173, P733, DOI 10.1126/science.173.3998.733; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.neuro.17.1.219; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1993, J PHYSL, V87, P10; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WIEDENMANN B, 1988, FEBS LETT, V240, P71, DOI 10.1016/0014-5793(88)80342-9; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	36	139	139	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					581	589		10.1016/0092-8674(95)90079-9	http://dx.doi.org/10.1016/0092-8674(95)90079-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758112	Bronze			2022-12-01	WOS:A1995QZ71000015
J	GUO, S; KEMPHUES, KJ				GUO, S; KEMPHUES, KJ			PAR-1, A GENE REQUIRED FOR ESTABLISHING POLARITY IN C-ELEGANS EMBRYOS, ENCODES A PUTATIVE SER/THR KINASE THAT IS ASYMMETRICALLY DISTRIBUTED	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN-KINASE; CYTOPLASMIC LOCALIZATION; CONSERVED FEATURES; SPLICED LEADER; SEQUENCE; MICROFILAMENTS; FAMILY; IDENTIFICATION; EMBRYOGENESIS	The first cleavage of C. elegans is asymmetric, generating daughter cells with different sizes, cytoplasmic components, and fates. Mutations in the par-1 gene disrupt this asymmetry. We report here that par-1 encodes a putative Ser/Thr kinase with similarity to kinases from yeasts and mammals, Two strong alleles have mutations in the kinase domain, suggesting that kinase activity is essential for par-1 function. PAR-1 protein is localized to the posterior periphery of the zygote and is distributed in a polar fashion preceding the asymmetric divisions of the germline lineage. Because PAR-1 distribution in the germline correlates with the distribution of germline-specific P granules, it is possible that PAR-1 functions in germline development as well as in establishing embryonic polarity.			GUO, S (corresponding author), CORNELL UNIV, GENET & DEV SECT, ITHACA, NY 14853 USA.				NICHD NIH HHS [HD27689] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027689] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CARLING D, 1994, J BIOL CHEM, V269, P11432; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENG NN, 1995, GENETICS, V139, P549; Davidson E. H., 1986, GENE ACTIVITY EARLY; FIRE A, 1991, DEVELOPMENT, V113, P503; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1992, NATURE, V357, P254; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; INGLIS JD, 1993, MAMM GENOME, V4, P401, DOI 10.1007/BF00360595; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MORTON DG, 1992, GENETICS, V130, P771; PARSA I, 1988, CANCER RES, V48, P2265; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHIERENBERG E, 1988, ROUX ARCH DEV BIOL, V197, P282, DOI 10.1007/BF00380022; SCHNABEL R, 1994, SCIENCE, V263, P1449, DOI 10.1126/science.8128230; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1986, J EMBRYOL EXP MORPH, V97, P15; SULSTON J, 1983, DEV BIOL, V100, P67; TELFER A, 1991, THESIS HARVARD U CAM	48	815	1060	11	137	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					611	620		10.1016/0092-8674(95)90082-9	http://dx.doi.org/10.1016/0092-8674(95)90082-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758115	hybrid			2022-12-01	WOS:A1995QZ71000018
J	HSU, HL; XIONG, J; GOEDDEL, DV				HSU, HL; XIONG, J; GOEDDEL, DV			THE TNF RECEPTOR 1-ASSOCIATED PROTEIN TRADD SIGNALS CELL-DEATH AND NF-KAPPA-B ACTIVATION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; EXPRESSION; DOMAIN; MONOCYTOGENES; ANTIBODIES; RESISTANT; INFECTION; SYSTEM; VIRUS	Many diverse activities of tumor necrosis factor (TNF) are signaled through TNF receptor 1 (TNFR1). We have identified a novel 34 kDa protein, designated TRADD, that specifically interacts with an intracellular domain of TNFR1 known to be essential for mediating programmed cell death. Overexpression of TRADD leads to two major TNF-induced responses, apoptosis and activation of NF-kappa B. The C-terminal 118 amino acids of TRADD are sufficient to trigger both of these activities and likewise sufficient for interaction with the death domain of TNFR1. TRADD-mediated cell death can be suppressed by the crmA gene, which encodes a specific inhibitor of the interleukin-1 beta-converting enzyme. However, NF-kappa B activation by TRADD is not inhibited by crmA expression, demonstrating that the signaling pathways for TNF-induced cell death and NF-kappa B activation are distinct.			HSU, HL (corresponding author), TULARIK INC,270 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							AUSUBEL FM, 1994, CURR PROT MOL BIOL, V1; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GEHR G, 1992, J IMMUNOL, V149, P911; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KRUPPA G, 1992, J IMMUNOL, V148, P3152; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MIURA M, 1993, CELL, V75, P656; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P587; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOMEI LD, 1991, CURR COMM CELL MOL B, V3, P5; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; WONG GHW, 1992, J IMMUNOL, V149, P3550	44	1681	1755	0	37	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					495	504		10.1016/0092-8674(95)90070-5	http://dx.doi.org/10.1016/0092-8674(95)90070-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758105	Bronze			2022-12-01	WOS:A1995QZ71000006
J	HUG, C; JAY, PY; REDDY, I; MCNALLY, JG; BRIDGMAN, PC; ELSON, EL; COOPER, JA				HUG, C; JAY, PY; REDDY, I; MCNALLY, JG; BRIDGMAN, PC; ELSON, EL; COOPER, JA			CAPPING PROTEIN-LEVELS INFLUENCE ACTIN ASSEMBLY AND CELL MOTILITY IN DICTYOSTELIUM	CELL			English	Article							F-ACTIN; LENGTH DISTRIBUTION; BINDING PROTEINS; AMEBOID CELLS; DISCOIDEUM; FILAMENTS; POLYMERIZATION; IDENTIFICATION; MORPHOGENESIS; STIMULATION	Actin assembly is important for cell motility, but the mechanism of assembly and how it relates to motility in vivo is largely unknown. In vitro, actin assembly can be controlled by proteins, such as capping protein, that bind filament ends. To investigate the function of actin assembly in vivo, we altered the levels of capping protein in Dictyostelium cells and found changes in resting and chemoattractant-induced actin assembly that were consistent with the in vitro properties of capping protein in capping but not nucleation. Significantly, overexpressers moved faster and underexpressers moved slower than control cells. Mutants also exhibited changes in cytoskeleton architecture. These results provide insights into in vivo actin assembly and the role of the actin cytoskeleton in motility.	WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	HUG, C (corresponding author), WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571	NIGMS NIH HHS [GM 38838, GM 38542] Funding Source: Medline; NINDS NIH HHS [NS 26150] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026150] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CASELLA JF, 1994, J BIOL CHEM, V269, P6992; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cooper John A., 1993, P34; CORTESE JD, 1988, J CELL BIOL, V107, P1477, DOI 10.1083/jcb.107.4.1477; COX D, 1994, J CELL BIOL, V128, P819; DOOLITTLE KW, 1995, DEV BIOL, V167, P118, DOI 10.1006/dbio.1995.1011; FURUKAWA R, 1993, BIOCHEMISTRY-US, V32, P12346, DOI 10.1021/bi00097a010; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HARTMAN R, 1993, COMPUT METH PROG BIO, V39, P195, DOI 10.1016/0169-2607(93)90021-C; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; JACOBSON K, 1984, P NATL ACAD SCI-BIOL, V81, P6747, DOI 10.1073/pnas.81.21.6747; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIU TY, 1992, MOL BIOL CELL, V3, P1403, DOI 10.1091/mbc.3.12.1403; MADDEN TL, 1994, J CELL BIOL, V126, P169, DOI 10.1083/jcb.126.1.169; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; PODOLSKI JL, 1988, J BIOL CHEM, V263, P638; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.biochem.55.1.987; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SIEGERT F, 1994, J CELL SCI, V107, P97; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; VOGEL G, 1980, J CELL BIOL, V86, P456; WATTS RG, 1994, CELL MOTIL CYTOSKEL, V28, P155, DOI 10.1002/cm.970280207; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; ZANER KS, 1988, J BIOL CHEM, V263, P4532	40	144	145	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					591	600		10.1016/0092-8674(95)90080-2	http://dx.doi.org/10.1016/0092-8674(95)90080-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758113	Bronze			2022-12-01	WOS:A1995QZ71000016
J	IKONEN, E; TAGAYA, M; ULLRICH, O; MONTECUCCO, C; SIMONS, K				IKONEN, E; TAGAYA, M; ULLRICH, O; MONTECUCCO, C; SIMONS, K			DIFFERENT REQUIREMENTS FOR NSF, SNAP, AND RAB PROTEINS IN APICAL AND BASOLATERAL TRANSPORT IN MDCK CELLS	CELL			English	Article							SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; PLASMA-MEMBRANE; GOLGI-NETWORK; SCHIZOSACCHAROMYCES-POMBE; ATTACHMENT PROTEINS; EPITHELIAL-CELLS; ALPHA-SNAP; GENE; VESICLES	We used an in vitro system based on streptolysin O-permeabilized MDCK cells to study the involvement of NSF, SNAP, SNAREs, and Rab proteins in polarized membrane transport of epithelial cells. In MDCK cells, transport from the trans-Golgi network (TGN) to the basolateral plasma membrane is inhibited by anti-NSF antibodies and stimulated by alpha-SNAP. In contrast, transport from the TGN to the apical cell surface is not affected by anti-NSF antibodies or alpha-SNAP. Furthermore, apical transport is insensitive to Rab-GDI and tetanus and botulinum neurotoxins, which inhibit basolateral transport, These results provide evidence that the Rab-NSF-SNAP-SNARE mechanism operates in basolateral transport, while other molecules constitute the machinery for vesicular delivery in the apical pathway.	TOKYO COLL PHARM, SCH LIFE SCI, HACHIOJI 19203, TOKYO, JAPAN; UNIV PADUA, CTR CONSIGLIO NAZL RIC BIOMEMBRANE, DIPARTIMENTO SCI BIOMED, I-35121 PADUA, ITALY	Tokyo University of Pharmacy & Life Sciences; University of Padua	IKONEN, E (corresponding author), EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69012 HEIDELBERG, GERMANY.			Simons, Kai/0000-0002-9231-9996				BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1992, METHOD ENZYMOL, V219, P319; CRAIGHEAD MW, 1993, MOL BIOL CELL, V4, P1069, DOI 10.1091/mbc.4.10.1069; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FIELDER K, 1994, EMBO J, V13, P1729; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FULLER SD, 1985, EMBO J, V4, P2475, DOI 10.1002/j.1460-2075.1985.tb03959.x; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; HUGHSON E, 1988, MOL BIOL INFECTIOUS, P79; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAFONT F, 1994, NATURE, V372, P801; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cellbio.8.1.395; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SIMONS K, 1995, IN PRSS HARVEY LECT; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; ULLRICH O, 1995, INPRESS METH ENZYMOL; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	60	216	217	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					571	580		10.1016/0092-8674(95)90078-0	http://dx.doi.org/10.1016/0092-8674(95)90078-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758111	Bronze			2022-12-01	WOS:A1995QZ71000014
J	JABRI, E; CARR, MB; HAUSINGER, RP; KARPLUS, PA				JABRI, E; CARR, MB; HAUSINGER, RP; KARPLUS, PA			THE CRYSTAL-STRUCTURE OF UREASE FROM KLEBSIELLA-AEROGENES	SCIENCE			English	Article							JACK-BEAN UREASE; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; HELICOBACTER-PYLORI; BETA-MERCAPTOETHANOL; PROTEIN-STRUCTURE; EC 3.5.1.5; NICKEL; GENES; SEQUENCE	The crystal structure of urease from Klebsiella aerogenes has been determined at 2.2 Angstrom resolution and refined to an R factor of 18.2 percent. The enzyme contains four structural domains: three with novel folds playing structural roles, and an (alpha beta)8 barrel domain, which contains the bi-nickel center. The two active site nickels are 3.5 Angstrom apart. One nickel ion is coordinated by three ligands (with low occupancy of a fourth ligand) and the second is coordinated by five ligands. A carbamylated lysine provides an oxygen ligand to each nickel, explaining why carbon dioxide is required for the activation of urease apoenzyme. The structure is compatible with a catalytic mechanism whereby urea ligates Ni-1 to complete its tetrahedral coordination and a hydroxide ligand of Ni-2 attacks the carbonyl carbon. A surprisingly high structural similarity between the urease catalytic domain and that of the zinc-dependent adenosine deaminase reveals a remarkable example of active site divergence.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Cornell University; Michigan State University; Michigan State University				Karplus, Paul/0000-0001-8725-6292; Jabri, Evelyn/0000-0002-5117-1892; Hausinger, Robert/0000-0002-3643-2054	NIGMS NIH HHS [5T32-GM08384-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008384] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER J, 1993, SCIENCE, V260, P159, DOI 10.1126/science.8469968; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BLAKELEY RL, 1983, BIOCHIM BIOPHYS ACTA, V744, P219, DOI 10.1016/0167-4838(83)90094-8; BOUTONNET NS, 1994, PROTEIN SCI, V3, P769; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CARR MB, IN PRESS MECHANISMS; CHOTHIA C, 1986, EMBO J, V4, P823; CLAYTON CL, 1990, NUCLEIC ACIDS RES, V18, P362, DOI 10.1093/nar/18.2.362; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P481, DOI 10.1139/o80-064; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FARBER GK, 1993, CURR OPIN STRUC BIOL, V3, P409, DOI 10.1016/S0959-440X(05)80114-9; FINNEGAN MG, 1991, J AM CHEM SOC, V113, P4030, DOI 10.1021/ja00010a076; GRIFFITH DP, 1979, UROL RES, V7, P215; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARTMAN FC, 1993, ANNU REV BIOCHEM, V63, P197; HAUSINGER RP, 1993, BIOCH NICKEL, pCH4; Hausinger RP, 1993, BIOCH NICKEL; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JABRI E, 1992, J MOL BIOL, V227, P934, DOI 10.1016/0022-2836(92)90232-9; JABRI E, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSE J, 1991, FEMS MICROBIOL LETT, V80, P277, DOI 10.1016/0378-1097(91)90609-E; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARTIN PR, 1992, J BIOL CHEM, V267, P20024; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MOBLEY HLT, IN PRESS MICROBIOL R; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; PARK IS, 1995, SCIENCE, V267, P1156, DOI 10.1126/science.7855593; PARK IS, 1993, PROTEIN SCI, V2, P1034, DOI 10.1002/pro.5560020616; PARK IS, 1993, J PROTEIN CHEM, V12, P51, DOI 10.1007/BF01024914; Polacco Joseph C., 1993, V145, P65; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; REARDON D, IN PRESS FASEB J; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sumner JB, 1926, J BIOL CHEM, V69, P435; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TODD MJ, 1991, J BIOL CHEM, V266, P10260; TODD MJ, 1991, J BIOL CHEM, V266, P24327; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WANG S, 1993, INORG CHEM, V33, P1589; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; 1994, ACTA CRYSTALLOGR, V50, P760	60	736	775	5	99	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					998	1004		10.1126/science.7754395	http://dx.doi.org/10.1126/science.7754395			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754395				2022-12-01	WOS:A1995QY93400026
J	KEPPLER, E; FRANZ, M; KORTH, A; REUSS, MK; BLAKE, JB; SEIDEL, R; QUENBY, JJ; WITTE, M				KEPPLER, E; FRANZ, M; KORTH, A; REUSS, MK; BLAKE, JB; SEIDEL, R; QUENBY, JJ; WITTE, M			OBSERVATIONS OF ENERGETIC PARTICLES WITH EPAC ON ULYSSES IN POLAR LATITUDES OF THE HELIOSPHERE	SCIENCE			English	Article							SOLAR-WIND; EVOLUTION; STREAM	Measurements with the Energetic Particle Composition instrument (EPAC) aboard Ulysses show particles from near the ecliptic that were apparently accelerated by shocks associated with a corotating interaction region. The particles were detected together with the shocks and even when shocks no longer arrived at Ulysses up to -65 degrees of heliographic latitude but not beyond. Particles could have reached these latitudes along magnetic fields; such connections to the outer lower latitude heliosphere evidently do not exist above that latitude. The accelerated streams have composition similar to solar wind abundances, no dispersion, and a net inward anisotropy. The underlying composition between the recurrent stream is similar to the anomalous component of cosmic rays. The channel sensitive to high-energy protons (>230 megaelectron volts) shows a 26-day variation of the flux superimposed on the heliospheric modulation of galactic ions.	AEROSP CORP, SPACE SCI LAB, LOS ANGELES, CA 90009 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, BLACKETT LAB, LONDON, ENGLAND	Aerospace Corporation - USA; Imperial College London	KEPPLER, E (corresponding author), MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY.							ADAMS J, 1993, 23RD P ICRC CALG, VSH, P358; BALOGH A, 1995, SPACE SCI REV, V72, P171, DOI 10.1007/BF00768774; BALOGH A, 1993, GEOPHYS RES LETT, V20, P2331, DOI 10.1029/93GL02621; BALOGH A, 1995, NUCL PHYS B, P69, DOI 10.1016/0920-5632(95)00008-W; BAME SJ, 1993, GEOPHYS RES LETT, V20, P2323, DOI 10.1029/93GL02630; BARNES CW, 1976, ASTROPHYS J, V210, pL91, DOI 10.1086/182311; CUMMINGS AC, 1995, GEOPHYS RES LETT, V22, P341, DOI 10.1029/94GL03343; CUMMINGS AC, 1993, 23RD P ICRC CALG, VSH, P202; FELDMAN WC, 1991, J GEOPHYS RES, V86, P5408; FRANZ M, 1995, SPACE SCI REV, V72, P339, DOI 10.1007/BF00768802; GLOECKLER G, 1995, SPACE SCI REV, V72, P321, DOI 10.1007/BF00768798; GOSLING JT, 1981, J GEOPHYS RES-SPACE, V86, P5438, DOI 10.1029/JA086iA07p05438; GOSLING JT, 1993, GEOPHYS RES LETT, V20, P2789, DOI 10.1029/93GL03116; GOSLING JT, 1995, SPACE SCI REV, V72, P99, DOI 10.1007/BF00768761; KEPPLER E, 1995, SPACE SCI REV, V72, P285, DOI 10.1007/BF00768792; KEPPLER E, 1992, ASTRON ASTROPHYS SUP, V92, P317; KEPPLER E, 1995, NUCL PHYS B, P87, DOI 10.1016/0920-5632(95)00010-7; KUNOW H, 1995, SPACE SCI REV, V72, P397, DOI 10.1007/BF00768811; MCKIBBEN RB, 1995, SPACE SCI REV, V72, P403, DOI 10.1007/BF00768812; PIZZO VJ, 1989, J GEOPHYS RES, V94, P8673, DOI 10.1029/JA094iA07p08673; REUSS MK, 1995, SPACE SCI REV, V72, P343, DOI 10.1007/BF00768803; RICHARDSON IG, 1993, J GEOPHYS RES-SPACE, V98, P13, DOI 10.1029/92JA01837; ROELOF EC, 1995, SPACE SCI REV, V72, P309, DOI 10.1007/BF00768796; SIMNETT GM, 1994, GEOPHYS RES LETT, V21, P1561, DOI 10.1029/94GL01061; SIMNETT GM, 1995, SPACE SCI REV, V72, P303, DOI 10.1007/BF00768795	25	28	28	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	1995	268	5213					1013	1016		10.1126/science.7754379	http://dx.doi.org/10.1126/science.7754379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754379				2022-12-01	WOS:A1995QY93400030
J	KUBOTA, Y; MIMURA, S; NISHIMOTO, SI; TAKISAWA, H; NOJIMA, H				KUBOTA, Y; MIMURA, S; NISHIMOTO, SI; TAKISAWA, H; NOJIMA, H			IDENTIFICATION OF THE YEAST MCM3-RELATED PROTEIN AS A COMPONENT OF XENOPUS DNA-REPLICATION LICENSING FACTOR	CELL			English	Article							CELL-FREE-EXTRACT; NUCLEAR-LOCALIZATION; EGG EXTRACTS; CYCLE; INVITRO; INITIATION; SEQUENCE; MITOSIS; MCM3	Replication licensing factor is thought to be involved in the strict control of the initiation of DNA replication in eukaryotes. We identified a 100 kDa protein as a candidate for the licensing factor in Xenopus egg extracts. This protein was required for replication; it bound to sperm DNA before the formation of nuclei and apparently dissociated from the nuclear DNA during the progression of replication without being transported into the nuclei. An immunologically homologous protein in HeLa cells behaved similarly to the Xenopus protein during the cell cycle. Cloning and sequencing of the cDNAs encoding the Xenopus and human proteins revealed that they are homologs of yeast Mcm3, a putative yeast DNA replication licensing factor.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN	Osaka University	KUBOTA, Y (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.							ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; HUTCHISON C, 1989, J CELL SCI, V93, P605; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LENO GH, 1994, J CELL BIOL, V127, P5, DOI 10.1083/jcb.127.1.5; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	253	255	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					601	609		10.1016/0092-8674(95)90081-0	http://dx.doi.org/10.1016/0092-8674(95)90081-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758114	Bronze			2022-12-01	WOS:A1995QZ71000017
J	LANZEROTTI, LJ; ARMSTRONG, TP; GOLD, RE; MACLENNAN, CG; ROELOF, EC; SIMNETT, GM; THOMSON, DJ; ANDERSON, KA; HAWKINS, SE; KRIMIGIS, SM; LIN, RP; PICK, M; SARRIS, ET; TAPPIN, SJ				LANZEROTTI, LJ; ARMSTRONG, TP; GOLD, RE; MACLENNAN, CG; ROELOF, EC; SIMNETT, GM; THOMSON, DJ; ANDERSON, KA; HAWKINS, SE; KRIMIGIS, SM; LIN, RP; PICK, M; SARRIS, ET; TAPPIN, SJ			OVER THE SOUTHERN SOLAR POLE - LOW-ENERGY INTERPLANETARY CHARGED-PARTICLES	SCIENCE			English	Article							ULYSSES	The heliosphere instrument for spectrum, composition, and anisotropy (HISCALE) recorded the fluxes of low-energy ions and electrons (>50 kiloelectron volts) when Ulysses crossed the southern solar polar region and revealed that the large-scale structure of the heliosphere to at least similar to-75 degrees was significantly influenced by the near-equatorial heliospheric current sheet. Electrons in particular were accelerated by the current sheet-produced and poleward-propagating interplanetary reverse shock at helioradii far from the Ulysses location. At heliolatitudes higher than similar to-75 degrees on the Ulysses ascent to the pole and similar to-50 degrees on the descent, small, less regular enhancements of the lowest energy electron fluxes were measured whose relations to the current sheet were less clear. The anomalous component of low-energy (similar to 2 to 5 megaelectron volts per nucleon) oxygen flux at the highest heliolatitudes was found to be similar to 10(-8) [per square centimeter per second per steradian (per kiloelectronvolt per nucleon)]; the anomalous Ne/O ratio was similar to 0.25.	UNIV KANSAS,DEPT PHYS,LAWRENCE,KS 66045; JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20723; UNIV BIRMINGHAM,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV CALIF BERKELEY,SPACE SCI LAB,BERKELEY,CA 94720; OBSERV PARIS,MEUDON,FRANCE; UNIV THRACE,XANTHI,GREECE	University of Kansas; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University of Birmingham; University of California System; University of California Berkeley; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Democritus University of Thrace	LANZEROTTI, LJ (corresponding author), AT&T BELL LABS,600 MT AVE,MURRAY HILL,NJ 07974, USA.		Roelof, Edmond/G-6654-2019; Krimigis, Stamatios/G-4591-2019	Roelof, Edmond/0000-0002-2270-0652; Krimigis, Stamatios/0000-0003-2781-2386				BALOGH A, 1995, SCIENCE, V268, P1007, DOI 10.1126/science.268.5213.1007; BAME SJ, 1993, GEOPHYS RES LETT, V20, P2323, DOI 10.1029/93GL02630; CUMMINGS AC, 1995, GEOPHYS RES LETT, V22, P341, DOI 10.1029/94GL03343; GOSLING JT, 1993, GEOPHYS RES LETT, V20, P2789, DOI 10.1029/93GL03116; LANZEROTTI LJ, 1992, ASTRON ASTROPHYS SUP, V92, P349; LANZEROTTI LJ, 1995, GEOPHYS RES LETT, V22, P333, DOI 10.1029/94GL03210; LANZEROTTI LJ, UNPUB; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; PHILLIPS JL, 1994, GEOPHYS RES LETT, V21, P1105, DOI 10.1029/94GL01065; PIZZO VJ, 1994, J GEOPHYS RES-SPACE, V99, P4173, DOI 10.1029/93JA03239; RICE SO, 1948, AT&T TECH J, V27, P109, DOI 10.1002/j.1538-7305.1948.tb01334.x; SARRIS ET, 1976, J GEOPHYS RES-SPACE, V81, P2341, DOI 10.1029/JA081i013p02341; SLEPIAN D, 1978, BELL SYST TECH J, V57, P1371, DOI 10.1002/j.1538-7305.1978.tb02104.x; SMITH EJ, 1993, GEOPHYS RES LETT, V20, P2327, DOI 10.1029/93GL02632; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; THOMSON DJ, 1990, PHILOS T R SOC A, V332, P539, DOI 10.1098/rsta.1990.0130; THOMSON DJ, UNPUB; TRATTNER KJ, 1995, GEOPHYS RES LETT, V22, P337, DOI 10.1029/94GL03305	18	21	21	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1010	1013		10.1126/science.7754378	http://dx.doi.org/10.1126/science.7754378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754378				2022-12-01	WOS:A1995QY93400029
J	LOPEZLOPEZ, JR; SHACKLOCK, PS; BALKE, CW; WIER, WG				LOPEZLOPEZ, JR; SHACKLOCK, PS; BALKE, CW; WIER, WG			LOCAL CALCIUM TRANSIENTS TRIGGERED BY SINGLE L-TYPE CALCIUM-CHANNEL CURRENTS IN CARDIAC-CELLS	SCIENCE			English	Article							PIG VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; INDUCED RELEASE; CA2+ RELEASE; HEART-CELLS; CONTRACTION; MUSCLE; DEPENDENCE; EXCHANGE; CA-2+	Excitation-contraction coupling was studied in mammalian cardiac cells in which the opening probability of L-type calcium (Ca2+) channels was reduced. Confocal microscopy during voltage-clamp depolarization revealed distinct local transients in the concentration of intracellular calcium ions ([Ca2+](i)). When voltage was varied, the latency to occurrence and the relative probability of occurrence of local [Ca2+](i) transients varied as predicted if Ca2+ release from the sarcoplasmic reticulum (SR) was linked tightly to Ca2+ flux through L-type Ca2+ channels but not to that through the Na-Ca exchanger or to average [Ca2+](i). Voltage had no effect on the amplitude of local [Ca2+](i) transients. Thus, the most efficacious ''Ca2+ signal'' for activating Ca2+ release from the SR may be a transient microdomain of high [Ca2+](i) beneath an individual, open L-type Ca2+ channel.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Wier, Withrow/AAE-2451-2020; López, José Ramón López/A-5541-2009	López, José Ramón López/0000-0002-3870-421X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050435, R01HL029473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02466, HL29473, HL50435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V472, P391, DOI 10.1113/jphysiol.1993.sp019953; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CARMELIET E, 1986, J PHYSIOL-LONDON, V376, P143, DOI 10.1113/jphysiol.1986.sp016146; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; GYORKE S, 1993, AM J PHYSIOL, V264, pC1505, DOI 10.1152/ajpcell.1993.264.6.C1505; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; ISENBERG G, 1994, J PHYSIOL-LONDON, V480, P423, DOI 10.1113/jphysiol.1994.sp020372; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEVI AJ, 1994, AM J PHYSIOL, V266, pH1422, DOI 10.1152/ajpheart.1994.266.4.H1422; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JA, UNPUB; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PELZER D, 1984, INSERM, V124, P415; RIOS E, 1994, BIOPHYS J, V67, P7, DOI 10.1016/S0006-3495(94)80451-5; ROSE WC, 1992, J PHYSIOL-LONDON, V456, P267, DOI 10.1113/jphysiol.1992.sp019336; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; VARRO A, 1993, PFLUG ARCH EUR J PHY, V423, P158, DOI 10.1007/BF00374975; WIER WG, 1980, SCIENCE, V207, P1085, DOI 10.1126/science.7355274; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037; WIER WG, 1993, BIOPHYS J, V65, P2270, DOI 10.1016/S0006-3495(93)81287-6; YASUI K, 1994, BIOPHYS J, V67, P457, DOI 10.1016/S0006-3495(94)80501-6	35	416	424	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1042	1045						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754383				2022-12-01	WOS:A1995QY93400039
J	MACMICKING, JD; NATHAN, C; HOM, G; CHARTRAIN, N; FLETCHER, DS; TRUMBAUER, M; STEVENS, K; XIE, QW; SOKOL, K; HUTCHINSON, N; CHEN, H; MUDGETT, JS				MACMICKING, JD; NATHAN, C; HOM, G; CHARTRAIN, N; FLETCHER, DS; TRUMBAUER, M; STEVENS, K; XIE, QW; SOKOL, K; HUTCHINSON, N; CHEN, H; MUDGETT, JS			ALTERED RESPONSES TO BACTERIAL-INFECTION AND ENDOTOXIC-SHOCK IN MICE LACKING INDUCIBLE NITRIC-OXIDE SYNTHASE	CELL			English	Article							METHYL-L-ARGININE; INTERFERON-GAMMA; SEPTIC SHOCK; MOLECULAR-CLONING; LISTERIA-MONOCYTOGENES; MACROPHAGE ACTIVATION; PASSIVE-IMMUNIZATION; MOUSE MACROPHAGES; CARDIAC MYOCYTES; INHIBITION	Mice deficient in inducible nitric oxide synthase (iNOS) were generated to test the idea that iNOS defends the host against infectious agents and tumor cells at the risk of contributing to tissue damage and shock. iNOS(-/-) mice failed to restrain the replication of Listeria monocytogenes in vivo or lymphoma cells in vitro. Bacterial endotoxic lipopolysaccharide (LPS) caused shock and death in anesthetized wild-type mice, but in iNOS(-/-) mice, the fall in central arterial blood pressure was markedly attenuated and early death averted. However, unanesthetized iNOS(-/-) mice suffered as much LPS-induced liver damage as wild type, and when primed with Propionobacterium acnes and challenged with LPS, they succumbed at the same rate as wild type. Thus, there exist both iNOS-dependent and iNOS-independent routes to LPS-induced hypotension and death.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT INFLAMMAT,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,ANIM RESOURCES LAB,RAHWAY,NJ 07065; CORNELL UNIV,LAB ANIM RES CTR,NEW YORK,NY 10021	Merck & Company; Merck & Company; Merck & Company; Cornell University	MACMICKING, JD (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL51967] Funding Source: Medline; NIAID NIH HHS [AI34543] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034543, R21AI034543] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BLOCK MI, 1993, J EXP MED, V178, P1085, DOI 10.1084/jem.178.3.1085; BONE RC, 1992, CRIT CARE MED, V20, P884, DOI 10.1097/00003246-199206000-00028; BOOCKVAR KS, 1994, INFECT IMMUN, V62, P1089, DOI 10.1128/IAI.62.3.1089-1100.1994; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; CONLAN JW, 1994, J EXP MED, V179, P259, DOI 10.1084/jem.179.1.259; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DING AH, 1988, J IMMUNOL, V141, P2407; EVANS TG, 1993, J IMMUNOL, V151, P907; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; FLORQUIN S, 1994, J EXP MED, V180, P1153, DOI 10.1084/jem.180.3.1153; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GRANGER DL, 1991, J IMMUNOL, V146, P1294; GREGORY SH, 1993, J IMMUNOL, V150, P2901; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HARBRECHT BG, 1994, HEPATOLOGY, V20, P1055, DOI 10.1002/hep.1840200439; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, NITRIC OXIDE L ARGIN, P189; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KOHLER J, 1993, J IMMUNOL, V151, P916; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MINNARD EA, 1994, ARCH SURG-CHICAGO, V129, P142; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; MUDGETT JS, 1995, IN PRESS ELECTROPORA; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OHISSON K, 1990, NATURE, V348, P550; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PASTOR C, 1994, CRIT CARE MED, V22, P465, DOI 10.1097/00003246-199403000-00017; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P6077; SCHILLING J, 1993, INTENS CARE MED, V19, P227, DOI 10.1007/BF01694775; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; STEINMAN RM, 1980, J EXP MED, V151, P1248; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TEALE DM, 1992, J ANTIMICROB CHEMOTH, V30, P839, DOI 10.1093/jac/30.6.839; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YALLAMPALLI C, 1994, AM J OBSTET GYNECOL, V170, P175	81	1260	1306	0	31	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					641	650		10.1016/0092-8674(95)90085-3	http://dx.doi.org/10.1016/0092-8674(95)90085-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538909	hybrid			2022-12-01	WOS:A1995QZ71000021
J	MATTHES, DJ; SINK, H; KOLODKIN, AL; GOODMAN, CS				MATTHES, DJ; SINK, H; KOLODKIN, AL; GOODMAN, CS			SEMAPHORIN-II CAN FUNCTION AS A SELECTIVE INHIBITOR OF SPECIFIC SYNAPTIC ARBORIZATIONS	CELL			English	Article							GROWTH CONE GUIDANCE; DROSOPHILA-MELANOGASTER; C-ELEGANS; MOTONEURONS; EXPRESSION; MOLECULE; NEURONS; MUSCLES; PROTEIN; EMBRYO	Previous studies showed that grasshopper semaphorin I, a transmembrane semaphorin, functions in vivo to steer a pair of growth cones, prevent defasciculation, and inhibit branching; and that chick collapsin, a secreted semaphorin, can function in vitro to cause growth cone collapse. Semaphorin II, a secreted semaphorin in Drosophila, is transiently expressed by a single large muscle during motoneuron outgrowth and synapse formation. To test the in vivo function of semaphorin II, we created transgenic Drosophila that generate ectopic semaphorin II expression by muscles that normally do not express it. The results show that semaphorin II can function in vivo as a selective target-derived signal that inhibits the formation of specific synaptic terminal arbors.			MATTHES, DJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Matthes, David/N-3529-2017	Matthes, David/0000-0002-0198-9661	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021294, R37HD021294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21294] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bate Michael, 1993, P1013; BROADIE K, 1993, DEVELOPMENT S, V119, P227; Campos-Ortega JAVH, 1985, EMBRYONIC DEV DROSOP; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOODMAN CS, 1993, CELL S, V10, P77; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V2, P61; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAGHERT PH, 1982, DEV BIOL, V94, P391, DOI 10.1016/0012-1606(82)90356-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WHARTON KA, 1993, MECH DEVELOP, V40, P141, DOI 10.1016/0925-4773(93)90072-6	32	183	184	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					631	639		10.1016/0092-8674(95)90084-5	http://dx.doi.org/10.1016/0092-8674(95)90084-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758117	Bronze			2022-12-01	WOS:A1995QZ71000020
J	MONACO, HL; RIZZI, M; CODA, A				MONACO, HL; RIZZI, M; CODA, A			STRUCTURE OF A COMPLEX OF 2 PLASMA-PROTEINS - TRANSTHYRETIN AND RETINOL-BINDING PROTEIN	SCIENCE			English	Article							CRYSTAL-STRUCTURE DETERMINATION; HUMAN SERUM TRANSTHYRETIN; AMINO-ACID-SEQUENCE; HEREDITARY AMYLOIDOSIS; PRE-ALBUMIN; PREALBUMIN; RESOLUTION; VARIANT; RECOGNITION; REFINEMENT	The three-dimensional structure of the complex formed by two plasma proteins, transthyretin and retinol-binding protein, was determined from x-ray diffraction data to a nominal resolution of 3.1 angstroms. One tetramer of transthyretin was bound to two molecules of retinol-binding protein. The two retinol-binding protein molecules established molecular interactions with the same transthyretin dimer, and each also made contacts with one of the other two monomers. Thus, the other two potential binding sites in a transthyretin tetramer were blocked. The amino acid residues of the retinol-binding protein that were involved in the contacts were close to the retinol-binding protein that were involved in the contacts were close to the retinol-binding site.			MONACO, HL (corresponding author), UNIV PAVIA,DEPT GENET,I-27100 PAVIA,ITALY.			Monaco, Hugo L./0000-0002-2067-0365				AQVIST J, 1992, J MOL GRAPHICS, V10, P120, DOI 10.1016/0263-7855(92)80065-L; BENSON MD, 1983, ARTHRITIS RHEUM, V26, P1493, DOI 10.1002/art.1780261211; BENSON MD, 1993, METABOLIC BASIS INHE, P6262; BERNI R, 1994, J BIOL CHEM, V269, P23395; BERNI R, 1990, EUR J BIOCHEM, V192, P507, DOI 10.1111/j.1432-1033.1990.tb19254.x; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DUAN W, 1991, EUR J BIOCHEM, V200, P679, DOI 10.1111/j.1432-1033.1991.tb16232.x; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HELLER J, 1975, J BIOL CHEM, V250, P3019; HORWITZ J, 1974, J BIOL CHEM, V249, P7181; JACOBSON DR, 1990, AM J HUM GENET, V47, P127; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; MARIUZZA RA, 1987, ANNU REV BIOPHYS BIO, V16, P139; MONACO HL, 1994, J MOL BIOL, V244, P110, DOI 10.1006/jmbi.1994.1708; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; PETERSON PA, 1971, J BIOL CHEM, V246, P44; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1974, EUR J BIOCHEM, V44, P1, DOI 10.1111/j.1432-1033.1974.tb03451.x; RAZ A, 1969, J BIOL CHEM, V244, P3230; STEINRAUF LK, 1993, J BIOL CHEM, V268, P2425; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; TRAGARDH L, 1980, J BIOL CHEM, V255, P9243; UENO S, 1990, BIOCHEM BIOPH RES CO, V169, P143, DOI 10.1016/0006-291X(90)91445-X; VANJAARSVELD PP, 1973, J BIOL CHEM, V248, P4698; WALLACE MR, 1988, AM J HUM GENET, V43, P182; WOJTCZAK A, 1993, J BIOL CHEM, V268, P6202; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728; ZAPPONI MC, 1992, EUR J BIOCHEM, V210, P937, DOI 10.1111/j.1432-1033.1992.tb17498.x	39	339	365	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1039	1041		10.1126/science.7754382	http://dx.doi.org/10.1126/science.7754382			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754382				2022-12-01	WOS:A1995QY93400038
J	PANZNER, S; DREIER, L; HARTMANN, E; KOSTKA, S; RAPOPORT, TA				PANZNER, S; DREIER, L; HARTMANN, E; KOSTKA, S; RAPOPORT, TA			POSTTRANSLATIONAL PROTEIN-TRANSPORT IN YEAST RECONSTITUTED WITH A PURIFIED COMPLEX OF SEC PROTEINS AND KAR2P	CELL			English	Article							PREPRO-ALPHA-FACTOR; ENDOPLASMIC-RETICULUM MEMBRANE; POST-TRANSLATIONAL TRANSLOCATION; CELL-FREE SYSTEM; POLYPEPTIDE TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEINS; ESCHERICHIA-COLI; SIGNAL SEQUENCE; INVITRO	We have reproduced the posttranslational mode of protein translocation across the endoplasmic reticulum membrane with reconstituted proteoliposomes containing a purified complex of seven yeast proteins. This Sec complex includes a heterotrimeric Sec61p complex, homologous to that in mammals, as well as all other membrane proteins found in genetic screens for translocation components. Efficient posttranslational translocation also requires the addition of lumenal Kar2p (BiP) and ATP. The trimeric Sec61p complex also exists as a separate entity that, in contrast with the large Sec complex, is associated with membrane-bound ribosomes. We therefore hypothesize that distinct membrane protein complexes function in co- and posttranslational translocation pathways.			PANZNER, S (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,D-13125 BERLIN,GERMANY.		Hartmann, Enno/C-5687-2013					ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; MEYER DI, 1982, NATURE, V297, P503; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHNEIDER HC, 1994, NATURE, V371, P7688; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V93, P557; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; YAMADA H, 1989, J BIOL CHEM, V264, P1723	37	317	327	1	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					561	570		10.1016/0092-8674(95)90077-2	http://dx.doi.org/10.1016/0092-8674(95)90077-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758110	Bronze			2022-12-01	WOS:A1995QZ71000013
J	SCHNEEWEIS, DM; SCHNAPF, JL				SCHNEEWEIS, DM; SCHNAPF, JL			PHOTOVOLTAGE OF RODS AND CONES IN THE MACAQUE RETINA	SCIENCE			English	Article							MONKEY MACACA-FASCICULARIS; TURTLE PHOTORECEPTORS; VISUAL TRANSDUCTION; SALAMANDER; SENSITIVITY; SEGMENTS; CAT	The kinetics, gain, and reliability of light responses of rod and cone photoreceptors are important determinants of overall Visual sensitivity. In voltage recordings from photoreceptors in an intact primate retina, rods were found to be functionally isolated from each other, unlike the tightly coupled rods of cold-blooded vertebrates. Cones were observed to receive excitatory input from rods, which indicates that the cone pathway also processes rod signals, This input might be expected to degrade the spatial resolution of mesopic vision.	UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL EYE INSTITUTE [R01EY007642, F32EY006399] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY07642, F32-EY06399] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BADER CR, 1979, J PHYSIOL-LONDON, V296, P1; BADER CR, 1982, J PHYSIOL-LONDON, V331, P253, DOI 10.1113/jphysiol.1982.sp014372; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BAYLOR DA, 1973, J PHYSIOL-LONDON, V234, P163, DOI 10.1113/jphysiol.1973.sp010340; BAYLOR DA, 1986, J PHYSIOL-LONDON, V371, P115, DOI 10.1113/jphysiol.1986.sp015964; BAYLOR DA, 1984, J PHYSIOL-LONDON, V387, P575; BAYLOR DA, 1976, COLD SPRING HARB SYM, V40, P529; CONNER JD, 1977, SCIENCE, V195, P698, DOI 10.1126/science.841308; CONNER JD, 1982, J PHYSIOL-LONDON, V332, P139, DOI 10.1113/jphysiol.1982.sp014406; COPENHAGEN DR, 1983, VISION RES, V4, P363; DETWILER PB, 1980, J PHYSIOL-LONDON, V300, P213, DOI 10.1113/jphysiol.1980.sp013159; FAIN GL, 1975, SCIENCE, V187, P838, DOI 10.1126/science.1114328; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KNIGHT R, 1993, VISION RES, V33, P2203, DOI 10.1016/0042-6989(93)90100-B; KRAFT TW, 1993, J PHYSIOL-LONDON, V464, P747, DOI 10.1113/jphysiol.1993.sp019661; LAMB TD, 1976, J PHYSIOL-LONDON, V263, P257, DOI 10.1113/jphysiol.1976.sp011631; NELSON R, 1977, J COMP NEUROL, V172, P109, DOI 10.1002/cne.901720106; Nelson R., 1985, NEUROCIRCUITRY RETIN, P109; RAVIOLA E, 1973, P NATL ACAD SCI USA, V70, P1677, DOI 10.1073/pnas.70.6.1677; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SCHNAPF JL, 1983, J PHYSIOL-LONDON, V343, P147, DOI 10.1113/jphysiol.1983.sp014886; SCHNAPF JL, 1983, NATURE, V296, P862; SMITH RG, 1986, J NEUROSCI, V6, P3505; YAGI T, 1994, J NEUROPHYSIOL, V71, P656, DOI 10.1152/jn.1994.71.2.656	26	236	240	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1053	1056		10.1126/science.7754386	http://dx.doi.org/10.1126/science.7754386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754386				2022-12-01	WOS:A1995QY93400042
J	SMITH, EJ; MARSDEN, RG; PAGE, DE				SMITH, EJ; MARSDEN, RG; PAGE, DE			ULYSSES ABOVE THE SUNS SOUTH-POLE - AN INTRODUCTION	SCIENCE			English	Article								Ulysses has explored the field and particle environment of the sun's polar region. The solar wind speed was fast and nearly constant above -50 degrees latitude. Compositional differences were observed in slow (low-latitude) solar wind and in fast (high-latitude) solar wind. The radial magnetic field did not change with latitude, implying that polar cap magnetic fields are transported, toward the equator. The intensity of galactic cosmic rays was nearly independent of latitude. Their access to the polar region is opposed by outward-traveling, large amplitude waves in the magnetic field.	EUROPEAN SPACE TECHNOL CTR,EUROPEAN SPACE AGCY,DEPT SPACE SCI,2200 AG NOORDWIJK,NETHERLANDS	European Space Agency	SMITH, EJ (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							BALOGH A, 1995, SCIENCE, V268, P1007, DOI 10.1126/science.268.5213.1007; FOUKAL PV, 1990, SOLAR ASTROPHYSICS; GEISS J, 1995, SCIENCE, V268, P1033, DOI 10.1126/science.7754380; GRZEDZIELSKI S, 1990, COSPAR C SERIES, V1; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; SIMPSON JA, 1995, SCIENCE, V268, P1019, DOI 10.1126/science.268.5213.1019; SMITH EJ, 1991, EOS T AGU, V72, P241; WENZEL KP, 1992, ASTRON ASTROPHYS SUP, V92, P207; Zirin H., 1988, ASTROPHYSICS SUN; 1992, ASTRON ASTROPHYS S, V92, P207	10	48	49	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1005	1007		10.1126/science.7754377	http://dx.doi.org/10.1126/science.7754377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754377				2022-12-01	WOS:A1995QY93400027
J	STANGER, BZ; LEDER, P; LEE, TH; KIM, E; SEED, B				STANGER, BZ; LEDER, P; LEE, TH; KIM, E; SEED, B			RIP - A NOVEL PROTEIN CONTAINING A DEATH DOMAIN THAT INTERACTS WITH FAS/APO-1 (CD95) IN YEAST AND CAUSES CELL-DEATH	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; FAS ANTIGEN; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; CONSERVED FEATURES; DNA FRAGMENTATION; CROSS-LINKING; KINASE FAMILY; TNF RECEPTOR	Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells. Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Pas: Pas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein. RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Pas corresponding to the murine lpr(cg) mutation. RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Pas and TNFR1 intracellular domains. Transient overexpression of RIP causes transfected cells to undergo the morphological changes characteristic of apoptosis. Taken together, these properties indicate that RIP is a novel form of apoptosis-inducing protein.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	STANGER, BZ (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CRISPE IN, 1994, IMMUNITY, V1, P347; DHEIN J, 1992, J IMMUNOL, V149, P3166; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; HELLER RA, 1992, CELL, V70, P47; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE SC, 1993, J BIOL CHEM, V268, P12164; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7053; Miller JH., 1972, EXPT MOL GENETICS; NEKART PA, 1994, IMMUNITY, V1, P343; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Rose M. D., 1990, METHODS YEAST GENETI, P155; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	840	894	0	28	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					513	523		10.1016/0092-8674(95)90072-1	http://dx.doi.org/10.1016/0092-8674(95)90072-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538908	Bronze			2022-12-01	WOS:A1995QZ71000008
J	SYMONS, JA; ALCAMI, A; SMITH, GL				SYMONS, JA; ALCAMI, A; SMITH, GL			VACCINIA VIRUS ENCODES A SOLUBLE TYPE-I INTERFERON RECEPTOR OF NOVEL STRUCTURE AND BROAD SPECIES-SPECIFICITY	CELL			English	Article							NUCLEOTIDE-SEQUENCE; GAMMA RECEPTOR; ALPHA RECEPTOR; MYXOMA VIRUS; CELLS; MICE; EXPRESSION; PROTEIN; GENOME; GENE	Vaccinia virus (VV) and other orthopoxviruses express a soluble type I interferon (IFN) receptor that for VV strain Western Reserve is encoded by gene B18R. The 60-65 kDa glycoprotein is related to the interleukin-l receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN receptors, which belong to the class II cytokine receptor family. The receptor has high affinity (K-D, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to human, rabbit, bovine, rat, and mouse type I IFNs. This may have aided VV replication in multiple host species during evolution. A VV B18R deletion mutant is attenuated in a murine intranasal model. This type I IFN receptor represents the fourth VV protein that interferes with IFN and the fourth soluble cytokine receptor expressed by poxviruses.			SYMONS, JA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Alcami, Antonio/F-8512-2015; Smith, Geoffrey L/G-2894-2012	Alcami, Antonio/0000-0002-3333-6016; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; AMANO H, 1979, J GEN VIROL, V44, P265, DOI 10.1099/0022-1317-44-1-265; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; Baxby D., 1981, TRENDS IMMUNOL, V3, P26; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; Downie AW, 1939, J PATHOL BACTERIOL, V48, P361, DOI 10.1002/path.1700480212; ENGELSTAD M, 1993, VIROLOGY, V194, P627, DOI 10.1006/viro.1993.1302; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; Fenner F., 1988, SMALLPOX ITS ERADICA; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS SN, 1990, VIROLOGY, V178, P626, DOI 10.1016/0042-6822(90)90367-Z; JOHNSON GP, 1993, VIROLOGY, V196, P381, DOI 10.1006/viro.1993.1494; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR SM, 1991, VIROLOGY, V180, P625, DOI 10.1016/0042-6822(91)90076-N; KOHONENCORISH MRJ, 1990, EUR J IMMUNOL, V20, P157, DOI 10.1002/eji.1830200123; LANGER JA, 1986, METHOD ENZYMOL, V119, P305; MACKETT M, 1979, J GEN VIROL, V45, P683, DOI 10.1099/0022-1317-45-3-683; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORIKAWA S, 1993, VIROLOGY, V193, P753, DOI 10.1006/viro.1993.1184; MOSS B, 1981, J VIROL, V40, P387, DOI 10.1128/JVI.40.2.387-395.1981; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; NOVICK D, 1992, FEBS LETT, V314, P445, DOI 10.1016/0014-5793(92)81523-O; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; PESKA S, 1987, ANNU REV BIOCHEM, V56, P727; RODRIGUEZ JR, 1991, VIROLOGY, V185, P929, DOI 10.1016/0042-6822(91)90575-V; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399; UEDA Y, 1972, VIROLOGY, V49, P794, DOI 10.1016/0042-6822(72)90535-1; UEDA Y, 1969, VIROLOGY, V38, P180, DOI 10.1016/0042-6822(69)90141-X; UEDA Y, 1990, VIROLOGY, V177, P588, DOI 10.1016/0042-6822(90)90524-U; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761; [No title captured]	60	407	437	4	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					551	560		10.1016/0092-8674(95)90076-4	http://dx.doi.org/10.1016/0092-8674(95)90076-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758109	Bronze			2022-12-01	WOS:A1995QZ71000012
J	WEIS, K; MATTAJ, IW; LAMOND, AI				WEIS, K; MATTAJ, IW; LAMOND, AI			IDENTIFICATION OF HSRP1-ALPHA AS A FUNCTIONAL RECEPTOR FOR NUCLEAR-LOCALIZATION SEQUENCES	SCIENCE			English	Article							RNA-POLYMERASE-II; BINDING-PROTEIN; 2 STEPS; IMPORT; TRANSLOCATION; ENVELOPE; SIGNALS; PATHWAY; PORE	Import of proteins into the nucleus is a two-step process, involving nuclear localization sequence (NLS)-dependent docking of the substrate at the nuclear envelope followed by translocation through the nuclear pore. A recombinant human protein, hSRP1 alpha, bound in vitro specifically and directly to substrates containing either a simple or bipartite NLS motif. hSRP1 alpha promoted docking of import substrates to the nuclear envelope and together with recombinant human Ran reconstituted complete nuclear protein import. Thus, hSRP1 alpha has the properties of a cytosolic receptor for both simple and bipartite NLS motifs.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X; Mattaj, Iain/0000-0002-5537-8284; Lamond, Angus/0000-0001-6204-6045				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1991, EMBO J, V10, P705; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRARLDE E, UNPUB; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; WEIS K, UNPUB; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YAO R, 1994, P NATL ACAD SCI USA, V91, P6880; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	317	325	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	1995	268	5213					1049	1053		10.1126/science.7754385	http://dx.doi.org/10.1126/science.7754385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754385				2022-12-01	WOS:A1995QY93400041
J	ZHENG, H; JIANG, MH; TRUMBAUER, ME; SIRINATHSINGHJI, DJS; HOPKINS, R; SMITH, DW; HEAVENS, RP; DAWSON, GR; BOYCE, S; CONNER, MW; STEVENS, KA; SLUNT, HH; SISODIA, SS; CHEN, HY; VANDERPLOEG, LHT				ZHENG, H; JIANG, MH; TRUMBAUER, ME; SIRINATHSINGHJI, DJS; HOPKINS, R; SMITH, DW; HEAVENS, RP; DAWSON, GR; BOYCE, S; CONNER, MW; STEVENS, KA; SLUNT, HH; SISODIA, SS; CHEN, HY; VANDERPLOEG, LHT			BETA-AMYLOID PRECURSOR PROTEIN-DEFICIENT MICE SHOW REACTIVE GLIOSIS AND DECREASED LOCOMOTOR-ACTIVITY	CELL			English	Article							ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; RAT-BRAIN; GENE; EXPRESSION; MOUSE; DOMAIN; CDNA	In several pedigrees of early onset familial Alzheimer's disease (FAD), point mutations in the beta-amyloid precursor protein (APP) gene are genetically linked to the disease. This finding implicates APP in the pathogenesis of Alzheimer's disease in these individuals. To understand the in vivo function of APP and its processing, we have generated an APP-null mutation in mice. Homozygous APP-deficient mice were viable and fertile. However, the mutant animals weighed 15%-20% less than age-matched wild-type controls. Neurological evaluation showed that the APP-deficient mice exhibited a decreased locomotor activity and forelimb grip strength, indicating a compromised neuronal or muscular function. In addition, four out of six homozygous mice showed reactive gliosis at 14 weeks of age, suggesting an impaired neuronal function as a result of the APP-null mutation.	MERCK SHARP & DOHME LTD, RES LABS, NEUROSCI RES CTR, West Point, PA 19486 USA; JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA	Merck & Company; Johns Hopkins University	ZHENG, H (corresponding author), MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT GENET & MOLEC BIO, ANIM RESOURCES LAB, RAHWAY, NJ 07065 USA.							BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FISHER S, 1991, P NATL ACAD SCI USA, V88, P1779, DOI 10.1073/pnas.88.5.1779; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KOSIK KS, 1992, NEUROBIOLOGY AGING, V13; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1994, ANNU REV MED, V45, P435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SARKOZI E, 1994, EXP NEUROL, V128, P27, DOI 10.1006/exnr.1994.1109; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1993, ANN NY ACAD SCI, V695, P169, DOI 10.1111/j.1749-6632.1993.tb23047.x; SOLA C, 1993, EUR J NEUROSCI, V5, P795, DOI 10.1111/j.1460-9568.1993.tb00931.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	51	543	562	2	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					525	531		10.1016/0092-8674(95)90073-X	http://dx.doi.org/10.1016/0092-8674(95)90073-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758106	hybrid			2022-12-01	WOS:A1995QZ71000009
J	BRITZCUNNINGHAM, SH; SHAH, MM; ZUPPAN, CW; FLETCHER, WH				BRITZCUNNINGHAM, SH; SHAH, MM; ZUPPAN, CW; FLETCHER, WH			MUTATIONS OF THE CONNEXIN43 GAP-JUNCTION GENE IN PATIENTS WITH HEART MALFORMATIONS AND DEFECTS OF LATERALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTATION MOUSE EMBRYO; CARDIAC DEFECTS; COMMUNICATION; PROTEIN; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; CHANNEL; FAMILY; CELLS	Background. Gap junctions are thought to have a crucial role in the synchronized contraction of the heart and in embryonic development. Connexin43, the major protein of gap junctions in the heart, is targeted by several protein kinases that regulate myocardial cell-cell coupling. We hypothesized that mutations altering sites critical to this regulation would lead to functional or developmental abnormalities of the heart. Methods. Connexin43 DNA from 25 normal subjects and 30 children with a Variety of congenital heart diseases was amplified by the polymerase chain reaction and sequenced. Mutant DNA was expressed in cell culture and examined for its effect on the regulation of cell-cell communication. Results. The 25 normal subjects and 23 of the 30 children with heart disease had no amino acid substitutions in connexin43. All six children with syndromes that included complex heart malformations had substitutions of one or more phosphorylatable serine or threonine residues. Four of these children had two independent mutations, suggesting an autosomal recessive disorder. Five of these children had substitutions of proline for serine at position 364. A seventh child, with a different heart condition, also had a point mutation in connexin43. Transfected cells expressing the Ser364Pro mutant connexin43 sequence showed abnormalities in the regulation of cell-cell communication, as compared with cells expressing normal connexin43. Conclusions. Mutations in the connexin43 gap-junction gene, which lead to abnormally regulated cell-cell communication, are associated with visceroatrial heterotaxia.	LOMA LINDA UNIV, DEPT PATHOL & HUMAN ANAT, LOMA LINDA, CA 92354 USA; JERRY L PETTIS MEM VET AFFAIRS MED CTR, MOLEC CYTOL LAB, LOMA LINDA, CA USA	Loma Linda University	BRITZCUNNINGHAM, SH (corresponding author), LOMA LINDA UNIV, DEPT PHYSIOL, LOMA LINDA, CA 92354 USA.							ARNOLD GL, 1983, AM J MED GENET, V16, P35, DOI 10.1002/ajmg.1320160107; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; CARMI R, 1992, AM J MED GENET, V44, P246, DOI 10.1002/ajmg.1320440228; CASEY B, 1993, NAT GENET, V5, P403, DOI 10.1038/ng1293-403; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FORSTHOEFEL KF, 1992, AM J CLIN PATHOL, V98, P98, DOI 10.1093/ajcp/98.1.98; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GODWIN AJ, 1993, MOL CELL BIOCHEM, V128, P293, DOI 10.1007/BF01076779; GOSHIMA K, 1971, EXP CELL RES, V65, P161, DOI 10.1016/S0014-4827(71)80062-9; HOWITT G, 1961, BRIT HEART J, V23, P494; KALIMI GH, 1988, J CELL BIOL, V107, P241, DOI 10.1083/jcb.107.1.241; KALIMI GH, 1989, J CELL BIOL, V109, P3015, DOI 10.1083/jcb.109.6.3015; KATZ AM, 1992, PHYSL HEART, P521; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOJIMA H, 1969, LANCET, V2, P701; LAIRD DW, 1990, J CELL SCI, V97, P109; LO CW, 1979, CELL, V18, P411, DOI 10.1016/0092-8674(79)90060-6; LO CW, 1979, CELL, V18, P399, DOI 10.1016/0092-8674(79)90059-X; Lynberg M C, 1990, MMWR CDC Surveill Summ, V39, P1; MCCHANE RH, 1989, SOUTHERN MED J, V82, P1312, DOI 10.1097/00007611-198910000-00032; MCKUSICK VA, 1995, MENDELIAN INHERITANC, V2, P1236; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NISHI M, 1991, DEV BIOL, V146, P117, DOI 10.1016/0012-1606(91)90452-9; NOONAN JA, 1978, AM J DIS CHILD, V132, P17, DOI 10.1001/archpedi.1978.02120260019001; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; RUANGVORAVAT CP, 1992, DEV DYNAM, V194, P261, DOI 10.1002/aja.1001940403; Sambrook J., 1989, MOL CLONING LAB MANU; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; VEENSTRA RD, 1986, SCIENCE, V233, P972, DOI 10.1126/science.2426781; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WHITE RL, 1985, AM J PHYSIOL, V249, pC447, DOI 10.1152/ajpcell.1985.249.5.C447; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L; 1989, MMWR-MORBID MORTAL W, V38, P633	45	330	349	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1323	1329		10.1056/NEJM199505183322002	http://dx.doi.org/10.1056/NEJM199505183322002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715640				2022-12-01	WOS:A1995QX85700002
J	BROTCHIE, PR; ANDERSEN, RA; SNYDER, LH; GOODMAN, SJ				BROTCHIE, PR; ANDERSEN, RA; SNYDER, LH; GOODMAN, SJ			HEAD POSITION SIGNALS USED BY PARIETAL NEURONS TO ENCODE LOCATIONS OF VISUAL-STIMULI	NATURE			English	Article							SACCADE-RELATED ACTIVITY; LATERAL INTRAPARIETAL AREA; ASSOCIATION CORTEX; EYE-MOVEMENTS; SPACE; GAZE; MACAQUE; MEMORY; 7A	THE mechanism for object location in the environment, and the perception of the external world as stable when eyes, head and body are moved, have long been thought to be centred on the posterior parietal cortex(1-8). However, head position signals, and their integration with visual and eye position signals to form a representation of space referenced to the body, have never been examined in any area of the cortex. Here we show that the visual and saccadic activities of parietal neurons are strongly affected by head position. The eye and head position effects are equivalent for individual neurons, indicating that the modulation is a function of gaze direction, regardless of whether the eyes or head are used to direct gaze. These data are consistent with the idea that the posterior parietal cortex contains a distributed representation of space in body-centred coordinates.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Snyder, Lawrence H/A-4593-2017					ANDERSEN RA, 1987, EXP BRAIN RES, V67, P316; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BIGUER B, 1988, BRAIN, V11, P1405; Critchley M., 1953, PARIETAL LOBES; DUHAMEL JR, 1992, SCIENCE, V255, P90; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; FOGASSI L, 1992, EXP BRAIN RES, V89, P686, DOI 10.1007/BF00229894; FULLER JH, 1983, BRAIN RES, V271, P241, DOI 10.1016/0006-8993(83)90286-X; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOODMAN SJ, 1990, P INT JOINT C NEUR N, P381; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; HYVARINEN J, 1982, PARIETAL CORTEX MONK; LACKNER JR, 1984, EXP NEUROL, V47, P177; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; LYNCH JC, 1980, BEHAV BRAIN SCI, V3, P485, DOI 10.1017/S0140525X00006324; MOUNTCASTLE V B, 1976, Neurosciences Research Program Bulletin, V14, P1; ROLL R, 1991, EXP BRAIN RES, V85, P423; SAKATA H, 1985, VISION RES, V25, P453, DOI 10.1016/0042-6989(85)90070-7; Snyder L. H., 1993, Society for Neuroscience Abstracts, V19, P770; TAYLOR JL, 1991, BRAIN, V114, P755, DOI 10.1093/brain/114.2.755; TOMLINSON RD, 1990, J NEUROPHYSIOL, V64, P1873, DOI 10.1152/jn.1990.64.6.1873; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	28	260	263	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					232	235		10.1038/375232a0	http://dx.doi.org/10.1038/375232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746323				2022-12-01	WOS:A1995QY88100062
J	CONOVER, JC; ERICKSON, JT; KATZ, DM; BIANCHI, LM; POUEYMIROU, WT; MCCLAIN, J; PAN, L; HELGREN, M; IP, NY; BOLAND, P; FRIEDMAN, B; WIEGAND, S; VEJSADA, R; KATO, AC; DECHIARA, TM; YANCOPOULOS, GD				CONOVER, JC; ERICKSON, JT; KATZ, DM; BIANCHI, LM; POUEYMIROU, WT; MCCLAIN, J; PAN, L; HELGREN, M; IP, NY; BOLAND, P; FRIEDMAN, B; WIEGAND, S; VEJSADA, R; KATO, AC; DECHIARA, TM; YANCOPOULOS, GD			NEURONAL DEFICITS, NOT INVOLVING MOTOR-NEURONS, IN MICE LACKING BDNF AND/OR NT4	NATURE			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; CELL-DEATH; BRAIN; MOTONEURONS; RECEPTORS	NERVE growth factor and other neurotrophins signal to neurons through the Trk family of receptor tyrosine kinases(1-6). TrkB is relatively promiscuous in vitro, acting as a receptor for brain-derived neurotrophic factor (BDNF), neurotrophin-4 (NT4) and, to a lesser extent, NT3 (refs 3-5). Mice lacking TrkB(7) show a more severe phenotype than mice lacking BDNF8,9, suggesting that TrkB may act as a receptor for additional ligands in vivo. To explore this possibility, we generated mice lacking NT4 or BDNF as well as mice lacking both neurotrophins. Unlike mice lacking other Trks(7,10,11) or neurotrophins(8,9,12-14), NT4-deficient mice are long-lived and show no obvious neurological defects. Analysis of mutant phenotypes revealed distinct neuronal populations with different neurotrophin requirements. Thus vestibular and trigeminal sensory neurons require BDNF but not NT4, whereas nodose-petrosal sensory neurons require both BDNF and NT4. Motor neurons, whose numbers are drastically reduced in mice lacking TrkB, are not affected even in mice lacking both BDNF and NT4. These results suggest that another ligand, perhaps NT3, does indeed act on TrkB in vivo.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; UNIV GENEVA,MED CTR,DEPT PHARMACOL,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,MED CTR,DIV CLIN NEUROMUSCULAR RES,CH-1211 GENEVA,SWITZERLAND	Case Western Reserve University; Regeneron; University of Geneva; University of Geneva				Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Bianchi, Lynne/0000-0002-5064-6972				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; BARBACID MJ, 1994, NEUROBIOLOGY, V25, P1386; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; EMFORS P, 1994, NATURE, V368, P147; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HERTZBERG T, 1994, DEV BIOL, V166, P801, DOI 10.1006/dbio.1994.1358; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI L, 1994, J NEUROBIOL, V15, P759; MALSONPIERRE PC, 1990, NEURON, V5, P501; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; POVER CM, 1991, ANAT REC, V231, P573, DOI 10.1002/ar.1092310419; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THALER CD, 1994, DEV BIOL, V161, P338, DOI 10.1006/dbio.1994.1035; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	30	354	360	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					235	238		10.1038/375235a0	http://dx.doi.org/10.1038/375235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746324				2022-12-01	WOS:A1995QY88100063
J	LIU, X; ERNFORS, P; WU, H; JAENISCH, R				LIU, X; ERNFORS, P; WU, H; JAENISCH, R			SENSORY BUT NOT MOTOR-NEURON DEFICITS IN MICE LACKING NT4 AND BDNF	NATURE			English	Article							TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; RECEPTOR; TRKB; SURVIVAL	NEUROTROPHINS play important roles in neuronal survival during vertebrate development(1-3). Neurotrophin-4 (NT4), alone or in combination with brain-derived neurotrophic factor (BDNF), has been suggested to be necessary for the survival of peripheral sensory neurons and central nervous system (CNS) neurons, including motor neurons(4-16). To define the role of NT4 in vivo, we generated mice lacking NT4 by gene targeting. NT4-deficient mice were viable but exhibited a loss of sensory neurons in the nodose-petrosal and geniculate ganglia. In contrast, motor neurons of the facial nucleus and sympathetic neurons of the superior cervical ganglion were unaffected, and there was no obvious loss of dopaminergic neurons in the substantia nigra. In mice lacking both NT4 and BDNF14,15, facial motor neurons remained unaffected, whereas the loss of sensory neurons was more severe than with either mutation alone. Thus NT4 is required during development for the survival of some peripheral sensory neurons but not sympathetic or motor neurons.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	LIU, X (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.			Ernfors, Patrik/0000-0002-1140-3986				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FISCHER W, 1994, P NATL ACAD SCI USA, V91, P8607, DOI 10.1073/pnas.91.18.8607; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HYMAN C, 1994, J NEUROSCI, V14, P335; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1994, ANN NEUROL, V35, pS13, DOI 10.1002/ana.410350706; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	29	316	319	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					238	241		10.1038/375238a0	http://dx.doi.org/10.1038/375238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746325				2022-12-01	WOS:A1995QY88100064
J	MARRERO, MB; SCHIEFFER, B; PAXTON, WG; HEERDT, L; BERK, BC; DELAFONTAINE, P; BERNSTEIN, KE				MARRERO, MB; SCHIEFFER, B; PAXTON, WG; HEERDT, L; BERK, BC; DELAFONTAINE, P; BERNSTEIN, KE			DIRECT STIMULATION OF JAK/STAT PATHWAY BY THE ANGIOTENSIN-II AT(1) RECEPTOR	NATURE			English	Article							PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; JAK2	THE peptide angiotensin II is the effector molecule of the renin-angiotensin system. All the haemodynamic effects of angiotensin II, including vasoconstriction! and adrenal aldosterone release, are mediated through a single class of cell-surface receptors known as AT(1) (refs 1, 2). These receptors contain the structural features of the G-protein-coupled receptor superfamily(3). We show here that angiotensin II induces the rapid phosphorylation of tyrosine in the intracellular kinases Jak2 and Tyk2 in rat aortic smooth-muscle cells and that this phosphorylation is associated with increase activity of Jak2. The Jak family substrates STAT1 and STAT2 (for signal transducers and activators of transcription) are rapidly tyrosine-phosphorylated in response to angiotensin II. We also find that Jak2 co-precipitates with the AT(1) receptor, indicating that G-protein-coupled receptors may be able to signal through the intracellular phosphorylation pathways used by cytokine receptors(4,5).	EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322; SANTA CRUZ BIOTECHNOL INC,SANTA CRUZ,CA 95060; UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195	Emory University; Emory University; University of Washington; University of Washington Seattle				Bernstein, Kenneth/0000-0001-8097-3272; Berk, Bradford/0000-0002-2767-4115; Delafontaine, Patrice/0000-0003-3744-3617				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MIURA O, 1994, BLOOD, V84, P1501; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; RUI H, 1994, J BIOL CHEM, V269, P5364; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0	28	644	663	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					247	250		10.1038/375247a0	http://dx.doi.org/10.1038/375247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746328				2022-12-01	WOS:A1995QY88100067
J	PEI, DQ; WEISS, SJ				PEI, DQ; WEISS, SJ			FURIN-DEPENDENT INTRACELLULAR ACTIVATION OF THE HUMAN STROMELYSIN-3 ZYMOGEN	NATURE			English	Article							SECRETORY PATHWAY; METALLOPROTEINASES; PRECURSOR; CLEAVAGE; CELLS; ENDOPROTEASE; INHIBITION; PROTEIN; FUSION; GENE	HUMAN stromelysin-3, a new member of the matrix metalloproteinase family, is expressed in tissues undergoing the active remodelling associated with embryonic development, wound healing and tumour invasion(1-3). But like all other members of the matrix metalloproteinase gene family, stromelysin3 is synthesized as an inactive precursor that must be processed to its mature form in order to express enzymic activity(4,5). Here we identify stromelysin-3 as the first matrix metalloproteinase to be discovered that can be processed directly to its enzymically active form by an obligate intracellular proteolytic event that occurs within the constitutive secretory pathway. Intracellular activation is regulated by an unusual 10-amino-acid insert sandwiched between the pro- and catalytic-domains of stromelysin-3, which is encrypted with an Arg-X-Arg-X-Lys-Arg recognition motif for the Golgi-associated proteinase, furin, a mammalian homologue of the yeast Kex2 pheromone convertase(6,7). A furin-stromelysin-3 processing axis not only differentiates the regulation of this enzyme from all previously characterized matrix metalloproteinases, but also identifies pro-protein convertases as potential targets for therapeutic intervention in matrix-destructive disease states.	UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Ausubel FM, 1994, CURR PROT MOL BIOL; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEN S, 1981, J BIOL CHEM, V256, P1816; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; DAVIES B, 1993, CANCER RES, V53, P2087; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1994, J BIOL CHEM, V269, P25849; REHEMTULLA A, 1992, BLOOD, V79, P2349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1991, J BIOL CHEM, V267, P8270; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	27	517	533	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					244	247		10.1038/375244a0	http://dx.doi.org/10.1038/375244a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746327	Green Submitted			2022-12-01	WOS:A1995QY88100066
J	PENNINGER, JM; WEN, T; TIMMS, E; POTTER, J; WALLACE, VA; MATSUYAMA, T; FERRICK, D; SYDORA, B; KRONENBERG, M; MAK, TW				PENNINGER, JM; WEN, T; TIMMS, E; POTTER, J; WALLACE, VA; MATSUYAMA, T; FERRICK, D; SYDORA, B; KRONENBERG, M; MAK, TW			SPONTANEOUS RESISTANCE TO ACUTE T-CELL LEUKEMIAS IN TCRV-GAMMA-1.1J-GAMMA-4C-GAMMA-4 TRANSGENIC MICE	NATURE			English	Article							DELTA-LYMPHOCYTES-T; GAMMA-DELTA; MYCOBACTERIUM-TUBERCULOSIS; ANTIGEN; RECEPTOR; EXPRESSION	THE concept of tumour surveillance implies that specific and nonspecific components of the immune system eliminate rumours in the early phase of malignancy(1,2). The immunological mechanisms that control growth-of preneoplastic cells are, however, not known. T cells expressing gamma delta T-cell receptors (TCR) were first described as lymphocytes with reactivity against various tumour cells, which suggests that gamma delta T cells could mediate tumour surveillance(3-6). Here we show that TCRV gamma 1.1J gamma 4C gamma 4 transgenic mice(7) are spontaneously resistant to acute T-cell leukaemias but cannot reject non-haematopoietic tumours. TCRV gamma 1.1J gamma 4C gamma 4(+) hybridomas isolated from these mice react in vitro against almost all haematopoietic tumour cell lines tested. Recognition of tumour cells depends on the gamma delta TCR but is independent of major histocompatibility complex (MHC) class I, MHC class II, or TAP-2 peptide transporter expression. Ligand recognition is influenced by the murine Nromp gene, which confers resistance or susceptibility to tuberculosis, lepra and leishmaniasis(8,9). These data indicate that TCRV gamma 1.1(+) T cells confer spontaneous immunity against haematopoietic rumours in vivo and link innate resistance to bacterial infections with tissue-specific tumour surveillance by gamma delta(+) T cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5X 1K9,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5X 1K9,CANADA; UNIV CALIF DAVIS,DEPT VET MICROBIOL & IMMUNOL,DAVIS,CA 95616; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of Toronto; University of Toronto; University of California System; University of California Davis; University of California System; University of California Los Angeles	PENNINGER, JM (corresponding author), UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,500 SHERBOURNE ST,TORONTO,ON M5X 1K9,CANADA.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; FERRICK DA, 1989, CELL, V57, P483, DOI 10.1016/0092-8674(89)90923-9; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; KABELITZ D, 1991, J EXP MED, V173, P1331, DOI 10.1084/jem.173.6.1331; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KLEIN G, 1993, CURR OPIN IMMUNOL, V5, P687, DOI 10.1016/0952-7915(93)90122-9; KRONENBERG M, 1994, CURR OPIN IMMUNOL, V6, P64, DOI 10.1016/0952-7915(94)90035-3; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MUNK ME, 1990, J IMMUNOL, V145, P2434; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; PARDOLL DM, 1993, CURR OPIN IMMUNOL, V5, P719, DOI 10.1016/0952-7915(93)90127-E; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SILVA CL, 1993, IMMUNOLOGY, V78, P35; UYEMURA K, 1992, J EXP MED, V174, P683; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; YEUNG RA, 1989, CELL, V59, P5	23	35	36	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					241	244		10.1038/375241a0	http://dx.doi.org/10.1038/375241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746326				2022-12-01	WOS:A1995QY88100065
J	RASTINEJAD, F; PERLMANN, T; EVANS, RM; SIGLER, PB				RASTINEJAD, F; PERLMANN, T; EVANS, RM; SIGLER, PB			STRUCTURAL DETERMINANTS OF NUCLEAR RECEPTOR ASSEMBLY ON DNA DIRECT REPEATS	NATURE			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; BINDING DOMAIN; RESPONSE ELEMENTS; X-RECEPTOR; VITAMIN-D; GLUCOCORTICOID RECEPTOR; GENE ENCODES; RXR-BETA; IDENTIFICATION	Nuclear receptor heterodimers recognize response elements composed of two direct repeats of the consensus sequence 5'-AGGTCA-3' separated by one to five base pairs. The 1.9 Angstrom crystal structure of the complex formed by the DNA-binding domains of the 9-cis retinoic acid receptor and thyroid hormone receptor bound to a thyroid-response element shows that the subunits interact through a DNA-supported interface involving the carboxy-terminal extension of the DNA-binding domain of the thyroid hormone receptor. The stereochemistry suggests a mechanism by which heterodimers recognize the inter-half-site spacing between direct repeats.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Yale University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIOCCO MM, 1994, J MOL BIOL, V235, P709; FREEDMAN L, IN PRESS 9TH P WORKS; GEWIRTH DT, IN PRESS NATURE STRU; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRESLEY JP, 1988, J APPL CRYSTALLOGR, V21, P572; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; XU W, 1993, COLD SPRING HARB SYM, V58, P133, DOI 10.1101/SQB.1993.058.01.017; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	50	453	463	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					203	211		10.1038/375203a0	http://dx.doi.org/10.1038/375203a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746322				2022-12-01	WOS:A1995QY88100053
J	TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ				TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ			SPECIFICITY IN CHAPERONIN-MEDIATED PROTEIN-FOLDING	NATURE			English	Article							CYTOPLASMIC CHAPERONIN; COMPLEX; TUBULIN; HOMOLOG	CHAPERONINS are ubiquitous multisubunit toroidal complexes that aid protein folding in an ATP-dependent manner(1-6). Current models of folding by the bacterial chaperonin GroEL depict its role as unfolding and releasing molecules that have misfolded, so that they can return to a potentially productive folding pathway in solution(7,8). Accordingly, a given target polypeptide might require several cycles of binding and ATP-driven release from different chaperonin complexes before reaching the native state. Surprisingly, cycling of a target protein does not guarantee its folding, and we report here that unfolded beta-actin or alpha-tubulin both form tight complexes when presented to either GroEL or its mitochondrial homologue, and both undergo cycles of release and rebinding upon incubation with ATP, but no native protein is produced. We conclude that different chaperonins produce distinctive spectra of folding intermediates.	NYU,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University								BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HORWICH AL, 1994, CELL, V74, P909; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	19	117	119	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					250	253		10.1038/375250a0	http://dx.doi.org/10.1038/375250a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746329				2022-12-01	WOS:A1995QY88100068
J	DESTAFANO, F				DESTAFANO, F			EFFECTS OF AGENT-ORANGE EXPOSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VIETNAM VETERANS; ADIPOSE-TISSUE; DIBENZOFURANS; DIOXINS				DESTAFANO, F (corresponding author), MARSHFIELD MED RES & EDUC FDN,MARSHFIELD,WI 54449, USA.							ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; KAHN PC, 1988, JAMA-J AM MED ASSOC, V259, P1661, DOI 10.1001/jama.259.11.1661; KANG HK, 1991, AM J PUBLIC HEALTH, V81, P344, DOI 10.2105/AJPH.81.3.344; SCHECTER A, 1987, 7TH INT S CHLOR DIOX; WOLFE WH, 1990, JAMA-J AM MED ASSOC, V264, P1824, DOI 10.1001/jama.264.14.1824; 1988, JAMA-J AM MED ASSOC, V259, P2715; 1989, HLTH STATUS VIETNAM, V2; 1990, ARCH INTERN MED, V150, P2495; 1988, JAMA-J AM MED ASSOC, V259, P2708; 1990, ARCH INTERN MED, V150, P2485; 1990, ARCH INTERN MED, V150, P2473; 1988, JAMA-J AM MED ASSOC, V260, P1249; 1987, JAMA-J AM MED ASSOC, V257, P790; 1988, JAMA-J AM MED ASSOC, V259, P2701	15	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1494	1494		10.1001/jama.273.19.1494	http://dx.doi.org/10.1001/jama.273.19.1494			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739073				2022-12-01	WOS:A1995QX41800029
J	ELLERBECK, EF; JENCKS, SF; RADFORD, MJ; KRESOWIK, TF; CRAIG, AS; GOLD, JA; KRUMHOLZ, HM; VOGEL, RA				ELLERBECK, EF; JENCKS, SF; RADFORD, MJ; KRESOWIK, TF; CRAIG, AS; GOLD, JA; KRUMHOLZ, HM; VOGEL, RA			QUALITY OF CARE FOR MEDICARE PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A 4-STATE PILOT-STUDY FROM THE COOPERATIVE CARDIOVASCULAR PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES; SURVIVAL; SMOKING	Objective.-To develop and test indicators of the quality of care for patients with acute myocardial infarction (AMI). Design.-Retrospective medical record review. Setting.-All acute care hospitals in Alabama, Connecticut, Iowa, and Wisconsin. Patients.-All hospitalizations for Medicare patients discharged with a principal diagnosis of AMI between June 1, 1992, and February 28, 1993, were identified (N=16 869). Main Outcome Measure.-Percentage of patients receiving appropriate interventions as defined by 11 quality-of-care indicators derived from clinical practice guidelines that were modified and updated in consultation with a national group of physicians and other health care professionals. Results.-We abstracted data from 16 124 (96%) of the hospitalizations, representing 14 108 primary hospitalizations and 2016 hospitalizations resulting from transfers. Potential exclusions to the use of standard treatments in AMI care were common with 90% and 70% of patients having potential exclusions for thrombolytics and beta-blockers, respectively. In cohorts of ''ideal candidates'' for specific interventions, 83% received aspirin, 69% received thrombolytics, and 70% received heparin during the initial hospitalization; 77% received aspirin and 45% received beta-blockers at discharge. Conclusions.-These data demonstrate that many Medicare patients may not be ideal candidates for standard AMI therapies, but these treatments are underused, even in the absence of discernible contraindications. Hospitals and physicians who apply these quality indicators to their practices are likely to find opportunities for improvement.	HLTH CARE FINANCING ADM,BUR HLTH STAND & QUAL,BALTIMORE,MD; CONNECTICUT PEER REVIEW ORG,MIDDLETOWN,CT; UNIV CONNECTICUT,DEPT CARDIOL,FARMINGTON,CT; IOWA FDN MED CARE,DES MOINES,IA; UNIV IOWA,DEPT SURG,IOWA CITY,IA 52242; ALABAMA QUAL ASSURANCE FDN,BIRMINGHAM,AL; UNIV ALABAMA,DEPT INTERNAL MED,BIRMINGHAM,AL; WISCONSIN PEER REVIEW ORG,MADISON,WI; MED COLL WISCONSIN,DEPT PREVENT MED,MILWAUKEE,WI 53226; UNIV WISCONSIN,MADISON,WI; YALE UNIV,SCH MED,CARDIOVASC SECT,NEW HAVEN,CT; UNIV MARYLAND,DEPT CARDIOL,BALTIMORE,MD	University of Connecticut; University of Iowa; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; Yale University; University System of Maryland; University of Maryland Baltimore			, Harlan/AAI-2875-2020; Ellerbeck, Edward/I-8438-2014	Ellerbeck, Edward/0000-0002-7774-2729; Kresowik, Timothy/0000-0003-4163-1573; Radford, Martha/0000-0001-7503-9557				[Anonymous], 1988, INT CLASSIFICATION D; AUDET AM, 1994, ANN INTERN MED, V120, P423, DOI 10.7326/0003-4819-120-5-199403010-00011; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; FISHER EB, 1990, AM REV RESPIR DIS, V142, P702, DOI 10.1164/ajrccm/142.3.702; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCGUIRE LB, 1990, ANN INTERN MED, V113, P705, DOI 10.7326/0003-4819-113-9-705; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SULLIVAN LW, 1992, 1992 HLTH CAR FIN AD; TIEFENBRUNN AJ, 1992, CIRCULATION, V85, P2311, DOI 10.1161/01.CIR.85.6.2311; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; 1992, JAMA-J AM MED ASSOC, V268, P2199; 1994, EMERGENCY DEP RAPID; 1990, JAMA-J AM MED ASSOC, V263, P2753; 1985, AM J CARDIOL, V56, pG1; 1990, STATA RELEASE 2 REFE	26	343	344	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1509	1514		10.1001/jama.273.19.1509	http://dx.doi.org/10.1001/jama.273.19.1509			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739077				2022-12-01	WOS:A1995QX41800033
J	FRIBERG, TR				FRIBERG, TR			RETINAL TEAR AFTER TEETH CLEANING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DENTAL EXTRACTION				FRIBERG, TR (corresponding author), UNIV PITTSBURGH,PITTSBURGH,PA 15260, USA.							GOPER G, 1977, ZAHN MUND KIEFERHEIL, V65, P278; JAFFE NS, 1984, CATARACT SURG ITS CO, P246; KING LP, 1993, GRAEF ARCH CLIN EXP, V231, P667, DOI 10.1007/BF00921963; MALDEN N, 1993, BRIT DENT J, V174, P334, DOI 10.1038/sj.bdj.4808168; YOUNG LM, 1994, PRINCIPLES PRACTICE, V2, P1084	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1493	1493		10.1001/jama.273.19.1493	http://dx.doi.org/10.1001/jama.273.19.1493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739072				2022-12-01	WOS:A1995QX41800028
J	GREENGOLD, MC				GREENGOLD, MC			SUDDEN-DEATH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1496	1496		10.1001/jama.273.19.1496	http://dx.doi.org/10.1001/jama.273.19.1496			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739074				2022-12-01	WOS:A1995QX41800030
J	WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH				WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH			VARIATION IN OFFICE-BASED QUALITY - A CLAIMS-BASED PROFILE OF CARE PROVIDED TO MEDICARE PATIENTS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY CARE; FAMILY PHYSICIANS; SPECIALTIES; POPULATION; INTERNISTS; ASSURANCE; OUTCOMES; SYSTEMS; MIX	Objectives.-To demonstrate that claims data ''profiling'' can be used as an ongoing method to support ambulatory care quality improvement; to measure the quality of office-based care provided to elderly patients with diabetes in three states; and to identify factors associated with better attainment of quality standards. Study Design.-A cross-sectional study based on a 100% sample of the Medicare claims (Part B and Part A) submitted between July 1, 1990, and June 30, 1991. Setting.-All primary care practices (both solo and group) actively seeing Medicare patients with diabetes in Alabama, Iowa, and Maryland (n=2980). Patients.-All elderly (greater than or equal to 65 years) Medicare patients seen by the study physicians and assigned a diagnosis of diabetes (n=97 388) by any office-based physician during the year. Main Outcome Measures.-The proportion of patients with diabetes receiving the following procedures (from any provider) at least once during the study period: hemoglobin A(1C) measurement, ophthalmologic examination, total cholesterol measurement, and blood glucose measurement. We considered the first three services to be optimally recommended and blood glucose measurement to be of limited use. Results.-Based on analyses of services provided in the ambulatory setting, we found that 84% of diabetics did not appear to receive the recommended hemoglobin A(1C) measurement, 54% did not see an ophthalmologist, and 45% received no cholesterol screening. Practice patterns varied considerably across the three states (up to 2.38-fold), even after adjusting for patient case mix and physician characteristics. Patients of general practitioners were less likely to meet recommended quality criteria than patients of internists or family practitioners. Patients receiving care from rural practitioners were less likely to receive services, either recommended or not, than those in urban locations. Conclusions.-Elderly patients with diabetes do not appear to be receiving optimal care. This study underscores the value of practice guideline development and dissemination in the ambulatory arena. This study provides substantial evidence that existing administrative claims data can be used to support ambulatory quality improvement activities.	BRANDEIS UNIV,HELLER GRAD SCH,INST HLTH POLICY,WALTHAM,MA 02254; PK NICOLLET MED FDN,MINNEAPOLIS,MN; HARVARD UNIV,SCH PUBL HLTH,CTR QUAL CARE RES & EDUC,BOSTON,MA 02115	Brandeis University; Harvard University; Harvard T.H. Chan School of Public Health	WEINER, JP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS HLTH SERV RES & DEV CTR,BALTIMORE,MD 21205, USA.		Garnick, Deborah w/I-9009-2012					ALLERHEILIGEN DA, 1990, DIABETES MELLITUS RE; BRANCH WT, 1987, OFFICE PRACTICE MED; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; Garnick D W, 1994, J Ambul Care Manage, V17, P44; Garnick D W, 1994, Int J Qual Health Care, V6, P163; GARNICK DW, 1994, JOINT COMM J QUAL IM, V20, P679, DOI 10.1016/S1070-3241(16)30117-1; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LASKER RD, 1992, INQUIRY-J HEALTH CAR, V29, P287; LATHERS A, 1995, J AMB CARE MANAGE, V18, P56; Lawthers A G, 1993, Jt Comm J Qual Improv, V19, P552; Leatherman S, 1991, QRB Qual Rev Bull, V17, P349; LINN LS, 1984, INQUIRY-J HEALTH CAR, V21, P266; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; PALMER RH, 1994, FINAL REPORT EXTERNA; PALSEY B, 1987, AM J PUBLIC HEALTH, V77, P659; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STARFIELD B, 1993, PRACTICE VARIATION O; TOBIN T, 1959, ECONOMETRICA, V26, P24; Weiner J P, 1990, QRB Qual Rev Bull, V16, P424; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; 1994, HLTH 1993; 1993, DEV EVALUATING METHO; 1988, DIABETES CARE, V11, P745; 1994, REPORT C 1994; 1989, DIABETES CARE, V12, P365	38	291	292	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1503	1508		10.1001/jama.273.19.1503	http://dx.doi.org/10.1001/jama.273.19.1503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739076				2022-12-01	WOS:A1995QX41800032
J	DAUTERMAN, K; PAK, PH; MAUGHAN, WL; NUSSBACHER, A; ARIE, S; LIU, CP; KASS, DA				DAUTERMAN, K; PAK, PH; MAUGHAN, WL; NUSSBACHER, A; ARIE, S; LIU, CP; KASS, DA			CONTRIBUTION OF EXTERNAL FORCES TO LEFT-VENTRICULAR DIASTOLIC PRESSURE - IMPLICATIONS FOR THE CLINICAL USE OF THE STARLING LAW	ANNALS OF INTERNAL MEDICINE			English	Article						VENTRICULAR FUNCTION, LEFT; VENTRICULAR DYSFUNCTION, LEFT; HEART CATHETERIZATION; CARDIAC OUTPUT; DIASTOLIC	VOLUME RELATIONS; PERICARDIUM; DOGS; CURVE; NITROGLYCERIN; RELAXATION; MECHANISM; AFTERLOAD; REDUCTION; OCCLUSION	Objective: To test whether a substantial proportion of measured resting left ventricular diastolic pressure stems from forces external to the left ventricle (such as right-heart filling) in normal and chronically diseased hearts. Design: Nonrandomized study with single intervention. Setting: University hospital. Patients: 29 patients referred for cardiac catheterization who had normal left ventricles and ejection fractions (n = 12); chronic heart disease due to idiopathic dilated cardiomyopathy (n = 6); ischemic heart disease(n = 6); or left ventricular hypertrophy (n = 5). Intervention: Acute reduction of external forces imposed on the left ventricle using balloon obstruction of inferior vena caval inflow to the right heart. Measurements: Continuous catheter-derived left ventricular pressure-volume data before and after abrupt obstruction of inferior vena caval inflow. Diastolic pressures were measured at the same volume just before atrial systole before and after sudden decrease of external (right-heart and pericardial) forces. The resulting decline in pressure was a measure of the contribution of these external forces to resting left ventricular diastolic pressure. Results: The decline in pressure when external forces were released averaged -19% +/- 13% with minimal change in left ventricular end-diastolic volume (-3.66% +/- 6.7%) and cardiac output (-5% +/- 8%). In all patients combined, the decline in pressure when external forces (Delta P-d) were released correlated with resting left ventricular diastolic pressure (LVP(d)) given by: Delta P-d = 0.38 x (LVP(d) 6) [r = 0.86, P < 0.0001]. This indicates that when resting diastolic pressure was more than 6 mm Hg, almost 38% of the pressure was due to external factors. This percentage was similar among all subgroups. Furthermore, the left ventricular diastolic pressure could be reduced by this percentage with only minimal compromise to ventricular filling and cardiac output. Conclusions: A substantial proportion of measured resting left ventricular diastolic pressure stems from forces extrinsic to the left ventricle rather than from diastolic stiffness in the left ventricle itself. This markedly influences the dependence of cardiac output on filling pressure and has important implications for clinical application of the Starling law.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; INST CORACAO, SAO PAULO, BRAZIL; VET GEN HOSP, TAIPEI, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine; Universidade de Sao Paulo					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47511] Funding Source: Medline; NIA NIH HHS [AG-12249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN EL, 1976, CIRCULATION, V54, P662, DOI 10.1161/01.CIR.54.4.662; APPLEGATE RJ, 1990, AM J PHYSIOL, V258, pH1079, DOI 10.1152/ajpheart.1990.258.4.H1079; APPLEGATE RJ, 1992, AM J PHYSIOL, V262, pH1725, DOI 10.1152/ajpheart.1992.262.6.H1725; BHARGAVA V, 1983, AM HEART J, V105, P995, DOI 10.1016/0002-8703(83)90402-7; BLANCHARD DG, 1992, CIRCULATION, V85, P1414, DOI 10.1161/01.CIR.85.4.1414; BRAUNWALD E, 1963, AM J MED, V34, P147, DOI 10.1016/0002-9343(63)90049-4; BRODIE BR, 1977, J CLIN INVEST, V59, P59, DOI 10.1172/JCI108622; CARROLL JD, 1986, CIRCULATION, V74, P815, DOI 10.1161/01.CIR.74.4.815; FREEMAN GL, 1984, CIRC RES, V54, P294, DOI 10.1161/01.RES.54.3.294; GILBERT JC, 1989, CIRC RES, V64, P827, DOI 10.1161/01.RES.64.5.827; JANICKI JS, 1980, AM J PHYSIOL, V238, pH494, DOI 10.1152/ajpheart.1980.238.4.H494; JANICKI JS, 1990, CIRCULATION, V81, P15; KASS DA, 1988, CATHETER CARDIO DIAG, V15, P192, DOI 10.1002/ccd.1810150314; KASS DA, 1993, ANN INTERN MED, V119, P466, DOI 10.7326/0003-4819-119-6-199309150-00004; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; KINGMA I, 1986, AM J CARDIOL, V57, P673, DOI 10.1016/0002-9149(86)90857-X; LANKFORD EB, 1990, AM J PHYSIOL, V258, pH1933, DOI 10.1152/ajpheart.1990.258.6.H1933; LEWINTER MM, 1982, CIRC RES, V50, P501, DOI 10.1161/01.RES.50.4.501; LUDBROOK PA, 1979, CIRCULATION, V59, P21, DOI 10.1161/01.CIR.59.1.21; LUDBROOK PA, 1977, CIRCULATION, V56, P937, DOI 10.1161/01.CIR.56.6.937; RAFF GL, 1981, CIRC RES, V48, P813, DOI 10.1161/01.RES.48.6.813; ROSS J, 1979, CIRCULATION, V59, P32, DOI 10.1161/01.CIR.59.1.32; SHIRATO K, 1978, CIRCULATION, V57, P1191, DOI 10.1161/01.CIR.57.6.1191; SLINKER BK, 1989, AM J PHYSIOL, V256, pH567, DOI 10.1152/ajpheart.1989.256.2.H567; STARLING EH, 1978, CIRC RES, V42, P433; TYBERG JV, 1978, EUR J CARDIOL, V7, P163; TYSON GS, 1984, CIRC RES, V54, P173, DOI 10.1161/01.RES.54.2.173	27	80	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					737	742		10.7326/0003-4819-122-10-199505150-00001	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717595				2022-12-01	WOS:A1995QX14700001
J	EMANUEL, L				EMANUEL, L			THE PRIVILEGE AND THE PAIN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											EMANUEL, L (corresponding author), HARVARD UNIV, SCH MED, DIV MED ETH, 641 HUNTINGTON AVE, BOSTON, MA 02115 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					797	798		10.7326/0003-4819-122-10-199505150-00012	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717605				2022-12-01	WOS:A1995QX14700012
J	HAMILL, RJ; HOUSTON, ED; GEORGHIOU, PR; WRIGHT, CE; KOZA, MA; CADLE, RM; GOEPFERT, PA; LEWIS, DA; ZENON, GJ; CLARRIDGE, JE				HAMILL, RJ; HOUSTON, ED; GEORGHIOU, PR; WRIGHT, CE; KOZA, MA; CADLE, RM; GOEPFERT, PA; LEWIS, DA; ZENON, GJ; CLARRIDGE, JE			AN OUTBREAK OF BURKHOLDERIA (FORMERLY PSEUDOMONAS) CEPACIA RESPIRATORY-TRACT COLONIZATION AND INFECTION ASSOCIATED WITH NEBULIZED ALBUTEROL THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; BENZALKONIUM CHLORIDE; EPIDEMIOLOGY	Objective: To investigate an outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection in mechanically ventilated patients. Design: A retrospective case-control and bacteriologic study, Setting: Veterans Affairs medical center. Patients: 42 mechanically ventilated patients who developed respiratory tract colonization or infection with B. cepacia and 135 ventilator-dependent controls who were not colonized and did not develop infections. Measurements: Clinical and demographic data; benzalkonium chloride concentrations and pH levels in albuterol sulfate solutions; repetitive-element polymerase chain reaction (PCR)-mediated molecular fingerprinting on eight patient isolates and three environmental B. cepacia isolates that were available for study. Results: 42 patients had B. cepacia respiratory tract colonization or infection. Observation of intensive care unit and respiratory care personnel showed faulty infection control procedures (for example, the same multiple-dose bottle of albuterol was used for many mechanically ventilated patients). More case patients (39 [92.9%]) than controls (95 [70.4%]; P = 0.006) received nebulized albuterol, and case patients (67.5 treatments) received more treatments than controls (18 treatments; P < 0.001). In-use albuterol solutions had pH values that were unstable, and benzalkonium chloride concentrations declined over time to levels capable of supporting bacterial growth. Medication nebulizers and in-use bottles of albuterol harbored B. cepacia. Molecular fingerprints of patient isolates and environmental B. cepacia isolates were identical using repetitive-element PCR. No further isolates of B. cepacia were identified after institution of appropriate infection control procedures. Conclusions: Multiple-dose medications and reliance on benzalkonium chloride as a medication preservative provide a mechanism for nosocomial spread of microorganisms, particularly if infection control procedures are not carefully followed. Repetitive-element PCR is a useful fingerprinting technique for molecular epidemiologic studies of B. cepacia.	TEXAS SO UNIV, HOUSTON, TX 77004 USA	Texas Southern University	HAMILL, RJ (corresponding author), BAYLOR COLL MED, VET AFFAIRS MED CTR, INFECT DIS SECT 111G, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							BARKER MJ, 1990, AM J INFECT CONTROL, V18, P139; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P2589, DOI 10.1128/JCM.31.10.2589-2593.1993; CRAVEN DE, 1984, AM J MED, V77, P834, DOI 10.1016/0002-9343(84)90520-5; DONOWITZ LG, 1991, INFECT CONT HOSP EP, V12, P186, DOI 10.2307/30146937; FRANK MJ, 1976, JAMA-J AM MED ASSOC, V236, P2418, DOI 10.1001/jama.236.21.2418; GEFTIC SG, 1979, APPL ENVIRON MICROB, V37, P505, DOI 10.1128/AEM.37.3.505-510.1979; GEORGHIOU PR, 1995, CLIN INFECT DIS, V20, P84, DOI 10.1093/clinids/20.1.84; JARVIS WR, 1987, EUR J EPIDEMIOL, V3, P233, DOI 10.1007/BF00149729; KARABIT MS, 1988, INT J PHARM, V46, P141, DOI 10.1016/0378-5173(88)90019-1; KUNDSIN RB, 1957, ARCH SURG-CHICAGO, V75, P1036; MARTONE WJ, 1987, EUR J EPIDEMIOL, V3, P222, DOI 10.1007/BF00149728; RABKIN CS, 1989, REV INFECT DIS, V11, P600; REBOLI AC, 1994, J CLIN MICROBIOL, V32, P2635, DOI 10.1128/JCM.32.11.2635-2640.1994; REBOLI AC, 1993, 1993 INF DIS  SOC AM, V17, P555; RICHARDSON NE, 1977, J PHARM PHARMACOL, V29, P717, DOI 10.1111/j.2042-7158.1977.tb11448.x; SIMMONS BP, 1982, INFECT CONT HOSP EP, V3, P327, DOI 10.1017/S0195941700056423; THOMAS JM, 1989, MOD SYN MET, V5, P249; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; WOODS CR, 1993, J CLIN MICROBIOL, V31, P1927, DOI 10.1128/JCM.31.7.1927-1931.1993; WOODS CR, 1992, J CLIN MICROBIOL, V30, P2921, DOI 10.1128/JCM.30.11.2921-2929.1992	20	94	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					762	766		10.7326/0003-4819-122-10-199505150-00005	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7536401				2022-12-01	WOS:A1995QX14700005
J	ROGGERO, E; ZUCCA, E; PINOTTI, G; PASCARELLA, A; CAPELLA, C; SAVIO, A; PEDRINIS, E; PATERLINI, A; VENCO, A; CAVALLI, F				ROGGERO, E; ZUCCA, E; PINOTTI, G; PASCARELLA, A; CAPELLA, C; SAVIO, A; PEDRINIS, E; PATERLINI, A; VENCO, A; CAVALLI, F			ERADICATION OF HELICOBACTER-PYLORI INFECTION IN PRIMARY LOW-GRADE GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE	ANNALS OF INTERNAL MEDICINE			English	Note							DISEASE; MALT	Objective: To determine the effect of eradicating Helicobacter pylori infection on the course of low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Design: Prospective cohort study. Setting: University internal medicine clinics, a referral oncology center in southern Switzerland, and a gastroenterology referral center in northern Italy. Patients: 26 patients with localized primary low-grade gastric MALT lymphoma. Intervention: Treatment for H. pylori infection (bismuth or omeprazole or both, amoxicillin, and metronidazole for 14 days). Main Outcome Measures: Endoscopic biopsy specimens of the gastric mucosa were obtained every 3 to 6 months after treatment for H. pylori infection. Results: Helicobacter pylori was completely eradicated in 25 of 26 patients, but 4 patients needed second-line antibiotic treatment to eradicate the microorganism. Disappearance or almost total regression of the lymphomatous tissue was observed in 15 of the 25 evaluable patients (60%; CI, 39% to 79%); however, disappearance or almost total regression was evident in the first biopsy specimen after treatment for H. pylori infection in only 8 of the 15 patients. Conclusions: Our study confirms recent anecdotal reports of regression of gastric MALT lymphoma after eradication of H. pylori and indicates that the growth of these extranodal lymphomas may depend on H. pylori.	OSPED SAN GIOVANNI BELLINZONA, SERV ONCOL, CH-6500 BELLINZONA, SWITZERLAND; OSPED MULTIZONALE, VARESE, ITALY; FBF, OSPED S ORSOLA, BRESCIA, ITALY; IST CANTONALE PATOL, LOCARNO, SWITZERLAND	Regional Hospital of Bellinzona & Valleys, San Giovanni				Zucca, Emanuele/0000-0002-5522-6109				BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PINOTTI G, 1992, HAEMATOLOGICA, V77, P405; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; SPATARO V, 1994, ANN ONCOL, V5, P954, DOI 10.1093/oxfordjournals.annonc.a058738; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WOTHERSPOON AC, 1992, HISTOPATHOLOGY, V20, P29, DOI 10.1111/j.1365-2559.1992.tb00912.x	12	376	386	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					767	769		10.7326/0003-4819-122-10-199505150-00006	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717599				2022-12-01	WOS:A1995QX14700006
J	FLORIN, THJ; HILLS, BA				FLORIN, THJ; HILLS, BA			DOES COUNTERPERFUSION SUPERSATURATION CAUSE GAS CYSTS IN PNEUMATOSIS CYSTOIDES COLI, AND CAN BREATHING HELIOX REDUCE THEM	LANCET			English	Article							INTESTINALIS; EXCRETION	The pathogenesis of pneumatosis cystoides coli remains obscure in the absence of an explanation for why pockets of gas should form in the first place and why they should be maintained in the wall and mesentery of the colon. Counterperfusion supersaturation could explain the formation and location of the gas cysts, which occur mostly near brood vessels on the mesenteric border of the colon, and the absence of methane gas in them. The hypothesis can be tested by treating patients with pneumatosis cystoides coli with heliox.	MATER MISERICORDIAE HOSP,MATER RES INST,BRISBANE,QLD 4101,AUSTRALIA	Mater Research	FLORIN, THJ (corresponding author), UNIV QUEENSLAND,DEPT MED,ST LUCIA,QLD 4067,AUSTRALIA.		Florin, Tim HJ/F-1890-2010					BLENKARN GD, 1971, AEROSPACE MED, V42, P141; CHRISTL SU, 1993, GASTROENTEROLOGY, V104, P392, DOI 10.1016/0016-5085(93)90406-3; COLLINS JM, 1978, J APPL PHYSIOL, V44, P914, DOI 10.1152/jappl.1978.44.6.914; ECKER JA, 1971, AM J GASTROENTEROL, V56, P125; ELLIS BW, 1980, BRIT MED J, V280, P763, DOI 10.1136/bmj.280.6216.763-a; FORGACS P, 1973, LANCET, V1, P579; GILLON J, 1979, GUT, V20, P1008, DOI 10.1136/gut.20.11.1008; HABOUBI NY, 1984, HISTOPATHOLOGY, V8, P145, DOI 10.1111/j.1365-2559.1984.tb02329.x; HAYDUK W, 1974, AICHE J, V20, P611, DOI 10.1002/aic.690200329; Hills B.A., 1988, BIOL SURFACTANT; HILLS BA, 1977, J APPL PHYSIOL, V42, P758, DOI 10.1152/jappl.1977.42.5.758; HILLS BA, 1969, CLIN SCI, V36, P185; HILLS BA, 1983, AM J PHYSIOL, V244, P561; HILS BA, 1977, DECOMPRESSION SICKNE; HUGHES DTD, 1966, GUT, V7, P553, DOI 10.1136/gut.7.5.553; KOSS LG, 1952, AMA ARCH PATHOL, V53, P523; LAMBERTSEN CJ, 1975, J APPL PHYSIOL, V39, P434, DOI 10.1152/jappl.1975.39.3.434; LEVITT MD, 1971, NEW ENGL J MED, V284, P1394, DOI 10.1056/NEJM197106242842502; MAHMOOD A, 1993, ARCH BIOCHEM BIOPHYS, V300, P280, DOI 10.1006/abbi.1993.1039; MCKAY LF, 1985, GUT, V26, P69, DOI 10.1136/gut.26.1.69; READ NW, 1984, GUT, V25, P839, DOI 10.1136/gut.25.8.839; REINHOFF WF, 1959, ANN SURG, V149, P593; STIENNON OA, 1951, AMA AM J DIS CHILD, V81, P651, DOI 10.1001/archpedi.1951.02040030664004; VANDERLINDEN W, 1979, SCAND J GASTROENTERO, V14, P173, DOI 10.3109/00365527909179864	24	26	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1220	1222		10.1016/S0140-6736(95)91996-1	http://dx.doi.org/10.1016/S0140-6736(95)91996-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739311				2022-12-01	WOS:A1995QX86100014
J	HALL, IP; WHEATLEY, A; WILDING, P; LIGGETT, SB				HALL, IP; WHEATLEY, A; WILDING, P; LIGGETT, SB			ASSOCIATION OF GLU-27 BETA(2)-ADRENOCEPTOR POLYMORPHISM WITH LOWER AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS	LANCET			English	Note								Cells expressing the Glu 27 beta(2)-adrenoceptor polymorphism show attenuated down-regulation of the receptor after long-term exposure to agonist. We studied beta(2)-adrenoceptor genotype for the Gln/Glu 27 polymorphism and airway reactivity in 65 patients with mild to moderate asthma. Glu 27 homozygotes had a four-fold higher geometric mean methacholine PD20 (provocative dose) than individuals who were homozygous for the wild-type (Gln 27) form of the receptor; heterozygotes had an intermediate value (3.23, 0.86, 1.96 mu mol, respectively), These data suggest that beta(2)-adrenoceptor genotype is important in the establishment of the asthmatic phenotype.	CITY HOSP,RESP MED UNIT,NOTTINGHAM NG5 1PB,ENGLAND; UNIV CINCINNATI,MED CTR,DEPT PULM & CRIT CARE MED,CINCINNATI,OH 45267	University of Nottingham; University of Cincinnati	HALL, IP (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,DIV THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND.		liggett, stephen b/E-7453-2012	Henry, Amanda/0000-0001-6299-7676; Hall, Ian/0000-0001-9933-3216; Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967, R56HL045967, R37HL045967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, IN PRESS AM J RESPIR; GUNNEBERG A, 1993, CLIN CHEM, V39, P2157; Postma D. S., 1994, European Respiratory Journal, V7, p423S; REISHAUS E, 1993, AM J RESPIR CELL MOL, V8, P334; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	6	260	273	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1213	1214		10.1016/S0140-6736(95)91994-5	http://dx.doi.org/10.1016/S0140-6736(95)91994-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739309				2022-12-01	WOS:A1995QX86100012
J	HERBERT, J				HERBERT, J			THE AGE OF DEHYDROEPIANDROSTERONE	LANCET			English	Editorial Material							SULFATE; MEN		UNIV CAMBRIDGE,MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND	University of Cambridge	HERBERT, J (corresponding author), UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE,ENGLAND.							ABADIE JM, 1993, DIABETES, V42, P662, DOI 10.2337/diabetes.42.5.662; BARRETTCONNOR E, 1994, J AM GERIATR SOC, V42, P420, DOI 10.1111/j.1532-5415.1994.tb07491.x; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BLAUER KL, 1991, ENDOCRINOLOGY, V129, P3174, DOI 10.1210/endo-129-6-3174; BROOKSGUNN J, 1989, CHILD DEV, V60, P40, DOI 10.2307/1131069; CASSON PR, 1993, AM J OBSTET GYNECOL, V169, P1536, DOI 10.1016/0002-9378(93)90431-H; DAYNES RA, 1990, EUR J IMMUNOL, V20, P793, DOI 10.1002/eji.1830200413; EBELING P, 1994, LANCET, V343, P1479, DOI 10.1016/s0140-6736(94)92587-9; EICH DM, 1993, CIRCULATION, V87, P261, DOI 10.1161/01.CIR.87.1.261; GOODYER IM, IN RESS PSYCHOL MED; GRAY A, 1991, PSYCHOSOM MED, V53, P375, DOI 10.1097/00006842-199107000-00003; HEDMAN M, 1992, CLIN EXP RHEUMATOL, V10, P25; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B; ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002; Sapolsky RM, 1992, STRESS AGING BRAIN M; SCHLEGEL ML, 1985, PHYSIOL BEHAV, V34, P867, DOI 10.1016/0031-9384(85)90005-8; SCHNEIDER LS, 1992, BIOL PSYCHIAT, V34, P867; WILLIAMS DP, 1993, J CLIN ENDOCR METAB, V77, P80, DOI 10.1210/jc.77.1.80	20	76	77	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1193	1194		10.1016/S0140-6736(95)91987-2	http://dx.doi.org/10.1016/S0140-6736(95)91987-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739304				2022-12-01	WOS:A1995QX86100005
J	HERINGS, RMC; DEBOER, A; STRICKER, BHC; LEUFKENS, HGM; PORSIUS, A				HERINGS, RMC; DEBOER, A; STRICKER, BHC; LEUFKENS, HGM; PORSIUS, A			HYPOGLYCEMIA ASSOCIATED WITH USE OF INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME	LANCET			English	Article							CAPTOPRIL; GLUCOSE	The use of angiotensin-converting-enzyme (ACE) inhibitors has been associated with increased insulin sensitivity in diabetic patients. Although such an effect could be beneficial in the treatment of hypertension or congestive heart failure in diabetic patients, it might also precipitate severe hypoglycaemia. To test this hypothesis we carried out a nested case-control study, using data in the Dutch PHARMO system (1986-92), among diabetic patients treated with insulin or with oral antidiabetic drugs, who were admitted to hospital with hypoglycaemia. We identified 94 patients who had been admitted with hypoglycaemia and selected 654 controls from the same cohort. With adjustment for a wide range of potential confounding factors, hypoglycaemia was significantly associated with current use of ACE inhibitors (odds ratio 2.8 [95% CI 1.4-5.7]). Both among users of insulin and among users of oral antidiabetic drugs, use of ACE inhibitors was significantly associated with an increased risk of hospital admission for hypoglycaemia (2.8 [1.2-6.4] and 4.1 [1.4-12.2], respectively). Although ACE inhibitors have several advantages over other antihypertensive drugs in diabetes, the risk of hypoglycaemia should be taken into account. Further investigation of the mechanism is needed since as many as 13.8% of all hospital admissions for hypoglycaemia might be attributable to use of ACE inhibitors.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	HERINGS, RMC (corresponding author), UNIV UTRECHT,UTRECHT INST PHARMACEUT SCI,DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY,POB 80082,3508 TB UTRECHT,NETHERLANDS.		Herings, Ron/AAE-4096-2021	Herings, Ron/0000-0002-2561-8734				ALLAN SG, 1986, LANCET, V1, P1035; ARUAZPANCHECHO C, 1990, AM J MED, V89, P811; BERNE C, 1991, J INTERN MED, V229, P119; DONNELLY R, 1992, J CARDIOVASC PHARM, V20, pS38, DOI 10.1097/00005344-199200111-00007; EVERETT J, 1994, DRUGS, V47, P286, DOI 10.2165/00003495-199447020-00004; FERRIERE M, 1985, ANN INTERN MED, V102, P134, DOI 10.7326/0003-4819-102-1-134_3; HERINGS RMC, 1992, J EPIDEMIOL COMMUN H, V46, P136, DOI 10.1136/jech.46.2.136; HERINGS RMC, 1993, THESIS UTRECHT U UTR; KAHN HA, 1989, STATISTICAL METHODS; OKSA A, 1992, J CARDIOVASC PHARM, V23, P79; PASSA P, 1987, DIABETES CARE, V10, P200, DOI 10.2337/diacare.10.2.200; RETT K, 1988, NEW ENGL J MED, V319, P1609; SEEFELDT T, 1990, DIABETIC MED, V7, P700, DOI 10.1111/j.1464-5491.1990.tb01473.x; SIEGHIERI G, 1992, DIABETIC MED, V9, P732; UEHARA M, 1994, DIABETOLOGIA, V37, P300, DOI 10.1007/BF00398058; WINOCOUR P, 1986, LANCET, V2, P461; 1994, DRUGS THERAPY PERSPE, V4, P10; 1994, PRESCRIRE, V3, P175; 1992, ANATOMICAL THERAPEUT	19	161	165	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1195	1198		10.1016/S0140-6736(95)91988-0	http://dx.doi.org/10.1016/S0140-6736(95)91988-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739305				2022-12-01	WOS:A1995QX86100006
J	HOOPER, DC				HOOPER, DC			FROM FLUOROQUINOLONES TO 2-PYRIDONES	LANCET			English	Editorial Material							NALIDIXIC-ACID; DNA GYRASE				HOOPER, DC (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114, USA.							ALDER JD, 1994, 34TH INT C ANT AG CH; CHIN NX, 1994, 34TH INT C ANT AG CH; CHU DTW, 1994, 34TH INT C ANT AG CH; ELIOPOULOS GM, 1994, 34TH INT C ANT AG CH; FLAMM RK, 1994, 34TH INT C ANT AG CH; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hooper David C., 1993, P53; Hooper David C., 1993, P489; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; LESHER GY, 1962, J MED PHARMACEUT CH, V5, P1063, DOI 10.1021/jm01240a021; MEULBROEK JA, 1994, 34TH INT C ANT AG CH; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1192	1193		10.1016/S0140-6736(95)91986-4	http://dx.doi.org/10.1016/S0140-6736(95)91986-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739303				2022-12-01	WOS:A1995QX86100004
J	JOHNSTON, SL; PATTEMORE, PK; SANDERSON, G; SMITH, S; LAMPE, F; JOSEPHS, L; SYMINGTON, P; OTOOLE, S; MYINT, SH; TYRRELL, DAJ; HOLGATE, ST				JOHNSTON, SL; PATTEMORE, PK; SANDERSON, G; SMITH, S; LAMPE, F; JOSEPHS, L; SYMINGTON, P; OTOOLE, S; MYINT, SH; TYRRELL, DAJ; HOLGATE, ST			COMMUNITY STUDY OF ROLE OF VIRAL-INFECTIONS IN EXACERBATIONS OF ASTHMA IN 9-11 YEAR-OLD CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							WHEEZY BRONCHITIS; RESPIRATORY-INFECTIONS; VIRUSES; SYMPTOMS; ADULTS; PRECIPITANTS; ASSOCIATION; CORONAVIRUS; CHILDHOOD	Objective-To study the association between upper and lower respiratory viral infections and acute exacerbations of asthma in schoolchildren in the community. Design-Community based 13 month longitudinal study using diary card respiratory symptom and peak expiratory flow monitoring to allow early sampling for viruses. Subjects-1O8 Children aged 9-11 years who had reported wheeze or cough, or both, in a questionnaire. Setting-Southampton and surrounding community. Main outcome measures-Upper and lower respiratory viral infections detected by polymerase chain reaction or conventional methods, reported exacerbations of asthma, computer identified episodes of respiratory tract symptoms or peak flow reductions. Results-Viruses were detected in 80% of reported episodes of reduced peak expiratory flow, 80% of reported episodes of wheeze, and in 85% of reported episodes of upper respiratory symptoms, cough, wheeze, and a fall in peak expiratory flow. The median duration of reported falls in peak expiratory flow was 14 days, and the median maximum fall in peak expiratory flow was 81 1/min. The most commonly identified virus type was rhinovirus. Conclusions-This study supports the hypothesis that upper respiratory viral infections are associated with 80-85% of asthma exacerbations in school age children.	UNIV SOUTHAMPTON,DEPT MED STAT & COMP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV LEICESTER,DEPT MICROBIOL,LEICESTER LE1 9HN,LEICS,ENGLAND; MRC,COMMON COLD UNIT,SALISBURY,WILTS,ENGLAND	University of Southampton; University of Leicester	JOHNSTON, SL (corresponding author), UNIV MED SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Johnston, Sebastian Lennox/I-2423-2012; Lampe, Fiona/I-5826-2019; Fahimifar, Sepideh/M-5303-2019	Johnston, Sebastian Lennox/0000-0003-3009-9200; Lampe, Fiona/0000-0001-6851-5471; Pattemore, Philip/0000-0002-4968-1287; Josephs, Lynn/0000-0002-7157-2992				BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; CARLSEN KH, 1984, ARCH DIS CHILD, V59, P310, DOI 10.1136/adc.59.4.310; CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; Gwaltney J.M., 1979, PRINCIPLES PRACTICE, V1st ed., P429; Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; JENNINGS LC, 1987, NEW ZEAL MED J, V100, P488; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1993, THESIS U SOUTHAMPTON, P99; KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980; LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MITCHELL I, 1976, ARCH DIS CHILD, V51, P707, DOI 10.1136/adc.51.9.707; MITCHELL I, 1978, ARCH DIS CHILD, V53, P106, DOI 10.1136/adc.53.2.106; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PHILLPOTTS RJ, 1983, J VIROL METHODS, V6, P267, DOI 10.1016/0166-0934(83)90041-1; PICADO C, 1992, THORAX, V47, P197, DOI 10.1136/thx.47.3.197; POTTER PC, 1984, S AFR MED J, V66, P397; ROLDAAN AC, 1982, EUR J RESPIR DIS, V63, P140; SCHMIDT NJ, 1979, DIAGNOSTIC PROCEDURE, P67; STORR J, 1989, ARCH DIS CHILD, V64, P103, DOI 10.1136/adc.64.1.103; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194	31	1467	1521	0	99	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1225	1229		10.1136/bmj.310.6989.1225	http://dx.doi.org/10.1136/bmj.310.6989.1225			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767192	Green Published			2022-12-01	WOS:A1995QY87700015
J	MEISEL, H; REIP, A; FALTUS, B; LU, MJ; PORST, H; WIESE, M; ROGGENDORF, M; KRUGER, DH				MEISEL, H; REIP, A; FALTUS, B; LU, MJ; PORST, H; WIESE, M; ROGGENDORF, M; KRUGER, DH			TRANSMISSION OF HEPATITIS-C VIRUS TO CHILDREN AND HUSBANDS BY WOMEN INFECTED WITH CONTAMINATED ANTI-D IMMUNOGLOBULIN	LANCET			English	Note								In 1978-79 a single-source outbreak of hepatitis C occurred in 2533 women who had received contaminated anti-D immunoglobulin. Children husbands of 74 women with self-limited, and of 86 women with chronic, hepatitis C were followed up for over 10-15 years. In 3 of 231 investigated children (1.3%) serological evidence for HCV infection was found. However, none of the children developed an apparent or chronic hepatitis. Serum samples oi the 94 husbands investigated showed no HCV antibodies or HCV RNA. We consider the risk of intrauterine or perinatal transmission of HCV, as welt as that of transmission through close family contacts, to be low. No evidence was found for sexual transmission from women to. men.	ST GEORGE HOSP, MED CLIN 2, LEIPZIG, GERMANY; CITY HOSP, MED CLIN 3, DRESDEN, GERMANY; UNIV ESSEN GESAMTHSCH, SCH MED, INST VIROL, ESSEN, GERMANY	Technische Universitat Dresden; Municipal Hospital Dresden; University of Duisburg Essen	MEISEL, H (corresponding author), HUMBOLDT UNIV BERLIN, CHARITE MED SCH, INST MED VIROL, D-10098 BERLIN, GERMANY.		Lu, Mengji/ABF-9410-2020					ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T; KOFF RS, 1992, ANN INTERN MED, V117, P967, DOI 10.7326/0003-4819-117-11-967; NI YH, 1994, J HEPATOL, V20, P641, DOI 10.1016/S0168-8278(05)80353-8; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; Roggendorf M, 1993, Arch Virol Suppl, V7, P27; TANZI E, 1993, ARCH VIROL, P229	10	121	122	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1209	1211		10.1016/S0140-6736(95)91992-9	http://dx.doi.org/10.1016/S0140-6736(95)91992-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537841				2022-12-01	WOS:A1995QX86100010
J	POWER, JP; LAWLOR, E; DAVIDSON, F; HOLMES, EC; YAP, PL; SIMMONDS, P				POWER, JP; LAWLOR, E; DAVIDSON, F; HOLMES, EC; YAP, PL; SIMMONDS, P			MOLECULAR EPIDEMIOLOGY OF AN OUTBREAK OF INFECTION WITH HEPATITIS-C VIRUS IN RECIPIENTS OF ANTI-D IMMUNOGLOBULIN	LANCET			English	Note								In a retrospective investigation of possible transmission of hepatitis C virus (HCV) by anti-rhesus D immunoglobulin (anti-D) in 1977, we compared variants infecting anti-D recipients in Ireland of one of the implicated batches with those of epidemiologically unrelated HCV-infected individuals. All 100 of the recipients of the batch investigated to date were infected with a single genotype (type 1), consistent with a single-source outbreak, whereas a wider range of genotypes (1, 2, and 3) were found in anti-HCV positive individuals from Ireland infected by different routes. Nucleotide sequences from a 222 base fragment from tbe NS-5 region of the genome amplified from stored aliquots of the implicated batch closely matched those detected in anti-D recipients 17 years after the transmission event. This study shows the value of molecular epidemiological techniques for identifying distant sources of infection, and for the epidemiological investigation of the current distribution and transmission of HCV in different populations.	UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; ST FINBARRS HOSP, BLOOD TRANSFUS SERV BOARD, CORK, IRELAND; BLOOD TRANSFUS SERV BOARD, DUBLIN 4, IRELAND; EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Edinburgh; University of Oxford			Holmes, Edward/GVR-9499-2022	Holmes, Edward/0000-0001-9596-3552; Simmonds, Peter/0000-0002-7964-4700				DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; HOLMES EC, 1993, NATURE, V364, P766, DOI 10.1038/364766b0; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; VIAZOV S, 1994, J VIROL METHODS, V48, P81, DOI 10.1016/0166-0934(94)90091-4	8	112	118	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1211	1213		10.1016/S0140-6736(95)91993-7	http://dx.doi.org/10.1016/S0140-6736(95)91993-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739308				2022-12-01	WOS:A1995QX86100011
J	ROSENBERG, WMC; PRINCE, C; KAKLAMANIS, L; FOX, SB; JACKSON, DG; SIMMONS, DL; CHAPMAN, RW; TROWELL, JM; JEWELL, DP; BELL, JI				ROSENBERG, WMC; PRINCE, C; KAKLAMANIS, L; FOX, SB; JACKSON, DG; SIMMONS, DL; CHAPMAN, RW; TROWELL, JM; JEWELL, DP; BELL, JI			INCREASED EXPRESSION OF CD44V6 AND CD44V3 IN ULCERATIVE-COLITIS BUT NOT COLONIC CROHNS-DISEASE	LANCET			English	Article							LYMPHOCYTE; FAMILY	Immune mechanisms, possibly involving cell-surface molecules such as CD44, have been invoked to explain the pathogenesis of inflammatory bowel disease. We used monoclonal antibodies against epitopes encoded within the variable region of CD44 to investigate CD44 isoform expression in colon, small intestine, and liver in patients with various intestinal disorders and in controls. Biopsy samples from patients with ulcerative colitis showed significantly increased epithelial expression of CD44 isoforms containing the v6 and v3 epitopes, detected with antibodies 2F10 and 3G5, respectively. CD44v6 was detected on colonic crypt epithelial cells in 23 of 25 ulcerative colitis samples compared with 3 of 18 colonic Crohn's disease samples (p=3.0x10(-6); odds ratio 57.5 [95% CI 6.83-702]) and 3 of 52 controls (22 normal colon, 10 infective colitis, 2 radiation colitis, and 18 colonic Crohn's disease; p<1x10(-8); odds ratio 199 [25.5-2294]). No significant expression of CD44v6, CD44v3, or CD44v8/9 was found in samples of normal proximal colon from 4 patients with distal ulcerative colitis, whereas samples from the affected area showed staining for CD44v6 and CD44v3. No expression of CD44 variants was found in 15 samples of normal small intestine, 11 small-bowel pouchitis, 8 coeliac disease, 3 small-bowel Crohn's disease, 6 normal liver, 6 primary biliary cirrhosis, or 9 primary sclerosing cholangitis. The high intensity of CD44v6 and v3 epitope expression on crypt epithelial cells in ulcerative colitis suggests that CD44 isoforms may have an important role in ulcerative colitis. Their detection could have diagnostic potential in differentiating ulcerative colitis from other forms of colonic inflammation including Crohn's disease.	JOHN RADCLIFFE HOSP,GASTROENTEROL UNIT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT CELLULAR SCI,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; University of Oxford	ROSENBERG, WMC (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.		Rosenberg, William/ABA-1071-2021; Fox, Stephen/G-9719-2016	Rosenberg, William/0000-0002-2732-2304; Fox, Stephen/0000-0002-7648-8896; , david/0000-0002-4133-9364				BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; FOX SB, 1994, CANCER RES, V54, P4539; GUNTHERT U, 1991, CELL, V65; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEIDER KH, 1992, J CELL BIOL, V120, P623; HODGSON HJF, 1983, INFLAMM BOWEL DIS, P86; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; WAKEFIELD AJ, 1989, LANCET, V2, P1057	19	76	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1205	1209		10.1016/S0140-6736(95)91991-0	http://dx.doi.org/10.1016/S0140-6736(95)91991-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537840				2022-12-01	WOS:A1995QX86100009
J	SRIDHAR, MK				SRIDHAR, MK			WHY DO PATIENTS WITH EMPHYSEMA LOSE WEIGHT	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; TUMOR-NECROSIS-FACTOR; MALNOURISHED PATIENTS		UNIV GLASGOW,DEPT HUMAN NUTR,GLASGOW G61 1BD,LANARK,SCOTLAND	University of Glasgow	SRIDHAR, MK (corresponding author), UNIV GLASGOW,DEPT RESP MED,GLASGOW G61 1BD,LANARK,SCOTLAND.							BAIN M, 1994, EUR RESPIR J, V7, P248; DEGODY I, 1994, AM J RESP CRIT CARE, V149, P1017; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; DONAHOE M, 1989, AM REV RESPIR DIS, V140, P385, DOI 10.1164/ajrccm/140.2.385; ELBORN JS, 1993, CLIN SCI, V85, P563, DOI 10.1042/cs0850563; ENGELEN MPKJ, 1994, EUR RESPIR J, V7, P1793, DOI 10.1183/09031936.94.07101793; FILLEY GF, 1968, AM J MED, V44, P26, DOI 10.1016/0002-9343(68)90234-9; FOWLER J, 1898, DISEASES LUNGS, P171; GREEN JH, 1992, CLIN SCI, V83, P109, DOI 10.1042/cs0830109; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P467; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; ROGERS RM, 1992, AM REV RESPIR DIS, V146, P1511, DOI 10.1164/ajrccm/146.6.1511; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435	13	29	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1190	1191		10.1016/S0140-6736(95)91984-8	http://dx.doi.org/10.1016/S0140-6736(95)91984-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739302				2022-12-01	WOS:A1995QX86100002
J	BENDELAC, A; LANTZ, O; QUIMBY, ME; YEWDELL, JW; BENNINK, JR; BRUTKIEWICZ, RR				BENDELAC, A; LANTZ, O; QUIMBY, ME; YEWDELL, JW; BENNINK, JR; BRUTKIEWICZ, RR			CD1 RECOGNITION BY MOUSE NK1(+) T-LYMPHOCYTES	SCIENCE			English	Article							ALPHA-BETA+ THYMOCYTES; LYMPHOKINE SECRETION; ANTIGEN; EXPRESSION; CELLS; THYMUS; CD4+; EPITHELIUM; SELECTION; MOLECULES	Rare major histocompatibility complex (MHC) class I-like CD1-specific T cells have been isolated from human blood, but it has not been determined whether these clones are part of a defined subset of CD1-specific T cells selected during T cell development, or whether their recognition of CD1 is a fortuitous cross-reaction. In mice, an entire subset of alpha beta thymocytes with a unique phenotype was found to be CD1-specific. This particular subset, and its human counterpart, provide evidence that CD1 has a general role in selecting and interacting with specialized alpha beta T cells.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Princeton University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BENDELAC, A (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Lantz, Olivier J/J-4960-2012; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Lantz, Olivier J/0000-0003-3161-7719; Brutkiewicz, Randy/0000-0002-7396-480X				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; ARASE H, 1994, J EXP MED, V180, P423, DOI 10.1084/jem.180.2.423; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BALK SP, 1991, J IMMUNOL, V146, P768; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; Bendelac A, 1992, Semin Immunol, V4, P187; BENDELAC A, UNPUB; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; Blumberg R S, 1994, Int Rev Immunol, V11, P15, DOI 10.3109/08830189409061714; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; COOK RG, 1983, J EXP MED, V158, P1012, DOI 10.1084/jem.158.3.1012; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9527; KOYASU S, 1994, J EXP MED, V179, P1957, DOI 10.1084/jem.179.6.1957; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MATZINGER P, UNPUB; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; QUILL H, 1987, J IMMUNOL, V138, P3704; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; TAKAHAMA Y, 1992, J IMMUNOL, V147, P2883; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	42	805	828	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					863	865		10.1126/science.7538697	http://dx.doi.org/10.1126/science.7538697			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7538697				2022-12-01	WOS:A1995QX85000035
J	BRUSCHWEILER, R; LIAO, XB; WRIGHT, PE				BRUSCHWEILER, R; LIAO, XB; WRIGHT, PE			LONG-RANGE MOTIONAL RESTRICTIONS IN A MULTIDOMAIN ZINC-FINGER PROTEIN FROM ANISOTROPIC TUMBLING	SCIENCE			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; DNA-BINDING DOMAIN; 5S RNA GENE; BACKBONE DYNAMICS; RELAXATION	Structural characterization of biomolecules in solution by nuclear magnetic resonance (NMR) spectroscopy is based primarily on the use of interproton distances derived from homonuclear cross-relaxation experiments. Information about short time-scale dynamics, on the other hand, is obtained from relaxation rates of heteronuclear spin pairs such as (N-1H)-N-15. By combining the two types of data and utilizing the dependence of heteronuclear NMR relaxation rates on anisotropic diffusional rotational tumbling, it is possible to obtain structural information about long-range motional correlations between protein domains. This approach was applied to characterize the relative orientations and mobilities of the first three zinc-finger domains of the Xenopus transcription factor TFIIIA in aqueous solution. The data indicate that the motions of the individual zinc-finger domains are highly correlated on time scales shorter than 10 nanoseconds and that the average conformation of the three-finger polypeptide is elongated.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Bruschweiler, Rafael/F-6624-2015	Wright, Peter/0000-0002-1368-0223	NIGMS NIH HHS [GM 36643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; Debye P., 1929, POLAR MOL, P72; FAVRO LD, 1960, PHYS REV, V107, P7; HUNTRESS WT, 1968, J CHEM PHYS, V48, P3524, DOI 10.1063/1.1669645; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIAO XB, 1994, J BIOMOL NMR, V4, P433; LIAO XY, UNPUB; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; ORNICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; Press WH., 1988, NUMERICAL RECIPES C; RADHAKRISHNAN I, UNPUB; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390	24	321	322	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					886	889		10.1126/science.7754375	http://dx.doi.org/10.1126/science.7754375			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754375				2022-12-01	WOS:A1995QX85000042
J	CHERNOFF, YO; LINDQUIST, SL; ONO, B; INGEVECHTOMOV, SG; LIEBMAN, SW				CHERNOFF, YO; LINDQUIST, SL; ONO, B; INGEVECHTOMOV, SG; LIEBMAN, SW			ROLE OF THE CHAPERONE PROTEIN HSP104 IN PROPAGATION OF THE YEAST PRION-LIKE FACTOR [PSI(+)]	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; OMNIPOTENT SUPPRESSORS; SUP35 GENE; DNA DAMAGE; SCRAPIE; SYSTEM; PRP	The yeast non-Mendelian factor [psi(+)] has been suggested to be a self-modified protein analogous to mammalian prions. Here it is reported that an intermediate amount of the chaperone protein Hsp104 was required for the propagation of the [psi(+)] factor. Overproduction or inactivation of Hsp104 caused the loss of [psi(+)]. These results suggest that chaperone proteins play a role in prion-like phenomena, and that a certain level of chaperone expression can cure cells of prions without affecting viability. This may lead to antiprion treatments that involve the alteration of chaperone amounts or activity.	OKAYAMA UNIV, FAC PHARMACEUT SCI, OKAYAMA 700, JAPAN; ST PETERSBURG STATE UNIV, DEPT GENET, ST PETERSBURG 199034, RUSSIA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Okayama University; Saint Petersburg State University; University of Chicago; Howard Hughes Medical Institute; University of Chicago	CHERNOFF, YO (corresponding author), UNIV ILLINOIS, DEPT BIOL SCI, CHICAGO, IL 60607 USA.		Inge-Vechtomov, Sergei G/L-4807-2013; Chernoff, Yury O/J-2833-2014	Inge-Vechtomov, Sergei G/0000-0002-2832-6825; Chernoff, Yury/0000-0002-8934-9051				AIGLE M, COMMUNICATION; BOREHAM DR, 1994, RADIAT RES, V137, P190, DOI 10.2307/3578811; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHEMOFF YO, UNPUB; CHERNOFF YO, 1992, BIOCHIMIE, V74, P455, DOI 10.1016/0300-9084(92)90086-T; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; CHERNOFF YO, 1992, NATO ASI SER H, V71, P101; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COX B, 1994, CURR BIOL, V4, P744, DOI 10.1016/S0960-9822(00)00167-6; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; Kim G., UNPUB; KOUNAKOV KA, UNPUB; LIEBMAN SW, 1979, J BACTERIOL, V139, P1068, DOI 10.1128/JB.139.3.1068-1071.1979; MAGEE T, COMMUNICATION; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; MCCLANAHAN T, 1986, MOL CELL BIOL, V6, P90, DOI 10.1128/MCB.6.1.90; MURAMATSU T, 1993, PHOTOCHEM PHOTOBIOL, V58, P809, DOI 10.1111/j.1751-1097.1993.tb04974.x; ONO B, 1991, CURR GENET, V19, P243, DOI 10.1007/BF00355049; ONO BI, 1986, GENETICS, V114, P363; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PATINO M, UNPUB; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Rothstein R., 1985, DNA CLONING, VII, P45; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHIRMER E, UNPUB; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; TAULIEN J, UNPUB; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Tikhodeev O.N., 1990, MOL MECH GENETIC PRO, P218; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; TUITE MF, 1994, NATURE, V370, P327, DOI 10.1038/370327a0; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAKEM LP, 1990, GENETICS, V124, P515; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	48	883	901	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					880	884		10.1126/science.7754373	http://dx.doi.org/10.1126/science.7754373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754373				2022-12-01	WOS:A1995QX85000040
J	DONG, JT; LAMB, PW; RINKERSCHAEFFER, CW; VUKANOVIC, J; ICHIKAWA, T; ISAACS, JT; BARRETT, JC				DONG, JT; LAMB, PW; RINKERSCHAEFFER, CW; VUKANOVIC, J; ICHIKAWA, T; ISAACS, JT; BARRETT, JC			KAI1, A METASTASIS SUPPRESSOR GENE FOR PROSTATE-CANCER ON HUMAN-CHROMOSOME 11P11.2	SCIENCE			English	Article							TRANSMEMBRANE PROTEINS; SYNCYTIUM FORMATION; TUMOR PROGRESSION; MOLECULAR-CLONING; INCLUDING CD9; CELL-FUSION; ANTIGEN; FAMILY; IDENTIFICATION; ANTIBODY	A gene from human chromosome 11p11.2 was isolated and was shown to suppress metastasis when introduced into rat AT6.1 prostate cancer cells. Expression of this gene, designated KAI1, was reduced in human cell lines derived from metastatic prostate tumors. KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites. KAI1 is evolutionarily conserved, is expressed in many human tissues, and encodes a member of a structurally distinct family of leukocyte surface glycoproteins. Decreased expression of this gene may be involved in the malignant progression of prostate and other cancers.	NIEHS, MOLEC CARCINOGENESIS LAB, ENVIRONM CARCINOGENESIS PROGRAM, RES TRIANGLE PK, NC 27709 USA; JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; CHIBA UNIV, SCH MED, DEPT UROL, CHIBA 260, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins Medicine; Chiba University			Criley, Jasminka/ABF-7288-2021	Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [CA 58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dong J.-K., UNPUB; DRICKAMER K, 1992, CURR OPIN STRUC BIOL, V2, P653; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; Horoszewicz JS, 1980, MODELS PROSTATE CANC, P115; HOTTA H, 1988, CANCER RES, V48, P2955; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; IMAI T, 1992, J IMMUNOL, V149, P2879; ISHIKAWA M, 1988, CANCER RES, V48, P665; KAIGHN ME, 1979, INVEST UROL, V17, P16; KONDOH M, 1993, MELANOMA RES, V3, P241; LEVY S, 1991, J BIOL CHEM, V266, P14597; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NICOLSON GL, 1991, BIOESSAYS, V13, P337, DOI 10.1002/bies.950130706; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RAMSHAW IA, 1983, INT J CANCER, V32, P471, DOI 10.1002/ijc.2910320414; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROSENBERG SA, 1987, SURGICAL TREATMENT M; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; STEEG P S, 1992, Current Opinion in Oncology, V4, P134, DOI 10.1097/00001622-199202000-00018; VUKANOVIC J, 1993, CANCER RES, V53, P1833	35	715	847	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					884	886		10.1126/science.7754374	http://dx.doi.org/10.1126/science.7754374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754374	Green Submitted			2022-12-01	WOS:A1995QX85000041
J	FEANY, MB; QUINN, WG				FEANY, MB; QUINN, WG			A NEUROPEPTIDE GENE DEFINED BY THE DROSOPHILA MEMORY MUTANT AMNESIAC	SCIENCE			English	Article							STIMULATES ADENYLATE-CYCLASE; SUBSTANCE-P-LIKE; IMMUNOREACTIVE NEURONS; MOLECULAR-CLONING; INITIATION CODON; LEARNING MUTANT; CDNA CLONES; MELANOGASTER; RUTABAGA; DUNCE	Mutations in genes required for associative learning and memory in Drosophila exist, but isolation of the genes has been difficult because most are defined by a single, chemically induced allele. Here, a simplified genetic screen was used to identify candidate genes involved in learning and memory. Second site suppressors of the dunce (dnc) female sterility phenotype were isolated with the use of transposon mutagenesis. One suppressor mutation that was recovered mapped in the amnesiac (amn) gene. Cloning of the locus revealed that amn encodes a previously uncharacterized neuropeptide gene. Thus, with the cloning of amn, specific neuropeptides are implicated in the memory process.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	FEANY, MB (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-618,CAMBRIDGE,MA 02139, USA.			Feany, Mel/0000-0003-0315-7970				ACEVESPINA EO, 1983, COLD SPRING HARB SYM, V48, P831, DOI 10.1101/SQB.1983.048.01.086; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELLEN HJ, 1987, DEV BIOL, V121, P432, DOI 10.1016/0012-1606(87)90180-1; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1988, ROUX ARCH DEV BIOL, V197, P258, DOI 10.1007/BF00380019; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; DUDAI Y, 1984, NEUROSCI LETT, V47, P119, DOI 10.1016/0304-3940(84)90416-6; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; ENGLES WR, 1985, FOCUS, V8, P6; FEANY MB, 1990, P NATL ACAD SCI USA, V87, P2795, DOI 10.1073/pnas.87.7.2795; FEANY MB, UNPUB; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HEINKOFF S, 1987, METHOD ENZYMOL, V154, P156; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; LEE CS, 1987, GENETICS, V116, P55; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NASSEL DR, 1990, BRAIN RES, V507, P225, DOI 10.1016/0006-8993(90)90276-H; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; TULLY T, 1990, COLD SH Q B, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7	39	227	232	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					869	873		10.1126/science.7754370	http://dx.doi.org/10.1126/science.7754370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754370				2022-12-01	WOS:A1995QX85000037
J	KANAI, N; LU, R; SATRIANO, JA; BAO, Y; WOLKOFF, AW; SCHUSTER, VL				KANAI, N; LU, R; SATRIANO, JA; BAO, Y; WOLKOFF, AW; SCHUSTER, VL			IDENTIFICATION AND CHARACTERIZATION OF A PROSTAGLANDIN TRANSPORTER	SCIENCE			English	Article							ISOLATED PERFUSED LUNG; RENAL PROSTAGLANDIN; E RECEPTOR; PROSTACYCLIN PGI2; EXPRESSION SYSTEM; PREGNANT RABBITS; RNA-POLYMERASE; METABOLISM; CLONING; CDNA	Carrier-mediated prostaglandin transport has been postulated to occur in many tissues. On the basis of sequence homology, the protein of unknown function encoded by the rat matrin F/G complementary DNA was predicted to be an organic anion transporter. Expression of the matrin F/G complementary DNA in HeLa cells or Xenopus oocytes conferred the property of specific transport of prostaglandins. The tissue distribution of matrin F/G messenger RNA and the sensitivity of matrin F/G-induced prostaglandin transport to inhibitors were similar to those of endogenous prostaglandin transport. The protein encoded by the matrin F/G complementary DNA is thus preferably called PGT because it is likely to function as a prostaglandin transporter.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, DIV RENAL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, P30DK041296, R01DK049688, R01DK038095] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38095, DK41296, DK23026, R01 DK049688] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ANDERSON MW, 1976, PROSTAGLANDINS, V11, P645, DOI 10.1016/0090-6980(76)90067-8; BAROODY RA, 1981, PROSTAGLANDINS, V21, P133, DOI 10.1016/0090-6980(81)90203-3; BIKHAZI AB, 1983, J PHARM SCI, V72, P296, DOI 10.1002/jps.2600720322; BITO LZ, 1976, PROSTAGLANDINS, V12, P639, DOI 10.1016/0090-6980(76)90043-5; BITO LZ, 1976, ADV PROSTAG THROMB R, V1, P297; BITO LZ, 1978, AM J PHYSIOL, V234, pF80, DOI 10.1152/ajprenal.1978.234.1.F80; BITO LZ, 1976, J PHARMACOL EXP THER, V198, P481; BITO LZ, 1976, J PHYSIOL-LONDON, V256, P257, DOI 10.1113/jphysiol.1976.sp011324; BITO LZ, 1975, AM J PHYSIOL, V229, P1580, DOI 10.1152/ajplegacy.1975.229.6.1580; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BOHMAN SO, 1977, PROSTAG OTH LIPID M, V14, P729, DOI 10.1016/0090-6980(77)90201-5; BOIE Y, 1994, J BIOL CHEM, V269, P12173; CAO ZD, 1984, BIOL REPROD, V31, P505, DOI 10.1095/biolreprod31.3.505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUTHBERT AW, 1984, BRIT J PHARMACOL, V82, P597, DOI 10.1111/j.1476-5381.1984.tb10798.x; DEVEREUX TR, 1987, PROSTAG LEUKOTR ESS, V27, P43, DOI 10.1016/0262-1746(87)90058-8; DIBENEDETTO FE, 1986, J NEUROCHEM, V46, P1725; DUSTING GJ, 1978, BRIT J PHARMACOL, V64, P315, DOI 10.1111/j.1476-5381.1978.tb17307.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ELING TE, 1977, PROSTAGLANDINS, V14, P51, DOI 10.1016/0090-6980(77)90156-3; ELING TE, 1976, AGENTS ACTIONS, V6, P543, DOI 10.1007/BF01973277; FARMAN N, 1987, AM J PHYSIOL, V252, pF53, DOI 10.1152/ajprenal.1987.252.1.F53; FERREIRA SH, 1967, NATURE, V216, P868, DOI 10.1038/216868a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GORDON JA, 1994, J AM SOC NEPHROL, V5, P680; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HAWKINS HJ, 1978, PROSTAGLANDINS, V16, P871, DOI 10.1016/0090-6980(78)90103-X; HAWKINS HJ, 1977, PROSTAGLANDINS, V14, P251, DOI 10.1016/0090-6980(77)90170-8; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRISH JM, 1979, AM J PHYSIOL, V237, pF268, DOI 10.1152/ajprenal.1979.237.4.F268; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JOHNSON M C R, 1970, Biochimica et Biophysica Acta, V218, P543, DOI 10.1016/0005-2760(70)90018-4; KANAI N, UNPUB; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINE L, 1985, ADV PROST THROMBOX L, V13; LEVINE L, 1988, ARACHIDONATE METABOL; LEVINE L, 1986, DIGEST DIS SCI S2, V31; LEVINE L, 1986, AM J MED, P80; MCGIFF J C, 1969, Nature (London), V223, P742, DOI 10.1038/223742b0; MCGUIRE JC, 1978, ARCH BIOCHEM BIOPHYS, V189, P92, DOI 10.1016/0003-9861(78)90118-2; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; Neame K. D., 1972, ELEMENTARY KINETICS; OKITA RT, 1990, ARCH BIOCHEM BIOPHYS, V279, P242, DOI 10.1016/0003-9861(90)90488-K; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; PITT BR, 1983, J PHARMACOL EXP THER, V227, P531; QUIROGA J, 1993, PHARMACOL THERAPEUT, V58, P67, DOI 10.1016/0163-7258(93)90067-N; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; RENNICK BR, 1977, AM J PHYSIOL, V233, pF133, DOI 10.1152/ajprenal.1977.233.2.F133; ROBINSON C, 1982, BIOCHIM BIOPHYS ACTA, V712, P315, DOI 10.1016/0005-2760(82)90349-6; ROSEMAN TJ, 1973, J PHARM SCI-US, V62, P1680, DOI 10.1002/jps.2600621021; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SCHLONDORFF D, 1986, AM J MED, V81, P1, DOI 10.1016/0002-9343(86)90903-4; SMITH WL, 1977, PROSTAGLANDINS, V13, P873, DOI 10.1016/0090-6980(77)90217-9; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; UEKAMA K, 1978, CHEM PHARM BULL, V26, pF58; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; ULMANN A, 1990, ADV PROST THROMBOX L, V21; ULMANN A, 1989, PROG CLIN BIOL RES, V312; ULMANN A, 1990, METHODS ENZYMOL, V187; WATABE A, 1993, J BIOL CHEM, V268, P20175; WONG PYK, 1978, BIOCHEM BIOPH RES CO, V83, P731, DOI 10.1016/0006-291X(78)91050-1; WONG PYK, 1981, FED PROC, V40, P2001	72	343	364	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					866	869		10.1126/science.7754369	http://dx.doi.org/10.1126/science.7754369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754369				2022-12-01	WOS:A1995QX85000036
J	LEE, JE; HOLLENBERG, SM; SNIDER, L; TURNER, DL; LIPNICK, N; WEINTRAUB, H				LEE, JE; HOLLENBERG, SM; SNIDER, L; TURNER, DL; LIPNICK, N; WEINTRAUB, H			CONVERSION OF XENOPUS ECTODERM INTO NEURONS BY NEUROD, A BASIC HELIX-LOOP-HELIX PROTEIN	SCIENCE			English	Review							INTERMEDIATE FILAMENT PROTEIN; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MESODERM FORMATION; ORGAN FORMATION; MYOGENIN GENE; ALPHA-TUBULIN; HLH PROTEINS; DROSOPHILA	Basic helix-loop-helix (bHLH) proteins are instrumental in determining cell type during development. A bHLH protein, termed NeuroD, for neurogenic differentiation, has now been identified as a differentiation factor for neurogenesis because (i) it is expressed transiently in a subset of neurons in the central and peripheral nervous systems at the time of their terminal differentiation into mature neurons and (ii) ectopic expression of neuroD in Xenopus embryos causes premature differentiation of neuronal precursors. Furthermore, neuroD can convert presumptive epidermal cells into neurons and also act as a neuronal determination gene. However, unlike another previously identified proneural gene (XASH-3), neuroD seems competent to bypass the normal inhibitory influences that usually prevent neurogenesis in ventral and lateral ectoderm and is capable of converting most of the embryonic ectoderm into neurons. The data suggest that neuroD may participate in the terminal differentiation step during vertebrate neuronal development.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; HOWARD HUGHES MED INST, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BAROFFIO A, 1991, DEVELOPMENT, V112, P301; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAND M, 1993, DEVELOPMENT, V119, P1; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CABERA CV, 1991, EMBO J, V10, P2965; CABERA CV, 1992, DEVELOPMENT, V115, P893; CAMPOSORTEGA JA, 1994, CELL, V77, P969, DOI 10.1016/0092-8674(94)90437-5; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; DALE L, 1987, DEVELOPMENT, V99, P527; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DENT JA, 1989, DEVELOPMENT, V105, P61; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EPPERLEIN HH, 1993, ANN ANAT, V175, P483, DOI 10.1016/S0940-9602(11)80207-4; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOILLENBERG S, UNPUB; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; JACOBSON M, 1968, DEV BIOL, V17, P219, DOI 10.1016/0012-1606(68)90062-6; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JIMENEZ F, 1993, CURR OPIN GENET DEV, V3, P626, DOI 10.1016/0959-437X(93)90099-B; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JONES EA, 1986, CELL, V44, P345, DOI 10.1016/0092-8674(86)90769-5; JONES EA, 1989, DEVELOPMENT, V107, P785; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KIRSTEN J, UNPUB; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAMATSCHEK B, 1994, DEVELOPMENT, V120, P815; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAMBORGHINI JE, 1980, J COMP NEUROL, V189, P323, DOI 10.1002/cne.901890208; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee J.-S., UNPUB; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NORDLANDER RH, 1989, DEV BRAIN RES, V50, P147, DOI 10.1016/0165-3806(89)90135-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PENG HB, 1991, METHOD CELL BIOL, V36, P659; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; RIBERA AB, 1993, J NEUROSCI, V13, P4988; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SADAGHIANI B, 1987, DEV BIOL, V124, P91, DOI 10.1016/0012-1606(87)90463-5; SINGSON A, 1994, GENE DEV, V8, P2058, DOI 10.1101/gad.8.17.2058; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H., 1938, EMBRYONIC DEV INDUCT; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SZARO BG, 1988, J COMP NEUROL, V273, P344, DOI 10.1002/cne.902730306; TENDONKELAAR HJ, 1991, ANAT EMBRYOL, V183, P589, DOI 10.1007/BF00187908; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WETTS R, 1993, DEV DYNAM, V198, P54, DOI 10.1002/aja.1001980106; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILSON R, IN PRESS NATURE; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	101	904	936	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					836	844		10.1126/science.7754368	http://dx.doi.org/10.1126/science.7754368			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754368				2022-12-01	WOS:A1995QX85000028
J	SERENO, MI; DALE, AM; REPPAS, JB; KWONG, KK; BELLIVEAU, JW; BRADY, TJ; ROSEN, BR; TOOTELL, RBH				SERENO, MI; DALE, AM; REPPAS, JB; KWONG, KK; BELLIVEAU, JW; BRADY, TJ; ROSEN, BR; TOOTELL, RBH			BORDERS OF MULTIPLE VISUAL AREAS IN HUMANS REVEALED BY FUNCTIONAL MAGNETIC-RESONANCE-IMAGING	SCIENCE			English	Article							POSITRON-EMISSION TOMOGRAPHY; HUMAN STRIATE CORTEX; HUMAN BRAIN; RETINOTOPIC ORGANIZATION; CORTICAL AREAS; MACAQUE MONKEY; TOPOGRAPHY; MRI; REPRESENTATION; CONNECTIONS	The borders of human visual areas V1, V2, VP, V3, and V4 were precisely and noninvasively determined. Functional magnetic resonance images were recorded during phase-encoded retinal stimulation. This volume data set was then sampled with a cortical surface reconstruction, making it possible to calculate the local visual field sign (mirror image Versus non-mirror image representation). This method automatically and objectively outlines area borders because adjacent areas often have the opposite field sign. Cortical magnification factor curves for striate and extrastriate cortical areas were determined, which showed that human visual areas have a greater emphasis on the center-of-gaze than their counterparts in monkeys. Retinotopically organized visual areas in humans extend anteriorly to overlap several areas previously shown to be activated by written words.	UNIV OSLO,DEPT NEUROPHYSIOL,N-0316 OSLO,NORWAY; HARVARD MIT DIV HLTH SCI & TECHNOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,BOSTON,MA 02129	University of Oslo; Harvard University; Harvard University; Massachusetts General Hospital	SERENO, MI (corresponding author), UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093, USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829; Kwong, Kenneth K./0000-0001-5056-2173	NEI NIH HHS [EY07980] Funding Source: Medline; NICHD NIH HHS [NICHD22614] Funding Source: Medline; NIMH NIH HHS [MH47035] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022614] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047035] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAKER JR, 1993, P SOC MAG RESON MED, V12, P1400; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; Carman G.J., 1990, THESIS CALTECH; CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103; CUSICK CG, 1984, J COMP NEUROL, V230, P311, DOI 10.1002/cne.902300302; DACEY DM, 1993, J NEUROSCI, V13, P5334, DOI 10.1523/JNEUROSCI.13-12-05334.1993; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; FELLEMAN D J, 1986, Society for Neuroscience Abstracts, V12, P1182; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FOSTER KH, 1985, J PHYSIOL-LONDON, V365, P331, DOI 10.1113/jphysiol.1985.sp015776; FOX PT, 1987, J NEUROSCI, V7, P913; GATTASS R, 1988, J NEUROSCI, V8, P1831; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; Jouandet M L, 1989, J Cogn Neurosci, V1, P88, DOI 10.1162/jocn.1989.1.1.88; Kaas JH, 1991, NEUROANATOMY VISUAL, P302; KRUBITZER LA, 1990, VISUAL NEUROSCI, V5, P165, DOI 10.1017/S0952523800000213; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NEUENSCHWANDER S, 1994, J COMP NEUROL, V340, P65, DOI 10.1002/cne.903400106; NEWSOME WT, 1986, J COMP NEUROL, V252, P129; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; OLAVARRIA J, 1985, J NEUROSCI METH, V15, P191, DOI 10.1016/0165-0270(85)90098-6; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; ROSA MGP, 1993, VISUAL NEUROSCI, V10, P827, DOI 10.1017/S0952523800006064; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; Schwartz E.L., 1990, COMPUTATIONAL NEUROS, P295; Schwartz Eric L., 1994, Cerebral Cortex, V10, P359; Sereno Martin I., 1991, P160; SERENO MI, 1994, CEREB CORTEX, V4, P601, DOI 10.1093/cercor/4.6.601; SERENO MI, IN PRESS CEREB CORTE; TOLHURST DJ, 1988, HUM NEUROBIOL, V6, P247; TOOTELL RB, 1981, SCIENCE, V214, P813, DOI 10.1126/science.7292014; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; TOOTELL RBH, IN PRESS J NEUROSCI; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; VANESSEN DC, 1978, J PHYSIOL-LONDON, V277, P193; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WISMER GL, 1988, J COMPUT ASSIST TOMO, V12, P259, DOI 10.1097/00004728-198803000-00014; ZEKI S, 1991, J NEUROSCI, V11, P641	49	1925	1952	4	124	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					889	893		10.1126/science.7754376	http://dx.doi.org/10.1126/science.7754376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754376				2022-12-01	WOS:A1995QX85000043
J	SPRINGER, PS; MCCOMBIE, WR; SUNDARESAN, V; MARTIENSSEN, RA				SPRINGER, PS; MCCOMBIE, WR; SUNDARESAN, V; MARTIENSSEN, RA			GENE TRAP TAGGING OF PROLIFERA, AN ESSENTIAL MCM2-3-5-LIKE GENE IN ARABIDOPSIS	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; REGULATORY ELEMENTS; CELL-CYCLE; DROSOPHILA; THALIANA; EXPRESSION; AMPLIFICATION; MERISTEM; MUTATION; EXCISION	Gene trap transposon mutagenesis can identify essential genes whose functions in later development are obscured by an early lethal phenotype. In higher plants, many genes are required for haploid gametophyte viability, so that the phenotypic effects of their disruption cannot be readily observed in the diploid plant body. The PROLIFERA (PRL) gene, identified by gene trap transposon mutagenesis in Arabidopsis, is required for megagametophyte and embryo development. Reporter gene expression patterns revealed that PRL was expressed in dividing cells throughout the plant. PRL is related to the MCM2-3-5 family of yeast genes that are required for the initiation of DNA replication.	COLD SPRING HARBOR LAB,LITA ANNENBERG HAZEN GENOME CTR,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				McCombie, W. Richard/0000-0003-1899-0682; Sundaresan, Venkatesan/0000-0002-4670-0630				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANCROFT I, 1993, PLANT CELL, V5, P631, DOI 10.1105/tpc.5.6.631; BANCROFT I, 1992, MOL GEN GENET, V233, P449, DOI 10.1007/BF00265443; BARKAN A, 1986, EMBO J, V5, P1421, DOI 10.1002/j.1460-2075.1986.tb04378.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BUSSEREAU F, 1993, YEAST, V9, P797, DOI 10.1002/yea.320090714; Carlson W. R., 1988, Corn and corn improvement. Third edition., P259; Cone K., 1989, Maize Genetics Cooperation News Letter, P68; CROXDALE J, 1992, DEV BIOL, V149, P158, DOI 10.1016/0012-1606(92)90272-I; DALTON S, COMMUNICATION; DAVIS EL, 1979, CAN J BOT, V57, P971, DOI 10.1139/b79-119; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FOE VE, 1989, DEVELOPMENT, V107, P1; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURNER IJ, 1993, PLANT J, V4, P917, DOI 10.1046/j.1365-313X.1993.04060917.x; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GROSSNIKLAUS U, UNPUB; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KARLINNEUMANN GA, 1991, PLANT CELL, V3, P573, DOI 10.1105/tpc.3.6.573; KAVANGH TA, 1987, EMBO J, V6, P3901; KERTBUNDIT S, 1991, P NATL ACAD SCI USA, V88, P5212, DOI 10.1073/pnas.88.12.5212; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORRWEAVER TL, 1994, TRENDS GENET, V10, P321, DOI 10.1016/0168-9525(94)90035-3; Patterson E. B., 1978, Maize breeding and genetics. Section 8. Cytogenetics., P693; PYKE KA, 1991, J EXP BOT, V42, P1407, DOI 10.1093/jxb/42.11.1407; REDEI GP, 1965, GENETICS, V51, P857; SCOFIELD SR, 1993, CELL, V75, P507, DOI 10.1016/0092-8674(93)90385-4; SKARNES WC, 1990, BIO-TECHNOL, V8, P827, DOI 10.1038/nbt0990-827; SPRINGER PT, UNPUB; STEEVES TA, 1969, CAN J BOTANY, V47, P1367, DOI 10.1139/b69-195; SUNDARESAN V, UNPUB; TOPPING JF, 1991, DEVELOPMENT, V112, P1009; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; VIZIR IY, 1994, GENETICS, V137, P1111; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; 1991, PROGRAM MANUAL GCG P	48	206	230	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					877	880		10.1126/science.7754372	http://dx.doi.org/10.1126/science.7754372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754372				2022-12-01	WOS:A1995QX85000039
J	TRAYNELIS, SF; HARTLEY, M; HEINEMANN, SF				TRAYNELIS, SF; HARTLEY, M; HEINEMANN, SF			CONTROL OF PROTON SENSITIVITY OF THE NMDA RECEPTOR BY RNA SPLICING AND POLYAMINES	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; EXCITATORY AMINO-ACIDS; PROTEIN-KINASE-C; HIPPOCAMPAL-NEURONS; SECONDARY-STRUCTURE; GLUCOSE DEPRIVATION; INDUCED CURRENTS; SINGLE-CHANNEL; RAT; GLUTAMATE	The function of the N-methyl-D-aspartate (NMDA)-preferring glutamate receptor can be regulated by extracellular pH, a process that may be important during ischemia in the brain or during seizures. Protons inhibit NMDA receptor function by 50 percent at pH 7.3 through interactions with the NR1 subunit, and both polyamines and NR1 exon 5 potentiate receptor function through relief of the tonic proton inhibition present at physiological pH. A single amino acid (lysine 211) was identified that mediates the effects of exon 5 in the rat brain. Electroneutral substitutions at this position restored pH sensitivity and, consequently, polyamine relief of tonic inhibition. This effect, together with the structural similarities between polyamines and the surface loop encoded by exon 5, suggest that exon 5 may act as a tethered pH-sensitive constitutive modulator of NMDA receptor function.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute	TRAYNELIS, SF (corresponding author), EMORY UNIV,DEPT PHARMACOL,ATLANTA,GA 30322, USA.				NINDS NIH HHS [NS28709, NS08549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; ARANEDA RC, 1993, NEUROSCI LETT, V152, P107, DOI 10.1016/0304-3940(93)90495-7; BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; BATES RG, 1978, ANAL CHEM, V50, P1295, DOI 10.1021/ac50031a026; BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISTENSEN BN, 1990, NEURON, V5, P471, DOI 10.1016/0896-6273(90)90086-U; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; HIRSCHMAN SZ, 1967, BIOPOLYMERS, V5, P227, DOI 10.1002/bip.1967.360050209; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII T, 1993, J BIOL CHEM, V268, P2836; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MELDRUM BS, 1992, EPILEPSY RES, V12, P189, DOI 10.1016/0920-1211(92)90040-Z; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; OBRENOVITCH TP, 1990, J NEUROPHYSIOL, V64, P1125, DOI 10.1152/jn.1990.64.4.1125; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; ROCK DM, 1992, MOL PHARMACOL, V41, P83; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STANDAERT DG, 1993, NEUROSCI LETT, V152, P161, DOI 10.1016/0304-3940(93)90508-I; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TEMPLETON DM, 1985, CAN J CHEM, V63, P3122, DOI 10.1139/v85-515; TOMBAUGH GC, 1993, J NEUROCHEM, V61, P793, DOI 10.1111/j.1471-4159.1993.tb03589.x; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WILLIAMS K, 1994, MOL PHARMACOL, V46, P161; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883; ZHENG X, 1994, NEURON, V12, P1	54	332	342	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					873	876		10.1126/science.7754371	http://dx.doi.org/10.1126/science.7754371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754371				2022-12-01	WOS:A1995QX85000038
J	BAYER, R; STRYKER, J; SMITH, MD				BAYER, R; STRYKER, J; SMITH, MD			TESTING FOR HIV-INFECTION AT HOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FALSE POSITIVE RATE; ANTIBODY		UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94105 USA; HENRY J KAISER JR FAMILY FDN, MENLO PK, CA 94024 USA	University of California System; University of California San Francisco	BAYER, R (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, 600 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER; NIMH NIH HHS [P50-MH43520] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JE, 1992, AM J PUBLIC HEALTH, V82, P1533, DOI 10.2105/AJPH.82.11.1533; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; Doll Lynda S., 1994, P302; GWINN M, 1992, J ACQ IMMUN DEF SYND, V5, P505; HARRIS HR, 1994, WASH POST       0409, pG1; HENRY K, 1988, JAMA-J AM MED ASSOC, V259, P229, DOI 10.1001/jama.259.2.229; KOOP CE, 1994, FDA BLOOD PRODUCTS A; Leary Warren E, 1994, N Y Times Web, pA18; LEARY WE, 1989, NY TIMES        0316, P15; MEYER KB, 1987, NEW ENGL J MED, V317, P238, DOI 10.1056/NEJM198707233170410; OCAMB K, 1994, POZ              JUN, P48; OSSIPKLEIN DJ, 1991, J CONSULT CLIN PSYCH, V59, P325, DOI 10.1037/0022-006X.59.2.325; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; ROSIN H, 1994, NEW REPUBLIC    0103, P12; SALBU SR, 1995, HASTINGS LAW J, V46, P403; SCHONBERG SK, 1994, COMMISSIONER FO 0629; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; VALDISERRI RO, 1993, PUBLIC HEALTH REP, V108, P12; WOFSY CB, 1987, SURGEON GENERALS WOR, P32; 1995, FED REGISTER, V60, P10087; 1990, JAMA-J AM MED ASSOC, V264, P2416; 1995, AIDS POLICY LAW, V10, P10; 1989, TIME            0418, P26; 1995, BUS WIRE        0208; 1994, HOME TESTING PRINCIP; 1994, ADV DATA VITAL HLTH, V243; 1995, FED REGISTER, V60, P10086	27	41	41	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1296	1299		10.1056/NEJM199505113321911	http://dx.doi.org/10.1056/NEJM199505113321911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW600	7708077				2022-12-01	WOS:A1995QW60000011
J	CRICK, F; KOCH, C				CRICK, F; KOCH, C			ARE WE AWARE OF NEURAL ACTIVITY IN PRIMARY VISUAL-CORTEX	NATURE			English	Article							SELECTIVE CELLS; MACAQUE; MONKEY; ORGANIZATION; CAT	It is usually assumed that people are visually aware of at least some of the neuronal activity in the primary visual area, V1, of the neocortex. But the neuroanatomy of the macaque monkey suggests that, although primates may be aware of neural activity in other visual cortical areas, they are not directly aware of that in area V1. There is some psychophysical evidence in humans that supports this hypothesis.	CALTECH, COMPUTAT & NEURAL SYST PROGRAM, PASADENA, CA 91125 USA	California Institute of Technology	CRICK, F (corresponding author), SALK INST BIOL STUDIES, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Koch, Christof/0000-0001-6482-8067				Barbas H, 1992, Adv Neurol, V57, P91; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BIRBAUMER N, 1990, PHYSIOL REV, V70, P1, DOI 10.1152/physrev.1990.70.1.1; BLACKWELL KT, 1988, J OPT SOC AM A, V5, P1772; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; COWEY A, 1995, NATURE, V373, P247, DOI 10.1038/373247a0; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Crick F., 1990, Seminars in the Neurosciences, V2, P263; CRICK F, 1993, NATURE, V361, P109, DOI 10.1038/361109a0; CRICK F, 1992, SCI AM, V267, P153, DOI 10.1038/scientificamerican0992-152; Crick F., 1994, ASTONISHING HYPOTHES; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; ECCLES JC, 1986, PROC R SOC SER B-BIO, V227, P411, DOI 10.1098/rspb.1986.0031; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FRIES W, 1990, VISUAL NEUROSCI, V4, P205, DOI 10.1017/S0952523800003357; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; FUSTERJM, 1989, PREFRONTAL CORTEX; GERFEN CR, 1994, MOTOR COGNITIVE FUNC, P78; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KOCH C, 1994, LARGE SCALE NEURONAL, P93; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; LEVITT JB, 1994, J NEUROPHYSIOL, V71, P2517, DOI 10.1152/jn.1994.71.6.2517; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MYERSON J, 1981, BEHAV ANAL LETT, V1, P149; PICKERSGILL MJ, 1961, Q J EXP PSYCHOL, V13, P168, DOI 10.1080/17470216108416489; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P281, DOI 10.1016/0166-2236(94)90057-4; SAINTCYR JA, 1990, J COMP NEUROL, V298, P129, DOI 10.1002/cne.902980202; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; Sherk H., 1986, CEREB CORTEX, P467, DOI DOI 10.1007/978-1-4613-2149-1_13; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1984, J COMP NEUROL, V223, P368, DOI 10.1002/cne.902230304; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0; ZEKI S, 1983, PROC R SOC SER B-BIO, V217, P449, DOI 10.1098/rspb.1983.0020; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	43	580	599	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	1995	375	6527					121	123		10.1038/375121a0	http://dx.doi.org/10.1038/375121a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753166				2022-12-01	WOS:A1995QX74100042
J	JIANG, WP; SWIGGARD, WJ; HEUFLER, C; PENG, M; MIRZA, A; STEINMAN, RM; NUSSENZWEIG, MC				JIANG, WP; SWIGGARD, WJ; HEUFLER, C; PENG, M; MIRZA, A; STEINMAN, RM; NUSSENZWEIG, MC			THE RECEPTOR DEC-205 EXPRESSED BY DENDRITIC CELLS AND THYMIC EPITHELIAL-CELLS IS INVOLVED IN ANTIGEN-PROCESSING	NATURE			English	Article							MACROPHAGE MANNOSE RECEPTOR; CARBOHYDRATE-RECOGNITION DOMAINS; LYMPHOCYTES-B; COMPLEX; BINDING; INTERNALIZATION; PROTEIN	DENDRITIC cells and thymic epithelial cells perform important immunoregulatory functions by presenting antigens in the form of peptides bound to cell-surface major histocompatibility complex (MHC) molecules to T cells(1-3). Whereas B cells are known to present specific antigens efficiently through their surface immunoglobins, a comparable mechanism for the capture and efficient presentation of diverse antigens by dendritic cells and thymic epithelial cells has not previously been described. We show here that their antigen-presentation function is associated with the high-level expression of DEC-205, an integral membrane protein homologous to the macrophage mannose receptor and related receptors which are able to bind carbohydrates and mediate endocytosis. DEC-205 is rapidly taken up by means of coated pits and vesicles, and is delivered to a multivesicular endosomal compartment that resembles the MHC class II-containing vesicles implicated in antigen presentation. Rabbit antibodies that bind DEC-205 are presented to reactive T-cell hybridomas 100-fold more efficiently than rabbit antibodies that do not bind DEC-205, Thus DEC-205 is a novel endocytic receptor that can be used by dendritic cells and thymic epithelial cells to direct captured antigens from the extracellular space to a specialized antigen-processing compartment.	ROCKEFELLER UNIV,MOLEC IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,CELLULAR PHYSIOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University			Steinman, Ralph/F-7729-2012; Nussenzweig, Michel/AAE-7292-2019					AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; HARRIS N, 1992, BLOOD, V80, P2363; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANZAVEECHIA A, 1985, NATURE, V314, P538; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	28	746	783	2	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					151	155		10.1038/375151a0	http://dx.doi.org/10.1038/375151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753172				2022-12-01	WOS:A1995QX74100053
J	KREGE, JH; JOHN, SWM; LANGENBACH, LL; HODGIN, JB; HAGAMAN, JR; BACHMAN, ES; JENNETTE, JC; OBRIEN, DA; SMITHIES, O				KREGE, JH; JOHN, SWM; LANGENBACH, LL; HODGIN, JB; HAGAMAN, JR; BACHMAN, ES; JENNETTE, JC; OBRIEN, DA; SMITHIES, O			MALE-FEMALE DIFFERENCES IN FERTILITY AND BLOOD-PRESSURE IN ACE-DEFICIENT MICE	NATURE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ESSENTIAL-HYPERTENSION; GENE; POLYMORPHISM; MOUSE; ASSOCIATION; EXPRESSION	ANGIOTENSIN-CONVERTING enzyme (ACE) is a dipeptidyl carboxypeptidase that generates the vasoconstricting peptide angiotensin II and inactivates the vasodilating peptide bradykinin(1). The gene encoding ACE is composed of two homologous regions and codes for both a somatic and testis isoenzyme(2-4). Experiments with hypertensive rats(5,6) and some(7-9), but not other(10-13), studies of humans suggest that sequences at or linked to the gene influence blood pressure. The testis-specific form of ACE has its own promoter within intron 12 (ref, 14), is encoded by the 3' region of the gene, and is found only in postmeiotic spermatogenic cells and sperm(15). Its function is unknown(16) Here we investigate the role of the Ace gene in blood pressure control and reproduction using mice generated to carry an insertional mutation that is designed to inactivate both forms of ACE. All homozygous female mutants were found to be fertile, but the fertility of homozygous male mutants was greatly reduced. Heterozygous males but not females had blood pressures that were 15-20 mm Hg less than normal, although both male and female heterozygotes had reduced serum ACE activity.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	KREGE, JH (corresponding author), UNIV N CAROLINA,DEPT INTERNAL MED,CHAPEL HILL,NC 27599, USA.			Jennette, John Charles/0000-0002-8081-6565	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026485] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; DURU K, 1994, AM J HYPERTENS, V7, P759, DOI 10.1093/ajh/7.8.759; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5313; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FORESTA C, 1991, INT J ANDROL, V14, P333, DOI 10.1111/j.1365-2605.1991.tb01101.x; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; HIGASHIMORI K, 1993, BIOCHEM BIOPH RES CO, V191, P399, DOI 10.1006/bbrc.1993.1231; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIM HS, IN PRESS P NATN ACAD; KREGE JH, IN PRESS HYPERTENSIO; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; MORISE T, 1994, LANCET, V343, P125, DOI 10.1016/S0140-6736(94)90859-1; SCHMIDT S, 1993, J HYPERTENS, V11, P345, DOI 10.1097/00004872-199304000-00003; SEN I, 1993, J BIOL CHEM, V268, P25748; SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILSON CM, 1981, BIOCHEM GENET, V19, P509, DOI 10.1007/BF00484623; ZEE RYL, 1992, BIOCHEM BIOPH RES CO, V184, P9, DOI 10.1016/0006-291X(92)91150-O	25	577	594	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					146	148		10.1038/375146a0	http://dx.doi.org/10.1038/375146a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753170				2022-12-01	WOS:A1995QX74100051
J	KROLEWSKI, AS; LAFFEL, LMB; KROLEWSKI, M; QUINN, M; WARRAM, JH				KROLEWSKI, AS; LAFFEL, LMB; KROLEWSKI, M; QUINN, M; WARRAM, JH			GLYCOSYLATED HEMOGLOBIN AND THE RISK OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STATISTICAL-METHOD; GLUCOSE CONTROL; COMPLICATIONS; NEPHROPATHY; DISEASE	Background. The risk of microalbuminuria in patients with insulin-dependent diabetes mellitus (IDDM) is thought to depend on the degree of hyperglycemia, but the relation between the degree of hyperglycemia and urinary albumin excretion has not been defined. Methods. We measured urinary albumin excretion in three random urine samples obtained at least one month apart from 1613 patients with IDDM. Microalbuminuria or overt albuminuria was considered to be present if the ratio of albumin (in micrograms) to creatinine (in milligrams) was 17 to 299 or greater than or equal to 300, respectively, for men and 25 to 299 or greater than or equal to 300, respectively, for women. Measurements of glycosylated hemoglobin (hemoglobin A(1)) obtained up to four years before the urine testing were used as an index of hyperglycemia. Twelve percent of the patients had overt albuminuria and were excluded from subsequent analyses. Results. The prevalence of microalbuminuria was 18 percent in patients with IDDM. It increased with increasing postpubertal duration of diabetes and, within each six-year interval of disease duration, it increased nonlinearly with the hemoglobin A(1) value. For hemoglobin A(1) values below 10.1 percent, the slope of the relation was almost flat, whereas for values above 10.1 percent, the prevalence of microalbuminuria rose steeply (P<0.001). For example, as the hemoglobin A(1) value increased from 8.1 to 10.1 percent, the odds of microalbuminuria increased by a factor of 1.3, but as the value increased from 10.1 to 12.1 percent, the odds were increased by a factor of 2.4. Conclusions. The risk of microalbuminuria in patients with IDDM increases abruptly above a hemoglobin A(1) value of 10.1 percent (equivalent to a hemoglobin A(1c) value of 8.1 percent), suggesting that efforts to reduce the frequency of diabetic nephropathy should be focused on reducing hemoglobin A(1) values that are above this threshold.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	KROLEWSKI, AS (corresponding author), JOSLIN DIABET CTR, EPIDEMIOL & GENET SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA.				NIDDK NIH HHS [R01-DK41526] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRASS CK, 1994, KIDNEY INT, V46, P613, DOI 10.1038/ki.1994.313; [Anonymous], 1988, SAS STAT GUIDE PERSO; BIRKETT NJ, 1992, AM J EPIDEMIOL, V136, P356, DOI 10.1093/oxfordjournals.aje.a116500; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; COONROD BA, 1993, DIABETES CARE, V16, P1376, DOI 10.2337/diacare.16.10.1376; DAHLJORGENSEN K, 1992, KIDNEY INT, V41, P920, DOI 10.1038/ki.1992.140; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; ERIKSSON J, 1992, DIABETIC MED, V9, P654, DOI 10.1111/j.1464-5491.1992.tb01862.x; JANNER M, 1994, EUR J PEDIATR, V153, P403; JONES RH, 1984, ANAL BIOCHEM, V141, P287, DOI 10.1016/0003-2697(84)90458-5; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LARKINS R, 1992, DIABETOLOGIA, V35, P1100; LARKINS RG, 1992, DIABETOLOGIA, V35, P499, DOI 10.1007/BF00400475; LIEVENS MM, 1988, CLIN CHEM, V34, P992; LITTLE RR, 1992, CLIN CHEM, V38, P2472; MACLURE M, 1992, AM J EPIDEMIOL, V135, P96; MENARD L, 1980, CLIN CHEM, V26, P1598; MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; NESTLER JE, 1990, DIABETES, V39, P1212, DOI 10.2337/diabetes.39.10.1212; PUGLIESE G, 1991, DIABETES METAB REV, V7, P35, DOI 10.1002/dmr.5610070106; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; ULM K, 1991, STAT MED, V10, P341, DOI 10.1002/sim.4780100306; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WARRAM JH, 1995, NEW ENGL J MED, V332, P1305, DOI 10.1056/NEJM199505113321915; Wilson R M, 1985, Diabet Med, V2, P167; YIP J, 1993, BRIT MED J, V306, P1235; 1990, P200 SAS I TECHN REP	33	385	393	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1251	1255		10.1056/NEJM199505113321902	http://dx.doi.org/10.1056/NEJM199505113321902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708068				2022-12-01	WOS:A1995QW60000002
J	LUO, Y; HURWITZ, J; MASSAGUE, J				LUO, Y; HURWITZ, J; MASSAGUE, J			CELL-CYCLE INHIBITION BY INDEPENDENT CDK AND PCNA BINDING DOMAINS IN P21(CIP1)	NATURE			English	Article							DEPENDENT KINASES; IDENTIFICATION; SUPPRESSION; SUBUNIT; P21	MAMMALIAN cell-cycle control by antimitogenic signals involves p21(Cip1/WAF1) (refs 1-4), p27(Kip1) (refs 5, 6) and p57(Kip2) (refs 7, 8), a family of proteins that bind to and inhibit cyclin-dependent kinases (CDKs) required for initiation of S phase. The protein p21 also binds to the DNA polymerase 6 processivity factor, proliferating-cell nuclear antigen (PCNA), and inhibits in vitro PCNA-dependent DNA replication(9,10). The CDK and PCNA inhibitory activities of p21 are shown here to be functionally independent and to reside in separate protein domains. The PCNA binding and inhibitory activities, which are not observed with p27 or p57, reside in the C-terminal domain of p21, whereas the CDK inhibitory activity resides in the conserved N-terminal domains of these proteins. When separately overexpressed in mammalian cells, the CDK and PCNA inhibitory domains prevent DNA replication, demonstrating a dual function of p21 as a cell-cycle inhibitor in vivo.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KELMAN Z, IN PRESS METH ENZYM; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	19	531	553	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					159	161		10.1038/375159a0	http://dx.doi.org/10.1038/375159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753174				2022-12-01	WOS:A1995QX74100055
J	REJTO, PA; BINDEWALD, E; CHANDLER, D				REJTO, PA; BINDEWALD, E; CHANDLER, D			VISUALIZATION OF FAST ENERGY-FLOW AND SOLVENT CAGING IN UNIMOLECULAR DYNAMICS	NATURE			English	Article							CONFORMATIONAL ISOMERIZATION; TRANSITION-STATE; CYCLOHEXANE; LIQUIDS; RELAXATION; ACTIVATION	ENERGY flow in solution between physically or chemically evolving solute molecules and the surrounding solvent significantly affects the nature of chemical dynamics in liquids. It determines the extent to which the statistical theory of reaction rates(1,2) is valid; the transfer of energy between solute and solvent influences the ease with which the transition state evolves into the products-the process central to transition-state theory. But analysing the energy flow in liquid-phase dynamics is difficult because these systems are so complex, and the degrees of freedom are consequently so numerous. Here we present a way to address this challenge. We introduce an approach for visualizing the energy flow directly, and apply it to the isomerization of cyclohexane (between boat and chair conformations) in liquid carbon disulphide, a process for which detailed information about the molecular motions is available from molecular dynamics simulations(8). Our method reveals in pictorial form the formation and relaxation of a solvent cage, and shows that the relaxation has a strong effect on energy flow to and from the transition state on sub-picosecond timescales. We anticipate that this visualization approach will be generally useful for elucidating dynamical molecular processes in solution.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Rejto, Paul/M-4782-2019					ANDERSON JB, 1973, J CHEM PHYS, V58, P4684, DOI 10.1063/1.1679032; Bennett C. H., 1977, ACS SYM SER, V46, P63, DOI DOI 10.1021/BK-1977-0046.CH004; BORKOVEC M, 1986, J CHEM PHYS, V85, P146, DOI 10.1063/1.451651; CAMPBELL DM, 1992, J CHEM PHYS, V96, P2717, DOI 10.1063/1.462019; CHANDLER D, 1988, FARADAY DISCUSS, V85, P329, DOI 10.1039/dc9888500329; CHANDLER D, 1978, J CHEM PHYS, V68, P2959, DOI 10.1063/1.436049; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; GERTNER BJ, 1991, J AM CHEM SOC, V113, P74, DOI 10.1021/ja00001a014; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/revmodphys.62.251; HASHA DL, 1981, J CHEM PHYS, V75, P1571, DOI 10.1063/1.442193; HASHA DL, 1982, J AM CHEM SOC, V104, P2290, DOI 10.1021/ja00372a029; JIMENEZ R, 1994, NATURE, V369, P471, DOI 10.1038/369471a0; Johnston H.S., 1966, GAS PHASE REACTION R; Keck J. C., 1967, ADV CHEM PHYS, V13, P85; MILLER WH, 1976, ACCOUNTS CHEM RES, V9, P306, DOI 10.1021/ar50104a005; PATRON F, 1991, CHEM PHYS, V152, P121, DOI 10.1016/0301-0104(91)80039-K; PICKETT HM, 1970, J AM CHEM SOC, V92, P7281; REJTO PA, 1994, J PHYS CHEM-US, V98, P12310, DOI 10.1021/j100098a028; SINGER SJ, 1986, J PHYS CHEM-US, V90, P6015, DOI 10.1021/j100280a111; STRAUSS HL, 1971, J CHEM EDUC, V48, P221, DOI 10.1021/ed048p221; Wigner E, 1938, T FARADAY SOC, V34, P0029, DOI 10.1039/tf9383400029; WILSON MA, 1990, CHEM PHYS, V149, P11, DOI 10.1016/0301-0104(90)80127-J	22	11	11	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					129	131		10.1038/375129a0	http://dx.doi.org/10.1038/375129a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753167				2022-12-01	WOS:A1995QX74100045
J	SAUER, F; FONDELL, JD; OHKUMA, Y; ROEDER, RG; JACKLE, H				SAUER, F; FONDELL, JD; OHKUMA, Y; ROEDER, RG; JACKLE, H			CONTROL OF TRANSCRIPTION BY KRUPPEL THROUGH INTERACTIONS WITH TFIIB AND TFIIE-BETA	NATURE			English	Article							ACTIVATION DOMAIN; RNA-POLYMERASE; DROSOPHILA; INITIATION; PROTEIN; REPRESSION; MECHANISM; SEQUENCE; BINDING; STRIPE	THE zinc-finger protein Kruppel (Kr)(1) is an integral part of the Drosophila segmentation gene cascade(2) and is essential in organogenesis during later embryonic development(3). In tissue culture, Kr regulates transcription(4-9). Monomeric Kr can act as a transcriptional activator, whereas Kr dimers formed at high concentrations cause repression(6). Here we show that Kr-dependent control of transcription involves functional interactions with components of the basal RNA polymerase II transcription machinery, which includes the initiation factors TFIIA, B, E, F, H and I (refs 10, 11) as well as the TATA-binding protein (TBP) and TBP-associated factors (TAFs) contained in the multisubunit TFIID (ref. 12). Our results indicate that when acting from a site close to a basal promoter, monomeric Kr interacts with TFIIB to activate transcription, whereas an interaction of the Kr dimer with TFIIE beta w, a subunit of TFIIE, results in transcriptional repression.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,D-37077 GOTTINGEN,GERMANY; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Max Planck Society; Rockefeller University								CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KIM TK, IN PRESS P NATN ACAD; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLIE JW, 1991, NATURE, V338, P39; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1992, NATURE, V358, P841; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1993, THESIS U OSNABRUCK G; SCHMUCKER D, 1992, NEURON, V5, P1025; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHUO P, 1990, GENE DEV, V5, P254	30	132	135	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					162	164		10.1038/375162a0	http://dx.doi.org/10.1038/375162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753175				2022-12-01	WOS:A1995QX74100056
J	SIMSKE, JS; KIM, SK				SIMSKE, JS; KIM, SK			SEQUENTIAL SIGNALING DURING CAENORHABDITIS-ELEGANS VULVAR INDUCTION	NATURE			English	Article							C-ELEGANS; CELL LINEAGES; TYROSINE KINASE; NEMATODE; GENE; PATTERN; ENCODES; LET-23	DURING the induction of the Caenorhabditis elegans vulva, cell signalling causes initially equipotent cells to express a reproducible pattern of cell fates(1,2). The position of the anchor cell determines the pattern of vulval precursor cell fates, such that the closest precursor cell (P6.p) expresses the primary cell fate, the next closest cells (P5.p and P7.p) both express the secondary cell fate, and each of the precursor cells located at a distance (P3.p, P4.p and P8.p) express the tertiary cell fate (Fig. 1a)(3-5). We present data indicating that this stereotypical pattern of cell fates can be generated by sequential signals. We identified genetic mosaic animals in which P5.p and P7.p were defective in the anchor-cell signal-transduction pathway and observed that these cells adopted the secondary cell fate, indicating that anchor-cell signal transduction is not required for the expression of the secondary cell fate. These results suggest that the anchor cell induces P6.p to express the primary cell fate, and that P6.p subsequently induces P5.p and P7.p to express the secondary cell fate.			SIMSKE, JS (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AROLAN RV, 1994, EMBO J, V13, P360; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER DM, 1993, GENETICS, V135, P741; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	30	109	116	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					142	146		10.1038/375142a0	http://dx.doi.org/10.1038/375142a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753169				2022-12-01	WOS:A1995QX74100050
J	TANAKA, Y; MORITA, CT; TANAKA, Y; NIEVES, E; BRENNER, MB; BLOOM, BR				TANAKA, Y; MORITA, CT; TANAKA, Y; NIEVES, E; BRENNER, MB; BLOOM, BR			NATURAL AND SYNTHETIC NONPEPTIDE ANTIGENS RECOGNIZED BY HUMAN GAMMA-DELTA T-CELLS	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EXPANSION; RECEPTOR; PROTEIN; SUBSET	T LYMPHOCYTES express either alpha beta or gamma delta T-cell receptor heterodimers(1,2). Most alpha beta T cells recognize antigenic peptides bound to major histocompatibility complex molecules but the antigen recognition and biological function of gamma delta T cells is unknown. A major human gamma delta T-cell subset expressing V gamma 2 and V delta 2 germline genes, but having diverse junctional sequences, is found in human mycobacterial lesions(3) and responds in vitro to antigens of bacteria and parasites(4-8). In addition, certain haematopoietic tumour cells are specifically recognized and lysed by these T cells(9). V gamma 2V delta 2-bearing T cells were shown to recognize mycobacterial antigens that are protease resistant and phosphatase sensitive(10-13). Because of the difficulty in isolating natural antigens from mycobacterial culture filtrates or extracts, we synthesized a series of monoalkyl phosphates, and found that some, particularly monoethyl phosphate, could mimic the activity of mycobacterial antigens in stimulating these gamma delta T cells(10). Here we report the identification of natural antigens produced by mycobacteria recognized by human V gamma 2V delta 2-bearing T cells as isopentenyl pyrophosphate and related prenyl pyrophosphate derivatives, compounds involved in the synthesis of complex polyisoprenoid compounds in microbial and mammalian cells. Substitution of phosphate for the pyrophosphate moiety, or elimination of the double bond, greatly reduced antigenic activity of these compounds. These results provide formal evidence that, in contrast to recognition of major histocompatibility complex-bound peptide antigens by alpha beta T cells, human gamma delta T cells can recognize naturally occurring small non-peptidic antigens.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294; Tanaka, Yoshimasa/0000-0002-5024-0614				Ames BN, 1966, METHOD ENZYMOL, VVIII, P115; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BUKOWSKI JF, 1994, J IMMUNOL, V153, P5133; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; ECKSTEIN F, 1975, BIOCHEMISTRY-US, V23, P5225; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; GOERLICH R, 1991, EUR J IMMUNOL, V21, P2613, DOI 10.1002/eji.1830211045; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA T, 1992, J CLIN INVEST, V90, P204, DOI 10.1172/JCI115837; HAVLIR DV, 1991, J CLIN INVEST, V87, P729, DOI 10.1172/JCI115053; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; Myant, 1981, BIOL CHOLESTEROL REL, P123, DOI DOI 10.1016/B978-0-433-22880-6.50010-2; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; POPJAK G, 1962, J BIOL CHEM, V237, P56; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHOEL B, 1994, EUR J IMMUNOL, V24, P1886, DOI 10.1002/eji.1830240826; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	27	819	848	2	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					155	158		10.1038/375155a0	http://dx.doi.org/10.1038/375155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753173				2022-12-01	WOS:A1995QX74100054
J	TOOTELL, RBH; REPPAS, JB; DALE, AM; LOOK, RB; SERENO, MI; MALACH, R; BRADY, TJ; ROSEN, BR				TOOTELL, RBH; REPPAS, JB; DALE, AM; LOOK, RB; SERENO, MI; MALACH, R; BRADY, TJ; ROSEN, BR			VISUAL-MOTION AFTEREFFECT IN HUMAN CORTICAL AREA MT REVEALED BY FUNCTIONAL MAGNETIC-RESONANCE-IMAGING	NATURE			English	Article							HUMAN BRAIN; SENSORY STIMULATION; CORTEX; INFORMATION; ACTIVATION; ADAPTATION; MOVEMENT	FUNCTIONAL magnetic resonance imaging (fMRI)(1-3) was used to measure local haemodynamic changes (reflecting electrical activity) in human visual cortex during production of the visual motion aftereffect, also known as the waterfall illusion(4,5). As in previous studies(6-9), human cortical area MT (V5) responded much better to moving than to stationary visual stimuli. Here we demonstrate a clear increase in activity in MT when subjects viewed a stationary stimulus undergoing illusory motion, following adaptation to stimuli moving in a single local direction. Control stimuli moving in reversing, opposed directions produced neither a perceptual motion aftereffect nor elevated fMRI levels postadaptation. The time course of the motion aftereffect (measured in parallel psychophysical tests) was essentially identical to the time course of the fMRI motion aftereffect. Because the motion aftereffect is direction specific, this indicates that cells in human area MT are also direction specific. In five other retinotopically defined cortical areas, similar motion-specific aftereffects were smaller than those in MT or absent.	UNIV CALIF SAN DIEGO, DEPT COGNIT SCI, LA JOLLA, CA 92093 USA; UNIV OSLO, DEPT NEUROPHYSIOL, OSLO, NORWAY	University of California System; University of California San Diego; University of Oslo	TOOTELL, RBH (corresponding author), MASSACHUSETTS GEN HOSP, NUCL MAGNET RESONANCE CTR, 149 13TH ST, BOSTON, MA 02129 USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829				ADAMS R, 1834, PHILOS MAG, V5, P373; ALIMAN JM, 1981, CORTICAL SENSORY ORG, V2, P171; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; CARNEY T, 1993, VISION RES, V33, P1977, DOI 10.1016/0042-6989(93)90022-O; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DUPONT P, 1994, J NEUROPHYSIOL, V72, P1420, DOI 10.1152/jn.1994.72.3.1420; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Frith CD, 1995, HUM BRAIN MAPP, V3, P153, DOI 10.1002/hbm.460030209; HAMMOND P, 1985, EXP BRAIN RES, V60, P411; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; MARTIN SG, 1988, J NEUROPHYSIOL, V59, P1314; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; NISHIDA S, 1994, VISION RES, V34, P2707, DOI 10.1016/0042-6989(94)90227-5; NISHIDA S, 1992, VISION RES, V32, P1635, DOI 10.1016/0042-6989(92)90156-D; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PETERSEN SE, 1985, BRAIN RES, V346, P146, DOI 10.1016/0006-8993(85)91105-9; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; SERENO MI, IN PRESS SCIENCE; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; VONDERHEYDT R, 1978, ARCH ITAL BIOL, V116, P248; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI S, 1993, P ROY SOC B-BIOL SCI, V252, P215, DOI 10.1098/rspb.1993.0068	30	452	459	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	1995	375	6527					139	141		10.1038/375139a0	http://dx.doi.org/10.1038/375139a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753168				2022-12-01	WOS:A1995QX74100049
J	VALITUTTI, S; MULLER, S; CELLA, M; PADOVAN, E; LANZAVECCHIA, A				VALITUTTI, S; MULLER, S; CELLA, M; PADOVAN, E; LANZAVECCHIA, A			SERIAL TRIGGERING OF MANY T-CELL RECEPTORS BY A FEW PEPTIDE-MHC COMPLEXES	NATURE			English	Article							PROTEIN KINASE-C; CLASS-II; ANTIGEN RECEPTOR; RECOGNITION; EXPRESSION; BINDING	T LMPHOCYTES can recognize and be activated by a very small number of complexes of peptide with major histocompatibility complex (MHC) molecules displayed on the surface of antigen-presenting cells (APCs)(1,2). The interaction between the T-cell receptor (TCR) and its ligand has low affinity and high off-rate(3-6). Both findings suggest that an extremely small number of TCRs must be engaged in interaction with APCs and raise the question of how so few receptors can transduce an activation signal. Here we show that a small number of peptide-MHC complexes can achieve a high TCR occupancy, because a single complex can serially engage and trigger up to similar to 200 TCRs, Furthermore, TCR occupancy is proportional to the T cell's biological response. Our findings suggest that the lovv affinity of the TCR can be instrumental in enabling a small number of antigenic complexes to be detected.			VALITUTTI, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Cella, Marina/G-8850-2011; Valitutti, Salvatore/M-2999-2014; Cella, Marina/ABA-8564-2020	Valitutti, Salvatore/0000-0002-6432-4421; Cella, Marina/0000-0003-1230-1313; Padovan, Elisabetta/0000-0002-8212-508X				BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CLARKE GR, 1994, EUR J IMMUNOL, V24, P837, DOI 10.1002/eji.1830240410; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LUTON F, 1994, J IMMUNOL, V153, P63; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; PADOVAN E, 1995, J EXP MED, V181, P1587, DOI 10.1084/jem.181.4.1587; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VOGT RF, 1989, CYTOMETRY, V10, P294, DOI 10.1002/cyto.990100308; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS AF, 1992, NATURE, V356, P746, DOI 10.1038/356746a0	25	970	988	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					148	151		10.1038/375148a0	http://dx.doi.org/10.1038/375148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753171				2022-12-01	WOS:A1995QX74100052
J	PSATY, BM; KOEPSELL, TD; YANEZ, ND; SMITH, NL; MANOLIO, TA; HECKBERT, SR; BORHANI, NO; GARDIN, JM; GOTTDIENER, JS; RUTAN, GH; SISCOVICK, DS; FURBERG, CD				PSATY, BM; KOEPSELL, TD; YANEZ, ND; SMITH, NL; MANOLIO, TA; HECKBERT, SR; BORHANI, NO; GARDIN, JM; GOTTDIENER, JS; RUTAN, GH; SISCOVICK, DS; FURBERG, CD			TEMPORAL PATTERNS OF ANTIHYPERTENSIVE MEDICATION USE AMONG OLDER ADULTS, 1989 THROUGH 1992 - AN EFFECT OF THE MAJOR CLINICAL-TRIALS ON CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR HEALTH; HIP FRACTURE; HYPERTENSION; DISEASE; RISK	Objective.-To describe the changing patterns of antihypertensive medication use in the years immediately before and after the publication of the results of three major clinical trials of the treatment of hypertension in older adults. Design.-In this cohort study, adults 65 years or older were examined annually on four occasions between June 1989 and May 1992, and the use of antihypertensive medications was assessed by inventory at each visit. The four visits defined the boundaries of three study periods. For each study period, participants receiving antihypertensive therapy were either continuous users (n = 1667, 1643, and 1605, respectively) or starters (n = 157, 142, 120) of hypertensive therapy. The large clinical trials that convincingly proved the efficacy and safety of low-dose diuretic therapy in older adults were published during the latter parts of period 2 and the early parts of period 3. Results.-Among starters, the proportion initiating therapy on diuretics increased from 35.9% in period 2 to 47.5% in period 3, significantly so among women (P=.04). The proportions initiating other drugs displayed no significant trends. Among continuous users, the use of diuretics, beta-blockers, and vasodilators generally decreased over the 3-year period, while the use of calcium channel blockers and angiotensin-converting enzyme inhibitors increased significantly in each of the three periods (P<.05). The decline of 2.7% in the prevalence of diuretic use in period 1 abated during period 2 (1.8% decline), and it slowed significantly (P=.03) to almost a complete halt during period 3 (0.2% decline). The rate of increase in the use of calcium channel blockers slowed significantly (P=.01) between period 1 (+6.7%) and period 3 (+2.8%). Conclusions.-Although other factors such as cost may have been important, the temporal trends in antihypertensive drug therapy coincided in time with and may have reflected in part the influence of the major clinical trials on the patterns of clinical practice.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98101; UNIV WASHINGTON,CTR CARDIOVASC HLTH STUDY COORDINATING,SEATTLE,WA 98101; NHLBI,BETHESDA,MD 20892; UNIV CALIF IRVINE,DIV CARDIOL,IRVINE,CA 92717; GEORGETOWN UNIV HOSP,DIV CARDIOL,WASHINGTON,DC 20007; VET ADM MED CTR,MEMPHIS,TN 38104; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Irvine; Georgetown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	PSATY, BM (corresponding author), UNIV WASHINGTON,DEPT MED,CARDIOVASC HLTH RES UNIT,1730 MINOR AVE,SUITE 1360,SEATTLE,WA 98101, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085080, N01HC085079, N01HC085081] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85080, N01-HC-85079, H01-HC-85081] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FURBERG CD, 1994, J INTERN MED, V235, P387, DOI 10.1111/j.1365-2796.1994.tb01093.x; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HUNE AL, 1993, PHARMACOTHERAPY, V13, P244; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OPARIL S, 1993, NEW ENGL J MED, V328, P959, DOI 10.1056/NEJM199304013281311; PASTY BM, 1993, HYPERTENSION PRIMER, P197; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RAY WA, 1989, LANCET, V1, P687; RAY WA, 1986, AM J MED, V81, P9, DOI 10.1016/0002-9343(86)90522-X; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; 1993, ARCH INTERN MED, V153, P154; 1994, HYPERTENSION, V23, P275; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	23	66	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1436	1438		10.1001/jama.273.18.1436	http://dx.doi.org/10.1001/jama.273.18.1436			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723157				2022-12-01	WOS:A1995QW27900031
J	van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM				van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM			CHANGES IN DUTCH OPINIONS ON ACTIVE EUTHANASIA, 1966 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL DECISIONS; LIFE; END		UNIV UTRECHT, CTR BIOETH & HLTH LAW, ROTTERDAM, NETHERLANDS	Utrecht University	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							Adriaansens H. P. M., 1981, VRIJWILLIG INITIATIE; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Ester P., 1993, INDIVIDUALIZING SOC; Inglehart RonaldF., 1977, SILENT REVOLUTION; Mayer William G., 1992, CHANGING AM MIND WHY; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; SCHUYT C, 1991, OP ZOEK NAAR HART VE; Seper F., 1980, DECLARATION EUTHANAS; Stimson J. A., 1991, PUBLIC OPINION AM MO; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; 1994, 1994 SOC CULT PLANN; 1988, EUTHANASIE PASTORAAT; 1987, BIOETHICS, V1, P163	15	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1411	1414		10.1001/jama.273.18.1411	http://dx.doi.org/10.1001/jama.273.18.1411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723147				2022-12-01	WOS:A1995QW27900010
J	BLACKSTONE, M				BLACKSTONE, M			COLORECTAL ADENOMAS ON FOLLOW-UP COLONOSCOPY - IS THE CANCER RISK UNCHANGED	LANCET			English	Editorial Material							POLYPS				BLACKSTONE, M (corresponding author), UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637, USA.							ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; NEUGUT AI, 1995, GASTROENTEROLOGY, V108, P402, DOI 10.1016/0016-5085(95)90066-7; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	7	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1126	1127		10.1016/S0140-6736(95)90970-2	http://dx.doi.org/10.1016/S0140-6736(95)90970-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723538				2022-12-01	WOS:A1995QW62200002
J	BOGOD, D				BOGOD, D			ADVANCES IN EPIDURAL ANALGESIA FOR LABOR - PROGRESS VERSUS PRUDENCE	LANCET			English	Editorial Material											BOGOD, D (corresponding author), CITY HOSP,DEPT ANAESTHESIA,NOTTINGHAM NG5 1PB,ENGLAND.							CHAMBERLAIN G, 1993, PAIN ITS RELIEF CHIL, P50; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; GAMBLING DR, 1988, ANESTH ANALG, V33, P249; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299; SMEDSTAD KG, 1988, CAN J ANAESTH, V35, P234, DOI 10.1007/BF03010616	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1129	1130		10.1016/S0140-6736(95)90973-7	http://dx.doi.org/10.1016/S0140-6736(95)90973-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723541				2022-12-01	WOS:A1995QW62200005
J	FERGUSON, AE; GIBSON, NA; AITCHISON, TC; PATON, JY				FERGUSON, AE; GIBSON, NA; AITCHISON, TC; PATON, JY			MEASURED BRONCHODILATOR USE IN PRESCHOOL-CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							MEDICATION	Objective-To investigate how parents use bronchodilator treatment for relief of symptoms when treating their asthmatic preschool children. Design-A commercial electromechanical timer device was attached to a large volume spacer to record the time and date of each use of inhaled bronchodilator over two months. The recorded time and dates were compared with symptoms noted in an asthma diary card. Setting-Large paediatric teaching hospital in Glasgow. Subjects-29 preschool children with moderately severe asthma attending a specialist paediatric asthma clinic. Main outcome measures-Inhaler use measured by the timer device; symptoms and inhaler use recorded by parents in a daily asthma diary. Results-Satisfactory data were obtained in 22 of the 29 children; the median number of study days was 53 (range 18-77). Asthmatic symptoms were recorded on a median of 30 (3-77) days. Bronchodilator was used on a median of 19 (2-73) days, or on 63% (7-100%) of days when symptoms occurred. The median number of puffs used in a day was 1 (range 0-100) and was significantly related to symptom severity in only 14 of the 22 children. In only two of the 22 children was bronchodilator given more frequently than four hourly, and only five children ever used more than 12 puffs a day. Conclusions-The frequency of parental administration of bronchodilator treatment was variable and not closely related to the parent's record of symptom severity. Parents often recorded symptoms in their children but did not treat them.	UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow	FERGUSON, AE (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,LANARK,SCOTLAND.							[Anonymous], 1993, THORAX, V48, pS1; ARCHER LNJ, 1985, ARCH DIS CHILD, V60, P473, DOI 10.1136/adc.60.5.473; BOSLEY CM, 1994, EUR RESPIR J, V7, P504, DOI 10.1183/09031936.94.07030504; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; GLEESON JGA, 1988, BRIT J DIS CHEST, V82, P172, DOI 10.1016/0007-0971(88)90039-3; Lenny W, 1994, EUR RESPIR REV, V4, P49; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1161	1164		10.1136/bmj.310.6988.1161	http://dx.doi.org/10.1136/bmj.310.6988.1161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767149	Green Published			2022-12-01	WOS:A1995QX56600019
J	GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; SCHNOHR, P; JENSEN, G				GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; SCHNOHR, P; JENSEN, G			MORTALITY ASSOCIATED WITH MODERATE INTAKES OF WINE, BEER, OR SPIRITS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; RED WINE; RISK; WOMEN; MEN	Objective-To examine the association between intake of different types of alcoholic drinks and mortality. Design-Prospective population study with baseline assessment of alcohol intake, smoking habit, income, education, and body mass index, and 10-12 years' follow up of mortality. Setting-Copenhagen city heart study, Denmark. Subjects-6051 men and 7234 women aged 30-70 years. Main outcome measure-Number and time of cause-specific deaths from 1976 to 1988. Results-The risk of dying steadily decreased with an increasing intake of wine-from a relative risk of 1.00 for the subjects who never drank wine to 0.51 (95% confidence interval 0.32 to 0.81) for those who drank three to five glasses a day. Intake of neither beer nor spirits, however, was associated with reduced risk. For spirits intake the relative risk of dying increased from 1.00 for those who never drank to 1.34 (1.05 to 1.71) for those with an intake of three to five drinks a day. The effects of the three types of alcoholic drinks seemed to be independent of each other, and no significant interactions existed with sex, age, education, income, smoking, or body mass index. Wine drinking showed the same relation to risk of death from cardiovascular and cerebrovascular disease as to risk of death from all causes. Conclusion-Low to moderate intake of wine is associated with lower mortality from cardiovascular and cerebrovascular disease and other causes. Similar intake of spirits implied an increased risk, while beer drinking did not affect mortality.	COPENHAGEN HOSP CORP,INST PREVENT MED,DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK; DANISH COMM ASSESSMENT SUBSTAND LIVES,COPENHAGEN,DENMARK; UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT MED GASTROENTEROL,ALCOHOL UNIT,DK-1168 COPENHAGEN,DENMARK; UNIV COPENHAGEN,RIGSHOSP,DEPT 7117,COPENHAGEN CITY HEART STUDY,DK-2100 COPENHAGEN,DENMARK	Aarhus University; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen			Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Gronbaek, Morten Klocker/0000-0002-8473-6474				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BOFFETTA P, 1990, EPIDEMIOLOGY, V1, P337; Carnacini A, 1994, ALCOLOGIA, V6, P41; CHEN J, 1992, INT J EPIDEMIOL, V2, P625; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; Gerdes L U, 1992, Ugeskr Laeger, V154, P3580; GRONBAEK M, 1994, BRIT MED J, V308, P302, DOI 10.1136/bmj.308.6924.302; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HENNEKENS CH, 1979, JAMA-J AM MED ASSOC, V242, P1973, DOI 10.1001/jama.242.18.1973; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KIMBALL AW, 1992, AM J EPIDEMIOL, V135, P1287, DOI 10.1093/oxfordjournals.aje.a116235; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KOZARAREVIC DJ, 1980, LANCET, V1, P613; MARMOT MG, 1981, LANCET, V1, P580; McCullagh P., 1983, GEN LINEAR MODELS, DOI 10.1007/978-1-4899-3244-0; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; SAELAN H, 1993, ALCOHOL DRUG ABUSE 1; SEIGNEUR M, 1990, J APPL CARDIOL, V5, P215; SHAPER AG, 1988, LANCET, V1, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801	31	495	504	2	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1165	1169		10.1136/bmj.310.6988.1165	http://dx.doi.org/10.1136/bmj.310.6988.1165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767150	Green Published			2022-12-01	WOS:A1995QX56600021
J	KALE, R				KALE, R			SOUTH-AFRICA HEALTH - TRADITIONAL HEALERS IN SOUTH-AFRICA - A PARALLEL HEALTH-CARE SYSTEM	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES											FREEMAN M, 1992, SOC SCI MED, V34, P1183, DOI 10.1016/0277-9536(92)90311-D; GRAHAM R, 1993, WHITE WOMAN WITCH DO, V229, P234; KARIM SSA, 1992, BRINDGING GAP PROJEC; MCVANN A, 1992, S AFR MED J, V81, P139; SEGAL I, 1994, BARAGWANATH HOSPITAL, P17; VANRENSBURG HCJ, 1982, PROFILE DISEASE HLTH, P180; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q; WOOD R, 1990, S AFR MED J, V77, P640	8	116	119	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1182	1185		10.1136/bmj.310.6988.1182	http://dx.doi.org/10.1136/bmj.310.6988.1182			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767156	Green Published			2022-12-01	WOS:A1995QX56600030
J	KELLY, DA; STANTON, A				KELLY, DA; STANTON, A			JAUNDICE IN BABIES - IMPLICATIONS FOR COMMUNITY SCREENING FOR BILIARY ATRESIA	BRITISH MEDICAL JOURNAL			English	Article								Although prompt referral of babies with biliary atresia ensures early surgery and improves outcome,(1) late referral persists in the United Kingdom, leading to calls for systematic screening of babies with neonatal jaundice persisting beyond 14 days.(2) This would entail reviewing the baby, establishing whether the stool is pigmented, testing urine for bilirubin, and measuring blood concentrations of conjugated and unconjugated bilirubin.(2 3) To evaluate the feasibility of systematic screening, we ascertained the prevalence of (a) jaundice in babies aged 2, 4, and 6 weeks, and (b) dark urine or pale stools as reported by the parents or a health visitor. We also established how often stools or urine of jaundiced babies were noted by health visitors at their first visit to gauge the effect on workload.	SOLIHULL HEALTHCARE NATL HLTH SERV TRUST,BIRMINGHAM B37 7XR,W MIDLANDS,ENGLAND; CHILDRENS HOSP,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND									FRIEDMAN L, 1978, BRIT MED J, V1, P1235, DOI 10.1136/bmj.1.6122.1235; HUSSEIN M, 1991, ARCH DIS CHILD, V66, P1177, DOI 10.1136/adc.66.10.1177; MACKINLAY GA, 1993, BRIT MED J, V306, P1426, DOI 10.1136/bmj.306.6890.1426; NELSON R, 1989, BRIT MED J, V298, P1471, DOI 10.1136/bmj.298.6686.1471; WINFIELD CR, 1978, ARCH DIS CHILD, V53, P506, DOI 10.1136/adc.53.6.506	5	35	38	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1172	1173		10.1136/bmj.310.6988.1172	http://dx.doi.org/10.1136/bmj.310.6988.1172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767152	Green Published			2022-12-01	WOS:A1995QX56600029
J	PETERSEN, C				PETERSEN, C			CRYPTOSPORIDIUM AND THE FOOD-SUPPLY	LANCET			English	Editorial Material											PETERSEN, C (corresponding author), SAN FRANCISCO GEN HOSP,DIV INFECT DIS,SAN FRANCISCO,CA 94110, USA.							BIER JW, 1991, J TROP MED PUBL 1222, pS144; DUPONT HL, IN PRESS N ENGL J ME; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCANULTY JM, 1994, JAMA-J AM MED ASSOC, V272, P1597, DOI 10.1001/jama.272.20.1597; MCGOWAN I, 1993, AIDS, V7, P349, DOI 10.1097/00002030-199303000-00007; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; MOLBAK K, 1993, BRIT MED J, V307, P417, DOI 10.1136/bmj.307.6901.417; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; Ungar B. L. P., 1990, Cryptosporidiosis of man and animals., P59	10	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1128	1129		10.1016/S0140-6736(95)90972-9	http://dx.doi.org/10.1016/S0140-6736(95)90972-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723540				2022-12-01	WOS:A1995QW62200004
J	ROLFE, S; HARPER, NJN				ROLFE, S; HARPER, NJN			ABILITY OF HOSPITAL DOCTORS TO CALCULATE DRUG DOSES	BRITISH MEDICAL JOURNAL			English	Article											ROLFE, S (corresponding author), MANCHESTER ROYAL INFIRM,DEPT ANAESTHESIA,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.							MULLER NF, 1992, EUROPEAN DRUG INDEX; SCRIMSHIRE JA, 1989, BRIT MED J, V298, P1497; 1994, AMPOULE LABELS NHS S; 1993, BRIT MED J, V306, P1589	4	66	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1173	1174		10.1136/bmj.310.6988.1173	http://dx.doi.org/10.1136/bmj.310.6988.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767153	Green Published			2022-12-01	WOS:A1995QX56600023
J	STEPHENS, R; SPURGEON, A; CALVERT, IA; BEACH, J; LEVY, LS; BERRY, H; HARRINGTON, JM				STEPHENS, R; SPURGEON, A; CALVERT, IA; BEACH, J; LEVY, LS; BERRY, H; HARRINGTON, JM			NEUROPSYCHOLOGICAL EFFECTS OF LONG-TERM EXPOSURE TO ORGANOPHOSPHATES IN SHEEP DIP	LANCET			English	Article							BEHAVIORAL-EVALUATION; PESTICIDES; WORKERS; SYSTEM	Organophosphate-based pesticides are widely used throughout the world. The acute effects of over-exposure to such compounds are well known. Concern has also been expressed that long-term exposure may result in damage to the nervous system. In a cross-sectional study, we compared neuropsychological performance in 146 sheep farmers who were exposed to organophosphates in the course of sheep dipping with 143 non-exposed quarry workers (controls). The farmers performed significantly worse than controls in tests to assess sustained attention and speed of information processing. These effects remained after adjustment for covariates. The farmers also showed greater vulnerability to psychiatric disorder than did the controls as measured by the General Health Questionnaire. There were no observed effects on short-term memory and learning. Repeated exposure to organophosphate-based pesticides appears to be associated with subtle changes in the nervous system. Measures should be taken to reduce exposure to organophosphates as far as possible during agricultural operations.	UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; HLTH & SAFETY EXECUT,OCCUPAT MED & HYG LAB,SHEFFIELD S3 7HQ,S YORKSHIRE,ENGLAND	University of Birmingham			Stephens, Richard/C-4062-2009	Stephens, Richard/0000-0002-5851-8975				BAKER EL, 1985, J OCCUP ENVIRON MED, V27, P206; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; DAVIES JE, 1991, AM J IND MED, V18, P327; DILLNER L, 1994, BRIT MED J, V308, P1001, DOI 10.1136/bmj.308.6935.1001; Gallo M.A., 1991, HDB PESTICIDE TOXICO, V2; GOLDBERG D, 1985, BRIT MED J, V291, P161, DOI 10.1136/bmj.291.6489.161; MAIZLISH N, 1987, AM J IND MED, V12, P153, DOI 10.1002/ajim.4700120205; MEARNS J, 1994, J CLIN PSYCHOL, V50, P286, DOI 10.1002/1097-4679(199403)50:2<286::AID-JCLP2270500223>3.0.CO;2-P; NIVEN KJM, 1993, IOM TM9303 I OCC MED; NUTLEY BP, 1993, PESTIC SCI, V38, P315, DOI 10.1002/ps.2780380406; RODNITZKY RL, 1975, ARCH ENVIRON HEALTH, V30, P98, DOI 10.1080/00039896.1975.10666651; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; STEENLAND K, 1994, AM J PUBLIC HEALTH, V84, P5; STOLLERY BT, 1988, SCAND J WORK ENV HEA, V14, P45, DOI 10.5271/sjweh.1951; STOLLERY BT, 1990, MICROCOMPUTERS PSYCH	16	240	250	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1135	1139		10.1016/S0140-6736(95)90976-1	http://dx.doi.org/10.1016/S0140-6736(95)90976-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW622	7723544				2022-12-01	WOS:A1995QW62200008
J	SULLIVAN, EA; KREISWIRTH, BN; PALUMBO, L; KAPUR, V; MUSSER, JM; EBRAHIMZADEH, A; FRIEDEN, TR				SULLIVAN, EA; KREISWIRTH, BN; PALUMBO, L; KAPUR, V; MUSSER, JM; EBRAHIMZADEH, A; FRIEDEN, TR			EMERGENCE OF FLUOROQUINOLONE-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY	LANCET			English	Note							CIPROFLOXACIN	22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.	NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; PUBL HLTH RES INST,CTR TB,NEW YORK,NY; BAYLOR COLL MED,DEPT PATHOL,MOLEC PATHOBIOL SECT,HOUSTON,TX 77030	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Baylor College of Medicine			Sullivan, Elizabeth A/V-6742-2017; Kapur, Vivek/F-7610-2013	Sullivan, Elizabeth A/0000-0002-8718-2753; Kapur, Vivek/0000-0002-9648-0138	NIAID NIH HHS [AI-37004, AI-09238] Funding Source: Medline; NIDA NIH HHS [DA-09238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CAMBAU E, 1994, J INFECT DIS, V170, P479, DOI 10.1093/infdis/170.2.479; COLLINS CH, 1985, J ANTIMICROB CHEMOTH, V16, P575, DOI 10.1093/jac/16.5.575; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HOFFKEN G, 1985, EUR J CLIN MICROBIOL, V4, P345, DOI 10.1007/BF02013667; KAHANA LM, 1992, DCIP ANN PHARMACOTHE, V25, P919; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KENNEDY N, 1993, AM REV RESPIR DIS, V148, P1547, DOI 10.1164/ajrccm/148.6_Pt_1.1547; Kent PT, 1985, GUIDE LEVEL 3 LAB; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; 1992, TUBERCLE LUNG DIS, V73, P59	10	105	112	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1148	1150		10.1016/S0140-6736(95)90980-X	http://dx.doi.org/10.1016/S0140-6736(95)90980-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723548				2022-12-01	WOS:A1995QW62200012
J	WILLEMSEN, R; MOHKAMSING, S; DEVRIES, B; DEVYS, D; VANDENOUWELAND, A; MANDEL, JL; GALJAARD, H; OOSTRA, B				WILLEMSEN, R; MOHKAMSING, S; DEVRIES, B; DEVYS, D; VANDENOUWELAND, A; MANDEL, JL; GALJAARD, H; OOSTRA, B			RAPID ANTIBODY-TEST FOR FRAGILE-X SYNDROME	LANCET			English	Note							CGG REPEAT; FMR-1; CARRIERS	Fragile X syndrome is the most common known cause of inherited mental retardation. Identification of patients and carriers of fragile X syndrome is usually done with a DNA test system but we have developed a rapid antibody to identify fragile X patients. This non-invasive test requires only 1 or 2 drops of blood and can be used for screening large groups of mentally retarded people and neonates for fragile X syndrome.	ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV STRASBOURG 1,CU,INSERM,CNRS,INST GENET & BIOL MOLEC & CELLULAIRE,STRASBOURG,FRANCE	Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Devys, Didier/0000-0001-9655-3512				DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; OOSTRA BA, 1993, J MED GENET, V30, P410, DOI 10.1136/jmg.30.5.410; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536	9	137	140	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1147	1148		10.1016/S0140-6736(95)90979-6	http://dx.doi.org/10.1016/S0140-6736(95)90979-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723547				2022-12-01	WOS:A1995QW62200011
J	WILLIAMS, AC				WILLIAMS, AC			DOPAMINE, DYSTONIA, AND THE DEFICIENT COFACTOR	LANCET			English	Editorial Material							TETRAHYDROBIOPTERIN				WILLIAMS, AC (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							FINK JK, 1988, NEUROLOGY, V38, P707, DOI 10.1212/WNL.38.5.707; FURUKAWA Y, 1993, ADV NEUROL, V60, P562; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; LEWITT PA, 1986, NEUROLOGY, V36, P760, DOI 10.1212/WNL.36.6.760; LOVENBERG W, 1979, SCIENCE, V204, P624, DOI 10.1126/science.432666; NYGAARD TG, 1993, NAT GENET, V5, P386, DOI 10.1038/ng1293-386; RAJPUT AH, 1994, ANN NEUROL, V35, P396, DOI 10.1002/ana.410350405; Segawa M., 1971, SHINRYO TOKYO, V24, P667; TAKAHASHI H, 1994, ANN NEUROL, V35, P354, DOI 10.1002/ana.410350317; WILLIAMS A, 1979, LANCET, V2, P410; WILLIAMS AC, 1980, J NEUROL NEUROSUR PS, V43, P735, DOI 10.1136/jnnp.43.8.735	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1130	1130		10.1016/S0140-6736(95)90974-5	http://dx.doi.org/10.1016/S0140-6736(95)90974-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723542				2022-12-01	WOS:A1995QW62200006
J	ALLEN, GJ; MUIR, SR; SANDERS, D				ALLEN, GJ; MUIR, SR; SANDERS, D			RELEASE OF CA2+ FROM INDIVIDUAL PLANT VACUOLES BY BOTH INSP(3) AND CYCLIC ADP-RIBOSE	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; CYTOPLASMIC CALCIUM; CHANNELS; MICROSOMES; MEMBRANE; PATHWAYS	Calcium mobilization from intracellular pools couples many stimuli to responses in plant cells. Cyclic adenosine 5'-diphosphoribose (cADPR), which interacts with a ryanodine receptor in certain animal cells, was shown to elicit calcium release at the vacuolar membrane of beet storage root. The vacuolar calcium release pathway showed similarities to cADPR-gated calcium release in animal cells, including inhibition by ruthenium red, ryanodine activation, and high affinity for cADPR [Michaelis constant (K-m) = 24 +/- 7 nanomolar]. Analysis by patch-clamping demonstrated that the cADPR-gated pathway in beet is voltage-dependent over the physiological range, does not spontaneously desensitize, and is colocalized with an inositol 1,4,5-trisphosphate (InsP(3))-gated calcium release pathway in individual vacuoles.			ALLEN, GJ (corresponding author), UNIV YORK, DEPT BIOL, PLANT LAB, POB 373, YORK YO1 5YW, N YORKSHIRE, ENGLAND.							ALEXANDRE J, 1990, NATURE, V343, P567, DOI 10.1038/343567a0; ALLEN GJ, 1994, PLANT CELL, V6, P685, DOI 10.1105/tpc.6.5.685; ALLEN GJ, 1994, PLANT J, V6, P687, DOI 10.1046/j.1365-313X.1994.6050687.x; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROSNAN JM, 1990, NATURE, V344, P593, DOI 10.1038/344593b0; BROSNAN JM, 1990, FEBS LETT, V260, P70, DOI 10.1016/0014-5793(90)80068-T; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COTE GG, 1994, BIOESSAYS, V16, P39, DOI 10.1002/bies.950160106; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GILROY S, 1993, J CELL SCI, V106, P453; HEDRICH R, 1987, NATURE, V329, P833, DOI 10.1038/329833a0; JOHANNES E, 1992, PLANT J, V2, P97, DOI 10.1111/j.1365-313X.1992.00097.x; JOHANNES E, 1992, PHILOS T R SOC B, V338, P105, DOI 10.1098/rstb.1992.0134; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WARD JM, 1994, PLANT CELL, V6, P669; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	32	282	296	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					735	737		10.1126/science.7732384	http://dx.doi.org/10.1126/science.7732384			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732384				2022-12-01	WOS:A1995QW60300053
J	ARPIN, C; DECHANET, J; VANKOOTEN, C; MERVILLE, P; GROUARD, G; BRIERE, F; BANCHEREAU, J; LIU, YJ				ARPIN, C; DECHANET, J; VANKOOTEN, C; MERVILLE, P; GROUARD, G; BRIERE, F; BANCHEREAU, J; LIU, YJ			GENERATION OF MEMORY B-CELLS AND PLASMA-CELLS IN-VITRO	SCIENCE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; ANTIGEN; CD40; LYMPHOCYTES; EXPRESSION; IGM	After germinal center B cells undergo somatic mutation and antigen selection, they become either memory B cells or plasma cells, but the signal requirements that control entry into either pathway have been unclear. When purified human germinal center cells were cultured with interleukin-2, interleukin-10, and cells expressing CD40 ligand, cells with characteristics of memory B cells were generated. Removal of CD40 ligand from the system resulted in terminal differentiation of germinal center B cells into cells with the characteristics of plasma cells. These results indicate that CD40 ligand directs the differentiation of germinal center B cells toward memory B cells rather than toward plasma cells.	SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE	Merck & Company; Schering Plough Corporation			van Kooten, Cees/E-5694-2018; Arpin, Christophe/M-3862-2014	van Kooten, Cees/0000-0002-6257-0899; Arpin, Christophe/0000-0003-0915-5554				ANDERSSON J, 1994, IMMUNOLOGY, V83, P16; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BUTCH AW, 1993, J IMMUNOL, V150, P39; CASAMAJORPALLEJ.M, IN PRESS J EXP MED; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; COLCO RF, 1983, J IMMUNOL, V131, P2254; FLUCKIGER AC, 1993, J EXP MED, V178, P1473, DOI 10.1084/jem.178.5.1473; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; HARADA H, 1993, BLOOD, V81, P2658; HOLDER MJ, 1993, INT IMMUNOL, V5, P1059, DOI 10.1093/intimm/5.9.1059; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOSCO MH, 1989, IMMUNOLOGY, V68, P312; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LIU YJ, IN PRESS IMMUNITY; LIU YJ, IN PRESS HDB EXPT IM, V2; MACHEYZERWILLIA.MG, 1993, J EXP MED, V178, P295; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; STROBER S, 1976, J IMMUNOL, V117, P1288; THORBECKE GJ, 1994, FASEB J, V8, P832, DOI 10.1096/fasebj.8.11.8070632; VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402; VANKOOTEN C, UNPUB; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	34	489	496	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					720	722		10.1126/science.7537388	http://dx.doi.org/10.1126/science.7537388			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7537388				2022-12-01	WOS:A1995QW60300049
J	BARBERIS, A; PEARLBERG, J; SIMKOVICH, N; FARRELL, S; REINAGEL, P; BAMDAD, C; SIGAL, G; PTASHNE, M				BARBERIS, A; PEARLBERG, J; SIMKOVICH, N; FARRELL, S; REINAGEL, P; BAMDAD, C; SIGAL, G; PTASHNE, M			CONTACT WITH A COMPONENT OF THE POLYMERASE-II HOLOENZYME SUFFICES FOR GENE ACTIVATION	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; SACCHAROMYCES-CEREVISIAE; GAL11 PROTEIN; INITIATION; BINDING; COMPLEX; MECHANISM; GALACTOSE; MUTATION; DOMAIN	In yeast strains bearing the point mutation called GAL11P (for potentiator), certain GAL4 derivatives lacking any classical activating region work as strong activators. The P mutation confers upon GAL11, a component of the RNA polymerase II holoenzyme, the ability to interact with a portion of the dimerization region of GAL4, The region of GAL11 affected by the P mutation is evidently functionally inert in ordinary cells, suggesting that this mutation is of no functional significance beyond creating an artificial target for the GAL4 dimerization fragment. From these observations and further analyses of GAL11, we propose that a single activator-holoenzyme contact can trigger gene activation simply by recruiting the latter to DNA.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,PROGRAM BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Harvard University			Reinagel, Pamela/ABI-7659-2020	Reinagel, Pamela/0000-0002-6338-2611				BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1994, NATURE, V368, P402, DOI 10.1038/368402a0; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NOGI Y, 1980, CURR GENET, V2, P115, DOI 10.1007/BF00420623; PTASHNE M, 1992, GENETIC SWITCH GENE; PTASHNE M, 1988, NATURE, V335, P983; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REINAGEL P, 1994, THESIS HARVARD U CAM; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSE MD, 1990, METHODS YEAST GENETI; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SUZUKI Y, 1988, MOL CELL BIOL, V12, P4806; THOMPSON CM, 1993, CELL, V73, P1367; THOMPSON CM, 1995, IN PRESS P NATL ACAD; VALLIER LG, 1991, GENETICS, V129, P675; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	53	238	245	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					359	368		10.1016/0092-8674(95)90389-5	http://dx.doi.org/10.1016/0092-8674(95)90389-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736588	Bronze			2022-12-01	WOS:A1995QW89400008
J	FAN, CM; PORTER, JA; CHIANG, C; CHANG, DT; BEACHY, PA; TESSIERLAVIGNE, M				FAN, CM; PORTER, JA; CHIANG, C; CHANG, DT; BEACHY, PA; TESSIERLAVIGNE, M			LONG-RANGE SCLEROTOME INDUCTION BY SONIC HEDGEHOG - DIRECT ROLE OF THE AMINO-TERMINAL CLEAVAGE PRODUCT AND MODULATION BY THE CYCLIC-AMP SIGNALING PATHWAY	CELL			English	Article							POLARITY GENE HEDGEHOG; FLOOR PLATE; DROSOPHILA; NOTOCHORD; PROTEIN; EMBRYO	A long-range signal encoded by the Sonic hedgehog (Shh) gene has been implicated as the ventral patterning influence from the notochord that induces sclerotome and represses dermomyotome in somite differentiation. Long-range effects of hedgehog (hh) signaling have been suggested to result either from local induction of a secondary diffusible signal or from the direct action of the highly diffusible carboxyterminal product of HH autoproteolytic cleavage. Here we provide evidence that the long-range somite patterning effects of SHH are instead mediated by a direct action of the amino-terminal cleavage product. We also show that pharmacological manipulations to increase the activity of cyclic AMP-dependent protein kinase A can selectively antagonize the effects of the amino-terminal cleavage product. Our results support the operation of a single evolutionarily conserved signaling pathway for both local and direct long-range inductive actions of HH family members.	UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL & NEUROSCI,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Johns Hopkins University	FAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIRAGYN A, 1994, J IMMUNOL METHODS, V168, P235, DOI 10.1016/0022-1759(94)90060-4; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COLAMARINO SA, 1985, IN PRESS CELL, V81; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; JOHNSON RD, 1994, CELL, V79, P1166; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; READ AP, 1995, NAT GENET, V9, P333, DOI 10.1038/ng0495-333; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROELINK H, 1995, CELL, V81, P446; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TANABE Y, 1995, IN PRESS CURR BIOL; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	43	319	340	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					457	465		10.1016/0092-8674(95)90398-4	http://dx.doi.org/10.1016/0092-8674(95)90398-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736597	hybrid			2022-12-01	WOS:A1995QW89400017
J	FENG, Y; ZHANG, FP; LOKEY, LK; CHASTAIN, JL; LAKKIS, L; EBERHART, D; WARREN, ST				FENG, Y; ZHANG, FP; LOKEY, LK; CHASTAIN, JL; LAKKIS, L; EBERHART, D; WARREN, ST			TRANSLATIONAL SUPPRESSION BY TRINUCLEOTIDE REPEAT EXPANSION AT FMR1	SCIENCE			English	Article							FRAGILE-X-SYNDROME; EUKARYOTIC MESSENGER-RNAS; CGG-REPEAT; SECONDARY STRUCTURE; I LOCUS; INITIATION; INSTABILITY; METHYLATION; PROTEIN; GENE	Fragile X syndrome is the result of the unstable expansion of a trinucleotide repeat in the 5'-untranslated region of the FMR1 gene. Fibroblast subclones from a mildly affected patient, each containing stable FMR1 alleles with 57 to 285 CGG repeats, were shown to exhibit normal steady-state levels of FMR1 messenger RNA. However, FMR protein was markedly diminished from transcript with more than 200 repeats. Such transcripts were associated with stalled 40S ribosomal subunits. These results suggest that a structural RNA transition beyond 200 repeats impedes the linear 40S migration along the 5'-untranslated region. This results in translational inhibition by trinucleotide repeat expansion.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Howard Hughes Medical Institute; Emory University; Emory University			Warren, Stephen T/A-2498-2012	Feng, Yue/0000-0002-7905-2182	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAIRN SB, 1988, MOL CELL BIOL, V8, P1591; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DANOFF A, 1988, J BIOL CHEM, V263, P16461; DEVRIES BBA, 1993, EUR J HUM GENET, V1, P72; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FENG Y, 1995, AM J HUM GENET, V56, P106; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HAGERMAN R, UNPUB; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KNIGHT SJL, 1992, AM J MED GENET, V43, P217, DOI 10.1002/ajmg.1320430135; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRUYER H, 1994, AM J HUM GENET, V54, P437; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; MACDONALD ME, 1993, GENOME REARRANGEMENT, V7, pCH2; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MERENSTEIN SA, 1994, J AM ACAD CHILD PSY, V33, P1316, DOI 10.1097/00004583-199411000-00014; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SNOW K, 1993, AM J HUM GENET, V53, P1217; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STALEY L, 1993, AM J DIS CHILD, V147, P724; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Taylor A. K., 1994, American Journal of Human Genetics, V55, pA18; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	43	258	262	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					731	734		10.1126/science.7732383	http://dx.doi.org/10.1126/science.7732383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732383				2022-12-01	WOS:A1995QW60300052
J	FENTEANY, G; STANDAERT, RF; LANE, WS; CHOI, S; COREY, EJ; SCHREIBER, SL				FENTEANY, G; STANDAERT, RF; LANE, WS; CHOI, S; COREY, EJ; SCHREIBER, SL			INHIBITION OF PROTEASOME ACTIVITIES AND SUBUNIT-SPECIFIC AMINO-TERMINAL THREONINE MODIFICATION BY LACTACYSTIN	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; THERMOPLASMA-ACIDOPHILUM; MICROBIAL METABOLITE; NEUROBLASTOMA-CELLS; DEGRADATION; CYCLIN; GENE; SEQUENCE; PATHWAY	Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces neurite outgrowth in a murine neuroblastoma cell line. Tritium-labeled lactacystin was used to identify the 20S proteasome as its specific cellular target. Three distinct peptidase activities of this enzyme complex (trypsin-like, chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing activities) were inhibited by lactacystin, the first two irreversibly and all at different rates. None of five other proteases were inhibited, and the ability of lactacystin analogs to inhibit cell cycle progression and induce neurite outgrowth correlated with their ability to inhibit the proteasome. Lactacystin appears to modify covalently the highly conserved amino-terminal threonine of the mammalian proteasome subunit X (also called MB1), a close homolog of the LMP7 proteasome subunit encoded by the major histocompatibility complex. This threonine residue may therefore have a catalytic role, and subunit X/MB1 may be a core component of an amino-terminal-threonine protease activity of the proteasome.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University			Fenteany, Gabriel/F-4944-2018; Standaert, Robert F/D-9467-2013; Standaert, Robert F./AAI-1532-2021	Fenteany, Gabriel/0000-0001-7407-2195; Standaert, Robert F/0000-0002-5684-1322; Fenteany, Gabriel/0000-0003-0335-4587				AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DESS DB, 1991, J AM CHEM SOC, V113, P7277, DOI 10.1021/ja00019a027; DUGGLEBY HJ, 1995, NATURE, V373, P265; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRUH K, 1992, J BIOL CHEM, V267, P22131; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HAFFTER P, 1991, NUCLEIC ACIDS RES, V19, P5075, DOI 10.1093/nar/19.18.5075; HAGLER J, UNPUB; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; TANAKA K, 1992, NEW BIOL, V4, P173; TSUBUKI, 1993, BIOCHEM BIOPH RES CO, V96, P1195; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	35	1471	1531	5	105	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					726	731		10.1126/science.7732382	http://dx.doi.org/10.1126/science.7732382			6	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732382				2022-12-01	WOS:A1995QW60300051
J	FERNANDEZSALGUERO, P; PINEAU, T; HILBERT, DM; MCPHAIL, T; LEE, SST; KIMURA, S; NEBERT, DW; RUDIKOFF, S; WARD, JM; GONZALEZ, FJ				FERNANDEZSALGUERO, P; PINEAU, T; HILBERT, DM; MCPHAIL, T; LEE, SST; KIMURA, S; NEBERT, DW; RUDIKOFF, S; WARD, JM; GONZALEZ, FJ			IMMUNE-SYSTEM IMPAIRMENT AND HEPATIC-FIBROSIS IN MICE LACKING THE DIOXIN-BINDING AH RECEPTOR	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; GENETIC-DIFFERENCES; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; EXPRESSION; CLONING; CANCER; TOXICITY; LOCUS; CDNA	The aryl hydrocarbon (Ah) receptor (AHR) mediates many carcinogenic and teratogenic effects of environmentally toxic chemicals such as dioxin. An AHR-deficient (Ahr(-/-)) mouse line was constructed by homologous recombination in embryonic stem cells. Almost half of the mice died shortly after birth, whereas survivors reached maturity and were fertile. The Ahr(-/-) mice showed decreased accumulation of lymphocytes in the spleen and lymph nodes, but not in the thymus. The livers of Ahr(-/-) mice were reduced in size by 50 percent and showed bile duct fibrosis. Ahr(-/-) mice were also nonresponsive with regard to dioxin-mediated induction of genes encoding enzymes that catalyze the metabolism of foreign compounds, Thus, the AHR plays an important role in the development of the liver and the immune system.	NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,GENET LAB,BETHESDA,MD 20892; NIMH,MOLEC GENET UNIT,BETHESDA,MD 20892; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; NCI,OFF LAB ANIM SCI,VET & TUMOR PATHOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fernandez-Salguero, Pedro M./J-8437-2014	Fernandez-Salguero, Pedro M./0000-0003-2839-5027	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R01ES006811] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES06811, P30 ES06096] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BIRNBAUM LS, 1994, ENVIRON HEALTH PERSP, V102, P676, DOI 10.2307/3432197; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DEVITO MJ, 1994, TOXICOL APPL PHARM, V124, P82, DOI 10.1006/taap.1994.1011; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; HILBERT DM, 1993, EUR J IMMUNOL, V23, P2412, DOI 10.1002/eji.1830231006; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUOSKONEN H, 1994, TOXICOL APPL PHARM, V124, P174; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; LI H, 1994, J BIOL CHEM, V269, P28098; LI W, 1994, ARCH BIOCHEM BIOPHYS, V315, P279, DOI 10.1006/abbi.1994.1501; LUCIER GW, 1993, ENVIRON HEALTH PERSP, V101, P36, DOI 10.2307/3431569; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; ROBERTSON RW, 1994, NUCLEIC ACIDS RES, V22, P1741, DOI 10.1093/nar/22.9.1741; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SHEN ZY, 1994, DNA CELL BIOL, V13, P763, DOI 10.1089/dna.1994.13.763; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343	34	884	908	3	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					722	726		10.1126/science.7732381	http://dx.doi.org/10.1126/science.7732381			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732381				2022-12-01	WOS:A1995QW60300050
J	FULOP, V; MOIR, JWB; FERGUSON, SJ; HAJDU, J				FULOP, V; MOIR, JWB; FERGUSON, SJ; HAJDU, J			THE ANATOMY OF A BIFUNCTIONAL ENZYME - STRUCTURAL BASIS FOR REDUCTION OF OXYGEN TO WATER AND SYNTHESIS OF NITRIC-OXIDE BY CYTOCHROME CD(1)	CELL			English	Article							PSEUDOMONAS-AERUGINOSA; PARACOCCUS-DENITRIFICANS; THIOSPHAERA-PANTOTROPHA; PROTEIN; GENE; DEHYDROGENASE; REFINEMENT; RESOLUTION; LOCATION; SEQUENCE	Cytochrome cd(1)-nitrite reductase is a bifunctional enzyme that catalyzes the one-electron reduction of nitrite to nitric oxide and the four-electron reduction of oxygen to water. The 1.55 Angstrom crystal structure of the dimeric enzyme from Thiosphaera pantotropha is reported here. The protein was sequenced from the X-ray structure. Each subunit contains a covalent c heme with two axial His ligands (His-17, His-69) and a unique noncovalent d(1) heme ligated by Tyr-25 and His-200. The d(1) heme is the mononuclear iron center where both oxygen and nitrite reduction take place. The two types of heme are located in separate domains whose arrangement suggests a mechanism requiring domain movement during catalysis.	UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford	FULOP, V (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Fulop, Vilmos/AAZ-7720-2021	Moir, James/0000-0003-2972-5235				AKEY CW, 1980, J MOL BIOL, V136, P19, DOI 10.1016/0022-2836(80)90364-2; ALEFOUNDER PR, 1980, BIOCHEM J, V192, P231, DOI 10.1042/bj1920231; ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERGER H, 1980, BIOCHIM BIOPHYS ACTA, V622, P355, DOI 10.1016/0005-2795(80)90047-1; BLATT Y, 1979, BIOCHEMISTRY-US, V18, P2917, DOI 10.1021/bi00580a037; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHOTHIA C, 1993, STRUCTURE, V1, P217, DOI 10.1016/0969-2126(93)90010-E; DEBOER APN, 1994, ANTON LEEUW INT J G, V66, P111, DOI 10.1007/BF00871635; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HOROWITZ PM, 1982, J BIOL CHEM, V257, P9258; HUYNH BH, 1982, J BIOL CHEM, V257, P9576; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JUNGST A, 1991, MOL GEN GENET, V225, P241, DOI 10.1007/BF00269855; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LAM Y, 1969, BIOCHIM BIOPHYS ACTA, V180, P459, DOI 10.1016/0005-2728(69)90025-5; LUDWIG W, 1993, INT J SYST BACTERIOL, V43, P363, DOI 10.1099/00207713-43-2-363; MAKINEN MW, 1983, SCIENCE, V222, P929, DOI 10.1126/science.6415814; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; MOIR JWB, 1993, THESIS OXFORD U OXFO; Moore G., 1990, CYTOCHROMES C EVOLUT; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; OHSHIMA T, 1993, J FERMENT BIOENG, V76, P82, DOI 10.1016/0922-338X(93)90061-C; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; SILVESTRINI MC, 1989, FEBS LETT, V254, P33, DOI 10.1016/0014-5793(89)81004-X; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SMITH GB, 1992, APPL ENVIRON MICROB, V58, P376, DOI 10.1128/AEM.58.1.376-384.1992; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1979, J MOL BIOL, V133, P185, DOI 10.1016/0022-2836(79)90257-2; TIMKOVICH R, 1985, ARCH BIOCHEM BIOPHYS, V240, P689, DOI 10.1016/0003-9861(85)90077-3; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P113; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; XIA ZX, 1992, J BIOL CHEM, V267, P22289; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379	50	255	265	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					369	377		10.1016/0092-8674(95)90390-9	http://dx.doi.org/10.1016/0092-8674(95)90390-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736589	Bronze			2022-12-01	WOS:A1995QW89400009
J	HAQ, TA; MASON, HS; CLEMENTS, JD; ARNTZEN, CJ				HAQ, TA; MASON, HS; CLEMENTS, JD; ARNTZEN, CJ			ORAL IMMUNIZATION WITH A RECOMBINANT BACTERIAL-ANTIGEN PRODUCED IN TRANSGENIC PLANTS	SCIENCE			English	Article							ESCHERICHIA-COLI; IMMUNE-RESPONSE; VIBRIO-CHOLERAE; B-SUBUNIT; PROTEINS; ENTEROTOXIN; VACCINE; TOXIN; IDENTIFICATION; TRANSLOCATION	The binding subunit of Escherichia coli heat-labile enterotoxin (LT-B) is a highly active oral immunogen. Transgenic tobacco and potato plants were made with the use of genes encoding LT-B or an LT-B fusion protein with a microsomal retention sequence. The plants expressed the foreign peptides, both of which formed oligomers that bound the natural ligand. Mice immunized by gavage produced serum and gut mucosal anti-LT-B immunoglobulins that neutralized the enterotoxin in cell protection assays. Feeding mice fresh transgenic potato tubers also caused oral immunization.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, PLANT BIOTECHNOL PROGRAM, HOUSTON, TX 77030 USA; TULANE UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, NEW ORLEANS, LA 70112 USA	Texas A&M University System; Tulane University					PHS HHS [1 R01 A136519-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNTZEN CJ, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P339; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CARDENAS L, 1993, INFECT IMMUN, V61, P4629; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENTS JD, 1978, INFECT IMMUN, V21, P1036, DOI 10.1128/IAI.21.3.1036-1039.1978; CLEMENTS JD, 1984, INFECT IMMUN, V46, P564, DOI 10.1128/IAI.46.2.564-569.1984; DEAIZPURUA HJ, 1988, J EXP MED, V167, P440, DOI 10.1084/jem.167.2.440; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HOLMGREN J, 1983, PROG ALLERGY, V33, P106; HOLMGREN J, 1992, IMMUNOBIOLOGY, V184, P157, DOI 10.1016/S0171-2985(11)80473-0; HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z; HORSCH RB, 1991, PLANT MOL BIOL MANUA; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES JDG, 1985, EMBO J, V4, P2411, DOI 10.1002/j.1460-2075.1985.tb03949.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; MESTECKY J, 1989, CURR TOP MICROBIOL, V146, P3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; PERL A, 1991, PLANT SCI, V73, P87, DOI 10.1016/0168-9452(91)90129-V; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SACK RB, 1980, J INFECT DIS, V142, P279, DOI 10.1093/infdis/142.2.279; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; WANDELT CI, 1992, PLANT J, V2, P181; WENZLER H, 1989, PLANT SCI, V63, P79, DOI 10.1016/0168-9452(89)90103-9	28	474	553	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					714	716		10.1126/science.7732379	http://dx.doi.org/10.1126/science.7732379			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732379				2022-12-01	WOS:A1995QW60300047
J	HEBERT, DN; FOELLMER, B; HELENIUS, A				HEBERT, DN; FOELLMER, B; HELENIUS, A			GLUCOSE TRIMMING AND REGLUCOSYLATION DETERMINE GLYCOPROTEIN ASSOCIATION WITH CALNEXIN IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INFLUENZA-VIRUS HEMAGGLUTININ; BINDING-PROTEINS; DISULFIDE BONDS; MICROSOMES; PURIFICATION; MEMBRANE; GLUCOSYLTRANSFERASE; INHIBITORS; MATURATION	To determine the role of N-linked oligosaccharides in the folding of glycoproteins, we analyzed the processing of in vitro translated influenza hemagglutinin (HA) in dog pancreas microsomes. We found that binding to calnexin, a membrane-bound molecular chaperone, was specific to molecules that possessed monoglucosylated core glycans. In the microsomes, these were generated either by glucose removal from the original triglucosylated core oligosaccharide by glucosidases I and II or by reglucosylation of already unglucosylated high mannose glycans. Release of fully folded HA from calnexin required the removal of the remaining glucose by glucosidase II. The results provided an explanation for trimming and reglucosylation activities in the endoplasmic reticulum and established a direct correlation between glycosylation and folding.			HEBERT, DN (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KERN G, 1993, PROTEIN SCI, V2, P1862, DOI 10.1002/pro.5560021108; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LE AQ, 1994, J BIOL CHEM, V269, P7514; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PIND S, 1994, J BIOL CHEM, V289, P12784; RAJOGAPALAN S, 1994, SCIENCE, V263, P387; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TATU U, 1995, IN PRESS EMBO J; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	51	448	453	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					425	433		10.1016/0092-8674(95)90395-X	http://dx.doi.org/10.1016/0092-8674(95)90395-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736594	hybrid			2022-12-01	WOS:A1995QW89400014
J	ICHTCHENKO, K; HATA, Y; NGUYEN, T; ULLRICH, B; MISSLER, M; MOOMAW, C; SUDHOF, TC				ICHTCHENKO, K; HATA, Y; NGUYEN, T; ULLRICH, B; MISSLER, M; MOOMAW, C; SUDHOF, TC			NEUROLIGIN-1 - A SPLICE SITE-SPECIFIC LIGAND FOR BETA-NEUREXINS	CELL			English	Article							BINDING PROTEIN; AGRIN; SEQUENCE; MEMBRANE; LAMININ	Neurexins are neuronal cell surface proteins with hundreds of isoforms generated by alternative splicing. Here we describe neuroligin 1, a neuronal cell surface protein that is enriched in synaptic plasma membranes and acts as a splice site-specific ligand for beta-neurexins. Neuroligin 1 binds to beta-neurexins only if they lack an insert in the alternatively spliced sequence of the G domain, but not if they contain an insert, The extracellular sequence of neuroligin 1 is composed of a catalytically inactive esterase domain homologous to acetylcholinesterase. In situ hybridization reveals that alternative splicing of neurexins at the site recognized by neuroligin 1 is highly regulated. These findings support a model whereby alternative splicing of neurexins creates a family of cell surface receptors that confers Interactive specificity onto their resident neurons.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ICHTCHENKO, K (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Missler, Markus/0000-0001-8008-984X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; DELAESCALERA S, 1990, EMBO J, V11, P3593; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SIKORAV JL, 1987, EMBO J, V7, P1865; Summers MD, 1987, MANUAL METHODS BACUL; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAKAGI Y, 1988, FEBS LETT, V282, P17; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V11, P4683; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	25	540	557	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					435	443		10.1016/0092-8674(95)90396-8	http://dx.doi.org/10.1016/0092-8674(95)90396-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736595	Bronze			2022-12-01	WOS:A1995QW89400015
J	KASS, DM; YUNG, YL				KASS, DM; YUNG, YL			LOSS OF ATMOSPHERE FROM MARS DUE TO SOLAR WIND-INDUCED SPUTTERING	SCIENCE			English	Article							OXYGEN ION PRECIPITATION; SPATIAL DISTRIBUTIONS; ENERGY DEPOSITION; EVOLUTION; CLIMATE; VENUS; CONSEQUENCES	Because Mars does not have a strong intrinsic magnetic field, the atmosphere is eroded by interactions with the solar wind. Early solar-system conditions enhanced the sputtering loss. It is calculated that similar to 3 bars of carbon dioxide (CO2) have been sputtered over the last 3.5 billion years. This significant increase over the previous estimate by Luhmann et al. of similar to 0.14 bar of CO2 is the result of the development of a more complete model. The model also predicts slightly greater loss of water-similar to 80 meters instead of the similar to 50 meters predicted by Luhmann et al. Because estimates of CO2 on early Mars range from 0.5 to 5 bars, the 0.14-bar estimate is insignificant but the similar to 3-bar estimate will have a large effect on our understanding of the planet's evolution.			KASS, DM (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.		Yung, Yuk/AAM-4850-2021	Yung, Yuk/0000-0002-4263-2562				FANALE FP, 1982, ICARUS, V50, P381, DOI 10.1016/0019-1035(82)90131-2; HODGES RR, 1993, J GEOPHYS RES-PLANET, V98, P10833, DOI 10.1029/93JE00998; HUNTEN DM, 1993, SCIENCE, V259, P915, DOI 10.1126/science.259.5097.915; ISHIMOTO M, 1986, J GEOPHYS RES, V91, P5793, DOI 10.1029/JA091iA05p05793; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHNSON RE, 1992, J GEOPHYS RES-SPACE, V97, P13911, DOI 10.1029/92JA01142; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; LUHMANN JG, 1991, J GEOPHYS RES-SPACE, V96, P5457, DOI 10.1029/90JA01753; McElroy M. B., 1977, Journal of Geophysical Research, V82, P4379, DOI 10.1029/JS082i028p04379; MCKAY CP, 1991, ICARUS, V90, P214, DOI 10.1016/0019-1035(91)90102-Y; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; SMITH PH, 1978, SPACE SCI REV, V22, P301; STEBBINGS RF, 1964, J GEOPHYS RES, V69, P2349, DOI 10.1029/JZ069i011p02349; ZAHNLE KJ, 1982, REV GEOPHYS, V20, P280, DOI 10.1029/RG020i002p00280; [No title captured]	16	84	85	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					697	699		10.1126/science.7732377	http://dx.doi.org/10.1126/science.7732377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732377				2022-12-01	WOS:A1995QW60300041
J	KIMHA, J; KERR, K; MACDONALD, PM				KIMHA, J; KERR, K; MACDONALD, PM			TRANSLATIONAL REGULATION OF OSKAR MESSENGER-RNA BY BRUNO, AN OVARIAN RNA-BINDING PROTEIN, IS ESSENTIAL	CELL			English	Article							BICOID MESSENGER-RNA; EARLY DROSOPHILA EMBRYO; GERM-CELL FORMATION; ANTEROPOSTERIOR POLARITY; EXUPERANTIA GENE; POSTERIOR POLE; LOCALIZATION; PATTERN; NANOS; ELEMENTS	Oskar (osk) protein directs the deployment of nanos (nos), the posterior body-patterning morphogen in Drosophila. To avoid inappropriate activation of nos, osk activity must appear only at the posterior pole of the oocyte, where the osk mRNA becomes localized during oogenesis. Here, we show that translation of osk mRNA is, and must be, repressed prior to its localization; absence of repression allows osk protein to accumulate throughout the oocyte, specifying posterior body patterning throughout the embryo. Translational repression is mediated by an ovarian protein, bruno, that binds specifically to bruno response elements (BREs), present in multiple copies in the osk mRNA 3'UTR. Addition of BREs to a heterologous mRNA renders it sensitive to translational repression in the ovary.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University								BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EPHRUSSI A, 1991, CELL, V68, P37; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; HAY B, 1990, DEVELOPMENT, V109, P425; HAZELRIGG T, 1990, GENETICS, V126, P607; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WEBSTER PJ, 1994, DEVELOPMENT, V120, P2027; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399	40	364	368	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					403	412		10.1016/0092-8674(95)90393-3	http://dx.doi.org/10.1016/0092-8674(95)90393-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736592	Bronze			2022-12-01	WOS:A1995QW89400012
J	LARSSON, SH; CHARLIEU, JP; MIYAGAWA, K; ENGELKAMP, D; RASSOULZADEGAN, M; ROSS, A; CUZIN, F; VANHEYNINGEN, V; HASTIE, ND				LARSSON, SH; CHARLIEU, JP; MIYAGAWA, K; ENGELKAMP, D; RASSOULZADEGAN, M; ROSS, A; CUZIN, F; VANHEYNINGEN, V; HASTIE, ND			SUBNUCLEAR LOCALIZATION OF WT1 IN SPLICING OR TRANSCRIPTION FACTOR DOMAINS IS REGULATED BY ALTERNATIVE SPLICING	CELL			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR LOCUS; CELL-NUCLEUS; GENE; RNA; SNRNP; INVIVO; DNA; PURIFICATION; RECOGNITION	WT1 is a tumor suppressor gene with a key role in urogenital development and the pathogenesis of Wilms' tumor. Two alternative splice sites in the WT1 transcript allow the gene to encode four proteins. These carry four Kruppel-type zinc fingers and to date have primarily been implicated in transcriptional control of genes involved in growth regulation. However, here we demonstrate colocalization of WT1 with splicing factors in the fetal kidney and testis and in expressing cell lines. Using immunoprecipitation, we show that two WT1 isoforms directly associate with one or a limited number of components in the spliceosomes and coiled bodies. Moreover, COS cell expression studies suggest that alternative splicing within the WT1 zinc finger region determines whether the protein localizes mainly with splicing factors or with DNA in transcription factor domains in the nucleus. We propose that WT1 plays roles in posttranscriptional processing of RNA as well as in transcription.	UNIV NICE, INSERM, U273, F-06108 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	LARSSON, SH (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		VAN HEYNINGEN, Veronica/GYE-0531-2022; Rassoulzadegan, Minoo/O-7939-2016; van Heyningen, Veronica/B-8039-2008	van Heyningen, Veronica/0000-0003-0359-0141	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bruening Wendy, 1994, Seminars in Developmental Biology, V5, P333, DOI 10.1006/sedb.1994.1042; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANNU REV GENET, V28, P523; Hogan B., 1986, MANIPULATING MOUSE E; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KENT GRL, 1994, THESIS U EDINBURGH M; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; Moore M., 1993, RNA WORLD, P303; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NEWMAN A, 1994, CURR OPIN CELL BIOL, V6, P360, DOI 10.1016/0955-0674(94)90027-2; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 1989, MOL CLONING LAB MANU; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	51	423	434	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					391	401		10.1016/0092-8674(95)90392-5	http://dx.doi.org/10.1016/0092-8674(95)90392-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736591	Bronze			2022-12-01	WOS:A1995QW89400011
J	LU, KP; HUNTER, T				LU, KP; HUNTER, T			EVIDENCE FOR A NIMA-LIKE MITOTIC PATHWAY IN VERTEBRATE CELLS	CELL			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; MAMMALIAN-CELLS; XENOPUS-OOCYTE; MOUSE OOCYTES; MITOSIS; ACTIVATION	NIMA is essential for entry into mitosis in Aspergillus nidulans. To examine whether there is a NIMA-like pathway in other eukaryotic cell cycles, we expressed NIMA and its dominant negative mutants in two different eukaryotic systems. In Xenopus oocytes, NIMA induced germinal vesicle breakdown without activating Mos, CDC2, or MAP kinase. In HeLa cells, NIMA induced premature mitotic events without activating CDCS, whereas the mutants caused a specific G2 arrest but did not block mutant CDC2(T14AY15F)-induced premature entry into mitosis. A sequence essential for both these phenotypes was mapped to a region of similar to 100 amino acids lying just after the catalytic domain of NIMA that shows a significant similarity to protein interaction domains in other proteins. These results provide evidence for the existence of a NIMA-like mitotic pathway in vertebrate cells.			LU, KP (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NCRR NIH HHS [RR04050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI T, 1991, DEVELOPMENT, V113, P789; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GARD DL, 1993, METHOD CELL BIOL, V38, P241; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; GAVIN AC, 1994, J CELL SCI, V107, P275; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARPER JW, 1993, CELL, V75, P805; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; JUNG T, 1993, INT J DEV BIOL, V37, P595; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; LETWIN K, 1992, EMBO J, V10, P3521; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MERRIAM RW, 1971, EXP CELL RES, V68, P81, DOI 10.1016/0014-4827(71)90589-1; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	47	146	154	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					413	424		10.1016/0092-8674(95)90394-1	http://dx.doi.org/10.1016/0092-8674(95)90394-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736593	Bronze			2022-12-01	WOS:A1995QW89400013
J	MA, JKC; HIATT, A; HEIN, M; VINE, ND; WANG, F; STABILA, P; VANDOLLEWEERD, C; MOSTOV, K; LEHNER, T				MA, JKC; HIATT, A; HEIN, M; VINE, ND; WANG, F; STABILA, P; VANDOLLEWEERD, C; MOSTOV, K; LEHNER, T			GENERATION AND ASSEMBLY OF SECRETORY ANTIBODIES IN PLANTS	SCIENCE			English	Article							LOCAL PASSIVE-IMMUNIZATION; IMMUNOGLOBULIN-A; MONOCLONAL-ANTIBODIES; STREPTOCOCCUS-MUTANS; EPITHELIAL TRANSPORT; MUCOSAL IMMUNITY; J-CHAIN; IGA; EXPRESSION; COMPONENT	Four transgenic Nicotiana tabacum plants were generated that expressed a murine monoclonal antibody kappa chain, a hybrid immunoglobulin A-G heavy chain, a murine joining chain, and a rabbit secretory component, respectively. Successive sexual crosses between these plants and filial recombinants resulted in plants that expressed all four protein chains simultaneously. These chains were assembled into a functional, high molecular weight secretory immunoglobulin that recognized the native streptococcal antigen I/II cell surface adhesion molecule. In plants, single cells are able to assemble secretory antibodies, whereas two different cell types are required in mammals. Transgenic plants may be suitable for large-scale production of recombinant secretory immunoglobulin A for passive mucosal immunotherapy. Plant cells also possess the requisite mechanisms for assembly and expression of other complex recombinant protein molecules.	PLANET BIOTECHNOL, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CELL BIOL, DIV PLANT BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Francisco	MA, JKC (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DEPT IMMUNOL, 28TH FLOOR, GUYS TOWER, LONDON SE1 9RT, ENGLAND.			mostov, keith/0000-0002-8123-6247; van Dolleweerd, Craig/0000-0002-1380-6930; Ma, Julian/0000-0003-0767-0042	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHNEN DJ, 1986, J CLIN INVEST, V77, P1841, DOI 10.1172/JCI112510; APODACA G, 1993, J BIOL CHEM, V268, P20380; BARNES WM, 1990, P NATL ACAD SCI USA, V87, P9183, DOI 10.1073/pnas.87.23.9183; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; HEIN MB, 1991, BIOTECHNOL PROGR, V7, P455, DOI 10.1021/bp00011a011; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; KILIAN M, 1988, MICROBIOL REV, V52, P296, DOI 10.1128/MMBR.52.2.296-303.1988; KNIGHT KL, 1975, J IMMUNOL, V115, P595; LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; MATSUUCHI L, 1986, P NATL ACAD SCI USA, V83, P456, DOI 10.1073/pnas.83.2.456; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.iy.12.040194.000431; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHNEIDERMAN RD, 1989, P NATL ACAD SCI USA, V86, P7561, DOI 10.1073/pnas.86.19.7561; SMITH R, 1989, ORAL MICROBIOL IMMUN, V4, P153, DOI 10.1111/j.1399-302X.1989.tb00243.x; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991	24	406	497	0	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					716	719		10.1126/science.7732380	http://dx.doi.org/10.1126/science.7732380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732380				2022-12-01	WOS:A1995QW60300048
J	NUDLER, E; KASHLEV, M; NIKIFOROV, V; GOLDFARB, A				NUDLER, E; KASHLEV, M; NIKIFOROV, V; GOLDFARB, A			COUPLING BETWEEN TRANSCRIPTION TERMINATION AND RNA-POLYMERASE INCHWORMING	CELL			English	Article							ELONGATION FACTOR-SII; ESCHERICHIA-COLI; TERNARY COMPLEXES; GENE-EXPRESSION; INVITRO; PROTEIN; DNA	Advancement of RNA polymerase of E. coli occurs in alternating laps of monotonic and inchworm-like movement. Cycles of inchworming are encoded in DNA and involve straining and relaxation of the ternary complex accompanied by characteristic leaping of DNA and RNA footprints. We demonstrate that the oligo(T) tract that constitutes a normal part of transcription terminators acts as an inchworming signal so that the leap coincides with the termination event. Prevention of leaping with a roadblock of cleavage-defective EcoRI protein results in suppression of RNA chain release at a termination site. The results indicate that straining and relaxation of RNA polymerase are steps in the termination mechanism.	RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW 123182, RUSSIA	Russian Academy of Sciences	NUDLER, E (corresponding author), PUBL HLTH RES INST, 455 1ST AVE, NEW YORK, NY 10016 USA.			Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DAUBE SS, 1995, IN PRESS P NATL ACAD; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LEE F, 1977, P NATL ACAD SCI USA, V74, P4365, DOI 10.1073/pnas.74.10.4365; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1989, J BIOL CHEM, V264, P10799; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG MT, 1989, J BIOL CHEM, V264, P2634; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	31	106	107	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					351	357		10.1016/0092-8674(95)90388-7	http://dx.doi.org/10.1016/0092-8674(95)90388-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736587	Bronze			2022-12-01	WOS:A1995QW89400007
J	PARSONS, R; LI, GM; LONGLEY, M; MODRICH, P; LIU, B; BERK, T; HAMILTON, SR; KINZLER, KW; VOGELSTEIN, B				PARSONS, R; LI, GM; LONGLEY, M; MODRICH, P; LIU, B; BERK, T; HAMILTON, SR; KINZLER, KW; VOGELSTEIN, B			MISMATCH REPAIR DEFICIENCY IN PHENOTYPICALLY NORMAL HUMAN-CELLS	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; CARCINOGENESIS; MUTATIONS; LOCUS; MEMORIAL; HOMOLOG; LECTURE	Tumor cells in patients with hereditary nonpolyposis colorectal cancer (HNPCC) are characterized by a genetic hypermutability caused by defects in DNA mismatch repair. A subset of HNPCC patients was found to have widespread mutations not only in their tumors, but also in their non-neoplastic cells. Although these patients had numerous mutations in all tissues examined, they had very few tumors. The hypermutability was associated with a profound defect in mismatch repair at the biochemical level. These results have implications for the relation between mutagenesis and carcinogenesis, and they suggest that mismatch repair deficiency is compatible with normal human development.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; MT SINAI HOSP,FAMILIAL GI CANC REGISTRY,TORONTO,ON M5G 1X5,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Duke University; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Johns Hopkins University; Johns Hopkins University			Li, Guo-Min/I-5016-2014	Parsons, Ramon/0000-0002-6656-3514; Modrich, Paul/0000-0001-8708-9885; Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R01CA035494, P50CA062924, R37CA035494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924, CA35494] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KNUDSON AG, 1985, CANCER RES, V45, P1437; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PARSONS R, UNPUB; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	33	301	326	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					738	740		10.1126/science.7632227	http://dx.doi.org/10.1126/science.7632227			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7632227				2022-12-01	WOS:A1995QW60300054
J	PREKER, PJ; LINGNER, J; MINVIELLESEBASTIA, L; KELLER, W				PREKER, PJ; LINGNER, J; MINVIELLESEBASTIA, L; KELLER, W			THE FIP1 GENE ENCODES A COMPONENT OF A YEAST PRE-MESSENGER-RNA POLYADENYLATION FACTOR THAT DIRECTLY INTERACTS WITH POLY(A) POLYMERASE	CELL			English	Article							MESSENGER-RNA POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; 3' END; POLY(A)-BINDING PROTEIN; BINDING DOMAIN; EXPRESSION; SEQUENCE; PURIFICATION; CLEAVAGE; COMPLEX	We have identified an essential gene, called FIP1, encoding a 327 amino acid protein interacting with yeast poly(A) polymerase (PAP1) in the two-hybrid assay, Recombinant FIP1 protein forms a 1:1 complex with PAP1 in vitro. At 37 degrees C, a thermosensitive allele of FIP1 shows a shortening of poly(A) tails and a decrease in the steady-state level of actin transcripts. When assayed for 3'-end processing in vitro, fip1 mutant extracts exhibit normal cleavage activity, but fail to polyadenylate the upstream cleavage product. Polyadenylation activity is restored by adding polyadenylation factor I (PF I). Antibodies directed against FIP1 specifically recognize a polypeptide in these fractions. Coimmunoprecipitation experiments reveal that RNA14, a subunit of cleavage factor I (CF I), directly interacts with FIP1, but not with PAP1, We propose a model in which PF I tethers PAP1 to CF I, thereby conferring specificity to poly(A) polymerase for pre-mRNA substrates.			PREKER, PJ (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND.		Minvielle-Sebastia, Lionel/M-7154-2014	Lingner, Joachim/0000-0002-2853-5803				ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; AGUILERA A, 1994, GENETICS, V136, P87; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, GUIDE YEAST GENETICS; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; RUSSO P, 1993, MOL CELL BIOL, V13, P7836, DOI 10.1128/MCB.13.12.7836; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sambrook J., 1989, MOL CLONING LAB MANU; SEE PY, 1989, PROTEIN STRUCTURE PR, P1; SMITH HE, 1990, MOL CELL BIOL, V10, P6103, DOI 10.1128/MCB.10.12.6103; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	54	113	115	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					379	389		10.1016/0092-8674(95)90391-7	http://dx.doi.org/10.1016/0092-8674(95)90391-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736590	Bronze			2022-12-01	WOS:A1995QW89400010
J	ROBERTSON, MP; MILLER, SL				ROBERTSON, MP; MILLER, SL			PREBIOTIC SYNTHESIS OF 5-SUBSTITUTED URACILS - A BRIDGE BETWEEN THE RNA WORLD AND THE DNA-PROTEIN WORLD	SCIENCE			English	Article							EARTHS PRIMITIVE ATMOSPHERE; ORIGIN; FORMALDEHYDE; EVOLUTION; CARBON; MODEL; WATER; CH4; CO2	Under prebiotic conditions, formaldehyde adds to uracil at the C-5 position to produce 5-hydroxymethyluracil with favorable rates and equilibria. Hydroxymethyluracil adds a variety of nucleophiles, such as ammonia, glycine, guanidine, hydrogen sulfide, hydrogen cyanide, imidazole, indole, and phenol, to give 5-substituted uracils with the side chains of most of the 20 amino acids in proteins. These reactions are sufficiently robust that, if uracil had been present on the primitive Earth, then these substituted uracils would also have been present. The ribozymes of the RNA world would have included many of the functional groups found in proteins today, and their catalytic activities may have been considerably greater than presently assumed.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARNUN A, 1983, J GEOPHYS RES-OCEANS, V88, P6662, DOI 10.1029/JC088iC11p06662; BARNUN A, 1978, ORIGINS LIFE EVOL B, V9, P93, DOI 10.1007/BF00931407; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DEISTER U, 1990, BER BUNSEN PHYS CHEM, V94, P594, DOI 10.1002/bbpc.19900940512; FERRIS JP, 1966, J AM CHEM SOC, V88, P1074, DOI 10.1021/ja00957a050; FERRIS JP, 1979, J ORG CHEM, V44, P1273, DOI 10.1021/jo01322a019; FERRIS JP, 1975, J AM CHEM SOC, V97, P2962, DOI 10.1021/ja00844a007; FRIEDMANN N, 1971, CHEM EVOLUTION ORIGI, P123; GIBSON HW, 1969, CHEM REV, V69, P673, DOI 10.1021/cr60261a005; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; MILLER SL, 1984, ORIGINS LIFE EVOL B, V14, P83, DOI 10.1007/BF00933643; MOORE ML, 1949, ORG REACTIONS, V5, P301; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORO J, 1984, ORIGINS LIFE EVOL B, V14, P237, DOI 10.1007/BF00933663; PINTO JP, 1980, SCIENCE, V210, P183, DOI 10.1126/science.210.4466.183; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON MP, UNPUB; SANCHEZ RA, 1967, J MOL BIOL, V30, P223; SCHLESINGER G, 1983, J MOL EVOL, V19, P383, DOI 10.1007/BF02101643; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WEBER AL, 1981, J MOL EVOL, V17, P273, DOI 10.1007/BF01795749; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Woese C., 1967, GENETIC CODE, P179; WONG JTF, 1991, ORIGINS LIFE EVOL B, V21, P165, DOI 10.1007/BF01809445; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	30	72	73	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					702	705		10.1126/science.7732378	http://dx.doi.org/10.1126/science.7732378			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732378				2022-12-01	WOS:A1995QW60300043
J	ROELINK, H; PORTER, JA; CHIANG, C; TANABE, Y; CHANG, DT; BEACHY, PA; JESSELL, TM				ROELINK, H; PORTER, JA; CHIANG, C; TANABE, Y; CHANG, DT; BEACHY, PA; JESSELL, TM			FLOOR PLATE AND MOTOR-NEURON INDUCTION BY DIFFERENT CONCENTRATIONS OF THE AMINO-TERMINAL CLEAVAGE PRODUCT OF SONIC HEDGEHOG AUTOPROTEOLYSIS	CELL			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; NERVOUS-SYSTEM; CHICK-EMBRYO; DROSOPHILA; TRANSCRIPTION; EXPRESSION; NOTOCHORD; PROTEINS; PATTERN	The differentiation of floor plate cells and motor neurons can be induced by Sonic hedgehog (SHH), a secreted signaling protein that undergoes autoproteolytic cleavage to generate amino- and carboxy-terminal products. We have found that both floor plate cells and motor neurons are induced by the aminoterminal cleavage product of SHH (SHH-N). the threshold concentration of SHH-N required for motor neuron induction is about 5-fold lower than that required for floor plate induction. Higher concentrations of SHH-N can induce floor plate cells at the expense of motor neuron differentiation. Our results suggest that the induction of floor plate cells and motor neurons by the notochord In vivo is mediated by exposure of neural plate cells to different concentrations of the aminoterminal product of SHH autoproteolytic cleavage.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	ROELINK, H (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.							ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTABA ARI, 1995, IN PRESS MOL CELL NE; ALTABA ARI, 1995, IN PRESS DEV BIOL; Ausubel F.M., 2002, SHORT PROTOCOLS MOL, V5th; AVERBUCHHELLER L, 1994, P NATL ACAD SCI USA, V91, P3247, DOI 10.1073/pnas.91.8.3247; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURNCROT DA, 1995, MOL CELL BIOL, V15, P2294; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, IN PRESS CELL, V81; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TANABE Y, 1995, IN PRESS CURR BIOL; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TASHIRO S, 1993, GENE, V124, P183; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	59	747	779	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					445	455		10.1016/0092-8674(95)90397-6	http://dx.doi.org/10.1016/0092-8674(95)90397-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736596	hybrid			2022-12-01	WOS:A1995QW89400016
J	WANG, DG; MEIER, TI; CHAN, CL; FENG, GH; LEE, DN; LANDICK, R				WANG, DG; MEIER, TI; CHAN, CL; FENG, GH; LEE, DN; LANDICK, R			DISCONTINUOUS MOVEMENTS OF DNA AND RNA IN RNA-POLYMERASE ACCOMPANY FORMATION OF A PAUSED TRANSCRIPTION COMPLEX	CELL			English	Article							ESCHERICHIA-COLI RNA; STRUCTURAL-ANALYSIS; TERNARY COMPLEXES; TERMINATION; BACTERIOPHAGE-T7; DISSECTION; SEQUENCES; CLEAVAGE; PROTEINS; INVITRO	A central enigma of transcriptional regulation is how the normally efficient transcription elongation complex stops at pause and termination signals. One possibility, raised by the discovery that RNA polymerase sometimes contracts its DNA footprint, is that discontinuous movements contribute to recognizing these signals. We report that E. coli RNA polymerase responds to sequences immediately downstream and upstream from the his leader pause site by changing neither its downstream DNA contact nor its upstream RNA contact for 8 bp preceding the pause. This compressed complex isomerizes to a paused conformation by an similar to 10 bp jump of its downstream DNA contact and simultaneous extrusion of an RNA hairpin that stabilizes the paused conformation. We suggest pausing and termination could be alternative outcomes of a similar isomerization that depend on the strength of contacts to 3'-proximal RNA remaining after the jump.	WASHINGTON UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,ST LOUIS,MO 63130	Washington University (WUSTL)	WANG, DG (corresponding author), WASHINGTON UNIV,DEPT BIOL,CAMPUS BOX 1137,ST LOUIS,MO 63130, USA.				NIGMS NIH HHS [GM-38660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R01GM038660, R37GM038660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], [No title captured]; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FENG GH, 1994, J BIOL CHEM, V269, P22282; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1994, J BIOL CHEM, V269, P22295; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; LUI B, 1994, P NATL ACAD SCI USA, V91, P10660; MASON SW, 1992, J BIOL CHEM, V267, P19418; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILSON K, 1995, J MOL BIOL, V244, P36; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	37	121	125	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					341	350		10.1016/0092-8674(95)90387-9	http://dx.doi.org/10.1016/0092-8674(95)90387-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7537637	Bronze			2022-12-01	WOS:A1995QW89400006
J	CARROLL, SB; WEATHERBEE, SD; LANGELAND, JA				CARROLL, SB; WEATHERBEE, SD; LANGELAND, JA			HOMEOTIC GENES AND THE REGULATION AND EVOLUTION OF INSECT WING NUMBER	NATURE			English	Article							DROSOPHILA EMBRYOS; ORIGIN; EXPRESSION; PROTEIN; SNAIL; LEG	THE evolution of wings catalysed the radiation of insects which make up some 75 per cent of known animals, Fossil evidence suggests that wings evolved from a segment of the leg(1) and that early pterygotes bore wings on all thoracic and abdominal segments(2). The pterygote body plan subsequently diverged producing orders bearing three, two or just one pair of thoracic wings. We have investigated the role of homeotic genes in pterygote evolution by examining their function in Drosophila wing development and their expression in a primitive apterygote. Wing formation is not promoted by any homeotic gene, but is repressed in different segments by different homeotic genes, We suggest here that wings first arose without any homeotic gene involvement in an ancestor with a homeotic 'groundplan' similar to modern winged insects and that wing formation subsequently fell under the negative control of individual homeotic genes at different stages of pterygote evolution.	UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	CARROLL, SB (corresponding author), HOWARD HUGHES MED INST,1525 LINDEN DR,MADISON,WI 53706, USA.			Weatherbee, Scott/0000-0002-0915-1329				AKAM M, 1988, DEVELOPMENT, V104, P123; ALBERGA A, 1991, DEVELOPMENT, V111, P983; ANDREW DJ, 1994, EMBO J, V13, P1132, DOI 10.1002/j.1460-2075.1994.tb06362.x; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; BATE M, 1991, DEVELOPMENT, V112, P755; BRAND AH, 1993, DEVELOPMENT, V119, P401; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; KEISH R, 1994, DEV GENET, V15, P19; Kukalova-Peck J., 1991, INSECTS AUSTR TXB ST, V1, P141; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LEVINE M, 1983, EMBO J, V2, P2037, DOI 10.1002/j.1460-2075.1983.tb01697.x; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAHAFFEY JW, 1987, GENETICS, V117, P51; MANN RS, 1994, DEVELOPMENT, V121, P3205; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; Raff R.A., 1983, EMBRYOS GENES EVOLUT; RILEY PD, 1987, GENE DEV, V1, P716, DOI 10.1101/gad.1.7.716; SIMPSON P, 1983, GENETICS, V105, P615; Snodgrass RE, 1935, PRINCIPLES INSECT MO; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1994, NATURE, V368, P298; WOOTTON R J, 1972, Palaeontology (Oxford), V15, P662	30	158	161	3	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					58	61		10.1038/375058a0	http://dx.doi.org/10.1038/375058a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723843				2022-12-01	WOS:A1995QW60400054
J	COLLARD, JF; COTE, F; JULIEN, JP				COLLARD, JF; COTE, F; JULIEN, JP			DEFECTIVE AXONAL-TRANSPORT IN A TRANSGENIC MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	NATURE			English	Article							DISEASE	AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disease of motor neurons, characterized by depositions of neurofilaments in the perikarya and proximal axons. The pathogenesis of ALS remains poorly understood, but two lines of evidence suggest that neurofilament accumulation may play a causal role. First, transgenic mice that overexpress neurofilament proteins show motor neuron degeneration(1-3) and, second, variant alleles of the neurofilament heavy-subunit gene (NF-H) have been found in some human ALS patients(4). To investigate hom disorganized neurofilaments might cause neurodegeneration, we examined axonal transport of newly synthesized proteins in mice that overexpress the human NF-H gene(1). We observed dramatic defects of axonal transport, not only of neurofilament proteins but also of other proteins, including tubulin and actin. Ultrastructural analysis revealed a paucity of cytoskeletal elements, smooth endoplasmic reticulum and especially mitochondria in the degenerating axons, We therefore propose that the neurofilament accumulations observed in these mice cause axonal degeneration by impeding the transport of components required for axonal maintenance, and that a similar mechanism may account for the pathogenesis of ALS in human patients.	MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA	McGill University								Chou SM., 1992, HDB AMYOTROPHIC LATE, P133; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DELISLE M, J NEUROL SCI, V63, P241; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1751; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; GUMEY ME, 1994, SCIENCE, V264, P1772; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HOFFMAN PN, 1975, J CELL BIOL, V66, P315; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; MCQUARRIE IG, 1989, NEUROBIOL AGING, V10, P359, DOI 10.1016/0197-4580(89)90049-3; Nixon RA, 1991, NEURONAL CYTOSKELETO, P283; OBLINGER MM, 1987, J NEUROSCI, V7, P453; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	14	395	405	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					61	64		10.1038/375061a0	http://dx.doi.org/10.1038/375061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536898				2022-12-01	WOS:A1995QW60400055
J	ENARI, M; HUG, H; NAGATA, S				ENARI, M; HUG, H; NAGATA, S			INVOLVEMENT OF AN ICE-LIKE PROTEASE IN FAS-MEDIATED APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; CELL-DEATH; COWPOX VIRUS; ANTI-FAS; EXPRESSION; ENZYME; INHIBITOR; RECEPTOR; ENCODES	FAS is a type-I membrane protein that transduces an apoptotic signal(1,2). Binding of Fas ligand or agonistic anti-Fas antibody to Fas kills the cells by apoptosis(3). Studies in the nematode Caenorhabditis elegans have suggested that proteases such as interleukin-1 beta-converting enzyme (ICE) or the product of the C. elegans cell-death gene ced-3 are involved in apoptotic signal transduction(4). The activity of ICE can be inhibited by the product of crmA, a cytokine-response modifier gene encoded by cowpox virus(5-7). We report here that expression of crmA inhibits cytotoxicity induced by anti-pas antibody or tumour necrosis factor (TNF). We have found a specific ICE inhibitor tetrapeptide (acetyl-Tyr-Val-Ala-Asp-chloromethylketone)(8,9) that also prevents apoptosis induced by anti-Fas antibody. These results suggest an involvement of an ICE-like protease in Fas-mediated apoptosis and TNF-induced cytotoxicity.	YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University	ENARI, M (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				CEHM A, 1992, J BIOL CHEM, V267, P10709; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	800	835	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					78	81		10.1038/375078a0	http://dx.doi.org/10.1038/375078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536900				2022-12-01	WOS:A1995QW60400059
J	HEGLUND, NC; WILLEMS, PA; PENTA, M; CAVAGNA, GA				HEGLUND, NC; WILLEMS, PA; PENTA, M; CAVAGNA, GA			ENERGY-SAVING GAIT MECHANICS WITH HEAD-SUPPORTED LOADS	NATURE			English	Article							WALKING	IN many areas of the world that lack a transportation infrastructure, people routinely carry extraordinary loads supported by their heads, for example the Sherpa of the Himalayas and the women of East Africa, It has previously been shown that African women from the Kikuyu and Luo tribes can carry loads substantially more cheaply than army recruits(1); however, the mechanism for their economy has remained unknown, Here we investigate, using a force platform, the mechanics of carrying head-supported loads by Kikuyu and Luo women, The weight-specific mechanical work, required to maintain the motion of the common centre of mass of the body and load, decreases with load in the African women, whereas it increases in control subjects, The decrease in work by the African women is a result of a greater conservation of mechanical energy resulting from an improved pendulum-like transfer of energy during each step, back and forth between gravitational potential energy and kinetic energy of the centre of mass.	UNIV CATHOLIQUE LOUVAIN,UNITE READAPTAT,B-1348 LOUVAIN,BELGIUM; UNIV MILAN,IST FISIOL UMANA,I-20133 MILAN,ITALY	Universite Catholique Louvain; University of Milan	HEGLUND, NC (corresponding author), PHAROS SYST INC,S CHELMSFORD,MA 01824, USA.		Cavagna, Giovanni A/G-3564-2013	Cavagna, Giovanni/0000-0003-3081-0939				ALEXANDER R, 1988, ELASTIC MECHANISMS A, P95; ALEXANDER RM, 1986, NATURE, V319, P623, DOI 10.1038/319623a0; CAVAGNA GA, 1975, J APPL PHYSIOL, V39, P174, DOI 10.1152/jappl.1975.39.1.174; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; HEGLUND NC, 1981, J EXP BIOL, V93, P333; JONES CDR, 1987, LANCET, V12, P1331; MALOIY GMO, 1986, NATURE, V319, P668, DOI 10.1038/319668a0; PANDOLF KB, 1977, J APPL PHYSIOL, V43, P577, DOI 10.1152/jappl.1977.43.4.577; WILLEMS PA, 1995, J EXP BIOL, V198, P379	9	124	125	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					52	54		10.1038/375052a0	http://dx.doi.org/10.1038/375052a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723841				2022-12-01	WOS:A1995QW60400052
J	LEIGHTON, PA; INGRAM, RS; EGGENSCHWILER, J; EFSTRATIADIS, A; TILGHMAN, SM				LEIGHTON, PA; INGRAM, RS; EGGENSCHWILER, J; EFSTRATIADIS, A; TILGHMAN, SM			DISRUPTION OF IMPRINTING CAUSED BY DELETION OF THE H19 GENE REGION IN MICE	NATURE			English	Article							GROWTH FACTOR-II; EARLY MOUSE EMBRYOGENESIS; BETA-GLOBIN; PGK-1 GENE; XIST GENE; EXPRESSION; RNA; DNA; PROMOTER; FRAGMENTS	The imprinted H19 gene, which encodes an untranslated RNA, lies at the end of a cluster of Imprinted genes in the mouse. Imprinting of the insulin-2 and insulin-like growth factor 2 genes, which lie about 100 kilobases upstream of H19, can be disrupted by maternal inheritance of a targeted deletion of the H19 gene and its flanking sequence. Animals inheriting the H19 mutation from their mothers are 27% heavier than those inheriting It from their fathers. Paternal inheritance of the disruption has no effect, which presumably reflects the normally silent state of the paternal gene. The somatic overgrowth of heterozygotes for the maternal deletion is attributed to a gain of function of insulin-like growth factor 2, rather than a loss of function of H19.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Princeton University; Columbia University	LEIGHTON, PA (corresponding author), PRINCETON UNIV, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA.			eggenschwiler, jonathan/0000-0001-6444-8865				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; GUILLEMOT F, 1994, GIDD, V371, P333; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; LEE JE, 1990, DEVELOPMENT, V110, P151; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POIRIER F, 1991, DEVELOPMENT, V113, P1105; REIS A, 1994, AM J HUM GENET, V54, P741; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SOLTER D, 1988, ANNU REV GENET, V22, P127; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZACHAR V, 1993, NUCLEIC ACIDS RES, V21, P2017, DOI 10.1093/nar/21.8.2017; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	50	659	669	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 4	1995	375	6526					34	39		10.1038/375034a0	http://dx.doi.org/10.1038/375034a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536897				2022-12-01	WOS:A1995QW60400046
J	LOS, M; VANDECRAEN, M; PENNING, LC; SCHENK, H; WESTENDORP, M; BAEUERLE, PA; DROGE, W; KRAMMER, PH; FIERS, W; SCHULZEOSTHOFF, K				LOS, M; VANDECRAEN, M; PENNING, LC; SCHENK, H; WESTENDORP, M; BAEUERLE, PA; DROGE, W; KRAMMER, PH; FIERS, W; SCHULZEOSTHOFF, K			REQUIREMENT OF AN ICE/CED-3 PROTEASE FOR FAS/APO-1-MEDIATED APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; INTERLEUKIN-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; VIRUS ENCODES; FAS; INDUCTION; RECEPTOR	THE Fas/APO-1 receptor is one of the major regulators of apoptosis(1-7). We report here that Fas/APO-1-mediated apoptosis requires the activation of a new class of cysteine proteases, including interleukin-1 beta-converting enzyme (ICE)(8-10) which are homologous to the product of the Caenorhabditis elegans cell-death gene ced-3 (refs 11, 12). Triggering of Fas/APO-1 rapidly stimulated the proteolytic activity of ICE. Overexpression of ICE, achieved by electroporation and microinjection, strongly potentiated Fas/APO-1-mediated cell death. In addition, inhibition of ICE activity by protease inhibitors, as well as by transient expression of the pox virus-derived serpin inhibitor CrmA or an antisense ICE construct, substantially suppressed Fas/APO-1-triggered cell death. We conclude that activation of ICE or an ICE-related protease is a critical event in Fas/APO-1-mediated cell death.	GERMAN CANC RES CTR,DIV IMMUNOCHEM,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,IMMUNOGENET TUMOIMMUNOL PROGRAM,W-6900 HEIDELBERG,GERMANY; UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY; STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Ghent University			Penning, Louis/AAC-7524-2019; Schulze-Osthoff, Klaus/N-9025-2013; Łos, Marek J/C-4038-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NETT MA, 1992, J IMMUNOL, V149, P3254; NIWA H, 1994, GENE, V108, P193; OEHM A, 1992, J BIOL CHEM, V267, P10709; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	26	654	677	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					81	83		10.1038/375081a0	http://dx.doi.org/10.1038/375081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536901	Green Submitted			2022-12-01	WOS:A1995QW60400060
J	LUNARDIISKANDAR, Y; BRYANT, JL; ZEMAN, RA; LAM, VH; SAMANIEGO, F; BESNIER, JM; HERMANS, P; THIERRY, AR; GILL, P; GALLO, RC				LUNARDIISKANDAR, Y; BRYANT, JL; ZEMAN, RA; LAM, VH; SAMANIEGO, F; BESNIER, JM; HERMANS, P; THIERRY, AR; GILL, P; GALLO, RC			TUMORIGENESIS AND METASTASIS OF NEOPLASTIC KAPOSIS-SARCOMA CELL-LINE IN IMMUNODEFICIENT MICE BLOCKED BY A HUMAN-PREGNANCY HORMONE	NATURE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LONG-TERM CULTURE; GROWTH-FACTOR; EXPRESSION; MECHANISMS; AUTOCRINE; PARACRINE; INVITRO; DEATH; HTLV	KAPOSI's sarcoma (KS) occurs more often in men than in women and HIV-1-associated KS has a high occurrence in homosexual men (over 30%). Most cultures of KS tumours yield cells with properties of hyperplastic (not malignant) endothelial cells under the control of several cytokines(1-7). The role of HIV-1 may be in promoting high levels of some cytokines and providing stimulation to angiogenesis by the HIV-1 Tat protein(8), which synergizes with basic fibroblast growth factor in promoting these effects(9), Here,ve describe an immortalized AIDS-KS cell line (KS Y-1) and show that these cells produce malignant metastatic tumours in nude mice and are killed in vitro and in vivo (apparently by apoptosis) by a pregnancy hormone, the beta-chain of human chorionic gonadotropin. Similarly, chorionic gonadotropin kills KS SLK, cells from another neoplastic cell line (established from a non-HIV-associated KS)(10), as well as the hyperplastic KS cells from clinical specimens grown in short-term culture, but does not kill normal endothelial cells, These results provide evidence that KS can evolve into a malignancy and have implications for the hormonal treatment of this tumour.	NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; NIDR, ANIM CARE UNIT, BETHESDA, MD 20892 USA; GYNECOL & OBSTET MED CTR, F-75017 PARIS, FRANCE; FREE UNIV BRUSSELS, HOP ST PIERRE, DEPT MALAD INFECT, B-1000 BRUSSELS, BELGIUM; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Southern California			thierry, alain/F-9492-2014					ASHITAKA Y, 1980, CHORIONIC GONADOTROP, P147; CAI J, 1994, AM J PATHOL, V145, P74; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; ELMAZAR MMA, 1989, REPROD TOXICOL, V3, P135, DOI 10.1016/0890-6238(89)90047-6; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FAN C, 1987, J CLIN ENDOCR METAB, V64, P313, DOI 10.1210/jcem-64-2-313; HORNE CHW, 1979, INVEST CELL PATHOL, V2, P217; JOHNSON MR, 1993, ACTA ENDOCRINOL-COP, V129, P121, DOI 10.1530/acta.0.1290121; KORNYEI JL, 1993, BIOL REPROD, V49, P1149, DOI 10.1095/biolreprod49.6.1149; LUNARDIISKANDAR Y, 1993, J EXP MED, V177, P741, DOI 10.1084/jem.177.3.741; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARTIN MC, 1991, BASIC CLIN ENDOCRINO, P543; MASOOD R, 1994, AIDS RES HUM RETROV, V10, P969, DOI 10.1089/aid.1994.10.969; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAHRAOUI Y, 1992, CELL IMMUNOL, V139, P318, DOI 10.1016/0008-8749(92)90074-Y; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SLEGAL B, 1990, CANCER, V65, P492; STIMSON WH, 1983, IMMUNOLOGY REPRODUCT, P281; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TORRY RJ, 1992, AM J REPROD IMMUNOL, V27, P171, DOI 10.1111/j.1600-0897.1992.tb00746.x; WIDE L, 1980, CHORIONIC GONADOTROP, P37	26	206	229	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	1995	375	6526					64	68		10.1038/375064a0	http://dx.doi.org/10.1038/375064a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723844	Green Submitted			2022-12-01	WOS:A1995QW60400056
J	MORROW, JD; FREI, B; LONGMIRE, AW; GAZIANO, JM; LYNCH, SM; SHYR, Y; STRAUSS, WE; OATES, JA; ROBERTS, LJ				MORROW, JD; FREI, B; LONGMIRE, AW; GAZIANO, JM; LYNCH, SM; SHYR, Y; STRAUSS, WE; OATES, JA; ROBERTS, LJ			INCREASE IN CIRCULATING PRODUCTS OF LIPID-PEROXIDATION (F-2-ISOPROSTANES) IN SMOKERS - SMOKING AS A CAUSE OF OXIDATIVE DAMAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; HUMAN-BLOOD-PLASMA; VITAMIN-C STATUS; CIGARETTE-SMOKING; PROSTANOIDS F2-ISOPROSTANES; ANTIOXIDANT; MACROPHAGES; METABOLITES; CAROTENES; MECHANISM	Background. It has been hypothesized that the pathogenesis of diseases induced by cigarette smoking involves oxidative damage by free radicals. However, definitive evidence that smoking causes the oxidative modification of target molecules in vivo is lacking. We conducted a study to determine whether the production of F-2-isoprostanes, which are novel products of lipid peroxidation, is enhanced in persons who smoke. Methods. We measured the levels of free F-2-isoprostanes in plasma, the levels of F-2-isoprostanes esterified to plasma lipids, and the urinary excretion of metabolites of F-2-isoprostanes in 10 smokers and 10 nonsmokers matched for age and sex. The short-term effects of smoking (three cigarettes smoked over 30 minutes) and the effects of two weeks of abstinence from smoking on levels of F-2-isoprostanes in the circulation were also determined in the smokers. Results. Plasma levels of free and esterified F-2-isoprostanes were significantly higher in the smokers (mean +/-SD, 242+/-147 and 574+/-217 pmol per liter, respectively) than in the nonsmokers (103+/-19 and 345+/-65 pmol per liter; P = 0.02 for free F-2-isoprostanes and P = 0.03 for esterified F-2-isoprostanes). Smoking had no short-term effects on the circulating levels of F-2-isoprostanes. However, the levels of free and esterified F-2-isoprostanes fell significantly after two weeks of abstinence from smoking (250+/-156 and 624+/-214 pmol per liter, respectively, before the cessation of smoking, as compared with 156+/-67 and 469+/-108 pmol per liter after two weeks' cessation; P=0.03 for free F-2-isoprostanes and P = 0.02 for esterified F-2-isoprostanes). Conclusions. The increased levels of F-2-isoprostanes in the circulation of persons who smoke support the hypothesis that smoking can cause the oxidative modification of important biologic molecules in vivo.	VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT PREVENT MED, DIV BIOSTAT, NASHVILLE, TN 37232 USA; BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, BOSTON, MA 02118 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, CARDIOL SECT, BOSTON, MA USA	Vanderbilt University; Vanderbilt University; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	MORROW, JD (corresponding author), VANDERBILT UNIV, DEPT PHARMACOL, 221 KIRKLAND HALL, 506 MRB, NASHVILLE, TN 37232 USA.		Lynch, Sean M/A-9354-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, R37GM042056, R01GM042056] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49954] Funding Source: Medline; NIGMS NIH HHS [GM-15431, GM-42056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWAD JA, 1993, J BIOL CHEM, V268, P4161; Bridges A B, 1993, Eur J Med, V2, P205; CAILLEUX A, 1993, FREE RADICAL RES COM, V18, P323, DOI 10.3109/10715769309147499; CANTIN A, 1985, EUR J RESPIR DIS, V66, P7; CHOW CK, 1993, ANN NY ACAD SCI, V686, P289, DOI 10.1111/j.1749-6632.1993.tb39189.x; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HARATS D, 1989, ATHEROSCLEROSIS, V79, P245, DOI 10.1016/0021-9150(89)90130-5; HESS D, 1991, INT J VITAM NUTR RES, V61, P232; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; KALRA J, 1991, INT J EXP PATHOL, V72, P1; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KYEREMATEN GA, 1982, CLIN PHARMACOL THER, V32, P769, DOI 10.1038/clpt.1982.235; LEHR HA, 1993, FREE RADICAL BIO MED, V14, P573, DOI 10.1016/0891-5849(93)90138-K; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MOHLER ER, 1992, CIRCULATION, V86, P865; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; OBRIEN PJ, 1988, FREE RADICAL BIO MED, V4, P169, DOI 10.1016/0891-5849(88)90025-1; PELLETIER O, 1970, AM J CLIN NUTR, V23, P520; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, V1, P233; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHONFELD G, 1989, ENDOCRINOLOGY, V3, P2424; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; YOKODE M, 1988, P NATL ACAD SCI USA, V85, P2344, DOI 10.1073/pnas.85.7.2344	34	1167	1190	2	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1198	1203		10.1056/NEJM199505043321804	http://dx.doi.org/10.1056/NEJM199505043321804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700313	Bronze			2022-12-01	WOS:A1995QV41500004
J	OCHS, A; ROSSLE, M; HAAG, K; HAUENSTEIN, KH; DEIBERT, P; SIEGERSTETTER, V; HUONKER, M; LANGER, M; BLUM, HE				OCHS, A; ROSSLE, M; HAAG, K; HAUENSTEIN, KH; DEIBERT, P; SIEGERSTETTER, V; HUONKER, M; LANGER, M; BLUM, HE			THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT PROCEDURE FOR REFRACTORY ASCITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERITONEOVENOUS SHUNTS; INTRAVENOUS ALBUMIN; PROSPECTIVE TRIAL; CIRRHOSIS; PARACENTESIS; SURVIVAL; LEVEEN	Background. Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment. Methods. Fifty of 62 consecutive patients with cirrhosis and refractory ascites were treated with the stent shunt - an expandable stent of metallic mesh placed between a major branch of the portal vein and one of the hepatic veins. Patients were followed for a mean (+/-SD) of 426+/-333 days. Results. The stent shunt was successfully placed in all patients and reduced the pressure gradient between the portal vein and the inferior vena cava by an average of 63 percent. Thirty-seven patients (74 percent) had complete responses (total remission of ascites within three months), and nine patients (18 percent) had partial responses. Four patients did not respond, including two who died within two weeks of shunt placement. After the procedure, 25 patients had hepatic encephalopathy, as compared with 20 patients before the procedure; although encephalopathy improved in 3 patients, new encephalopathy developed in 8 patients. In the 28 of the 33 patients followed for more than six months who were evaluated, the mean serum creatinine concentration was 1.5+/-0.09 mg per deciliter (133+/-8 mu mol per liter) before placement of the stent shunt, 1.5+/-1.6 mg per deciliter (133+/-141 mu mol per liter) one week after the procedure, and 0.9+/-0.3 mg per deciliter (80+/-27 mu mol per liter) after six months (P=0.008 for the comparison of concentrations before and six months after the procedure). Renal function did not improve in the six patients with organic kidney disease. Procedure-related complications developed in 16 patients. During followup, an additional 29 patients died - 10 of progressive liver disease and 19 of other causes. Survival for at least one year was associated with a patient's being under 60 years of age, having a serum bilirubin level before placement of the stent shunt of less than 1.3 mg per deciliter (22 mu mol per liter), and having a complete response. Conclusions. Our findings in an uncontrolled prospective study suggest that the transjugular intrahepatic portosystemic stent-shunt procedure was an effective treatment for many patients with liver cirrhosis and refractory ascites, but mortality from underlying diseases was substantial.	UNIV FREIBURG,SCH MED,DEPT MED,D-79106 FREIBURG,GERMANY; UNIV FREIBURG,SCH MED,DEPT RADIOL,D-79106 FREIBURG,GERMANY	University of Freiburg; University of Freiburg			Deibert, Peter/AAE-4623-2020					ARROYO V, 1986, SEMIN LIVER DIS, V6, P353, DOI 10.1055/s-2008-1040617; Arroyo V, 1989, GASTROENTEROL INT, V2, P195; BERNHOFT RA, 1982, ARCH SURG-CHICAGO, V117, P631; BORIES P, 1986, J HEPATOL, V3, P212, DOI 10.1016/S0168-8278(86)80028-9; BURCHELL AR, 1968, ANN SURG, V168, P655, DOI 10.1097/00000658-196810000-00012; CAMPBELL DP, 1973, AM J SURG, V126, P748, DOI 10.1016/S0002-9610(73)80062-5; CAPONE RR, 1978, DIGEST DIS SCI, V23, P867; ELCHEROTH J, 1994, WORLD J SURG, V18, P240; EPSTEIN M, 1994, J AM SOC NEPHROL, V4, P1735; EPSTEIN M, 1989, NEW ENGL J MED, V321, P1675, DOI 10.1056/NEJM198912143212410; FERRAL H, 1993, RADIOLOGY, V189, P795, DOI 10.1148/radiology.189.3.8234706; FERRO D, 1992, SCAND J GASTROENTERO, V27, P852, DOI 10.3109/00365529209000153; FRANCO D, 1988, ARCH SURG-CHICAGO, V123, P987; FULENWIDER JT, 1986, ARCH SURG-CHICAGO, V121, P351; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; HAUENSTEIN KH, 1995, INTERVENTIONAL RADIO, V194, P175; KELLERMAN PS, 1990, ANN INTERN MED, V112, P889, DOI 10.7326/0003-4819-112-12-889; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LAKE JR, 1993, TRANSPLANT P, V25, P1766; LEVEEN HH, 1974, ANN SURG, V180, P580, DOI 10.1097/00000658-197410000-00023; LLOVET JM, 1993, AM J GASTROENTEROL, V88, P388; MARTINET JP, 1994, HEPATOLOGY, V20, pA113; MOSKOVITZ M, 1990, AM J GASTROENTEROL, V85, P917; OCHS A, 1993, J HEPATOL, V18, P217, DOI 10.1016/S0168-8278(05)80249-1; ORLOFF MJ, 1970, ANN NY ACAD SCI, V170, P213, DOI 10.1111/j.1749-6632.1970.tb37015.x; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; RUNYON BA, 1994, NEW ENGL J MED, V330, P337, DOI 10.1056/NEJM199402033300508; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; SAUNDERS JB, 1981, BRIT MED J, V282, P263, DOI 10.1136/bmj.282.6260.263; SCHOLZ DG, 1989, AM J GASTROENTEROL, V84, P540; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403; Tamaki A, 1968, Surg Forum, V19, P324; VILLARREAL LG, 1993, GASTROENTEROL HEPATO, V16, P18	36	387	389	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1192	1197		10.1056/NEJM199505043321803	http://dx.doi.org/10.1056/NEJM199505043321803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700312				2022-12-01	WOS:A1995QV41500003
J	PARSONS, LM; FOX, PT; DOWNS, JH; GLASS, T; HIRSCH, TB; MARTIN, CC; JERABEK, PA; LANCASTER, JL				PARSONS, LM; FOX, PT; DOWNS, JH; GLASS, T; HIRSCH, TB; MARTIN, CC; JERABEK, PA; LANCASTER, JL			USE OF IMPLICIT MOTOR IMAGERY FOR VISUAL SHAPE-DISCRIMINATION AS REVEALED BY PET	NATURE			English	Article							CEREBRAL BLOOD-FLOW; VOLUNTARY MOVEMENTS; CORTEX; BRAIN	POSITRON emission tomography (PET) can be used to map brain regions that are active when a visual object (for example, a hand) is discriminated from its mirror form. Chronometric studies(1-3) suggest that viewers 'solve' this visual shape task by mentally modelling it as a reaching task, implicitly moving their left hand into the orientation of any left-hand stimulus (and conversely for a right-hand stimulus). Here we describe an experiment in which visual and somatic processing are dissociated by presenting right hands to the left visual field and vice versa, Frontal (motor), parietal (somatosensory) and cerebellar (sensorimotor) regions similar to those activated by actual(4,5) and imagined(6-8) movement are strongly activated, whereas primary somatosensory and motor cortices are not, We conclude that mental imagery is realized at intermediate-to-high order, modality-specific cortical systems, but does not require primary cortex and is not constrained to the perceptual systems of the presented stimuli.	UNIV TEXAS, DEPT PSYCHOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	PARSONS, LM (corresponding author), UNIV TEXAS, HLTH SCI CTR, CTR RES IMAGING, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Lancaster, Jack L/F-2994-2010; Galantucci, Bruno/E-5770-2010; Fox, Peter/B-4725-2010	Fox, Peter/0000-0002-0465-2028; Parsons, Lawrence/0000-0001-7498-8742				Andersen RA, 1987, HDB PHYSL 1, VV, P483; BIEDERMAN I, 1990, INVITATION COGNITIVE, V2, P41; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; DUM RP, 1991, LIFE SCI R, V50, P383; FOX P T, 1987, Society for Neuroscience Abstracts, V13, P1433; FOX PT, 1989, J NUCL MED, V30, P141; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDBERG ME, 1990, J NEUROPHYSIOL, V64, P489, DOI 10.1152/jn.1990.64.2.489; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; Heilman KM., 1993, CLIN NEUROPSYCHOLOGY, P279; Heilman KM., 1993, INT J CLIN NEUROPSYC, V3dr edn, P141; HINTON GE, 1988, COGNITION, V30, P1, DOI 10.1016/0010-0277(88)90002-9; Johnson-Laird P.N., 1989, FDN COGNITIVE SCI, P469; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; Marr D., 1982, VISION; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; PARSONS LM, 1987, J EXP PSYCHOL GEN, V116, P172, DOI 10.1037/0096-3445.116.2.172; PARSONS LM, 1987, COGNITIVE PSYCHOL, V19, P178, DOI 10.1016/0010-0285(87)90011-9; PERRETT DI, 1994, CARN S COGN, P33; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MJ, 1994, IMAGES MIND, V30, P90; ROLAND PE, 1982, J NEUROPHYSIOL, V48, P467, DOI 10.1152/jn.1982.48.2.467; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; Shepard R.N., 1982, MENTAL IMAGES THEIR, DOI 10.2307/1422825; STEIN JF, 1991, BRAIN SPACE, P185; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TANJI J, 1994, NEUROSCI RES, V19, P251, DOI 10.1016/0168-0102(94)90038-8; TARR MJ, 1995, PSYCHON B REV, V2, P55, DOI 10.3758/BF03214412; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549	30	522	530	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					54	58		10.1038/375054a0	http://dx.doi.org/10.1038/375054a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723842				2022-12-01	WOS:A1995QW60400053
J	PEUNOVA, N; ENIKOLOPOV, G				PEUNOVA, N; ENIKOLOPOV, G			NITRIC-OXIDE TRIGGERS A SWITCH TO GROWTH ARREST DURING DIFFERENTIATION OF NEURONAL CELLS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE CELLS; RIBONUCLEOTIDE REDUCTASE; NADPH DIAPHORASE; SYNTHASE; PROLIFERATION; CLONING; MACROPHAGES; HEPATOCYTES; GENE	ARREST Of cell division is a prerequisite for cells to enter a program of terminal differentiation. Mitogenesis and cytostasis of neuronal cell precursors can be induced by the same or by different growth or trophic factors(1-9). Response of PC12 cells to nerve growth factor (NGF) involves a proliferative phase that is followed by growth arrest and differentiation. Here we present evidence that the cytostatic effect of NGF is mediated by nitric oxide (NO), a second messenger molecule with both para- and autocrine properties ties that can diffuse freely and act within a restricted volume(10-14). We show that NGF induces different forms of nitric oxide synthase (NOS) in neuronal cells, that nitric oxide (NO) acts as a cytostatic agent in these cells, that inhibition of NOS leads to reversal of NGF-induced cytostasis and thereby prevents full differentiation, and that capacity of a mutant cell line to differentiate can be rescued by exogenous NO, We suggest that induction of NOS is an important step in the commitment of neuronal precursors and that NOS serves as a growth arrest gene, initiating the switch to cytostasis during differentiation.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				ANDERSON DJA, 1993, REV NEUROSCI, V16, P129; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; Jacobson M., 1991, DEV NEUROBIOLOGY; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LILIEN LE, 1985, NATURE, V317, P632; MCKAY R, 1990, COLD SPRING HARB SYM, V55, P291; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	28	454	468	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					68	73		10.1038/375068a0	http://dx.doi.org/10.1038/375068a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536899				2022-12-01	WOS:A1995QW60400057
J	SCHAFER, WR; KENYON, CJ				SCHAFER, WR; KENYON, CJ			A CALCIUM-CHANNEL HOMOLOG REQUIRED FOR ADAPTATION TO DOPAMINE AND SEROTONIN IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							GENETICS; NEURONS	PROCESSING and storage of information by the nervous system requires the ability to modulate the response of excitable cells to neurotransmitter. A simple process of this type, known as adaptation or desensitization, occurs when prolonged stimulation triggers processes that attenuate the response to neurotransmitter. Here we report that the Caenorhabditis elegans gene unc-2 is required for adaptation to two neurotransmitters, dopamine and serotonin. A loss-of-function mutation in unc-2 resulted in failure to adapt either to paralysis by dopamine or to stimulation of egg laying by serotonin. In addition, unc-2 mutants displayed behaviours similar to those induced by serotonin treatment. We found that unc-2 encodes a homologue of a voltage-sensitive calcium-channel alpha-1 subunit. Expression of unc-2 occurs in two types of neurons implicated in the control of egg laying, a behaviour regulated by serotonin, Unc-2 appears to be required in modulatory neurons to downregulate the response of the egg-laying muscles to serotonin, We propose that adaptation to serotonin occurs through activation of an Unc-2-dependent calcium influx, which modulates the postsynaptic response to serotonin, perhaps by inhibiting the release of a potentiating neuropeptide.			SCHAFER, WR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Schafer, William/0000-0002-6676-8034				AKERIB CC, 1994, GENETICS, V138, P1105; ALBERTSON DG, 1993, GENETICS, V134, P211; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BRENNER S, 1974, GENETICS, V77, P71; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; HERMAN RK, 1984, GENETICS, V108, P165; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.ne.17.030194.002151; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SEYDOUX G, IN PRESS METH CELL B; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1983, GENETICS, V104, P619; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0	23	225	237	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					73	78		10.1038/375073a0	http://dx.doi.org/10.1038/375073a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723846				2022-12-01	WOS:A1995QW60400058
J	SCHUMACHER, MA; DIXON, MM; KLUGER, R; JONES, RT; BRENNAN, RG				SCHUMACHER, MA; DIXON, MM; KLUGER, R; JONES, RT; BRENNAN, RG			ALLOSTERIC TRANSITION INTERMEDIATES MODELED BY CROSS-LINKED HEMOGLOBINS	NATURE			English	Article							LIGANDED T-STATE; HUMAN-HEMOGLOBIN; CARBON-MONOXIDE; OXYGEN-BINDING; RESOLUTION; DEOXYHEMOGLOBIN; STEREOCHEMISTRY; DYNAMICS	THE structural end-points of haemoglobin's transition from its low-oxygen-affinity (T) to high-oxygen-affinity CR) state, have been well established by X-ray crystallography(1-7), but short-lived intermediates have proved less amenable to X-ray studies, Here we use chemical crosslinking to fix these intermediates for structural characterization. We describe the X-ray structures of three haemoglobins, alpha(2) beta(1)S(82)beta, alpha(2) beta(1)Tm(82)beta and alpha(2) beta(1,82)Tm(82)beta, which were crosslinked between the amino groups of residues beta Val1 and beta Lys82 by 3,3'-stilbenedicarboxylic acid (S) or trimesic acid (Tm) while in the deoxy state, and saturated with carbon monoxide before crystallization. alpha(2) beta(1)S(82)beta, which has almost normal oxygen affinity, is completely in the R-state conformation; however, alpha(2) beta(1)Tm(82)beta and alpha(2) beta(1,82)Tm(82)beta, both of which have low oxygen affinity, have been prevented from completing their transition into the R state and display many features of a transitional intermediate, These haemoglobins therefore represent a snapshot of the nascent R state.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV TORONTO,DEPT CHEM,LASH MILLER LABS,TORONTO,ON M5S 1A1,CANADA	University of Michigan System; University of Michigan; University of Toronto	SCHUMACHER, MA (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Brennan, Richard/0000-0001-7647-485X; Kluger, Ronald/0000-0002-1749-2094				ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DEREWENDA Z, 1990, J MOL BIOL, V211, P515, DOI 10.1016/0022-2836(90)90262-K; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P3; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRANKE G, 1894, ARCH LARYNGOL RHINOL, V1, P230; JONES RT, 1993, BIOCHEMISTRY-US, V32, P215, DOI 10.1021/bi00052a028; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLUGER R, 1992, BIOCHEMISTRY-US, V31, P7551, DOI 10.1021/bi00148a016; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; Perutz M.F., 1968, Journal of Crystal Growth, V2, P54, DOI 10.1016/0022-0248(68)90071-7; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SILVA MM, 1992, J BIOL CHEM, V267, P17248; SMITH FR, 1991, PROTEINS, V10, P81, DOI 10.1002/prot.340100202; SMITH FR, 1994, PROTEINS, V18, P295, DOI 10.1002/prot.340180310; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	25	81	82	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					84	87		10.1038/375084a0	http://dx.doi.org/10.1038/375084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723849	Green Submitted			2022-12-01	WOS:A1995QW60400061
J	FITTEN, LJ; PERRYMAN, KM; WILKINSON, CJ; LITTLE, RJ; BURNS, MM; PACHANA, N; MERVIS, JR; MALMGREN, R; SIEMBIEDA, DW; GANZELL, S				FITTEN, LJ; PERRYMAN, KM; WILKINSON, CJ; LITTLE, RJ; BURNS, MM; PACHANA, N; MERVIS, JR; MALMGREN, R; SIEMBIEDA, DW; GANZELL, S			ALZHEIMER AND VASCULAR DEMENTIAS AND DRIVING - A PROSPECTIVE ROAD AND LABORATORY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GERIATRIC SUBJECTS; DISEASE; PERFORMANCE; ATTENTION; PERCEPTION; SKILLS	Objective.-To characterize on-the-road, behind-the-wheel driving abilities and related laboratory performances of subjects with mild Alzheimer's disease (AD) and vascular dementia. Design.-Prospective, experimental study involving two mild dementia and three age and health control groups. Road test reliability and validity were assessed. Setting.-Greater western Los Angeles. Subjects were enrolled from the community by referral and from the Veterans Affairs dementia and diabetes clinics. Participants.-Eighty-seven driving subjects were enrolled; 83 completed the study. A sample of eligible dementia clinic subjects consisting of 15 mild AD patients met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association probable AD criteria, while 12 met Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and Hachinski diagnostic criteria for multi-infarct dementia (vascular dementia). Clinic control subjects consisted of 15 age-matched patients with diabetes and without a history of stroke or dementia. Community controls consisted of 26 healthy, age-matched, older subjects (>60 years) and 16 young subjects (20 to 35 years). Main Outcome Measures.-Drive score from the Sepulveda (Calif) road test and laboratory measures of attention, perception, and memory. Results.-The drive scores in the mild AD group (mean, 22.1; SD, 3.8) and in the vascular dementia group (mean, 24.0; SD, 7.8) differed significantly (P<.001 studentized range test) from the drive scores in the diabetic control group (mean, 31.5; SD, 3.9), the older control group (mean, 32.6; SD, 2.8), and the young control group (mean, 33.6; SD, 3.2). Drive score among the three control groups did not vary significantly. Short-term memory (Sternberg), visual tracking, and Folstein Mini-Mental State Examination scores correlated best with drive score, with a cumulative R(2) of 0.68. Drive score and number of collisions and moving violations per 1000 miles driven were negatively correlated (r=-0.38; P<.02). Conclusions.-Based on this study, type and degree of cognitive impairment are better predictors of driving skills than age or medical diagnosis per se. Specific testing protocols for drivers with potential cognitive impairment may detect unsafe drivers more effectively than using age or medical diagnosis alone as criteria for license restriction or revocation.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90024; DEPT VET AFFAIRS MED CTR,GERIATR PSYCHIAT SECT,SEPULVEDA,CA 91343; SO CALIF RES INST,CULVER CITY,CA; UNIV MICHIGAN,DEPT BIOMATH,ANN ARBOR,MI; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles			Little, Roderick/H-2440-2011; Pachana, Nancy A./AAB-9235-2022; Pachana, Nancy A./HCI-4798-2022; Pachana, Nancy A./C-6807-2016	Pachana, Nancy A./0000-0002-8927-4205				[Anonymous], ALZHEIMERS DIS; BRURSSON B, 1989, SCAND J SOC MED, V17, P253; BURNS M, 1990, J OCCUP ENVIRON MED, V32, P320, DOI 10.1097/00043764-199004000-00012; BURNS M, 1986, J CLIN PSYCHIAT, V47, P252; CARR D, 1990, J AM GERIATR SOC, V38, P1145, DOI 10.1111/j.1532-5415.1990.tb01379.x; CROSS PS, 1986, EPIDEMIOLOGY DEMENTI; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; DUBINSKY RM, 1992, J AM GERIATR SOC, V40, P1112, DOI 10.1111/j.1532-5415.1992.tb01799.x; EVANS L, 1988, J GERONTOLOGY S, V43, pS189; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.ne.11.030188.001033; GRACA JL, 1988, CLIN GERIATR MED, V2, P577; HILLS BL, 1980, PERCEPTION, V9, P183, DOI 10.1068/p090183; HUNT LA, 1990, ANN NEUROL, V28, P228; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; LOGSDON RG, 1992, J GEN INTERN MED, V7, P583, DOI 10.1007/BF02599195; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; Mackworth J, 1970, VIGILANCE ATTENTION; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MORRISON JH, 1987, BRAIN RES, V416, P331, DOI 10.1016/0006-8993(87)90914-0; MORRISON JH, 1990, IMAGING CEREBRAL TOP, P19; MOSKOWITZ H, 1986, NEUROPSYCHOBIOLOGY, V15, P38, DOI 10.1159/000118285; OLSON PL, 1986, HUM FACTORS, V28, P91, DOI 10.1177/001872088602800110; PARASURAMAN R, 1991, HUM FACTORS, V33, P539, DOI 10.1177/001872089103300506; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rubin D.B., 1987, MULTIPLE IMPUTATION, P1; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SCHAFER JL, 1991, THESIS HARVARD U BOS; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; WOLFKLEIN GP, 1989, J AM GERIATR SOC, V37, P730, DOI 10.1111/j.1532-5415.1989.tb02234.x; 1987, DIAGNOSTIC STATISTIC; 1992, STATISTICAL ABSTRACT, P612	37	191	192	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1360	1365		10.1001/jama.273.17.1360	http://dx.doi.org/10.1001/jama.273.17.1360			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715061				2022-12-01	WOS:A1995QV30700021
J	FLEG, JL; SHAPIRO, EP; OCONNOR, F; TAUBE, J; GOLDBERG, AP; LAKATTA, EG				FLEG, JL; SHAPIRO, EP; OCONNOR, F; TAUBE, J; GOLDBERG, AP; LAKATTA, EG			LEFT-VENTRICULAR DIASTOLIC FILLING PERFORMANCE IN OLDER MALE-ATHLETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; HEART-RATE; EXERCISE; AGE; HYPERTROPHY; CONTRACTION; POPULATION; INDEXES; PRELOAD; HUMANS	Objective.-To determine whether older men who have undergone intensive endurance training over many years demonstrate less age-associated impairment of early diastolic left ventricular (LV) filling performance than their sedentary peers. Design.-Cross-sectional prospective study. Setting.-Community-dwelling research volunteers. Participants.-Sixteen older competitive male endurance athletes aged 52 through 76 years and 17 young (40 years) and 23 older (52 through 76 years) sedentary control subjects from the Baltimore Longitudinal Study of Aging. Intervention.-All subjects underwent resting Doppler echocardiography and determination of maximal aerobic capacity (Vo(2)max) during graded treadmill exercise. Doppler echocardiographic studies were interpreted without knowledge of the subject's age or exercise habits. Main Outcome Measures.-Doppler-derived measures of LV diastolic filling performance: peak early (E) filling velocity, peak late (A) filling velocity, ratio of peak E to peak A velocities (E/A), and atrial filling fraction. Results.-Older athletes demonstrated higher Vo(2)max (47+/-6 mL/kg per minute [mean+/-SD]) than either the young controls (41 +/-7 mL/kg per minute) or older controls (30+/-7 mL/kg per minute) (P<.05) as evidence of their superior conditioning status. However, peak E diastolic LV filling velocity was higher in young controls (79+/-17 cm/s) than in older athletes (56+/-15 cm/s) or older controls 68+/-18 cm/s) (P<.001). This age difference persisted after normalizing peak E velocity for mitral stroke volume. Peak EIA ratio and atrial filling fraction were also similar in older athletes (1.2+/-0.5 and 0.41+/-0.1, respectively) and older controls (1.1+/-0.4 and 0.41+/-0.1, respectively), and differed significantly from corresponding values of 1.7+/-0.4 and 0.33+/-0.1 in young controls (P<.001 and P<.05, respectively), By multiple regression analysis, age but not treadmill Vo(2)max was a significant predictor of peak E velocity, peak A velocity, peak E/A ratio, and atrial filling fraction. Conclusion.-Older men with a long history of intensive endurance training demonstrate impaired early diastolic LV filling similar to that of their sedentary peers. Thus, impairment of early diastolic filling appears to be intrinsic to normative aging and not secondary to the reduction in aerobic capacity that accompanies the aging process.	JOHNS HOPKINS UNIV,BAYVIEW MED CTR,DIV CARDIOL,BALTIMORE,MD; UNIV MARYLAND,SCH MED,DIV GERONTOL,BALTIMORE,MD	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	FLEG, JL (corresponding author), NIA,GERONTOL RES CTR,CARDIOVASC SCI LAB,4940 EASTERN AVE,BALTIMORE,MD 21224, USA.		Shapiro, Edward/AAG-1611-2020; Lakatta, Edward G/AAL-1447-2020	Lakatta, Edward/0000-0002-4772-0035	NATIONAL INSTITUTE ON AGING [P01AG004402, R01AG007660] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04402, R01-AG-07660] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLETON CP, 1991, J AM COLL CARDIOL, V17, P227, DOI 10.1016/0735-1097(91)90731-N; ARORA RR, 1987, J AM COLL CARDIOL, V9, P1255, DOI 10.1016/S0735-1097(87)80464-3; BONOW RO, 1988, J AM COLL CARDIOL, V11, P50, DOI 10.1016/0735-1097(88)90166-0; BOWMAN LK, 1988, J AM COLL CARDIOL, V12, P937, DOI 10.1016/0735-1097(88)90458-5; BRYG RJ, 1987, AM J CARDIOL, V59, P971, DOI 10.1016/0002-9149(87)91136-2; CHOONG CY, 1987, J AM COLL CARDIOL, V10, P800, DOI 10.1016/S0735-1097(87)80273-5; COLAN SD, 1985, J AM COLL CARDIOL, V6, P545, DOI 10.1016/S0735-1097(85)80111-X; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DOUGLAS PS, 1992, J APPL PHYSIOL, V72, P1969, DOI 10.1152/jappl.1992.72.5.1969; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; FAGARD R, 1987, J AM COLL CARDIOL, V9, P1250, DOI 10.1016/S0735-1097(87)80463-1; FINKELHOR RS, 1986, J AM COLL CARDIOL, V8, P289, DOI 10.1016/S0735-1097(86)80042-0; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; FORTNEY S, 1992, J APPL PHYSIOL, V73, P2693, DOI 10.1152/jappl.1992.73.6.2693; GARDIN JM, 1979, J CLIN ULTRASOUND, V7, P439, DOI 10.1002/jcu.1870070606; GERSTENBLITH G, 1977, CIRCULATION, V56, P273, DOI 10.1161/01.CIR.56.2.273; GRANGER CB, 1985, J AM COLL CARDIOL, V5, P862, DOI 10.1016/S0735-1097(85)80424-1; GWATHMEY JK, 1990, J APPL PHYSIOL, V69, P1366, DOI 10.1152/jappl.1990.69.4.1366; HARRISON MR, 1991, AM J CARDIOL, V87, P622; KITZMAN DW, 1991, J AM COLL CARDIOL, V18, P1243, DOI 10.1016/0735-1097(91)90542-H; LEVY WC, 1993, CIRCULATION, V88, P116, DOI 10.1161/01.CIR.88.1.116; MATSUDA M, 1983, J APPL PHYSIOL, V55, P323, DOI 10.1152/jappl.1983.55.2.323; MIYATAKE K, 1984, AM J CARDIOL, V53, P587; Rose G, 1968, CARDIOVASCULAR SURVE; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SARTORI MP, 1987, AM J CARDIOL, V59, P1179, DOI 10.1016/0002-9149(87)90871-X; SCHULMAN SP, 1992, AM J PHYSIOL, V263, pH1932, DOI 10.1152/ajpheart.1992.263.6.H1932; SHAPIRO LM, 1983, BRIT HEART J, V50, P534; SHOCK NW, 1984, NIH842450 PUBL, P45; SPURGEON HA, 1983, AM J PHYSIOL, V244, pH513, DOI 10.1152/ajpheart.1983.244.4.H513; STARNES JW, 1983, AM J PHYSIOL, V245, P560; STODDARD MF, 1989, CIRCULATION, V79, P1226, DOI 10.1161/01.CIR.79.6.1226; SWINNE CJ, 1992, AM J CARDIOL, V69, P823, DOI 10.1016/0002-9149(92)90518-4; TAKEMOTO KA, 1992, AM HEART J, V124, P143, DOI 10.1016/0002-8703(92)90932-L; TATE CA, 1990, AM J PHYSIOL, V258, pH431, DOI 10.1152/ajpheart.1990.258.2.H431	36	80	80	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1371	1375		10.1001/jama.273.17.1371	http://dx.doi.org/10.1001/jama.273.17.1371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715063				2022-12-01	WOS:A1995QV30700023
J	HEBERT, LE; SCHERR, PA; BECKETT, LA; ALBERT, MS; PILGRIM, DM; CHOWN, MJ; FUNKENSTEIN, HH; EVANS, DA				HEBERT, LE; SCHERR, PA; BECKETT, LA; ALBERT, MS; PILGRIM, DM; CHOWN, MJ; FUNKENSTEIN, HH; EVANS, DA			AGE-SPECIFIC INCIDENCE OF ALZHEIMERS-DISEASE IN A COMMUNITY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEMENTING ILLNESSES; SENILE DEMENTIA; UNITED-STATES; PREVALENCE; PERIODS; LUNDBY; RATES	Objective.-To determine age-specific incidence rates of clinically diagnosed Alzheimer's disease. Design.-Cohort, followed a mean of 4.3 years. Setting.-East Boston, Mass. Participants.-Of 2313 persons aged 65 years and older who were initially free of Alzheimer's disease, 1601 participated in the ascertainment of incident disease (80% of survivors), 409 declined participation, and 303 died before the end of the follow-up period. A stratified sample of 642 persons received detailed clinical evaluation. Outcome Measure.-Diagnosis of new probable Alzheimer's disease through structured clinical evaluation including neurologic, neuropsychological, and psychiatric examination. Community incidence rates were computed by 5-year age groups, adjusted for gender, single year of age, length of follow-up interval, and sampling design. Results.-The estimated annual incidence of Alzheimer's disease in the population was 0.6% (95% confidence interval [CI], 0.3% to 0.9%) for persons aged 65 to 69 years, 1.0% (95% CI, 0.6% to 1.4%) for persons aged 70 to 74 years, 2.0% (95% CI, 1.3% to 2.7%) for persons aged 75 to 79 years, 3.3% (95% CI, 2.2% to 4.4%) for persons aged 80 to 84 years, and 8.4% (95% CI, 3.7% to 13.1%) for persons aged 85 years and older. Conclusions.-The incidence of Alzheimer's disease is substantial and is approximately 14 times higher among persons older than 85 years compared with those between 65 and 69 years of age.	RUSH UNIV,RUSH ALZHEIMERS DIS CTR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,AGING STUDIES BRANCH,ATLANTA,GA 30341; MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Rush University; Rush University; Centers for Disease Control & Prevention - USA; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	HEBERT, LE (corresponding author), RUSH INST AGING,1645 W JACKSON BLVD,SUITE 675,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [U01AG006789, P30AG010161, R01AG005362] Funding Source: NIH RePORTER; NIA NIH HHS [AG05362, AG06789, AG10161] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKESSON HO, 1969, HUM HERED, V19, P546, DOI 10.1159/000152266; ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; ARONSON MK, 1991, ARCH INTERN MED, V151, P989, DOI 10.1001/archinte.151.5.989; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BECKETT LA, 1992, J CLIN EPIDEMIOL, V45, P393, DOI 10.1016/0895-4356(92)90040-T; Benton A.L., 1974, REVISED VISUAL RETEN, Vfourth; COPELAND JRM, 1992, BRIT J PSYCHIAT, V161, P230, DOI 10.1192/bjp.161.2.230; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EVANS DA, 1990, AM J EPIDEMIOL, V134, P403; EVANS RA, 1993, OSTEOPOROSIS INT, V3, P71, DOI 10.1007/BF01623376; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; GRUENBERG EM, 1987, SOC STRESS DISEASE; HAGNELL O, 1981, NEUROPSYCHOBIOLOGY, V7, P201, DOI 10.1159/000117852; JARVIK LF, 1980, ARCH GEN PSYCHIAT, V37, P280; KAPLAN E, 1976, BOSTON NAMING TEST; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; KAY DWK, 1966, J PSYCHOSOM RES, V10, P3, DOI 10.1016/0022-3999(66)90128-0; KOKMEN E, 1988, NEUROLOGY, V38, P975, DOI 10.1212/WNL.38.6.975; LARSSON T, 1963, ACTA PSYCHIATR SCA S, V167, P1; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, P127, DOI 10.1159/000110922; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRSKY A, 1978, ED BRAIN 77 YB 2; MOLSA PK, 1982, ACTA NEUROL SCAND, V65, P541; MORGAN K, 1992, NEUROEPIDEMIOLOGY, V11, P80, DOI 10.1159/000110995; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; RORSMAN B, 1986, NEUROPSYCHOBIOLOGY, V15, P122, DOI 10.1159/000118254; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SAYETTA RB, 1986, J CHRON DIS, V39, P271, DOI 10.1016/0021-9681(86)90049-4; SCHOENBERG BS, 1987, ANN NEUROL, V22, P724, DOI 10.1002/ana.410220608; SPENCER G, 1984, US BUREAU CENSUS P25, V952; TAEUBER CM, 1983, US BUREAU CENSUS P23, V128; TORREY BB, 1987, US BUREAU CENSUS P95, V78	36	325	335	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1354	1359		10.1001/jama.273.17.1354	http://dx.doi.org/10.1001/jama.273.17.1354			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715060				2022-12-01	WOS:A1995QV30700020
J	KANE, RL				KANE, RL			IMPROVING THE QUALITY OF LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME PATIENTS; OUTCOMES; IMPACT	Quality of long-term care can be improved by changing the strategies used to monitor it. Nursing home care has been the subject of intensive regulations, while it has been neglected by physicians. Newer forms of long-term care are coming under stricter oversight, which may stifle the innovations they offer. Greater but different attention is needed: more creativity can be fostered with better accountability by emphasizing long-term care outcomes. It is unrealistic to require that long-term care patients will improve; good outcomes are defined as doing as well as or better than expected. The Minimum Data Set for nursing homes offers a mechanism to generate data on many pertinent outcomes. An outcomes focus would encourage more collective action by the various parties involved in providing long-term care, including physicians. Clinicians are reluctant to assume responsibility for outcomes they feel unable to strongly influence, but they must recognize that part of their role is to engender cooperation from the myriad participants in long-term care, including patients and their families. Better-quality long-term care may cost more, but it may be possible to use less expensive personnel more creatively if current regulations are modified. Managed care arrangements offer one vehicle for reorganizing care and could provide the appropriate incentives to make positive changes. However, they could also lead to minimalist strategies. Accountability for realistic outcomes can provide the needed countervailing regulatory pressure.			KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNESOTA CHAIR LONG TERM CARE & AGING,420 DELAWARE ST SE,BOX 197,MINNEAPOLIS,MN 55455, USA.				NATIONAL INSTITUTE ON AGING [K07AG000622] Funding Source: NIH RePORTER; NIA NIH HHS [5K07-AG00622] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELSTEIN AS, 1972, J MED EDUC, V47, P85; FOX PD, 1991, INITIATIVES SERVICE; FRIEDMAN B, 1993, J AM GERIATR SOC, V41, P1144, DOI 10.1111/j.1532-5415.1993.tb06465.x; GARRARD J, 1990, MED CARE, V28, P271, DOI 10.1097/00005650-199003000-00007; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Institute of Medicine report, 1986, IMPROVING QUALITY CA; Kane R.A., 1981, ASSESSING ELDERLY; Kane R L, 1976, J Community Health, V2, P1, DOI 10.1007/BF01349487; Kane R L, 1976, J Community Health, V1, P233, DOI 10.1007/BF01324582; KANE RA, 1994, HEALTH CARE FINANC R, V16, P69; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; Kane RA, 1993, ASSISTED LIVING US N; KANE RA, IN PRESS MILBANK Q; KANE RA, 1995, DELEGATION NURSING A; KANE RA, 1990, EVERYDAY ETHICS SOLV; KANE RL, 1983, GERONTOLOGIST, V23, P200, DOI 10.1093/geront/23.2.200; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1991, J AM GERIATR SOC, V39, P359, DOI 10.1111/j.1532-5415.1991.tb02900.x; KANE RL, 1993, ANNU REV PUBL HEALTH, V14, P545, DOI 10.1146/annurev.pu.14.050193.002553; KUROWSKI BD, 1982, HE222C182 US DEP HLT; MALONE JK, 1993, J HLTH CARE BENE JAN, P51; MANGEN DJ, 1984, HLTH PROGRAM EVALUAT; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MENDELSON MA, 1974, TENDER LOVING GREED; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS R, 1974, GERONTOLOGIST, V14, P14, DOI 10.1093/geront/14.1.14; MORRIS R, 1980, AM J PUBLIC HEALTH, V70, P471, DOI 10.2105/AJPH.70.5.471; ROGERS A, 1989, PUBLIC HEALTH REP, V104, P222; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P35; SIU AL, 1993, J CLIN EPIDEMIOL, V46, P1093, DOI 10.1016/0895-4356(93)90108-D; TERESI JA, 1992, GERONTOLOGIST, V32, P148, DOI 10.1093/geront/32.2.148; Vladeck B.C., 1980, UNLOVING CARE NURSIN; WEISSERT WG, 1989, HLTH CARE ELDERLY IN; 1990, MEDICARE STRATEGY QU; 1993, MEDICARE AM HLTH CAR	40	68	69	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1376	1380		10.1001/jama.1995.03520410070029	http://dx.doi.org/10.1001/jama.1995.03520410070029			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715064				2022-12-01	WOS:A1995QV30700024
J	OUSLANDER, JG; SCHNELLE, JF; UMAN, G; FINGOLD, S; NIGAM, JG; TUICO, E; BATESJENSEN, B				OUSLANDER, JG; SCHNELLE, JF; UMAN, G; FINGOLD, S; NIGAM, JG; TUICO, E; BATESJENSEN, B			PREDICTORS OF SUCCESSFUL PROMPTED VOIDING AMONG INCONTINENT NURSING-HOME RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; MUSCLE EXERCISE; CARE; MANAGEMENT; FACILITIES; PATIENT; WOMEN	Objective.-To develop a simple, noninvasive assessment strategy that will enable nursing home staff to identify incontinent residents who respond well to prompted voiding. Design.-Incontinent nursing home residents underwent an extensive clinical and functional assessment and then 7 days of prompted voiding. Data from the assessment and the first 3 days of prompted voiding were used to predict responsiveness to the intervention. Setting.-Seven nursing homes. Patients.-A cohort of 191 incontinent, long-stay nursing home residents who passed a simple behavioral screen (able to state their name or reliably point to one of two named objects). Intervention.-Prompted voiding was carried out by trained research nurse's aides from 7 AM to 7 PM for 7 days, The intervention was maintained in responsive residents 5 days per week for an additional 9 weeks. Main Outcome Measures.-Physical checks for wetness were done by research staff hourly from 7 AM to 7 PM for 3 days in a baseline condition, during days 5 through 7 of the 7-day prompted voiding intervention, and for 3 days at the end of 9 weeks of prompted voiding in the responsive group. Outcome measures were percentage of checks wet and response to prompted voiding, with ''responders'' defined as residents with an average of one or fewer wet episode per day on days 5 through 7 of prompted voiding. Results.-Seventy-eight (41%) of the residents were responders. Their wet percentage went from 26.7% to 6.4% at the end of 1 week and was maintained at 9.6% after 9 weeks of prompted voiding. The best predictors of responsiveness were the wet percentage and the appropriate toileting percentage during the first 3 days of prompted voiding, the self-care subscale score of the Multidimensional Observational Scale for the Elderly, and the ability to ambulate without human assistance. The best sensitivity and specificity in identifying responders was achieved when either the wet percentage was lower than 20% or the appropriate toileting percentage was higher than 66% during the first 3 days of prompted voiding (sensitivity, 87%; specificity, 69%). Those residents falsely identified as responders by these criteria still had a 46% relative reduction in wetness. Conclusions.-A substantial proportion of nursing home residents respond well to prompted voiding, The most responsive residents can be easily identified using data collected during a 3-day trial of the intervention, The assessment strategy is consistent with federal guidelines and could be used to facilitate quality control by assessing changes in percentage of wetness from the expected norm.	UNIV CALIF LOS ANGELES,BORUN CTR GERONTOL RES,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MULTICAMPUS PROGRAM GERIATR MED & GERONTOL,LOS ANGELES,CA 90024; JEWISH HOME AGING,RESEDA,CA 91335	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Bates-Jensen, Barbara/ABA-3726-2020		NATIONAL INSTITUTE ON AGING [R37AG008678] Funding Source: NIH RePORTER; NIA NIH HHS [R37AGO8678] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURGIO LD, 1994, J AM GERIATR SOC, V42, P315, DOI 10.1111/j.1532-5415.1994.tb01758.x; BURNS PA, 1993, J GERONTOL, V48, pM167; BURTON JR, 1988, J AM GERIATR SOC, V36, P693, DOI 10.1111/j.1532-5415.1988.tb07170.x; COLLING J, 1988, NURS CLIN N AM, V23, P279; COLLING J, 1992, J AM GERIATR SOC, V39, P135; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; HU TW, 1989, JAMA-J AM MED ASSOC, V261, P2656, DOI 10.1001/jama.261.18.2656; Igou J, 1986, Clin Geriatr Med, V2, P873; OUSLANDER J, 1989, J AM GERIATR SOC, V37, P715, DOI 10.1111/j.1532-5415.1989.tb02232.x; OUSLANDER JG, 1987, J GERONTOL, V42, P631, DOI 10.1093/geronj/42.6.631; OUSLANDER JG, IN PRESS ANN INTERN; OUSLANDER JG, 1991, MED CARE NURSING HOM, P163; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; SCHNELLE JF, 1990, GERONTOLOGIST, V30, P373, DOI 10.1093/geront/30.3.373; SCHNELLE JF, 1993, J AM GERIATR SOC, V41, P1259, DOI 10.1111/j.1532-5415.1993.tb07312.x; SCHNELLE JF, 1991, J AM GERIATR SOC, V39, P165, DOI 10.1111/j.1532-5415.1991.tb01620.x; SCHNELLE JF, 1991, MANAGING URINARY INC; SCHNELLE JF, 1992, GERONTOLOGIST, V33, P114; WELLS TJ, 1990, J AM GERIATR SOC, V38, P333, DOI 10.1111/j.1532-5415.1990.tb03515.x; 1992, AHCPR920038 AG HLTH; 1991, RESIDENT ASSESSMENT; 1991, FED REG         0926, V56, P48865	25	91	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1366	1370						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715062				2022-12-01	WOS:A1995QV30700022
J	TINETTI, ME; INOUYE, SK; GILL, TM; DOUCETTE, JT				TINETTI, ME; INOUYE, SK; GILL, TM; DOUCETTE, JT			SHARED RISK-FACTORS FOR FALLS, INCONTINENCE, AND FUNCTIONAL DEPENDENCE - UNIFYING THE APPROACH TO GERIATRIC SYNDROMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PERSONS; URINARY-INCONTINENCE; COMMUNITY; PREDICTORS; PEOPLE	Objective.-To determine whether a set of factors representing impairments in multiple areas could be identified that predisposes to falling, incontinence, and functional dependence. Design.-Population-based cohort with a 1-year follow-up. Setting.-General community. Participants.-A total of 927 New Haven, Conn, residents, aged 72 years and older who completed the baseline and 1-year interviews. Main Outcome Measures.-At least one episode of urinary incontinence per week, at least two falls during the follow-up year, and dependence on human help for one or more basic activities of daily living. Results.-At 1 year, urinary incontinence was reported by 16%, at least two falls by 10%, and functional dependence by 20% of participants. The four independent predisposing factors for the outcomes of incontinence, falling, and functional dependence included slow timed chair stands (lower extremity impairment), decreased arm strength (upper extremity impairment), decreased vision and hearing (sensory impairment), and either a high anxiety or depression score (affective impairment). There was a significant increase in each of incontinence, falling, and functional dependence as the number of these predisposing factors increased. For example, the proportion of participants experiencing functional dependence doubled (7% to 14% to 28% to 60%) (chi(2)=119.8; P<.001) as the number of predisposing factors increased from zero to one to two to at least three. Conclusions.-Our findings suggest that predisposition to geriatric syndromes and functional dependence may result when impairments in multiple domains compromise compensatory ability. It may be possible to restore compensatory ability and prevent or delay the onset of several geriatric syndromes and, perhaps, functional dependence by modifying a shared set of predisposing factors. Perhaps it is time to take a more unified approach to the geriatric syndromes and functional dependence.	YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA	Yale University	TINETTI, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.		Inouye, Sharon/R-7216-2019; Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NIA NIH HHS [P60AG10469, AG07449] Funding Source: Medline; PHS HHS [K08AB00524] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469, R01AG007449] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER NB, 1994, J AM GERIATR SOC, V42, P93, DOI 10.1111/j.1532-5415.1994.tb06081.x; [Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Cahalan D., 1969, AM DRINKING PRACTICE; CORNONIHUNTLEY J, 1986, DHHS NIH862443 NAT I; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, JAMA-J AM MED ASSOC, V267, P827; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; Hosmer D, 2013, APPL LOGISTIC REGRES; Houston K A, 1993, Clin Geriatr Med, V9, P157; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MARTIN GR, 1993, ANNU REV MED, V44, P419, DOI 10.1146/annurev.me.44.020193.002223; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RESNICK NM, 1994, J AM GERIATR SOC, V42, P202, DOI 10.1111/j.1532-5415.1994.tb04953.x; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RESNICK NM, 1992, HOSP PRACT      1015, P552; Reuben D. B., 1991, GERIATRICS REV SYLLA, P117; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.149.7.1628; SIU AL, 1993, J AM GERIATR SOC, V41, P78, DOI 10.1111/j.1532-5415.1993.tb05952.x; SMITH LA, 1990, J AM GERIATR SOC, V38, P993, DOI 10.1111/j.1532-5415.1990.tb04422.x; Spielberger CD, 1970, STAI MANUAL; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, IN PRESS J AM GERIAT; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212	33	599	616	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1348	1353		10.1001/jama.273.17.1348	http://dx.doi.org/10.1001/jama.273.17.1348			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715059				2022-12-01	WOS:A1995QV30700019
J	TORRENS, PR; LYNCH, BS; BONNIE, RJ				TORRENS, PR; LYNCH, BS; BONNIE, RJ			GROWING-UP TOBACCO FREE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											TORRENS, PR (corresponding author), INST MED,COMM PREVENTING NICOTINE ADDICT CHILDREN & YOUTH,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1326	1326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715049				2022-12-01	WOS:A1995QV30700003
J	BLUMBERG, HM; WATKINS, DL; BERSCHLING, JD; ANTLE, A; MOORE, P; WHITE, N; HUNTER, M; GREEN, B; RAY, SM; MCGOWAN, JE				BLUMBERG, HM; WATKINS, DL; BERSCHLING, JD; ANTLE, A; MOORE, P; WHITE, N; HUNTER, M; GREEN, B; RAY, SM; MCGOWAN, JE			PREVENTING THE NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						INFECTION CONTROL; TUBERCULOSIS; CROSS INFECTION; HEALTH PERSONNEL; TUBERCULIN TEST	HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; OUTBREAK	Objective: To study the efficacy of expanded tuberculosis infection control measures consisting primarily of administrative controls. Design: Descriptive case series. Setting: University-affiliated, inner-city hospital. Interventions: Introduction of expanded tuberculosis infection control measures (including an expanded respiratory isolation policy). Measurements: The number of tuberculosis exposure episodes and skin test conversion rates of health care workers were measured before and after implementation of expanded infection control measures. Tuberculosis exposure episodes (the number of patients who were not placed in respiratory isolation at admission but who subsequently had a diagnosis of acid-fast bacilli smear-positive pulmonary tuberculosis during that admission or within 2 weeks of discharge) were compared for two time periods: the 8 months before and the 28 months after implementation of infection control measures. Tuberculin skin test conversion rates among health care workers were evaluated during a 2.5-year period. Results: After expanded infection control measures were implemented, the number of tuberculosis exposure episodes decreased from 4.4 per month (35 episodes among 103 patient admissions for potentially infectious tuberculosis over 8 months) to 0.6 per month (18 episodes among 358 patient admissions for smear-positive pulmonary tuberculosis over 28 months) (odds ratio, 9.72; 95% CI, 4.99 to 19.25 [P < 0.001]). The cumulative number of days per month that potentially infectious patients with tuberculosis were not in isolation decreased from 35.4 to 3.3 (P < 0.001). A concomitant decrease in tuberculin skin test conversion rates in health care workers was seen; 6-month tuberculin skin test conversion rates decreased steadily from 3.3% (118 conversions in 3579 health care workers; 1/92 to 6/92), 1.7%, 1.4%, 0.6%, to 0.4% (23 conversions in 5153 workers [1/94 to 6/94]) (P < 0.001). Conclusions: Infection control measures effectively prevented nosocomial transmission of tuberculosis to health care workers. Administrative controls appear to be the most important component of a tuberculosis infection control program and should be the first focus of such a program, especially at public hospitals, where resources are most likely to be limited.	GRADY MEM HOSP, CLIN MICROBIOL LAB, ATLANTA, GA 30335 USA; GRADY MEM HOSP, DEPT EPIDEMIOL, ATLANTA, GA 30335 USA; GRADY MEM HOSP, OCCUPAT HLTH SERV, ATLANTA, GA 30365 USA		BLUMBERG, HM (corresponding author), EMORY UNIV, SCH MED, DIV INFECT DIS, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.		Blumberg, Henry/W-2156-2019; mcgowan, john e/G-5404-2011	Blumberg, Henry/0000-0002-3110-2443; Ray, Susan/0000-0002-6327-088X	NHLBI NIH HHS [K07 HL03078-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J., 1995, Journal of Investigative Medicine, V43, p38A; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BEEKMANN SE, 1993, INFECT CONT HOSP EP, V14, P228; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689, DOI 10.1086/646671; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FELLA P, 1994, AM J INFECT CONTROL, V22, P100; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FLORA GS, 1990, CHEST, V98, P1056, DOI 10.1378/chest.98.5.1056; GREIFINGER R, 1992, Morbidity and Mortality Weekly Report, V41, P507; HAAS DW, 1994, AM J MED, V96, P439, DOI 10.1016/0002-9343(94)90171-6; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JACOBS RF, 1994, CLIN INFECT DIS, V19, P1, DOI 10.1093/clinids/19.1.1; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Kent PT, 1985, GUIDE LEVEL 3 LAB; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; NOLTE FS, 1995, IN PRESS MANUAL CLIN; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P305; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; ZAZA S, 1992, 1992 WORLD C TUB BET; E74193 AM SOC TEST M; 1992, MMWR-MORBID MORTAL W, V41, P55	32	146	149	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					658	663		10.7326/0003-4819-122-9-199505010-00003	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702227				2022-12-01	WOS:A1995QV15100003
J	OWENS, DK; HARRIS, RA; SCOTT, PM; NEASE, RF				OWENS, DK; HARRIS, RA; SCOTT, PM; NEASE, RF			SCREENING SURGEONS FOR HIV-INFECTION - A COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review						COST-BENEFIT ANALYSIS; SURGEONS; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; MASS SCREENING	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HEALTH-CARE WORKERS; UNITED-STATES-ARMY; HEPATITIS-B VIRUS; CONTROLLED TRIAL; SEXUAL-BEHAVIOR; AIDS EDUCATION; CONDOM USE; TRIMETHOPRIM SULFAMETHOXAZOLE	Objective To determine the cost-effectiveness of a policy to screen surgeons for human immunodeficiency virus (HIV) infection to prevent transmission of HIV to patients having invasive procedures. Design: Cost-effectiveness analysis. Results: A one-time national screening program would identify approximately 137 surgeons with HIV infection (range, 28 to 423 surgeons) and would prevent approximately 4.3 infections (range, 1.9 to 21.3 infections) in patients treated by infected surgeons and 0.9 infections (range, 0 to 12.9 infections) in sexual partners of infected surgeons at a direct cost of $8.1 million and an induced cost of approximately $44 million. It would result in expenditures of $458 000 per year of life saved (range, $147 000 to $687 000 per year of life saved), whereas an annual screening program would result in expenditures of approximately $1.1 million per year of life saved (range, $338 000 to $1 886 000 per year of life saved). If the prevalence of HIV infection in surgeons is estimated to be three times our base-case estimate (an increase from 0.1% to 0.3%), annual screening would result in expenditures of approximately $741 000 per year of life saved. If the probability of seroconversion after a patient is exposed to a contaminated instrument is increased to 5.0% from our base-case estimate of 0.29%, an annual screening program would still cost more than $228 000 per year of life saved. Conclusion: Screening surgeons for HIV to prevent transmission of HIV to patients having invasive procedures requires expenditures per year of life saved that are considerably in excess of those of most accepted health interventions. Surveillance studies of patients treated by surgeons infected with HIV should be continued to confirm that transmission of HIV to patients having invasive procedures is rare.	STANFORD UNIV, STANFORD, CA 94305 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA	Stanford University; Dartmouth College	OWENS, DK (corresponding author), DEPT VET AFFAIRS MED CTR, GEN INTERNAL MED SECT 111A, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA.				AHRQ HHS [RD3 HSO7232-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BELL DM, 1992, INFECT AGENT DIS, V1, P263; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BIDDLECOM AE, 1992, J ACQ IMMUN DEF SYND, V5, P1131; BILLY JOG, 1993, FAM PLANN PERSPECT, V25, P52, DOI 10.2307/2136206; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; CALSYN DA, 1992, AM J PUBLIC HEALTH, V82, P573, DOI 10.2105/AJPH.82.4.573; CAMPBELL LS, 1991, SOUTHERN MED J, V84, P22, DOI 10.1097/00007611-199101000-00007; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CHAVEY WE, 1994, J FAM PRACTICE, V38, P249; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; ELSADR W, 1994, PHS AHCPR940572 US D; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FUCHS VR, 1986, HEALTH ECON, P49; GAFNI A, 1993, CAN MED ASSOC J, V148, P913; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GARCIA A, 1992, 8 HARV U DUTCH F AID, pC348; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM D, 1988, DETAILED DIAGNOSES P; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; Hahn B., 1992, ANN EXPENSES SOURCES; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HEDLUND K, 1990, AIDS 90S SCI POLICY, P256; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1994, INFECT CONT HOSP EP, V15, P631, DOI 10.2307/30145273; HIATT RA, 1990, ARCH INTERN MED, V150, P833, DOI 10.1001/archinte.150.4.833; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HILTS PJ, 1991, NY TIMES        0927, pA8; HUNT AJ, 1991, AIDS, V5, P723, DOI 10.1097/00002030-199106000-00012; JEWETT JF, 1993, JAMA-J AM MED ASSOC, V269, P1144, DOI 10.1001/jama.269.9.1144; KAMENGA M, 1989, AIDS SCI SOCIAL CHAL, V1, P703; KU LC, 1992, FAM PLANN PERSPECT, V24, P100, DOI 10.2307/2135538; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LETTAU LA, 1992, INFECT CONT HOSP EP, V13, P336, DOI 10.1086/646541; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LIFSON A, 1989, 5 INT C AIDS MONTR, P60; LINDAN C, 1990, AIDS 90S SCI POLICY, P256; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OWENS DK, 1992, AM J MED, V92, P503, DOI 10.1016/0002-9343(92)90747-Y; OWENS DK, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P153; OWENS DK, 1990, AIDS 90S SCI POLICY, V3, P308; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; PADIAN NS, 1990, AM J PUBLIC HEALTH, V80, P990, DOI 10.2105/AJPH.80.8.990; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; ROBACK G, 1992, PHYSICIAN CHARACTERI; ROBERT L, 1993, 1ST NAT F INF DIS NA, P1; ROSENTHAL E, 1991, NY TIMES        1020, pB5; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SCHULMAN KA, 1994, INFECT CONT HOSP EP, V15, P147, DOI 10.1086/646882; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SELL RL, 1994, INFECT CONT HOSP EP, V15, P635, DOI 10.2307/30145274; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; SONENSTEIN FL, 1989, FAM PLANN PERSPECT, V21, P152, DOI 10.2307/2135805; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VITTECOQ D, 1992, 8 HARV U DUTCH F AID, P45; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WELCH J, 1989, LANCET, V1, P205; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WITHERS BG, 1992, MIL MED, V157, P80, DOI 10.1093/milmed/157.2.80; WOOD FW, 1990, AM PROFILE OPINIONS; Yawn B P, 1992, Fam Med, V24, P355; 1991, MMWR-MORBID MORTAL W, V40, P377; 1988, MMWR-MORBID MORTAL W, V37, P229; 1988, MMWR-MORBID MORTAL W, V37, P239; 1992, MMWR-MORBID MORTAL W, V41, P344; 1993, STATISTICAL ABSTRACT; 1994, PHYSICIAN CHARACTERI; 1991, NY TIMES        1020, P7; 1992, 8 HARV U DUTCH F AID, pC348; 1993, MMWR-MORBID MORTAL W, V42, P329; 1994, SOCIOECONOMIC CHARAC; 1990, MMWR-MORBID MORTAL W, V39, P489; 1992, STATISTICAL ABSTRACT; 1990, VITAL STATISTICS US; 1990, MMWR-MORBID MORTAL W, V39, P380	108	39	39	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					641	652		10.7326/0003-4819-122-9-199505010-00001	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00001			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702225				2022-12-01	WOS:A1995QV15100001
J	ROBERT, LM; CHAMBERLAND, ME; CLEVELAND, JL; MARCUS, R; GOOCH, BF; SRIVASTAVA, PU; CULVER, DH; JAFFE, HW; MARIANOS, DW; PANLILIO, AL; BELL, DM				ROBERT, LM; CHAMBERLAND, ME; CLEVELAND, JL; MARCUS, R; GOOCH, BF; SRIVASTAVA, PU; CULVER, DH; JAFFE, HW; MARIANOS, DW; PANLILIO, AL; BELL, DM			INVESTIGATIONS OF PATIENTS OF HEALTH-CARE WORKERS INFECTED WITH HIV - THE CENTERS-FOR-DISEASE-CONTROL AND PREVENTION DATABASE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HEALTH PERSONNEL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; ACQUIRED IMMUNODEFICIENCY SYNDROME; RISK	HUMAN-IMMUNODEFICIENCY-VIRUS; LOOK-BACK; TRANSMISSION; SURGEON; DENTISTS; ABSENCE; RISK	Objective: To assess the risk for transmission of the human immunodeficiency virus (HIV) from an infected health care worker to patients. Design: Survey of investigators from health departments, hospitals, and other agencies who had elected to notify patients who had received care from health care workers infected with HIV. Measurements: Information was collected about infected health care workers, their work practices, their patients' HIV test results, procedures that they did on those of their patients who were tested for HIV, and patient notification procedures. Results: As of 1 January 1995, information about investigations of 64 health care workers infected with HIV was reported to the Centers for Disease Control and Prevention; HIV test results were available for approximately 22 171 patients of 51 of the 64 health care workers. For 37 of the 51 workers, no seropositive patients were reported among 13 063 patients tested for HIV. For the remaining 14 health care workers, 113 seropositive patients were reported among 9108 patients. Epidemiologic and laboratory follow-up did not show any health care worker to have been a source of HIV for any of the patients tested. Conclusion: Despite limitations, these data are consistent with previous assessments that state that the risk for transmission of HIV from a health care worker to a patient is very small. These data also support current recommendations that state that retrospective patient notification need not be done routinely.	CTR DIS CONTROL & PREVENT, CTR PREVENT SERV, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ROBERT, LM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, HOSP INFECT PROGRAM, 1600 CLIFTON RD, MAILSTOP E-68, ATLANTA, GA 30333 USA.			Marcus, Ruthanne/0000-0002-9094-0674				[Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARMSTRONG FP, 1987, MIL MED, V152, P414; ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BABINCHAK TJ, 1994, CHEST, V106, P681, DOI 10.1378/chest.106.3.681; BEK M, 1994, NEW S WALES PUBLIC H, V5, P83; BELL DM, 1992, INFECT AGENT DIS, V1, P263; CARDO D, 1994, INTERSCIENCE C ANTIM; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; Comer R W, 1991, J Dent Educ, V55, P187; Cottone J A, 1992, J Dent Educ, V56, P536; Crawshaw S C, 1994, Commun Dis Rep CDR Rev, V4, pR125; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; Heuer M A, 1992, J Dent Educ, V56, P528; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; LONGFIELD JN, 1994, J INFECT DIS, V169, P1, DOI 10.1093/infdis/169.1.1; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; TAPPER ML, 1992, INFECT CONT HOSP EP, V13, P482, DOI 10.1086/646577; Taylor M, 1992, J Dent Educ, V56, P540; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141	27	64	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					653	657		10.7326/0003-4819-122-9-199505010-00002	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702226				2022-12-01	WOS:A1995QV15100002
J	BARKER, DJP; WINTER, PD; OSMOND, C; PHILLIPS, DIW; SULTAN, HY				BARKER, DJP; WINTER, PD; OSMOND, C; PHILLIPS, DIW; SULTAN, HY			WEIGHT-GAIN IN INFANCY AND CANCER OF THE OVARY	LANCET			English	Note								The geographic association between ovarian cancer and tall stature suggests a link with rapid growth in early childhood. Among 5585 women born in Hertfordshire, UK, 41 who died from ovarian cancer had had a high rate of weight in infancy. Whereas their mean birthweight was the same as that of the other women, their mean weight at 1 year was higher (22.3 pounds [10.1 kg] vs 21.4 pounds [9.7 kg], p=0.01). These observations are consistent with the hypothesis that ovarian cancer is linked to altered patterns of gonadotropin release established in utero when the fetal hypothalamus is imprinted.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; BALASCH J, 1993, HUM REPROD, V8, P990, DOI 10.1093/oxfordjournals.humrep.a138215; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BERAL V, 1978, LANCET, V1, P1083; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Pfeiffer CA, 1936, AM J ANAT, V58, P195, DOI 10.1002/aja.1000580112; VONSAAL FS, 1980, SCIENCE, V208, P597; WHITTEMORE AS, 1989, CANCER RES, V49, P4047	10	35	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1087	1088		10.1016/S0140-6736(95)90821-8	http://dx.doi.org/10.1016/S0140-6736(95)90821-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7619123				2022-12-01	WOS:A1995QV41100013
J	CHENG, KK; DUFFY, SW; DAY, NE; LAM, TH; CHUNG, SF; BADRINATH, P				CHENG, KK; DUFFY, SW; DAY, NE; LAM, TH; CHUNG, SF; BADRINATH, P			STOPPING DRINKING AND RISK OF ESOPHAGEAL CANCER	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; ESOPHAGEAL CANCER; ALCOHOL; CONSUMPTION	Objective-To examine the effect of stopping drinking on the risk of oesophageal cancer. Design-Hospital based case-control study. Setting-Surgical departments of four district general hospitals and general practices in Hong Kong. Subjects-Cases were 400 consecutive admissions of patients with histologically confirmed diagnosis of oesophageal cancer during a 21 month period in 1989-90 (87% response rate). Controls were 1598 patients selected from the same surgical departments as the cases and from the general practices from which the cases were originally referred (95% response rate). Main outcome measure-Relative risk of developing oesophageal cancer after stopping drinking (adjusted for age, education, place of birth, smoking, and diet). Results-Current light drinking (<200 g ethanol/week) was not associated with significant increase in risk. Among former drinkers risk fell more quickly in moderate (200-599 g/week) than heavy (greater than or equal to 600 g/week) drinkers. Even among heavy drinkers, however, risk had dropped substantially after five to nine years of not drinking. The results suggest that the time taken for risk to return to that in subjects who never drink was 10-14 years for moderate drinkers and 15 years or more, if ever, for heavy drinkers. Conclusion-Risk of oesophageal cancer decreases fairly rapidly with time after abstaining from drinking. This new finding could be used in health promotion to encourage behavioural changes, especially in heavy drinkers, who have a very high risk of developing oesophageal cancer. It also suggests that alcoholic beverages have a strong effect on the late stage of carcinogenesis.	MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; UNIV HONG KONG,DEPT COMMUNITY MED,HONG KONG,HONG KONG; UNIV CAMBRIDGE,DEPT COMMUNITY MED,CAMBRIDGE,ENGLAND	MRC Biostatistics Unit; University of Hong Kong; University of Cambridge	CHENG, KK (corresponding author), UNIV BIRMINGHAM,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Cheng, Kar/AAL-8899-2021; Lam, Tai Hing/C-4317-2009	Cheng, Kar/0000-0002-1516-1857; Lam, Tai Hing/0000-0002-2033-9971; Chung, Siu Fung/0000-0001-6640-5893				Alcohol Drinking, 1988, IARC MONOGRAPHS EVAL; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BRESLOW N. E., 1980, STATISTICAL METHODS; BYERS T, 1982, LANCET, V1, P799; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312; DAY NE, 1980, JNCI-J NATL CANCER I, V64, P977; HIATT RA, 1988, CANCER RES, V48, P2284; MARTINEZ I, 1969, J NATL CANCER I, V42, P1069; ROSENBERG L, 1982, LANCET, V1, P267; SHOPLAND DR, 1990, IARC SCI PUBL, V103, P77; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; [No title captured]; [No title captured]	14	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1094	1097		10.1136/bmj.310.6987.1094	http://dx.doi.org/10.1136/bmj.310.6987.1094			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742674	Green Published			2022-12-01	WOS:A1995QW61800013
J	FIELD, K; THOROGOOD, M; SILAGY, C; NORMAND, C; ONEILL, C; MUIR, J				FIELD, K; THOROGOOD, M; SILAGY, C; NORMAND, C; ONEILL, C; MUIR, J			STRATEGIES FOR REDUCING CORONARY RISK-FACTORS IN PRIMARY-CARE - WHICH IS MOST COST-EFFECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the relative cost effectiveness of a range of screening and intervention strategies for preventing coronary heart disease in primary care. Subjects-7840 patients aged 35-64 years who were participants in a trial of modifying coronary heart disease Ask factors in primary care. Design-Effectiveness of interventions assumed and the potential years of life gained estimated from a risk equation calculated from Framingham study data. Main outcome measure-The cost per year of life gained. Results-The most cost effective strategy was minimal screening of blood pressure and personal history of vascular disease, which cost pound 310-pound 930 per year of life gained for men and pound 1100-pound 3460 for women excluding treatment of raised blood pressure. The extra cost per life year gained by adding smoking history to the screening was pound 400-pound 6300 in men. AU strategies were more cost effective in men than in women and more cost effective in older age groups. Lipid lowering drugs accounted for at least 70% of the estimated costs of all strategies. Cost effectiveness was greatest when drug treatment was limited to those with cholesterol concentrations above 9.5 mmol/l. Conclusions-Universal screening and intervention strategies are an inefficient approach to reducing the coronary heart disease burden. A basic strategy for screening and intervention, targeted at older men with raised blood pressure and limiting the use of cholesterol lowering drugs to those with very high cholesterol concentrations would be most cost effective.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; GWENT COLL,NEWPORT BUSINESS SCH,NEWPORT NP9 5XR,GWENT,WALES; FLINDERS UNIV S AUSTRALIA,SCH MED,DEPT GEN PRACTICE,ADELAIDE,SA 5001,AUSTRALIA; UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,GEN PRACTICE RES GRP,OXFORD OX2 6HE,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of Wales Newport; Flinders University South Australia; Radcliffe Infirmary; University of Oxford				Normand, Charles/0000-0002-0885-5754				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; LANGHAM SJ, 1994, HLTH CARE NEEDS ASSE, V1, P341; SILAGY C, 1994, J CLIN EPIDEMIOL, V47, P993, DOI 10.1016/0895-4356(94)90114-7; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1991, DH123 OFF POP CENS S	8	60	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1109	1112		10.1136/bmj.310.6987.1109	http://dx.doi.org/10.1136/bmj.310.6987.1109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742678	Green Published			2022-12-01	WOS:A1995QW61800018
J	FRANKLIN, KA; NILSSON, JB; SAHLIN, C; NASLUND, U				FRANKLIN, KA; NILSSON, JB; SAHLIN, C; NASLUND, U			SLEEP-APNEA AND NOCTURNAL ANGINA	LANCET			English	Note							MECHANISMS; APNEA	Hypoxaemia occurs with sloop apnoea and might induce nocturnal angina. Sleep apnoea was found in 9 of 10 patients with nocturnal angina pectoris. Nocturnal angina diminished during treatment of sleep apnoea by continuous positive airway-pressure, and the number of nocturnal myocardial ischaemic events measured by computerised vector-cardiography was reduced.	UNIV HOSP NO SWEDEN,DEPT INTERNAL MED,S-90185 UMEA,SWEDEN	Umea University	FRANKLIN, KA (corresponding author), UNIV HOSP NO SWEDEN,DEPT PULM MED & ALLERGOL,S-90185 UMEA,SWEDEN.			Franklin, Karl/0000-0002-5306-1697; Naslund, Ulf/0000-0003-4100-8298				BALFORS EM, 1994, AM J RESP CRIT CARE, V150, P1587, DOI 10.1164/ajrccm.150.6.7952619; CHIERCHIA S, 1980, CIRCULATION, V61, P759, DOI 10.1161/01.CIR.61.4.759; GUILLEMINAULT C, 1984, LANCET, V1, P126; JENSEN SM, 1994, CORONARY ARTERY DIS, V5, P507; QUYYUMI AA, 1984, LANCET, V1, P1207; SULLIVAN CE, 1981, LANCET, V1, P862; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	7	189	193	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1085	1087		10.1016/S0140-6736(95)90820-X	http://dx.doi.org/10.1016/S0140-6736(95)90820-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715342				2022-12-01	WOS:A1995QV41100012
J	GRAHAM, JR				GRAHAM, JR			HELICOBACTER-PYLORI - HUMAN PATHOGEN OR SIMPLY AN OPPORTUNIST	LANCET			English	Editorial Material							PEPTIC-ULCER DISEASE; GASTRITIS; CAMPYLOBACTER; INFECTION				GRAHAM, JR (corresponding author), SYDNEY HOSP,ALAN MCGUINNESS GASTROENTEROL UNIT,SYDNEY,NSW 2000,AUSTRALIA.							Adelberg, 1982, REV MED MICROBIOLOGY; BAYERDORFFER E, 1993, NEW ENGL J MED, V329, P60, DOI 10.1056/NEJM199307013290116; CHANDRAKUMARAN K, 1994, GUT, V35, P1033, DOI 10.1136/gut.35.8.1033; FALLINGBORG J, 1992, SCAND J GASTROENTERO, V27, P388, DOI 10.3109/00365529209000093; FONG TL, 1991, GASTROENTEROLOGY, V100, P328, DOI 10.1016/0016-5085(91)90199-U; FORBES G, 1994, MED J AUSTRALIA, V161, P291, DOI 10.5694/j.1326-5377.1994.tb127445.x; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; KOOP H, 1991, DIGESTION, V48, P230, DOI 10.1159/000200698; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MCCORMICK PA, 1991, GUT, V32, P351, DOI 10.1136/gut.32.4.351; ROSS JS, 1992, AM J PATHOL, V141, P721; SAEED ZA, 1991, DIGEST DIS SCI, V36, P15, DOI 10.1007/BF01300080; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; TAHA AS, 1993, GUT, V34, P580, DOI 10.1136/gut.34.5.580; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734; UPPAL R, 1991, ARCH INTERN MED, V151, P760, DOI 10.1001/archinte.151.4.760	19	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1095	1097		10.1016/S0140-6736(95)90824-2	http://dx.doi.org/10.1016/S0140-6736(95)90824-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715345				2022-12-01	WOS:A1995QV41100016
J	GULY, UM; MITCHELL, RG; COOK, R; STEEDMAN, DJ; ROBERTSON, CE				GULY, UM; MITCHELL, RG; COOK, R; STEEDMAN, DJ; ROBERTSON, CE			PARAMEDICS AND TECHNICIANS ARE EQUALLY SUCCESSFUL AT MANAGING CARDIAC-ARREST OUTSIDE HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR-FIBRILLATION; CARDIOPULMONARY-RESUSCITATION; HEARTSTART-SCOTLAND; FLYING SQUAD; DEFIBRILLATION; SURVIVAL; EMERGENCY; EXPERIENCE; EPINEPHRINE; STATEMENT	Objective-To examine the effect on survival of treatment by ambulance paramedics and ambulance technicians after cardiac arrest outside hospital. Design-Prospective study over two years from 1 April 1992 to 31 March 1994. Setting-Accident and emergency department of university teaching hospital. Subjects-502 consecutive adult patients with out of hospital cardiopulmonary arrest of cardiac origin. Interventions-Treatment by ambulance technicians or paramedics both equipped with semiautomatic defibrillators. Main outcome measures-Rate of return of spontaneous circulation, hospital admission, and survival to hospital discharge. Results-Rates of return of spontaneous circulation, hospital admission, and survival to hospital discharge were not significantly different for patients treated by paramedics as opposed to ambulance technicians. Paramedics spent significantly longer at the scene of the arrest than technicians (P<0.0001). Conclusions-The response of ambulance paramedics to patients with cardiopulmonary arrest outside hospital does not provide improved outcome when compared with ambulance technicians using basic techniques and equipped with semi-automatic defibrillators.	ROYAL EDINBURGH INFIRM,DEPT ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh								ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BOSSAERT L, 1989, RESUSCITATION, V17, pS55, DOI 10.1016/0300-9572(89)90091-9; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, RESUSCITATION, V21, P960; CUMMINS RO, 1995, JAMA-J AM MED ASSOC, V253, P2408; CUSACK S, 1992, ARCH EMERG MED, V9, P203; DARK PM, 1990, SCOT MED J, V35, P73, DOI 10.1177/003693309003500304; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DICKEY W, 1991, Q J MED, V80, P729; DYBVIK T, 1995, IN PRESS RESUSCITATI; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; HARRISON EE, 1981, ANN EMERG MED, V10, P420, DOI 10.1016/S0196-0644(81)80309-5; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P117; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; KOSTER R, 1992, RESUSCITATION, V24, P143, DOI 10.1016/0300-9572(92)90020-D; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; MARTIN DR, 1993, RESUSCITATION, V26, P63, DOI 10.1016/0300-9572(93)90164-L; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; SCHUTTLER J, 1991, ANAESTHESIST, V40, P172; SEDGWICK ML, 1994, RESUSCITATION, V27, P55, DOI 10.1016/0300-9572(94)90022-1; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; SMITH JP, 1986, CAN J PREHOSP MED, V1, P5; STIELL IG, 1992, NEW ENGL J MED, V327, P1047; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; STULTS KR, 1986, AM J EMERG MED, V4, P491, DOI 10.1016/S0735-6757(86)80001-8; VONPLANTA M, 1992, RESUSCITATION, V24, P227, DOI 10.1016/0300-9572(92)90182-C; WEAVER WD, 1990, CIRCULATION, V82, P2027, DOI 10.1161/01.CIR.82.6.2027; 1991, NATIONAL HLTH SERVIC; 1993, HLTH NATION KEY AREA	36	59	59	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1091	1094		10.1136/bmj.310.6987.1091	http://dx.doi.org/10.1136/bmj.310.6987.1091			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742673	Green Published			2022-12-01	WOS:A1995QW61800012
J	KUNANUSONT, C; FOY, HM; KREISS, JK; RERKSNGARM, S; PHANUPHAK, P; RAKTHAM, S; PAU, CP; YOUNG, NL				KUNANUSONT, C; FOY, HM; KREISS, JK; RERKSNGARM, S; PHANUPHAK, P; RAKTHAM, S; PAU, CP; YOUNG, NL			HIV-1 SUBTYPES AND MALE-TO-FEMALE TRANSMISSION IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROSEXUAL TRANSMISSION; DISEASE STAGE; RISK-FACTORS; TYPE-1; INFECTION; POPULATIONS; AIDS; PROSTITUTES; ASSOCIATION	We examined the risk factors for heterosexual transmission of HIV in a case-control study of couples in Thailand. 90 HIV-positive men and their regular sex partners were enrolled at the immune clinic, Chulalongkorn Hospital, where 92% of male index cases had HIV-1 serotype A (subtype E). Most index cases had acquired HIV through sexual intercourse. 95 couples were enrolled at 15 detoxification clinics, where 79% of them had HIV-1 serotype B (subtype B). Most men had acquired HIV through injecting drug use (IDU). The HIV seroconcordance rate was higher in the immune clinic (69%) than in the IDU clinics (48% overall, and 27% after excluding female partners who were IDUs) (p<0.01). The rate was also higher among couples in whom the male index case was infected with serotype A (subtype E) compared with serotype B (subtype B) (70% vs 52%, OR 2.1, 95% CI 1.2-4.2). When we excluded couples in whom the female was also an IDU, the difference in concordance rates was even more pronounced (70% vs 26%, OR 6.8, 95% CI 2.7-17.6). Viral factors or subjects' characteristics may have contributed to the concordance rates. In a multivariate logistic regression analysis, HIV-1 serotype A (subtype E) of male partners (adjusted OR 3.1, 95% CI 1.1-9.0) and history of IDU in female partners (adjusted OR 4.8, 95% CI 1.4-15.9) remained independently associated with HIV seroconcordance. This study suggests that HIV-1 subtype E may be associated with higher risk of heterosexual transmission than subtype B. If so, the predominance of subtype E in Thailand may have contributed to the rapid spread of the HIV epidemic.	UNIV WASHINGTON,SEATTLE,WA 98195; CHULALONGKORN HOSP,BANGKOK,THAILAND; BANGKOK METROPOLITAN ADM,BANGKOK,THAILAND; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; HIV AIDS COLLABORAT,NONTHABURI,THAILAND	University of Washington; University of Washington Seattle; Chulalongkorn University; Centers for Disease Control & Prevention - USA	KUNANUSONT, C (corresponding author), MINIST PUBL HLTH,DEPT COMMUNICABLE DIS CONTROL,DIV AIDS,NONTHABURI 11000,THAILAND.				FIC NIH HHS [D43-TW00007] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000007] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; AUWANIT W, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P53; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; CAMERON DW, 1989, LANCET, V2, P403; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHOTPITAYASUNON.T, 1994, 10TH INT C AIDS YOK; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; FIORE JR, 1993, AIDS, V7, P29, DOI 10.1097/00002030-199301000-00004; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HOLMES KK, 1988, J ACQ IMMUN DEF SYND, V1, P602; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MOSS GB, 1991, J INFECT DIS, V164, P588, DOI 10.1093/infdis/164.3.588; MYERS G, 1992, HUMAN RETROVIRUSES A; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; PAU CP, 1993, 1ST NAT C HUM RETR R; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; WENIGER B, 1994, 10TH INT C AIDS YOK; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; 1992, BRIT MED J, V304, P809	30	164	168	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1078	1083						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715340				2022-12-01	WOS:A1995QV41100010
